Drug_ID,Drug_Name,PubChem_CID,Synonymous,Therapeutic_Class,Drug_Type,InChI,InChIKey,Canonical_SMILES,CAS_Number,Formula,ChEBI,Disease_Class
D0001,Abacavir,441300,"Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC",Anti-Hiv Agents,Small molecule,"1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1",MCGSCOLBFJQGHM-SCZZXKLOSA-N,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,136470-78-5,C14H18N6O,421707,1C60-1C62: Human immunodeficiency virus disease
D0002,Abametapir (topical),15664,"5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl",Topical Anti-Infectives,Small molecule,"1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3",PTRATZCAGVBFIQ-UHFFFAOYSA-N,CC1=CN=C(C=C1)C2=NC=C(C=C2)C,1762-34-1,C12H12N2,.,1G00: Pediculosis
D0003,Abarelix,16131215,"Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10",Antineoplastics,Small molecule,"1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1",AIWRTTMUVOZGPW-HSPKUQOVSA-N,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C,183552-38-7,C72H95ClN14O14,337298,2C82: Prostate cancer
D0004,Abatacept,.,Orencia (TN),Antirheumatics,Protein/peptide,.,.,.,.,.,.,FA20: Rheumatoid arthritis
D0005,Abciximab,.,ReoPro (TN),Anticoagulants,Monoclonal antibody,.,.,.,.,.,.,BA40: Angina pectoris
D0006,Abemaciclib,46220502,Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);,Antineoplastics/Cdk 4/6 Inhibitors,Small molecule,"1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,1231929-97-7,C27H32F2N8,.,2C60-2C6Y: Breast cancer; 2A00-2F9Z: Solid tumour/cancer
D0007,Abiraterone,132971,Abiraterone (AR inhibitor),Antineoplastics,Small molecule,"1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,154229-19-3,C24H31NO,68642,2C82: Prostate cancer
D0008,Acalabrutinib,71226662,Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326,Antineoplastics/Bruton Tyrosine Kinase Inhibitor,Small molecule,"1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,1420477-60-6,C26H23N7O2,.,2A82: Mature B-cell leukaemia; 2A85: Mature B-cell lymphoma
D0009,Acarbose,41774,"acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1-&gt;4)-alpha-D-glucopyranosyl-(1-&gt;4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369",Antidiabetic Agents,Small molecule,"1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1",XUFXOAAUWZOOIT-UGEKTDRHSA-N,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,56180-94-0,C25H43NO18,2376,5A2Y: Acute diabete complication; BA00-BE2Z: Cardiovascular disease
D0010,Acebutolol,1978,Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone,Antihypertensive Agents,Small molecule,"1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)",GOEMGAFJFRBGGG-UHFFFAOYSA-N,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,37517-30-9,C18H28N2O4,2379,BA00-BA04: Hypertension
D0011,Acetaminophen,1983,acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet,Analgesics,Small molecule,"1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)",RZVAJINKPMORJF-UHFFFAOYSA-N,CC(=O)NC1=CC=C(C=C1)O,103-90-2,C8H9NO2,46195,MG30-MG3Z: Pain
D0012,Acetazolamide,1986,"Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox",Anticonvulsants,Small molecule,"1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)",BZKPWHYZMXOIDC-UHFFFAOYSA-N,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,59-66-5,C4H6N4O3S2,27690,9C61: Glaucoma
D0013,Acetohexamide,1989,Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide,Antidiabetic Agents,Small molecule,"1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)",VGZSUPCWNCWDAN-UHFFFAOYSA-N,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,968-81-0,C15H20N2O4S,28052,5A2Y: Acute diabete complication
D0014,Acetohydroxamic acid,1990,"AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)",Antiinfective Agents,Small molecule,"1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)",RRUDCFGSUDOHDG-UHFFFAOYSA-N,CC(=O)NO,546-88-3,C2H5NO2,27777,GC08: Urinary tract infection
D0015,Acetylcholine,187,"acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine;  Miochol; Miochol-e",Cardiovascular Agents,Small molecule,"1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1",OIPILFWXSMYKGL-UHFFFAOYSA-N,CC(=O)OCC[N+](C)(C)C,51-84-3,C7H16NO2+,15355,9B10: Cataract
D0016,Acetylcysteine,12035,"Acetadone EF; Acetadote ALF; Acetylcysteine, Cumberland Pharmaceuticals",Expectorants/Antidotes,Small molecule,"1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1",PWKSKIMOESPYIA-BYPYZUCNSA-N,CC(=O)NC(CS)C(=O)O,616-91-1,C5H9NO3S,28939,DB90-DB9Z: Liver disease
D0017,Acetylsalicylic acid,2244,ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard,Analgesics,Small molecule,"1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",BSYNRYMUTXBXSQ-UHFFFAOYSA-N,CC(=O)OC1=CC=CC=C1C(=O)O,50-78-2,C9H8O4,15365,MG30-MG3Z: Pain; BA41-BA43: Myocardial infarction; BA00-BE2Z: Cardiovascular disease
D0018,Acitretin,5284513,"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",Keratolytic Agents,Small molecule,"1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+",IHUNBGSDBOWDMA-AQFIFDHZSA-N,CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC,55079-83-9,C21H26O3,50173,EA90: Psoriasis
D0019,Aclidinium,11434515,Aclidinium; UNII-K17VY42F6C; K17VY42F6C; CHEBI:65346; 727649-81-2; CHEMBL551466; (3R)-3-[2-hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane; (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; SCHEMBL72141; GTPL7449; SCHEMBL15096073; CHEMBL1194325; DTXSID00223070; ZINC30691727; BDBM50296331; DB08897; AJ-84146; AB01565828_02; 1-(3-Phenoxypropyl)-3alpha-[hydroxybis(2-thienyl)acetyloxy]-1-azoniabicyclo[2.2.2]octane,Anticholinergic Agents/Bronchodilators,Small molecule,"1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1",ASMXXROZKSBQIH-VITNCHFBSA-N,C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5,727649-81-2,C26H30NO4S2+,65346,CA22: Chronic obstructive pulmonary disease
D0020,Acrivastine,5284514,"Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid",Antiinflammatory Agents,Small molecule,"1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+",PWACSDKDOHSSQD-IUTFFREVSA-N,CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O,87848-99-5,C22H24N2O2,83168,CA08: Vasomotor/allergic rhinitis
D0021,Activated charcoal,5462310,"05105_FLUKA; 05110_FLUKA; 05112_FLUKA; 05113_FLUKA; 05120_FLUKA; 05123_FLUKA; 101239-80-9; 106907-70-4; 109766-76-9; 114680-00-1; 115344-49-5; 116788-82-0; 12424-49-6; 124760-06-1; 12751-41-6; 12768-98-8; 12789-22-9; 130960-03-1; 131640-45-4; 133136-50-2; 1333-86-4; 1343-03-9; 137322-21-5; 137906-62-8; 138464-41-2; 1399-57-1; 147335-73-7; 155660-93-8; 156854-02-3; 158271-80-8; 159251-18-0; 161551_SIAL; 16291-96-6; 16291-96-6 (Parent); 164973-65-3; 179607-25-1; 18002_RIEDEL; 18002_SUPELCO; 18006_RIEDEL; 18008_RIEDEL; 18008_SIAL; 181719-82-4; 182761-22-4; 186708-92-9; 186708-96-3; 208519-32-8; 208728-20-5; 208728-21-6; 214540-86-0; 22874_FLUKA; 22874_SIAL; 242233_SIAL; 242241_SIAL; 242268_SIAL; 242276_SIAL; 26837-67-2; 282863_ALDRICH; 282863_SIAL; 29204_FLUKA; 29204_SIAL; 29238_FLUKA; 292591_SIAL; 2P3VWU3H10; 308068-56-6; 326874-96-8; 329428_SIAL; 332461_ALDRICH; 332461_SIAL; 37196-29-5; 37265-44-4; 37265-48-8; 37771_FLUKA; 37771_SIAL; 37996_FLUKA; 37996_SIAL; 390127_SIAL; 39422-04-3; 39434-34-9; 39988_FLUKA; 3B4-2186; 429685-07-4; 484164_ALDRICH; 496537_ALDRICH; 496545_ALDRICH; 496553_ALDRICH; 496561_ALDRICH; 496588_ALDRICH; 496596_ALDRICH; 50814-81-8; 51127_FLUKA; 51127_SIAL; 519308_ALDRICH; 52623-24-2; 53095-52-6; 53663_FLUKA; 53663_SIAL; 53851-02-8; 55353-42-9; 55607-95-9; 56257-79-5; 56257-80-8; 56274-59-0; 566149-76-6; 56729-25-0; 56729-26-1; 572497_ALDRICH; 58517-29-6; 58899_FLUKA; 61512-59-2; 633100_ALDRICH; 636398_ALDRICH; 63661-31-4; 64365-11-3; 64365-11-3 (activated); 64427-56-1; 64900-31-8; 65407-06-9; 67167-41-3; 675342_SIAL; 681225-93-4; 6C; 72343_FLUKA; 72343_SIAL; 72536-89-1; 72840-52-9; 73560-38-0; 7440-44-0; 75026-75-4; 76416-61-0; 76632-92-3; 7782-40-3; 7782-42-5; 798556-12-4; 798556-14-6; 79921-09-8; 81180-26-9; 82600-58-6; 82696-74-0; 82696-75-1; 82701-02-8; 82701-03-9; 82701-04-0; 82701-05-1; 82701-06-2; 82709-42-0; 83138-28-7; 83797-07-3; 84739-05-9; 857167-12-5; 87934-03-0; 89341_FLUKA; 89341_SIAL; 89440_ALDRICH; 89440_FLUKA; 90452-98-5; 90597-58-3; 93067_FLUKA; 93067_SIAL; 95681_FLUKA; 95681_SIAL; 96831_FLUKA; 96831_SIAL; 97708-44-6; 97793-37-8; 97876_FLUKA; 97876_SIAL; AC1NUWBM; Acetylene black; Acticarbone; Actidose; Activated carbon; Activated charcoal; Activated Charcoal Norit; Activated Charcoal Norit(R); Activated charcoal, iodinated; Adsorba; Adsorbit; Aerodag G; AG 1500; AG 3 (Adsorbent); AG 5; AG 5 (Adsorbent); AGN-PC-0LQUF1; AK (Adsorbent); AKOS015914131; Amoco PX 21; Animal bone charcoal; Anthrasorb; Aqua nuchar; Aquadag; AR 3; Aroflow; Arogen; Arotone; Arovel; Arrow; ART 2; AS 1; AT 20; ATJ-S; ATJ-S graphite; Atlantic; AU 3; BAU; BG 6080; Black 140; Black Kosmos 33; Black lead; Black pearls; Bone charcoal; C; C.I. 77265; C.I. 77266; C.I. Pigment Black 10; C.I. Pigment Black 6; C.I. Pigment Black 7; C2194; C2764_SIAL; C2889_SIAL; C3014_SIAL; C3345_SIAL; C4386_SIAL; C5510_SIAL; C6289_SIAL; C9157_SIAL; Calcotone Black; Cancarb; Canesorb; Canlub; Carbo activatus; Carbo vegetabilis; Carbodis; Carbolac; Carbolac 1; Carbomet; Carbomix; Carbon; Carbon Activated; CARBON BLACK; Carbon Black BV and V; Carbon black, acetylene; Carbon black, channel; Carbon black, furnace; Carbon black, lamp; Carbon black, thermal; CARBON NANOTUBE; Carbon nanotube, single-walled; Carbon powder; Carbon, activate; Carbon, activated; Carbon, activated [UN1362] [Spontaneously combustible]; Carbon, amorphous; Carbon, colloidal; Carbon, Vitreous; Carbon-12; Carbone; carbonium; carbono; Carbopol Extra; Carbopol M; Carbopol Z 4; Carbopol Z Extra; Carbosieve; Carbosorbit R; Caswell No. 161; Cb 50; CCRIS 7235; CCRIS 8681; CCRIS 9467; Cecarbon; Ceylon Black Lead; CF 8; CF 8 (Carbon); Channel black; Char, from refuse burner; Charbon; CHARCOAL; Charcoal  bone; Charcoal activated; Charcoal activated Norit; Charcoal activated Norit(R); Charcoal bone; Charcoal, activated; Charcoal, activated [USP]; Charcoal, except activated; Charcodote; CHEBI:27594; CI 77266; CI Pigment black 7; CK3; CLF II; CMB 200; CMB 50; Coke powder; Colgon BPL; Colgon PCB 12X30; Colgon PCB-D; Collocarb; Columbia carbon; Columbia LCK; Conductex; Conductex 900; Continex; Corax A; Corax P; CPB 5000; Croflex; Crolac; CUZ 3; CWN 2; D&C Black No. 2; D002244; D006108; Darco; DC 2; Degussa; Delussa Black FW; DIAMOND; Durex O; Eagle Germantown; EG 0; EINECS 215-609-9; EINECS 231-153-3; EINECS 231-953-2; EINECS 231-955-3; EINECS 264-846-4; Electrographite; ELF 78; Elftex; EPA Pesticide Chemical Code 016001; Essex; Excelsior; EXP-F; Explosion Acetylene Black; Explosion Black; Farbruss; Fecto; Filtrasorb; Filtrasorb 200; Filtrasorb 400; Flamruss; Formocarbine; Fortafil 5Y; FT-0621888; FT-0623469; Fullerene soot; Furnace black; Furnal; Furnex; Furnex N 765; Gas Black; Gas-furnace black; Gastex; GK 2; GK 3; GP 60; GP 60S; GP 63; Grafoil; Grafoil GTA; graphene; Graphite; Graphite (all forms except graphite fibers); Graphite (natural), dust; Graphite (synthetic); GRAPHITE, NATURAL; Graphite, synthetic; Graphitic acid; Graphnol N 3M; Grosafe; GS 2; GY 70; H 451; Hitco HMG 50; HSDB 2017; HSDB 5037; HSDB 7713; HSDB 953; Huber; Humenegro; Hydrodarco; I14-114468; I14-45191; I14-52609; IG 11; Impingement Black; Impingement carbons; Irgalite 1104; Jado; K 257; Ketjenblack EC; Kohlenstoff; Korobon; Kosmink; Kosmobil; Kosmolak; Kosmos; Kosmotherm; Kosmovar; Lamp black; Lampblack; LS-51900; LS-59580; MA 100 (Carbon); Magecol; Medicinal carbon; Metanex; MG 1; Micronex; Miike 20; Mineral carbon; Modulex; Mogul; Mogul L; Molacco; Monarch 1300; Monarch 700; MPG 6; Neo Spectra Beads AG; Neo-spectra II; Neo-Spectra Mark II; Neotex; Niteron 55; Norit; NORIT A, U.S.P.; Nuchar; Oil-furnace Black; OU-B; P 33 (carbon black); P1250; P68; Papyex; Peach black; Pelikan C 11/1431a; Pelletex; Permablak 663; PG 50; Philblack; Philblack N 550; Philblack N 765; Philblack O; Pigment black 6; Pigment black 7; Plumbago; Plumbago (graphite); Printex; Printex 60; Pyro-Carb 406; Raven; Raven 30; Raven 420; Raven 500; Raven 8000; Rebonex; Regal; Regal 300; Regal 330; Regal 400R; Regal 600; Regal 99; Regal SRF; Regent; RL04457; Rocol X 7119; Royal spectra; RTR-024045; S 1; S 1 (Graphite); Schungite; Sevacarb; Seval; Shawinigan Acetylene Black; Shell carbon; Shungite; Silver graphite; Single wall carbon nanotube; SKG; SKLN 1; SKT; SKT (adsorbent); Special Black 1V & V; Special schwarz; Spheron; Spheron 6; Statex; Statex N 550; Sterling MT; Sterling N 765; Sterling NS; Sterling SO 1; Stove Black; SU 2000; Suchar 681; Super-carbovar; Super-spectra; Superba; Supersorbon IV; Supersorbon S 1; SWCNT; Swedish Black Lead; Swine fly ash; SWNT; Therma-atomic Black; Thermal Acetylene Black; Thermal black; Thermatomic; Thermax; Thermblack; Tinolite; TM 30; Toka Black 4500; Toka Black 5500; Toka Black 8500; TR-024045; U 02; Ucar 38; Ultracarbon; UN1362; UNII-2P3VWU3H10; UNII-4QQN74LH4O; UNII-4XYU5U00C4; Vitreous Carbon; VVP 66-95; W8209; Watercarb; Whetlerite; Witcarb 940; XE 340; XF 4175L; GRAPHITE POWDER; Coconut Charcoal; Carbon, Darco? G-60, Activated; G0500; G0501; G0502; N0968; N0969; Nanodiamond (particle size : <10nm) (Amine-modified); Nanodiamond (particle size : <10nm) (Carboxyl-modified); Carbon Nanotube Multi-walled 10-20nm(diam.), 5-15microm(length); Carbon Nanotube Multi-walled 10-30nm(diam.), 5-15microm(length); Carbon Nanotube Multi-walled 20-40nm(diam.), 1-2microm(length); Carbon Nanotube Multi-walled 20-40nm(diam.), 5-15microm(length); Carbon Nanotube Multi-walled 40-60nm(diam.), 1-2microm(length); Carbon Nanotube Multi-walled 40-60nm(diam.), 5-15microm(length); Carbon Nanotube Multi-walled 60-100nm(diam.), >5microm(length); Carbon Nanotube Aligned Multi-walled 10-20nm(diam.), 5-15microm(length); 1034343-98-0; Carbon Nanotube Single-walled (>85%) below 3nm(Average diam.), over 5microm(Average length)",Antidotes,Small molecule,InChI=1S/C,OKTJSMMVPCPJKN-UHFFFAOYSA-N,[C],.,C,.,NE6Z: Unspecific substance harmful effect
D0022,Acyclovir,135398513,acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir,Antiviral Agents,Small molecule,"1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)",MKUXAQIIEYXACX-UHFFFAOYSA-N,C1=NC2=C(N1COCCO)N=C(NC2=O)N,59277-89-3,C8H11N5O3,2453,1A24-1D9Z: Virus infection; 1F00: Herpes simplex infection
D0023,Adalimumab,.,Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN),Antirheumatics,Monoclonal antibody,.,.,.,.,.,.,FA20: Rheumatoid arthritis
D0024,Adapalene (topical),60164,"Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid",Dermatologic Agents,Small molecule,"1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",LZCDAPDGXCYOEH-UHFFFAOYSA-N,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,106685-40-9,C28H28O3,31174,ED80: Acne vulgaris
D0025,Adenosine,60961,"Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine",Antiarrhythmic Agents,Small molecule,"1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1",OIRDTQYFTABQOQ-KQYNXXCUSA-N,C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N,5536-17-4,C10H13N5O4,16335,BC81: Supraventricular tachyarrhythmia
D0026,Afatinib,10184653,"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens",Multikinase Inhibitors,Small molecule,"1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,850140-72-6,C24H25ClFN5O3,61390,2C25: Lung cancer
D0027,Aflibercept,.,Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye,Vegf/Vegfr Inhibitors,Protein/peptide,.,.,.,.,.,.,2B91: Colorectal cancer
D0028,Albendazole,2082,"Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole",Antiprotozoal Agents,Small molecule,"1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)",HXHWSAZORRCQMX-UHFFFAOYSA-N,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,54965-21-8,C12H15N3O2S,16664,1F90: Parasitic worm infestation
D0029,Albiglutide,145994868,"Albiglutide Fragment; 782500-75-8; Albiglutide; tanzeum; Albugon; Eperzan; Albiglutide [USAN:INN]; UNII-5E7U48495E; HSDB 8282; GSK716155; 5E7U48495E; GSK 716155; S3734; Albugon, a recombinant human glucagon-like peptide 1-albumin protein; ((8-glycine)human glucagon-like peptide 1-(7-36)-peptidyl)((8-glycine)human glucagon-like peptide 1-(7-36)-peptidyl)(human serum albumin (585 residues)); 7-36-Glucagon-like peptide I (8-glycine) (human), fusion protein with 7-36-glucagon-like peptide I (8-glycine) (human) fusion protein with serum",Glp-1 Agonists/Antidiabetic Agents,Protein/peptide,"InChI=1S/C148H224N40O45/c1-16-76(10)119(145(231)166-79(13)125(211)174-103(59-85-62-158-90-35-24-23-34-88(85)90)135(221)176-99(55-73(4)5)136(222)185-117(74(6)7)143(229)173-92(36-25-27-51-149)127(213)160-65-109(196)167-91(122(153)208)38-29-53-157-148(154)155)187-137(223)101(56-82-30-19-17-20-31-82)177-132(218)97(46-50-115(204)205)172-131(217)93(37-26-28-52-150)170-124(210)78(12)164-123(209)77(11)165-130(216)96(43-47-108(152)195)169-111(198)66-161-129(215)95(45-49-114(202)203)171-133(219)98(54-72(2)3)175-134(220)100(58-84-39-41-87(194)42-40-84)178-140(226)105(68-189)181-142(228)107(70-191)182-144(230)118(75(8)9)186-139(225)104(61-116(206)207)179-141(227)106(69-190)183-147(233)121(81(15)193)188-138(224)102(57-83-32-21-18-22-33-83)180-146(232)120(80(14)192)184-112(199)67-162-128(214)94(44-48-113(200)201)168-110(197)64-159-126(212)89(151)60-86-63-156-71-163-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,158,189-194H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,195)(H2,153,208)(H,156,163)(H,159,212)(H,160,213)(H,161,215)(H,162,214)(H,164,209)(H,165,216)(H,166,231)(H,167,196)(H,168,197)(H,169,198)(H,170,210)(H,171,219)(H,172,217)(H,173,229)(H,174,211)(H,175,220)(H,176,221)(H,177,218)(H,178,226)(H,179,227)(H,180,232)(H,181,228)(H,182,230)(H,183,233)(H,184,199)(H,185,222)(H,186,225)(H,187,223)(H,188,224)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,154,155,157)/t76-,77-,78-,79-,80+,81+,89+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,117+,118+,119+,120+,121+/m1/s1",JYDZPPZAYQTOIV-OTSUTHPESA-N,CC[C@@H](C)[C@@H](C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N,.,C148H224N40O45,.,.
D0030,Aldesleukin,.,Proleukin (TN),Antineoplastics,Interferons,.,.,.,.,.,.,2C90: Renal cell carcinoma; 2B33: Malignant haematopoietic neoplasm
D0031,Alectinib,49806720,"1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2;  Alectinib; 9-ethyl-6,6-dimethyl-",Multikinase Inhibitors,Small molecule,"1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,1256580-46-7,C30H34N4O2,90936,2C25: Lung cancer
D0032,Alefacept,.,Amevive (TN),Analgesics,Small molecule,.,.,.,.,.,.,MG30-MG3Z: Pain
D0033,Alemtuzumab,.,Campath (TN); MabCampath (TN); Campath-1H (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A82: Mature B-cell leukaemia; 8A40: Multiple sclerosis
D0034,Alendronic acid,2088,"Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate",Bone Density Conservation Agents,Small molecule,"1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)",OGSPWJRAVKPPFI-UHFFFAOYSA-N,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,66376-36-1,C4H13NO7P2,2567,FB85: Bone paget disease; FB83: Low bone mass disorder
D0035,Alfentanil,51263,"Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide",Anesthetics,Small molecule,"1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3",IDBPHNDTYPBSNI-UHFFFAOYSA-N,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC,71195-58-9,C21H32N6O3,2569,9A76-9A78: Corneal disease
D0036,Alfuzosin,2092,"Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide",Antihypertensive Agents,Small molecule,"1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)",WNMJYKCGWZFFKR-UHFFFAOYSA-N,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,81403-80-7,C19H27N5O4,51141,GA90: Prostate hyperplasia
D0037,Alimemazine,5574,"Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine",Antihistamines,Small molecule,"1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3",ZZHLYYDVIOPZBE-UHFFFAOYSA-N,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C,84-96-8,C18H22N2S,9725,CA08: Vasomotor/allergic rhinitis
D0038,Aliskiren,5493444,"Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]",Antihypertensive Agents,Small molecule,"1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1",UXOWGYHJODZGMF-QORCZRPOSA-N,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,173334-57-1,C30H53N3O6,601027,BA00-BA04: Hypertension
D0039,Alitretinoin (topical),449171,.,Antineoplastics,Small molecule,"1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+",SHGAZHPCJJPHSC-ZVCIMWCZSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,1241893,C20H28O2,50648,2B57: Kaposi sarcoma
D0040,Allopurinol,135401907,"Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP",Antimetabolites,Small molecule,"1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)",OFCNXPDARWKPPY-UHFFFAOYSA-N,C1=NNC2=C1C(=O)NC=N2,315-30-0,C5H4N4O,40279,5C55: Inborn purine/pyrimidine/nucleotide metabolism error
D0041,Almotriptan,123606,"Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine",Antimigraine Agents,Small molecule,"1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3",WKEMJKQOLOHJLZ-UHFFFAOYSA-N,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3,154323-57-6,C17H25N3O2S,520985,8A80: Migraine
D0042,Alogliptin,11450633,"850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203;  UNII-JHC049LO86",Antidiabetic Agents,Small molecule,"1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1",ZSBOMTDTBDDKMP-OAHLLOKOSA-N,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N,850649-61-5,C18H21N5O2,72323,5A11: Type 2 diabetes mellitus
D0043,Alosetron,2099,"Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride",Gastrointestinal Agents,Small molecule,"1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)",JSWZEAMFRNKZNL-UHFFFAOYSA-N,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,122852-42-0,C17H18N4O,253342,DD91: Irritable bowel syndrome
D0044,Alpelisib,56649450,"alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide",Pi3K Inhibitors,Small molecule,"1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,1217486-61-7,C19H22F3N5O2S,93752,2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer
D0045,Alprazolam,2118,"Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3",VREFGVBLTWBCJP-UHFFFAOYSA-N,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,28981-97-7,C17H13ClN4,2611,6B00-6B0Z: Anxiety disorder; 8A61-8A6Z: Epilepsy/seizure
D0046,Alprostadil,5280723,"Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil",Vasodilator Agents,Small molecule,"1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1",GMVPRGQOIOIIMI-DWKJAMRDSA-N,CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,745-65-3,C20H34O5,15544,HA00-HA01: Sexual dysfunction; BD54: Diabetic foot ulcer
D0047,Alteplase,.,Activase (TN),Thrombolytics,Protein/peptide,.,.,.,.,.,.,BB00: Pulmonary thromboembolism
D0048,Altretamine,2123,"Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine",Antineoplastics,Small molecule,1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,645-05-6,C9H18N6,24564,2C73: Ovarian cancer
D0049,Aluminum hydroxide,10176082,"aluminum;trihydroxide; Dried aluminum hydroxide gel; Aluminium hydroxide gel, dried; aluminium trihydroxide; aluminum hyroxide; Hydroxyde d' aluminium; Dried aluminium hydroxide; Aluminium hydroxide, dried; Aluminum hydroxide gel, dried; CHEMBL1200706; DTXSID2036405; NIOSH/BD0708000; Di-mu-hydroxytetrahydroxydialuminum; AF-260; AKOS015904617; Aluminum, di-mu-hydroxytetrahydroxydi-; DB06723; BD07080000; Q407125; J-014205; UNII-F41V936QZM component WNROFYMDJYEPJX-UHFFFAOYSA-K",Antacids,Small molecule,InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3,WNROFYMDJYEPJX-UHFFFAOYSA-K,[OH-].[OH-].[OH-].[Al+3],.,AlH3O3,.,.
D0050,Alvimopan,5488548,"Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid",Analgesics,Small molecule,"1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1",UPNUIXSCZBYVBB-JVFUWBCBSA-N,CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O,156053-89-3,C25H32N2O4,135686,DE2Z: Digestive system disease
D0051,Amantadine,2130,"Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane",Antiviral Agents,Small molecule,"1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2",DKNWSYNQZKUICI-UHFFFAOYSA-N,C1C2CC3CC1CC(C2)(C3)N,768-94-5,C10H17N,2618,1E30-1E32: Influenza
D0052,Ambenonium,2131,"Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]",Antiarrhythmic Agents,Small molecule,"1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2",OMHBPUNFVFNHJK-UHFFFAOYSA-P,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl,7648-98-8,C28H42Cl2N4O2+2,2627,8C6Y: Myasthenia gravis
D0053,Ambrisentan,6918493,"Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid",Agents For Pulmonary Hypertension,Small molecule,"1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1",OUJTZYPIHDYQMC-LJQANCHMSA-N,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,177036-94-1,C22H22N2O4,135949,BB01: Pulmonary hypertension
D0054,Amifampridine,5918,"3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913",Cholinergic Muscle Stimulants,Small molecule,"1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)",OYTKINVCDFNREN-UHFFFAOYSA-N,C1=CN=CC(=C1N)N,54-96-6,C5H7N3,135948,8C62: Lambert-Eaton syndrome
D0055,Amifostine,2141,Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310,Cytoprotective Agent,Small molecule,"1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)",JKOQGQFVAUAYPM-UHFFFAOYSA-N,C(CN)CNCCSP(=O)(O)O,20537-88-6,C5H15N2O3PS,2636,CA00: Nasopharyngitis
D0056,Amikacin,37768,"Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A",Antibiotics,Small molecule,"1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1",LKCWBDHBTVXHDL-RMDFUYIESA-N,C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,37517-28-5,C22H43N5O13,2637,1A00-1C4Z: Bacterial infection; 1B10-1B14: HIV-infected patients with tuberculosis
D0057,Amikacin (liposome),37768,"Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A",Antibiotics,Small molecule,"1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1",LKCWBDHBTVXHDL-RMDFUYIESA-N,C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,37517-28-5,C22H43N5O13,2637,1A00-1C4Z: Bacterial infection; 1B10-1B14: HIV-infected patients with tuberculosis
D0058,Amiloride,16231,"Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)",Diuretics,Small molecule,"1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)",XSDQTOBWRPYKKA-UHFFFAOYSA-N,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,2609-46-3,C6H8ClN7O,2639,BD10-BD1Z: Heart failure
D0059,Aminobenzoic acid,978,"4-aminobenzoic acid; 150-13-0; p-aminobenzoic acid; PABA; para-aminobenzoic acid; Vitamin BX; AMINOBENZOIC ACID; p-Carboxyaniline; 4-Carboxyaniline; Sunbrella; Benzoic acid, 4-amino-; p-Carboxyphenylamine; Hachemina; Paraminol; 1-Amino-4-carboxybenzene; Pabacyd; Pabafilm; Pabamine; Paranate; Amben; Potaba; Romavit; Bacterial vitamin H1; Vitamin H'; Anticanitic vitamin; Chromotrichia factor; RVPaba Lipstick; Papacidum; Rvpaba; Trichochromogenic factor; Anti-chromotrichia factor; Super Shade by Coppertone; Benzoic acid, p-amino-; Acidum paraminobenzoicum; Vitamin H1; ABEE; Pabagel; Pabanol; 4-AMINO-BENZOIC ACID; benzoic acid, 4-amino; Caswell No. 033B; Kyselina p-aminobenzoova; MFCD00007894; p-Aminobenzoesaeure; 4-azaniumylbenzoate; 4-Aminobenzoesaeure; 4-Carboxyphenylamine; Acido p-aminobenzoico; PAB; gamma-Aminobenzoic acid; Acido p-aminobenzoico [Italian]; UNII-TL2TJE8QTX; Kyselina p-aminobenzoova [Czech]; para-aminobenzoate; Anticantic vitamin; 4-aminobenzoic-acid; EPA Pesticide Chemical Code 233300; BRN 0471605; p-amino benzoic acid; p-amino-Benzoic acid; CHEBI:30753; AI3-02436; TL2TJE8QTX; Aminobenzoic acid (USP); Aminobenzoic acid [USP]; .gamma.-Aminobenzoic acid; Aniline-4-carboxylic acid; CHEMBL542; AMINOBENZOIC ACID, PARA; NSC-7627; Benzoic acid, 4-amino-, homopolymer; NCGC00091051-01; 4-aminobenzoicacid; DSSTox_CID_4466; DSSTox_RID_77411; DSSTox_GSID_24466; 25136-77-0; CAS-150-13-0; SMR000471833; CCRIS 6209; HSDB 6840; NSC 7627; EINECS 205-753-0; Aminobenzoate; Actipol; p-carboxy aniline; amino benzoic acid; p-aminobezoic acid; gamma-Aminobenzoate; 4-aminobezoic acid; Trochromogenic factor; Aniline-4-carboxylate; 4-Amino benzoic acid; 4-(amino)benzoic acid; Antichromotrichia factor; Spectrum_000036; RVPaba lipstick (TN); P-AMINO-BENZOATE; Spectrum2_000123; Spectrum3_000294; Spectrum4_000142; Spectrum5_000778; Tetracaine EP Impurity A; P-Aminobenzoic Acid,(S); bmse000066; bmse000887; bmse000916; Epitope ID:115017; AMINOBENZOIC-4 ACID; EC 205-753-0; SCHEMBL8249; 4-Aminobenzoic acid, 99%; H-4-ABZ-OH; Oprea1_221096; BSPBio_001828; KBioGR_000584; KBioSS_000396; ZINC920; MLS001066325; MLS001335919; MLS001335920; Para Amino Benzoic Acid USP; BIDD:ER0375; DivK1c_000783; SPBio_000166; PARA AMINO BENZOIC ACID; 4-Aminobenzoic acid-[13C6]; RARECHEM AL BO 0238; component of Presun (Salt/Mix); DTXSID6024466; SCHEMBL13232108; KBio1_000783; KBio2_000396; KBio2_002964; KBio2_005532; KBio3_001328; NSC7627; NINDS_000783; OTAVA-BB 1509951; P-AMINOBENZOIC ACID 100G; HMS2269E10; HMS3870E13; LABOTEST-BB LTBB000459; ACT09225; HY-B1008; Tox21_111069; Tox21_201702; Tox21_300087; BDBM50145829; LABOTEST-BB LT03328355; s4510; STK397441; AKOS000118983; Tox21_111069_1; AC-8107; AM86626; AS00762; CCG-266139; CS-4505; DB02362; MCULE-3535374816; IDI1_000783; 4-Aminobenzoic acid, analytical standard; NCGC00091051-02; NCGC00091051-03; NCGC00091051-04; NCGC00253923-01; NCGC00259251-01; AS-12493; NCI60_041683; SY003749; SBI-0051277.P003; DB-028695; 4-Aminobenzoic acid, ReagentPlus(R), 99%; A0269; FT-0617557; 4-Aminobenzoic acid, >=98.0% (HPLC/NT); 4-Aminobenzoic acid, ReagentPlus(R), >=99%; C00568; D02456; A809010; Q284959; 4-Aminobenzoic acid, Vetec(TM) reagent grade, 98%; Q-200432; 4-Aminobenzoic acid, purified by sublimation, >=99%; Z57127446; 4-Aminobenzoic acid, 98.5-100.2%, SAJ first grade; 4-Aminobenzoic acid, SAJ special grade, 99.5-100.2%; F2191-0259; 4A5E7DD8-8A22-4642-86BF-05B778C0C78E; 4-Aminobenzoic acid, European Pharmacopoeia (EP) Reference Standard; Aminobenzoic acid, United States Pharmacopeia (USP) Reference Standard; Aminobenzoic Acid, Pharmaceutical Secondary Standard; Certified Reference Material",Vitamins,Small molecule,"InChI=1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)",ALYNCZNDIQEVRV-UHFFFAOYSA-N,C1=CC(=CC=C1C(=O)O)N,.,C7H7NO2,.,.
D0060,Aminocaproic acid,564,"6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid;  ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid",Antifibrinolytic Agents,Small molecule,"1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)",SLXKOJJOQWFEFD-UHFFFAOYSA-N,C(CCC(=O)O)CCN,60-32-2,C6H13NO2,16586,GA20-GA21: Bleeding disorder; NE81: Procedure injury
D0061,Aminoglutethimide,2145,"Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine",Antineoplastics,Small molecule,"1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)",ROBVIMPUHSLWNV-UHFFFAOYSA-N,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,125-84-8,C13H16N2O2,2654,5A70: Cushing syndrome
D0062,Aminolevulinic acid,137,"Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)",Malignancy Photosensitizers,Small molecule,"1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)",ZGXJTSGNIOSYLO-UHFFFAOYSA-N,C(CC(=O)O)C(=O)CN,106-60-5,C5H9NO3,17549,ED80: Acne vulgaris; EK90: Epidermal dysplasias
D0063,Aminolevulinic acid (topical),137,"Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)",Malignancy Photosensitizers,Small molecule,"1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)",ZGXJTSGNIOSYLO-UHFFFAOYSA-N,C(CC(=O)O)C(=O)CN,106-60-5,C5H9NO3,17549,ED80: Acne vulgaris; EK90: Epidermal dysplasias
D0064,Aminophylline,9433,Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN),Bronchodilators,Small molecule,"1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2",FQPFAHBPWDRTLU-UHFFFAOYSA-N,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,317-34-0,C16H24N10O4,2659,CA23: Asthma
D0065,Aminosalicylic acid,4649,"4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium",Aminosalicylates,Small molecule,"1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)",WUBBRNOQWQTFEX-UHFFFAOYSA-N,C1=CC(=C(C=C1N)O)C(=O)O,65-49-6,C7H7NO3,27565,1B10-1B12: Tuberculosis; DD72: Indeterminate colitis
D0066,Amiodarone,2157,"Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran",Antiarrhythmic Agents,Small molecule,"1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3",IYIKLHRQXLHMJQ-UHFFFAOYSA-N,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,1951-25-3,C25H29I2NO3,2663,BC71: Ventricular tachyarrhythmia
D0067,Amisulpride,2159,"Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide",Antipsychotic Agents,Small molecule,"1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)",NTJOBXMMWNYJFB-UHFFFAOYSA-N,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,71675-85-9,C17H27N3O4S,64045,6A20: Schizophrenia
D0068,Amitriptyline,2160,"Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene",Analgesics,Small molecule,"1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",KRMDCWKBEZIMAB-UHFFFAOYSA-N,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,50-48-6,C20H23N,2666,6A70-6A7Z: Depression
D0069,Amlodipine,2162,"Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",Antihypertensive Agents,Small molecule,"1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3",HTIQEAQVCYTUBX-UHFFFAOYSA-N,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,88150-42-9,C20H25ClN2O5,2668,BA00-BA04: Hypertension
D0070,Ammonium chloride,25517,AMMONIUM CHLORIDE; 12125-02-9; Salmiac; Sal ammoniac; Ammonium muriate; Ammoniumchlorid; Ammoneric; Darammon; Amchlor; Ammonium chloride ((NH4)Cl); Chlorammonic; Salammonite; Ammoniumklorid; Elektrolyt; Chloramon; Ammonchlor; Sal ammonia; Ammon Chlor; Ammonii Chloridum; Ammonium Chloratum; Cloruro de Amonio; Muriate of Ammonia; Gen-Diur (Spain); Chlorammonic [France]; Ammonium chloride fume; Chlorid amonny [Czech]; ammoniumchloride; Ammoniumchlorid [German]; azanium chloride; Chlorid ammonia [Czech]; Ammonium Chloride Tablets; Ammonium C,Minerals And Electrolytes,Small molecule,1S/ClH.H3N/h1H;1H3,NLXLAEXVIDQMFP-UHFFFAOYSA-N,[NH4+].[Cl-],12125-02-9,ClH4N,.,GC08: Urinary tract infection
D0071,Amobarbital,2164,"AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",VIROVYVQCGLCII-UHFFFAOYSA-N,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,57-43-2,C11H18N2O3,2673,7A00-7A0Z: Insomnia
D0072,Amoxapine,2170,"Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine",Antidepressants,Small molecule,"1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2",QWGDMFLQWFTERH-UHFFFAOYSA-N,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,14028-44-5,C17H16ClN3O,2675,6A70-6A7Z: Depression
D0073,Amoxicillin,33613,"AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1",LSQZJLSUYDQPKJ-NJBDSQKTSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,26787-78-0,C16H19N3O5S,2676,1A00-1C4Z: Bacterial infection
D0074,Amphetamine,3007,"Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore",Cns Stimulants,Small molecule,"1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3",KWTSXDURSIMDCE-UHFFFAOYSA-N,CC(CC1=CC=CC=C1)N,300-62-9,C9H13N,2679,6A05: Attention deficit hyperactivity disorder
D0075,Amphotericin B,5280965,"ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)",Antifungal Agents,Small molecule,"1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1",APKFDSVGJQXUKY-INPOYWNPSA-N,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,1397-89-3,C47H73NO17,.,1F29-1F2F: Fungal infection; 1F2Z: Mycose
D0076,Amphotericin B (cholesteryl sulfate),5280965,"ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)",Antifungal Agents,Small molecule,"1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1",APKFDSVGJQXUKY-INPOYWNPSA-N,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,1397-89-3,C47H73NO17,.,1F29-1F2F: Fungal infection; 1F2Z: Mycose
D0077,Amphotericin B (lipid complex),5280965,"ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)",Antifungal Agents,Small molecule,"1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1",APKFDSVGJQXUKY-INPOYWNPSA-N,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,1397-89-3,C47H73NO17,.,1F29-1F2F: Fungal infection; 1F2Z: Mycose
D0078,Amphotericin B (liposomal),5280965,"ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)",Antifungal Agents,Small molecule,"1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1",APKFDSVGJQXUKY-INPOYWNPSA-N,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,1397-89-3,C47H73NO17,.,1F29-1F2F: Fungal infection; 1F2Z: Mycose
D0079,Ampicillin,6249,"ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1",AVKUERGKIZMTKX-NJBDSQKTSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C,69-53-4,C16H19N3O4S,28971,1A00-1C4Z: Bacterial infection
D0080,Amprenavir,65016,"AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide",Anti-Hiv Agents,Small molecule,"1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1",YMARZQAQMVYCKC-OEMFJLHTSA-N,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,161814-49-9,C25H35N3O6S,40050,1C60-1C62: Human immunodeficiency virus disease
D0081,Amprenavir (oral solution),65016,"AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide",Anti-Hiv Agents,Small molecule,"1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1",YMARZQAQMVYCKC-OEMFJLHTSA-N,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,161814-49-9,C25H35N3O6S,40050,1C60-1C62: Human immunodeficiency virus disease
D0082,Amrinone,3698,"Amrinone; 60719-84-8; inamrinone; Inocor; Wincoram; Cordemcura; Cartonic; Amrinonum [INN-Latin]; Amcoral; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Win-40680; Vesistol; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; WIN 40680; 5-Amino-(3,4'-bipyridin)-6(1H)-one; AWD 08-250; [3,4'-Bipyridin]-6(1H)-one, 5-amino-; UNII-JUT23379TN; 5-amino-3,4'-bipyridin-6(1H)-one; Amrinone lactate; MLS000069829; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN; (3,4'-BIPYRIDIN)-6(1H)-ONE, 5-AMINO-; 3-amino-5-pyridin-4-ylpyridin-2-ol; NSC-759805; 3-amino-5-(pyridin-4-yl)pyridin-2-ol; 5-Amino[3,4'-bipyridin]-6(1H)-one; NCGC00164379-01; Amrinona; Amrinonum; CAS-60719-84-8; DSSTox_CID_2603; DSSTox_RID_76655; DSSTox_GSID_22603; Inamrinone (USP); Amcoral (TN); CCRIS 3794; 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one; Amrinone (JAN/INN); Inamrinone [USAN:USP]; EINECS 262-390-0; BRN 0744819; Prestwick_44; Amrinone [INN]; Amrinone,(S); Spectrum_001350; Opera_ID_1054; Prestwick0_000800; Prestwick1_000800; Prestwick2_000800; Prestwick3_000800; Spectrum2_001980; Spectrum3_000956; Spectrum4_001069; Spectrum5_000999; cid_3698; SCHEMBL44012; BSPBio_000940; KBioGR_001398; KBioSS_001830; 5-25-15-00181 (Beilstein Handbook Reference); MLS001074083; DivK1c_000136; SPECTRUM1503084; SPBio_002139; SPBio_002879; BPBio1_001034; CHEBI:2686; GTPL7202; DTXSID9022603; SCHEMBL13457017; BDBM34651; HMS500G18; KBio1_000136; KBio2_001830; KBio2_004398; KBio2_006966; KBio3_002052; C01CE01; NINDS_000136; HMS1570O22; HMS2097O22; HMS2234F12; HMS3264E16; HMS3369J10; HMS3714O22; Pharmakon1600-01503084; BCP12764; HY-B1294; ZINC8673078; Tox21_112110; Tox21_301847; CCG-39487; NSC759805; STK590307; AKOS005512516; Tox21_112110_1; DB01427; KS-5178; MCULE-2781267039; NSC 759805; CID 5281003; IDI1_000136; NCGC00016896-01; NCGC00016896-02; NCGC00016896-03; NCGC00016896-06; NCGC00095984-01; NCGC00255137-01; AC-12186; AC-33137; BA166404; 5-Amino(3,4'-bipyridine)-6-(1H)-one; 5-Amino-(3,4?-bipyridin)-6(1H)-one; 3-Amino-5-(4-pyridinyl)-2(1H)pyridinone; 3-azanyl-5-pyridin-4-yl-1H-pyridin-2-one; CS-0013064; FT-0601595; C75837; D00231; AB00052312-04; AB00052312_05; 3-Amino-5-(4-pyridinyl)-1,2-dihydro-2-pyridone; 719A848; A832852; Q422724; SR-00000002445; SR-00000002445-2; W-105234; 3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one; BRD-K45924332-001-04-4; BRD-K45924332-001-07-7; Amrinone, United States Pharmacopeia (USP) Reference Standard; 216151-27-8",Cardiovascular Agents,Small molecule,"InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)",RNLQIBCLLYYYFJ-UHFFFAOYSA-N,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,.,C10H9N3O,.,.
D0083,Amyl Nitrite,10026,"Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644 ",Antidotes,Small molecule,"1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3",CSDTZUBPSYWZDX-UHFFFAOYSA-N,CCCCCON=O,463-04-7,C5H11NO2,55344,BA40: Angina pectoris
D0084,Anagrelide,135409400,"Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one",Antithrombotic Agents,Small molecule,"1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)",OTBXOEAOVRKTNQ-UHFFFAOYSA-N,C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3,68475-42-3,C10H7Cl2N3O,142290,3B63: Thrombocytosis
D0085,Anakinra,146171046,NULL,Antiinflammatory Agents,Interferons,"InChI=1S/C20H23N5O7S2/c1-5-9-6-33-16-12(15(27)25(16)13(9)17(28)29)23-14(26)11(10-7-34-19(21)22-10)24-32-8-31-18(30)20(2,3)4/h5,7,12,16H,1,6,8H2,2-4H3,(H2,21,22)(H,23,26)(H,28,29)/b24-11+",HMLGSIZOMSVISS-BHGWPJFGSA-N,CC(C)(C)C(=O)OCO/N=C(\\C1=CSC(=N1)N)/C(=O)NC2C3N(C2=O)C(=C(CS3)C=C)C(=O)O,.,C20H23N5O7S2,.,.
D0086,Anastrozole,2187,"Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile",Antineoplastics,Small molecule,"1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3",YBBLVLTVTVSKRW-UHFFFAOYSA-N,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,120511-73-1,C17H19N5,2704,2C60-2C6Y: Breast cancer
D0087,Anisindione,2197,"Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione",Anticoagulants,Small molecule,"1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3",XRCFXMGQEVUZFC-UHFFFAOYSA-N,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,117-37-3,C16H12O3,133809,3B10: Coagulation defect
D0088,Anistreplase,.,.,Thrombolytics,Protein/peptide,.,.,.,.,.,.,BA41-BA43: Myocardial infarction
D0089,Anthrax vaccine,.,"Anthrax vaccine, DynPort/AVANT; Injectable anthrax vaccine, DynPort/AVANT; Anthrax vaccine (injectable), DynPort/AVANT",Vaccines,Vaccine,.,.,.,.,.,.,1G40-1G41: Sepsis
D0090,"Antihemophilic factor, human recombinant",.,"Antihemophilic factor (recombinant); Antihemophilic factor recombinant; Antihemophilic factor, human recombinant; Antihemophilic factor, recombinant; DB00025; Factor VIII (rDNA); Factor VIII (Recombinant); Factor VIII recombinFactor VIII, recombinantHuman Factor VIII (Recombinant)Human factor VIII recombinantOctocog alfarAHFRecombinant antihemophilic factor VIII",Recombinant Coagulation Factor Viii,Protein/peptide,.,.,.,.,.,.,.
D0091,Antilymphocyte immunoglobulin (horse),.,"Antilymphocyte immunoglobulin (horse); Anti-thymocyte Globulin (Equine); Anti-thymocyte globulin equine; DB09312; eATG; equine ATG; Equine thymocyte immune globulin; hATG; Horse anti-thymocyte globulin; Horse ATG; Lymphocyte immune globulin anti-thymocyte globulin (equine); Lymphocyte immune globulin, anti-thymocyte globulin",Immune Globulins,Monoclonal antibody,.,.,.,.,.,.,.
D0092,Antithrombin Alfa,.,"Antithrombin (recombinant); Antithrombin Alfa; Antithrombin III, recombinant; Antithrombin III,recombinant; DB11166",Recombinant Antithrombin,Protein/peptide,.,.,.,.,.,.,.
D0093,Antithrombin III human,.,"Antithrombin III; Antithrombin III (human); Antithrombin III human; Antithrombin III human plasma-derived; Antithrombin III, human; Antithrombin III,human; AT-III; DB11598; Heparin cofactor B",Recombinant Antithrombin,Protein/peptide,.,.,.,.,.,.,.
D0094,Antithymocyte immunoglobulin (rabbit),.,"Anti-human thymocyte immunoglobulin, rabbit; Anti-thymocyte globulin (rabbit); Anti-thymocyte globulin rabbit; Antithymocyte immunoglobulin; Antithymocyte immunoglobulin (rabbit); Anti-T-lymphocyte immune globulin, rabbit; DB00098; Lapine T-lymphocyte immune globulin; Rabbit anti-human thymocyte globulin; Rabbit anti-human thymocyte globulin (rATG); Rabbit anti-human thymocyte immunoglobulin; Rabbit antithymocyte globulin; Rabbit anti-thymocyte immunoglobulin; Rabbit ATG; rATG; Thymoglobulin; Thymoglobuline",Antiinflammatory Agents,Polyclonal antibody,.,.,.,.,.,.,.
D0095,Apalutamide,24872560,Arn-509 (AR inhibitor),Antiandrogens,Small molecule,"1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)",HJBWBFZLDZWPHF-UHFFFAOYSA-N,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,956104-40-8,C21H15F4N5O2S,.,2A60: Acute myeloid leukaemia; 2C82: Prostate cancer
D0096,Apixaban,10182969,"GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd",Anticoagulants/Factor Xa Inhibitors,Small molecule,"1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)",QNZCBYKSOIHPEH-UHFFFAOYSA-N,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,503612-47-3,C25H25N5O4,72296,DB61-GB90: Thrombosis
D0097,Apomorphine,6005,"Apomorphine (intranasal, Parkinson's disease)",Dopaminergic Antiparkinsonism Agents,Small molecule,"1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1",VMWNQDUVQKEIOC-CYBMUJFWSA-N,CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,58-00-4,C17H17NO2,48538,8A00: Parkinsonism; HA00-HA01: Sexual dysfunction
D0098,Apraclonidine,2216,"Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine",Ophthalmic Glaucoma Agents,Small molecule,"1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)",IEJXVRYNEISIKR-UHFFFAOYSA-N,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl,66711-21-5,C9H10Cl2N4,2788,9C40: Optic nerve disorder
D0099,Apremilast,11561674,"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide",Antirheumatics,Small molecule,"1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1",IMOZEMNVLZVGJZ-QGZVFWFLSA-N,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,608141-41-9,C22H24N2O7S,78540,EA90: Psoriasis
D0100,Aprepitant,135413536,"Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one",Antiemetics,Small molecule,"1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1",ATALOFNDEOCMKK-OITMNORJSA-N,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,170729-80-3,C23H21F7N4O3,499361,6A70-6A7Z: Depression; MD90: Nausea/vomiting; 2A00-2F9Z: Solid tumour/cancer
D0101,Arbutamine,60789,"Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol",Cardiotonic Agents,Small molecule,"1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1",IIRWWTKISYTTBL-SFHVURJKSA-N,C1=CC(=CC=C1CCCCNCC(C2=CC(=C(C=C2)O)O)O)O,128470-16-6,C18H23NO4,50580,BA80: Coronary atherosclerosis
D0102,Ardeparin,772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D0103,Arformoterol,3083544,67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate,Bronchodilators,Small molecule,"1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1",BPZSYCZIITTYBL-YJYMSZOUSA-N,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,67346-49-0,C19H24N2O4,408174,CA22: Chronic obstructive pulmonary disease; CA23: Asthma
D0104,Argatroban,92722,"Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid",Anticoagulants,Small molecule,"1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1",KXNPVXPOPUZYGB-IOVMHBDKSA-N,CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,74863-84-6,C23H36N6O5S,94385,DB61-GB90: Thrombosis
D0105,Aripiprazole,60795,"129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236;  Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination",Antipsychotic Agents,Small molecule,"1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",CEUORZQYGODEFX-UHFFFAOYSA-N,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,129722-12-9,C23H27Cl2N3O2,31236,6A70-6A7Z: Depression; 6A20: Schizophrenia; 6A60: Bipolar disorder; 5C58: Inborn porphyrin/heme metabolism error
D0106,Armodafinil,9690109,"Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, &gt; YFGHCGITMMYXAQ-LJQANCHMSA-N",Cns Stimulants,Small molecule,"1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1",YFGHCGITMMYXAQ-LJQANCHMSA-N,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,112111-43-0,C15H15NO2S,77590,2A00-2F9Z: Solid tumour/cancer
D0107,Arsenic trioxide,14888,Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+),Antineoplastics,Small molecule,1S/2As.3O/q2*+3;3*-2,QTLQKAJBUDWPIB-UHFFFAOYSA-N,[O-2].[O-2].[O-2].[As+3].[As+3],1327-53-3,As2O3,.,2A85: Mature B-cell lymphoma
D0108,Artemether,68911,"Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri",Antimalarial Agents,Small molecule,"1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1",SXYIRMFQILZOAM-HVNFFKDJSA-N,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC)C,71963-77-4,C16H26O5,195280,1F40-1F45: Malaria
D0109,Artesunate,6917864,"Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid",Antimalarial Agents,Small molecule,"1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1",FIHJKUPKCHIPAT-AHIGJZGOSA-N,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,88495-63-0,C19H28O8,63918,1F40-1F45: Malaria
D0110,Articaine,32170,"Articaine; Carticaine; 23964-58-1; Articaine [INN:BAN]; Articainum [INN-Latin]; Articaina [INN-Spanish]; Hoe-045; Ultracain; HOE 045; methyl 4-methyl-3-[(N-propylalanyl)amino]thiophene-2-carboxylate; methyl 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylate; Methyl (4-methyl-3-(2-(propylamino)propionamido)-2-thiophencarboxylat); Q-200652; Articainum; Articaina; 4-Methyl-3-(2-(propylamino)propionamido)-2-thiophenecarboxylic acid, methyl ester; 2-Thiophenecarboxylicacid, 4-methyl-3-[[1-oxo-2-(propylamino)propy",Local Anesthetics,Small molecule,"1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)",QTGIAADRBBLJGA-UHFFFAOYSA-N,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC,23964-58-1,C13H20N2O3S,91834,9A76-9A78: Corneal disease
D0111,Ascorbic acid,54670067,"l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid",Vitamins,Small molecule,"1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1",CIWBSHSKHKDKBQ-JLAZNSOCSA-N,C(C(C1C(=C(C(=O)O1)O)O)O)O,50-81-7,C6H8O6,29073,5B55-5B5F: Vitamin deficiency; GC08: Urinary tract infection
D0112,Asenapine,3036780,"Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole",Atypical Antipsychotics,Small molecule,"1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1",VSWBSWWIRNCQIJ-GJZGRUSLSA-N,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,65576-45-6,C17H16ClNO,71246,6A20: Schizophrenia
D0113,Asparaginase Erwinia chrysanthemi,.,Erwinaze (TN),Antineoplastics,Protein/peptide,.,.,.,.,.,.,2A85: Mature B-cell lymphoma
D0114,Asparaginase Escherichia coli,.,Asparaginase; Asparaginase (E. coli); Asparaginase Escherichia coli; Colaspase; DB00023; Escherichia coli L-asparaginase; L-asparaginase; L-asparagine amidohydrolase,Antineoplastics,Protein/peptide,.,.,.,.,.,.,.
D0115,Astemizole,2247,"Alermizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizolum; Astesen; Emdar; Esmacen; Fustermizol; Hestazol; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; Kelp; Laridal; Metodih; Metodik; Paralergin; Retolen; Rifedot; Rimbol; Romadin; Simprox; Urdrim; Wareezol; Waruzol; AlacanBrand of Astemizole; Alonga Brand of Astemizole; Astemizol Alonga; Astemizol [German]; Astemizol ratiopharm; Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole ratiopharm Brand; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Esteve Brand of Astemizole; Fustery Brand of Astemizole; ICN Brand of Astemizole; Janssen Brand of Astemizole; Lesvi Brand of Astemizole; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Ratiopharm Brand of Astemizole; Reig Jofre Brand of Astemizole; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Vita Brand of Astemizole; R 42512; [3H]Astemizole; Alonga, Astemizol; Astemizol [INN-Spanish]; Astemizolum [INN-Latin]; HISMANAL (TN); Hismanal (TN); MJD-30; Nono-Nastizol A; Novo-mastizol A; Ratiopharm, Astemizol; Astemizole [USAN:BAN:INN]; GNF-PF-2461; Astemizole (JAN/USP/INN); Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole",Antiallergic Agents,Small molecule,"1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)",GXDALQBWZGODGZ-UHFFFAOYSA-N,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,68844-77-9,C28H31FN4O,2896,CA08: Vasomotor/allergic rhinitis
D0116,Atazanavir,148192,"198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide",Anti-Hiv Agents,Small molecule,"1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1",AXRYRYVKAWYZBR-GASGPIRDSA-N,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,198904-31-3,C38H52N6O7,37924,1C60-1C62: Human immunodeficiency virus disease
D0117,Atenolol,2249,"Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide",Antihypertensive Agents,Small molecule,"1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)",METKIMKYRPQLGS-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,29122-68-7,C14H22N2O3,2904,BA00-BA04: Hypertension
D0118,Atezolizumab,.,.,Antineoplastics/Anti-Pd-1 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2C30: Melanoma; 2C60-2C6Y: Breast cancer; 2C94: Bladder cancer; 2B91: Colorectal cancer; 2B33: Malignant haematopoietic neoplasm; 2A37: Myelodysplastic syndrome; 2C90: Renal cell carcinoma; 2B60-2D01: Squamous cell carcinoma; 2C92: Ureteral cancer; 2C12: Liver cancer; 2C73: Ovarian cancer; 2C82: Prostate cancer; 2A60: Acute myeloid leukaemia; 2A80: Follicular lymphoma; 2B72: Stomach cancer; 2A83: Multiple myeloma; 2C10: Pancreatic cancer; 2C25: Lung cancer; 2A00-2F9Z: Solid tumour/cancer; CA02-CB40: Ulcer; 2C25: Non-small cell lung cancer
D0119,Atomoxetine,54841,Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine,Cns Stimulants/Adrenergic Uptake Inhibitors,Small molecule,"1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1",VHGCDTVCOLNTBX-QGZVFWFLSA-N,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,83015-26-3,C17H21NO,127342,6A05: Attention deficit hyperactivity disorder
D0120,Atorvastatin,60823,"Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1",XUKUURHRXDUEBC-KAYWLYCHSA-N,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,134523-00-5,C33H35FN2O5,39548,BA00-BE2Z: Cardiovascular disease
D0121,Atovaquone,74989,"Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ",Antifungal Agents,Small molecule,"1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2",BSJMWHQBCZFXBR-UHFFFAOYSA-N,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,94015-53-9,C22H19ClO3,575568,1F29-1F2F: Fungal infection
D0122,Atracurium,47319,"Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate",Neuromuscular Blocking Agents,Small molecule,"1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2",YXSLJKQTIDHPOT-UHFFFAOYSA-N,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,64228-79-1,C53H72N2O12+2,2914,9A76-9A78: Corneal disease
D0123,Atropine,174174,"dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate",Antiarrhythmic Agents,Small molecule,"1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?",RKUNBYITZUJHSG-PJPHBNEVSA-N,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,51-55-8,C17H23NO3,16684,NE6Z: Unspecific substance harmful effect
D0124,Atropine (ophthalmic),174174,"dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate",Antiarrhythmic Agents,Small molecule,"1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?",RKUNBYITZUJHSG-PJPHBNEVSA-N,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,51-55-8,C17H23NO3,16684,NE6Z: Unspecific substance harmful effect
D0125,Attapulgite,56842194,"Parepectolin; Palygorskit; Palygorskite; Actapulgite; Permagel; Attagel; Rheaban; Attasorb; Attacote; Attaclay; Diluex; Zeogel; Toxi-sorb bolus; Clay, attapulgite; Pharmasorb-colloidal; Attagel 40; Attagel 50; Attagel 150; Toxi-sorb calf bolus; Attapulgite-type clay; Min-U-Gel FG; Palygorskit [German]; Attaclay X 250; RVM-FG; Min-U-Gel 200; Min-U-Gel 400; 200U/P-Rvm; Palygorskite fibres (&lt;5 um); Attapulgite, activated [USP]; HSDB 410; Polygorskite fibers (&gt; 5 um in length); X 250; Long palygorskite (attapulgite) fibres (&gt;5 um)",Antidiarrheals,Small molecule,1S/2Al.2Mg.15H2O.4Si/h;;;;15*1H2;;;;/p-1,DGMCGTFMFPEQLT-UHFFFAOYSA-M,O.O.O.O.O.O.O.O.O.O.O.O.O.O.[OH-].[Mg].[Mg].[Al].[Al].[Si].[Si].[Si].[Si],12174-11-7,Al2H29Mg2O15Si4-,.,ME05: Bowel habit change
D0126,Auranofin,24199313,"Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate",Antirheumatics,Small molecule,"1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1",AUJRCFUBUPVWSZ-UHFFFAOYSA-M,CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+],34031-32-8,C20H34AuO9PS,.,FA2Z: Inflammatory arthropathy
D0127,Aurothioglucose,454937,AUROTHIOGLUCOSE; HMS3262I11; LP00685,Antirheumatics,Small molecule,"1S/C6H12O5S.Au/c7-1-2-3(8)4(9)5(10)6(12)11-2;/h2-10,12H,1H2;/q;+1/p-1/t2-,3-,4+,5-,6?;/m1./s1",XHVAWZZCDCWGBK-BMZZJELJSA-M,C(C1C(C(C(C(O1)[S-])O)O)O)O.[Au+],12192-57-3,C6H11AuO5S,.,FA20: Rheumatoid arthritis
D0128,Avanafil,9869929,Stendra (TN),Impotence Agents,Small molecule,"1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1",WEAJZXNPAWBCOA-INIZCTEOSA-N,COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl,330784-47-9,C23H26ClN7O3,66876,HA00-HA01: Sexual dysfunction
D0129,Avapritinib,118023034,"1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine",Multikinase Inhibitors,Small molecule,"1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1",DWYRIWUZIJHQKQ-SANMLTNESA-N,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,1703793-34-3,C26H27FN10,.,2A21: Mastocytosis; 2B5B: Gastrointestinal stromal tumour
D0130,Avatrombopag,9852519,AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542,Platelet-Stimulating Agents,Small molecule,"1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)",OFZJKCQENFPZBH-UHFFFAOYSA-N,C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl,570406-98-3,C29H34Cl2N6O3S2,.,3B64: Thrombocytopenia
D0131,Avibactam,9835049,"Avibactam; Avibactam free acid; NXL104; AVE-1330A free acid; 1192500-31-4; Avibactam (free acid); UNII-7352665165; CHEMBL1689063; CHEBI:85984; [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; 396731-14-9; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; (1R,2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; Avibactam [USAN:INN]; Nxl-104 free acid; SCHEMBL1666807; GTPL10761; AMY24028; AVI; ZINC9302239; BDBM50339145; CS-0593; DB09060; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; HY-14879; E80372; Q15410251; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octan-2-carboxamide; SULFURIC ACID, MONO[(1R,2S,5R)-2-(AMINOCARBONYL)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCT-6-YL] ESTER",Cephalosporins/Beta-Lactamase Inhibitors,Small molecule,"InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1",NDCUAPJVLWFHHB-UHNVWZDZSA-N,C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N,.,C7H11N3O6S,.,.
D0132,Axicabtagene ciloleucel,.,.,Antineoplastics,Autologous cell transplant,.,.,.,.,.,.,2A85: Mature B-cell lymphoma; 2B33: Malignant haematopoietic neoplasm; 2A81: Diffuse large B-cell lymphoma; 2A80: Follicular lymphoma
D0133,Axitinib,6450551,"AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)",Antineoplastics,Small molecule,"1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,319460-85-0,C22H18N4OS,66910,2C90: Renal cell carcinoma
D0134,Azacitidine,9444,"Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC",Antineoplastics,Small molecule,"1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",NMUSYJAQQFHJEW-KVTDHHQDSA-N,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,320-67-2,C8H12N4O5,2038,2A37: Myelodysplastic syndrome
D0135,Azatadine,19861,"Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine",Antihistamines,Small molecule,"1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3",SEBMTIQKRHYNIT-UHFFFAOYSA-N,CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1,3964-81-6,C20H22N2,2946,CA08: Vasomotor/allergic rhinitis
D0136,Azathioprine,2265,"Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine",Immunosuppressive Agents,Small molecule,"1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)",LMEKQMALGUDUQG-UHFFFAOYSA-N,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],446-86-6,C9H7N7O2S,2948,NE84: Transplant rejection
D0137,Azelastine (nasal),2267,Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one,Antiallergic Agents,Small molecule,"1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3",MBUVEWMHONZEQD-UHFFFAOYSA-N,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,58581-89-8,C22H24ClN3O,2950,9A60: Conjunctiva disorder
D0138,Azilsartan medoxomil,135409642,TAK 491,Antihypertensive Agents,Small molecule,"1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)",QJFSABGVXDWMIW-UHFFFAOYSA-N,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C,863031-21-4,C30H24N4O8,68845,BA00-BA04: Hypertension
D0139,Azithromycin,447043,azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955,Macrolides,Small molecule,"1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1",MQTOSJVFKKJCRP-BICOPXKESA-N,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,83905-01-5,C38H72N2O12,2955,1A61-1A6Z: Syphilis
D0140,Aztreonam,5742832,"Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid",Antibiotics,Small molecule,"1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1",WZPBZJONDBGPKJ-VEHQQRBSSA-N,CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N,78110-38-0,C13H17N5O8S2,161680,1A00-1C4Z: Bacterial infection
D0141,Bacampicillin,441397,"Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester",Antibiotics,Small molecule,"1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1",PFOLLRNADZZWEX-FFGRCDKISA-N,CCOC(=O)OC(C)OC(=O)C1C(SC2N1C(=O)C2NC(=O)C(C3=CC=CC=C3)N)(C)C,50972-17-3,C21H27N3O7S,2968,1A00-1C4Z: Bacterial infection
D0142,Bacitracin,10909430,"Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA",Antibiotics,Small molecule,"1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1",CLKOFPXJLQSYAH-ABRJDSQDSA-N,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,1405-87-4,C66H103N17O16S,35862,1F28-1G0Z: Skin and skin-structure infection
D0143,Baclofen,2284,"Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA;  ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid",Muscle Relaxants,Small molecule,"1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)",KPYSYYIEGFHWSV-UHFFFAOYSA-N,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,1134-47-0,C10H12ClNO2,2972,8A40: Multiple sclerosis; LD55: Fragile X chromosome
D0144,Baloxavir marboxil,124081896,UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527,Antiviral Agents,Small molecule,"1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1",RZVPBGBYGMDSBG-GGAORHGYSA-N,COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F,1985606-14-1,C27H23F2N3O7S,.,1E30-1E32: Influenza
D0145,Balsalazide,54585,"Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid",Antiinflammatory Agents,Small molecule,"1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)",IPOKCKJONYRRHP-UHFFFAOYSA-N,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,80573-04-2,C17H15N3O6,267413,DD72: Indeterminate colitis
D0146,Baricitinib,44205240,"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant",Antirheumatics,Small molecule,"1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)",XUZMWHLSFXCVMG-UHFFFAOYSA-N,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,1187594-09-7,C16H17N7O2S,95341,FA20: Rheumatoid arthritis
D0147,Basiliximab,.,Simulect (TN),Immunomodulatory Agents,Monoclonal antibody,.,.,.,.,.,.,NE84: Transplant rejection
D0148,Beclomethasone dipropionate,21700,"BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; 5534-09-8; Beclovent; Beconase; Vancenase; Beclazone; Becloforte; Beclomet; Beclorhinol; Propaderm; Sanasthmax; Sanasthmyl; Vanceril; Aerobec; Aldecin; Beclacin; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Qvar; QNASL; Beconase AQ; SCH 18020W; Beclate; Becodisks; Benconase; Propaderm Forte; CHEBI:3002; (11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione; Inalone O; Inalone R; UNII-5B307S63B2; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Chloro-11beta-hydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 5B307S63B2; Becloturmant; Respocort; Anceron; Becloval; [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate; Viarex; Alanase; Aldecina; Aldecine; Atomase; Rhinosol; Turbinal; Ventolair; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Rhino Clenil; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-[2-(propionyloxy)acetyl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate; 9-chloro-16beta-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate; Qvar 80; Vanceril Double Strength; Beconasol; Inalone; Menaderm; QVAR 40; MFCD00135613; NSC-755901; Beclovent (TN); NCGC00094596-03; Vanceril (TN); Beclazone 250; Prestwick_990; EINECS 226-886-0; KW-053; Qnasl (TN); Beclometasone dipropionato; Prestwick0_000855; Prestwick1_000855; Prestwick2_000855; Prestwick3_000855; beclomethasone-dipropionate; SCHEMBL6890; DSSTox_CID_28656; DSSTox_RID_82926; Propionic acid beclomethasone; DSSTox_GSID_48730; BSPBio_000869; MLS002154034; SPBio_002790; BPBio1_000957; GTPL5894; CHEMBL1200500; DTXSID3048730; SCH 8020W; SGX-201; SGX-202; SGX-203; Beclomethasone dipropionate (USP); HMS1570L11; HMS2097L11; HMS2235O23; HMS3259H03; HMS3714L11; Beclometasone dipropionate (JP17); 9-Chloro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; beclomethasone dipropionate anhydrous; Pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-; ZINC3938744; Tox21_113168; HY-13571A; s3078; AKOS015951275; AC-2159; CCG-220855; CS-1503; DB00394; NC00610; NSC 755901; Beclomethasone dipropionate [USAN:USP]; NCGC00179392-01; (11beta,16beta)-9-chloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; CPD001233361; Pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-; Pregna-1,4-diene-3,20-dione, 9-chloro-16-beta-methyl-11-beta,17,21-trihydroxy-, 17,21-dipropionate; SMR001233361; CAS-5534-09-8; B4464; C07813; D00689; D89082; 534B098; Q421475; BRD-K97810537-001-03-7; BRD-K97810537-001-13-6; Beclomethasone dipropionate, analytical standard, for drug analysis; Beclometasone (beclomethasone) dipropionate, British Pharmacopoeia (BP) Assay Standard; Beclomethasone dipropionate, anhydrous, European Pharmacopoeia (EP) Reference Standard; Beclomethasone Dipropionate, Pharmaceutical Secondary Standard; Certified Reference Material; Beclomethasone dipropionate, United States Pharmacopeia (USP) Reference Standard; [(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; 2-[(1R,2S,10S,11S,13S,14R,15S,17S)-1-chloro-17-hydroxy-2,13,15-trimethyl-5-oxo-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate; 9alpha-chloro-16beta-methyl-3,20-dioxo-1,4-pregnadiene-11beta,17,21-triol 17,21-dipropionate; Beclometasone dipropionate for peak identification, European Pharmacopoeia (EP) Reference Standard; Beclometasone dipropionate for system suitability, European Pharmacopoeia (EP) Reference Standard",Inhaled Corticosteroids,Small molecule,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",KUVIULQEHSCUHY-XYWKZLDCSA-N,CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)Cl)O)C)C)OC(=O)CC,.,C28H37ClO7,.,.
D0149,Bedaquiline,5388906,SIRTURO (TN),Antituberculosis Agents,Small molecule,"1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1",QUIJNHUBAXPXFS-XLJNKUFUSA-N,CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O,843663-66-1,C32H31BrN2O2,72292,MG50-MG52: Antimicrobial drug resistance
D0150,Belantamab mafodotin,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A83: Multiple myeloma
D0151,Belatacept,.,Nulojix (TN); Belatacept (USAN/INN),Selective Immunosuppressants,Protein/peptide,.,.,.,.,.,.,NE84: Transplant rejection
D0152,Belimumab,.,Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN),Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,4A40: Lupus erythematosus
D0153,Belinostat,6918638,Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684,Antineoplastics,Small molecule,"1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",NCNRHFGMJRPRSK-MDZDMXLPSA-N,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,866323-14-0,C15H14N2O4S,61076,2A00-2F9Z: Solid tumour/cancer; 2B33: Malignant haematopoietic neoplasm; 2A90: Mature T-cell lymphoma
D0154,Belladonna,265028,BELLADONNA TOTAL ALKALOIDS; Belladonnine sulfate; 510-25-8; beta-Belladonnine;Belladonna Alkaloids,Anticholinergic Agents/Antispasmodics,Small molecule,"InChI=1S/C34H42N2O4/c1-35-23-12-13-24(35)19-27(18-23)39-32(37)30-16-17-34(22-8-4-3-5-9-22,31-11-7-6-10-29(30)31)33(38)40-28-20-25-14-15-26(21-28)36(25)2/h3-11,23-28,30H,12-21H2,1-2H3",GERIGMSHTUAXSI-UHFFFAOYSA-N,CN1C2CCC1CC(C2)OC(=O)C3CCC(C4=CC=CC=C34)(C5=CC=CC=C5)C(=O)OC6CC7CCC(C6)N7C,.,C34H42N2O4,.,1A40: Infectious gastroenteritis/colitis
D0155,Bempedoic acid,10472693,"ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-",Antihyperammonia Agents,Small molecule,"1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)",HYHMLYSLQUKXKP-UHFFFAOYSA-N,CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O,738606-46-7,C19H36O5,149601,BA00-BE2Z: Cardiovascular disease; 5C80: Hyper-lipoproteinaemia
D0156,Benazepril,5362124,"Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid",Antihypertensive Agents,Small molecule,"1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1",XPCFTKFZXHTYIP-PMACEKPBSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O,86541-75-5,C24H28N2O5,3011,BA00-BA04: Hypertension
D0157,Bendamustine,65628,"Bendamustine; 16506-27-7; 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid; Bendamustine free base; 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid; UNII-9266D9P3PQ; Treanda (TN); SDX 105; 9266D9P3PQ; 16506-27-7 (free base); Ribomustine; Bendeka; Levact; NCGC00181170-01; 1H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-; DSSTox_CID_26888; DSSTox_RID_81991; DSSTox_GSID_46888; Bendamustinum [Latin]; Bendamustina; Bendamustina [Spanish]; Bendamustinum; CAS-16506-27-7; Bendamustine [INN:BAN]; 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-; HSDB 7763; Bendamustine (INN); SCHEMBL26319; CHEMBL487253; GTPL7478; SDX105; DTXSID2046888; NIOSH/DD6304600; CHEBI:135515; BDBM173621; 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid; BCP04111; ZINC4214955; Tox21_112771; 2-Benzimidazolebutyric acid, 5-(bis(2-chloroethyl)amino)-1-methyl-; MFCD00866481; s5939; 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid; AKOS022181343; omega-(1-Methyl-5-bis(beta-chloroethyl)aminobenzimidazole-(2)-butyric acid; Tox21_112771_1; BCP9000389; DB06769; SDCCGSBI-0633739.P001; NCGC00181170-02; NCGC00181170-03; NCGC00181170-10; AC-22488; AS-73546; HY-13567; BCP0726000100; CS-0007192; DD63046000; FT-0742187; D07501; AB01273966-01; AB01273966-02; AB01273966_03; US9096627, CY190602; 506B277; Q425745; J-010179; BRD-K17068645-003-02-6; 5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzimidazole-2-butanoic acid; 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}butanoic acid",Antineoplastics,Small molecule,"InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)",YTKUWDBFDASYHO-UHFFFAOYSA-N,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,.,C16H21Cl2N3O2,.,.
D0158,Bendroflumethiazide,2315,"Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide",Antihypertensive Agents,Small molecule,"1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)",HDWIHXWEUNVBIY-UHFFFAOYSA-N,C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2,73-48-3,C15H14F3N3O4S2,3013,BA00: Essential hypertension
D0159,Benzalkonium (topical),2330,"Benzalkonium; Benzyldimethyltridecylammonium; 47309-59-1; benzyl-dimethyl-tridecylazanium; SPBio_001472; Benzalkonium ion; Benzalkonium cation; Spectrum_001442; Spectrum2_001566; Spectrum3_001597; Spectrum4_000861; Spectrum5_001097; Benzyldimethyltridecylaminium; BSPBio_003194; KBioGR_001521; KBioSS_001922; DivK1c_000825; SCHEMBL7125738; CHEMBL1187417; KBio1_000825; KBio2_001922; KBio2_004490; KBio2_007058; KBio3_002694; CHEBI:188978; NINDS_000825; ZINC8214735; IDI1_000825; QTL1_000011; N-Benzyl-N,N-dimethyltridecan-1-aminium; NCGC00178214-01; NCGC00178214-02; NCGC00178214-04; SBI-0051833.P002; FT-0622628; AB00053823_02",Topical Anesthetics,Small molecule,"InChI=1S/C22H40N/c1-4-5-6-7-8-9-10-11-12-13-17-20-23(2,3)21-22-18-15-14-16-19-22/h14-16,18-19H,4-13,17,20-21H2,1-3H3/q+1",VVZBFOKBSDGVGZ-UHFFFAOYSA-N,CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,.,C22H40N+,.,.
D0160,Benzatropine,1201549,"Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI)",Antiparkinson Agents,Small molecule,"1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?",GIJXKZJWITVLHI-YOFSQIOKSA-N,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,86-13-5,C21H25NO,3048,8A00: Parkinsonism
D0161,Benzhydrocodone,49836084,"Benzhydrocodone; UNII-75MS0AAZ9I; 75MS0AAZ9I; 1259440-61-3; Benzhydrocodone [USAN:INN]; Benzhydrocodone (USAN/INN); D10612; Q19596036; 6,7-Didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6-yl benzoate; Morphinan-6-ol, 6,7-didehydro-4,5-epoxy-3-methoxy-17-methyl-, 6-benzoate, (5alpha)-",Narcotic Analgesics,Small molecule,"InChI=1S/C25H25NO4/c1-26-13-12-25-17-9-11-20(29-24(27)15-6-4-3-5-7-15)23(25)30-22-19(28-2)10-8-16(21(22)25)14-18(17)26/h3-8,10-11,17-18,23H,9,12-14H2,1-2H3/t17-,18+,23-,25-/m0/s1",VPMRSLWWUXNYRY-PJCFOSJUSA-N,CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=CC4)OC(=O)C6=CC=CC=C6,.,C25H25NO4,.,.
D0162,Benznidazole,31593,BENZNIDAZOLE; Radanil; Benzonidazole; 22994-85-0; Benznidazol; benzonidazol; Benznidazolum;Ro 07-1051; Rochagan; UNII-YC42NRJ1ZD; Benznidazolum [INN-Latin]; Benznidazol [INN-Spanish]; Ro 71051; NSC 299972; Benznidazole [INN]; CCRIS 2200,Trypanocidal Agents,Small molecule,"1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)",CULUWZNBISUWAS-UHFFFAOYSA-N,C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-],22994-85-0,C12H12N4O3,133833,1F53: Chagas disease; 1D51-1F53: Trypanosomiasis
D0163,Benzocaine (topical),2337,"Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester",Anesthetics,Small molecule,"1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3",BLFLLBZGZJTVJG-UHFFFAOYSA-N,CCOC(=O)C1=CC=C(C=C1)N,34584,C9H11NO2,116735,9A76-9A78: Corneal disease
D0164,Benzonatate,7699,"Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester",Antitussives,Small molecule,"1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3",MAFMQEKGGFWBAB-UHFFFAOYSA-N,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,104-31-4,C30H53NO11,3032,MD12: Cough
D0165,Benzphetamine,5311017,"Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine",Cns Stimulants,Small molecule,"1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1",YXKTVDFXDRQTKV-HNNXBMFYSA-N,CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2,156-08-1,C17H21N,3044,5B80-5B81: Obesity
D0166,Benzthiazide,2343,"Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",Antihypertensive Agents,Small molecule,"1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)",NDTSRXAMMQDVSW-UHFFFAOYSA-N,C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N,91-33-8,C15H14ClN3O4S3,3047,BA00: Essential hypertension
D0167,Benzylpenicillin,5904,penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid,Antibiotics,Small molecule,"1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",JGSARLDLIJGVTE-MBNYWOFBSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,61-33-6,C16H18N2O4S,18208,.
D0168,Benzylpenicillin (potassium),5904,penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid,Antibiotics,Small molecule,"1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",JGSARLDLIJGVTE-MBNYWOFBSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,61-33-6,C16H18N2O4S,18208,.
D0169,Benzylpenicillin (sodium),5904,penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid,Antibiotics,Small molecule,"1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",JGSARLDLIJGVTE-MBNYWOFBSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,61-33-6,C16H18N2O4S,18208,.
D0170,Bepridil,2351,Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline,Antiarrhythmic Agents,Small molecule,"1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3",UIEATEWHFDRYRU-UHFFFAOYSA-N,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3,64706-54-3,C24H34N2O,3061,BA40: Angina pectoris
D0171,Berotralstat,137528262,"UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide",Hereditary Angioedema Agents,Small molecule,"1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1",UXNXMBYCBRBRFD-MUUNZHRXSA-N,C1CC1CNC(C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N,1809010-50-1,C30H26F4N6O,.,4A00: Innate/adaptive immunodeficiency
D0172,Betamethasone,9782,"betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",UREBDLICKHMUKA-DVTGEIKXSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,378-44-9,C22H29FO5,3077,1A00-CA43: Postoperative inflammation
D0173,Betaxolol,2369,Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol,Antihypertensive Agents,Small molecule,"1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3",NWIUTZDMDHAVTP-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O,63659-18-7,C18H29NO3,3082,BA00-BA04: Hypertension
D0174,Betaxolol (ophthalmic),2369,Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol,Antihypertensive Agents,Small molecule,"1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3",NWIUTZDMDHAVTP-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O,63659-18-7,C18H29NO3,3082,BA00-BA04: Hypertension
D0175,Bethanechol,2370,"Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium",Parasympathomimetics,Small molecule,"1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1",NZUPCNDJBJXXRF-UHFFFAOYSA-O,CC(C[N+](C)(C)C)OC(=O)N,674-38-4,C7H17N2O2+,3084,MF50: Abnormal micturition
D0176,Betrixaban,10275777,Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3,Anticoagulants/Factor Xa Inhibitors,Small molecule,"1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)",XHOLNRLADUSQLD-UHFFFAOYSA-N,CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl,330942-05-7,C23H22ClN5O3,140421,BD72: Venous thromboembolism; 8B1Z: Cerebral ischaemia
D0177,Bevacizumab,.,Bevacizumab (ophthalmic slow-release tissue tablet),Vegf/Vegfr Inhibitors,Monoclonal antibody,.,.,.,.,.,.,2A00-2F9Z: Solid tumour/cancer; 2B91: Colorectal cancer; 2C25: Lung cancer; 2D50-2E2Z: Metastatic tumour; 2C73: Ovarian cancer
D0178,Bexarotene,82146,"Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA",Antineoplastics,Small molecule,"1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)",NAVMQTYZDKMPEU-UHFFFAOYSA-N,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,153559-49-0,C24H28O2,50859,2B01: Mycosis fungoides
D0179,Bexarotene (topical),82146,"Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA",Antineoplastics,Small molecule,"1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)",NAVMQTYZDKMPEU-UHFFFAOYSA-N,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,153559-49-0,C24H28O2,50859,2B01: Mycosis fungoides
D0180,Bicalutamide,2375,"Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide",Antineoplastics,Small molecule,"1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)",LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,90357-06-5,C18H14F4N2O4S,91617,2C82: Prostate cancer
D0181,Bictegravir,90311989,"Bictegravir; 1611493-60-7; GS-9883; GS-9883-01; UNII-8GB79LOJ07; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 8GB79LOJ07; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide; Bictegravir [INN]; Bictegravir [USAN:INN]; bictegravirum; GS 9883; Bictegravir (USAN/INN); CHEMBL3989866; SCHEMBL15914278; GTPL11575; CHEBI:172943; BDBM330048; AMY12383; BCP25703; EX-A3161; GS9883; s5911; DB11799; DT-0020; 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-; AC-30658; HY-17605; CS-0014685; D10909; N16998; US9663528, 42; A902376; Q27270406; GS-9883; GS 9883; GS9883; GS-9883-01; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0?,?]hexadeca-4,7-diene-7-carboxamide; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide",Antiviral Agents,Small molecule,"InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1",SOLUWJRYJLAZCX-LYOVBCGYSA-N,C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F,.,C21H18F3N3O5,.,.
D0182,Binimetinib,10288191,"606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME",Multikinase Inhibitors,Small molecule,"1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,606143-89-9,C17H15BrF2N4O3,145371,2C30: Melanoma
D0183,Biperiden,2381,"Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol",Antiparkinson Agents,Small molecule,"1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2",YSXKPIUOCJLQIE-UHFFFAOYSA-N,C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,514-65-8,C21H29NO,3112,8A00: Parkinsonism
D0184,Bisacodyl,2391,"bisacodyl; 603-50-9; Dulcolax; Bicol; Durolax; Brocalax; Stadalax; Sanvacual; Hillcolax; Fenilaxan; Endokolat; Theralax; Dulcolan; Nigalax; Laxorex; Laxadin; Neolax; Laxine; Ivilax; Eulaxan; Ulcolax; Telemin; Laxans; Godalax; Zetrax; Pyrilax; Sk-bisacodyl; Laxanin N; Bisacodylum; Bisacodilo; Deficol; LACO; LA96a; Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester); HalfLytely; Bisacodylum [INN-Latin]; Bisacodilo [INN-Spanish]; (Pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate; Bis(p-acetoxyphenyl)-2-pyridylmethane",Laxatives,Small molecule,"1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3",KHOITXIGCFIULA-UHFFFAOYSA-N,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,603-50-9,C22H19NO4,3125,DD91: Irritable bowel syndrome
D0185,Bismuth subcitrate potassium,53297469,"Bismuth subcitrate potassium; 880149-29-1; Bismuth subcitrate potassium (USAN); BISMUTHSUBCITRATEPOTASSIUM; s4093; CCG-270467; A14937; D09739; AB01568270_01; bismuth;pentapotassium;2-hydroxypropane-1,2,3-tricarboxylate",Bismuth Salt Agents,Small molecule,"InChI=1S/2C6H8O7.Bi.5K/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;;/q;;+3;5*+1/p-6",PSMGOGIPZBBORN-UHFFFAOYSA-H,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[K+].[K+].[K+].[K+].[K+].[Bi+3],.,C12H10BiK5O14+2,.,.
D0186,Bismuth subgallate,16682999,"BISMUTH SUBGALLATE; 99-26-3; Bismuthsubgallate; Wismutgallathydroxid; Gallic acid bismuth basic salt; bismuth gallate; Dermatol puder; 2,7-dihydroxy-1,3,2-benzodioxabismole-5-carboxylic acid; 1,3,2-Benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy-; basic bismuth 3,4,5-trihydroxybenzoate; NCGC00166280-01; Bismuth subgallas; Bismutum subgallicum; Basic bismuth gallate; Wismutgallat, basisches; Caswell No. 098B; 2,7-dihydroxybenzo[d][1,3,2]dioxabismole-5-carboxylic acid; Dermatol; C7H5BiO6; Bismuth(III) gallate basic hydrate; EINECS 202-742-2; EPA Pesticide Chemical Code 098601; bismuth-subgallate; Dermatol (TN); Bismuth subgallate [USAN:USP:JAN]; basisches Wismutgallat; Bismuth 3,4,5-trihydroxybenzoate, basic; Dihydroxy(3,4,5-trihydroxybenzoato-O')bismuth; SCHEMBL7892; DSSTox_CID_26588; DSSTox_RID_81746; DSSTox_GSID_46588; Bismuth, dihydroxy(3,4,5-trihydroxybenzoato-O')-; DTXSID3046588; Bismuth subgallate (JP17/USP); CHEBI:31292; BISMUTH(III) GALLATE, BASIC; HY-B1560; Tox21_112388; MFCD00044980; MFCD01632692; DB13909; CAS-99-26-3; NCGC00166280-02; CS-0013442; V1743; D01398; E75771",Antidiarrheals,Small molecule,"InChI=1S/C7H6O5.Bi.H2O/c8-4-1-3(7(11)12)2-5(9)6(4)10;;/h1-2,8-10H,(H,11,12);;1H2/q;+2;/p-2",XXCBNHDMGIZPQF-UHFFFAOYSA-L,C1=C(C=C2C(=C1O)O[Bi]O2)C(=O)O.O,.,C7H6BiO6,.,.
D0187,Bismuth subsalicylate,16682734,"BISMUTH SUBSALICYLATE; 14882-18-9; Bismuth oxysalicylate; Bismuth oxide salicylate; Wismutsubsalicylat; 4H-1,3,2-Benzodioxabismin-4-one, 2-hydroxy-; Basic bismuth salicylate; Bismuthi subsalicylas; Bismutum subsalicylicum; Bismuth(III) subsalicylate; pink bismuth; Stabisol; Vismut; Spiromak forte; NCGC00166299-01; Trigastronol; 2-Hydroxy-benzo[1,3,2]dioxabismin-4-one; C7H5BiO4; Bismuth oxysalicylate;Bismuth(III) salicylate basic; 2-hydroxy-2H,4H-benzo[d]1,3-dioxa-2-bismacyclohexan-4-one; Bismuth salicylate, basic; Wismutsalicylat, basisches; Bismuth, oxo(salicylato)-; Bismogenol tosse inj; CCRIS 4751; HSDB 332; Salicylic acid basic bismuth salt; Salicylic acid, bismuth basic salt; EINECS 238-953-1; Bismuth, (2-hydroxybenzoato-O1,O2)oxo-; Bismuth, (2-hydroxybenzoato-O(1),O(2))oxo-; Wismutoxidsalicylat; 2-Hydroxybenzoic acid bismuth (3+) salt, basic; bismuth-subsalicylate; MFCD00085368; Pepto-bismol (TN); Bismuth subsalicylate [USAN:USP:JAN]; (2-Hydroxybenzoato-O(sup 1))-oxobismuth; DSSTox_CID_4622; 2-Hydroxy-4H-1,3,2-benzodioxabismin-4-one; EC 238-953-1; DSSTox_RID_77471; DSSTox_GSID_24622; Bismuth subsalicylate [USAN); MLS000069654; DTXSID6024622; Bismuth subsalicylate (JAN/USP); CHEBI:261649; HMS2093H13; Pharmakon1600-01505412; HY-B0550; Tox21_112398; NSC759117; AKOS015888405; CCG-213424; DB01294; NSC 759117; NSC-759117; NCGC00166299-03; 2-hydroxy-1,3,2-benzodioxabismin-4-one; AS-65783; SMR000059234; SBI-0206855.P001; CAS-14882-18-9; V1775; C07870; D00728; AB00489978_02; Bismuth, (2-hydroxybenzoato-O1,O2)oxo- (9CI); 2-hydroxy-4H-benzo[d][1,3,2]dioxabismin-4-one; SR-05000001933; J-008518; SR-05000001933-1; Bismuth(III) subsalicylate, 99.9% trace metals basis; Bismuth(III) salicylate basic, purum, >=97.0% (KT); Bismuth subsalicylate, United States Pharmacopeia (USP) Reference Standard; 87-27-4",Antidiarrheals,Small molecule,"InChI=1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+2;/p-2",QBWLKDFBINPHFT-UHFFFAOYSA-L,C1=CC=C2C(=C1)C(=O)O[Bi]O2.O,.,C7H6BiO4,.,.
D0188,Bisoprolol,2405,Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol,Antihypertensive Agents,Small molecule,"1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3",VHYCDWMUTMEGQY-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O,66722-44-9,C18H31NO4,3127,BA00-BA04: Hypertension
D0189,Bivalirudin,16129704,128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu,Antithrombotic Agents,Small molecule,"1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1",OIRCOABEOLEUMC-GEJPAHFPSA-N,CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N,128270-60-0,C98H138N24O33,59173,3B64: Thrombocytopenia
D0190,Bleomycin,5360373,BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide,Antineoplastics,Small molecule,"1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1",OYVAGSVQBOHSSS-WXFSZRTFSA-O,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,11056-06-7,C55H84N17O21S3+,.,2B30: Hodgkin lymphoma
D0191,Blinatumomab,.,AMG 103; Blincyto,Antineoplastics/Cd19 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2A85: Mature B-cell lymphoma; 2A81: Diffuse large B-cell lymphoma
D0192,Boceprevir,10324367,"Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide",Protease Inhibitors,Small molecule,"1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1",LHHCSNFAOIFYRV-DOVBMPENSA-N,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,394730-60-0,C27H45N5O5,68621,1E50-1E51: Hepatitis virus infection
D0193,Bortezomib,387447,"179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate",Antineoplastics,Small molecule,"1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,179324-69-7,C19H25BN4O4,52717,2A83: Multiple myeloma; 2B33: Malignant haematopoietic neoplasm; 2A85: Mature B-cell lymphoma
D0194,Bosentan,104865,"Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide",Antihypertensive Agents,Small molecule,"1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)",GJPICJJJRGTNOD-UHFFFAOYSA-N,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,147536-97-8,C27H29N5O6S,51450,BB01: Pulmonary hypertension
D0195,Bosutinib,5328940,"SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor  3rd gen)",Antineoplastics,Small molecule,"1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,380843-75-4,C26H29Cl2N5O3,39112,2C60-2C6Y: Breast cancer
D0196,Botulinum toxin type A,.,"Botox; Botulinum A Toxin; Botulinum Neurotoxin A; Botulinum Neurotoxin Type A; Botulinum Toxin A; Botulinum Toxin Type A; botulinum toxin-A; Botulinum Toxins, Type A; Clostridium botulinum A Toxin; Clostridium Botulinum Toxin Type A; Meditoxin; Neuronox; Neurotoxin A, Botulinum; Oculinum; Onabotulinumtoxin A; OnabotulinumtoxinA; Toxin A, Botulinum; Toxin, Botulinum AVistabelVistabex",Muscle Relaxants,Protein/peptide,.,.,.,.,.,.,.
D0197,Botulinum Toxin Type B,.,BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN),Antidystonic Agents,Protein/peptide,.,.,.,.,.,.,8A00: Parkinsonism
D0198,Bremelanotide,9941379,Bremelanotide (USAN/INN); PT-141; Rekynda,Melanocortin Receptor Agonists,Small molecule,"1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1",FFHBJDQSGDNCIV-MFVUMRCOSA-N,CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C,189691-06-3,C50H68N14O10,.,HA00-HA01: Sexual dysfunction; HA00: Hypoactive sexual desire dysfunction
D0199,Brentuximab vedotin,.,Adcetris (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B30: Hodgkin lymphoma
D0200,Bretylium,2431,"Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium",Antiarrhythmic Agents,Small molecule,"1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1",AAQOQKQBGPPFNS-UHFFFAOYSA-N,CC[N+](C)(C)CC1=CC=CC=C1Br,59-41-6,C11H17BrN+,3172,BC71: Ventricular tachyarrhythmia
D0201,Brexanolone,92786,"516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102",Antidepressants,Small molecule,"1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1",AURFZBICLPNKBZ-SYBPFIFISA-N,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,516-54-1,C21H34O2,50169,6E20-6E8Z: Mental/behavioural/neurodevelopmental disorder; 8A04: Tremor-related disorder; 8A66: Status epilepticus; 6A70-6A7Z: Depression
D0202,Brexpiprazole,11978813,Brexpiprazole,Atypical Antipsychotics,Small molecule,"1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)",ZKIAIYBUSXZPLP-UHFFFAOYSA-N,C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,913611-97-9,C25H27N3O2S,134716,6A70-6A7Z: Depression
D0203,Brexucabtagene autoleucel,.,4MD2J2T8SJ; Brexucabtagene autoleucel; Brexucabtagene autoleucel [INN]; Brexucabtagene autoleucel [USAN]; Brexucabtagene autoleucel [WHO-DD]; KTE-X19; UNII-4MD2J2T8SJ,Antineoplastics,Autologous cell transplant,.,.,.,.,.,.,.
D0204,Brigatinib,68165256,1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958,Multikinase Inhibitors,Small molecule,"1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)",AILRADAXUVEEIR-UHFFFAOYSA-N,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,1197953-54-0,C29H39ClN7O2P,.,2C25: Lung cancer; 2A90: Mature T-cell lymphoma
D0205,Brimonidine (ophthalmic),2435,"brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine",Ophthalmic Glaucoma Agents,Small molecule,"1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)",XYLJNLCSTIOKRM-UHFFFAOYSA-N,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,59803-98-4,C11H10BrN5,3175,9C61: Glaucoma
D0206,Brimonidine (topical),2435,"brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine",Ophthalmic Glaucoma Agents,Small molecule,"1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)",XYLJNLCSTIOKRM-UHFFFAOYSA-N,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,59803-98-4,C11H10BrN5,3175,9C61: Glaucoma
D0207,Brinzolamide (ophthalmic),68844,"Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R",Ophthalmic Glaucoma Agents,Small molecule,"1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",HCRKCZRJWPKOAR-JTQLQIEISA-N,CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC,138890-62-7,C12H21N3O5S3,3176,9C61: Glaucoma
D0208,Brivaracetam,9837243,Rikelta; UCB-34714; Brivaracetam (USAN/INN),Anticonvulsants,Small molecule,"1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1",MSYKRHVOOPPJKU-BDAKNGLRSA-N,CCCC1CC(=O)N(C1)C(CC)C(=O)N,357336-20-0,C11H20N2O2,133013,8A61-8A6Z: Epilepsy/seizure; MG30-MG3Z: Pain
D0209,Brodalumab,.,AMG 827,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis; CA23: Asthma
D0210,Bromfenac,60726,Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid,Antiinflammatory Agents,Small molecule,"1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)",ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,91714-94-2,C15H12BrNO3,240107,1A00-CA43: Postoperative inflammation
D0211,Bromfenac (ophthalmic),60726,Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid,Antiinflammatory Agents,Small molecule,"1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)",ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,91714-94-2,C15H12BrNO3,240107,1A00-CA43: Postoperative inflammation
D0212,Bromocriptine,31101,"Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine",Antiparkinson Agents,Small molecule,"1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1",OZVBMTJYIDMWIL-AYFBDAFISA-N,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,25614-03-3,C32H40BrN5O5,3181,8A00: Parkinsonism
D0213,Bromotheophylline,11808,"8-Bromotheophylline; 10381-75-6; Bromotheophylline; Theophylline, 8-bromo-; 8-Bromo-1,3-dimethyl-1H-purine-2,6(3H,9H)-dione; 8-bromo-1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl-; UNII-FZG87K1MQ6; 8-Bromotheophyline; 8-bromo-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; FZG87K1MQ6; 8-bromo-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 8-Bromo-1,3-dimethyl-3,7-dihydro-purine-2,6-dione; CHEMBL316160; MFCD00022664; 8-bromo-1,3-dimethyl-3,7-dihydro-1H-pyrine-2,6-dione; NCGC00167564-01; 1H-Purine-2,6-dione, 8-bromo-3,9-dihydro-1,3-dimethyl-; DSSTox_CID_24768; DSSTox_RID_80459; DSSTox_GSID_44768; CAS-10381-75-6; EINECS 233-846-6; 8-bromo-theophylline; NSC 164940; Oprea1_299436; Oprea1_509676; MLS004754491; SCHEMBL237881; DTXSID7044768; AMMD00018; Tox21_112559; BBL012666; BDBM50045345; CCG-19376; MFCD01848460; NSC164940; STK803299; AKOS000274376; AKOS001283003; Tox21_112559_1; ZINC100005670; AM85456; DB14018; GS-5727; HY-W088152; MCULE-1062341165; NSC-164940; NCGC00167564-03; NCGC00167564-04; SMR002397689; SY023545; DB-040487; B3456; CS-0130336; FT-0636693; Z3068; EN300-17892; 8-bromanyl-1,3-dimethyl-7H-purine-2,6-dione; H10528; AB01300038-01; AB01300038_03; A800812; AF-399/37411012; SR-01000479300; 1H-Purine-2, 8-bromo-3,7-dihydro-1,3-dimethyl-; SR-01000479300-1; W-108837; Q27278353; Z57161790; 8-bromo-1,3-dimethyl-1H-purine-2,6(3H, 7H)-dione; F0807-0406",Diuretics,Small molecule,"InChI=1S/C7H7BrN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)",SKTFQHRVFFOHTQ-UHFFFAOYSA-N,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br,.,C7H7BrN4O2,.,.
D0214,Brompheniramine,6834,"Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine",Antiallergic Agents,Small molecule,"1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",ZDIGNSYAACHWNL-UHFFFAOYSA-N,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2,86-22-6,C16H19BrN2,3183,CA08: Vasomotor/allergic rhinitis
D0215,Budesonide,5281004,"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione",Antiinflammatory Agents,Small molecule,"1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1",VOVIALXJUBGFJZ-KWVAZRHASA-N,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,51333-22-3,C25H34O6,3207,CA23: Asthma
D0216,Budesonide (nasal),5281004,"Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione",Antiinflammatory Agents,Small molecule,"1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1",VOVIALXJUBGFJZ-KWVAZRHASA-N,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,51333-22-3,C25H34O6,3207,CA23: Asthma
D0217,Bumetanide,2471,"Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid",Diuretics,Small molecule,"1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)",MAEIEVLCKWDQJH-UHFFFAOYSA-N,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,28395-03-1,C17H20N2O5S,3213,BD10-BD1Z: Heart failure
D0218,Bupivacaine,2474,"Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide",Anesthetics,Small molecule,"1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",LEBVLXFERQHONN-UHFFFAOYSA-N,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,38396-39-3,C18H28N2O,77431,9A76-9A78: Corneal disease; MG30-MG3Z: Pain
D0219,Buprenorphine,644073,"Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone  (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M",Analgesics,Small molecule,"1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",RMRJXGBAOAMLHD-IHFGGWKQSA-N,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,52485-79-7,C29H41NO4,3216,MG30-MG3Z: Pain; 8A80: Migraine; 6E20-6E8Z: Mental/behavioural/neurodevelopmental disorder
D0220,Bupropion,444,"bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one;  Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone",Antidepressants,Small molecule,"1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3",SNPPWIUOZRMYNY-UHFFFAOYSA-N,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,34911-55-2,C13H18ClNO,3219,6C4A: Nicotine use disorder
D0221,Burosumab,.,Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29,Metabolic Agents,Monoclonal antibody,.,.,.,.,.,.,5C63: Vitamin/non-protein cofactor absorption/transport disorder
D0222,Buspirone,2477,"Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione",Antianxiety Agents,Small molecule,"1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,36505-84-7,C21H31N5O2,3223,6B00-6B0Z: Anxiety disorder
D0223,Busulfan,2478,"Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate",Antineoplastics,Small molecule,"1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3",COVZYZSDYWQREU-UHFFFAOYSA-N,CS(=O)(=O)OCCCCOS(=O)(=O)C,55-98-1,C6H14O6S2,28901,2A20: Myeloproliferative neoplasm
D0224,Butabarbital,2479,"Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione",Antianxiety Agents,Small molecule,"1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)",ZRIHAIZYIMGOAB-UHFFFAOYSA-N,CCC(C)C1(C(=O)NC(=O)NC1=O)CC,125-40-6,C10H16N2O3,3228,7A00-7A0Z: Insomnia
D0225,Butalbital,2481,"Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid",Analgesics,Small molecule,"1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)",UZVHFVZFNXBMQJ-UHFFFAOYSA-N,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,77-26-9,C11H16N2O3,102524,6B00-6B0Z: Anxiety disorder; 8A80-8A84: Headache
D0226,Butorphanol,5361092,"Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL",Analgesics,Small molecule,"1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1",IFKLAQQSCNILHL-QHAWAJNXSA-N,C1CCC2(C3CC4=C(C2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,42408-82-2,C21H29NO2,3242,MG30-MG3Z: Pain
D0227,Cabazitaxel,9854073,Jevtana; Taxoid XRP6258; Jevtana (TN),Antineoplastics/Mitotic Inhibitors,Small molecule,"1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1",BMQGVNUXMIRLCK-OAGWZNDDSA-N,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,183133-96-2,C45H57NO14,63584,2C60-2C6Y: Breast cancer; 2A00-2F9Z: Solid tumour/cancer
D0228,Cabergoline,54746,Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea,Antineoplastics,Small molecule,"1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1",KORNTPPJEAJQIU-KJXAQDMKSA-N,CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C,81409-90-7,C26H37N5O2,3286,5A60-5A61: Pituitary gland disorder
D0229,Cabotegravir,54713659,"Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265",Antiviral Agents,Small molecule,"1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1",WCWSTNLSLKSJPK-LKFCYVNXSA-N,CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,1051375-10-0,C19H17F2N3O5,.,1C60-1C62: Human immunodeficiency virus disease
D0230,Cabozantinib,25102847,Cabometyx; Cometriq,Vegf/Vegfr Inhibitors,Small molecule,"1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,849217-68-1,C28H24FN3O5,72317,2D10: Thyroid cancer; 2C73: Ovarian cancer
D0231,Caffeine,2519,"CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline",Antihypertensive Agents,Small molecule,"1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3",RYYVLZVUVIJVGH-UHFFFAOYSA-N,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,21399,C8H10N4O2,27732,BA21: Orthostatic hypotension
D0232,Calaspargase pegol,.,UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A85: Mature B-cell lymphoma; 2B33: Malignant haematopoietic neoplasm
D0233,Calcifediol,5283731,"Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol",Vitamins,Small molecule,"1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1",JWUBBDSIWDLEOM-DTOXIADCSA-N,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,19356-17-3,C27H44O2,17933,5B55-5B5F: Vitamin deficiency
D0234,Calcitriol,5280453,"calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101;  Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)",Vitamins,Small molecule,"1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1",GMRQFYUYWCNGIN-NKMMMXOESA-N,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,32222-06-3,C27H44O3,17823,LC30: Hair/hair growth developmental defect
D0235,Calcium acetate,6116,Phoslo; Phoslo Gelcaps; Phoslyra; Eliphos,Phosphate Binders,Small molecule,"1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",VSGNNIFQASZAOI-UHFFFAOYSA-L,CC(=O)[O-].CC(=O)[O-].[Ca+2],62-54-4,C4H6CaO4,3310,5C64: Mineral absorption/transport disorder
D0236,Calcium carbonate,10112,"Aragonite; CALCIUM CARBONATE; 471-34-1; Limestone; Calcite; Chalk; Carbonic acid calcium salt (1:1); Aeromatt; Calcium carbonate (1:1); Calofort U; Precipitated calcium carbonate; calciumcarbonate; Calcite (Ca(Co3)); 1317-65-3; CaCO3; Calciumcarbonat; Kalziumkarbonat; Calcium carbonate slurry; Calcium carbonate, powder; kohlensaurer Kalk; UNII-H0G9379FGK; carbonato de calcio; Chalk, Precipitated; carbonate de calcium; Marble; CI 77220; calcium trioxidocarbonate; Calcium carbonate [USP]; Carbonate (calcium); Kalkspar; CHEBI:3311; H0G9379FGK; MFCD00010906; Akadama; Albacar; Albafil; Albaglos; Atomite; Calcicoll; Calibrite; Calmote; Calseeds; Calwhite; Carbium; Chemcarb; Clefnon; Duramite; Hydrocarb; Kotamite; Microcarb; Micromya; Neoanticid; Atomit; Calmos; Caltec; Dacote; Marfil; Levigated chalk; Allied whiting; Tums; Marble white; Calcium carbonate (USP); Camel-carb; Camel-wite; Camel-tex; Britomya M; Britomya S; Calofort S; Calofort T; Calopake F; Calopake H; Hakuenka O; Multiflex MM; Multiflex SC; Albaglos SF; Calopake FS; Calopake PC; Carusis P; Garolite SA; Gilder's whiting; Hakuenka CC; Hakuenka DD; Hakuenka PX; Hakuenka PZ; Homocal D; Multifex MM; Neolite F; Calcene CO; Calcene NC; Calcene TM; Carbium MM; Hakuenka CCR; Neolite SP; Crystic prefil S; Neolite TPS; Calcilit 8; Carborex 2; Cal-Sup; Microwhite 25; R Jutan; Calcium Carbonate Nanopowder; Hakuenka T-DD; Brilliant 15; Filtex White Base; Hydrocarb 60; Hydrocarb 65; Marblewhite 325; Cal-Light SA; Calcidar 40; Carbital 90; Durcal 2NH; Non-Fer-Al; CCC G-white; Kredafil RM 5; Brilliant BR 15; Calofil A 4; Calofil B 1; Calofil E 2; C.I. Pigment White 18; Calcilit 100; Hakuenka R 06; Micromic CR 16; Calcium monocarbonate; Durcal 10; Durcal 40; Monocalcium carbonate; Brilliant 1500; Calofor U 50; Calopake high opacity; CCC No.AA oolitic; Eskalon 100; Eskalon 200; Eskalon 400; Eskalon 800; Finncarb 6002; C 50 (carbonate); Kredafil 150 Extra; Albacar 5970; Caswell No. 139; Eskalon 1500; MSK-PO; MSK-C; MSK-G; MSK-K; MSK-P; MSK-V; NCC-P; Slaker rejects; Marble dust; Mylanta soothing lozenges; Natural calcium carbonate; Oyster shell; Ground limestone; MC-T; Calcium, Reference Standard Solution; Durcal C 640305; P-Lite 500; P-Lite 700; Di-Gel Tablets; Carbonic Acid Calcium Salt; Precipitated chalk; EGRI M 5; Pigment white 18; KULU 40; Calcium carbonate, precipitated; BRT 30; CCRIS 1333; HSDB 927; NCC 45; Tylenol Headache Plus; BS 32; Vaterite (Ca(CO3)); BRT 1500; Carbonic acid, calcium salt (1:1); EINECS 207-439-9; AX 363; BF 200; KS 500; NS 100; NS 200; NS 400; EPA Pesticide Chemical Code 073502; KS 1300; KS 1500; KS 1800; KS 2100; NS 2500; Glauberitum; Calcitum; N 34; N 43; Caltan; Calcii carbonas; Kalk; Chalk Powder; Coral Calcium; Hydrolyzed pearl; Marble Chips; carbonate calcium; C.I. 77220; K 250; Han shui shi; Chalk, pure; Limestone, ground; calcium carb onate; Copper Nickel Foil; Marble, CP; Phx cal-carb buffer; T 130-2500; Cal-sup (TN); CCaO3; calcium(II) carbonate; Calcium carbonate, CP; Calcium (as carbonate); Calcium Carbonate,(S); Acid controller complete; Calcium Carbonate (AS); EC 207-439-9; SCHEMBL3261; Calcium Carbonate Dispersion; Calcium carbonate, technical; Precpitated calcium carbonate; Calcium Carbonate Granular DC; Calcium Carbonate Precipitated; Ca (C O3); Calcium (as calcium carbonate); Calcium Carbonate Nanoparticles; Calcium Carbonate Microparticles; CHEMBL1200539; DTXSID3036238; INS NO.170(I); NDI 443; Calcium carbonate, ReagentPlus(R); Calcium carbonate,puratronic powder; INS-170(I); Calcium carbonate, AR, >=98.5%; Calcium carbonate, LR, >=98.5%; AKOS015903256; Calcium carbonate, precipitated (JAN); Calcium carbonate, chelometric standard; Children's mylanta upset stomach relief; DB06724; Precipitated calcium carbonate (JP17); Calcium carbonate, BioXtra, >=99.0%; Calcium carbonate, Monocalcium carbonate; 13701-58-1; Calcium carbonate, powder A.C.S. reagent; E-170(I); E170; S266; Calcium carbonate, puriss. p.a., >=99%; Calcium carbonate, USP, 98.0-100.5%; Calcium carbonate, NIST(R) SRM(R) 915b; E 170; FT-0623383; Calcium carbonate (99.999%-Ca) PURATREM; C08129; Calcium carbonate, SAJ first grade, >=98.0%; Calcium carbonate, tested according to Ph.Eur.; D00932; Q23767; Calcium carbonate, 99.999% trace metals basis; Calcium carbonate, JIS special grade, >=99.5%; Calcium carbonate, p.a., 99.0%, ACS reagent; Calcium carbonate, >=99.995% trace metals basis; Calcium carbonate, Vetec(TM) reagent grade, 99%; Calcium carbonate, ACS reagent, >=99.0%, powder; Calcium carbonate, BioUltra, precipitated, >=99.0% (KT); Calcium carbonate, powder, <=30 mum particle size, 98%; Calcium carbonate, primary reference standard, 99.95-100.05%; NBS 18 (carbon isotopes in carbonatite), NIST(R) RM 8543; Calcium Carbonate, Trace metals grade 99.99% trace metals basis; Calcium Carbonate (AS), United States Pharmacopeia (USP) Reference Standard; Calcium carbonate, BioReagent, suitable for insect cell culture, >=99.0%; Calcium, Ion chromatography standard solution, Specpure?, Ca2+ 1000?g/ml; Calcium carbonate, ACS reagent, chelometric standard, 99.95-100.05% dry basis; Calcium carbonate, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Calcium carbonate, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), >=99%; Calcium carbonate, Pharmaceutical Secondary Standard; Certified Reference Material; Calcium carbonate, certified reference material for titrimetry, certified by BAM, according to ISO 17025, >=99.5%; Calcium carbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E170, precipitated, 98.5-100.5% (based on anhydrous substance)",Antacids/Minerals And Electrolytes,Small molecule,"InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",VTYYLEPIZMXCLO-UHFFFAOYSA-L,C(=O)([O-])[O-].[Ca+2],.,CCaO3,.,.
D0237,Calcium chloride,24844,Calcium Chloride 10% In Plastic Container,Minerals And Electrolytes,Small molecule,1S/Ca.2ClH.2H2O/h;2*1H;2*1H2/q+2;;;;/p-2,LLSDKQJKOVVTOJ-UHFFFAOYSA-L,O.O.[Cl-].[Cl-].[Ca+2],10035-04-8,CaCl2H4O2,.,5C64: Mineral absorption/transport disorder
D0238,Calcium citrate,13136,"Calcium citrate; Tricalcium dicitrate; 813-94-5; Acicontral; TRICALCIUM CITRATE; Calcitrate; Calcium citrate, tribasic; Citracal; UNII-86117BWO7P; Calcium Citrate anhydrous; Calcium 2-hydroxy-1,2,3-propanetricarboxylate (3:2); tricalcium citrate tetrahydrate; 2-Hydroxy-1,2,3-propanetricarboxylic acid calcium salt (2:3); 86117BWO7P; tricalcium;2-hydroxypropane-1,2,3-tricarboxylate; Citrical; calcium 2-hydroxypropane-1,2,3-tricarboxylate (3:2); Tribasic calcium citrate; Calcium citrate [USAN]; 5785-44-4; HSDB 5756; Citric acid, calcium salt (2:3); EINECS 212-391-7; calciumcitrate; Calcimax; Lime citrate; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, calcium salt (2:3); Calcium (as citrate); Calcium Citrate Powder; calcium citrate tribasic; EC 212-391-7; Calcium Citrate USP, FCC; tricalcium bis(citric acid); INS NO.333(III); INS-333(III); CHEMBL2106123; DTXSID7061148; citric acid calcium salt (2:3); CHEBI:190513; E-333(III); AKOS015839590; DB11093; Calcium Citrate Malate Glycinate 21% 40M; Q420280; Calcium Citrate Malate Carbonate 23%, Coarse Granu; J-509604; calcium 2-hydroxypropane-1,2,3-tricarboxylate (3/2); tricalcium bis(2-hydroxypropane-1,2,3-tricarboxylic acid)",Minerals And Electrolytes,Small molecule,"InChI=1S/2C6H8O7.3Ca/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6",FNAQSUUGMSOBHW-UHFFFAOYSA-H,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2],.,C12H10Ca3O14,.,.
D0239,Calcium glubionate anhydrous,64776,"Calcium glubionate anhydrous; 97635-31-9; calcium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate; EINECS 307-393-0; Calcium D-gluconate lactobionate; (D-gluconato)(lactobionato)calcium; (4-O-beta-D-Galactopyranosyl-D-gluconato-O1)(D-gluconato-O1)calcium; DB13142; Calcium, (4-O-beta-D-galactopyranosyl-D-gluconato-O1)(D-gluconato-O1)-",Minerals And Electrolytes,Small molecule,"InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6+,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1",YPCRNBPOUVJVMU-LCGAVOCYSA-L,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Ca+2],.,C18H32CaO19,.,.
D0240,Calcium glucoheptonate,62859,Calcii glucoheptonas; CALCIUM GLUCEPTATE; Glucoheptonate de calcium; Glucoheptonato calcico; Calcium glucoheptonate; Calcium glucoheptonate (1:2); Calcii glucoheptonas [INN-Latin]; EINECS 249-383-8; Glucoheptonato calcico [INN-Spanish]; Calcium gluceptate [USP]; Glucoheptonate de calcium [INN-French]; Calcihept; CHEBI:3314; glucoheptonate; 29039-00-7; Calcium gluceptate (USP); Calcium glucoheptonate (INN); Calcium glucoheptonate [INN]; Calcii glucoheptonas [Latin]; Calcium gluceptate [USAN]; Calcium Stanley; UNII-L11651398J,Minerals And Electrolytes,Small molecule,"1S/2C7H14O8.Ca/c2*8-1-2(9)3(10)4(11)5(12)6(13)7(14)15;/h2*2-6,8-13H,1H2,(H,14,15);/q;;+2/p-2/t2*2-,3-,4+,5-,6?;/m11./s1",FATUQANACHZLRT-KMRXSBRUSA-L,C(C(C(C(C(C(C(=O)[O-])O)O)O)O)O)O.C(C(C(C(C(C(C(=O)[O-])O)O)O)O)O)O.[Ca+2],29039-00-7,C14H26CaO16,3314,5B5K: Mineral deficiency
D0241,Calcium gluconate,9290,"CALCIUM GLUCONATE; 299-28-5; Calcium D-gluconate; D-Gluconic acid, calcium salt (2:1); Gluconate Calcium; UNII-SQE6VB453K; Calcarea gluconica; Glucobiogen; Calciofon; Calcium di-gluconate; Calcium gluconate anhydrous; Gluconic Acid Calcium Salt; Calcium gluconate, anhydrous; SQE6VB453K; Calglucon; Ebucin; Gluconate de calcium; Almora; calcium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Calcicol; Calcipur; Calglucol; Dragocal; Kalpren; Novocal; MFCD00064209; Calcium hexagluconate; Gluconic acid hemicalcium salt; Calcium D-gluconate, anhydrous; 152772-65-1; Gluconato di calcio; Calcium D-gluconate (1:2); Gluconate de calcium [French]; Gluconato di calcio [Italian]; CCRIS 1336; HSDB 994; Calcium Gluconate [USAN:JAN]; EINECS 206-075-8; Gluconic acid, calcium salt; Calcii gluconas; Gluconic acid, calcium salt (2:1), D-; 2,3,4,5,6-Pentahydroxycaproic Acid hemicalcium salt; Gluconic acid, calcium salt, D-; NSC-744619; calcium bis(D-gluconate); Calcium gluconate (USP); L-Gluconic acid calcium salt; SCHEMBL24132; CHEBI:3309; INS NO.578; Boron Gluconate Blend 5% 40M; CHEMBL2106119; DTXSID2029618; INS-578; AKOS015895893; DB11126; NSC 744619; AS-80559; E-578; G0037; C08133; D00935; A876351; Q413739; W-202243; Calcium D-gluconate gel, 2.5% w/w Aqueous Solution; calcium bis[(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate]",Minerals And Electrolytes,Small molecule,"InChI=1S/2C6H12O7.Ca/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",NEEHYRZPVYRGPP-IYEMJOQQSA-L,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Ca+2],.,C12H22CaO14,.,.
D0242,Calcium glycerophosphate,120096,"calcium glycerophosphate; 27214-00-2; calcium 2,3-dihydroxypropyl phosphate; 1336-00-1; Calcium glycerol phosphate; Calcium 1-glycerophosphate; 126-95-4; calcium;2,3-dihydroxypropyl phosphate; Glycerol phosphate calcium salt hydrate; 1,2,3-Propanetriol, mono(dihydrogen phosphate), calcium salt (1:1); MFCD00151656; CALCIUM GLYCERINOPHOSPHATE; 2,3-Dihydroxypropyl (dihydrogen phosphate), calcium salt; Calcium 2,3-hydroxypropyl phosphate; EINECS 204-813-3; EINECS 215-643-4; MFCD00042643; Calcii glycerophosphas; 1,2,3-Propanetriol, 1-(dihydrogen phosphate), calcium salt (1:1); C3H7CaO6P; SCHEMBL4237; CHEMBL2106124; DTXSID40873179; CS-B1784; HY-B2203; EINECS 249-312-0; AKOS015962876; AC-2077; P752; FT-0700768; FT-0775133; J-006411; J-017324; Q27286832; 4-AMINO-ALPHA-DIETHYLAMINO-O-CRESOLDIHYDROCHLORIDE",Minerals And Electrolytes,Small molecule,"InChI=1S/C3H9O6P.Ca/c4-1-3(5)2-9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2",IWIRHXNCFWGFJE-UHFFFAOYSA-L,C(C(COP(=O)([O-])[O-])O)O.[Ca+2],.,C3H7CaO6P,.,.
D0243,Calcium lactate,13144,"calcium lactate; 814-80-2; Calcium dilactate; Calphosan; Hemicalcium L-lactate; calcium;2-hydroxypropanoate; calcium 2-hydroxypropanoate; Lactic acid, calcium salt (2:1); Propanoic acid, 2-hydroxy-, calcium salt (2:1); Calcium 2-hydroxypropanoate (1:2); 2-Hydroxypropanoic acid calcium salt; 5743-48-6; 63690-56-2; DSSTox_CID_236; 28305-25-1; Conclyte calcium; DSSTox_RID_75451; DSSTox_GSID_20236; Calcium lactate, anhydrous; C6H10CaO6; Ca lactate; 2-HYDROXYPROPANOICACIDCALCIUMSALT,TRIHYDRATE; UNII-2URQ2N32W3; CAS-814-80-2; Calcium Lactate [USAN:JAN]; CCRIS 3669; HSDB 976; Calcium lactate anhydrous; EINECS 212-406-7; AI3-04468; calcium bis(2-hydroxypropanoate); calcium dl-lactate; 2URQ2N32W3; EINECS 227-266-2; Calcium (as lactate); Ins No.327; EC 212-406-7; SCHEMBL4319; CHEMBL2106111; DTXSID0020236; HY-B2227A; INS-327; Lactic acid calcium salt (2:1); AMY37027; INS-327-; Tox21_201378; Tox21_302896; Bis(2-hydroxypropanoic acid) calcium; AKOS015837558; DB13231; NCGC00256365-01; NCGC00258929-01; P973; DB-023012; CS-0021602; E-327; FT-0623403; FT-0652809; F16480; A840142; Q419693",Minerals And Electrolytes,Small molecule,"InChI=1S/2C3H6O3.Ca/c2*1-2(4)3(5)6;/h2*2,4H,1H3,(H,5,6);/q;;+2/p-2",MKJXYGKVIBWPFZ-UHFFFAOYSA-L,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Ca+2],.,C6H10CaO6,.,.
D0244,Calcium Phosphate,24456,"Calcium phosphate; 7758-87-4; TRICALCIUM PHOSPHATE; Synthos; Calcium phosphate tribasic; Calcium orthophosphate; Tricalcium diphosphate; Calcigenol simple; beta-TCP; Phosphoric acid, calcium salt (2:3); Tricalcium orthophosphate; beta-Tricalcium phosphate; Calcium tertiary phosphate; Tertiary calcium phosphate; tri-calcium phosphate; tricalcium;diphosphate; FEMA No. 3081; 10103-46-5; Calciresorb;TCP; Phosphoric acid, calcium salt; UNII-K4C08XP666; tricalcium bis(phosphate); CHEBI:9679; K4C08XP666; Synthograft; Bonarka; Cerasorb; OSferion; Natural whitlockite; Caswell No. 148; Ceredex; Multifos; Ostram; Vitoss; TricOs; Calipharm T; Tricafos P; Calcium phosphate (3:2); 21063-37-6; Tricalcium bis(orthophosphate); CCRIS 3668; HSDB 879; JAX TCP; Calcium phosphate (Ca3(PO4)2); Calcium orthophosphate, tri-(tert); Tricalcium phosphate (Ca3(PO4)2); EINECS 231-840-8; EPA Pesticide Chemical Code 076401; Posture (calcium supplement); bone phosphate; Phosphoric acid calcium(2+) salt (2:3); Ca3(PO4)2; Bone ash; calcium-phosphate; alpha-TCP; Calcium phosphates; tricalciumphosphate; EINECS 233-283-6; Posture (TN); Hydroxyapatite Powder; MFCD00015984; Phosphoric acid, calcium salt (1:?); calcium phosphate basic; beta tricalcium phosphate; AI3-25607; alpha-Tricalcium phosphate; Ca3O8P2; EC 231-840-8; BONE POWDER, PURIFIED; INS NO.341(III); INS-341(III); CHEMBL2106566; DTXSID1049803; E-341(III); AKOS015833108; CX-0072; DB11348; S338; Tricalcium bis(orthophosphate), with a fluorine content of less than 0,005 % by weight on the dry anhydrous product; Calcium phosphate, tribasic (ca.37% Ca); CS-0013475; FT-0645103; C08136; D00938; Q278387; UNII-97Z1WI3NDX component QORWJWZARLRLPR-UHFFFAOYSA-H; UNII-279O8I0433 component QORWJWZARLRLPR-UHFFFAOYSA-H; Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, >=95% beta-phase basis (unsintered powder); Calcium phosphate, purum p.a., >=96.0% (calc. as Ca3(PO4)2, KT); Tricalcium phosphate hydrate, nanopowder, <200 nm particle size (BET); alpha-tri-Calcium phosphate, puriss. p.a., >=75% alpha-phase basis (sinterted powder); alpha-tri-Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, puriss. p.a., >=95% beta-phase basis (sintered powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (sintered Powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (unsintered powder)",Minerals And Electrolytes/Phosphate Binders,Small molecule,"InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6",QORWJWZARLRLPR-UHFFFAOYSA-H,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2],.,Ca3O8P2,.,.
D0245,Canagliflozin,24812758,"842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0",Antidiabetic Agents,Small molecule,"1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1",XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,842133-18-0,C24H25FO5S,73274,5A11: Type 2 diabetes mellitus; GB61: Chronic kidney disease; 5A10: Diabetes mellitus
D0246,Canakinumab,.,Ilaris (TN),Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,4A44: Vasculitis; EB00-EB05: Urticaria; FA20: Rheumatoid arthritis; 4A60: Monogenic autoinflammatory syndrome
D0247,Cangrelor,9854012,"Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)",Antiplatelet Agents,Small molecule,"1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1",PAEBIVWUMLRPSK-IDTAVKCVSA-N,CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O,163706-06-7,C17H25Cl2F3N5O12P3S2,90841,DB61-GB90: Thrombosis
D0248,Cannabidiol,644019,"cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N",Anticonvulsants,Small molecule,"1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1",QHMBSVQNZZTUGM-ZWKOTPCHSA-N,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,13956-29-1,C21H30O2,69478,8A62: Epileptic encephalopathy; 8A61-8A6Z: Epilepsy/seizure
D0249,Capecitabine,60953,"Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)",Antineoplastics,Small molecule,"1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1",GAGWJHPBXLXJQN-UORFTKCHSA-N,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,154361-50-9,C15H22FN3O6,31348,2B91: Colorectal cancer; 2C60-2C6Y: Breast cancer
D0250,Caplacizumab,.,.,Platelet Aggregation Inhibitors,Monoclonal antibody,.,.,.,.,.,.,3B64: Thrombocytopenia
D0251,Capmatinib,25145656,"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O",Multikinase Inhibitors,Small molecule,"1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,1029712-80-8,C23H17FN6O,.,2C12: Liver cancer; 2A00: Brain cancer; 2C25: Lung cancer
D0252,Capreomycin,3000502,"Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide",Antibiotics,Small molecule,"1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1",VCOPTHOUUNAYKQ-WBTCAYNUSA-N,CC1C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)NC(C(=O)NCC(C(=O)N1)N)C2CCN=C(N2)N)CNC(=O)CC(CCCN)N.C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CNC(=O)CC(CCCN)N)CO)N)N,11003-38-6,C50H88N28O15,.,1A00-1C4Z: Bacterial infection; 1B10-1B21: Mycobacterium infection
D0253,Capsicum,.,"(6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; (6e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; (E)8-methyl-N-vanillyl-6-Nonenamide; (E)-8-Methyl-N-vanillyl-6-nonenamide; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); (E)-Capsaicin; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; 1217899-52-9; 404-86-4; 4DY; 6-Nonenamide, (E)-; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; 6-nonenamide,n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-,(6e)-; 7553-53-9; 8-Methyl-N-vanillyl-(trans)-6-nonenamide; 8-Methyl-N-vanillyl-6E-nonenamide; 8-Methyl-N-Vanillyl-6-Nonenamide; 8-Methyl-N-vanillyl-6-nonenamide, (E)-; 8-Methyl-N-vanillyl-trans-6-nonenamide; AB00053098_12; AB00053098-11; AC-10114; Adlea; AKOS007930159; ALGRX 4975; ALGRX-4975; AMY25669; Ausanil; Axsain; BBL027836; BDBM20461; BDBM86537; Bitter orange extract 30%; BPBio1_001053; BRD-K37056290-001-01-1; BRD-K50590187-001-06-6; BRN 2816484; BSPBio_000957; BSPBio_001548; BSPBio_002917; C06866; C-1700; capsacin(E); Capsaicin; Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); Capsaicin (in oleoresin of capsicum); Capsaicin (JAN/USP); Capsaicin (Natural); Capsaicin [in oleoresin of capsicum]; Capsaicin [USAN]; Capsaicin [USP:INN]; Capsaicin 10 microg/mL in Acetonitrile; Capsaicin, >=95%, from Capsicum sp.; Capsaicin, analytical standard; Capsaicin, certified reference material, TraceCERT(R); Capsaicin, European Pharmacopoeia (EP) Reference Standard; Capsaicin, from Capsicum sp., >=50% (HPLC); Capsaicin, from natural source; CAPSAICIN, NATURAL; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material; Capsaicin, United States Pharmacopeia (USP) Reference Standard; Capsaicin,(S); Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide; NGX-4010; CAPSAICINE; Capsaicinoid; CAPSAICINOIDS; Capsicine; Capzasin-hp; CAS_404-86-4; CAS-404-86-4; Caswell No. 158; CCG-39657; CCG-39908; CCRIS 1588; CHEBI:3374; CHEBI:94524; CHEMBL294199; Citrus Aurantium 30%; Citrus Aurantium Extract; CITRUS AURANTIUM PE; Cntx-4975; CS-0181240; CS-1518; D00250; DB06774; depletes Substance P; Dolenon; DSSTox_CID_241; DSSTox_GSID_20241; DSSTox_RID_75455; DTXSID9020241; E-CAPSAICIN; EI-125; EINECS 206-969-8; EPA Pesticide Chemical Code 070701; epsilon-capsaicin; FEMA No. 3404; GTPL2486; HMS1361N10; HMS1570P19; HMS1791N10; HMS1921H11; HMS1989N10; HMS2089N11; HMS2092D21; HMS2097P19; HMS2230O23; HMS3402N10; HMS3414F11; HMS3649N15; HMS3678F11; HMS501B16; HSDB 954; HY-10448; HY-10448A; IDI1_000354; IDI1_034018; isoamyl4-methoxycinnamate; Isodecenoate; Isodecenoic acid vanillylamide; KS-5181; LMFA08020085; LS-14673; M1149; MCULE-8056866140; MEGxp0_001448; Methyl-N-vanillyl-6-noneneamide; MFCD00017259; Mioton; MLS002154049; MR3H3; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; N0C781; N1667; N735; NCGC00017337-02; NCGC00017337-03; NCGC00017337-04; NCGC00017337-05; NCGC00017337-06; NCGC00017337-07; NCGC00017337-08; NCGC00017337-09; NCGC00017337-10; NCGC00017337-11; NCGC00017337-12; NCGC00017337-13; NCGC00017337-17; NCGC00017337-18; NCGC00090853-01; NCGC00090853-02; NCGC00090853-03; NCGC00090853-04; NCGC00090853-06; NCGC00090853-07; NCGC00090853-08; NCGC00090853-09; NCGC00090853-10; NCGC00090853-11; NCGC00090853-12; NCGC00257869-01; NCI-C56564; neurotoxic; NGX 4010; NGX-1998; NGX-3781; NGX-4010; NGX-7325; NSC 56353; NSC_2548; NSC56353; NSC-56353; NSC757844; NSC-757844; Ovocap; Pharmakon1600-01501128; Prestwick_204; Prestwick2_000879; Prestwick3_000879; Q273169; Qutenza; Qutenza;Vanilloid; Ratden pe 40; S07O44R1ZM; s1990; SBI-0052593.P002; SCHEMBL8085; SCHEMBL8086; SDCCGMLS-0066678.P001; SMP2_000337; SMR000718774; SPECTRUM1501128; Spectrum5_000538; SR-05000001861; SR-05000001861-1; SR-05000001861-4; SR-05000001861-5; SR-05000001861-6; SR-05000001861-9; starbld0019180; STL372889; Styptysat; TNP00277; Togarashi orenji; Tox21_110817; Tox21_200315; TQ-1018; trans-8-Methyl-N-vanillyl-6-nonenamide; Transacin; trans-Capsaicin; trans-Capsaicin-d3; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; UNII-S07O44R1ZM; UNII-UW86K581WY component YKPUWZUDDOIDPM-SOFGYWHQSA-N; UPCMLD-DP092; UPCMLD-DP092:001; UPCMLD-DP092:002; Vanilloid; ZINC1530575; Zostrix; ZOSTRIX (TN); Zostrix HP; ",Herbal Products,Natural product,.,.,.,.,.,.,.
D0254,Captopril,44093,"Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline",Antihypertensive Agents,Small molecule,"1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1",FAKRSMQSSFJEIM-RQJHMYQMSA-N,CC(CS)C(=O)N1CCCC1C(=O)O,62571-86-2,C9H15NO3S,3380,BA00-BA04: Hypertension
D0255,Carbamazepine,2554,"Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals",Anticonvulsants/Antimanic Agents,Small molecule,"1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)",FFGPTBGBLSHEPO-UHFFFAOYSA-N,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,298-46-4,C15H12N2O,3387,2B72: Stomach cancer; 8A61-8A6Z: Epilepsy/seizure; 5A10: Diabetes mellitus
D0256,Carbamoylcholine (ophthalmic),2551,"Carbamylcholine; Carbastat; Carbamoylcholine; 462-58-8; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium; 2-carbamoyloxyethyl(trimethyl)azanium; UNII-54Z8M50D6Q; 54Z8M50D6Q; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium; 2-[(AMINOCARBONYL)OXY]-N,N,N-TRIMETHYLETHANAMINIUM; Carboptic; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; CHEMBL14; CARBAMYL-CHOLINE; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; Choline, carbonate (ester); CCE; CAS-51-83-2; NCGC00163219-01; choline carbamate; carbamylcholinechloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-; Spectrum_000094; 1uv6; 2260-51-7; Prestwick0_000880; Prestwick1_000880; Prestwick2_000880; Prestwick3_000880; Spectrum2_000114; Spectrum3_000324; Spectrum4_000261; Spectrum5_000934; Lopac-C-4382; CHEMBL965; SCHEMBL2792; Lopac0_000243; BSPBio_000959; BSPBio_001927; GTPL298; KBioGR_000722; KBioSS_000514; DivK1c_000725; SPBio_000128; SPBio_002880; BPBio1_001055; DTXSID0048397; KBio1_000725; KBio2_000514; KBio2_003082; KBio2_005650; KBio3_001147; NINDS_000725; HMS2089I06; 2-carbamoyloxyethyl-trimethylazanium; ZINC3079342; BDBM50004656; STL371210; AKOS025247582; CCG-204338; DB00411; MCULE-5642570831; IDI1_000725; NCGC00015237-01; NCGC00015237-02; NCGC00015237-03; NCGC00015237-04; NCGC00015237-05; NCGC00015237-13; NCGC00162103-01; SBI-0050231.P004; AB00053795; AB00053795-08; AB00053795_09; AB00053795_10; Q27458733",Ophthalmic Glaucoma Agents,Small molecule,"InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1",VPJXQGSRWJZDOB-UHFFFAOYSA-O,C[N+](C)(C)CCOC(=O)N,.,C6H15N2O2+,.,.
D0257,Carbenicillin,20824,"CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1",FPPNZSSZRUTDAP-UWFZAAFLSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,4697-36-3,C17H18N2O6S,3393,GC08: Urinary tract infection
D0258,Carbidopa,34359,"Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate",Antiparkinson Agents,Small molecule,"1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1",TZFNLOMSOLWIDK-JTQLQIEISA-N,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,28860-95-9,C10H14N2O4,39585,8A00: Parkinsonism
D0259,Carbinoxamine,2564,"Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine",Antihistamines,Small molecule,"1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3",OJFSXZCBGQGRNV-UHFFFAOYSA-N,CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,486-16-8,C16H19ClN2O,3398,CA08: Vasomotor/allergic rhinitis
D0260,Carboplatin,426756,"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)",Antineoplastics,Small molecule,"1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2",VSRXQHXAPYXROS-UHFFFAOYSA-N,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],41575-94-4,C6H12N2O4Pt,31355,2C73: Ovarian cancer
D0261,Carfilzomib,11556711,Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide,Protease Inhibitors,Small molecule,"1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,868540-17-4,C40H57N5O7,65347,2A83: Multiple myeloma; 2C25: Lung cancer
D0262,Cariprazine,11154555,"Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH",Atypical Antipsychotics,Small molecule,"1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)",KPWSJANDNDDRMB-UHFFFAOYSA-N,CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,839712-12-8,C21H32Cl2N4O,90933,6A60: Bipolar disorder
D0263,Carisoprodol,2576,carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol,Muscle Relaxants,Small molecule,"1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)",OFZCIYFFPZCNJE-UHFFFAOYSA-N,CCCC(C)(COC(=O)N)COC(=O)NC(C)C,78-44-4,C12H24N2O4,3419,FA00-FC0Z: Musculoskeletal disorder
D0264,Carmustine,2578,"Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK;  BCNU; Injectable carmustine, Direct Therapeutics",Alkylating Agents,Small molecule,"1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)",DLGOEMSEDOSKAD-UHFFFAOYSA-N,C(CCl)NC(=O)N(CCCl)N=O,154-93-8,C5H9Cl2N3O2,3423,2C12: Liver cancer; 2A00: Brain cancer
D0265,Carteolol,2583,"Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one",Antihypertensive Agents,Small molecule,"1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)",LWAFSWPYPHEXKX-UHFFFAOYSA-N,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O,51781-06-7,C16H24N2O3,3437,9C61: Glaucoma
D0266,Carteolol (ophthalmic),2583,"Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one",Antihypertensive Agents,Small molecule,"1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)",LWAFSWPYPHEXKX-UHFFFAOYSA-N,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O,51781-06-7,C16H24N2O3,3437,9C61: Glaucoma
D0267,Carvedilol,2585,"Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol",Vasodilator Agents,Small molecule,"1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3",OGHNVEJMJSYVRP-UHFFFAOYSA-N,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,72956-09-3,C24H26N2O4,3441,BD10-BD1Z: Heart failure
D0268,Caspofungin,2826718,"CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0",Antifungal Agents,Small molecule,"1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1",JYIKNQVWKBUSNH-OGZDCFRISA-N,CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O,162808-62-0,C52H88N10O15,474180,1F29-1F2F: Fungal infection
D0269,Castor oil,14030006,"CASTOR OIL; Ricinus oil; 8001-79-4; Olio di ricino; Xenaderm; Venelex; Castor oil, specified according to the requirements of Ph.Eur.; Optase; Trypsin complex; UNII-D5340Y2I9G; Castor oil [USP:JAN]; SCHEMBL12939325; D5340Y2I9G; 1-O,2-O,3-O-Tris[(Z)-12-hydroxy-9-octadecenoyl]glycerol; 89958-32-7; 8013-56-7; 8041-95-0; 8041-22-3; 151438-72-1; 898831-11-3; 8036-08-6; 8015-57-4",Nutritional Supplements,Small molecule,"1S/C57H104O9/c1-4-7-10-31-40-51(58)43-34-25-19-13-16-22-28-37-46-55(61)64-49-54(66-57(63)48-39-30-24-18-15-21-27-36-45-53(60)42-33-12-9-6-3)50-65-56(62)47-38-29-23-17-14-20-26-35-44-52(59)41-32-11-8-5-2/h25-27,34-36,51-54,58-60H,4-24,28-33,37-50H2,1-3H3/b34-25-,35-26-,36-27-",ZEMPKEQAKRGZGQ-AAKVHIHISA-N,CCCCCCC(CC=CCCCCCCCC(=O)OCC(COC(=O)CCCCCCCC=CCC(CCCCCC)O)OC(=O)CCCCCCCC=CCC(CCCCCC)O)O,8001-79-4,C57H104O9,.,DD91: Irritable bowel syndrome
D0270,Cedazuridine,25267009,"Cedazuridine; 1141397-80-9; UNII-39IS23Q1EW; 39IS23Q1EW; CHEMBL3237547; E7727; (4R)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one; (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine; (R)-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-hydroxytetrahydropyrimidin-2(1H)-one; Cedazuridine [INN]; Cedazuridine [USAN]; Cedazuridine [USAN:INN]; SCHEMBL172256; GTPL11101; EX-A5549; BDBM50007029; WHO 10741; ASTX727 (cedazuridine + decitabine); ASTX727 COMPONENT CEDAZURIDINE; AT22227; ASTX-727 COMPONENT CEDAZURIDINE; compound 7a [PMID: 24520856]; HY-109081; E-7727; A937507; Uridine, 2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4R)-; (4R)-4-Hydroxy-1-(2,2-difluoro-2-deoxy-beta-D-ribofuranosyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one",Antineoplastics,Small molecule,"InChI=1S/C9H14F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4-7,14-16H,1-3H2,(H,12,17)/t4-,5-,6-,7-/m1/s1",VUDZSIYXZUYWSC-DBRKOABJSA-N,C1CN(C(=O)N[C@@H]1O)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,.,C9H14F2N2O5,.,.
D0271,Cefaclor,51039,"Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1",QYIYFLOTGYLRGG-GPCCPHFNSA-N,C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl,53994-73-3,C15H14ClN3O4S,3478,1A00-1C4Z: Bacterial infection
D0272,Cefadroxil,47965,"CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1",BOEGTKLJZSQCCD-UEKVPHQBSA-N,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,50370-12-2,C16H17N3O5S,3479,1A00-1C4Z: Bacterial infection
D0273,Cefalotin,6024,"Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1",XIURVHNZVLADCM-IUODEOHRSA-N,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O,153-61-7,C16H16N2O6S2,124991,1A00-1C4Z: Bacterial infection
D0274,Cefamandole,456255,"Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid",Antibiotics,Small molecule,"1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1",OLVCFLKTBJRLHI-AXAPSJFSSA-N,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(C4=CC=CC=C4)O)SC2)C(=O)O,34444-01-4,C18H18N6O5S2,3480,1A00-1A09: Anaerobic bacterial infection
D0275,Cefapirin,30699,"CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid",Antibiotics,Small molecule,"1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1",UQLLWWBDSUHNEB-CZUORRHYSA-N,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O,21593-23-7,C17H17N3O6S2,554446,1G40-1G41: Sepsis
D0276,Cefazolin,33255,"CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid",Antibiotics,Small molecule,"1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1",MLYYVTUWGNIJIB-BXKDBHETSA-N,CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O,25953-19-9,C14H14N8O4S3,474053,1A00-1C4Z: Bacterial infection
D0277,Cefdinir,6915944,"CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1",RTXOFQZKPXMALH-GHXIOONMSA-N,C=CC1=C(N2C(C(C2=O)NC(=O)C(=NO)C3=CSC(=N3)N)SC1)C(=O)O,91832-40-5,C14H13N5O5S2,3485,1A00-1C4Z: Bacterial infection
D0278,Cefditoren,9870843,"Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1",KMIPKYQIOVAHOP-YLGJWRNMSA-N,CC1=C(SC=N1)C=CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,104145-95-1,C19H18N6O5S3,59343,1A00-1C4Z: Bacterial infection
D0279,Cefepime,5479537,"Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate",Antibiotics,Small molecule,"1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1",HVFLCNVBZFFHBT-ZKDACBOMSA-N,C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-],88040-23-7,C19H24N6O5S2,478164,1A00-1C4Z: Bacterial infection
D0280,Cefiderocol,77843966,"Cephalosporin, GSK2696266; S-649266",Cephalosporins/Beta-Lactamase Inhibitors,Small molecule,"1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1",DBPPRLRVDVJOCL-FQRUVTKNSA-N,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)[O-],1225208-94-5,C30H34ClN7O10S2,.,GC08: Urinary tract infection; CA00-CA40: Pneumococcal infection; PK80-PK81: Medical/surgical procedure injury; CA40: Pneumonia
D0281,Cefixime,5362065,"CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1",OKBVVJOGVLARMR-QSWIMTSFSA-N,C=CC1=C(N2C(C(C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O,79350-37-1,C16H15N5O7S2,472657,1A00-1C4Z: Bacterial infection
D0282,Cefmetazole,42008,"CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid",Antibiotics,Small molecule,"1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1",SNBUBQHDYVFSQF-HIFRSBDPSA-N,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,56796-20-4,C15H17N7O5S3,3489,1A00-1C4Z: Bacterial infection
D0283,Cefonicid,43594,"Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1",DYAIAHUQIPBDIP-AXAPSJFSSA-N,C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O,61270-58-4,C18H18N6O8S3,3491,1A00-1C4Z: Bacterial infection
D0284,Cefoperazone,44187,"Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1",GCFBRXLSHGKWDP-XCGNWRKASA-N,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,62893-19-0,C25H27N9O8S2,3493,1A00-1C4Z: Bacterial infection
D0285,Cefotaxime,5742673,Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*),Antibiotics,Small molecule,"1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1",GPRBEKHLDVQUJE-QSWIMTSFSA-N,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,63527-52-6,C16H17N5O7S2,204928,1A00-1C4Z: Bacterial infection
D0286,Cefotetan,53025,"Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1",SRZNHPXWXCNNDU-RHBCBLIFSA-N,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O,69712-56-7,C17H17N7O8S4,3499,1A00-1C4Z: Bacterial infection
D0287,Cefoxitin,441199,"Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1",WZOZEZRFJCJXNZ-ZBFHGGJFSA-N,COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3,35607-66-0,C16H17N3O7S2,209807,1A00-1C4Z: Bacterial infection
D0288,Cefpodoxime,6335986,"CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1",WYUSVOMTXWRGEK-HBWVYFAYSA-N,COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,80210-62-4,C15H17N5O6S2,3504,1A00-1C4Z: Bacterial infection
D0289,Cefprozil,5281006,"Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1",WDLWHQDACQUCJR-ZAMMOSSLSA-N,CC=CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,92676-86-3,C18H19N3O5S,3506,1A00-1C4Z: Bacterial infection
D0290,Cefradine,38103,"Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",RDLPVSKMFDYCOR-UEKVPHQBSA-N,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CCC=CC3)N)SC1)C(=O)O,38821-53-3,C16H19N3O4S,3547,1A00-1C4Z: Bacterial infection
D0291,Ceftaroline fosamil,9852981,"ceftaroline; Ceftaroline fosamil; 229016-73-3; Ceftaroline inner salt; PPI-0903; TAK 599; CHEBI:70718; Ceftaroline Fosamil Inner salt; TAK-599; Ceftaroline fosamil (inner salt); UNII-7P6FQA5D21; (6R,7R)-7-[[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7P6FQA5D21; (6R,7R)-7-({(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino)-3-{[4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 400827-46-5; ceftarolina fosamilo; Pyridinium, 4-[2-[[(6R,7R)-2-carboxy-7-[[(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methyl-, inner salt; PPI0903; Ceftaroline fosamil [USAN:INN:BAN]; ceftarolinum fosamilum; Ceftaroline fosamil anhydrous; CHEMBL501122; SCHEMBL1464037; TAK599; DTXSID60177444; BDBM50482776; DB06590; HY-14738; Pyridinium, 4-(2-(((6R,7R)-2-carboxy-7-(((2Z)-2-(ethoxyimino)-1-oxo-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)ethyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)thio)-4-thiazolyl)-1-methyl-, inner salt; CS-0003529; (6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-({(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino)-3-{[4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-3,4-didehydrocepham-4-carboxylate",Cephalosporins/Beta-Lactamase Inhibitors,Small molecule,"InChI=1S/C22H21N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37)/b26-13-/t14-,19-/m1/s1",ZCCUWMICIWSJIX-NQJJCJBVSA-N,CCO/N=C(/C1=NSC(=N1)NP(=O)(O)O)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],.,C22H21N8O8PS4,.,.
D0292,Ceftazidime,5481173,"Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate",Antibiotics,Small molecule,"1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1",ORFOPKXBNMVMKC-DWVKKRMSSA-N,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-],72558-82-8,C22H22N6O7S2,3508,1A00-1C4Z: Bacterial infection
D0293,Ceftibuten,5282242,"CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1",UNJFKXSSGBWRBZ-BJCIPQKHSA-N,C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O,97519-39-6,C15H14N4O6S2,3510,CA20: Bronchitis
D0294,Ceftizoxime,6533629,"Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid",Antibiotics,Small molecule,"1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1",NNULBSISHYWZJU-LLKWHZGFSA-N,CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)O,68401-81-0,C13H13N5O5S2,553473,1A00-1C4Z: Bacterial infection
D0295,Ceftolozane,53234134,"CEFTOLOZANE; 689293-68-3; UNII-37A4IES95Q; Ceftolozane sulfate; 37A4IES95Q; CXA-101; (6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Ceftolozane [USAN:INN]; ceftolozano; ceftolozanum; (6R,7R)-3-([3-Amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl)-7-([(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Ceftolozane (USAN); SCHEMBL14663407; CHEBI:134719; DB09050; D10097; (6R,7R)-3-((5-Amino-4-(((2-aminoethyl)carbamoyl)amino)-1-methyl-1H-pyrazol-2-ium-2- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylate; (6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-7-{[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-3-((3-amino-4-(3-(2-aminoethyl)ureido)-2-methyl-1H-pyrazol-2-ium-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((4-((((2- aminoethyl)amino)carbonyl)amino)-2,3-dihydro-3-imino-2-methyl-1H-pyrazol-1- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-, (6R,7R)-; 7-{[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-[ (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-3,4-didehydrocepham-4-carboxylate",Cephalosporins/Beta-Lactamase Inhibitors,Small molecule,"InChI=1S/C23H30N12O8S2/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42)/b31-11-/t12-,18-/m1/s1",JHFNIHVVXRKLEF-DCZLAGFPSA-N,CC(C)(C(=O)O)O/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-],.,C23H30N12O8S2,.,.
D0296,Ceftriaxone,5479530,"Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1",VAAUVRVFOQPIGI-SPQHTLEESA-N,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,73384-59-5,C18H18N8O7S3,29007,1A00-1C4Z: Bacterial infection
D0297,Cefuroxime,5479529,"Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid",Antibiotics,Small molecule,"1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1",JFPVXVDWJQMJEE-IZRZKJBUSA-N,CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O,55268-75-2,C16H16N4O8S,3515,CA42: Acute bronchitis
D0298,Celecoxib,2662,"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide",Analgesics,Small molecule,"1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,169590-42-5,C17H14F3N3O2S,41423,FA20: Rheumatoid arthritis; MG30-MG3Z: Pain
D0299,Cemiplimab,.,REGN2810; REGN-2810; REGN 2810,Antineoplastics/Anti-Pd-1 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2C30: Melanoma
D0300,Cenobamate,11962412,"Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352",Anticonvulsants,Small molecule,"1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1",GFHAXPJGXSQLPT-VIFPVBQESA-N,C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl,913088-80-9,C10H10ClN5O2,.,8A61-8A6Z: Epilepsy/seizure
D0301,Cephalexin,27447,"Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid",Antibiotics,Small molecule,"1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O,15686-71-2,C16H17N3O4S,3534,1A00-1C4Z: Bacterial infection
D0302,Ceritinib,57379345,"ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337;  ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim",Multikinase Inhibitors,Small molecule,"1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,1032900-25-6,C28H36ClN5O3S,78432,2C25: Lung cancer
D0303,Cerivastatin,446156,"cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1",SEERZIQQUAZTOL-ANMDKAQQSA-N,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)O)O)O,145599-86-6,C26H34FNO5,3558,5C80: Hyper-lipoproteinaemia; 2A83: Multiple myeloma
D0304,Certolizumab pegol,.,NULL,Tnf Alfa Inhibitors,Monoclonal antibody,.,.,.,.,.,.,.
D0305,Cetirizine,2678,Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid,Antiallergic Agents,Small molecule,"1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)",ZKLPARSLTMPFCP-UHFFFAOYSA-N,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,83881-51-0,C21H25ClN2O3,3561,CA08: Vasomotor/allergic rhinitis
D0306,Cetuximab,.,Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B91: Colorectal cancer
D0307,Cetylpyridinium (topical),2683,"CETYLPYRIDINIUM; 1-hexadecylpyridinium; 1-hexadecylpyridin-1-ium; 7773-52-6; Ceepryn; N-Hexadecylpyridinium; UNII-CUB7JI0JV3; Cetylpyridinum; CUB7JI0JV3; Hexadecylpyridinium; CHEBI:32914; MLS002695907; Pyridinium, 1-hexadecyl-; SMR001398783; BRN 1431415; 1-cetylpyridinium; 5-20-05-00233 (Beilstein Handbook Reference); 1-Hexadecyl-pyridinium; Cetylpyridinium (DCF); Spectrum_000116; starbld0000860; Spectrum2_000460; Spectrum3_000335; Spectrum4_000272; Spectrum5_000675; cid_8816; BSPBio_001969; KBioGR_000764; KBioSS_000556; 1-cetylpyridin-1-ium;bromide; DivK1c_000346; SCHEMBL122873; SPBio_000540; CHEMBL305906; DTXSID8047979; BDBM80992; KBio1_000346; KBio2_000556; KBio2_003124; KBio2_005692; KBio3_001189; NEUSVAOJNUQRTM-UHFFFAOYSA-; NINDS_000346; ZINC6845963; STK177346; AKOS005410694; DB11073; MCULE-6149173520; IDI1_000346; QTL1_000018; NCGC00091023-02; NCGC00091023-03; NCGC00091023-04; NCGC00091023-05; SBI-0051276.P003; D07666; AB00053792_07; AB00053792_08; BRD-K87700323-003-03-6; Q27115152",Topical Agents,Small molecule,"InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1",NEUSVAOJNUQRTM-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1,.,C21H38N+,.,.
D0308,Cevimeline,83898,"Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine",Parasympathomimetics,Small molecule,"1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1",WUTYZMFRCNBCHQ-PSASIEDQSA-N,CC1OC2(CN3CCC2CC3)CS1,107233-08-9,C10H17NOS,.,4A43: Sjogren syndrome
D0309,Chamomile,5280443,"apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di",Herbal Products,Small molecule,"1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H",KZNIFHPLKGYRTM-UHFFFAOYSA-N,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,520-36-5,C15H10O5,18388,.
D0310,Chenodeoxycholic acid,10133,"474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum",Gallstone Solubilizing Agents,Small molecule,"1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1",RUDATBOHQWOJDD-BSWAIDMHSA-N,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,474-25-9,C24H40O4,16755,DC11: Cholelithiasis
D0311,Chloral hydrate,2707,"chloral hydrate; 302-17-0; 2,2,2-Trichloroethane-1,1-diol; Trichloroacetaldehyde hydrate; Noctec; Tosyl; Chloral monohydrate; Phaldrone; Chloraldurat; Nycoton; Kessodrate; Chloradorm; Rectules; Lorinal; Felsules; Cohidrate; Trawotox; Oradrate; Sontec; Somnos; Nycton; Hynos; Escre; Dormal; Knockout drops; Trichloracetaldehyd-hydrat; Somni Sed; 1,1-Ethanediol, 2,2,2-trichloro-; SK-Chloral hydrate; Chloralhydrate; Aquachloral; Somnote; 2,2,2-Trichloro-1,1-ethanediol; Hydrate de chloral; 1,1,1-Trichloro-2,2-ethanediol; Trichloroacetaldehyde mono",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H",RNFNDJAIBTYOQL-UHFFFAOYSA-N,C(C(Cl)(Cl)Cl)(O)O,302-17-0,C2H3Cl3O2,28142,6C40: Substance abuse
D0312,Chlorambucil,2708,Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN),Antineoplastics,Small molecule,"1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)",JCKYGMPEJWAADB-UHFFFAOYSA-N,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,305-03-3,C14H19Cl2NO2,28830,2A82: Mature B-cell leukaemia
D0313,Chloramphenicol,5959,"Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin&#174; D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol",Antibiotics,Small molecule,"1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1",WIIZWVCIJKGZOK-RKDXNWHRSA-N,C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],56-75-7,C11H12Cl2N2O5,17698,1A00-1C4Z: Bacterial infection
D0314,Chloramphenicol (ophthalmic),5959,"Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin&#174; D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol",Antibiotics,Small molecule,"1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1",WIIZWVCIJKGZOK-RKDXNWHRSA-N,C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],56-75-7,C11H12Cl2N2O5,17698,1A00-1C4Z: Bacterial infection
D0315,Chloramphenicol (otic),5959,"Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin&#174; D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol",Antibiotics,Small molecule,"1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1",WIIZWVCIJKGZOK-RKDXNWHRSA-N,C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],56-75-7,C11H12Cl2N2O5,17698,1A00-1C4Z: Bacterial infection
D0316,Chlorcyclizine,2710,"chlorcyclizine; Chlorcycline; Alergicide; Perazyl; 82-93-9; Chlorocycline; Trihistan; Chlorocyclizine; Histantine; Di-paralen; Histachlorazene; Diparalene; Histantin; Compound 47-282; Chlorcyclizine free base; 1-(4-Chlorobenzhydryl)-4-methylpiperazine; N-Methyl-N'-(4-chlorobenzhydryl)piperazine; NSC 25246; Di-Paralene; 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine; CHEMBL22150; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-methyl-; NSC25246; 1-((4-Chlorophenyl)phenylmethyl)-4-methylpiperazine; 1-[(4-Chlorophenyl)phenylmethyl]-4-methylpiperazine; NSC-25246; 82-93-9 (FREE BASE); 1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazine; Piparalene; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-methylpiperazine; Clorciclizina [DCIT]; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-4-methyl-; Chlorcyclizinum; Clorciclizina; Clorciclizinio; Chlorcyclizine [INN:BAN]; Chlorcyclizinum [INN-Latin]; Clorciclizinio [INN-Spanish]; HSDB 3217; EINECS 201-446-0; BRN 0272719; 1-(p-Chloro-alpha-phenylbenzyl)-4-methylpiperazine; Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-methyl-; Prestwick0_000706; Prestwick1_000706; Prestwick2_000706; Prestwick3_000706; SCHEMBL4383; Oprea1_854942; BSPBio_000891; DivK1c_000210; SPBio_002812; BPBio1_000981; DTXSID9048011; CHEBI:94402; KBio1_000210; COMPD 47-282; NINDS_000210; Chlorcyclizine, >=98% (HPLC); BDBM50329371; PDSP1_000150; PDSP2_000149; AKOS015962157; DB08936; MCULE-4720374498; WLN: T6N DNTJ AYR&R DG& D1; IDI1_000210; NCGC00179384-01; NCGC00179384-10; AC-15952; SBI-0206679.P002; AB00053788; AB00053788_09; Q2393323; BRD-A57133233-003-03-7; BRD-A57133233-003-06-0; 1-[(4-chlorophenyl)-phenyl-methyl]-4-methyl-piperazine; 1-[(4-Chloro-phenyl)-phenyl-methyl]-4-methyl-piperazine; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl- (9CI)",Antihistamines,Small molecule,"InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3",WFNAKBGANONZEQ-UHFFFAOYSA-N,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,.,C18H21ClN2,.,.
D0317,Chlordiazepoxide,2712,"Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine",Antianxiety Agents,Small molecule,"1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3",BUCORZSTKDOEKQ-UHFFFAOYSA-N,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,58-25-3,C16H14ClN3O,3611,6B00-6B0Z: Anxiety disorder
D0318,Chlormezanone,2717,"Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide",Analgesics,Small molecule,"1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3",WEQAYVWKMWHEJO-UHFFFAOYSA-N,CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl,80-77-3,C11H12ClNO3S,3619,6B00-6B0Z: Anxiety disorder
D0319,Chloroprocaine,8612,"Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester",Anesthetics,Small molecule,"1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3",VDANGULDQQJODZ-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl,133-16-4,C13H19ClN2O2,3636,9A76-9A78: Corneal disease
D0320,Chloroquine,2719,Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244,Antimalarial Agents,Small molecule,"1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)",WHTVZRBIWZFKQO-UHFFFAOYSA-N,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,19851,C18H26ClN3,3638,1F40-1F45: Malaria
D0321,Chlorothiazide,2720,"Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",Antihypertensive Agents,Small molecule,"1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)",JBMKAUGHUNFTOL-UHFFFAOYSA-N,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,58-94-6,C7H6ClN3O4S2,3640,BD10-BD1Z: Heart failure
D0322,Chlorphenesin,7697,Maolate,Analgesics,Small molecule,"1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2",MXOAEAUPQDYUQM-UHFFFAOYSA-N,C1=CC(=CC=C1OCC(CO)O)Cl,104-29-0,C9H11ClO3,3642,FB56: Soft tissue disorder; NA00-ND5Z: Injury; 1F29-1F2F: Fungal infection
D0323,Chlorpheniramine,2725,"Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine",Antiallergic Agents,Small molecule,"1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",SOYKEARSMXGVTM-UHFFFAOYSA-N,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,113-92-8,C16H19ClN2,52010,CA08: Vasomotor/allergic rhinitis
D0324,Chlorpromazine,2726,Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80,Antipsychotic Agents,Small molecule,"1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3",ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,34468-21-8,C17H19ClN2S,3647,6A20: Schizophrenia
D0325,Chlorpropamide,2727,Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide,Antidiabetic Agents,Small molecule,"1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)",RKWGIWYCVPQPMF-UHFFFAOYSA-N,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,94-20-2,C10H13ClN2O3S,3650,5A11: Type 2 diabetes mellitus
D0326,Chlorthalidone,2732,"Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine",Antihypertensive Agents,Small molecule,"1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)",JIVPVXMEBJLZRO-UHFFFAOYSA-N,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,77-36-1,C14H11ClN2O4S,3654,MG29: Oedema; BA00-BA04: Hypertension
D0327,Chlorzoxazone,2733,"Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one",Analgesics,Small molecule,"1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)",TZFWDZFKRBELIQ-UHFFFAOYSA-N,C1=CC2=C(C=C1Cl)NC(=O)O2,95-25-0,C7H4ClNO2,3655,MG31: Acute pain
D0328,Cholecalciferol,5280795,"Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol",Vitamins,Small molecule,"1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1",QYSXJUFSXHHAJI-YRZJJWOYSA-N,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,67-97-0,C27H44O,28940,5B55-5B5F: Vitamin deficiency
D0329,Cholestyramine,137699107,Cholestyramine; CHOLESTYRAMINE RESIN; 11041-12-6; Azane;2-methylbutane;trimethyl-[[4-(5-phenylhexan-3-yl)phenyl]methyl]azanium;chloride,Bile Acid Sequestrants,Small molecule,"InChI=1S/C22H32N.C5H12.ClH.H3N/c1-6-20(16-18(2)21-10-8-7-9-11-21)22-14-12-19(13-15-22)17-23(3,4)5;1-4-5(2)3;;/h7-15,18,20H,6,16-17H2,1-5H3;5H,4H2,1-3H3;1H;1H3/q+1;;;/p-1",POJQWPZVKOFVHS-UHFFFAOYSA-M,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],.,C27H47ClN2,.,.
D0330,Cholic Acid,221493,"cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N",Digestive Enzymes,Small molecule,"1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",BHQCQFFYRZLCQQ-OELDTZBJSA-N,CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C,81-25-4,C24H40O5,16359,5C52-5C59: Synthesis disorder; 5C57: Peroxisomal disease
D0331,Choline salicylate,54686350,"2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1)",Salicylates,Small molecule,"1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1",UDKCHVLMFQVBAA-UHFFFAOYSA-M,C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-],2016-36-6,C12H19NO4,3668,1A00-CA43: Postoperative inflammation
D0332,Chromium picolinate,151932,"Chromium picolinate; 14639-25-9; Chromium(III) Picolinate; Chromium(III) Pyridine-2-carboxylate; chromiumpicolinate; chromium(3+);pyridine-2-carboxylate; 15713-60-7; UNII-S71T8B8Z6P; C18H12CrN3O6; Chromium (III) picolinate;Cr(Pic)3; CCRIS 8310; chromium(3+) tripyridine-2-carboxylate; 2-Pyridinecarboxylic acid, chromium salt; S71T8B8Z6P; MFCD00068715; Pyridine-2-carboxylic Acid Chromium(III) Salt; chromium tris-picolinate; DSSTox_CID_4831; Picolinic acid/chromium salt; DSSTox_RID_77546; DSSTox_GSID_24831; DTXSID1024831; BCP21370; Tox21_200574; BBL033863; chromium; pyridine-2-carboxylic acid; STL146656; AKOS005720870; AC-9849; DB11255; NCGC00248744-01; NCGC00258128-01; SY037125; CAS-14639-25-9; DB-042842; FT-0623788; P1347; A808500; J-008216; J-803060; Q2329715; CCRIS 8310; CCRIS-8310; CCRIS8310; Chromax; chromium; pyridine-2-carboxylic acid;Chromium picolinate",Minerals And Electrolytes,Small molecule,"InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3",CBDQOLKNTOMMTL-UHFFFAOYSA-K,C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].C1=CC=NC(=C1)C(=O)[O-].[Cr+3],.,C18H12CrN3O6,.,.
D0333,Ciclesonide,6918155,"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate",Antiallergic Agents,Small molecule,"1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1",LUKZNWIVRBCLON-GXOBDPJESA-N,CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6,126544-47-6,C32H44O7,31397,CB40-CB7Z: Respiratory system disease; CA23: Asthma
D0334,Ciclesonide (nasal),6918155,"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate",Antiallergic Agents,Small molecule,"1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1",LUKZNWIVRBCLON-GXOBDPJESA-N,CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6,126544-47-6,C32H44O7,31397,CB40-CB7Z: Respiratory system disease; CA23: Asthma
D0335,Cidofovir,60613,"CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate",Anti-Hiv Agents,Small molecule,"1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1",VWFCHDSQECPREK-LURJTMIESA-N,C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O,113852-37-2,C8H14N3O6P,3696,1D82: Cytomegaloviral disease
D0336,Cilostazol,2754,"cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470;  Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one",Vasodilator Agents,Small molecule,"1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)",RRGUKTPIGVIEKM-UHFFFAOYSA-N,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,73963-72-1,C20H27N5O2,31401,BD40: Arterial occlusive disease
D0337,Cimetidine,2756,"Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine",Antiulcer Agents,Small molecule,"1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)",AQIXAKUUQRKLND-UHFFFAOYSA-N,CC1=C(N=CN1)CSCCNC(=NC)NC#N,51481-61-9,C10H16N6S,3699,DA22: Gastro-oesophageal reflux disease
D0338,Cinacalcet,156419,Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine,Calcimimetics,Small molecule,"1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1",VDHAWDNDOKGFTD-MRXNPFEDSA-N,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,226256-56-0,C22H22F3N,48390,5A51: Hyper-parathyroidism; GC2Z: Urinary system disease
D0339,Cinchocaine (topical),3025,"Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide",Anesthetics,Small molecule,"1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)",PUFQVTATUTYEAL-UHFFFAOYSA-N,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,85-79-0,C20H29N3O2,247956,9A76-9A78: Corneal disease
D0340,Cinoxacin,2762,"Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid",Antiinfective Agents,Small molecule,"1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)",VDUWPHTZYNWKRN-UHFFFAOYSA-N,CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3,28657-80-9,C12H10N2O5,3716,GC08: Urinary tract infection
D0341,Ciprofloxacin,2764,ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy,Quinolones/Antibiotics,Small molecule,"1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)",MYSWGUAQZAJSOK-UHFFFAOYSA-N,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,85721-33-1,C17H18FN3O3,100241,1A00-1C4Z: Bacterial infection; 1B74-1F40: Gram-positive bacterial infection; 2E92: Digestive organ benign neoplasm; CA25: Cystic fibrosis
D0342,Cisapride,6917698,cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825;  Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454,Gastrointestinal Agents,Small molecule,"1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1",DCSUBABJRXZOMT-IRLDBZIGSA-N,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,81098-60-4,C23H29ClFN3O4,3720,DA22: Gastro-oesophageal reflux disease; DE2Z: Digestive system disease
D0343,Cisatracurium,62887,Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free,Neuromuscular Blocking Agents,Small molecule,"1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1",YXSLJKQTIDHPOT-LJCJQEJUSA-N,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,96946-41-7,C53H72N2O12+2,140621,MB47: Tonus and reflex abnormality
D0344,Cisplatin,5702198,Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy),Antineoplastics,Small molecule,1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2,LXZZYRPGZAFOLE-UHFFFAOYSA-L,N.N.Cl[Pt]Cl,15663-27-1,Cl2H6N2Pt,.,2A00-2F9Z: Solid tumour/cancer; 2B51: Osteosarcoma
D0345,Citalopram,2771,"Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile",Antidepressants,Small molecule,"1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3",WSEQXVZVJXJVFP-UHFFFAOYSA-N,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,59729-33-8,C20H21FN2O,77397,6A70-6A7Z: Depression
D0346,Citicoline,13804,Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine,Activator Of Brain Metabolism,Small molecule,"1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1",RZZPDXZPRHQOCG-OJAKKHQRSA-N,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,987-78-0,C14H26N4O11P2,16436,8B1Z: Cerebral ischaemia
D0347,Citrus bioflavonoids,.,"Citrus bioflavonoids; Bioflavonoids; Bioflavonoids,citrus; Citrus bioflavonoid; DB14586; Hesperidin complex",Antioxidant,Small molecule,.,.,.,.,.,.,.
D0348,Cladribine,20279,"Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine",Antineoplastics,Small molecule,"1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1",PTOAARAWEBMLNO-KVQBGUIXSA-N,C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,4291-63-8,C10H12ClN5O3,567361,8A40: Multiple sclerosis; 2A82: Mature B-cell leukaemia
D0349,Clarithromycin,84029,"Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a",Antibiotics,Small molecule,"1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1",AGOYDEPGAOXOCK-KCBOHYOISA-N,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,81103-11-9,C38H69NO13,3732,1A00-1C4Z: Bacterial infection
D0350,Clavulanic acid,5280980,"Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))",Antibiotics,Small molecule,"1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1",HZZVJAQRINQKSD-PBFISZAISA-N,C1C2N(C1=O)C(C(=CCO)O2)C(=O)O,58001-44-8,C8H9NO5,48947,1A00-1C4Z: Bacterial infection
D0351,Clemastine,26987,Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin,Antiallergic Agents,Small molecule,"1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1",YNNUSGIPVFPVBX-NHCUHLMSSA-N,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C,15686-51-8,C21H26ClNO,3738,CA08: Vasomotor/allergic rhinitis
D0352,Clevidipine,153994,"Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3",Antihypertensives Agent,Small molecule,"1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3",KPBZROQVTHLCDU-UHFFFAOYSA-N,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,167221-71-8,C21H23Cl2NO6,135738,BA00-BA04: Hypertension
D0353,Clidinium,2784,"clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,;  Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate",Analgesics,Small molecule,"1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1",HOOSGZJRQIVJSZ-UHFFFAOYSA-N,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,7020-55-5,C22H26NO3+,3743,DD91: Irritable bowel syndrome
D0354,Clindamycin,446598,"Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin",Antibiotics,Small molecule,"1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1",KDLRVYVGXIQJDK-AWPVFWJPSA-N,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,18323-44-9,C18H33ClN2O5S,.,ED80: Acne vulgaris
D0355,Clindamycin (topical),446598,"Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin",Antibiotics,Small molecule,"1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1",KDLRVYVGXIQJDK-AWPVFWJPSA-N,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,18323-44-9,C18H33ClN2O5S,.,ED80: Acne vulgaris
D0356,Clobazam,2789,"Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410;  Onfi",Benzodiazepine Anticonvulsants,Small molecule,"1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3",CXOXHMZGEKVPMT-UHFFFAOYSA-N,CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,22316-47-8,C16H13ClN2O2,31413,6B00-6B0Z: Anxiety disorder; 8A61-8A6Z: Epilepsy/seizure
D0357,Clofarabine,119182,"CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048",Antineoplastics,Small molecule,"1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1",WDDPHFBMKLOVOX-AYQXTPAHSA-N,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,123318-82-1,C10H11ClFN5O3,681569,2A85: Mature B-cell lymphoma; 2A37: Myelodysplastic syndrome
D0358,Clofazimine,2794,"clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2;  CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine",Antiinflammatory Agents,Small molecule,"1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3",WDQPAMHFFCXSNU-UHFFFAOYSA-N,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,2030-63-9,C27H22Cl2N4,3749,DD70: Crohn disease; 1B10-1B21: Mycobacterium infection
D0359,Clofedanol,2795,"Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]",Anesthetics,Small molecule,"1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3",WRCHFMBCVFFYEQ-UHFFFAOYSA-N,CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O,791-35-5,C17H20ClNO,135207,MD12: Cough; 9A76-9A78: Corneal disease
D0360,Clofibrate,2796,"Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate",Antihyperammonia Agents,Small molecule,"1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3",KNHUKKLJHYUCFP-UHFFFAOYSA-N,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,637-07-0,C12H15ClO3,3750,5C80: Hyper-lipoproteinaemia
D0361,Clomipramine,2801,"Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)",Antidepressants,Small molecule,"1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3",GDLIGKIOYRNHDA-UHFFFAOYSA-N,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,303-49-1,C19H23ClN2,47780,6A70-6A7Z: Depression
D0362,Clonazepam,2802,"Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one",Anticonvulsants,Small molecule,"1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)",DGBIGWXXNGSACT-UHFFFAOYSA-N,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,1622-61-3,C15H10ClN3O3,3756,8A61-8A6Z: Epilepsy/seizure
D0363,Clonidine,2803,"clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form);  Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE",Antihypertensive Agents,Small molecule,"1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)",GJSURZIOUXUGAL-UHFFFAOYSA-N,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,4205-90-7,C9H9Cl2N3,3757,BA00-BA04: Hypertension; 8C0Z: Neuropathy
D0364,Clopidogrel,60606,"clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals",Antiplatelet Agents,Small molecule,"1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",GKTWGGQPFAXNFI-HNNXBMFYSA-N,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,113665-84-2,C16H16ClNO2S,37941,DB61-GB90: Thrombosis
D0365,Clorazepic acid,2809,"Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)",XDDJGVMJFWAHJX-UHFFFAOYSA-N,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O,23887-31-2,C16H11ClN2O3,3761,6B00-6B0Z: Anxiety disorder
D0366,Clostridium tetani toxoid antigen (formaldehyde inactivated),.,"Clostridium tetani toxoid antigen (formaldehyde inactivated); DB10583; Tetanus toxoid; Tetanus toxoid adsorbed; tetanus toxoid vaccine, inactivated",Vaccines,Vaccine,.,.,.,.,.,.,.
D0367,Clotrimazole,2812,Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole,Antifungal Agents,Small molecule,"1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H",VNFPBHJOKIVQEB-UHFFFAOYSA-N,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,23593-75-1,C22H17ClN2,3764,1F29-1F2F: Fungal infection
D0368,Clove,.,"5,7-dihydroxy-2-methyl-8-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 8-b-D-Glucopyranosyl-5,7-dihydroxy-2-methyl-4H-1-benzopyran-4-one; 8-C-Glucopyranosylnoreugenin; 8-Glucosyl-5,7-dihydroxy-2-methylchromone; CHEBI:175535; Clove 3; Isobiflorin; chromium(3+) trichloride; Chromium(III); chloride",Herbal Products,Natural product,.,.,.,.,.,.,.
D0369,Cloxacillin,6098,"Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid",Antibiotics,Small molecule,"1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1",LQOLIRLGBULYKD-JKIFEVAISA-N,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,61-72-3,C19H18ClN3O5S,49566,1A00-1C4Z: Bacterial infection
D0370,Clozapine,135398737,"Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",Antipsychotic Agents,Small molecule,"1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3",QZUDBNBUXVUHMW-UHFFFAOYSA-N,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,5786-21-0,C18H19ClN4,3766,6A20: Schizophrenia
D0371,Coagulation Factor IX Human,.,Coagulation Factor IX Human; Antihemophilic factor B; Coagulation factor IX (human); DB13152; Factor IX (Human); Human coagulation factor IX,Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0372,Coagulation factor VIIa Recombinant Human,.,Coagulation factor VIIa Recombinant Human; Coagulation factor VIIa; Coagulation factor VIIa (recombinant); DB00036; Eptacog alfa; Eptacog alfa (activated); rFVIIa,Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0373,Coagulation factor X human,.,"1363853-26-2; BY4TSK952Y; Damoctocog alfa pegol; Damoctocog alfa pegol [INN]; Des-(743-1636)-(1804-(S-(1-(3-((3-(2,3-bis(omega-methoxypoly(oxyethylene))propoxy)propyl)amino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine)(k>c))human coagulation factor viii; Q27274954; UNII-BY4TSK952Y",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0374,Coal tar (topical),.,NULL,Topical Agents,Small molecule,.,.,.,.,.,.,.
D0375,Cobicistat,25151504,"1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl",Antiviral Agents,Small molecule,"1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1",ZCIGNRJZKPOIKD-CQXVEOKZSA-N,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,1004316-88-4,C40H53N7O5S2,72291,1C60-1C62: Human immunodeficiency virus disease
D0376,Cobimetinib,16222096,"Cobimetinib fumarate; Cobimetinib Fumarate; Cobimetinib hemifumarate; Xl-518 hemifumarate; GDC-0973 hemifumarate; UNII-6EXI96H8SV; 6EXI96H8SV; Cobimetinib fumarate [USAN]; 1369665-02-0; Cobimetinib fumarate (USAN); Cotellic (TN); CHEMBL2364607; CHEBI:90853; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1); D10615; bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate",Multikinase Inhibitors,Small molecule,"1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,934660-93-2,C21H21F3IN3O2,90851,2C30: Melanoma; 2C60-2C6Y: Breast cancer; 2D42: Head and neck cancer; 2C90: Renal cell carcinoma; 2C92: Ureteral cancer; 2A00-2F9Z: Solid tumour/cancer
D0377,Cocaine (nasal),446220,"Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C"" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)",Anesthetics,Small molecule,"1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1",ZPUCINDJVBIVPJ-LJISPDSOSA-N,CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,50-36-2,C17H21NO4,27958,9A76-9A78: Corneal disease
D0378,Cocaine (topical),446220,"Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C"" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)",Anesthetics,Small molecule,"1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1",ZPUCINDJVBIVPJ-LJISPDSOSA-N,CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC,50-36-2,C17H21NO4,27958,9A76-9A78: Corneal disease
D0379,Codeine,5284371,"codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate",Analgesics,Small molecule,"1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1",OROGSEYTTFOCAN-DNJOTXNNSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,76-57-3,C18H21NO3,16714,MG30-MG3Z: Pain; MD12: Cough
D0380,Colchicine,6167,"Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine",Antigout Agents,Small molecule,"1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1",IAKHMKGGTNLKSZ-INIZCTEOSA-N,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,64-86-8,C22H25NO6,27882,FA25: Gout
D0381,Colesevelam,160051,CholestaGel; Welchol; Colesevelam hydrochloride; Welchol DM; GT31-104; GT31-104HB,Bile Acid Sequestrants,Small molecule,"1S/C13H27N.C12H27N2.C3H5ClO.C3H7N.2ClH/c1-3-5-6-7-8-9-10-11-13-14-12-4-2;1-5-10-13-11-8-6-7-9-12-14(2,3)4;4-1-3-2-5-3;1-2-3-4;;/h4,14H,2-3,5-13H2,1H3;5,13H,1,6-12H2,2-4H3;3H,1-2H2;2H,1,3-4H2;2*1H/q;+1;;;;/p-1",VTAKZNRDSPNOAU-UHFFFAOYSA-M,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],182815-44-7,C31H67Cl3N4O,.,5C80: Hyper-lipoproteinaemia
D0382,Colestipol,62816,Colestid; Colestipol Hydrochloride; Flavored Colestid,Bile Acid Sequestrants,Small molecule,"1S/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2",GMRWGQCZJGVHKL-UHFFFAOYSA-N,C1C(O1)CCl.C(CNCCNCCNCCN)N,90366-83-9,C11H28ClN5O,.,5C80: Hyper-lipoproteinaemia
D0383,Colistimethate,70789202,Colistimethate; Colistin Sulfomethate; Colistinmethanesulfonic acid; DB01111; NCGC00094630-03,Antibiotics,Small molecule,"InChI=1S/C58H110N16O28S5/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102)/p-5",BSSIRFLGSWHWDE-UHFFFAOYSA-I,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O,.,C58H105N16O28S5-5,.,.
D0384,Collagenase clostridium histolyticum,.,Xiaflex (TN),Collagenase Enzyme,Protein/peptide,.,.,.,.,.,.,4B20: Sarcoidosis
D0385,Conestat alfa,.,"C1 Esterase Inhibitor (Recombinant); C1 Inhibitor (Recombinant); Complement C1 esterase inhibitor; Conestat alfa; DB09228; Human C1-inhibitor (recombinant, rabbit derived); Recombinant complement C1 esterase inhibitor; Recombinant human C1 inhibitor; Recombinant human C1-inhibitor; Recombinant human C1-inhibitor rabbit milk derived",Hereditary Angioedema Agents,Protein/peptide,.,.,.,.,.,.,.
D0386,Conivaptan,151171,"Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide",Vasopressin Antagonists,Small molecule,"1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)",IKENVDNFQMCRTR-UHFFFAOYSA-N,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,210101-16-9,C32H26N4O2,681850,5C72: Hypo-osmolality/hyponatraemia
D0387,Conjugated estrogens,45357473,"Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate",Estrogens,Small molecule,"1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1",VUCAHVBMSFIGAI-TWCWWGPMSA-M,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],.,C18H21NaO5S,.,GA30: Menopausal disorder; CA08: Vasomotor/allergic rhinitis
D0388,Conjugated estrogens (topical),45357473,"Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate",Estrogens,Small molecule,"1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1",VUCAHVBMSFIGAI-TWCWWGPMSA-M,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],.,C18H21NaO5S,.,GA30: Menopausal disorder; CA08: Vasomotor/allergic rhinitis
D0389,Copanlisib,135565596,Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS,Pi3K Inhibitors,Small molecule,"1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)",MWYDSXOGIBMAET-UHFFFAOYSA-N,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,1032568-63-0,C23H28N8O4,.,2A80: Follicular lymphoma; 2B33: Malignant haematopoietic neoplasm
D0390,Copper gluconate,10692,"Copper gluconate; 527-09-3; Copper(II)gluconate; Copper(II) gluconate; Copper di-D-gluconate; CUPRIC GLUCONATE; Copper(II) D-gluconate; UNII-RV823G6G67; Copper gluconate [USP]; Copper(II) (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; RV823G6G67; copper;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Copper gluconate (USP); 13005-35-1; Gluconates; Gluconic Acid Copper(II) Salt; Cupric gluconate monohydrate; Copper, bis(D-gluconato)-; coppergluconate; Copper D-gluconate (1:2); CCRIS 3652; HSDB 261; Bis(D-gluconato-O1,O2)copper; Gluconic acid, copper(2+) salt; Gluconic acid, copper(2+) salt (2:1), D-; Copper, bis(D-gluconato-O1,O2)-; EINECS 208-408-2; Copper(2+) D-gluconate, (1:2); Bis(D-gluconato)copper; Chelates of copper gluconate; SCHEMBL23076; Copper Gluconate 14% 40M; DTXSID4035960; CHEBI:31431; Copper,bis(D-gluconato-kO1,kO2)-; AKOS015901520; CS-W011576; DB11246; AS-14692; Copper, bis(D-gluconato-kappaO1,kappaO2)-; G0275; Gluconic acid, copper(2+) salt (2:1) D-; D02395; Copper, bis (D-gluconato-O(sup 1),O(sup 2))-; Q3109285",Minerals And Electrolytes,Small molecule,"InChI=1S/2C6H12O7.Cu/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",OCUCCJIRFHNWBP-IYEMJOQQSA-L,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Cu+2],.,C12H22CuO14,.,.
D0391,Copper oxodotreotide Cu-64,.,64cu-dotatate; CHEMBL4297339; Copper 64-dota-tate; Copper cu-64 dotatate; Copper dotatate cu-64; Copper oxodotreotide cu-64,Diagnostic Radiopharmaceuticals,Small molecule,.,.,.,.,.,.,.
D0392,Corticotropin,16132265,"corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine",Corticosteroids,Hormones,"1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1",IDLFZVILOHSSID-OVLDLUHVSA-N,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N,12427-33-7,C207H308N56O58S,3892,GB61: Chronic kidney disease; 5A70: Cushing syndrome
D0393,Crizotinib,11626560,Xalkori (TN); novel ALK inhibitors,Multikinase Inhibitors,Small molecule,"1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,877399-52-5,C21H22Cl2FN5O,64310,2C25: Lung cancer
D0394,Cromoglicic acid,2882,Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN),Antiasthmatic Agents,Small molecule,"1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)",IMZMKUWMOSJXDT-UHFFFAOYSA-N,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,16110-51-3,C23H16O11,59773,CA23: Asthma; CA08: Vasomotor/allergic rhinitis
D0395,Cyanocobalamin,5311498,cyanocobalamin; 68-19-9,Vitamins,Small molecule,"1S/C62H90N13O14P.CN.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-2;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;/q;-1;+3/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",FDJOLVPMNUYSCM-WZHZPDAFSA-L,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co+3],68-19-9,C63H88CoN14O14P,.,3A00-3A9Z: Anemia
D0396,Cyclandelate,2893,"cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207",Vasodilator Agents,Small molecule,"1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3",WZHCOOQXZCIUNC-UHFFFAOYSA-N,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,456-59-7,C17H24O3,3988,6D80-6D8Z: Dementia
D0397,Cyclizine,6726,Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine,Antiemetics,Small molecule,"1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3",UVKZSORBKUEBAZ-UHFFFAOYSA-N,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,82-92-8,C18H22N2,3994,MD90: Nausea/vomiting
D0398,Cyclobenzaprine,2895,"Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.",Antidepressants,Small molecule,"1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3",JURKNVYFZMSNLP-UHFFFAOYSA-N,CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31,303-53-7,C20H21N,3996,6A70-6A7Z: Depression
D0399,Cyclopentolate (ophthalmic),2905,"Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester",Parasympatholytics,Small molecule,"1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3",SKYSRIRYMSLOIN-UHFFFAOYSA-N,CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O,512-15-2,C17H25NO3,4024,QA00: General examination
D0400,Cyclophosphamide,2907,"ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide",Antineoplastics,Small molecule,"1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)",CMSMOCZEIVJLDB-UHFFFAOYSA-N,C1CNP(=O)(OC1)N(CCCl)CCCl,50-18-0,C7H15Cl2N2O2P,4027,2A00-2F9Z: Solid tumour/cancer
D0401,Cycloserine,6234,"D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin;  Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One",Antiinfective Agents,Small molecule,"1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1",DYDCUQKUCUHJBH-UWTATZPHSA-N,C1C(C(=O)NO1)N,68-41-7,C3H6N2O2,40009,1B10-1B14: HIV-infected patients with tuberculosis; 1A00-1C4Z: Bacterial infection; 6B20: Obsessive-compulsive disorder
D0402,Cyclosporine,5284373,cyclosporin A; cyclosporine; Neoral; Cyclosporin; Ciclosporine; Sandimmun; Sang-35,Antiviral Agents,Small molecule,"1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",PMATZTZNYRCHOR-CGLBZJNRSA-N,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,59865-13-3,C62H111N11O12,4031,1D64-1D65: COVID-19
D0403,Cyproheptadine,2913,"Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene",Antihistamines,Small molecule,"1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3",JJCFRYNCJDLXIK-UHFFFAOYSA-N,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,129-03-3,C21H21N,4046,FA20: Rheumatoid arthritis
D0404,Cytarabine,6253,"Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one",Antineoplastics,Small molecule,"1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1",UHDGCWIWMRVCDJ-CCXZUQQUSA-N,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,147-94-4,C9H13N3O5,28680,2A85: Mature B-cell lymphoma
D0405,Cytarabine (liposomal),6253,"Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one",Antineoplastics,Small molecule,"1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1",UHDGCWIWMRVCDJ-CCXZUQQUSA-N,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,147-94-4,C9H13N3O5,28680,2A85: Mature B-cell lymphoma
D0406,Dabrafenib,44462760,"1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436",Multikinase Inhibitors,Small molecule,"1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,1195765-45-7,C23H20F3N5O2S2,75045,2C30: Melanoma
D0407,Dacarbazine,135398738,"Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide",Antineoplastics,Small molecule,"1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+",FDKXTQMXEQVLRF-ZHACJKMWSA-N,CN(C)N=NC1=C(NC=N1)C(=O)N,891986,C6H10N6O,94587,2C30: Melanoma
D0408,Daclatasvir,25154714,1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410,Ns5A Inhibitors,Small molecule,"1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1",FKRSSPOQAMALKA-CUPIEXAXSA-N,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,1009119-64-5,C40H50N8O6,82977,1E50-1E51: Hepatitis virus infection
D0409,Dacomitinib,11511120,PF-00299804,Antineoplastics/Her2 Inhibitors,Small molecule,"1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+",LVXJQMNHJWSHET-AATRIKPKSA-N,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,1110813-31-4,C24H25ClFN5O2,91466,2C25: Lung cancer
D0410,Dactinomycin,457193,"Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide",Antineoplastics,Small molecule,"1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1",RJURFGZVJUQBHK-IIXSONLDSA-N,CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C,50-76-0,C62H86N12O16,27666,2A00-2F9Z: Solid tumour/cancer
D0411,Dalbavancin,16134627,Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba,Glycopeptide Antibiotics,Small molecule,"1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1",KGPGQDLTDHGEGT-SZUNQUCBSA-N,CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,171500-79-1,C88H100Cl2N10O28,82721,1A00-1C4Z: Bacterial infection
D0412,Dalfampridine,1727,Ampyra (TN),Cns Agents,Small molecule,"1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",NUKYPUAOHBNCPY-UHFFFAOYSA-N,C1=CN=CC=C1N,504-24-5,C5H6N2,34385,8A40: Multiple sclerosis
D0413,Dalfopristin,6323289,"5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE",Antibiotics,Small molecule,"1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1",SUYRLXYYZQTJHF-VMBLUXKRSA-N,CCN(CC)CCS(=O)(=O)C1CCN2C1C(=O)OC(C(C=CC(=O)NCC=CC(=CC(CC(=O)CC3=NC(=CO3)C2=O)O)C)C)C(C)C,112362-50-2,C34H50N4O9S,4309,1A00-1C4Z: Bacterial infection
D0414,Dalteparin,772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D0415,Danaparoid,.,Orgaran (TN),Anticoagulants,Small molecule,.,.,.,.,.,.,BD71: Deep vein thrombosis
D0416,Danazol,28417,"Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol",Fertility Agents,Small molecule,"1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1",POZRVZJJTULAOH-LHZXLZLDSA-N,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,17230-88-5,C22H27NO2,4315,GA20: Menstrual cycle bleeding disorder; 2C60-2C6Y: Breast cancer
D0417,Dantrolene,6914273,"Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione",Muscle Relaxants,Small molecule,"1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+",OZOMQRBLCMDCEG-VIZOYTHASA-N,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],7261-97-4,C14H10N4O5,.,MG26: Fever
D0418,Dapagliflozin,9887712,"BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol",Antidiabetic Agents,Small molecule,"1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1",JVHXJTBJCFBINQ-ADAARDCZSA-N,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,461432-26-8,C21H25ClO6,85078,5A11: Type 2 diabetes mellitus
D0419,Dapsone,2955,"Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline",Antiinflammatory Agents,Small molecule,"1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2",MQJKPEGWNLWLTK-UHFFFAOYSA-N,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,80-08-0,C12H12N2O2S,4325,CA40: Pneumonia
D0420,Dapsone (topical),2955,"Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline",Antiinflammatory Agents,Small molecule,"1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2",MQJKPEGWNLWLTK-UHFFFAOYSA-N,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,80-08-0,C12H12N2O2S,4325,CA40: Pneumonia
D0421,Daptomycin,16134395,"Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox",Antibiotics,Small molecule,"1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1",DOAKLVKFURWEDJ-RWDRXURGSA-N,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,103060-53-3,C72H101N17O26,600103,1A00-1C4Z: Bacterial infection
D0422,Daratumumab,.,.,Antineoplastics/Cd38 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2A83: Multiple myeloma
D0423,Darbepoetin alfa,.,Aranesp (TN),Antianemic Agents,Protein/peptide,.,.,.,.,.,.,3A00-3A9Z: Anemia
D0424,Darifenacin,444031,"Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN];  Emselex; Emselex (TN); Enablex (TN)",Urinary Antispasmodics,Small molecule,"1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1",HXGBXQDTNZMWGS-RUZDIDTESA-N,C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,133099-04-4,C28H30N2O2,391960,GC50: Functional bladder disorder
D0425,Darolutamide,67171867,"1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen",Antiandrogens,Small molecule,"1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1",BLIJXOOIHRSQRB-PXYINDEMSA-N,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,1297538-32-9,C19H19ClN6O2,.,2C82: Prostate cancer
D0426,Darunavir,213039,"206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl;  Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",Antiviral Agents,Small molecule,"1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1",CJBJHOAVZSMMDJ-HEXNFIEUSA-N,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,206361-99-1,C27H37N3O7S,367163,1C60-1C62: Human immunodeficiency virus disease
D0427,Dasabuvir,56640146,"Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; ABT333; UNII-DE54EQW8T1; ABT 333; Dasabuvir (ABT-333); DE54EQW8T1; CHEBI:85182; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; Dasabuvir [USAN:INN]; Dasabuvir (USA",Antiviral Agents,Small molecule,"1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)",NBRBXGKOEOGLOI-UHFFFAOYSA-N,CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O,1132935-63-7,C26H27N3O5S,85182,1E50-1E51: Hepatitis virus infection
D0428,Dasatinib,3062316,"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel",Antineoplastics,Small molecule,"1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,302962-49-8,C22H26ClN7O2S,49375,2A20: Myeloproliferative neoplasm; 2A83: Multiple myeloma
D0429,Daunorubicin,30323,"daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142;  Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline",Antineoplastics,Small molecule,"1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1",STQGQHZAVUOBTE-VGBVRHCVSA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,20830-81-3,C27H29NO10,41977,2A60: Acute myeloid leukaemia; 2A00-2F9Z: Solid tumour/cancer; 2B57: Kaposi sarcoma
D0430,Daunorubicin (liposomal),30323,"daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142;  Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline",Antineoplastics,Small molecule,"1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1",STQGQHZAVUOBTE-VGBVRHCVSA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,20830-81-3,C27H29NO10,41977,2A60: Acute myeloid leukaemia; 2A00-2F9Z: Solid tumour/cancer; 2B57: Kaposi sarcoma
D0431,Decitabine,451668,"AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2&prime;-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2&prime;-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc",Antineoplastics,Small molecule,"1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1",XAUDJQYHKZQPEU-KVQBGUIXSA-N,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,2353-33-5,C8H12N4O4,50131,2A37: Myelodysplastic syndrome
D0432,Deferasirox,214348,Deferasirox,Chelating Agents,Small molecule,"1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",BOFQWVMAQOTZIW-UHFFFAOYSA-N,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,201530-41-8,C21H15N3O4,49005,5C64: Mineral absorption/transport disorder
D0433,Deferiprone,2972,Ferriprox (TN),Chelating Agents,Small molecule,"1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3",TZXKOCQBRNJULO-UHFFFAOYSA-N,CC1=C(C(=O)C=CN1C)O,30652-11-0,C7H9NO2,68554,3A50: Thalassaemia
D0434,Deferoxamine,2973,"deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; 70-51-9; Deferrioxamine; Deferoxamin; Deferoxaminum; DFOM; Desferin; Desferral; Desferrin; Desferex; Desferan; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; Desferriferrioxamin B; UNII-J06Y7MXW4D; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina ; Deferoxamine",Antiviral Agents,Small molecule,"1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)",UBQYURCVBFRUQT-UHFFFAOYSA-N,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,70-51-9,C25H48N6O8,4356,1D64-1D65: COVID-19
D0435,Defibrotide,135565962,"STA-1474; Defibrotide sodium; UNII-E1942E7K32; E1942E7K32; Defibrotide; 1118915-78-8; SCHEMBL419884; CHEMBL3674153; JNWFIPVDEINBAI-UHFFFAOYSA-N; BDBM176684; BCP24376; BCP23704; 83712-60-1; US9120745, 3; Q27276739; Defibrotide sodium",Antiviral Agents,Small molecule,"1S/C20H21N4O6P/c1-11(2)14-9-15(17(25)10-18(14)30-31(27,28)29)19-21-22-20(26)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25H,1-3H3,(H,22,26)(H2,27,28,29)",JNWFIPVDEINBAI-UHFFFAOYSA-N,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)OP(=O)(O)O,1118915-78-8,C20H21N4O6P,.,1D64-1D65: COVID-19
D0436,Deflazacort,189821,C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927,Glucocorticoids,Small molecule,"1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1",FBHSPRKOSMHSIF-GRMWVWQJSA-N,CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C,14484-47-0,C25H31NO6,135720,8C70: Muscular dystrophy
D0437,Degarelix,16136245,Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2,Hormones/Antineoplastics,Small molecule,"1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1",MEUCPCLKGZSHTA-XYAYPHGZSA-N,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C,214766-78-6,C82H103ClN18O16,135961,2C82: Prostate cancer
D0438,Delafloxacin,487101,"Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN)",Quinolones/Antibiotics,Small molecule,"1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)",DYDCPNMLZGFQTM-UHFFFAOYSA-N,C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O,189279-58-1,C18H12ClF3N4O4,.,1A00-1C4Z: Bacterial infection
D0439,Delavirdine,5625,"DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine",Anti-Hiv Agents,Small molecule,"1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3",WHBIGIKBNXZKFE-UHFFFAOYSA-N,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,136817-59-9,C22H28N6O3S,119573,1C60-1C62: Human immunodeficiency virus disease
D0440,Demecarium (ophthalmic),5966,"Demecarium; Demecarium ion; Demecarium cation; UNII-ILP8XJ8R5K; ILP8XJ8R5K; CHEBI:59719; 16505-84-3; Demecarium [VANDF]; Demecarium [WHO-DD]; demarcarium; Prestwick3_000616; SCHEMBL61421; BSPBio_000552; BPBio1_000608; CHEMBL1201229; DTXSID2046965; ZINC3875376; (m-Hydroxyphenyl)trimethylammonium decamethylenebis(methylcarbamate); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl(-N,N'-dimethyldecamethylenediamine; DB00944; 3,3'-(1,10-Decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethylbenzenaminium); Benzenaminium, 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-; NCGC00179526-01; NCGC00179526-03; NCGC00179526-05; AB00513869; 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium); N,N,N-trimethyl-3-{[methyl(10-{methyl[3-(trimethylazaniumyl)phenoxycarbonyl]amino}decyl)carbamoyl]oxy}anilinium",Ophthalmic Glaucoma Agents,Small molecule,"InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2",RWZVPVOZTJJMNU-UHFFFAOYSA-N,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C,.,C32H52N4O4+2,.,.
D0441,Demeclocycline,54680690,"Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline",Antibiotics,Small molecule,"1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1",GUXHBMASAHGULD-SEYHBJAFSA-N,CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,127-33-3,C21H21ClN2O8,4392,CA20: Bronchitis; ED80: Acne vulgaris; 1C1G: Lyme borreliosis
D0442,Denileukin diftitox,.,.,Antineoplastics,Interferons,.,.,.,.,.,.,2A60-2B33: Leukaemia; 2C25: Lung cancer
D0443,Denosumab,.,Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN),Bone Resorption Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FB83: Low bone mass disorder; FA20: Rheumatoid arthritis; 2C82: Prostate cancer
D0444,Deserpidine,8550,"Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)",Antihypertensive Agents,Small molecule,"1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1",CVBMAZKKCSYWQR-WCGOZPBSSA-N,COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,131-01-1,C32H38N2O8,27478,BA00-BA04: Hypertension
D0445,Desflurane,42113,"Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane",Anesthetics,Small molecule,"1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H",DPYMFVXJLLWWEU-UHFFFAOYSA-N,C(C(F)(F)F)(OC(F)F)F,57041-67-5,C3H2F6O,4445,9A76-9A78: Corneal disease
D0446,Desipramine,2995,"Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl",Antidepressants,Small molecule,"1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3",HCYAFALTSJYZDH-UHFFFAOYSA-N,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,50-47-5,C18H22N2,47781,6A05: Attention deficit hyperactivity disorder; 6A70-6A7Z: Depression
D0447,Desirudin,16129703,Iprivask (TN),Anticoagulants,Small molecule,"1S/C287H440N80O110S6/c1-25-133(19)226-281(470)345-161(87-125(3)4)235(424)306-111-208(395)320-180(116-370)266(455)344-175(101-219(415)416)237(426)307-105-202(389)316-151(62-75-212(401)402)242(431)321-145(41-30-33-81-288)240(429)339-170(96-197(297)384)258(447)326-152(57-70-193(293)380)249(438)351-185(121-481-478-118-182-239(428)310-107-201(388)313-147(55-68-191(291)378)232(421)303-108-205(392)317-169(95-196(296)383)257(446)322-146(42-31-34-82-289)241(430)350-186(271(460)360-226)122-482-479-119-183(268(457)323-149(61-74-211(399)400)234(423)304-110-207(394)319-179(115-369)265(454)342-173(99-200(300)387)264(453)357-223(130(13)14)279(468)355-182)352-253(442)164(90-128(9)10)335-269(458)184-120-480-483-123-187(354-262(451)177(103-221(419)420)347-283(472)230(137(23)374)362-263(452)167(93-141-49-53-144(377)54-50-141)346-278(467)224(131(15)16)359-276(465)222(301)129(11)12)272(461)363-229(136(22)373)282(471)330-157(66-79-216(409)410)248(437)348-178(114-368)238(427)309-106-203(390)315-150(56-69-192(292)379)243(432)340-171(97-198(298)385)259(448)334-163(89-127(7)8)252(441)353-184)270(459)358-225(132(17)18)280(469)364-228(135(21)372)277(466)311-112-204(391)314-148(60-73-210(397)398)233(422)305-113-209(396)356-231(138(24)375)286(475)367-86-38-46-190(367)275(464)331-159(43-32-35-83-290)284(473)365-84-36-44-188(365)273(462)328-153(58-71-194(294)381)247(436)349-181(117-371)267(456)338-168(94-142-104-302-124-312-142)256(445)341-172(98-199(299)386)260(449)343-174(100-218(413)414)236(425)308-109-206(393)318-176(102-220(417)418)261(450)337-165(91-139-39-28-27-29-40-139)254(443)327-154(63-76-213(403)404)244(433)325-158(67-80-217(411)412)250(439)361-227(134(20)26-2)285(474)366-85-37-45-189(366)274(463)329-156(65-78-215(407)408)245(434)324-155(64-77-214(405)406)246(435)336-166(92-140-47-51-143(376)52-48-140)255(444)333-162(88-126(5)6)251(440)332-160(287(476)477)59-72-195(295)382/h27-29,39-40,47-54,104,124-138,145-190,222-231,368-377H,25-26,30-38,41-46,55-103,105-123,288-290,301H2,1-24H3,(H2,291,378)(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H,302,312)(H,303,421)(H,304,423)(H,305,422)(H,306,424)(H,307,426)(H,308,425)(H,309,427)(H,310,428)(H,311,466)(H,313,388)(H,314,391)(H,315,390)(H,316,389)(H,317,392)(H,318,393)(H,319,394)(H,320,395)(H,321,431)(H,322,446)(H,323,457)(H,324,434)(H,325,433)(H,326,447)(H,327,443)(H,328,462)(H,329,463)(H,330,471)(H,331,464)(H,332,440)(H,333,444)(H,334,448)(H,335,458)(H,336,435)(H,337,450)(H,338,456)(H,339,429)(H,340,432)(H,341,445)(H,342,454)(H,343,449)(H,344,455)(H,345,470)(H,346,467)(H,347,472)(H,348,437)(H,349,436)(H,350,430)(H,351,438)(H,352,442)(H,353,441)(H,354,451)(H,355,468)(H,356,396)(H,357,453)(H,358,459)(H,359,465)(H,360,460)(H,361,439)(H,362,452)(H,363,461)(H,364,469)(H,397,398)(H,399,400)(H,401,402)(H,403,404)(H,405,406)(H,407,408)(H,409,410)(H,411,412)(H,413,414)(H,415,416)(H,417,418)(H,419,420)(H,476,477)/t133-,134-,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1",XYWBJDRHGNULKG-OUMQNGNKSA-N,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CN=CN7)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C,120993-53-5,C287H440N80O110S6,.,BD71: Deep vein thrombosis
D0448,Desloratadine,124087,"Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine",Antiallergic Agents,Small molecule,"1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",JAUOIFJMECXRGI-UHFFFAOYSA-N,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,100643-71-8,C19H19ClN2,291342,CA08: Vasomotor/allergic rhinitis
D0449,Desmopressin,5311065,"Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin;  Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals",Antidiuretic Hormones,Small molecule,"1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1",NFLWUMRGJYTJIN-PNIOQBSNSA-N,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,16679-58-6,C46H64N14O12S2,4450,5A2Y: Acute diabete complication
D0450,Desogestrel,40973,"Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol",Contraceptive Agents,Small molecule,"1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1",RPLCPCMSCLEKRS-BPIQYHPVSA-N,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CCCCC34,54024-22-5,C22H30O,4453,QA21: Contraceptive management
D0451,Desvenlafaxine,125017,"Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233",Snris/Antidepressants,Small molecule,"1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3",KYYIDSXMWOZKMP-UHFFFAOYSA-N,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,93413-62-8,C16H25NO2,83527,6A70-6A7Z: Depression; GA30: Menopausal disorder
D0452,Deutetrabenazine,73437646,Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN],Vmat2 Inhibitors,Small molecule,"1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3",MKJIEFSOBYUXJB-VFJJUKLQSA-N,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC,1392826-25-3,C19H27NO3,.,8A02: Dystonic disorder; 8A01: Choreiform disorder
D0453,Dexamethasone,5743,"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",UREBDLICKHMUKA-CXSFZGCWSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,18296,C22H29FO5,41879,FA20: Rheumatoid arthritis
D0454,Dexamethasone (nasal),5743,"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",UREBDLICKHMUKA-CXSFZGCWSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,18296,C22H29FO5,41879,FA20: Rheumatoid arthritis
D0455,Dexamethasone (ophthalmic),5743,"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",UREBDLICKHMUKA-CXSFZGCWSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,18296,C22H29FO5,41879,FA20: Rheumatoid arthritis
D0456,Dexbrompheniramine,16960,"Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine",Antihistamines,Small molecule,"1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1",ZDIGNSYAACHWNL-HNNXBMFYSA-N,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2,132-21-8,C16H19BrN2,59269,CA08: Vasomotor/allergic rhinitis
D0457,Dexfenfluramine,66265,DEXFENFLURAN; Dexfenfluramine (INN); Redux (TN); (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine,Appetite Depressants,Small molecule,"1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1",DBGIVFWFUFKIQN-VIFPVBQESA-N,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,3239-44-9,C12H16F3N,439329,5B80-5B81: Obesity
D0458,Dexlansoprazole,9578005,"dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN);  Kapidex; KS-1075; Lansoprazole",Proton Pump Inhibitors,Small molecule,"1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1",MJIHNNLFOKEZEW-RUZDIDTESA-N,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,138530-94-6,C16H14F3N3O2S,135931,DA22: Gastro-oesophageal reflux disease; DA25: Oesophageal ulcer; DA61: Peptic ulcer; DA60: Gastric ulcer
D0459,Dexmedetomidine,5311068,"Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1",CUHVIMMYOGQXCV-NSHDSACASA-N,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,113775-47-6,C13H16N2,4466,MB24: Mood/affect symptom
D0460,Dexmethylphenidate,154101,"Dexmethylphenidate; d-threo-Methylphenidate; (+)-threo-Methylphenidate; Focalin; UNII-M32RH9MFGP; d-Methylphenidate; 40431-64-9; D-TMP; Dexmethylphenidate [INN]; M32RH9MFGP; CHEMBL827; CHEBI:51860; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; Focalin XR; Dexmethylphenidate (INN); methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; Methyl D-phenidate; Dex methylphenidate; D-MPH; threo-(+)-Methylphenidate; Attenade; dexmetilfenidato; dexmethylphenidatum; dex-methylphenidate; d-threo methylphenidate; Methylphenidate d-threo-form; SCHEMBL34326; GTPL7554; DTXSID70893769; ZINC896711; 40572-71-2; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, (alphaR,2R)-; BDBM50062915; PDSP1_000871; PDSP1_000903; PDSP2_000857; PDSP2_000889; DB06701; D07806; Q1207210; UNII-207ZZ9QZ49 component DUGOZIWVEXMGBE-CHWSQXEVSA-N; 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, (.alpha.S,2S)-",Norepinephrine-Dopamine Reuptake Inhibitor,Small molecule,"InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1",DUGOZIWVEXMGBE-CHWSQXEVSA-N,COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2,.,C14H19NO2,.,.
D0461,Dexrazoxane,71384,"24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum;  Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187",Antineoplastics,Small molecule,"1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1",BMKDZUISNHGIBY-ZETCQYMHSA-N,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,24584-09-6,C11H16N4O4,50223,.
D0462,Dextran (-1),4125253,Isomaltotri-itol; Isomaltosaccharide; CHEBI:27649; DEXTRAN; alpha-D-glucopyranosyl-(1-&gt;6)-alpha-D-glucopyranosyl-(1-&gt;6)-D-glucose; O-alpha-D-Glucopyranosyl-(1.6)-O-alpha-D-glucopyranosyl-(1.6)-D-glucose; AC1NUSPK; SCHEMBL206877; CHEMBL1697742; ZINC64622163; I14-57292,Plasma Expanders,Small molecule,"1S/C18H32O16/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18/h1,5-18,20-30H,2-4H2",FZWBNHMXJMCXLU-UHFFFAOYSA-N,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O,9004-54-0,C18H32O16,.,DB61-GB90: Thrombosis
D0463,Dextran (high molecular weight),4125253,Isomaltotri-itol; Isomaltosaccharide; CHEBI:27649; DEXTRAN; alpha-D-glucopyranosyl-(1-&gt;6)-alpha-D-glucopyranosyl-(1-&gt;6)-D-glucose; O-alpha-D-Glucopyranosyl-(1.6)-O-alpha-D-glucopyranosyl-(1.6)-D-glucose; AC1NUSPK; SCHEMBL206877; CHEMBL1697742; ZINC64622163; I14-57292,Plasma Expanders,Small molecule,"1S/C18H32O16/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18/h1,5-18,20-30H,2-4H2",FZWBNHMXJMCXLU-UHFFFAOYSA-N,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O,9004-54-0,C18H32O16,.,DB61-GB90: Thrombosis
D0464,Dextran (low molecular weight),4125253,Isomaltotri-itol; Isomaltosaccharide; CHEBI:27649; DEXTRAN; alpha-D-glucopyranosyl-(1-&gt;6)-alpha-D-glucopyranosyl-(1-&gt;6)-D-glucose; O-alpha-D-Glucopyranosyl-(1.6)-O-alpha-D-glucopyranosyl-(1.6)-D-glucose; AC1NUSPK; SCHEMBL206877; CHEMBL1697742; ZINC64622163; I14-57292,Plasma Expanders,Small molecule,"1S/C18H32O16/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18/h1,5-18,20-30H,2-4H2",FZWBNHMXJMCXLU-UHFFFAOYSA-N,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O,9004-54-0,C18H32O16,.,DB61-GB90: Thrombosis
D0465,Dextroamphetamine,5826,"D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga",Cns Stimulants,Small molecule,"1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1",KWTSXDURSIMDCE-QMMMGPOBSA-N,CC(CC1=CC=CC=C1)N,51-64-9,C9H13N,4469,7A20: Narcolepsy; 6A05: Attention deficit hyperactivity disorder
D0466,Dextromethorphan,5360696,"Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)",Analgesics,Small molecule,"1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1",MKXZASYAUGDDCJ-NJAFHUGGSA-N,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,125-71-3,C18H25NO,4470,MD12: Cough
D0467,Dextropropoxyphene,10100,"Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane",Analgesics,Small molecule,"1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1",XLMALTXPSGQGBX-GCJKJVERSA-N,CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C,469-62-5,C22H29NO2,51173,MG30-MG3Z: Pain
D0468,"Dextrose, unspecified form",5793,"D-Glucopyranose; Glucopyranose; D-Glc; D-Glcp; Glucodin; Meritose; Clintose L; Roferose ST; CPC hydrate; Clearsweet 95; 2280-44-6; Staleydex 95M; CHEBI:4167; Glucopyranoside; D-Glucopyranoside; Glc; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Glucopyranose, D-; DSSTox_CID_2910; Glucose solution; D-Glucopyranose, anhydrous; glc-ring; D-glucose-ring; Cartose Cerelose; Staleydex 130; Glucose 40; EINECS 218-914-5; Meritose 200; Glc-OH",Caloric Supply Agents,Small molecule,"1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1",WQZGKKKJIJFFOK-GASJEMHNSA-N,C(C1C(C(C(C(O1)O)O)O)O)O,2280-44-6,C6H12O6,4167,.
D0469,Dextrothyroxine,8730,"D-Thyroxine; Dextrothyroxine; 51-49-0; Choloxin; (R)-2-Amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid; Biotirmone; UNII-4W9K63FION; (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; D-T4; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine; D-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; CHEMBL559; 4W9K63FION; CHEBI:30659; Debetrol; Dethyrona; Detyroxin; Dextroid; Dextroxin; Dextrothyroxinum; Dextrothyroxine [BAN]; EINECS 200-102-7; CAS-51-48-9; D-Thyroxine, 99%; D-4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzylalanine; SCHEMBL61194; GTPL6951; BCBcMAP01_000232; DTXSID60199000; ACT03142; HY-A0152; ZINC3830994; BDBM50225220; MFCD00063056; AKOS007930308; DB00509; (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic aci d; SMP1_000296; NCGC00016228-01; DS-18593; CS-0017477; 051T490; A871266; Q5268499; UNII-QR0BV3BRIA component XUIIKFGFIJCVMT-GFCCVEGCSA-N; D-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzylalanine; D-thyroxine free acid; Thyroxine; 98%",Antihyperammonia Agents,Small molecule,"InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1",XUIIKFGFIJCVMT-GFCCVEGCSA-N,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)O)N,.,C15H11I4NO4,.,.
D0470,Dezocine,3033053,"SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol",Analgesics,Small molecule,"1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1",VTMVHDZWSFQSQP-VBNZEHGJSA-N,CC12CCCCCC(C1N)CC3=C2C=C(C=C3)O,53648-55-8,C16H23NO,4474,MG30-MG3Z: Pain
D0471,Diamorphine,5462328,Diamorphine (TN),Narcotic Analgesics,Small molecule,"1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1",GVGLGOZIDCSQPN-PVHGPHFFSA-N,CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C,561-27-3,C21H23NO5,27808,6B60: Dissociative neurological symptom disorder
D0472,Diatrizoate,2140,Diatrizoate sodium,Ionic Iodinated Contrast Media,Small molecule,"1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)",YVPYQUNUQOZFHG-UHFFFAOYSA-N,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,117-96-4,C11H9I3N2O4,53691,GC2Z: Urinary system disease
D0473,Diazepam,3016,"diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol;  Diazepam (intranasal, epilepsy)",Benzodiazepine Anticonvulsants,Small molecule,"1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3",AAOVKJBEBIDNHE-UHFFFAOYSA-N,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,439-14-5,C16H13ClN2O,49575,8A61-8A6Z: Epilepsy/seizure
D0474,Diazoxide,3019,"Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1",Antihypertensive Agents,Small molecule,"1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)",GDLBFKVLRPITMI-UHFFFAOYSA-N,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,364-98-7,C8H7ClN2O2S,4495,BA00-BA04: Hypertension
D0475,Dichloralphenazone,10188,"Dichloralphenazone; Dichloralantipyrine; 480-30-8; UNII-YYX637R279; YYX637R279; 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one, compd. with 2,2,2-trichloro-1,1-ethanediol (1:2); Kloralfenazon; Dormuphar; Ibiodorm; Sominat; Welldorm; Sedor; Dichloralantipyrin; EINECS 207-546-0; 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-, compd. with 2,2,2-trichloro-1,1-ethanediol (1:2); Antipyrine, compound with chloral hydrate (1:2); Dichloralphenazone [USP:INN:BAN]; Dichloralphenazone civ; Dichloralphenazone (USP); 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one, compound with 2,2,2-trichloroethane-1,1-diol (1:2); SCHEMBL115159; ANTIPYRINE, compd. with CHLORAL HYDRATE (1:2); CHEMBL1697834; DTXSID2022919; 1,5-dimethyl-2-phenylpyrazol-3-one;2,2,2-trichloroethane-1,1-diol; DB01495; FT-0750065; D03785; Q5272471; 1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one - 2,2,2-trichloroethane-1,1-diol (1:2); 1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one compound with 2,2,2-trichloroethane-1,1-diol (1:2)",Antimigraine Agents,Small molecule,"InChI=1S/C11H12N2O.2C2H3Cl3O2/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10;2*3-2(4,5)1(6)7/h3-8H,1-2H3;2*1,6-7H",ATKXDQOHNICLQW-UHFFFAOYSA-N,CC1=CC(=O)N(N1C)C2=CC=CC=C2.C(C(Cl)(Cl)Cl)(O)O.C(C(Cl)(Cl)Cl)(O)O,.,C15H18Cl6N2O5,.,.
D0476,Diclofenac,3033,"Diclofenac (sodium matrix patch, pain)",Nsaids/Analgesics,Small molecule,"1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)",DCOPUUMXTXDBNB-UHFFFAOYSA-N,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,15307-86-5,C14H11Cl2NO2,47381,FA00-FA05: Osteoarthritis
D0477,Diclofenac (ophthalmic),3033,"Diclofenac (sodium matrix patch, pain)",Nsaids/Analgesics,Small molecule,"1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)",DCOPUUMXTXDBNB-UHFFFAOYSA-N,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,15307-86-5,C14H11Cl2NO2,47381,FA00-FA05: Osteoarthritis
D0478,Diclofenac (topical),3033,"Diclofenac (sodium matrix patch, pain)",Nsaids/Analgesics,Small molecule,"1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)",DCOPUUMXTXDBNB-UHFFFAOYSA-N,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,15307-86-5,C14H11Cl2NO2,47381,FA00-FA05: Osteoarthritis
D0479,Diclofenamide,3038,"dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis;  Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE",Ophthalmic Glaucoma Agents,Small molecule,"1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)",GJQPMPFPNINLKP-UHFFFAOYSA-N,C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N,120-97-8,C6H6Cl2N2O4S2,101085,9C61: Glaucoma
D0480,Dicloxacillin,18381,"Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1",YFAGHNZHGGCZAX-JKIFEVAISA-N,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,3116-76-5,C19H17Cl2N3O5S,4511,1A00-1C4Z: Bacterial infection
D0481,Dicoumarol,54676038,"Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3&prime;-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin",Anticoagulants,Small molecule,"1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2",DOBMPNYZJYQDGZ-UHFFFAOYSA-N,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,66-76-2,C19H12O6,4513,DB61-GB90: Thrombosis; GA20-GA21: Bleeding disorder
D0482,Dicyclomine,3042,"Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride",Anticholinergic Agents,Small molecule,"1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3",CURUTKGFNZGFSE-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,77-19-0,C19H35NO2,4514,DD91: Irritable bowel syndrome
D0483,Didanosine,135398739,"didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927",Anti-Hiv Agents,Small molecule,"1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1",BXZVVICBKDXVGW-NKWVEPMBSA-N,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,69655-05-6,C10H12N4O3,490877,1C60-1C62: Human immunodeficiency virus disease
D0484,Dienestrol (topical),667476,"Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol",Estrogens,Small molecule,"1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+",NFDFQCUYFHCNBW-SCGPFSFSSA-N,CC=C(C1=CC=C(C=C1)O)C(=CC)C2=CC=C(C=C2)O,13029-44-2,C18H18O2,4518,GA30: Menopausal disorder
D0485,Dienogest,68861,"Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one;  Natazia (TN)",Contraceptives,Small molecule,"1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1",AZFLJNIPTRTECV-FUMNGEBKSA-N,CC12CCC3=C4CCC(=O)C=C4CCC3C1CCC2(CC#N)O,65928-58-7,C20H25NO2,70708,GA10: Endometriosis; QA21: Contraceptive management
D0486,Diethylpropion,7029,Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone;  Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone,Cns Stimulants,Small molecule,"1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3",XXEPPPIWZFICOJ-UHFFFAOYSA-N,CCN(CC)C(C)C(=O)C1=CC=CC=C1,90-84-6,C13H19NO,4530,5B80-5B81: Obesity; 8A80: Migraine
D0487,Diethylstilbestrol,448537,"Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol ""2"" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol",Antineoplastics,Small molecule,"1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+",RGLYKWWBQGJZGM-ISLYRVAYSA-N,CCC(=C(CC)C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,56-53-1,C18H20O2,41922,GA02: Vaginitis
D0488,Difenoxin,34328,"Difenoxin; Diphenoxylic acid; Difenoxine; Motofen; Difenoxinum; Diphenoxin; Lyspafen; 28782-42-5; Difenoxina; diphenoxilic acid; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid; UNII-3ZZ5BJ9F2Q; 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid; MCN-JR-15,403-11; ISONIPECOTIC ACID, 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-; 3ZZ5BJ9F2Q; CHEBI:4534; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-; R 15,403 [AS HYDROCHLORIDE]; R-15403; Difenossina [DCIT]; Difenossina; Difenoxilic acid; Difenoxylic acid; Difenoxinum [INN-Latin]; Difenoxina [INN-Spanish]; Difenoxin [USAN:INN:BAN]; McN-JR 15403-11; McN-JR 15,403-11; Motofen (Salt/Mix); 1-(3-Cyan-3,3-diphenylpropyl)-4-phenyl-4-piperidincarbonsaeure; Acscn-9168; Difenoxin (USAN/INN); SCHEMBL123801; R-15403 (Salt/Mix); GTPL7592; IDS-ND-007; Diphenoxylate related compound a; CHEMBL1201321; DTXSID0022931; ZINC601317; Difenoxin hydrochloride (Salt/Mix); McN-JR-15403-11; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid; DB01501; R-15403 [aS hydrochloride] (Salt/Mix); C07871; D03809; SR-01000944433; Q5275251; SR-01000944433-1; 1-[3-cyano-3,3-di(phenyl)propyl]-4-phenylpiperidine-4-carboxylic acid",Antidiarrheals,Small molecule,"InChI=1S/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)",UFIVBRCCIRTJTN-UHFFFAOYSA-N,C1CN(CCC1(C2=CC=CC=C2)C(=O)O)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4,.,C28H28N2O2,.,.
D0489,Diflunisal,3059,"Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid",Analgesics,Small molecule,"1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)",HUPFGZXOMWLGNK-UHFFFAOYSA-N,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,22494-42-4,C13H8F2O3,39669,MG30-MG3Z: Pain
D0490,Digitoxin,441207,"Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]",Antiarrhythmic Agents,Small molecule,"1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1",WDJUZGPOPHTGOT-XUDUSOBPSA-N,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CCC7C8=CC(=O)OC8)O)C)C)C)C)O)O,71-63-6,C41H64O13,28544,BD10-BD1Z: Heart failure; BC9Z: Cardiac arrhythmia
D0491,Digoxin,2724385,"digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674;  Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin",Antiarrhythmic Agents,Small molecule,"1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1",LTMHDMANZUZIPE-PUGKRICDSA-N,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,20830-75-5,C41H64O14,4551,BD10-BD1Z: Heart failure; BC9Z: Cardiac arrhythmia
D0492,Digoxin Immune Fab (Ovine),.,"DB00076; Digitalis antitoxin; Digoxin Immune Fab (Ovine); Digoxin Immune Fab, Ovine; Digoxin-specific Antibody Fragments; Ovine digoxin immune fab",Antidotes,Monoclonal antibody,.,.,.,.,.,.,.
D0493,Dihydrocodeine,5284543,"Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine",Narcotic Analgesics,Small molecule,"1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1",RBOXVHNMENFORY-DNJOTXNNSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(CC4)O,125-28-0,C18H23NO3,135276,MG30: Chronic pain
D0494,Dihydroergotamine,10531,Migranal (TN),Antimigraine Agents,Small molecule,"1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1",LUZRJRNZXALNLM-JGRZULCMSA-N,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,511-12-6,C33H37N5O5,4562,8A80: Migraine
D0495,Dihydrotachysterol,5311071,"Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol",Antihypoparathyroid Agents,Small molecule,"1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1",ILYCWAKSDCYMBB-OPCMSESCSA-N,CC1CCC(CC1=CC=C2CCCC3(C2CCC3C(C)C=CC(C)C(C)C)C)O,67-96-9,C28H46O,4591,5B5K: Mineral deficiency
D0496,Diiodohydroxyquinoline,3728,"iodoquinol; Diiodohydroxyquinoline; 83-73-8; 5,7-diiodoquinolin-8-ol; 5,7-Diiodo-8-hydroxyquinoline; 5,7-Diiodo-8-quinolinol; Diiodoquin; DIIODOHYDROXYQUIN; Yodoxin; Diodoquin; Sebaquin; Diodohydroxyquin; Dijodoxichinoline; 8-Quinolinol, 5,7-diiodo-; Enterodiamoebin; Moebiquin; Floraquin; Enterosept; Dinoleine; Lanodoxin; Embequin; Diodoxylin; Searlequin; Disoquin; Direxiode; Diodoquine; Diamoebin; Quinadome; Fluoraquin; Zoaquin; Ioquin; Dyodin; Di-quinol; Stanquinate; Rafamebin; 5,7-Diiodo-oxine; Ioquin suspension; Dijodoxichinolinum",Antiamoebic Agents,Small molecule,"1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",UXZFQZANDVDGMM-UHFFFAOYSA-N,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,83-73-8,C9H5I2NO,5950,1A36: Amoebiasis
D0497,Diltiazem,39186,"Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one",Antihypertensive Agents,Small molecule,"1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1",HSUGRBWQSSZJOP-RTWAWAEBSA-N,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,56209-45-1,C22H26N2O4S,101278,BA00-BA04: Hypertension
D0498,Dimenhydrinate,10660,"Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)",Antiemetics,Small molecule,"1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)",NFLLKCVHYJRNRH-UHFFFAOYSA-N,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,523-87-5,C24H28ClN5O3,94848,MD90: Nausea/vomiting
D0499,Dimethyl fumarate,637568,DIMETHYL FUMARATE,Selective Immunosuppressants,Small molecule,"1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+",LDCRTTXIJACKKU-ONEGZZNKSA-N,COC(=O)C=CC(=O)OC,624-49-7,C6H8O4,76004,8A40: Multiple sclerosis
D0500,Dimethyl sulfoxide,679,Rimso-50,Genitourinary Tract Agents,Small molecule,1S/C2H6OS/c1-4(2)3/h1-2H3,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,CS(=O)C,67-68-5,C2H6OS,28262,FA20: Rheumatoid arthritis
D0501,Dinutuximab,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C25: Lung cancer
D0502,Diphenhydramine,3100,"diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl;  Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM",Antiallergic Agents,Small molecule,"1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3",ZZVUWRFHKOJYTH-UHFFFAOYSA-N,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,58-73-1,C17H21NO,4636,AB31: Episodic vestibular syndrome
D0503,Diphenhydramine (topical),3100,"diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl;  Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM",Antiallergic Agents,Small molecule,"1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3",ZZVUWRFHKOJYTH-UHFFFAOYSA-N,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,58-73-1,C17H21NO,4636,AB31: Episodic vestibular syndrome
D0504,Diphenoxylate,13505,"Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride",Analgesics,Small molecule,"1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3",HYPPXZBJBPSRLK-UHFFFAOYSA-N,CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,915-30-0,C30H32N2O2,4639,ME05: Bowel habit change
D0505,Dipivefrin (ophthalmic),3105,"AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)",Ophthalmic Glaucoma Agents,Small molecule,"1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3",OCUJLLGVOUDECM-UHFFFAOYSA-N,CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C,52365-63-6,C19H29NO5,4646,9C61: Glaucoma
D0506,Dipyridamole,3108,"Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine",Vasodilator Agents,Small molecule,"1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2",IZEKFCXSFNUWAM-UHFFFAOYSA-N,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,58-32-2,C24H40N8O4,4653,BA00-BA04: Hypertension
D0507,Diroximel fumarate,73330464,"Diroximel fumarate; 1577222-14-0; 2-(2,5-Dioxopyrrolidin-1-yl)ethyl methyl fumarate; UNII-K0N0Z40J3W; K0N0Z40J3W; ALKS-8700; Diroximel Fumarete; Diroximel fumarate [INN]; ALKS8700; SCHEMBL15499960; CHEMBL3989944; SCHEMBL15511916; Diroximel fumarate [USAN:INN]; RDC5108; MolPort-046-033-659; Diroximel Fumarete(ALKS-8700); RDC-5108; ZINC215286156; AKOS027256112; AS-55046; TZ001258; 2-(2,5-Dioxopyrrolidin-1-yl)ethyl methyl (2E)-but- 2-enedioate; 2-Butenedioic acid (2E)-, 1-(2-(2,5-dioxo-1-pyrrolidinyl)ethyl) 4-methyl ester",Selective Immunosuppressants,Small molecule,"1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+",YIMYDTCOUQIDMT-SNAWJCMRSA-N,COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O,1577222-14-0,C11H13NO6,.,8A40: Multiple sclerosis
D0508,Disopyramide,3114,Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide,Antiarrhythmic Agents,Small molecule,"1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)",UVTNFZQICZKOEM-UHFFFAOYSA-N,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C,671200,C21H29N3O,4657,BC71: Ventricular tachyarrhythmia; MF50: Abnormal micturition
D0509,Disulfiram,3117,"Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)",Alcohol Deterrents,Small molecule,"1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",AUZONCFQVSMFAP-UHFFFAOYSA-N,CCN(CC)C(=S)SSC(=S)N(CC)CC,97-77-8,C10H20N2S4,4659,6C40: Substance abuse
D0510,Dobutamine,36811,"Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol",Cardiotonic Agents,Small molecule,"1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3",JRWZLRBJNMZMFE-UHFFFAOYSA-N,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,34368-04-2,C18H23NO3,4670,BD10-BD1Z: Heart failure
D0511,Docetaxel,148124,"EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate",Antineoplastics,Small molecule,"1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",ZDZOTLJHXYCWBA-VCVYQWHSSA-N,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,114977-28-5,C43H53NO14,4672,2A00-2F9Z: Solid tumour/cancer
D0512,Docusate,11339,"DOCUSATE; Docusate hydrogen; Dioctyl sulfosuccinic acid; Spolion 8; 1,4-Bis(2-ethylhexyl) sulfosuccinate; 10041-19-7; EINECS 233-124-0; CHEBI:534; 1,4-Bis(2-ethylhexyl) 2-sulphosuccinate; Butanedioic acid, sulfo-, 1,4-bis(2-ethylhexyl) ester; HNSDLXPSAYFUHK-UHFFFAOYSA-N; Butanedionic acid, sulfo-, 1,4-bis(2-ethylhexyl) ester; Butanedioic acid, 2-sulfo-, 1,4-bis(2-ethylhexyl) ester; 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonic acid; Doc-Q-Lace; Dioctylsulfosuccinsaeure; 1-(2-Tolyl)ethanone",Laxatives,Small molecule,"1S/C20H38O7S/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2/h16-18H,5-15H2,1-4H3,(H,23,24,25)",HNSDLXPSAYFUHK-UHFFFAOYSA-N,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,10041-19-7,C20H38O7S,534,DD91: Irritable bowel syndrome
D0513,Dofetilide,71329,"Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE",Antiarrhythmic Agents,Small molecule,"1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3",IXTMWRCNAAVVAI-UHFFFAOYSA-N,CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C,115256-11-6,C19H27N3O5S2,4681,BC9Z: Cardiac arrhythmia
D0514,Dolasetron,3033818,"Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate",Antiemetics,Small molecule,"1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?",UKTAZPQNNNJVKR-AKJUYKBHSA-N,C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54,115956-12-2,C19H20N2O3,94561,MD90: Nausea/vomiting
D0515,Dolutegravir,54726191,"1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (",Antiviral Agents,Small molecule,"1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1",RHWKPHLQXYSBKR-BMIGLBTASA-N,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,1051375-16-6,C20H19F2N3O5,76010,1C60-1C62: Human immunodeficiency virus disease
D0516,Donepezil,3152,"Donepezil (transdermal patch, Alzheimer's disease)",Cholinesterase Inhibitors,Small molecule,"1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3",ADEBPBSSDYVVLD-UHFFFAOYSA-N,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,120014-06-4,C24H29NO3,53289,8A20: Alzheimer disease
D0517,Dopamine,681,"Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol",Cardiotonic Agents,Small molecule,"1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2",VYFYYTLLBUKUHU-UHFFFAOYSA-N,C1=CC(=C(C=C1CCN)O)O,51-61-6,C8H11NO2,18243,8A00: Parkinsonism; BA20-BA21: Hypotension
D0518,Doravirine,58460047,Doravirine; 1338225-97-0; UNII-913P6LK81M; MK1439; 913P6LK81M; MK 1439,Antiviral Agents,Small molecule,"1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)",ZIAOVIPSKUPPQW-UHFFFAOYSA-N,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,1338225-97-0,C17H11ClF3N5O3,.,1C60-1C62: Human immunodeficiency virus disease
D0519,Doripenem,73303,"Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",Carbapenems,Small molecule,"1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1",AVAACINZEOAHHE-VFZPANTDSA-N,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O,148016-81-3,C15H24N4O6S2,135928,GC08: Urinary tract infection; 1B74-1F40: Gram-positive bacterial infection
D0520,Dornase alfa,.,DNase,Antiviral Agents,Protein/peptide,.,.,.,.,.,.,1D64-1D65: COVID-19
D0521,Dorzolamide (ophthalmic),5284549,"Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE",Antihypertensive Agents,Small molecule,"1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1",IAVUPMFITXYVAF-XPUUQOCRSA-N,CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C,120279-96-1,C10H16N2O4S3,4702,9C61: Glaucoma
D0522,Doxacurium,60169,"Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride",Analgesics,Small molecule,"1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2",GBLRQXKSCRCLBZ-UHFFFAOYSA-N,C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C,133814-18-3,C56H78N2O16+2,4706,MB47: Tonus and reflex abnormality
D0523,Doxapram,3156,"Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)",Cns Stimulants,Small molecule,"1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3",XFDJYSQDBULQSI-UHFFFAOYSA-N,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,309-29-5,C24H30N2O2,681848,CB40-CB7Z: Respiratory system disease
D0524,Doxazosin,3157,"Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine",Antihypertensive Agents,Small molecule,"1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)",RUZYUOTYCVRMRZ-UHFFFAOYSA-N,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,74191-85-8,C23H25N5O5,4708,BA00-BA04: Hypertension
D0525,Doxepin,667477,"Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin;  Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin",Antidepressants,Small molecule,"1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+",ODQWQRRAPPTVAG-GZTJUZNOSA-N,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,1668-19-5,C19H21NO,.,6A70-6A7Z: Depression
D0526,Doxepin (topical),667477,"Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin;  Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin",Antidepressants,Small molecule,"1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+",ODQWQRRAPPTVAG-GZTJUZNOSA-N,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,1668-19-5,C19H21NO,.,6A70-6A7Z: Depression
D0527,Doxercalciferol,5281107,"Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)",Vitamins,Small molecule,"1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1",HKXBNHCUPKIYDM-CGMHZMFXSA-N,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,54573-75-0,C28H44O2,4712,GB61: Chronic kidney disease
D0528,Doxorubicin,31703,"doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin",Antineoplastics,Small molecule,"1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1",AOJJSUZBOXZQNB-TZSSRYMLSA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,23214-92-8,C27H29NO11,28748,2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer; 2C12: Liver cancer
D0529,Doxorubicin (liposomal),31703,"doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin",Antineoplastics,Small molecule,"1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1",AOJJSUZBOXZQNB-TZSSRYMLSA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,23214-92-8,C27H29NO11,28748,2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer; 2C12: Liver cancer
D0530,Doxycycline,54671203,"Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline",Antiinflammatory Agents,Small molecule,"1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1",SGKRLCUYIXIAHR-AKNGSSGZSA-N,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,564-25-0,C22H24N2O8,50845,DA0C: Periodontal disease; DA0D: Gingival/edentulous alveolar ridge disorder; BD54: Diabetic foot ulcer
D0531,Doxycycline (topical),54671203,"Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline",Antiinflammatory Agents,Small molecule,"1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1",SGKRLCUYIXIAHR-AKNGSSGZSA-N,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,564-25-0,C22H24N2O8,50845,DA0C: Periodontal disease; DA0D: Gingival/edentulous alveolar ridge disorder; BD54: Diabetic foot ulcer
D0532,Doxylamine,3162,"Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3",HCFDWZZGGLSKEP-UHFFFAOYSA-N,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C,469-21-6,C17H22N2O,51380,SC00: Morning sickness disorder
D0533,Dronabinol,16078,"Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP;  Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol",Analgesics,Small molecule,"1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1",CYQFCXCEBYINGO-IAGOWNOFSA-N,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,26514,C21H30O2,66964,6B80: Anorexia nervosa; MD90: Nausea/vomiting
D0534,Dronedarone,208898,Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide,Group Iii Antiarrhythmics,Small molecule,"1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3",ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC,141626-36-0,C31H44N2O5S,50659,BA40: Angina pectoris; BC81: Supraventricular tachyarrhythmia
D0535,Droperidol,3168,"DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one",Antipsychotic Agents,Small molecule,"1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)",RMEDXOLNCUSCGS-UHFFFAOYSA-N,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,548-73-2,C22H22FN3O2,4717,MD90: Nausea/vomiting
D0536,Drospirenone,68873,"DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta",Contraceptive Agents,Small molecule,"1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1",METQSPRSQINEEU-HXCATZOESA-N,CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,67392-87-4,C24H30O3,50838,QA21: Contraceptive management
D0537,Drotrecogin alfa,.,Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN),Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,8B1Z: Cerebral ischaemia; 1G40-1G41: Sepsis
D0538,Droxidopa,92974,"droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-",Vasopressors,Small molecule,"1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1",QXWYKJLNLSIPIN-JGVFFNPUSA-N,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,23651-95-8,C9H11NO5,31524,8D87: Autonomic nervous system disorder
D0539,Duloxetine,60835,"Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine",Antidepressants,Small molecule,"1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",ZEUITGRIYCTCEM-KRWDZBQOSA-N,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,116539-59-4,C18H19NOS,36795,6A70-6A7Z: Depression
D0540,Dupilumab,.,"REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis",Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA80: Atopic eczema; CA23: Asthma
D0541,Durvalumab,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C10: Pancreatic cancer; 2A00-2F9Z: Solid tumour/cancer; 2C17: Biliary tract cancer; 2A81: Diffuse large B-cell lymphoma; 2C12: Liver cancer; 2C30: Melanoma; 2C92: Ureteral cancer
D0542,Dutasteride,6918296,"Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide",Antineoplastics,Small molecule,"1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1",JWJOTENAMICLJG-QWBYCMEYSA-N,CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C,164656-23-9,C27H30F6N2O2,521033,GA90: Prostate hyperplasia; 2C82: Prostate cancer
D0543,Duvelisib,50905713,Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;,Pi3K Inhibitors,Small molecule,"1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1",SJVQHLPISAIATJ-ZDUSSCGKSA-N,CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,1201438-56-3,C22H17ClN6O,131169,2A82: Mature B-cell leukaemia; 2A80: Follicular lymphoma; FA20: Rheumatoid arthritis
D0544,Dyphylline,3182,"Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline",Bronchodilators,Small molecule,"1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3",KSCFJBIXMNOVSH-UHFFFAOYSA-N,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,479-18-5,C10H14N4O4,4728,CA23: Asthma
D0545,Echinacea,.,"(1S,2S,3S,4R)-1,2,3-trihydroxycyclohexane-1,4-diyl (2E,2'E)bis[3-(3,4-dihydroxyphenyl)acrylate]; 9178AF; CHEMBL1533705; Cynarin (Echinacea)(1,3-Dicaffeoylquinic Acid); ZINC17263722",Herbal Products,Natural product,.,.,.,.,.,.,.
D0546,Echothiophate (ophthalmic),10548,"Echothiophate; Ecothiopate; Ecothiopatum; Phospholine iodide; 6736-03-4; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium; UNII-0F350BVT6S; 0F350BVT6S; CHEBI:4753; Echothiophate ion; Ecothiopate cation; Echothiophate cation; BRN 1794025; GTPL9074; SCHEMBL1048167; CHEMBL1201341; (2-Mercaptoethyl)trimethylammonium S-ester with O,O'-diethylphosphorothioate; DB01057; AMMONIUM, (2-MERCAPTOETHYL)TRIMETHYL-, S-ESTER with O,O-DIETHYLPHOSPHOROTHIOATE; NCGC00522018-01; (2-diethoxyphosphinylthioethyl)trimethylammonium; C06975; Q4352952; diethyl {[2-(trimethylazaniumyl)ethyl]sulfanyl}phosphonate; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium; 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide",Ophthalmic Glaucoma Agents,Small molecule,"InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1",BJOLKYGKSZKIGU-UHFFFAOYSA-N,CCOP(=O)(OCC)SCC[N+](C)(C)C,.,C9H23NO3PS+,.,.
D0547,Econazole (topical),3198,"Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole",Antifungal Agents,Small molecule,"1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",LEZWWPYKPKIXLL-UHFFFAOYSA-N,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,27220-47-9,C18H15Cl3N2O,82873,1F2D: Non-dermatophyte superficial dermatomycose; 1F23: Candidosis; 1F28: Dermatophytosis
D0548,Eculizumab,.,"Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion",Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,9B75: Macular degeneration
D0549,Edetate calcium disodium anhydrous,6093170,"Edetate calcium disodium; Calcium disodium versenate; UNII-5M645317UB; Disodium ((ethylenedinitrilo)tetraacetato)calciate(2-) hydrate; 5M645317UB; 23411-34-9; Edetate calcium disodium [USAN:USP]; Calciate(2-), ((N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycinato))(4-)-N,N',O,O',ON,ON')-, disodium, hydrate, (OC-6-21)-; Calciate (2-), ((N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycinato))(4-)-N,N',O,O',O(sup N),O(sup N)')-, disodium, hydrate, (OC-6-21)-; 50322-16-2",Chelating Agents,Small molecule,"1S/C10H16N2O8.Ca.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4",SHWNNYZBHZIQQV-UHFFFAOYSA-J,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Ca+2],62-33-9,C10H12CaN2Na2O8,4757,.
D0550,Edetate disodium anhydrous,8759,"EDTA disodium dihydrate; Disodium EDTA dihydrate; Disodium edetate dihydrate; Disodium (ethylenedinitrilo)tetraacetate dihydrate; Ethylenediaminetetraacetic acid disodium salt dihydrate; 6381-92-6; Na2H2EDTA.2H2O; CHEBI:64758; disodium 2,2',2'',2'''-(ethane-1,2-diyldiammonio)tetraacetate--water (1/2)",Chelating Agents,Small molecule,"1S/C10H16N2O8.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;2*+1/p-2",ZGTMUACCHSMWAC-UHFFFAOYSA-L,C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+],139-33-3,C10H14N2Na2O8,64734,BC65: Genetic cardiac arrhythmia
D0551,Edoxaban,10280735,"EDOXABAN; 480449-70-5; SAVAYSA; 912273-65-5; DU-176; UNII-NDU3J18APO; DU-176b; NDU3J18APO; N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide; CHEMBL1269025; CHEBI:85973; 480449-70-5 (free base); C24H30ClN7O4S; Edoxaban [USAN:INN]; Edoxaban (USAN/INN); SCHEMBL330046; AMY508; GTPL7575; HSDB 8406; DTXSID50197398; AOB87348; EX-A5582; BDBM50328731; MFCD13195544; s4429; ZINC43200832; AKOS005146069; CS-1331; DB09075; NCGC00378907-01; NCGC00378907-02; NCGC00378907-03; AS-35107; HY-10264; N-(5-Chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide; QC-10007; X1006; X3723; D09710; 449E705; A860576; Q21011234; Ethanediamide, N1-(5-chloro-2-pyridinyl)-N2-((1S,2R,4S)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-; N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide; N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide; N(1)-(5-chloropyridin-2-yl)-N(2)-{(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl}ethanediamide; N-(5-Chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide; N-(5-Chloro-2-pyridinyl)-N'-[4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide;; N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide; N-(5-Chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide; N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl) ethanediamide; N1-(5-Chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide; N1-(5-Chloropyridin-2-yl)-N2-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide",Anticoagulants/Factor Xa Inhibitors,Small molecule,"InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1",HGVDHZBSSITLCT-JLJPHGGASA-N,CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,.,C24H30ClN7O4S,.,.
D0552,Edrophonium,3202,"EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium",Antidotes,Small molecule,"1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1",VWLHWLSRQJQWRG-UHFFFAOYSA-O,CC[N+](C)(C)C1=CC(=CC=C1)O,312-48-1,C10H16NO+,251408,8C6Y: Myasthenia gravis
D0553,Efalizumab,.,Raptiva; Raptiva (TN); Efalizumab (USAN/INN),Immunomodulatory Agents,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis; NE84: Transplant rejection
D0554,Efavirenz,64139,"EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one",Anti-Hiv Agents,Small molecule,"1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1",XPOQHMRABVBWPR-ZDUSSCGKSA-N,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,154598-52-4,C14H9ClF3NO2,119486,1C60-1C62: Human immunodeficiency virus disease
D0555,Elagolix,11250647,"Elagolix; 834153-87-6; UNII-5B2546MB5Z; NBI-56418; 5B2546MB5Z; NBI56418; NBI 56418; Elagolix [USAN:INN]; Orilissa; ELA gOLIX; Elagolix (USAN/INN); SCHEMBL1642523; GTPL8362; CHEMBL1208155; DTXSID40232348; ABT-620; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; EX-A1765; BCP08827; ZINC49888891; CS-5329; SB16700; DB11979; compound 10b [PMID 19006286]; HY-14789; AN-27202; D09335; Z-3253; 153E876; Butanoic acid, 4-(((1R)-2-(5-(2-flu",Gonadotropin-Releasing Hormone Antagonists,Small molecule,"1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1",HEAUOKZIVMZVQL-VWLOTQADSA-N,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,834153-87-6,C32H30F5N3O5,.,2E86: Uterine fibroid
D0556,Elbasvir,71661251,MK 8742; 632L571YDK; MK8742; Elbasvir [USAN:INN]; MK8742; Elbasvir,Antiviral Agents,Small molecule,"1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1",BVAZQCUMNICBAQ-PZHYSIFUSA-N,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,1370468-36-2,C49H55N9O7,132967,1D64-1D65: COVID-19
D0557,Eletriptan,77993,Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole,Antimigraine Agents,Small molecule,"1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1",PWVXXGRKLHYWKM-LJQANCHMSA-N,CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,143322-58-1,C22H26N2O2S,50922,8A80: Migraine
D0558,Elexacaftor,134587348,"Elexacaftor; 2216712-66-0; VX-445; UNII-RRN67GMB0V; RRN67GMB0V; Elexacaftor (USAN); Elexacaftor [USAN]; (S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide; N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide; 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)-; Elexacaftor (VX-445); Elexacaftor/Ivacaftor/Tezacaftor; CHEMBL4298128; SCHEMBL20239811; GTPL10552; EX-A3637; s8851; VX-445VX-445; WHO 11180; AT16051; DB15444; Compound 1 [WO2018107100A1]; HY-111772; CS-0090942; D11507; A930250",Cftr Combinations,Small molecule,"InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1",MVRHVFSOIWFBTE-INIZCTEOSA-N,C[C@H]1CC(N(C1)C2=C(C=CC(=N2)N3C=CC(=N3)OCC(C)(C)C(F)(F)F)C(=O)NS(=O)(=O)C4=CN(N=C4C)C)(C)C,.,C26H34F3N7O4S,.,.
D0559,Eliglustat,23652731,"ELIGLUSTAT; 491833-29-5; Genz 99067; Genz-99067; GENZ-112638; UNII-DR40J4WA67; Eliglustat free base; N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide; DR40J4WA67; CHEBI:82752; 491833-29-5 (free base); MFCD19443735; N-[(1r,2r)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide; Eliglustat (Tartrate); Eliglustat [USAN:INN]; Eliglustat (USAN/INN); Eliglustat(Genz-99067); Eliglustat; Genz 99067; SCHEMBL421755; GTPL7536; CHEMBL2110588; DTXSID20964175; EX-A2301; s7852; ZINC72267023; AKOS022185521; CA10006; CCG-101413; CS-5424; DB09039; NCGC00509905-01; BS-17368; HY-14885; N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1-ylmethyl)ethyl)octanamide; Octanamide, N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl)-; D09893; F53213; Q21011224; 1000191-50-3; N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-7-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide; N-[1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanimidic acid",Metabolic Agents,Small molecule,"InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1",FJZZPCZKBUKGGU-AUSIDOKSSA-N,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O,.,C23H36N2O4,.,.
D0560,Elotuzumab,.,BMS-901608,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A83: Multiple myeloma
D0561,Eltrombopag,135449332,"Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid",Platelet-Stimulating Agents,Small molecule,"1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)",SVOQIEJWJCQGDQ-UHFFFAOYSA-N,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,496775-61-2,C25H22N4O4,85010,3B64: Thrombocytopenia
D0562,Eluxadoline,11250029,MuDelta,Peripheral Opioid Receptor Mixed Agonists/Antagonists,Small molecule,"1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1",QFNHIDANIVGXPE-FNZWTVRRSA-N,CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N,864821-90-9,C32H35N5O5,85980,DD91: Irritable bowel syndrome
D0563,Elvitegravir,5277135,EVG,Antiviral Agents,Small molecule,"1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1",JUZYLCPPVHEVSV-LJQANCHMSA-N,CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O,697761-98-1,C23H23ClFNO5,72289,1C60-1C62: Human immunodeficiency virus disease
D0564,Emapalumab,.,emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X,Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,4A01: Adaptive immunity immunodeficiency
D0565,Empagliflozin,11949646,"864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol",Antidiabetic Agents,Small molecule,"1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1",OBWASQILIWPZMG-QZMOQZSNSA-N,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,864070-44-0,C23H27ClO7,82720,5A10: Diabetes mellitus
D0566,Emtricitabine,60877,"Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC",Anti-Hiv Agents,Small molecule,"1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",XQSPYNMVSIKCOC-NTSWFWBYSA-N,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,143491-57-0,C8H10FN3O3S,31536,1C60-1C62: Human immunodeficiency virus disease; 1E50-1E51: Hepatitis virus infection
D0567,Enalapril,5388962,Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid,Antihypertensive Agents,Small molecule,"1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1",GBXSMTUPTTWBMN-XIRDDKMYSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,75847-73-3,C20H28N2O5,4784,BA00-BA04: Hypertension
D0568,Enasidenib,89683805,AG-221 (IDH2 inhibitor),Antineoplastics,Small molecule,"1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)",DYLUUSLLRIQKOE-UHFFFAOYSA-N,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O,1446502-11-9,C19H17F6N7O,145374,2A60: Acute myeloid leukaemia; 2A41: BCR-ABL1-negative chronic myeloid leukaemia
D0569,Encorafenib,50922675,Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib),Multikinase Inhibitors,Small molecule,"1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1",CMJCXYNUCSMDBY-ZDUSSCGKSA-N,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,1269440-17-6,C22H27ClFN7O4S,.,2C30: Melanoma
D0570,Enflurane,3226,"Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane",Anesthetics,Small molecule,"1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H",JPGQOUSTVILISH-UHFFFAOYSA-N,C(C(OC(F)F)(F)F)(F)Cl,13838-16-9,C3H2ClF5O,4792,9A76-9A78: Corneal disease
D0571,Enfortumab vedotin,.,DB13007; Enfortumab vedotin; enfortumab vedotin-ejfv,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,.
D0572,Enfuvirtide,16130199,Enfuvirtide; Pentafuside; Fuzeon; DP178; DP-178; T-20; CHEBI:608828; T 20; Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2; T20; Dp 178; Fuzeon (TM); Fuzeon T-20; T 20 (peptide); Enfurvitide (T-20); Enfuvirtide+PRO 140; Enfuvirtide + T1144; TNX-355 & Efuvirtide; T20-LAI; Enfuvirtide [USAN:INN:BAN]; CHEMBL525076; HSDB 7341; DTXSID20166672; GNA & G-20; HHA & T-20; PENTAFUSIDE (TRIVIAL NAME); BDBM50023615; T-20+PRO 140; GP41 127-162 AA; 5A8 & T-20; R-698; T20 + T1144; Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2 & PRO 140 (Anti-CCR5 monoclonal antibody); Humanized monoclonal antibody to CD4 & Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2; Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 & Galanthus nivalis agglutinin (GNA); Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 & Hippeastrum hybrid agglutinin( HHA); Acetyl-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2; AcTyrThrSerLeuIleHisSerLeuIleGluGluSerGlnAsnGlnGlnGluLysAsnGluGlnGluLeuLeuGluLeuAspLysTrpAlaSerLeuTrpAsnTrpPheNH2; T-20-LAI [Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2],Antiviral Agents,Protein/peptide,"InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1",PEASPLKKXBYDKL-FXEVSJAOSA-N,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C,.,C204H301N51O64,.,.
D0573,Enoxacin,3229,"Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid",Antiinfective Agents,Small molecule,"1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)",IDYZIJYBMGIQMJ-UHFFFAOYSA-N,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,74011-58-8,C15H17FN4O3,157175,GC08: Urinary tract infection
D0574,Enoxaparin,772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D0575,Entacapone,5281081,"Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide",Antiparkinson Agents,Small molecule,"1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",JRURYQJSLYLRLN-BJMVGYQFSA-N,CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N,130929-57-6,C14H15N3O5,4798,8A00: Parkinsonism
D0576,Entecavir,135398508,"Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate",Antiviral Agents,Small molecule,"1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1",QDGZDCVAUDNJFG-FXQIFTODSA-N,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,142217-69-4,C12H15N5O3,473990,1E50-1E51: Hepatitis virus infection
D0577,Entrectinib,25141092,"1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK",Multikinase Inhibitors,Small molecule,"1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)",HAYYBYPASCDWEQ-UHFFFAOYSA-N,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,1108743-60-7,C31H34F2N6O2,.,2A00-2F9Z: Solid tumour/cancer; 2B91: Colorectal cancer; 2D11: Adrenal cancer; 2C60-2C6Y: Breast cancer; 2C25: Non-small cell lung cancer
D0578,Enzalutamide,15951529,MDV3100; Enzalutamide (AR inhibitor),Antiandrogens,Small molecule,"1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,915087-33-1,C21H16F4N4O2S,68534,2C82: Prostate cancer
D0579,Ephedrine,9294,"Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin",Cns Stimulants,Small molecule,"1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1",KWGRBVOPPLSCSI-WPRPVWTQSA-N,CC(C(C1=CC=CC=C1)O)NC,299-42-3,C10H15NO,15407,CA23: Asthma
D0580,Ephedrine (nasal),9294,"Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin",Cns Stimulants,Small molecule,"1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1",KWGRBVOPPLSCSI-WPRPVWTQSA-N,CC(C(C1=CC=CC=C1)O)NC,299-42-3,C10H15NO,15407,CA23: Asthma
D0581,Epinephrine,5816,"ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol",Vasoconstrictor Agents,Small molecule,"1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1",UCTWMZQNUQWSLP-VIFPVBQESA-N,CNCC(C1=CC(=C(C=C1)O)O)O,51-43-4,C9H13NO3,28918,4A80-4A8Z: Allergic/hypersensitivity disorder
D0582,Epinephrine (ophthalmic),5816,"ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol",Vasoconstrictor Agents,Small molecule,"1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1",UCTWMZQNUQWSLP-VIFPVBQESA-N,CNCC(C1=CC(=C(C=C1)O)O)O,51-43-4,C9H13NO3,28918,4A80-4A8Z: Allergic/hypersensitivity disorder
D0583,Epinephrine (topical),5816,"ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol",Vasoconstrictor Agents,Small molecule,"1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1",UCTWMZQNUQWSLP-VIFPVBQESA-N,CNCC(C1=CC(=C(C=C1)O)O)O,51-43-4,C9H13NO3,28918,4A80-4A8Z: Allergic/hypersensitivity disorder
D0584,Epirubicin,41867,"Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin",Antineoplastics,Small molecule,"1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1",AOJJSUZBOXZQNB-VTZDEGQISA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,56420-45-2,C27H29NO11,47898,2A00-2F9Z: Solid tumour/cancer
D0585,Eplerenone,443872,"Epoxymexrenone; Inspra; Selara; CGP-30083; Inspra (TN); SC-66110; Eplerenone (JAN/USAN/INN); Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone",Antihypertensive Agents,Small molecule,"1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1",JUKPWJGBANNWMW-VWBFHTRKSA-N,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,107724-20-9,C24H30O6,31547,BD10-BD1Z: Heart failure
D0586,Epoprostenol,5282411,"Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid",Antihypertensive Agents,Small molecule,"1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1",KAQKFAOMNZTLHT-OZUDYXHBSA-N,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,35121-78-9,C20H32O5,15552,BB01: Pulmonary hypertension
D0587,Eprosartan,5281037,133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan,Antihypertensive Agents,Small molecule,"1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+",OROAFUQRIXKEMV-LDADJPATSA-N,CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O,133040-01-4,C23H24N2O4S,4814,BA00-BA04: Hypertension
D0588,Eptifibatide,448812,"Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid",Anticoagulants,Small molecule,"1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1",CZKPOZZJODAYPZ-LROMGURASA-N,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,188627-80-7,C35H49N11O9S2,291902,BA40: Angina pectoris
D0589,Eravacycline,54726192,"TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals",Tetracyclines,Small molecule,"1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1",AKLMFDDQCHURPW-ISIOAQNYSA-N,CN(C)C1C2CC3CC4=C(C=C(C(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F,1207283-85-9,C27H31FN4O8,.,1A40: Infectious gastroenteritis/colitis; 1E30-1E32: Influenza
D0590,Erdafitinib,67462786,"1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino",Multikinase Inhibitors,Small molecule,"1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3",OLAHOMJCDNXHFI-UHFFFAOYSA-N,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,1346242-81-6,C25H30N6O2,.,2A80-2A86: Lymphoma; 2C92: Ureteral cancer; 2C94: Bladder cancer; 2A00-2F9Z: Solid tumour/cancer
D0591,Ergocalciferol,5280793,"Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol",Vitamins,Small molecule,"1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1",MECHNRXZTMCUDQ-RKHKHRCZSA-N,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,50-14-6,C28H44O,28934,5A50: Hypo-parathyroidism
D0592,Ergometrine,443884,"Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide",Oxytocics,Small molecule,"1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1",WVVSZNPYNCNODU-XTQGRXLLSA-N,CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,60-79-7,C19H23N3O2,4822,JA43: Postpartum haemorrhage
D0593,Ergotamine,8223,"Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione",Analgesics,Small molecule,"1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1",XCGSFFUVFURLIX-VFGNJEKYSA-N,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C,379-79-3,C33H35N5O5,64318,8A80-8A84: Headache
D0594,Eribulin,11354606,.,Antineoplastics/Mitotic Inhibitors,Small molecule,"1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1",UFNVPOGXISZXJD-JBQZKEIOSA-N,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,253128-41-5,C40H59NO11,63587,2C60-2C6Y: Breast cancer
D0595,Erlotinib,176870,"Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline",Antineoplastics,Small molecule,"1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,183321-74-6,C22H23N3O4,114785,2C25: Lung cancer; 2B90: Colon cancer; 2C10: Pancreatic cancer
D0596,Ertapenem,150610,"Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1",JUZNIMUFDBIJCM-ANEDZVCMSA-N,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O,153832-46-3,C22H25N3O7S,404903,1A00-1C4Z: Bacterial infection
D0597,Erythromycin,12560,"Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery",Antibiotics,Small molecule,"1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1",ULGZDMOVFRHVEP-RWJQBGPGSA-N,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,114-07-8,C37H67NO13,42355,1A00-1C4Z: Bacterial infection
D0598,Erythropoietin,11751549,"NuPIAO; Erythropoietin (second generation, anemia/blood cell mobilization); Erythropoietin (second generation, anemia/blood cell mobilization), 3SBio",Erythropoiesis Agents,Hormones,"1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1",OXCMYAYHXIHQOA-UHFFFAOYSA-N,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],124750-99-8,C22H22ClKN6O,.,3A00-3A9Z: Anemia
D0599,Escitalopram,146570,"Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram",Antidepressants,Small molecule,"1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1",WSEQXVZVJXJVFP-FQEVSTJZSA-N,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,128196-01-0,C20H21FN2O,36791,6A70-6A7Z: Depression
D0600,Esketamine,182137,"(S)-Ketamine; l-Ketamine; (S)-(-)-Ketamine; 33643-46-8; S-Ketamine; UNII-50LFG02TXD; 50LFG02TXD; (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone; CHEBI:60799; esketamine HCl; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)-; 6740-88-1 (Parent); Esketamine [USAN:INN:BAN]; S-Ketamin; S-(-)-Ketamine; Esketamine (USAN/INN); AC1L4AD8; DSSTox_CID_27787; DSSTox_RID_82562; DSSTox_GSID_47810; SCHEMBL5512024; GTPL9152; CHEMBL395091; DTXSID6047810; YQEZ",Antidepressants,Small molecule,"1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1",YQEZLKZALYSWHR-ZDUSSCGKSA-N,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,33643-46-8,C13H16ClNO,60799,6A70-6A7Z: Depression
D0601,Eslicarbazepine,9881504,Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix,Anticonvulsants,Small molecule,"1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1",BMPDWHIDQYTSHX-AWEZNQCLSA-N,C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O,104746-04-5,C15H14N2O2,.,8A61-8A6Z: Epilepsy/seizure
D0602,Esmolol,59768,"ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate",Antihypertensive Agents,Small molecule,"1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3",AQNDDEOPVVGCPG-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,81147-92-4,C16H25NO4,88206,BC81: Supraventricular tachyarrhythmia
D0603,Esomeprazole,9568614,"Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole",Antiulcer Agents,Small molecule,"1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1",SUBDBMMJDZJVOS-DEOSSOPVSA-N,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,119141-88-7,C17H19N3O3S,50275,DA61: Peptic ulcer
D0604,Estazolam,3261,"Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine",Anticonvulsants,Small molecule,"1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2",CDCHDCWJMGXXRH-UHFFFAOYSA-N,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,29975-16-4,C16H11ClN4,4858,7A00-7A0Z: Insomnia
D0605,Esterified estrogens,.,.,Estrogens,Small molecule,.,.,.,.,.,.,2C60-2C6Y: Breast cancer
D0606,Estradiol,5757,"Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol",Estrogens,Small molecule,"1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",VOXZDWNPVJITMN-ZBRFXRBCSA-N,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O,17916-67-5,C18H24O2,16469,2C60-2C6Y: Breast cancer
D0607,Estradiol (topical),5757,"Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol",Estrogens,Small molecule,"1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",VOXZDWNPVJITMN-ZBRFXRBCSA-N,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O,17916-67-5,C18H24O2,16469,2C60-2C6Y: Breast cancer
D0608,Estramustine,259331,"Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]",Antineoplastics,Small molecule,"1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1",FRPJXPJMRWBBIH-RBRWEJTLSA-N,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,2998-57-4,C23H31Cl2NO3,4868,2C82: Prostate cancer
D0609,Estrone,5870,"Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one",Antimenopausal Agents,Small molecule,"1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1",DNXHEGUUPJUMQT-CBZIJGRNSA-N,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O,53-16-7,C18H22O2,17263,GA30: Menopausal disorder
D0610,Estrone sulfate,3001028,[3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate,Estrogens,Small molecule,"1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1",JKKFKPJIXZFSSB-CBZIJGRNSA-N,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,481-97-0,C18H22O5S,17474,.
D0611,Estrone sulfate (topical),3001028,[3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate,Estrogens,Small molecule,"1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1",JKKFKPJIXZFSSB-CBZIJGRNSA-N,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,481-97-0,C18H22O5S,17474,.
D0612,Eszopiclone,969472,"Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1",GBBSUAFBMRNDJC-INIZCTEOSA-N,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,138729-47-2,C17H17ClN6O3,53760,7A00-7A0Z: Insomnia
D0613,Etacrynic acid,3278,"Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid",Diuretics,Small molecule,"1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)",AVOLMBLBETYQHX-UHFFFAOYSA-N,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,58-54-8,C13H12Cl2O4,4876,BA00: Essential hypertension
D0614,Etanercept,.,"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon",Antirheumatics,Monoclonal antibody,.,.,.,.,.,.,FA20: Rheumatoid arthritis; EB40: Pemphigus; ME84: Spinal pain
D0615,Etelcalcetide,71511839,Velcalcetide; Parsabiv; UNII-60ME133FJB; 1262780-97-1; 60ME133FJB; etelcalcetide HCl; Etelcalcetide [USAN:INN]; Etelcalcetide (USAN/INN); Etelcalcetide Hydrochloride(AMG-416),Calcimimetics,Small molecule,"1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1",ANIAZGVDEUQPRI-ZJQCGQFWSA-N,CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C,1262780-97-1,C38H73N21O10S2,134700,5A51: Hyper-parathyroidism; 2A37: Myelodysplastic syndrome
D0616,Ethambutol,14052,"Aethambutolum; Diambutol; EMB; Etambutol; Etambutolo; Ethambutolum; Etibi; Miambutol; Myambutol; Purderal; Servambutol; Tibutol; Etambutolo [DCIT]; CL 40881 (dihydrochloride); D-Ethambutol; Etambutol [INN-Spanish]; Ethambutol & EEP; Ethambutol & Propolis; Ethambutol (INN); Ethambutol [INN:BAN]; Ethambutol, meso form; Ethambutol, racemic mixture; Ethambutolum [INN-Latin]; Myambutol (TN); Myambutol (dihydrochloride); Servambutol (TN); Ethambutol, (-)-isomer; D,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-2,2'-(Ethylenediimino)bis(1-butanol); D-2,2'-(Ethylenediimino)di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-2,2'-(Ethylenediimino)di-1-butanol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-Ethambutol; (+)-ethambutol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (S,S)-ethambutol; 2,2'-(1,2-Ethylenediimino)-di-1-butanol; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol",Antitubercular Agents,Small molecule,"1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1",AEUTYOVWOVBAKS-UWVGGRQHSA-N,CCC(CO)NCCNC(CC)CO,74-55-5,C10H24N2O2,4877,1B10-1B12: Tuberculosis
D0617,Ethanol,702,"Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA",Analgesics,Small molecule,"1S/C2H6O/c1-2-3/h3H,2H2,1H3",LFQSCWFLJHTTHZ-UHFFFAOYSA-N,CCO,64-17-5,C2H6O,16236,GC00: Cystitis; MG30: Chronic pain
D0618,Ethchlorvynol,5281077,Alvinol; Arvynol; Etchlorvinolo; Etclorvinol; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethchlorvynolum;Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline; A 71; Aethyl-chlorvynol; Beta-Chlorovinyl ethyl ethynyl carbinol; Beta-Chlorvinyl ethyl ethynyl carbinol; Etclorvinol [INN-Spanish]; Ethchlorvynolum [INN-Latin]; Ethyl beta-chlorovinyl ethynyl carbinol; Placidyl (TN); Ethchlorvynol [USAN:INN:BAN]; Ethchlorvynol (JAN/USP/INN); (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; 1-Chloro-3-ethylpent-1-4-yn-3-ol; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol,Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+",ZEHYJZXQEQOSON-AATRIKPKSA-N,CCC(C=CCl)(C#C)O,113-18-8,C7H9ClO,4882,7A00-7A0Z: Insomnia
D0619,Ethinylestradiol,5991,"Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta",Estrogens,Small molecule,"1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1",BFPYWIDHMRZLRN-SLHNCBLASA-N,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O,57-63-6,C20H24O2,4903,GA30: Menopausal disorder
D0620,Ethosuximide,3291,"Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide",Analgesics,Small molecule,"1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)",HAPOVYFOVVWLRS-UHFFFAOYSA-N,CCC1(CC(=O)NC1=O)C,77-67-8,C7H11NO2,4887,8A61-8A6Z: Epilepsy/seizure
D0621,Ethotoin,3292,"Accenon; Ethotoine; Ethotoinum; Etotoina; Peganone; Pegoanone; Abbott brand of ethotoin; Accenon (TN); Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Peganone (TN); Ethotoin [INN:BAN:JAN]; Ethotoin (JAN/USP/INN); (+-)-3-Ethyl-5-phenylhydantoin; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenylhydantoin; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 3-ethyl-5-phenylimidazolidine-2,4-dione",Anticonvulsants,Small molecule,"1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)",SZQIFWWUIBRPBZ-UHFFFAOYSA-N,CCN1C(=O)C(NC1=O)C2=CC=CC=C2,86-35-1,C11H12N2O2,4888,8A61-8A6Z: Epilepsy/seizure
D0622,Etidocaine,37497,Duranest,Local Anesthetics,Small molecule,"1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)",VTUSIVBDOCDNHS-UHFFFAOYSA-N,CCCN(CC)C(CC)C(=O)NC1=C(C=CC=C1C)C,36637-18-0,C17H28N2O,4904,MG30-MG3Z: Pain
D0623,Etidronic acid,3305,"EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL",Bone Density Conservation Agents,Small molecule,"1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)",DBVJJBKOTRCVKF-UHFFFAOYSA-N,CC(O)(P(=O)(O)O)P(=O)(O)O,2809-21-4,C2H8O7P2,4907,FB85: Bone paget disease
D0624,Etodolac,3308,"etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1",Analgesics,Small molecule,"1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)",NNYBQONXHNTVIJ-UHFFFAOYSA-N,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,41340-25-4,C17H21NO3,4909,MG30-MG3Z: Pain
D0625,Etomidate,667484,"Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester",Analgesics,Small molecule,"1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1",NPUKDXXFDDZOKR-LLVKDONJSA-N,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,33125-97-2,C14H16N2O2,4910,9A76-9A78: Corneal disease
D0626,Etonogestrel,6917715,"Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel",Contraceptive Agents,Small molecule,"1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1",GCKFUYQCUCGESZ-BPIQYHPVSA-N,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,54048-10-1,C22H28O2,50777,QA21: Contraceptive management
D0627,Etoposide,36462,"etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside",Antineoplastics,Small molecule,"1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1",VJJPUSNTGOMMGY-MRVIYFEKSA-N,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,33419-42-0,C29H32O13,4911,2A00-2F9Z: Solid tumour/cancer
D0628,Etravirine,193962,"Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR",Anti-Hiv Agents,Small molecule,"1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)",PYGWGZALEOIKDF-UHFFFAOYSA-N,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,269055-15-4,C20H15BrN6O,63589,1C60-1C62: Human immunodeficiency virus disease
D0629,Everolimus,6442177,"Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress",Antineoplastics,Small molecule,"1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,159351-69-6,C53H83NO14,68478,2C90: Renal cell carcinoma
D0630,Exemestane,60198,"Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione",Antineoplastics,Small molecule,"1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1",BFYIZQONLCFLEV-DAELLWKTSA-N,CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C,107868-30-4,C20H24O2,4953,2C60-2C6Y: Breast cancer
D0631,Ezetimibe,150311,"Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone",Antihyperammonia Agents,Small molecule,"1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1",OLNTVTPDXPETLC-XPWALMASSA-N,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,163222-33-1,C24H21F2NO3,49040,5C80: Hyper-lipoproteinaemia
D0632,Ezogabine,121892,"Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester",Anticonvulsants,Small molecule,"1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)",PCOBBVZJEWWZFR-UHFFFAOYSA-N,CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N,150812-12-7,C16H18FN3O2,68584,8A61-8A6Z: Epilepsy/seizure; 4A62: Behcet disease
D0633,Factor IX Complex (Human),.,"4F-PCC; APCC; Coagulation factor IX complex human; Coagulation factor IX, II, VII and X in combination; DB11330; Factor IX Complex; Factor IX Complex (Human); Factor IX complex human; Factor IX complex,human; Factor IX Fraction; PCC; Plasma Concentrate Factor IX; Prothrombin complex concentrate; Prothrombin complex concentrate (human)",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0634,Factor XIII (human),.,"DB12909; Factor XIII; Factor XIII (fibrin stabilising factor); Factor XIII (human); Factor XIII concentrate (human); factor XIII, human; Fibrinoligase",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0635,Famciclovir,3324,"FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine",Antiviral Agents,Small molecule,"1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)",GGXKWVWZWMLJEH-UHFFFAOYSA-N,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,104227-87-4,C14H19N5O4,4974,1A24-1D9Z: Virus infection
D0636,Famotidine,5702160,"Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine;  Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide",Antiulcer Agents,Small molecule,"1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)",XUFQPHANEAPEMJ-UHFFFAOYSA-N,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,76824-35-6,C8H15N7O2S3,4975,DA61: Peptic ulcer
D0637,Febuxostat,134018,"Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid",Antihyperuricemic Agents,Small molecule,"1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",BQSJTQLCZDPROO-UHFFFAOYSA-N,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,144060-53-7,C16H16N2O3S,31596,5C55: Inborn purine/pyrimidine/nucleotide metabolism error
D0638,Fedratinib,16722836,TG101348,Multikinase Inhibitors,Small molecule,"1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)",JOOXLOJCABQBSG-UHFFFAOYSA-N,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4,936091-26-8,C27H36N6O3S,91408,2A20: Myeloproliferative neoplasm
D0639,Felbamate,3331,"Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate",Anticonvulsants,Small molecule,"1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)",WKGXYQFOCVYPAC-UHFFFAOYSA-N,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,25451-15-4,C11H14N2O4,4995,8A61-8A6Z: Epilepsy/seizure
D0640,Felodipine,3333,"Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",Antihypertensive Agents,Small molecule,"1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3",RZTAMFZIAATZDJ-UHFFFAOYSA-N,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,72509-76-3,C18H19Cl2NO4,585948,BA00-BA04: Hypertension
D0641,Fenfluramine,3337,"Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine",Cns Stimulants,Small molecule,"1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3",DBGIVFWFUFKIQN-UHFFFAOYSA-N,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,458-24-2,C12H16F3N,5000,8A61-8A6Z: Epilepsy/seizure; 8A62: Epileptic encephalopathy; 5B80-5B81: Obesity
D0642,Fenofibrate,3339,"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate",Antihyperammonia Agents,Small molecule,"1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",YMTINGFKWWXKFG-UHFFFAOYSA-N,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,49562-28-9,C20H21ClO4,5001,5C80: Hyper-lipoproteinaemia
D0643,Fenofibric acid,64929,"Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287",Antihyperammonia Agents,Small molecule,"1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)",MQOBSOSZFYZQOK-UHFFFAOYSA-N,CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,42017-89-0,C17H15ClO4,83469,BA00-BE2Z: Cardiovascular disease
D0644,Fenoldopam,3341,"Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol",Antihypertensive Agents,Small molecule,"1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2",TVURRHSHRRELCG-UHFFFAOYSA-N,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O,67227-56-9,C16H16ClNO3,5002,BA00-BA04: Hypertension
D0645,Fenoprofen,3342,"Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid",Antiinflammatory Agents,Small molecule,"1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)",RDJGLLICXDHJDY-UHFFFAOYSA-N,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,29679-58-1,C15H14O3,5004,FA20: Rheumatoid arthritis
D0646,Fentanyl,3345,"fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT];  Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals",Narcotic Analgesics,Small molecule,"1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",PJMPHNIQZUBGLI-UHFFFAOYSA-N,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,437-38-7,C22H28N2O,119915,MB40: Sensation disturbance; MG30-MG3Z: Pain; MG30: Chronic pain
D0647,Ferric carboxymaltose,86278165,Ferinject; Injectafer; Ferric carboxymaltose,Iron Supplement,Small molecule,"1S/C24H42O22.Fe.2H2O.O/c25-1-5(29)18(11(32)14(35)21(39)40)44-23-16(37)12(33)20(7(3-27)42-23)46-24-17(38)13(34)19(8(4-28)43-24)45-22-15(36)10(31)9(30)6(2-26)41-22;;;;/h5-20,22-38H,1-4H2,(H,39,40);;2*1H2;/q;+3;;;-2/p-2/t5-,6-,7-,8-,9-,10+,11+,12-,13-,14+,15-,16-,17-,18+,19-,20-,22-,23-,24-;;;;/m1..../s1",MFBBZTDYOYZJGB-HAONTEFVSA-L,C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3],9007-72-1,C24H44FeO25-,.,3A00: Iron deficiency anaemia
D0648,Ferric derisomaltose,86278348,"Ferric derisomaltose; 1345510-43-1; iron(3+);(2S,3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexane-1,2,3,4,5-pentol; DB15617",Iron Supplement,Small molecule,"InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1",JTQTXQSGPZRXJF-DOJSGGEQSA-N,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)OC[C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O)O)O)O)O)O)O.[Fe+3],.,C18H34FeO16+3,.,.
D0649,Ferrous fumarate,6433164,"Ferrous fumarate; Iron(II) fumarate; 141-01-5; Iron(2+) fumarate; ferrousfumarate; UNII-R5L488RY0Q; Iron fumarate; Feostat; 2-Butenedioic acid (2E)-, iron(2+) salt (1:1); R5L488RY0Q; Fersamal; Palafer; Galfer; Fumar; Ircon; Ercoferro; Feroton; Ferrofume; Ferronat; Ferrone; Ferrotemp; Fumafer; Fumiron; Hemoton; Toleron; Tolferain; Tolifer; Cpiron; Firon; One-iron; Erco-Fer; Fumar-F; Ferrocite; Fumaric acid, iron(2+) salt; CCRIS 6896; EINECS 205-447-7; Ferrofumarate; Ferrous fumarate [USP:JAN]; FUMARIC ACID, IRON(2+) SALT (1:1); 2-Butenedioic acid (E)-, iron(2+) salt (1:1); Feostat (TN); Ferrum (TN); 2-Butenedioic acid (2E)-, iron(2+) salt; 2-Butenedioic acid, (E)-, iron(2+) salt; C4H2FeO4; SCHEMBL24284; SCHEMBL24286; Ferrous fumarate (JAN/USP); 2-Butenedioic acid (2E)-, iron(2+) salt (1:?); DTXSID7047148; CHEBI:31607; AMY8976; (E)-but-2-enedioate;iron(2+); HY-B1651; EINECS 231-731-5; AKOS015918237; DB14491; 7705-12-6; CS-0013603; D01194; Q416370; J-007445; J-521364; 2-Butenedioic acid (E)-, iron(2+) salt (1:1) (9CI)",Iron Supplement,Small molecule,"InChI=1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;",PMVSDNDAUGGCCE-TYYBGVCCSA-L,C(=C/C(=O)[O-])\\C(=O)[O-].[Fe+2],.,C4H2FeO4,.,.
D0650,Ferrous gluconate,23616740,"FERROUS GLUCONATE; Ferrousgluconate; UNII-781E2AXH0K; Fergon; Iron gluconate; Iron(II) Gluconate; 781E2AXH0K; 299-29-6; 18829-42-0; iron(2+);(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Ferroglyconicum; Biofergate; Ferronicum; Glucoferron; Cerevon; Feravol; Ferlucon; Ferrose; Flourish; Glucomax; Gluferate; Nionate; Entron; Fenton; Ferox; Irox; Ferro-agepha; Ferrum polon; Gluco-ferrum; Ray-gluciron; Iromon (gador); Fergon preparations; Iron-II gluconate; Irox (gador); Ferrin 55; Gluconic acid iron salt; Ferrous gluconate [USAN]; HSDB 461; Iron digluconate; Iron, bis(D-gluconato-O1,O2)-; EINECS 206-076-3; 6047-12-7; Ferrous gluconate anhydrous; Gluconic acid, iron(2+) salt (2:1), D-; EC 206-076-3; SCHEMBL35424; Iron(II) gluconate, anhydrous; Iron(2+) gluconate (1:2); AKOS015901488; DB14488; Gluconic acid, iron(2+) salt (2:1); D-gluconic acid, iron(2+) salt (2:1); Iron, bis(D-gluconato-kappaO1,kappaO2)-; Q421291",Iron Supplement,Small molecule,"InChI=1S/2C6H12O7.Fe/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",VRIVJOXICYMTAG-IYEMJOQQSA-L,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Fe+2],.,C12H22FeO14,.,.
D0651,Ferrous sulfate anhydrous,24393,"ferrous salt; FERROUS SULFATE; Iron(II) sulfate; 7720-78-7; Iron sulfate; Iron(2+) sulfate; Iron sulphate; Ferrous sulfate anhydrous; Iron sulfate (1:1); Iron(2+) sulphate; FeSO4; Sulfuric acid, iron(2+) salt (1:1); Iron(II) sulfate (1:1); Sulfuric acid, iron(2+) salt; UNII-2IDP3X9OUD; 2IDP3X9OUD; iron(2+) sulfate (anhydrous); Iron vitriol; Iron(2+) sulfate; Combiron; Odophos; Kesuka; Sal chalybis; Green Salts; Quickfloc (salt); Slow Fe; Ferrosulfat [German]; Ferrosulfat; CCRIS 6796; HSDB 465; SFE 171; EINECS 231-753-5; NSC 57631; NSC 146177; Sulfuric acid, iron(2+) salt (1:?); AI3-51903; 16547-58-3; iron(II)sulphate; Fe(II) sulphate; iron(II) sulphate; EINECS 240-616-9; iron(2+);sulfate; iron (II) sulphate; errous hydrogen sulfide; Ferrous sulfate, 98%; ferrous sulfate (anh.); Fe.SO4; Fe(II)SO4; DSSTox_CID_9688; EC 231-753-5; ferrous sulfate (anhydrous); DSSTox_RID_78808; iron(2+) sulfate (anh.); DSSTox_GSID_29688; Iron(II) sulfate (FeSO4); DTXSID0029688; CHEBI:75832; Ferrous Sulphate Exsiccated (Dried); Tox21_202580; 8644AF; DB13257; NCGC00260129-01; CAS-7720-78-7; FT-0626420; Q214863; 8063-79-4",Iron Supplement,Small molecule,"InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",BAUYGSIQEAFULO-UHFFFAOYSA-L,[O-]S(=O)(=O)[O-].[Fe+2],.,FeO4S,.,.
D0652,Ferumoxides,6432052,AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric,Mri Contrast Media,Small molecule,1S/3Fe.4O/q+2;2*+3;4*-2,WTFXARWRTYJXII-UHFFFAOYSA-N,[O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3],119683-68-0,Fe3O4,.,2C12: Liver cancer; DB90-DB9Z: Liver disease
D0653,Ferumoxsil,.,DB09507; Ferumoxsil; Siloxane-coated superparamagnetic iron oxide,Mri Contrast Media,Small molecule,.,.,.,.,.,.,.
D0654,Ferumoxytol,14789,"MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4",Iron Supplement,Small molecule,1S/3Fe.2H2O.2O/h;;;2*1H2;;/q;2*+1;;;;/p-2,UCNNJGDEJXIUCC-UHFFFAOYSA-L,O[Fe]=O.O[Fe]=O.[Fe],1309-38-2,Fe3H2O4,50821,GB61: Chronic kidney disease
D0655,Fesoterodine,6918558,"Fesoterodine; 286930-02-7; (R) Fesoterodine; UNII-621G617227; [2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate; 621G617227; 250214-44-9; (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate; Fesoterodine [INN:BAN]; [2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate; Fesoterodine (INN); FESO; SCHEMBL121127; GTPL7473; CHEMBL1201764; DTXSID80182853; CHEBI:135920; CS-M2392; ZINC1552908; AKOS015841710; DB06702; NCGC00346540-01; NCGC00346540-02; NCGC00346540-03; AC-32493; HY-70053; X5024; D07226; AB01274866-01; AB01274866_02; 930F027; Q4482372; 2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate; Propanoic acid, 2-methyl-, 2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester",Urinary Antispasmodics,Small molecule,"InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1",DCCSDBARQIPTGU-HSZRJFAPSA-N,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2,.,C26H37NO3,.,.
D0656,Fexofenadine,3348,"Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid",Antiallergic Agents,Small molecule,"1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)",RWTNPBWLLIMQHL-UHFFFAOYSA-N,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,83799-24-0,C32H39NO4,5050,CA08: Vasomotor/allergic rhinitis
D0657,Fibrinogen human,.,"Coagulation Factor I; DB09222; Factor I (fibrinogen); Factor I human; Fibrinogen; Fibrinogen (human); Fibrinogen Concentrate (Human); Fibrinogen concentrate human; Fibrinogen human; Fibrinogen human plasma-derived; Fibrinogen, human; Human fibrinogen",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D0658,Fidaxomicin,10034073,Dificid (TN),Macrolides,Small molecule,"1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1",ZVGNESXIJDCBKN-UUEYKCAUSA-N,CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C,873857-62-6,C52H74Cl2O18,.,1A04: Clostridium difficile enterocolitis
D0659,Filgrastim,.,"LA-EP2006; lipegfilgrastim; N-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with alpha-methyl-omega-hydroxypoly(oxyethylene); Neulasta; PEG SD-01; pegfilgrastim; PEG-rmetHuG-CSF; SD-01, polyethylene glycol-conjugated filgrastim; SD-01-filgrastim; XM-22",Colony Stimulating Factors,Protein/peptide,.,.,.,.,.,.,.
D0660,Finasteride,57363,"Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one",Antihyperplasia Agents,Small molecule,"1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1",DBEPLOCGEIEOCV-WSBQPABSSA-N,CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C,98319-26-7,C23H36N2O2,5062,GA90: Prostate hyperplasia
D0661,Fingolimod,107970,"2-Amino-2-(4-octylphenethyl)propane-1,3-diol",Selective Immunosuppressants,Small molecule,"1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3",KKGQTZUTZRNORY-UHFFFAOYSA-N,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,162359-55-9,C19H33NO2,63115,8A40: Multiple sclerosis
D0662,Flavoxate,3354,"Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester",Parasympatholytics,Small molecule,"1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3",SPIUTQOUKAMGCX-UHFFFAOYSA-N,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,15301-69-6,C24H25NO4,5088,.
D0663,Flax seed,.,DB10708; Flax seed; flaxseed allergenic extract; Flaxseed extract,Herbal Products,Natural product,.,.,.,.,.,.,.
D0664,Flecainide,3356,"flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide;  Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide",Antiarrhythmic Agents,Small molecule,"1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)",DJBNUMBKLMJRSA-UHFFFAOYSA-N,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,54143-55-4,C17H20F6N2O3,75984,BC71: Ventricular tachyarrhythmia; BC81: Supraventricular tachyarrhythmia
D0665,Flibanserin,6918248,"Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one",Cns Agents,Small molecule,"1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)",PPRRDFIXUUSXRA-UHFFFAOYSA-N,C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F,167933-07-5,C20H21F3N4O,90865,6A60-6E23: Mood disorder; HA00-HA01: Sexual dysfunction
D0666,Floxuridine,5790,"floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside;  Sterile fudr (TN); Floxuridine/5-fluorouracil",Estrogens/Antimetabolites,Small molecule,"1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1",ODKNJVUHOIMIIZ-RRKCRQDMSA-N,C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O,50-91-9,C9H11FN2O5,60761,2A00-2F9Z: Solid tumour/cancer; 2B91: Colorectal cancer
D0667,Fluconazole,3365,"Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol",Antifungal Agents,Small molecule,"1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2",RFHAOTPXVQNOHP-UHFFFAOYSA-N,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,86386-73-4,C13H12F2N6O,46081,1F29-1F2F: Fungal infection
D0668,Flucytosine,3366,"Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P",Antifungal Agents,Small molecule,"1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)",XRECTZIEBJDKEO-UHFFFAOYSA-N,C1=NC(=O)NC(=C1F)N,2022-85-7,C4H4FN3O,5100,BB40-BA42: Endocarditis
D0669,Fludarabine,657237,"FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)",Antineoplastics,Small molecule,"1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1",HBUBKKRHXORPQB-FJFJXFQQSA-N,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,21679-14-1,C10H12FN5O4,94701,2B33: Malignant haematopoietic neoplasm
D0670,Fludeoxyglucose (18F),170049,"29702-43-0; 2-Deoxy-2-fluoro-D-glucose; 2-Fluoro-2-deoxy-D-glucose; Fludeoxyglucose; (2R,3S,4R,5R)-2-fluoro-3,4,5,6-tetrahydroxyhexanal; fluorodeoxyglucose; UNII-ZO2JV75L55; ZO2JV75L55; CHEBI:49135; 2-deoxy-2-fluoro-aldehydo-D-glucose; MFCD00077527; 2-Deoxy-2-fluoromannose; Fludeoxyglucose [VANDF]; alpha-D-Glucopyranose, 2-deoxy-2-fluoro; SCHEMBL38895; CHEMBL1908940; 2-Fluoro-2-deoxy-D-glucopyranose; ZINC1846431; 3648AC; AKOS006272985; 2-fluoro-3,4,5,6-tetrahydroxy-hexanal; AS-59436; DB-006112; D3023; 702D430; A820014; W-202232; Q27121494; WURCS=2.0/1,1,0/[o2122h_2*F]/1/",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1",AOYNUTHNTBLRMT-SLPGGIOYSA-N,C([C@H]([C@H]([C@@H]([C@H](C=O)F)O)O)O)O,.,C6H11FO5,.,.
D0671,Fludrocortisone,31378,"fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF;  Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone",Antiinflammatory Agents,Small molecule,"1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1",AAXVEMMRQDVLJB-BULBTXNYSA-N,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F,127-31-1,C21H29FO5,50885,5C72: Hypo-osmolality/hyponatraemia
D0672,Flunisolide,82153,"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione",Antiasthmatic Agents,Small molecule,"1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",XSFJVAJPIHIPKU-XWCQMRHXSA-N,CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C,542449,C24H31FO6,5106,CA08: Vasomotor/allergic rhinitis
D0673,Flunisolide (nasal),82153,"Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione",Antiasthmatic Agents,Small molecule,"1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",XSFJVAJPIHIPKU-XWCQMRHXSA-N,CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C,542449,C24H31FO6,5106,CA08: Vasomotor/allergic rhinitis
D0674,Fluorometholone (ophthalmic),9878,"Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione",Antiallergic Agents,Small molecule,"1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1",FAOZLTXFLGPHNG-KNAQIMQKSA-N,CC1CC2C3CCC(C3(CC(C2(C4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,426-13-1,C22H29FO4,31625,CA22: Chronic obstructive pulmonary disease
D0675,Fluorouracil,3385,"5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;  Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU",Immunosuppressive Agents,Small molecule,"1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)",GHASVSINZRGABV-UHFFFAOYSA-N,C1=C(C(=O)NC(=O)N1)F,51-21-8,C4H3FN2O2,46345,2A00-2F9Z: Solid tumour/cancer; 2B91: Colorectal cancer
D0676,Fluoxetine,3386,"Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine",Antidepressants,Small molecule,"1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3",RTHCYVBBDHJXIQ-UHFFFAOYSA-N,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,54910-89-3,C17H18F3NO,86990,6A70-6A7Z: Depression
D0677,Fluoxymesterone,6446,"Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one",Hormones/Antineoplastics,Small molecule,"1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1",YLRFCQOZQXIBAB-RBZZARIASA-N,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C)O)C)O)F,76-43-7,C20H29FO3,5120,2C60-2C6Y: Breast cancer
D0678,Fluphenazine,3372,"FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334;  Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)",Antipsychotic Agents,Small molecule,"1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2",PLDUPXSUYLZYBN-UHFFFAOYSA-N,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,69-23-8,C22H26F3N3OS,5123,6A20-6A25: Psychotic disorder
D0679,Flurazepam,3393,"Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3",SAADBVWGJQAEFS-UHFFFAOYSA-N,CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,17617-23-1,C21H23ClFN3O,5128,7A00-7A0Z: Insomnia
D0680,Flurbiprofen,3394,"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid",Antiinflammatory Agents,Small molecule,"1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",SYTBZMRGLBWNTM-UHFFFAOYSA-N,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,5104-49-4,C15H13FO2,5130,FA20: Rheumatoid arthritis
D0681,Flurbiprofen (ophthalmic),3394,"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid",Antiinflammatory Agents,Small molecule,"1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",SYTBZMRGLBWNTM-UHFFFAOYSA-N,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,5104-49-4,C15H13FO2,5130,FA20: Rheumatoid arthritis
D0682,Flutamide,3397,"Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)",Antineoplastics,Small molecule,"1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)",MKXKFYHWDHIYRV-UHFFFAOYSA-N,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,13311-84-7,C11H11F3N2O3,5132,2C82: Prostate cancer
D0683,Fluticasone,5311101,"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate",Antiinflammatory Agents,Small molecule,"1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1",MGNNYOODZCAHBA-GQKYHHCASA-N,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,90566-53-3,C22H27F3O4S,5134,CA08: Vasomotor/allergic rhinitis
D0684,Fluticasone (nasal),5311101,"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate",Antiinflammatory Agents,Small molecule,"1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1",MGNNYOODZCAHBA-GQKYHHCASA-N,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,90566-53-3,C22H27F3O4S,5134,CA08: Vasomotor/allergic rhinitis
D0685,Fluticasone (topical),5311101,"Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate",Antiinflammatory Agents,Small molecule,"1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1",MGNNYOODZCAHBA-GQKYHHCASA-N,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,90566-53-3,C22H27F3O4S,5134,CA08: Vasomotor/allergic rhinitis
D0686,Fluvastatin,446155,"Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1",FJLGEFLZQAZZCD-MCBHFWOFSA-N,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,93957-54-1,C24H26FNO4,38565,5C80: Hyper-lipoproteinaemia
D0687,Fluvoxamine,5324346,Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine,Antidepressants,Small molecule,"1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+",CJOFXWAVKWHTFT-XSFVSMFZSA-N,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,54739-18-3,C15H21F3N2O2,5138,6A70-6A7Z: Depression
D0688,Folic acid,135398658,folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; Folacid; PteGlu; Vitamin B9; Folvite; Pteroyl-L-glutamic acid; Vitamin Bc; Acifolic; Cytofol; Incafolic; Foliamin; Folsaure; Folicet; Millafol; Folipac; Folettes; Folsan; Folbal; Folsav; Vitamin Be; Pteroyl-L-monoglutamic acid; Mittafol; Folan; Facid; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Pteroylmonoglutamate; Acfol (Spain); Foldine; Folcysteine; Folasic (Australia); Folcidin; Folaemin [Netherlands]; Nifolin; [3H]folic acid,Vitamins,Small molecule,"1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1",OVBPIULPVIDEAO-LBPRGKRZSA-N,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,59-30-3,C19H19N7O6,27470,5B50-5B71: Nutritional deficiency; 3A02: Folate deficiency anaemia
D0689,Fomepizole,3406,Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride,Antidotes,Small molecule,"1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)",RIKMMFOAQPJVMX-UHFFFAOYSA-N,CC1=CNN=C1,7554-65-6,C4H6N2,5141,NE61: Eexposure to noxious substances harmful effect
D0690,Fondaparinux,5282448,"Fondaparinux; 104993-28-4; Natural heparin pentasaccharide; Arixtra; UNII-J177FOW5JL; CHEBI:61033; J177FOW5JL; TRISULFOAMINO HEPARIN PENTASACCHARIDE; a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-b-D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-2-O-sulfo-a-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate); methyl 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-beta-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-2-O-sulfo-alpha-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranoside; SR 90107; HSDB 7845; C31H53N3O49S8; GTPL6819; CHEMBL1201202; SCHEMBL17655218; DTXSID10146903; BDBM50511579; DB00569; Y1945; Q27077698; (2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxan-3-yl]oxy-5-(sulfoamino)-4-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[(2R,3R; alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate); WURCS=2.0/5,5,4/[a2122h-1a_1-5_1*OC_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a2121A-1a_1-5_2*OSO/3=O/3=O][a2122h-1a_1-5_2*NSO/3=O/3=O_3*OSO/3=O/3=O_6*OSO/3=O/3=O][a2122A-1b_1-5][a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O]/1-2-3-4-5/a4-b1_b4-c1_c4-d1_d4-e1",Anticoagulants/Factor Xa Inhibitors,Small molecule,"InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1",KANJSNBRCNMZMV-ABRZTLGGSA-N,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O,.,C31H53N3O49S8,.,.
D0691,Formoterol,3410,"Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate",Sympathomimetics,Small molecule,"1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)",BPZSYCZIITTYBL-UHFFFAOYSA-N,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,73573-87-2,C19H24N2O4,63082,CA23: Asthma
D0692,Fosamprenavir,131536,"Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester",Anti-Hiv Agents,Small molecule,"1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1",MLBVMOWEQCZNCC-OEMFJLHTSA-N,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N,226700-79-4,C25H36N3O9PS,82941,1C60-1C62: Human immunodeficiency virus disease
D0693,Fosaprepitant,135413538,"Fosaprepitant; 172673-20-0; Ivemend; UNII-6L8OF9XRDC; Fosaprepitant free acid; 6L8OF9XRDC; Fosaprepitant dimeglumine; [5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-3-oxo-1H-1,2,4-triazol-2-yl]phosphonic acid; CHEBI:64321; L-758298; L-758,298; L 758298; MK-0517; Fosaprepitant [INN:BAN]; fosaprepitantum; C23H22F7N4O6P; Emend for injection; Fosaprepitant (INN); fosaprepitant-dimeglumine; SCHEMBL309491; GTPL7623; CHEMBL1199324; ZINC3939013; NSC794608; AKOS025149465; AM84605; BCP9000702; CS-1760; DB06717; NSC-794608; NCGC00390240-01; AC-25507; HY-14407; Y0425; D10895; 673F200; L785,298; Q5473324; L 785,298; L-785,298; (3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-2,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid; (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid; [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-2H-1,2,4-triazol-1-yl]phosphonic acid; [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4H-1,2,4-triazol-1-yl]phosphonic acid; [3-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazole-1-yl]phosphonic acid; Phosphonic acid, (3-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl)-; Phosphonic acid, (3-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl)-, (2R-(2alpha(R*),3alpha))-",Antiemetics,Small molecule,"InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1",BARDROPHSZEBKC-OITMNORJSA-N,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F,.,C23H22F7N4O6P,.,.
D0694,Foscarnet,3415,"foscarnet; Phosphonoformic acid; Phosphonoformate; Carboxyphosphonic acid; 4428-95-9; Foscarmet; phosphonocarboxylic acid; Dihydroxyphosphinecarboxylic acid oxide; UNII-364P9RVW4X; phosphonomethanoic acid; CHEMBL666; 364P9RVW4X; CHEBI:127780; dihydroxyphosphanecarboxylic acid oxide; Phgosphonocarboxylic acid; NSC313410; Formic acid, phosphono-; Forscarnet; Phosphinecarboxylic acid, dihydroxy-, oxide; HSDB 8122; 1nki; J05AD01; Foscarnet (PFA); Spectrum_001359; PFA & rIFN.alpha.A; Spectrum2_000668; Spectrum3_001484; Spectrum4_000840; Spectrum5_000932; phosphonoformic acid(PFA); MSL & PFA; Phosphono-formic acid(PFA); hydroxycarbonylphosphonic acid; SCHEMBL23633; BSPBio_003067; Foscarnet & IFN-.ALPHA.; KBioGR_001419; KBioSS_001839; DivK1c_000915; SPBio_000735; GTPL5497; DTXSID0048478; KBio1_000915; KBio2_001839; KBio2_004407; KBio2_006975; KBio3_002567; NINDS_000915; ZINC8101109; BDBM50011181; Phosphonoformic acid & IFN-.ALPHA.; AKOS006281397; DB00529; IDI1_000915; Phosphonoformic acid trisodium salt hexa; (PFA)dihydroxyphosphinecarboxylic acid oxide; dihydroxyphosphinecarboxylic acid oxide(PFA); C06456; Q420387; 6-(2-Nitrophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody",Antiviral Agents,Small molecule,"InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)",ZJAOAACCNHFJAH-UHFFFAOYSA-N,C(=O)(O)P(=O)(O)O,.,CH3O5P,.,.
D0695,Fosinopril,55891,"Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1",BIDNLKIUORFRQP-FKDWWROVSA-N,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3,98048-97-6,C30H46NO7P,5163,BA00-BA04: Hypertension
D0696,Fosnetupitant,71544786,"Fosnetupitant; 1703748-89-3; UNII-T672P80L2S; 07-PNET; T672P80L2S; 1703748-89-3 (inner salt); (4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methylpiperazin-1-ium-1-yl)methyl hydrogen phosphate; Fosnetupitant [INN]; Fosnetupitant (USAN/INN); Fosnetupitant [USAN:INN]; CHEMBL3989917; SCHEMBL18691167; EX-A5775; DB14019; HY-17615; Piperazinium, 4-(5-((2-(3,5-bis(trifluoromethyl)phenyl)-2-methyl-1-oxopropyl)methylamino)-4-(2-methylphenyl)-2-pyridinyl)-1-methyl-1-((phosphonooxy)methyl)-, inner salt; CS-0014699; D11065; Q27289729; [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate",Antiemetics,Small molecule,"InChI=1S/C31H35F6N4O5P/c1-20-8-6-7-9-24(20)25-17-27(40-10-12-41(5,13-11-40)19-46-47(43,44)45)38-18-26(25)39(4)28(42)29(2,3)21-14-22(30(32,33)34)16-23(15-21)31(35,36)37/h6-9,14-18H,10-13,19H2,1-5H3,(H-,43,44,45)",HZIYEEMJNBKMJH-UHFFFAOYSA-N,CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CC[N+](CC4)(C)COP(=O)(O)[O-],.,C31H35F6N4O5P,.,.
D0697,Fosphenytoin,56339,"Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester",Anticonvulsants,Small molecule,"1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)",XWLUWCNOOVRFPX-UHFFFAOYSA-N,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3,93390-81-9,C16H15N2O6P,5165,8A61-8A6Z: Epilepsy/seizure
D0698,Fospropofol,3038498,"Fospropofol; 258516-89-1; UNII-LZ257RZP7K; [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate; LZ257RZP7K; Methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate; DEA No. 2138; Fospropofol [INN]; GTPL7475; SCHEMBL3821874; CHEMBL1201766; DTXSID50870295; CHEBI:135193; ZINC2519740; DB06716; FT-0727559; Q5473368",Anesthetics,Small molecule,"InChI=1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)",QVNNONOFASOXQV-UHFFFAOYSA-N,CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O,.,C13H21O5P,.,.
D0699,Fostamatinib,11671467,901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN],Coagulation Modifiers,Small molecule,"1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)",GKDRMWXFWHEQQT-UHFFFAOYSA-N,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,901119-35-5,C23H26FN6O9P,.,3B64: Thrombocytopenia; FA20: Rheumatoid arthritis
D0700,Fostemsavir,11319217,"BMS-216; BMS-248; BMS-378806; BMS-626529; BMS-705; BMS-806; BMS-806 series; BMS-853; HIV-1 attachment inhibitors, BMS; HIV-1 entry inhibitors, BMS; BMS-488043 follow-on compounds, BMS; HIV-1 attachment inhibitors, Bristol-Myers Squibb",Antiviral Agents,Small molecule,"1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)",SWMDAPWAQQTBOG-UHFFFAOYSA-N,CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC,864953-29-7,C25H26N7O8P,.,1C60-1C62: Human immunodeficiency virus disease
D0701,Frangula purshiana bark,.,Cascara sagrada; DB15478; Frangula purshiana bark,Herbal Products,Natural product,.,.,.,.,.,.,.
D0702,Frovatriptan,77992,"Allegro; Auradol; Frova; Frovelan; Migard; Miguard; Rilamig; Allergo filmtabletten; SB 209509; Allergo filmtabletten(TN); Frova (TN); Frovatriptan (INN); SB-209509; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide",Antimigraine Agents,Small molecule,"1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1",XPSQPHWEGNHMSK-SECBINFHSA-N,CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N,158747-02-5,C14H17N3O,134991,8A80: Migraine
D0703,Fulvestrant,104741,"Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI",Antineoplastics,Small molecule,"1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1",VWUXBMIQPBEWFH-WCCTWKNTSA-N,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,129453-61-8,C32H47F5O3S,31638,2C60-2C6Y: Breast cancer
D0704,Furosemide,3440,"Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid",Diuretics,Small molecule,"1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)",ZZUFCTLCJUWOSV-UHFFFAOYSA-N,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,54-31-9,C12H11ClN2O5S,47426,BD10-BD1Z: Heart failure
D0705,Gabapentin,3446,Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid,Analgesics,Small molecule,"1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)",UGJMXCAKCUNAIE-UHFFFAOYSA-N,C1CCC(CC1)(CC(=O)O)CN,60142-96-3,C9H17NO2,42797,8A61-8A6Z: Epilepsy/seizure; 2A00-2F9Z: Solid tumour/cancer
D0706,Gadoxetic acid,56841043,Gadoxetic acid; Gd-EOB-DTPA; gadoxetate; UNII-3QJA87N40S; 135326-11-3; 2-[[(2S)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron; Gadoxetic acid [INN]; Primovist; 3QJA87N40S; Dihydrogen (N((2s)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-)gadolinate(2-).; Dihydrogen (N-((2S)-2-(bis(carboxymethyl)amino)-3-(p-ethoxyphenyl)propyl)-N-(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))gadolinate(2-),Mri Contrast Media,Small molecule,"InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3/p-3/t17-;/m0./s1",PCZHWPSNPWAQNF-LMOVPXPDSA-K,[H+].[H+].CCOC1=CC=C(C=C1)C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Gd+3],.,C23H30GdN3O11,.,.
D0707,Galantamine,9651,"GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol",Parasympathomimetics,Small molecule,"1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1",ASUTZQLVASHGKV-JDFRZJQESA-N,CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O,357-70-0,C17H21NO3,42944,8A20: Alzheimer disease
D0708,Gallium chloride Ga-67,73415785,"gallium chloride ga-67; Gallium chloride Ga 67; Gallium chloride,Ga-67; Gallium (67Ga) chloride; Gallium chloride, Ga-67; Gallium (Ga-67) chloride; UNII-A04B19O2B0; A04B19O2B0; DB14550; Q27273453",Diagnostic Radiopharmaceuticals,Small molecule,InChI=1S/3ClH.Ga/h3*1H;/q;;;+3/p-3/i;;;1-3,UPWPDUACHOATKO-MPZFSRPWSA-K,[Cl-].[Cl-].[Cl-].[67Ga+3],.,Cl3Ga,.,.
D0709,Gallium nitrate,61635,Ganite (TN),Antineoplastics,Small molecule,1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1,CHPZKNULDCNCBW-UHFFFAOYSA-N,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ga+3],13494-90-1,GaN3O9,.,5B91: Mineral excesses
D0710,Ganciclovir,135398740,"ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512",Antiviral Agents,Small molecule,"1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)",IRSCQMHQWWYFCW-UHFFFAOYSA-N,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,82410-32-0,C9H13N5O4,465284,1A24-1D9Z: Virus infection
D0711,Garlic,.,"1-(prop-2-enyldisulfanyl)propane;3-prop-2-enylsulfinylsulfanylprop-1-ene;3-(prop-2-enyltrisulfanyl)prop-1-ene; 8000-78-0; Oils, garlic",Herbal Products,Natural product,.,.,.,.,.,.,.
D0712,Gatifloxacin,5379,"Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid",Antiinfective Agents,Small molecule,"1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)",XUBOMFCQGDBHNK-UHFFFAOYSA-N,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,112811-59-3,C19H22FN3O4,5280,CA07-CA4Z: Respiratory infection
D0713,Gefitinib,123631,"Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine",Antineoplastics,Small molecule,"1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,184475-35-2,C22H24ClFN4O3,49668,2A00-2F9Z: Solid tumour/cancer; 2C93: Urethral cancer; 2D42: Head and neck cancer
D0714,Gemcitabine,60750,Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN),Antineoplastics,Small molecule,"1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1",SDUQYLNIPVEERB-QPPQHZFASA-N,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,95058-81-4,C9H11F2N3O4,175901,2A00-2F9Z: Solid tumour/cancer
D0715,Gemfibrozil,3463,"ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid",Antihyperammonia Agents,Small molecule,"1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)",HEMJJKBWTPKOJG-UHFFFAOYSA-N,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,25812-30-0,C15H22O3,5296,5C80: Hyper-lipoproteinaemia
D0716,Gemifloxacin,9571107,"Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid",Antibiotics,Small molecule,"1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+",ZRCVYEYHRGVLOC-HYARGMPZSA-N,CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F,175463-14-6,C18H20FN5O4,101853,1A00-1C4Z: Bacterial infection
D0717,Gemtuzumab ozogamicin,.,Mylotarg (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A60: Acute myeloid leukaemia
D0718,Gentamicin,3467,"Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside",Antibiotics,Small molecule,"1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3",CEAZRRDELHUEMR-UHFFFAOYSA-N,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,1403-66-3,C21H43N5O7,.,1A00-1C4Z: Bacterial infection
D0719,Gentamicin (topical),3467,"Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside",Antibiotics,Small molecule,"1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3",CEAZRRDELHUEMR-UHFFFAOYSA-N,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,1403-66-3,C21H43N5O7,.,1A00-1C4Z: Bacterial infection
D0720,Gilteritinib,49803313,UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199,Multikinase Inhibitors,Small molecule,"1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,1254053-43-4,C29H44N8O3,145372,2A60: Acute myeloid leukaemia
D0721,Ginger,442138,"Absinthin; 1362-42-1; Absinthiin; Absynthin; (+)-absinthin; UNII-OE5992O64P; OE5992O64P; (1R,2R,5S,8S,9S,12S,13R,14S,15S,16R,17S,20S,21S,24S)-12,17-dihydroxy-3,8,12,17,21,25-hexamethyl-6,23-dioxaheptacyclo[13.9.2.0(1,16).0(2,14).0(4,13).0(5,9).0(20,24)]hexacosa-3,25-diene-7,22-dione; Ginger; Ginger Root Powder; C30H40O6; NSC 407315; SCHEMBL873059; CHEBI:2366; CHEMBL4647301; HY-N0742; ZINC8214476; s3288; AC-35046; CS-0009774; Y0021; C09286; Q332313",Herbal Products,Natural product,"InChI=1S/C30H40O6/c1-12-11-18-20-21(30(12)24(18)29(6,34)10-8-17-14(3)27(32)36-25(17)30)15(4)19-22(20)28(5,33)9-7-16-13(2)26(31)35-23(16)19/h11,13-14,16-18,20-25,33-34H,7-10H2,1-6H3/t13-,14-,16-,17-,18+,20-,21-,22-,23-,24-,25-,28-,29-,30+/m0/s1",PZHWYURJZAPXAN-ILOFNVQHSA-N,C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O,.,C30H40O6,.,.
D0722,Ginkgo biloba,.,"119460-49-0; 15291-75-5; 291G755; 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4H)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1R-(1alpha,3beta,3aS*,4beta,6aalpha,7aalpha,7balpha,8alpha,10aalpha,11 aS*))-; 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4H)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1R,3S,3aS,4R,6aR,7aR,7bR,8S,10aS,11aS)-; AB00827840-06; AKOS030485969; AS-17563; BDBM50292287; BN 52020; BN52020; BN-52020; CHEMBL465161; DB06743; DTXSID10873222; Ginkgolide A; Ginkgolide A from Ginkgo biloba leaves; ginkgolide-A; HMS2089P12; HMS2864P03; MFCD00133365; MLS001216228; Q-100178; Q27095718; SMR000544404; SR-01000801389; SR-01000801389-2; TAZ2DPR77B; UNII-TAZ2DPR77B; V0723; ZINC4245650",Herbal Products,Natural product,.,.,.,.,.,.,.
D0723,Ginseng,420552,"Ginseng; Prosapogenin; Panax ginseng extract; 50647-08-0; bis[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate; NSC124670; CHEMBL1970059; CHEBI:189965; NSC-124670; XP173068; 2,3-Dihydroxy-6b-hydroxymethyl-4,6a,11,11,14b-pentamethyl-2,3,4,4a,5,6,6a,6b,7,8,9,10,11,12,12a,14,14a,14b-octadecahydro-1H-picene-4,8a-dicarboxylic acid bis-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl) ester; bis[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl] 2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate",Herbal Products,Natural product,"InChI=1S/C42H66O17/c1-37(2)10-11-41(36(55)59-34-31(52)29(50)27(48)23(17-44)57-34)12-13-42(18-45)19(20(41)14-37)6-7-24-38(3)15-21(46)32(53)40(5,25(38)8-9-39(24,42)4)35(54)58-33-30(51)28(49)26(47)22(16-43)56-33/h6,20-34,43-53H,7-18H2,1-5H3",YDQIRODFTJGGMP-UHFFFAOYSA-N,CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C(=O)OC6C(C(C(C(O6)CO)O)O)O)O)O)C)C)C2C1)CO)C(=O)OC7C(C(C(C(O7)CO)O)O)O)C,.,C42H66O17,.,.
D0724,Givosiran,119058042,"1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280",Metabolic Agents,Small interfering RNA,"1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1",RUPXJRIDSUCQAN-PQNNUJSWSA-N,CC1CC(CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCOC4C(C(C(C(O4)CO)O)O)NC(=O)C)O,1639325-43-1,C78H139N11O30,.,5C58: Inborn porphyrin/heme metabolism error
D0725,Glasdegib,25166913,Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2,Antineoplastics/Hedgehog Pathway Inhibitors,Small molecule,"1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1",SFNSLLSYNZWZQG-VQIMIIECSA-N,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,1095173-27-5,C21H22N6O,145428,2A40: Chronic myelomonocytic leukaemia; 2A00-2F9Z: Solid tumour/cancer
D0726,Glecaprevir,66828839,"Glecaprevir; ABT-493; UNII-K6BUU8J72P; 1365970-03-1; K6BUU8J72P; A-1282576.0; 1365970-03-1 (free); ABT 493; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10carboxamide; Glecaprevir [USAN]; Maviret; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17, 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; O31; ABT-493(Glecaprevir); Glecaprevir (USAN/INN); SCHEMBL883097; ABT493; CHEMBL3545363; GTPL11267; (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide; AMY38157; EX-A1940; s5720; CS-8098; DB13879; AC-33419; HY-17634; J3.646.120I; D10814; A-1282576; A-12825760; 3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-((1R,2R)-2-(difluoromethyl)-1-((1-methylcyclopropane-1-sulfonyl)carbamoyl)cyclopropyl)-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta(18,19)(1,10,17,3,6)trioxadiazacyclononadecino(11,12-b)quinoxaline-10-carboxamide; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop; (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro- 5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12- methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10- carboxamide hydrate; Cyclopropanecarboxamide, N-((((1R,2R)-2-((4,4-difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl)oxy)cyclopentyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)-, cyclic (1->2)-ether, (1R,2R)-; ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,",Antiviral Agents,Small molecule,"InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1",MLSQGNCUYAMAHD-ITNVBOSISA-N,CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C,.,C38H46F4N6O9S,.,.
D0727,Glimepiride,3476,"Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P",Antidiabetic Agents,Small molecule,"1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)",WIGIZIANZCJQQY-UHFFFAOYSA-N,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,261361-60-8,C24H34N4O5S,5383,5A2Y: Acute diabete complication
D0728,Glipizide,3478,"Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea",Antidiabetic Agents,Small molecule,"1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)",ZJJXGWJIGJFDTL-UHFFFAOYSA-N,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,29094-61-9,C21H27N5O4S,5384,5A2Y: Acute diabete complication
D0729,Glutamic acid,33032,"Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid",Dietary Supplement,Small molecule,"1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1",WHUUTDBJXJRKMK-VKHMYHEASA-N,C(CC(=O)O)C(C(=O)O)N,56-86-0,C5H9NO4,16015,6A20: Schizophrenia
D0730,Glyburide,3488,Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide,Antidiabetic Agents,Small molecule,"1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",ZNNLBTZKUZBEKO-UHFFFAOYSA-N,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,10238-21-8,C23H28ClN3O5S,5441,5A2Y: Acute diabete complication; 8B20: Ischaemic/haemorrhagic stroke
D0731,Glycerin,753,"glycerol; glycerin; 56-81-5; Glycerine; 1,2,3-Propanetriol; PROPANE-1,2,3-TRIOL; Glycyl alcohol; Trihydroxypropane; Glyceritol; Propanetriol; Osmoglyn; 1,2,3-trihydroxypropane; Polyglycerine; Glycerin, synthetic; Grocolene; Glysanin; Glyrol; Dagralax; Ophthalgan; Vitrosupos; Glycerin, anhydrous; Synthetic glycerin; Glycerinum; Synthetic glycerine; Optim; Moon; Star; Glycerin mist; Incorporation factor; Glycerin (mist); Glycerolum; 90 Technical glycerine; Glycerine mist; Citifluor AF 2; Bulbold; Cristal; Glicerina [DCIT]; Caswell No. 469; 25618-55-7; Propanetriol (VAN); Glycerin base; FEMA No. 2525; Glycerin, natural; Glicerol [INN-Spanish]; Glycerolum [INN-Latin]; Clyzerin, wasserfrei; Pricerine 9091; Clyzerin, wasserfrei [German]; Emery 916; CCRIS 2295; HSDB 492; EPA Pesticide Chemical Code 063507; Tryhydroxypropane; UNII-PDC6A3C0OX; Polyglycerol; Collyrium Fresh-Eye Drops; AI3-00091; Glycerin,anhydrous; NSC 9230; BRN 0635685; IFP; Monoctanoin Component D; di-o-tolylphenylphosphine; DYNASTIN 7; MFCD00004722; PDC6A3C0OX; 1,2,3-trihydroxypropanol; CHEBI:17754; Glycerin anhydrous; NSC9230; Glycerol (INN); Glycerol [INN]; NSC-9230; 101662-08-2; 144086-02-2; NCGC00090950-03; Diacylglycerol(35:0); DSSTox_CID_662; rac-Glycerol-1-13C; DSSTox_RID_75717; DSSTox_GSID_20663; 107283-02-3; 144086-03-3; 153050-05-6; 18803-09-3; 1H-Thieno[3,4-d]iMidazole-4-pentanaMide, hexahydro-2-oxo-N-[6-oxo-6-(2-propenylaMino)hexyl]-, (3aS,4; 2-Propenoic acid, polymer with 2,2-bis(hydroxymethyl)-1,3-propanediol, methyloxirane and oxirane; Glycerin [JAN]; Glycerol; Propane-1,2,3-Triol; Glicerina; Glicerol; Heterochromatin-specific nonhistone chromosomal protein HP-1; 2-Propenoic acid, polymer with oxirane and 1,2,3-propanetriol; DAG 31:3; DAG 35:0; DAG(35:0); Glycerol, ACS reagent, >=99.5%; Poly[oxy(2-hydroxy-1,3-propanediyl)], alpha-hydro-omega-hydroxy-; Glyceol Opthalgan; Glycerin - mist; DG 31:3; DG 35:0; CAS-56-81-5; 26403-55-4; DG(31:3); DG(35:0); GOL; Mackstat H 66; WURCS=2.0/1,1,0/[h2h]/1/; Glycerin [USP:JAN]; RG-S; EINECS 200-289-5; alditol; Glycerin - mist, Respirable; Neutracett; Glyceol; Glyzerin; Oelsuess; glycerine usp; Artifical tears; C3H8O3; D-glycerol; L-glycerol; Organic Glycerin; Glycerol solution; Organic Glycerine; Glycerine (crude); Polyhydric alcohols; 1,3-Propanetriol; Glycerol, ultrapure; Glycerin USP grade; Glycerine 96%; Glycerol 85%; diacylglycerol 31:3; diacylglycerol 35:0; Glycerin 99.5%; Glycerine 96% USP; 1,3-Trihydroxypropane; 90 Technical glycerin; Emery 912; diacylglycerol(31:3); Dl-[1-13C]Glycerol; E 422; Glycerin (JP17/USP); Glycerin 99.5% USP; Glycerine 99.7% USP; bmse000184; bmse000807; bmse000856; CHEMBL692; MolMap_000024; EC 200-289-5; Glycerol, >=99.5%; Glycerol, biochemical grade; Glycerin Reagent Grade ACS; WLN: Q1YQ1Q; Glycerine (Fragrance Grade); 2-hydroxylpropane-1,3-diol; Glycerol, LR, >=98%; Glycerol, analytical standard; 4-01-00-02751 (Beilstein Handbook Reference); 8043-29-6; Glycerol, Cell Culture Grade; Glycerol-[1,3-13C2]; Glycerin, concentrated (JAN); Glycerol min 98%, anhydrous; Concentrated glycerin (JP17); Glycerol 3 M solution, 3 M; Glycerol, >=99% (GC); M 314429; GTPL5195; INS NO.422; QSPL 181; DTXSID9020663; Glycerol, AR, >=99.5%; Pentrioxido sulfurico glycerincol; CHEBI:17522; Glycerol, >99%, FCC, FG; Glycerol, technical grade, 95%; Glycerol, ultrapure, HPLC Grade; INS-422; 2w97; CHEBI:131416; CHEBI:178017; CHEBI:189439; Glycerol, ACS reagent, 99.5%; Glycerol, Molecular Biology Grade; Pharmakon1600-01300020; ZINC895048; Glycerol, Vetec(TM) reagent grade; Glycerol solution, 86-89% (T); HY-B1659; STR02073; Glycerine 912 (96% CP/USP); Tox21_111043; Tox21_202077; Tox21_300144; c0066; DAG(31:3); Glycerol, BioXtra, >=99% (GC); Glycerol, ReagentPlus(R), >=99%; NSC759633; s2766; STL199174; AKOS000120102; CS-6964; DB09462; Glycerol, USP, 99.0-101.0%; MCULE-6349111826; NSC-759633; GLYCERIN; PROPANE-1,2,3-TRIOL; Glycerolglycerin; Propane-1,2,3-Triol; PZN 7474853; Glycerol, SAJ first grade, >=98.0%; NCGC00090950-01; NCGC00090950-02; NCGC00090950-04; NCGC00090950-05; NCGC00253975-01; NCGC00259626-01; BP-31039; E422; Glycerol, for molecular biology, >=99%; Glycerol, JIS special grade, >=99.0%; Glycerol, Vetec(TM) reagent grade, 99%; Glycerin, meets USP testing specifications; E-422; FT-0626742; FT-0669018; FT-0697060; G0316; Glycerol, ultrapure, Spectrophotometric Grade; Glycerol, ReagentPlus(R), >=99.0% (GC); Glycerol, spectrophotometric grade, >=99.5%; C00116; D00028; D92249; A831186; Glycerol solution, puriss. p.a., 86-89% (T); Glycerol, tested according to Ph.Eur., anhydrous; Q132501; BRD-K73866522-001-02-6; Glycerol-Gelatine, for mounting (histochemical slides); F0001-1470; 8DFDFCD7-1ED2-4373-845E-054F5AD00089; UNII-VFU0OU98LO component PEDCQBHIVMGVHV-UHFFFAOYSA-N; Glycerin, United States Pharmacopeia (USP) Reference Standard; Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material; Glycerol, BioUltra, for molecular biology, anhydrous, >=99.5% (GC); Glycerol, p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 98.0-101.0%; Glycerol, puriss. p.a., ACS reagent, anhydrous, dist., >=99.5% (GC); ASTM(R) D6584 Glycerin solution, 500 mug/mL in pyridine, analytical standard; ASTM(R) D6584 Glycerin solution, certified reference material, 500 mug/mL in pyridine; Glycerol solution, puriss., meets analytical specification of Ph.??Eur., BP, 84-88%; Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, >=99% (GC); Glycerol, polymer-bound, extent of labeling: 1-2 mmol/g glycerol loading, 1 % cross-linked with divinylbenzene; Glycerol, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E422, anhydrous, 99.0-101.0% (alkalimetric)",Topical Emollients,Small molecule,"InChI=1S/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2",PEDCQBHIVMGVHV-UHFFFAOYSA-N,C(C(CO)O)O,.,C3H8O3,.,.
D0732,Glycerol phenylbutyrate,10482134,GT4P; HPN-100; Glyceryl tri-(4-phenylbutyrate),Urea Cycle Disorder Agents,Small molecule,"1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2",ZSDBFLMJVAGKOU-UHFFFAOYSA-N,C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3,611168-24-2,C33H38O6,134745,DB90-DB9Z: Liver disease
D0733,Glycopyrronium,3494,"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,",Topical Agents,Small molecule,"1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1",ANGKOCUUWGHLCE-UHFFFAOYSA-N,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,13283-82-4,C19H28NO3+,94449,8A20: Alzheimer disease
D0734,Glycopyrronium (topical),3494,"13283-82-4; (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate; Glycopyrronium (USAN); NCGC00179456-02; Tovanor Breezhaler; zlchem 10; beta-1-Methyl-3-pyrrolidyl-alpha-cyclopentylmandelate methobromide; G00010-Watson-Int; Prestwick2_000746; Prestwick1_000746; Prestwick3_000746; Prestwick0_000746; AC1Q60WT; BSPBio_000732; SCHEMBL133002; SPBio_002671; AC1L1G28; BPBio1_000806; GTPL7459; Pyrrolidinium,",Topical Agents,Small molecule,"1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1",ANGKOCUUWGHLCE-UHFFFAOYSA-N,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,13283-82-4,C19H28NO3+,94449,8A20: Alzheimer disease
D0735,Goldenseal,.,"84603-60-1; EINECS 283-261-5; Extract of golden seal; Golden seal, Hydrastis canadensis, ext.; Goldenseal; Goldenseal powder; Guna-lympho; Hydrastis; Hydrastis canadensis extract; Opsonat",Herbal Products,Natural product,.,.,.,.,.,.,.
D0736,Golimumab,.,Simponi (TN); Golimumab (USAN/INN),Tnf Alfa Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FA20: Rheumatoid arthritis; DD72: Indeterminate colitis
D0737,Goserelin,5311128,AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN),Antineoplastics,Small molecule,"1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1",BLCLNMBMMGCOAS-URPVMXJPSA-N,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,65807-02-5,C59H84N18O14,5523,2C60-2C6Y: Breast cancer
D0738,Granisetron,5284566,"BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide",Antiemetics,Small molecule,"1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+",MFWNKCLOYSRHCJ-AGUYFDCRSA-N,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,109889-09-0,C18H24N4O,5537,MD90: Nausea/vomiting
D0739,Grazoprevir,44603531,"Grazoprevir; 1350514-68-9; MK-5172; MK5172; UNII-8YE81R1X1J; Grazoprevir monohydrate; MK 5172; MK-5172 ANHYDROUS; MK-5172 MONOHYDRATE; 8YE81R1X1J; (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide; Grazoprevir [INN]; Grazoprevir anhydrous; MK-5172; Grazoprevir; SCHEMBL2175313; CHEMBL2063090; GTPL11573; DTXSID50159234; CHEBI:132975; EX-A2253; BDBM50485492; s3728; ZINC95551509; AKOS030253227; CCG-270451; CS-1374; DB11575; ino[11,12-b]quinoxaline-8-carboxamide; analog 15 [PMID: 24900473]; NCGC00378916-02; AC-29227; AS-55861; HY-15298; D82934; A887766; Zepatier [elbasvir (NS5A inhibitor) + grazoprevir]; Q19786991; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di; (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0?,??.0?,??.0??,??]nonacosa-3,5,7,9,11-pentaene-27-carboxamide; (1R,2S)-N-[[[(1R,2R)-2-[5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, cyclic (1-->2)-ether;MK-5172; (33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide; oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec",Antiviral Agents,Small molecule,"InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1",OBMNJSNZOWALQB-NCQNOWPTSA-N,CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCC[C@@H]7C[C@H]7OC(=O)N1,.,C38H50N6O9S,.,.
D0740,Grepafloxacin,72474,"Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid",Antibiotics,Small molecule,"1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)",AIJTTZAVMXIJGM-UHFFFAOYSA-N,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,119914-60-2,C19H22FN3O3,5543,CA20: Bronchitis; 1A00-1C4Z: Bacterial infection
D0741,Griseofulvin,441140,"Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione",Antifungal Agents,Small molecule,"1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1",DDUHZTYCFQRHIY-RBHXEPJQSA-N,CC1CC(=O)C=C(C12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,126-07-8,C17H17ClO6,27779,1F28: Dermatophytosis
D0742,Guanabenz,5702063,"GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine",Sympatholytics,Small molecule,"1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+",WDZVGELJXXEGPV-YIXHJXPBSA-N,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,60329-03-5,C8H8Cl2N4,5553,BA00: Essential hypertension
D0743,Guanadrel,38521,"GUANADREL; 40580-59-4; Guanadrelum [INN-Latin]; Guanadrelum; Guanadrel [INN]; 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine; CHEBI:5555; Guanadrel (INN); N-(1,4-Dioxaspiro[4.5]dec-2-ylmethyl)guanidine; Hylorel (TN); 1-{1,4-dioxaspiro[4.5]decan-2-ylmethyl}guanidine; (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine; Prestwick0_000767; Prestwick1_000767; Prestwick2_000767; Prestwick3_000767; CHEMBL1037; BSPBio_000814; SCHEMBL180963; SPBio_002753; BPBio1_000896; GTPL7193; DTXSID2048533; EX-A4513; AKOS026777091; DB00226; MCULE-3794032460; NCGC00179419-01; NCGC00179419-05; AB00513917; FT-0669066; C07035; D08029; AB00513917_02; 1-(1,4-dioxaspiro[4.5]dec-2-ylmethyl)guanidine; L001259; 2-{1,4-dioxaspiro[4.5]decan-2-ylmethyl}guanidine; Q5613557; 2-((1,4-dioxaspiro[4.5]decan-2-yl)methyl)guanidine",Antiadrenergic Agents,Small molecule,"InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)",HPBNRIOWIXYZFK-UHFFFAOYSA-N,C1CCC2(CC1)OCC(O2)CN=C(N)N,.,C10H19N3O2,.,.
D0744,Guanethidine,3518,"Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine",Antihypertensive Agents,Small molecule,"1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)",ACGDKVXYNVEAGU-UHFFFAOYSA-N,C1CCCN(CCC1)CCN=C(N)N,55-65-2,C10H22N4,5557,BA00: Essential hypertension
D0745,Guanfacine,3519,"GUANFACINE; 29110-47-2; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; UNII-30OMY4G3MK; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; 30OMY4G3MK; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; SPD 503; Guanfacina; Guanfacinum; Guanfacine [INN:BAN]; NSC-759121; NCGC00015469-05; EINECS 249-442-8; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Guanfacine-13C-15N3; Lopac-G-1043; CHEMBL862; LON 798 (Salt/Mix); Lopac0_000519; SCHEMBL35094; BSPBio_000377; GTPL522; RASPBERRYKETONEGLUCOSIDE; SPBio_002298; BPBio1_000415; DTXSID9046944; BDBM81984; BCP09647; NSC_3519; ZINC3872738; Guanfacine hydrochloride (Salt/Mix); HY-17416A; (2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; AKOS030255657; CCG-204609; DB01018; NSC 759121; SDCCGSBI-0050502.P002; MRF-0000019; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; CAS-29110-48-3; CAS_29110-47-2; FT-0669067; FT-0669068; C07037; D08031; AB01563079_01; A902647; A918619; L000286; L013430; J-017394; Q5613599; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride;Guanfacine HCl",Antiadrenergic Agents,Small molecule,"InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)",INJOMKTZOLKMBF-UHFFFAOYSA-N,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,.,C9H9Cl2N3O,.,.
D0746,Guanidine,3520,"guanidine; Iminourea; Aminomethanamidine; Carbamidine; 113-00-8; Carbamamidine; Guanidin; Imidourea; Aminoformamidine; UNII-JU58VJ6Y3B; CHEBI:42820; JU58VJ6Y3B; H2N-C(=NH)-NH2; Guanidine, Hydrochloride; Gu; GAI; Guanidine, free base; EINECS 204-021-8; BRN 0506044; HSDB 7603; CHEMBL821; Epitope ID:140101; NCIOpen2_007946; 4-03-00-00148 (Beilstein Handbook Reference); (NH2)2C=NH; GTPL4783; DTXSID0023117; BCP26146; ZINC8101126; BDBM50420178; STL223269; AKOS009031425; DB00536; MCULE-1152750770; SBI-0207070.P001; FT-0626820; C17349; AB00053583_04; 113G008; Q183309; A9B89FF5-2922-47CC-82CE-AC4157B624AE; Ribavirin Impurity T; Iminourea;Diaminomethanimine;Guanidinebase;Carbamidine; 90332-86-8; GZ6",Cholinergic Muscle Stimulants,Small molecule,"InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)",ZRALSGWEFCBTJO-UHFFFAOYSA-N,C(=N)(N)N,.,CH5N3,.,.
D0747,Guselkumab,.,NULL,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,.
D0748,Halazepam,31640,"Halazepamum; Pacinone; Paxipam; Sch 12041; Schering 12041; Alapryl (TN); Halazepamum [INN-Latin]; Pacinone (TN); Paxipam (TN); Sch-12041; Halazepam (USAN/INN); Halazepam [USAN:BAN:INN]; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on",Antianxiety Agents,Small molecule,"1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2",WYCLKVQLVUQKNZ-UHFFFAOYSA-N,C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F,23092-17-3,C17H12ClF3N2O,5603,6B00-6B0Z: Anxiety disorder
D0749,Halofantrine,37393,"Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride",Antimalarial Agents,Small molecule,"1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3",FOHHNHSLJDZUGQ-UHFFFAOYSA-N,CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O,69756-53-2,C26H30Cl2F3NO,94392,1F40-1F45: Malaria
D0750,Haloperidol,3559,Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN],Antipsychotic Agents,Small molecule,"1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",LNEPOXFFQSENCJ-UHFFFAOYSA-N,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,52-86-8,C21H23ClFNO2,5613,6A20: Schizophrenia
D0751,Halothane,3562,"Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan",Anesthetics,Small molecule,"1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H",BCQZXOMGPXTTIC-UHFFFAOYSA-N,C(C(F)(F)F)(Cl)Br,151-67-7,C2HBrClF3,5615,9A76-9A78: Corneal disease
D0752,Hemin,26945,"heme; protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin",Heme Iron Supplement,Small molecule,"1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2",KABFMIBPWCXCRK-UHFFFAOYSA-L,CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[Fe+2],14875-96-8,C34H32FeN4O4,.,.
D0753,Heparin,772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D0754,Heparin (flush),772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D0755,Hepatitis A Vaccine,.,"D022362; Havrix; Hepatitis A Vaccine; Hepatitis A Vaccines; Hepatovirus Vaccines; Vaccine, Hepatitis A; Vaccines, Hepatitis A; Vaccines, Hepatovirus; Vaqta",Vaccines,Vaccine,.,.,.,.,.,.,.
D0756,Hepatitis B Vaccine (Recombinant),.,DB11627; HBSAG; Hepatitis B antigen; Hepatitis B surface antigen; Hepatitis B Surface Antigen (rDNA); Hepatitis B surface antigen (recombinant); Hepatitis B surface antigen vaccine; Hepatitis B surface antigens; Hepatitis B Vaccine; Hepatitis B Vaccine (Recombinant); Hepatitis B virus hbsag surface protein antigen; Hepatitis-B surface antigen,Vaccines,Vaccine,.,.,.,.,.,.,.
D0757,Hexachlorophene (topical),3598,"Acigena; Almederm; Armohex; Bilevon; Bivelon; Cotofilm; Dermadex; Distodin; Eleven; Esaclorofene; Exofene; Fascol; Fomac; Fostril; Gamophen; Gamophene; Hexabalm; Hexachlorofen; Hexachlorophane; Hexachlorophen; Hexachlorophenum; Hexaclorofeno; Hexafen; Hexascrub; Hexide; Hexophene; Hexosan; Isobac; Nabac; PHisoHex; Phisodan; Ritosept; Septisol; Septofen; Steral; Steraskin; Surofene; TRICHLOROPHENE; Tersaseptic; Trisophen; Turgex; Blockade Anti Bacterial Finish; Brevity Blue Liquid Bacteriostatic Scouring Cream; Brevity Blue Liquid Sanitizing Scouring Cream; Enditch Pet Shampoo; Esaclorofene [DCIT]; Fo stril; Hexachlorofen [Czech]; Hexachlorophene [INN]; Hilo Cat Flea Powder; Hilo Flea Powder; Neosept V; Pedigree Dog Shampoo Bar; Scrubteam Surgical Spongebrush; Staphene O; AT 7; B 32; H3P; Hexachlorophene [UN2875] [Poison]; KUC106447N; M0219; Nabac 25 ec; AT-7; AT17 (TN); AT7 (TN); Acigena (TN); Almederm (TN); At-17; B & b Flea Kontroller for Dogs Only; B 32 (VAN); Bilevon (TN); E-Z Scrub; En-Viron D Concentrated Phenolic Disinfectant; Exofene (TN); Fesia-sin; Fostril (TN); G-11; G-Eleven; G-II; Gamophen (TN); Germa-Medica; Hexa-Germ; Hexachlorophene, Pharma; Hexachlorophenum [INN-Latin]; Hexaclorofeno [INN-Spanish]; Hexaphene-LV; Hexosan (TN); PRE-OP II; Phiso-Scrub; Phisohex(TN); Pre-Op; Septi-Soft; Septisol (TN); Solu-Heks; Soy-dome; Ster-zac; Surgi-Cen; Surgi-Cin; Surofene (TN); Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; G-11 (TN); GERMA-MEDICA (MG); Germa-Medica (TN); Hexachlorophene (USP/INN); KSC-19-051; Methylenebis(3,4,6-trichlorophenol); Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-Methylene bis(3,4,6-trichlorophenol); 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2'-Methylenebis[3,4,6-trichlorophenol]; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2-Methylene-bis-[3,4,6-trichlorophenol]; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol",Antiinfective Agents,Small molecule,"1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2",ACGUYXCXAPNIKK-UHFFFAOYSA-N,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,70-30-4,C13H6Cl6O2,5693,1A00-1C4Z: Bacterial infection
D0758,Histrelin,25077993,Supprelin (TN),Hormones/Antineoplastics,Small molecule,"1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1",HHXHVIJIIXKSOE-QILQGKCVSA-N,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,76712-82-8,C66H86N18O12,5739,5A80: Ovarian dysfunction; GA10: Endometriosis; 5A60-5A61: Pituitary gland disorder
D0759,Homatropine,5282593,"HOMATROPINE; 87-00-3; Homatropin; DL-HOMATROPINE; Homoatropine; Mandelyltropeine; Homotropine; Mandelytropeine; CHEBI:5747; Benzeneacetic acid, a-hydroxy-,(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1aH,3aH-Tropan-3a-ol mandelate (ester) hydrobromide; Mandelic acid, 3d-tropanyl ester; Omatropina; Methylhomatropinum; Omatropina [DCIT]; 3alpha-Tropylmandelat; Tropinmandelsaeureester; NCGC00179630-03; Homatropine [INN:BAN]; DL-Mandelsaeure-tropylester; Tropine, mandelate (ester); s ethyl; EINECS 201-716-8; (+-)-Homatropine; BRN 0087959; Prestwick0_000062; Prestwick1_000062; Prestwick2_000062; Prestwick3_000062; (RS)-3alpha(1alphaH,5alphaH)-Tropanylmandelat; DSSTox_CID_24014; DSSTox_RID_80098; DSSTox_GSID_44014; SCHEMBL23969; BSPBio_000243; 5-21-01-00234 (Beilstein Handbook Reference); SPBio_002164; BPBio1_000269; MEGxp0_001876; CHEMBL1618018; DTXSID6044014; SCHEMBL15275620; ACon1_000253; CHEBI:91858; DTXSID00858826; Tox21_113104; 6348AF; AC-1301; DB11181; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate; CAS-87-00-3; NCGC00179630-01; NCGC00179630-02; C07814; AB00694561_08; 087H003; Q1038115; BRD-A74975734-004-02-4; BRD-A74975734-004-10-7; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol, mandelate (ester); (3-exo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate; [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate; alpha-Hydroxybenzeneacetic acid (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3alpha-yl ester; 16175-57-8",Mydriatics,Small molecule,"InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14?,15?",ZTVIKZXZYLEVOL-DGKWVBSXSA-N,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O,.,C16H21NO3,.,.
D0760,Homatropine (ophthalmic),5282593,"HOMATROPINE; 87-00-3; Homatropin; DL-HOMATROPINE; Homoatropine; Mandelyltropeine; Homotropine; Mandelytropeine; CHEBI:5747; Benzeneacetic acid, a-hydroxy-,(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1aH,3aH-Tropan-3a-ol mandelate (ester) hydrobromide; Mandelic acid, 3d-tropanyl ester; Omatropina; Methylhomatropinum; Omatropina [DCIT]; 3alpha-Tropylmandelat; Tropinmandelsaeureester; NCGC00179630-03; Homatropine [INN:BAN]; DL-Mandelsaeure-tropylester; Tropine, mandelate (ester); s ethyl; EINECS 201-716-8; (+-)-Homatropine; BRN 0087959; Prestwick0_000062; Prestwick1_000062; Prestwick2_000062; Prestwick3_000062; (RS)-3alpha(1alphaH,5alphaH)-Tropanylmandelat; DSSTox_CID_24014; DSSTox_RID_80098; DSSTox_GSID_44014; SCHEMBL23969; BSPBio_000243; 5-21-01-00234 (Beilstein Handbook Reference); SPBio_002164; BPBio1_000269; MEGxp0_001876; CHEMBL1618018; DTXSID6044014; SCHEMBL15275620; ACon1_000253; CHEBI:91858; DTXSID00858826; Tox21_113104; 6348AF; AC-1301; DB11181; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate; CAS-87-00-3; NCGC00179630-01; NCGC00179630-02; C07814; AB00694561_08; 087H003; Q1038115; BRD-A74975734-004-02-4; BRD-A74975734-004-10-7; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol, mandelate (ester); (3-exo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate; [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate; alpha-Hydroxybenzeneacetic acid (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3alpha-yl ester; 16175-57-8",Mydriatics,Small molecule,"InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14?,15?",ZTVIKZXZYLEVOL-DGKWVBSXSA-N,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O,.,C16H21NO3,.,.
D0761,Human botulinum neurotoxin A/B immune globulin,.,Botulism immune globulin intravenous (human); Botulism immune globulin intravenous (human) (BIG-IV); Botulism immune globulin IV human; DB14115; Human botulinum neurotoxin A/B immune globulin; Human-derived botulism antitoxin antibodies,Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D0762,Human C1-esterase inhibitor,.,"C1 Esterase Inhibitor (Human); C1 inhibitor; C1 inhibitor (human); C1 inhibitor human; C1-esterase inhibitor, human; C1-INH; C1-inhibiting factor; C1-inhibitor, plasma derived; DB06404; Human C1 inhibitor; Human C1-esterase inhibitor; Plasma protease C1 inhibitor",Hereditary Angioedema Agents,Protein/peptide,.,.,.,.,.,.,.
D0763,Human cytomegalovirus immune globulin,.,CMVIG; CMV-immune globulin; Cytomegalovirus immunoglobulin; DB13886; Human cytomegalovirus immune globulin,Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D0764,Human immunoglobulin G (intramuscular),.,NULL,Immune Globulins,Protein/peptide,.,.,.,.,.,.,.
D0765,Human immunoglobulin G (intravenous),.,"145464-27-3; 7J34AKZ6YU; Immune globulin Intravenous; Immune globulin Intravenous Pentetate; Immune globulin Intravenous Pentetate [USAN]; Immunoglobulin G (human polyclonal Macroscint), disufide with human polyclonal Macroscint light chain, dimer, N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycine conjugate;; Immunoglobulin G (human polyclonal Macroscint), disulfide with human polyclonal Macroscint light chain, dimer, N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycine conjugate; Macroscint; RWJ 28299",Immune Globulins,Protein/peptide,.,.,.,.,.,.,.
D0766,Human immunoglobulin G (subcutaneous),.,NULL,Immune Globulins,Protein/peptide,.,.,.,.,.,.,.
D0767,Human papillomavirus type 11 L1 capsid protein antigen,.,"DB10300; Human papillomavirus type 11 L1 capsid protein antigen; L1 protein, Human papillomavirus type 11 Vaccine; Recombinant human papillomavirus type 11 L1 protein",Vaccines,Vaccine,.,.,.,.,.,.,.
D0768,Human Rho(D) immune globulin,.,"Anti-D (RH) immunoglobulin (human); Anti-D immunoglobulin; Anti-D immunoglobulins; DB11597; Human anti-D immunoglobulin; Human Rho(D) immune globulin; IGG, Rho (D); Immunoglobulin human anti-RH; Rh0(D) Immune Globulin Intravenous (Human); Rho (D) immune globulin,human; Rho D immune globulin human; Rho(D) immune globulin (human); Rho(D) immune globulin human; Rho(D) immune globulin IM human",Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D0769,Hyaluronic acid,.,AKOS037515522; FT-0627096; Hyaluronan,Viscosupplementation Agents,Small molecule,.,.,.,.,.,.,.
D0770,Hydralazine,3637,"Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine",Antihypertensive Agents,Small molecule,"1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)",RPTUSVTUFVMDQK-UHFFFAOYSA-N,C1=CC=C2C(=C1)C=NN=C2NN,86-54-4,C8H8N4,5775,BA00-BA04: Hypertension
D0771,Hydrochlorothiazide,3639,"Acesistem; Acuilix; Acuretic; Aldazida; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Briazide; Caplaril; Carozide; Catiazida; Chlorizide; Chlorosulthiadil; Chlorzide; Chlothia; Cidrex; Clorana; Condiuren; Diaqua; Dichlorosal; Dichlorotride; Dichlothiazide; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Didral; Dihydran; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Disothiazid; Diurogen; Dixidrasi; Drenol; Esidrex; Esidrix; Esoidrina; Fluvin; HCT; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroclorotiazida; Hidroronol; Hidrosaluretil; Hidrotiazida; Hyclosid; Hydril; HydroDIURIL; Hydrochlorat; Hydrochlorot; Hydrochlorothiazid; Hydrochlorothiazidum; Hydrochlorthiazide; Hydrochlorthiazidum; Hydrocot; Hydrodiuretic; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hytrid; Idroclorotiazide; Idrotiazide; Indroclor; Ivaugan; Manuril; Maschitt; Medozide; Megadiuril; Microzide; Mictrin; Mikorten; Modurcen; Moduretic; Natrinax; Nefrix; Nefrol; Neoflumen; Newtolide; Novodiurex; Oretic; Pantemon; Panurin; Roxane; Saldiuril; Sectrazide; Selozide; Servithiazid; Spironazide; Tandiur; Thiaretic; Thiuretic; Thlaretic; Timolide; Unazid; Urodiazin; Urozide; Vaseretic; Vetidrex; Aquazide H; Chlorsulfonamidodihydrobenzothiadiazine dioxide; Component of Aldactazide; Component of Aldoril; Component of Butizide Prestabs; Component of Caplaril; Component of Cyclex; Component of Dyazide; Component of Esimil; Concor Plus; Diclot ride; Hydro Par; Hydrochlorothiazide Intensol; Idroclorotiazide [DCIT]; Lotensin HCT; Panurin dichloride; Raunova Plus; Diu 25 Vigt; H 4759; MaybridgeCompound 10; Mazide 25 mg; Su 5879; Aldactazide 25/25; Aldectazide 50/50; Apo-Hydro; Aquazide H (TN); Aquazide-H; Dichlotride (TN); Diu-melusin; Esidrex (TN); Esidrix (TN); HCT-Isis; Hidro-Niagrin; Hidroclorotiazida [INN-Spanish]; Hydrex-semi; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydro-Saluric; Hydro-T; Hydro-chlor; HydroSaluric (TN); Hydrochlorothiazidum [INN-Latin]; Hydrodiuril (TN); Hydrozide Injection, Veterinary; Jen-Diril; Microzide (TN); Neo-Flumen; Neo-Minzil; Neo-codema; Oretic (TN); Ro-hydrazide; AF-614/30832002; Apo-Hydro (TN); Hydrochlorothiazide [INN:BAN:JAN]; Hydrochlorothiazide (JP15/USP/INN); Dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; 3,4-Dihydrochlorothiazide; 6-Chloro-7-sulfamoyl-3, 4-dihy",Diuretics,Small molecule,"1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",JZUFKLXOESDKRF-UHFFFAOYSA-N,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,58-93-5,C7H8ClN3O4S2,5778,BA00-BA04: Hypertension
D0772,Hydrocodone,5284569,"HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193;  Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug",Analgesics,Small molecule,"1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1",LLPOLZWFYMWNKH-CMKMFDCUSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,125-29-1,C18H21NO3,5779,MG30-MG3Z: Pain
D0773,Hydrocortisone,5754,"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone",Antiinflammatory Agents,Small molecule,"1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",JYGXADMDTFJGBT-VWUMJDOOSA-N,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,50-23-7,C21H30O5,17650,1A00-CA43: Postoperative inflammation; 5A71: Adrenogenital disorder
D0774,Hydrocortisone (ophthalmic),5754,"Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone",Antiinflammatory Agents,Small molecule,"1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",JYGXADMDTFJGBT-VWUMJDOOSA-N,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,50-23-7,C21H30O5,17650,1A00-CA43: Postoperative inflammation; 5A71: Adrenogenital disorder
D0775,Hydroflumethiazide,3647,"Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide",Diuretics,Small molecule,"1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)",DMDGGSIALPNSEE-UHFFFAOYSA-N,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,135-09-1,C8H8F3N3O4S2,5784,BD10-BD1Z: Heart failure
D0776,Hydromorphone,5284570,"hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one;  DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug",Analgesics,Small molecule,"1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1",WVLOADHCBXTIJK-YNHQPCIGSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4,466-99-9,C17H19NO3,5790,MG30-MG3Z: Pain; MG30: Chronic pain
D0777,Hydroxocobalamin,70689311,"AlphaRedisol; Axion; Axlon; Cobalex; Codroxomin; Cyanokit; Depogamma; Docclan; Docelan; Docelvita; Docevita; Duradoce; Hidroxocobalamina; Hydrobamine; Hydrocobalamin; Hydrogrisevit; Hydrovit; Hydroxocobalaminacetat; Hydroxocobalamine; Hydroxocobalaminum; Hydroxocobemine; Hydroxomin; Hydroxycobalamin; Hydroxycobalamine; Hyxobamine; Idrogrisevit; Idrossocobalamina; Oxobemin; Vibeden; Vitadurin; Alpha Cobione; Ciplamin H; Hydro Cobex; Hydroxocobalamin acetate; Hydroxocobalamin monohydrochloride; Hydroxy Cobal; Idrossocobalamina [DCIT]; Primabalt RP; Hydroxocobalamin Vitamin B12; Hydroxy vitamin B12; Ohb12; Vitamin B12a; Vitamin B12b; Acti-B12; AlphaRedisol (TN); Benzimidazolyl ribofuranosyl phosphate deriv.; Cyanokit (TN); Ducobee-Hy; Duralta-12; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamine [INN-French]; Hydroxocobalaminum [INN-Latin]; Hydroxycob(lll)alamin; Lyovit-H; Neo-Betalin 12; Neo-cytamen; Neo-macrabin; Neo-rojamin; OH-Cbl; OH-Duphar; Oxolamine (arcum); Redisol-H; Sytobex-H; Vitamin B(sub 12a); Vitamin B-12b; Hydroxocobalamin (JAN/USP/INN); Hydroxocobalamin [USAN:INN:BAN:JAN]; Alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin(alkaline soln.), OH-replaces CN-in Cyanocobalamin); Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)",Vitamins,Small molecule,"1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",DQOCFCZRZOAIBN-WZHZPDAFSA-L,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2],13422-51-0,C62H90CoN13O15P,.,5B55-5B5F: Vitamin deficiency; NB32: Intrathoracic organs injury
D0778,Hydroxyamphetamine (ophthalmic),3651,"4-(2-Aminopropyl)phenol; hydroxyamphetamine; Paredrine; 103-86-6; 4-Hydroxyamphetamine; Norpholedrine; Oxamphetamine; Norveritol; Pulsoton; p-HYDROXYAMPHETAMINE; Hydroxyamfetamine; Oksamfetamin; Oxamfetamin; Oxamphetaminium; Paredrinex; Nov-Pholedrin; Paradrine; Pedrolon; p-(2-Aminopropyl)phenol; Phenol, 4-(2-aminopropyl)-; Phenol,4-(2-aminopropyl)-; Hydroxyamphetamide; Phenol, p-(2-aminopropyl)-; 1-p-Hydroxyphenyl-2-propylamine; 2-Amino-1-(p-hydroxyphenyl)propane; .alpha.-Methyltyramine; DL-p-Hydroxyamphetamine; alpha-Methyltyramine; NSC 170995; dl-4-hydroxyamphetamine; 1518-86-1; DL-p-(2-Aminopropyl)phenol; 4-Hydroxy-.alpha.-methylphenethylamine; NSC-170995; p-Hydroxy-.alpha.-methylphenethylamine; p-Hydroxy-alpha-methylphenethylamine; 4-Hydroxy-alpha-methylphenethylamine; UNII-FQR280JW2N; EINECS 203-152-8; BRN 2413849; Hydroxyamfetamine [INN:BAN]; FQR280JW2N; Predrolon (Salt/Mix); Spectrum_001243; Spectrum3_001037; Spectrum4_001174; Spectrum5_001674; (RS)-4-hydroxyamphetamine; Hydroxyamphetamine,(+/-); Racemic p-hydroxyamphetamine; WLN: Z3R DQ; CHEMBL1546; 4-(2-amino-propyl)-phenol; BSPBio_002853; KBioGR_001807; KBioSS_001723; 3-13-00-01709 (Beilstein Handbook Reference); SCHEMBL125440; DTXSID3023134; BDBM81459; KBio2_001723; KBio2_004291; KBio2_006859; KBio3_002073; CHEBI:103855; HY-B1098; NSC_3651; 1-(4-Hydroxyphenyl)propane-2-amine; NSC170995; PDSP1_001107; PDSP2_001091; AKOS000155358; AKOS017269170; CS-4687; DB09352; MCULE-6999513658; Phenol, 4-(2-aminopropyl)- (9CI); NCGC00178433-01; NCGC00178433-02; BS-13447; CAS_103-86-6; Phenol, p-(2-aminopropyl)-, (.+/-.)-; EN300-53926; Phenol, 4-(2-aminopropyl)-, (.+/-.)-; AB01563354_01; Q5955531; BRD-A80871782-004-01-0; Z57102382",Mydriatics,Small molecule,"InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3",GIKNHHRFLCDOEU-UHFFFAOYSA-N,CC(CC1=CC=C(C=C1)O)N,.,C9H13NO,.,.
D0779,Hydroxychloroquine,3652,Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258,Antimalarial Agents,Small molecule,"1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)",XXSMGPRMXLTPCZ-UHFFFAOYSA-N,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,118-42-3,C18H26ClN3O,5801,1F40-1F45: Malaria
D0780,Hydroxyurea,3657,"Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA",Antineoplastics,Small molecule,"1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",VSNHCAURESNICA-UHFFFAOYSA-N,C(=O)(N)NO,127-07-1,CH4N2O2,44423,2A20: Myeloproliferative neoplasm
D0781,Hydroxyzine,3658,"Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2",ZQDWXGKKHFNSQK-UHFFFAOYSA-N,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,68-88-2,C21H27ClN2O2,5818,6B00-6B0Z: Anxiety disorder
D0782,Hyoscyamine,154417,"L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine",Antiarrhythmic Agents,Small molecule,"1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1",RKUNBYITZUJHSG-VFSICIBPSA-N,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,101-31-5,C17H23NO3,17486,DE2Z: Digestive system disease
D0783,Ibandronate,60852,"BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate",Bone Density Conservation Agents,Small molecule,"1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)",MPBVHIBUJCELCL-UHFFFAOYSA-N,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,114084-78-5,C9H23NO7P2,.,FB83: Low bone mass disorder
D0784,Ibritumomab tiuxetan,.,2-[[2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid; 206181-63-7; Ibritumomab; Ibritumomab tiuxetan; Zevalin,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,.
D0785,Ibrutinib,24821094,PCI-32765; Ibrutinib (BTK inhibitor),Antineoplastics/Bruton Tyrosine Kinase Inhibitor,Small molecule,"1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,936563-96-1,C25H24N6O2,76612,2B33: Malignant haematopoietic neoplasm; 2A81: Diffuse large B-cell lymphoma; 2A80: Follicular lymphoma; 2A85: Mature B-cell lymphoma; 2C10: Pancreatic cancer; 2A00-2F9Z: Solid tumour/cancer
D0786,Ibuprofen,3672,"ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid;  Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN",Analgesics,Small molecule,"1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",HEFNNWSXXWATRW-UHFFFAOYSA-N,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,15687-27-1,C13H18O2,5855,MG30-MG3Z: Pain
D0787,Ibutilide,60753,"Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate",Antiarrhythmic Agents,Small molecule,"1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3",ALOBUEHUHMBRLE-UHFFFAOYSA-N,CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,122647-31-8,C20H36N2O3S,5856,BC81: Supraventricular tachyarrhythmia
D0788,Idarubicin,42890,"DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin",Antineoplastics,Small molecule,"1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1",XDXDZDZNSLXDNA-TZNDIEGXSA-N,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,58957-92-9,C26H27NO9,42068,2A60: Acute myeloid leukaemia
D0789,Idelalisib,11625818,"Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE",Pi3K Inhibitors,Small molecule,"1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,870281-82-6,C22H18FN7O,82701,2A82: Mature B-cell leukaemia
D0790,Ifosfamide,3690,"Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide",Antineoplastics,Small molecule,"1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)",HOMGKSMUEGBAAB-UHFFFAOYSA-N,C1CN(P(=O)(OC1)NCCCl)CCCl,3778-73-2,C7H15Cl2N2O2P,5864,2A00-2F9Z: Solid tumour/cancer
D0791,Iloperidone,71360,"Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone",Atypical Antipsychotics,Small molecule,"1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3",XMXHEBAFVSFQEX-UHFFFAOYSA-N,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,133454-47-4,C24H27FN2O4,65173,6A20: Schizophrenia
D0792,Iloprost,5311181,"Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure",Antihypertensive Agents,Small molecule,"1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1",HIFJCPQKFCZDDL-ACWOEMLNSA-N,CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O,78919-13-8,C22H32O4,63916,BB01: Pulmonary hypertension
D0793,Imatinib,5291,Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI,Antineoplastics,Small molecule,"1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,152459-95-5,C29H31N7O,45783,2A20: Myeloproliferative neoplasm; 2A21: Mastocytosis; 2C25: Lung cancer; 2C0Z: Malignant intestine neoplasm; 2A85: Mature B-cell lymphoma
D0794,Imipenem,104838,"Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",Antibiotics,Small molecule,"1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1",ZSKVGTPCRGIANV-ZXFLCMHBSA-N,CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O,64221-86-9,C12H17N3O4S,471744,1A00-1C4Z: Bacterial infection
D0795,Imipramine,3696,"Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)",Antidepressants,Small molecule,"1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3",BCGWQEUPMDMJNV-UHFFFAOYSA-N,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,50-49-7,C19H24N2,47499,6A70-6A7Z: Depression
D0796,Imiquimod (topical),57469,"Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline",Antiviral Agents,Small molecule,"1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",DOUYETYNHWVLEO-UHFFFAOYSA-N,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,99011-02-6,C14H16N4,36704,2C30-2C37: Skin cancer
D0797,Indacaterol,6918554,"312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one;  QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone",Bronchodilators,Small molecule,"1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1",QZZUEBNBZAPZLX-QFIPXVFZSA-N,CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,312753-06-3,C24H28N2O3,68575,CA22: Chronic obstructive pulmonary disease; CA23: Asthma
D0798,Indapamide,3702,"Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide",Antihypertensive Agents,Small molecule,"1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)",NDDAHWYSQHTHNT-UHFFFAOYSA-N,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,26807-65-8,C16H16ClN3O3S,5893,BA00-BA04: Hypertension
D0799,Indinavir,5362440,"Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide",Anti-Hiv Agents,Small molecule,"1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1",CBVCZFGXHXORBI-PXQQMZJSSA-N,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,150378-17-9,C36H47N5O4,44032,1C60-1C62: Human immunodeficiency virus disease
D0800,Indomethacin,3715,"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin",Antiinflammatory Agents,Small molecule,"1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)",CGIGDMFJXJATDK-UHFFFAOYSA-N,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,53-86-1,C19H16ClNO4,49662,FA20: Rheumatoid arthritis
D0801,Inebilizumab,.,.,Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,8E4A: Nervous system paraneoplastic/autoimmune disorder
D0802,Infliximab,.,Remicade (TN),Immunosuppressive Agents,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis; FA20: Rheumatoid arthritis; CA23: Asthma
D0803,Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated),.,DB14444; Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated); Influenza a Virus A/california/7/2009(h1n1)-like Antigen (Propiolactone Inactivated),Vaccines,Vaccine,.,.,.,.,.,.,.
D0804,Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated),.,NULL,Vaccines,Vaccine,.,.,.,.,.,.,.
D0805,Inotersen,121492004,UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915,Metabolic Agents,Small molecule,"1S/C230H318N69O121P19S19/c1-98-53-280(219(312)262-178(98)231)140-43-110(121(382-140)66-364-425(328,444)406-114-47-144(292-90-254-150-183(236)244-85-249-188(150)292)387-126(114)71-368-423(326,442)404-112-45-142(282-59-104(7)197(303)274-225(282)318)383-122(112)67-363-421(324,440)403-111-44-141(281-58-103(6)196(302)273-224(281)317)385-124(111)69-366-427(330,446)410-119-52-149(297-95-260-156-194(297)268-217(242)271-204(156)310)391-130(119)75-372-431(334,450)419-167-139(401-215(177(167)362-42-32-352-22)299-97-261-157-195(299)269-218(243)272-205(157)311)84-381-438(341,457)418-165-136(398-213(175(165)360-40-30-350-20)291-64-109(12)202(308)279-230(291)323)82-379-437(340,456)417-163-135(397-211(173(163)358-38-28-348-18)289-62-107(10)200(306)277-228(289)321)81-378-435(338,454)414-161-132(394-209(171(161)356-36-26-346-16)286-56-101(4)181(234)265-222(286)315)78-375-433(336,452)412-159-120(65-300)392-207(169(159)354-34-24-344-14)288-61-106(9)199(305)276-227(288)320)402-422(325,441)367-70-125-115(48-145(386-125)293-91-255-151-184(237)245-86-250-189(151)293)407-426(329,445)365-68-123-113(46-143(384-123)283-60-105(8)198(304)275-226(283)319)405-424(327,443)371-74-129-118(51-148(390-129)296-94-259-155-193(296)267-216(241)270-203(155)309)409-429(332,448)370-72-127-116(49-146(388-127)294-92-256-152-185(238)246-87-251-190(152)294)408-428(331,447)369-73-128-117(50-147(389-128)295-93-257-153-186(239)247-88-252-191(153)295)411-430(333,449)374-77-138-166(176(361-41-31-351-21)214(400-138)298-96-258-154-187(240)248-89-253-192(154)298)420-439(342,458)380-83-137-164(174(359-39-29-349-19)212(399-137)290-63-108(11)201(307)278-229(290)322)416-436(339,455)377-80-134-162(172(357-37-27-347-17)210(396-134)287-57-102(5)182(235)266-223(287)316)415-434(337,453)376-79-133-160(170(355-35-25-345-15)208(395-133)285-55-100(3)180(233)264-221(285)314)413-432(335,451)373-76-131-158(301)168(353-33-23-343-13)206(393-131)284-54-99(2)179(232)263-220(284)313/h53-64,85-97,110-149,158-177,206-215,300-301H,23-52,65-84H2,1-22H3,(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H,342,458)(H2,231,262,312)(H2,232,263,313)(H2,233,264,314)(H2,234,265,315)(H2,235,266,316)(H2,236,244,249)(H2,237,245,250)(H2,238,246,251)(H2,239,247,252)(H2,240,248,253)(H,273,302,317)(H,274,303,318)(H,275,304,319)(H,276,305,320)(H,277,306,321)(H,278,307,322)(H,279,308,323)(H3,241,267,270,309)(H3,242,268,271,310)(H3,243,269,272,311)/t110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,206+,207+,208+,209+,210+,211+,212+,213+,214+,215+,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?/m0/s1",KLEGMTRDCCDFJK-XDQSQZFTSA-N,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)OC8C(OC(C8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)O,1492984-65-2,C230H318N69O121P19S19,.,5D00: Amyloidosis
D0806,Inotuzumab ozogamicin,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B33: Malignant haematopoietic neoplasm; 2A85: Mature B-cell lymphoma
D0807,Insulin aspart (aspart protamine),118984445,Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human),Antidiabetic Agents,Small molecule,"1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1",WEDIKSVWBUKTRA-WTKGVUNUSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,116094-23-6,C256H381N65O79S6,.,5A2Y: Acute diabete complication
D0808,Insulin aspart (aspart),118984445,Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human),Antidiabetic Agents,Small molecule,"1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1",WEDIKSVWBUKTRA-WTKGVUNUSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,116094-23-6,C256H381N65O79S6,.,5A2Y: Acute diabete complication
D0809,Insulin degludec,118984462,Tresiba (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1",FYZPCMFQCNBYCY-WIWKJPBBSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,844439-96-9,C274H411N65O81S6,.,5A10-5A11: Type-1/2 diabete
D0810,Insulin detemir,16137271,"Insulin detemir; UNII-4FT78T86XV; 4FT78T86XV; NN-304; Levemir; Levemir Penfill; Levemir Insulin; Levemir Innolet; Levemir Flexpen; 169148-63-4; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human); 270588-25-5",Antidiabetic Agents,Small molecule,"1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1",UGOZVNFCFYTPAZ-IOXYNQHNSA-N,CCCCCCCCCCCCCC(=O)NCCCCC(C(=O)O)NC(=O)C1CCCN1C(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC4=CC=CC=C4)NC(=O)CNC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C5CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C6CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)C(CC(C)C)NC(=O)C(CC9=CNC=N9)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)N)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N6)C(C)CC)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)NC(CC(=O)N)C(=O)O,169148-63-4,C267H402N64O76S6,.,5A10-5A11: Type-1/2 diabete
D0811,Insulin glargine,118984454,Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin,Antidiabetic Agents,Small molecule,"1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1",COCFEDIXXNGUNL-RFKWWTKHSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,160337-95-1,C267H404N72O78S6,.,1F40-1F45: Malaria; 5A10: Diabetes mellitus; 5A11: Type 2 diabetes mellitus; 5A2Y: Acute diabete complication
D0812,Insulin glulisine,16136701,.,Antidiabetic Agents,Hormones,"1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1",RCHHVVGSTHAVPF-ZPHPLDECSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,207748-29-6,C258H384N64O78S6,.,5A2Y: Acute diabete complication
D0813,Insulin human,118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0814,"Insulin human (inhalation, rapid acting)",118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0815,Insulin human (isophane),118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0816,Insulin human (regular),118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0817,Insulin human (zinc extended),118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0818,Insulin human (zinc),118984375,Oral-lyn (TN),Insulin/Antidiabetic Agents,Hormones,"1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",PBGKTOXHQIOBKM-FHFVDXKLSA-N,CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN,11061-68-0,C257H383N65O77S6,5931,5A10: Diabetes mellitus
D0819,Insulin lispro,16132438,WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN];  Humalog (TN); Insulin Lispro,Antidiabetic Agents,Small molecule,"1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1",WNRQPCUGRUFHED-DETKDSODSA-N,CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)CN.CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)O)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CC7=CN=CN7)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC8=CC=CC=C8)N,133107-64-9,C257H389N65O77S6,.,5A2Y: Acute diabete complication
D0820,Insulin lispro (protamine),16132438,WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN];  Humalog (TN); Insulin Lispro,Antidiabetic Agents,Small molecule,"1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1",WNRQPCUGRUFHED-DETKDSODSA-N,CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)CN.CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)O)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CC7=CN=CN7)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC8=CC=CC=C8)N,133107-64-9,C257H389N65O77S6,.,5A2Y: Acute diabete complication
D0821,"Interferon alfa-2a, Recombinant",.,"DB00034; Interferon alfa-2a; Interferon alfa-2a (recombinant); Interferon alfa-2a, Recombinant; Interferon alfa-2a,recombinant; Interferon alpha-2a; Interferon-alfa-2a; Recombinant human interferon alfa-2a; Recombinant human interferon-alfa-2a; rIFN-alpha-2a; SH-polypeptide-46",Interferons,Interferons,.,.,.,.,.,.,.
D0822,Interferon alfa-2b,71306834,Intron A; Viraferon,Antineoplastics,Small molecule,"1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1",MIXCUJKCXRNYFM-UHFFFAOYSA-M,CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+],98530-12-2,C16H17Cl3I2N3NaO5S,.,2C30: Melanoma
D0823,Interferon alfacon-1,.,Advaferon; Infergen; Advaferon (TN); Infergen (TN); Interferon alfacon-1 (genetical recombination); Interferon alfacon-1 (USAN/INN); Interferon alfacon-1 (genetical recombination) (JAN),Antineoplastics,Interferons,.,.,.,.,.,.,1E50-1E51: Hepatitis virus infection
D0824,Interferon alfa-n1,.,Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN),Antiviral Agents,Interferons,.,.,.,.,.,.,2A20: Myeloproliferative neoplasm
D0825,Interferon alfa-n3,.,"Alferon LDO; Interferon alfa-n3 (oral); Interferon alfa-n3 (oral), Hemispherx; Interferon alfa-n3 (oral), InterferonSciences",Interferons,Interferons,.,.,.,.,.,.,1C60-1C62: Human immunodeficiency virus disease
D0826,Interferon beta-1a,.,Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN),Immunomodulatory Agents,Protein/peptide,.,.,.,.,.,.,8A40: Multiple sclerosis
D0827,Interferon beta-1b,.,Betaferon (TN); Betaseron (TN),Immunomodulatory Agents,Interferons,.,.,.,.,.,.,8A40: Multiple sclerosis
D0828,Interferon gamma-1b,.,.,Immunomodulatory Agents,Interferons,.,.,.,.,.,.,4A00: Innate/adaptive immunodeficiency
D0829,Iobenguane (I-131),60860,"Iobenguane; 80663-95-2; m-Iodobenzylguanidine; Metaiodobenzylguanidine; meta-Iodobenzylguanidine; 3-Iodobenzylguanidine; 2-[(3-iodophenyl)methyl]guanidine; UNII-35MRW7B4AD; MIBG; Guanidine, ((3-iodophenyl)methyl)-; 139755-80-9; Guanidine,N-[(3-iodophenyl)methyl]-; 2-(3-Iodobenzyl)guanidine; 35MRW7B4AD; (3-Iodobenzyl)guanidine; NCGC00015572-04; SR-01000075167; Prestwick-07A11; starbld0001019; Iobenguane (127-i); meta-iodobenzyl guanidine; Prestwick0_000490; Prestwick1_000490; Prestwick2_000490; Prestwick3_000490; Lopac-I-9890; 2-m-iodo-benzyl guanidine; CHEMBL818; 1-(3-Iodobenzyl)guanidine; Lopac0_000644; BSPBio_000359; SCHEMBL140591; SPBio_002280; BPBio1_000395; ((3-iodophenyl)methyl)guanidine; DTXSID4048438; CHEBI:92769; 1-[(3-iodophenyl)methyl]guanidine; ZINC1538318; CCG-204731; DB06704; SDCCGSBI-0050624.P002; NCGC00015572-01; NCGC00015572-02; NCGC00015572-03; NCGC00015572-06; NCGC00015572-09; NCGC00162211-01; DA-02654; Q3154058; SR-01000075167-1; BRD-K43860855-065-03-6",Therapeutic Radiopharmaceuticals,Small molecule,"InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)",PDWUPXJEEYOOTR-UHFFFAOYSA-N,C1=CC(=CC(=C1)I)CN=C(N)N,.,C8H10IN3,.,.
D0830,Iodide I-131,167195,"Iodide ion I-131; Iodide-131; iodine-131(1-); UNII-4GC1FOQ22U; 4GC1FOQ22U; 14914-30-8; Iodide (131I-); Radioiodine; Iodide, isotope of mass 131; Iodide I-131 ion; Iodide ion I 131; Iodide I-131; Iodide ion, I-131; (~131~I)Iodide; Iodide (131I1-); DTXSID70933558; DB09293; Q27259563",Radiopharmaceuticals,Small molecule,InChI=1S/HI/h1H/p-1/i1+4,XMBWDFGMSWQBCA-RNFDNDRNSA-M,[131I-],.,I-,.,.
D0831,Iodipamide,3739,"Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid",Ionic Iodinated Contrast Media,Small molecule,"1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)",FFINMCNLQNTKLU-UHFFFAOYSA-N,C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,606-17-7,C20H14I6N2O6,31176,DC11: Cholelithiasis
D0832,Iodixanol,3724,Acupaque; Visipaque; DU-6807; 2-5410-3A,Non-Ionic Iodinated Contrast Media,Small molecule,"1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)",NBQNWMBBSKPBAY-UHFFFAOYSA-N,CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(=C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,92339-11-2,C35H44I6N6O15,31705,BA00-BE2Z: Cardiovascular disease
D0833,Iohexol,3730,"iohexol; 66108-95-0; Omnipaque; Nycodenz; Exypaque; Iohexolum; Omnipaque 240; Omnipaque 70; Omnipaque 140; Omnipaque 180; Omnipaque 210; Omnipaque 300; Omnipaque 350; WIN 39424; UNII-4419T9MX03; CHEBI:31709; N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide; 5-[acetyl(2,3-dihydroxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; WIN-39424; 5-[Acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide; N1,N3-bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide; 4419T9MX03; 1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; NCGC00166000-01; DSSTox_CID_3157; 5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide; DSSTox_RID_76895; DSSTox_GSID_23157; Histodenz; Iohexolum [INN-Latin]; 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; 5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide; SMR000857075; EINECS 266-164-2; BRN 2406632; Oraltag; C19H26I3N3O9; Omnipaque (TN); 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; n,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide; Prestwick_802; CAS-66108-95-0; Iohexol [USAN:USP:INN:BAN:JAN]; Histodenz; ; ; Nycodenz; Prestwick0_000512; Prestwick1_000512; Prestwick2_000512; Prestwick3_000512; Nycodenz;Omnipaque;Exypaque; EC 266-164-2; Iohexol, analytical standard; SCHEMBL26501; BSPBio_000463; MLS001332585; MLS001332586; MLS002153854; Iohexol (JP17/USP/INN); SPBio_002384; BPBio1_000511; CHEMBL1200455; DTXSID6023157; BCBcMAP01_000051; HMS1569H05; HMS2096H05; HMS2235D07; HMS3369O04; HMS3713H05; ALBB-028959; AMY21804; BCP31800; HY-B0594; Tox21_112286; BDBM50247977; MFCD00077732; s4531; AKOS015895399; Tox21_112286_1; AC-1934; CCG-220512; DB01362; NSC 759636; SMP1_000152; NCGC00166000-02; NCGC00166000-04; AS-12699; FT-0627276; I0903; D01817; D91214; Histodenz(TM), nonionic density gradient medium; 108I950; A835339; Q410683; SR-01000838892; SR-01000838892-2; Iohexol, European Pharmacopoeia (EP) Reference Standard; Iohexol, United States Pharmacopeia (USP) Reference Standard; 5-(N-dhp-acetamido)-2,4,6-triiodo-N,N'-B is-dhp-isophthalami; Iohexol, Pharmaceutical Secondary Standard; Certified Reference Material; Iohexol for peak identification, European Pharmacopoeia (EP) Reference Standard; 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide; 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; N1,N3-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide; N1,N3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide",Non-Ionic Iodinated Contrast Media,Small molecule,"InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)",NTHXOOBQLCIOLC-UHFFFAOYSA-N,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,.,C19H26I3N3O9,.,.
D0834,Iopamidol,65492,Iopamiro; Iopamiron; Isovue; Niopam,Non-Ionic Iodinated Contrast Media,Small molecule,"1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1",XQZXYNRDCRIARQ-LURJTMIESA-N,CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O,60166-93-0,C17H22I3N3O8,31711,BA00-BE2Z: Cardiovascular disease
D0835,Iopodic acid,5241,Oragrafin Calcium; Bilivist; Oragrafin Sodium,Non-Ionic Iodinated Contrast Media,Small molecule,"1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)",YQNFBOJPTAXAKV-UHFFFAOYSA-N,CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)O)I)I,5587-89-3,C12H13I3N2O2,81496,5A02: Thyrotoxicosis
D0836,Iopromide,3736,Proscope; Ultrakon; Ultravist; Ultravist 300; Ultravist 370; ZK-35760; SH-L-414C,Non-Ionic Iodinated Contrast Media,Small molecule,"1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)",DGAIEPBNLOQYER-UHFFFAOYSA-N,CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I,73334-07-3,C18H24I3N3O8,63578,.
D0837,Iothalamic acid,3737,"iotalamic acid; IOTHALAMIC ACID; 2276-90-6; 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid; UNII-16CHD79MIX; 5-Acetamido-2,4,6-triiodo-N-methylisophthalamic acid; 16CHD79MIX; MI-216; NSC-759891; Acidum jotalamicum; Acido iotalamico; Acide iotalamique; Acidum iotalamicum; Acide iotalamique [INN-French]; Acido iotalamico [INN-Spanish]; Acidum iotalamicum [INN-Latin]; EINECS 218-897-4; MI 216; Iothalamic acid [USAN:USP]; iothalamic-acid-d3; Benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-; Iotalamic acid [INN]; Iothalamic acid (USP); EC 218-897-4; SCHEMBL38419; Iotalamic acid (JP17/INN); IOTHALAMICACID(200MG); CHEMBL1201300; DTXSID5023164; SCHEMBL23630220; CHEBI:31713; HMS3264D13; Pharmakon1600-01503836; BCP13316; HY-B1053; ZINC3830961; 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic acid; NSC759891; AKOS025402283; Benzoic acid,3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]-; AC-7611; CCG-213208; CS-4575; DB09133; NSC 759891; NCGC00183042-01; FT-0740526; D01258; AB01563288_01; 276I906; SR-01000944232; Q-201246; Q6064129; SR-01000944232-1; 5-Acetylamino-2,4,6-triiodo-N-methyl-isophthalamic acid; 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamate",Ionic Iodinated Contrast Media,Small molecule,"InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)",UXIGWFXRQKWHHA-UHFFFAOYSA-N,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I,.,C11H9I3N2O4,.,.
D0838,Ioversol,3741,"ioversol; 87771-40-2; Optiray; Optiray 320; Ioversolum [Latin]; Optiray 240; Optiray 350; Optiray 160; MP-328; UNII-N3RIB7X24K; LOVERSOL; BRN 7155654; N3RIB7X24K; MP 328; 1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-; DSSTox_RID_80927; DSSTox_CID_25521; N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide; DSSTox_GSID_45521; Optiray 300; Ioversolum",Non-Ionic Iodinated Contrast Media,Small molecule,"1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)",AMDBBAQNWSUWGN-UHFFFAOYSA-N,C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO,87771-40-2,C18H24I3N3O9,31717,BA00-BE2Z: Cardiovascular disease
D0839,Ioxilan,3743,"ioxilan; 107793-72-6; Oxilan; Ioxitol; UNII-A4YJ7J11TG; A4YJ7J11TG; NSC-760056; 5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; N-(2,3-Dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamide; NCGC00182070-02; DSSTox_CID_28643; DSSTox_RID_82913; DSSTox_GSID_48717; Ioxilane; Ioxilanum; CAS-107793-72-6; Oxilan-300; Oxilan-350; Ioxilane [INN-French]; Ioxilanum [INN-Latin]; Ioxilan [USAN:USP:INN]; Imagenil; Loxilan; CCRIS 6727; Oxilan-300 (TN); Ioxilan (JAN/USP/INN); SCHEMBL25634; IOXILAN (400 MG); CHEMBL1201075; DTXSID0048717; CHEBI:135884; HMS3264D15; MOLI000985; Pharmakon1600-01503838; Tox21_113127; NSC760056; AKOS016014026; Tox21_113127_1; CCG-213210; DB09135; NSC 760056; NCGC00182070-03; HY-109513; CS-0031230; FT-0627286; D02161; AB01563289_01; SR-01000883963; J-002011; Q6064819; SR-01000883963-1; 3-(3-Methyl-4-oxo-thiazolidin-2-ylideneamino)-benzoicacid; 1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-; 5-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N-(2-hydroxyethyl)-N -(2,3-dihydroxypropyl)-isophthalamide; 5-[Acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamide; N-(2,3-Dihdroxypropyl)-N -(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoiosphthalamide; N-(2,3-dihydroxypropyl)-N'-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide",Non-Ionic Iodinated Contrast Media,Small molecule,"InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)",UUMLTINZBQPNGF-UHFFFAOYSA-N,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I,.,C18H24I3N3O8,.,.
D0840,Ipecac,.,Ipecac syrup,Emetic Agents,Small molecule,.,.,.,.,.,.,NE6Z: Unspecific substance harmful effect
D0841,Ipilimumab,.,BMS-734016; MDX-010; MDX-101; Yervoy (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C30: Melanoma
D0842,Ipratropium,657309,"Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane",Bronchodilators,Small molecule,"1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?",OEXHQOGQTVQTAT-BZQJJPTISA-N,CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,60205-81-4,C20H30NO3+,5956,CA22: Chronic obstructive pulmonary disease
D0843,Ipratropium (nasal),657309,"Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane",Bronchodilators,Small molecule,"1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?",OEXHQOGQTVQTAT-BZQJJPTISA-N,CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,60205-81-4,C20H30NO3+,5956,CA22: Chronic obstructive pulmonary disease
D0844,Irbesartan,3749,"irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169;  Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan",Antihypertensive Agents,Small molecule,"1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",YOSHYTLCDANDAN-UHFFFAOYSA-N,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,138402-11-6,C25H28N6O,5959,BA00-BA04: Hypertension
D0845,Irinotecan,60838,"Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde",Antineoplastics,Small molecule,"1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1",UWKQSNNFCGGAFS-XIFFEERXSA-N,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,97682-44-5,C33H38N4O6,80630,2B91: Colorectal cancer
D0846,Irinotecan (liposomal),60838,"Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde",Antineoplastics,Small molecule,"1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1",UWKQSNNFCGGAFS-XIFFEERXSA-N,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,97682-44-5,C33H38N4O6,80630,2B91: Colorectal cancer
D0847,Iron,23925,"Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP",Iron Supplement,Small molecule,1S/Fe,XEEYBQQBJWHFJM-UHFFFAOYSA-N,[Fe],7439-89-6,Fe,18248,3A00: Iron deficiency anaemia
D0848,Iron Dextran,105075,"Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1)",Iron Supplement,Small molecule,"1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)",MVZXTUSAYBWAAM-UHFFFAOYSA-N,OS(=O)(=O)O.[Fe],9004-66-4,FeH2O4S,.,3A00: Iron deficiency anaemia
D0849,Iron protein succinylate,.,DB11209; Iron protein succinylate,Iron Supplement,Small molecule,.,.,.,.,.,.,.
D0850,Iron sucrose,91663255,"Iron sugar; Saccharated iron; Saccharated iron oxide; Sucroferric oxyhydroxide; Saccharated ferric oxide; FERRIC HYDROXIDE SUCROSE COMPLEX; Ferrivenin; Venoferrum; Encifer; Feojectin; Ferijet; Hippiron; Proferrin; Sucrofer; Velphoro; Iviron; Fesin; Ferum Hausmann; Ferrum Vitis; Neo-ferrum; Ferosoft S; Fe-back; Ferplex SS; Fe-lib; Colliron I.V.; Sucrose, iron complex; Ferrum Hausmann i.v.; Iron oxide, saccharated; Succharated ferric oxide; Ferric oxide, saccharated; UNII-FZ7NYF5N8L; FZ7NYF5N8L; IRON SUCROSE COMPLEX; IRON OXIDE SACCHARATED; Iron sucrose [USAN:USP:BAN]; EINECS 232-464-7; NSC 27278; XI 921; XI-921; Succharated ferric oxide [USAN:JAN]; DB09146; Ferric saccharate ...iron oxide (mix.); IRON(III) HYDROXIDE SUCROSE COMPLEX; Q27888379",Iron Supplement,Small molecule,"InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1",FWZTTZUKDVJDCM-CEJAUHOTSA-M,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)O)O)O.O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3],.,C12H29Fe5Na2O23,.,.
D0851,Isatuximab,.,.,Antineoplastics/Cd38 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2A83: Multiple myeloma
D0852,Isavuconazonium,6918606,"Drochloride; Monohydrochloride; RO-0098557; N-Methylglycine [2-[N-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1H-1,2,4-triazolium-4-yl]ethoxy]carbonyl]-N-methylamino]-3-pyridinyl]methyl ester chloride; 1-[3(R)-[4-(4-Cyanophenyl)thiazol-2-yl]-2(R)-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[1-[N-methyl-N-[3-[2-(methylamino)acetoxymethyl]pyridin-2-yl]carbamoyloxy]ethyl]-1H-1,2,4-triazol-4-ium chloride, hy",Azole Antifungals,Small molecule,"1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1",RSWOJTICKMKTER-QXLBVTBOSA-N,CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O,742049-41-8,C35H35F2N8O5S+,85978,1F29-1F2F: Fungal infection
D0853,Isocarboxazid,3759,"BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide",Antidepressants,Small molecule,"1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)",XKFPYPQQHFEXRZ-UHFFFAOYSA-N,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,59-63-2,C12H13N3O2,93635,6A70-6A7Z: Depression
D0854,Isoetharine,3762,"Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol",Bronchodilators,Small molecule,"1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3",HUYWAWARQUIQLE-UHFFFAOYSA-N,CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C,530-08-5,C13H21NO3,6005,CA23: Asthma
D0855,Isoflurane,3763,"Aerrane; Forane; Forene; IsoFlo; Isoflurano; Isofluranum; AErrane (Veterinary); Forane (TN); Isoflurane [Anaesthetics, volatile]; Isoflurano [INN-Spanish]; Isofluranum [INN-Latin]; R-E 235dal; Isoflurane (JP15/USP/INN); Isoflurane [USAN:BAN:INN:JAN]; Isoflurane [USAN:INN:BAN:JAN]; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane",Anesthetics,Small molecule,"1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H",PIWKPBJCKXDKJR-UHFFFAOYSA-N,C(C(F)(F)F)(OC(F)F)Cl,26675-46-7,C3H2ClF5O,6015,9A76-9A78: Corneal disease
D0856,Isoflurophate (ophthalmic),5936,"DFP; DIFP; Diflupyl; Diflurophate; Diisopropylfluorfosfat; Diisopropylfluorophosphate; Diisopropylfluorphosphorsaeureester; Diisopropylphosphofluoridate; Diisopropylphosphorofluoridate; Dyflos; Floropryl; Fluoropryl; Fluorostigmine; Fluostigmine; Fluropryl; Isofluorophate; Isofluorphate; Isoflurophosphate; Neoglaucit; Di isopropylphosphorofluoridate; Diisopropoxyphosphoryl fluoride; Diisopropyl fluoridophosphate; Diisopropyl fluorophosphate; Diisopropyl fluorophosphonate; Diisopropyl phosphofluoridate; Diisopropyl phosphorofluoridate; Diisopropylfluorfosfat [Czech]; Diisopropylfluorophosphoric acid ester; Diisopropylfluorphosphorsaeureester [German]; Disiopropyl fluorophosphonate; Fluorodiisopropyl phosphate; Isoflurophate [USP]; Isopropyl fluophosphate; Isopropyl phosphorofluoridate; Merck Brand of Isoflurophate; Phosphoric acid diisopropyl ester fluoride; EA 1152; TL 466; DIISOPROPYL-FLUOROPHOSPHATE; Di-isopropylphosphorofluoridate; Floropryl (TN); Fluophosphoric acid, diisopropyl ester; Fluorophosphoric acid, diisopropyl ester; Isoflurophate (USP); PF-3; Phosphorofluoridic acid, diisopropyl ester; T-1703; Bis(1-methylethyl) Phosphorofluoridate; Dipropan-2-yl phosphorofluoridoate; O,O-Diisopropyl fluorophosphate; Bis(propan-2-yl) fluorophosphate; O,O'-Diisopropyl phosphoryl fluoride; Phosphorofluoridic acid, bis(1-methylethyl) ester; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane",Ophthalmic Glaucoma Agents,Small molecule,"1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3",MUCZHBLJLSDCSD-UHFFFAOYSA-N,CC(C)OP(=O)(OC(C)C)F,55-91-4,C6H14FO3P,17941,9C61: Glaucoma
D0857,Isometheptene,22297,Octin (TN),Analgesics,Small molecule,"1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3",XVQUOJBERHHONY-UHFFFAOYSA-N,CC(CCC=C(C)C)NC,503-01-5,C9H19N,134765,2A00-2F9Z: Solid tumour/cancer
D0858,Isoniazid,3767,Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.,Antitubercular Agents,Small molecule,"1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)",QRXWMOHMRWLFEY-UHFFFAOYSA-N,C1=CN=CC=C1C(=O)NN,54-85-3,C6H7N3O,6030,1B10-1B14: HIV-infected patients with tuberculosis
D0859,Isoprenaline,3779,"isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409",Cardiotonic Agents,Small molecule,"1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3",JWZZKOKVBUJMES-UHFFFAOYSA-N,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,7683-59-2,C11H17NO3,64317,BC63: Conduction disorder; 2C30: Melanoma
D0860,Isosorbide,12597,"AT-101, Atumida; Hyperpermeability inhibitor (hemorrhagic shock), Atumida",Antianginal Agents,Small molecule,"1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1",KLDXJTOLSGUMSJ-JGWLITMVSA-N,C1C(C2C(O1)C(CO2)O)O,652-67-5,C6H10O4,6060,MG40: Shock
D0861,Isosorbide dinitrate,6883,"Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol",Vasodilator Agents,Small molecule,"1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1",MOYKHGMNXAOIAT-JGWLITMVSA-N,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],87-33-2,C6H8N2O8,6061,DB50: Anal fissure/fistula; BA40: Angina pectoris
D0862,Isosorbide mononitrate,27661,"Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn",Vasodilator Agents,Small molecule,"1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1",YWXYYJSYQOXTPL-SLPGGIOYSA-N,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O,16051-77-7,C6H9NO6,6062,8D64: Hydrocephalus
D0863,Isotretinoin,5282379,"Accutane; Amnesteem; Claravis; Isotane; Isotretinoine; Isotretinoino; Isotretinoinum; Isotrex; Roaccutan; Roaccutane; Roacutan; Sotret; Teriosal; Neovitamin A acid; R 3255; Ro 4 3780; Ro 43780; Accutane (TN); Amnesteem (TN); BML2-E07; CIP-Isotretinoin; Claravi (TN); Clarus (TN); Decutan (TN); Isotane (TN); Isotretinoin (USP); Isotretinoin Zinc Salt, 13 cis Isomer; Isotretinoine [INN-French]; Isotretinoino [INN-Spanish]; Isotretinoinum [INN-Latin]; Izotek (TN); Oratane (TN); Ro 4-3780; Ro-43780; Roaccutane (TN); Sotret (TN); Isotretinoin [USAN:INN:BAN]; Ro-4-3780; Isotretinoin Zinc Salt, 13-cis-Isomer; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (7E,9E,11E,13Z)-retinoic acid; 13-RA; 13-cis RA; 13-cis-Vitamin A acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid",Antiacne Agents/Antineoplastics,Small molecule,"1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-",SHGAZHPCJJPHSC-XFYACQKRSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,4759-48-2,C20H28O2,6067,ED80: Acne vulgaris
D0864,Isoxsuprine,3783,.,Peripheral Vasodilators,Small molecule,"1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3",BMUKKTUHUDJSNZ-UHFFFAOYSA-N,CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,395-28-8,C18H23NO3,91855,8B22-8B2Z: Cerebrovascular disease
D0865,Isradipine,3784,"Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester",Antihypertensive Agents,Small molecule,"1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3",HMJIYCCIJYRONP-UHFFFAOYSA-N,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,75695-93-1,C19H21N3O5,6073,BA00-BA04: Hypertension; 1F00: Herpes simplex infection
D0866,Istradefylline,5311037,"KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione",Antiparkinson Agents,Small molecule,"1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+",IQVRBWUUXZMOPW-PKNBQFBNSA-N,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C,155270-99-8,C20H24N4O4,134726,6C4Z: Unspecific substance use disorder; 8A00: Parkinsonism
D0867,Itraconazole,55283,"Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one",Antifungal Agents,Small molecule,"1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1",VHVPQPYKVGDNFY-ZPGVKDDISA-N,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,84625-61-6,C35H38Cl2N8O4,6076,1F29-1F2F: Fungal infection
D0868,Ivabradine,132999,"Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN]",Cardiovascular Agents,Small molecule,"1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1",ACRHBAYQBXXRTO-OAQYLSRUSA-N,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC,155974-00-8,C27H36N2O5,85966,BA40: Angina pectoris
D0869,Ivacaftor,16220172,Kalydeco (TN),Cftr Combinations,Small molecule,"1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",PURKAOJPTOLRMP-UHFFFAOYSA-N,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,873054-44-5,C24H28N2O3,66901,CA25: Cystic fibrosis
D0870,Ivermectin,6321424,I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN),Antiprotozoal Agents,Small molecule,"1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1",AZSNMRSAGSSBNP-XPNPUAGNSA-N,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,71827-03-7,C48H74O14,63941,1F6B: Strongyloidiasis
D0871,Ivermectin (topical),6321424,I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN),Antiprotozoal Agents,Small molecule,"1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1",AZSNMRSAGSSBNP-XPNPUAGNSA-N,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,71827-03-7,C48H74O14,63941,1F6B: Strongyloidiasis
D0872,Ivosidenib,71657455,UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767,Antineoplastics,Small molecule,"1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1",WIJZXSAJMHAVGX-DHLKQENFSA-N,C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N,1448347-49-6,C28H22ClF3N6O3,145430,2B33: Malignant haematopoietic neoplasm; 2A60: Acute myeloid leukaemia; 2C12: Liver cancer
D0873,Ixabepilone,6445540,Azaepothilone B; BMS-247550; Ixempra (TN),Antineoplastics/Mitotic Inhibitors,Small molecule,"1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1",FABUFPQFXZVHFB-PVYNADRNSA-N,CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,219989-84-1,C27H42N2O5S,63605,2C60-2C6Y: Breast cancer
D0874,Ixazomib,25183872,.,Protease Inhibitors,Small molecule,"1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,1072833-77-2,C14H19BCl2N2O4,90942,2A83: Multiple myeloma
D0875,Ixekizumab,.,LY2439821,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis; FA21: Psoriatic arthritis
D0876,Kanamycin,6032,"Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside",Antibiotics,Small molecule,"1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1",SBUJHOSQTJFQJX-NOAMYHISSA-N,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N,21558,C18H36N4O11,17630,1A00-1C4Z: Bacterial infection
D0877,Kaolin,56841936,"KAOLIN; 1332-58-7; China clay; Argilla; Porcelain clay; Bolus alba; White bole; Glomax; Light kaolin; Kaolin(superfine); Hydrated aluminum silicate; Kaolin clay slurry; Alphagloss; Altowhites; Alfaplate; Alphacoat; Altowhite; Apsilex; Argiflex; Bentone; Comalco; Electros; Emathlite; Hydrite; Kaopaous; Langford; Mcnamee; Parclay; Vanclay; Fitrol; Arcilla blanca; oxo-oxoalumanyloxy-[oxo(oxoalumanyloxy)silyl]oxysilane;dihydrate; Argilla alba; Comalco Kaolin; Osmo kaolin; Kaolin colloidal; beta Coat; Astra-Glaze; Snow tex; ASP Ultrafine; Kao-gel; Century HC; Kaophills-2; AA Kaolin; Clay (kaolin); Acidic white clays; BOL Blanc; ASP (mineral); Burgess 10; Airflo V 8; Amazon 88; Amazon 90; Argirec B 22; Argirec KN 15; Bilt Plate 156; Fitrol desiccite 25; Clays, white, acidic; Amazon Kaolin 855D; Kaolin [USP:JAN]; CB 1 (clay); CB 2 (clay); Clay 347; Metakaolin; Weisserton; Chishizhi; Kaolinum; Bolus; Natural kaolin; Red halloysite; Clay Nanopowder; Clay slurry; Heavy kaolin; Kaolin light; Kaolin Nanoclay; Nanoclay Powder; Alumina silicata; CCRIS 9288; HSDB 630; Kaolin, natural; Halloysitum rubrum; Perlite Clay Mix; Clay Nanoparticles; Kaolinum ponderosum; EPA Pesticide Chemical Code 100104; Expanded Perlite Powder; Perlite Nanoclay Powder; Halloysite Clay Nanotubes; Aluminum silicate hydroxide; Hydrated aluminium silicate; Aluminium silicate dihydrate; Aluminum Silicate (Hydrated); Nanoclay Montmorillonite 20A; Expanded Perlite Nanoparticles; Montmorillonite Bentonite Clay; Halloysite Nanotubes Properties; CHEMBL3833365; CHEBI:140503; Nanoclay Modified Asphalt Materials; Expanded Perlite Powder / Nanopowder; Shelsite 30B Montmorillonite Nanoparticles; FT-0627569; J-521617; 95077-05-7",Herbal Products,Natural product,InChI=1S/2Al.O5Si2.2H2O.2O/c;;1-6(2)5-7(3)4;;;;/h;;;2*1H2;;/q2*+1;-2;;;;,NLYAJNPCOHFWQQ-UHFFFAOYSA-N,O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O,.,Al2H4O9Si2,.,.
D0878,Kava,5281052,"Kava; 9000-38-8; 2-[(E)-2-cyclohexa-1,5-dien-1-ylethenyl]-4-methoxy-2,3-dihydropyran-6-one; DB01322; Q27092746",Herbal Products,Natural product,"InChI=1S/C14H16O3/c1-16-13-9-12(17-14(15)10-13)8-7-11-5-3-2-4-6-11/h3,5-8,10,12H,2,4,9H2,1H3/b8-7+",OMNGEVNATYFZGG-BQYQJAHWSA-N,COC1=CC(=O)OC(C1)/C=C/C2=CCCC=C2,.,C14H16O3,.,.
D0879,Ketamine,3821,"Calypsol; Cetamina; Green; Ketaject; Ketalar; Ketaminum; Ketanest; Ketoject; Ketolar; Tekam; KETAMINE HCL; Ketalar base; Ketamine Base; Special K; Special K [street name]; CLSTA 20; T385; Cetamina [INN-Spanish]; Dl-Ketamine; Ketalar (TN); Ketamine (INN); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Ketanest (TN); Ketaset (TN); Tekam (TN); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-(9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-(9CI); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)-(8CI); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone",Analgesics,Small molecule,"1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3",YQEZLKZALYSWHR-UHFFFAOYSA-N,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,6740-88-1,C13H16ClNO,6121,9A76-9A78: Corneal disease
D0880,Ketoconazole,456201,"KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine",Antifungal Agents,Small molecule,"1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1",XMAYWYJOQHXEEK-OZXSUGGESA-N,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,65277-42-1,C26H28Cl2N4O4,48336,1F29-1F2F: Fungal infection
D0881,Ketoprofen,3825,"Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid",Analgesics,Small molecule,"1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)",DKYWVDODHFEZIM-UHFFFAOYSA-N,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,22071-15-4,C16H14O3,6128,MG30-MG3Z: Pain; FA00-FA05: Osteoarthritis; MG30: Chronic pain; 8A80: Migraine
D0882,Ketorolac,3826,"Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid",Analgesics,Small molecule,"1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)",OZWKMVRBQXNZKK-UHFFFAOYSA-N,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,74103-06-3,C15H13NO3,76223,1A00-CA43: Postoperative inflammation
D0883,Ketorolac (ophthalmic),3826,"Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid",Analgesics,Small molecule,"1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)",OZWKMVRBQXNZKK-UHFFFAOYSA-N,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,74103-06-3,C15H13NO3,76223,1A00-CA43: Postoperative inflammation
D0884,Labetalol,3869,Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide,Antihypertensive Agents,Small molecule,"1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)",SGUAFYQXFOLMHL-UHFFFAOYSA-N,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,36894-69-6,C19H24N2O3,6343,BA00-BA04: Hypertension
D0885,Lacosamide,219078,"Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide",Analgesics,Small molecule,"1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1",VPPJLAIAVCUEMN-GFCCVEGCSA-N,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,175481-36-4,C13H18N2O3,135939,8A61-8A6Z: Epilepsy/seizure; 8C0Z: Neuropathy
D0886,Lactic acid,612,"lactic acid; 2-hydroxypropanoic acid; DL-Lactic acid; 50-21-5; 2-hydroxypropionic acid; Milk acid; lactate; Polylactic acid; Tonsillosan; Racemic lactic acid; Ordinary lactic acid; Ethylidenelactic acid; Propanoic acid, 2-hydroxy-; Lactovagan; Acidum lacticum; Kyselina mlecna; DL-Milchsaeure; alpha-Hydroxypropionic acid; 26100-51-6; 1-Hydroxyethanecarboxylic acid; Lactic acid, dl-; Aethylidenmilchsaeure; Lacticum acidum; (RS)-2-Hydroxypropionsaeure; FEMA No. 2611; 598-82-3; Kyselina 2-hydroxypropanova; Propionic acid, 2-hydroxy-; CCRIS 2951; HSDB 800; (+-)-2-Hydroxypropanoic acid; Lactic acid, tech grade; Propanoic acid, hydroxy-; SY-83; alpha-Hydroxypropanoic acid; DL- lactic acid; NSC 367919; AI3-03130; Purac FCC 80; Purac FCC 88; MFCD00004520; (R)-2-Hydroxy-propionic acid;H-D-Lac-OH; CHEBI:78320; Poly(L-lactide); Lactic acid USP; NSC-367919; NCGC00090972-01; 2-hydroxy-propionic acid; Lactic acid (natural); E 270; DSSTox_CID_3192; (+/-)-Lactic acid; C01432; DSSTox_RID_76915; DSSTox_GSID_23192; Milchsaure [German]; Milchsaure; FEMA Number 2611; Kyselina mlecna [Czech]; Cheongin samrakhan; UNII-3B8D35Y7S4; CAS-50-21-5; Cheongin Haewoohwan; Cheongin Haejanghwan; Kyselina 2-hydroxypropanova [Czech]; EINECS 200-018-0; EINECS 209-954-4; Lactic acid [USP:JAN]; EPA Pesticide Chemical Code 128929; BRN 5238667; lactasol; 1-Hydroxyethane 1-carboxylic acid; Biolac; Lurex; 2-Hydroxy-2-methylacetic acid; Lactide Polymer; MFCD00064266; Chem-Cast; L- Lactic acid; DL-Polylactic acid; Lactate (TN); Lactic acid,buffered; 3B8D35Y7S4; 2-Hydropropanoic acid; 2-Hydroxypropionicacid; 4b5w; (+,-)-Lactic acid; Propanoic acid, (+-); HIPURE 88; (.+/-.)-Lactic acid; EC 200-018-0; Lactic acid (7CI,8CI); Lactic acid (JP17/USP); Lactic acid, 85%, FCC; NCIOpen2_000884; .alpha.-Hydroxypropanoic acid; .alpha.-Hydroxypropionic acid; Lactic acid, unspecified form; (RS)-2-hydroxypropanoic acid; Lactic Acid (Fragrance Grade); INS NO.270; DL-Lactic Acid (90per cent); L-(+)-Lactic acid, 98%; CHEMBL1200559; DTXSID7023192; Lactic acid, natural, >=85%; (+/-)-2-hydroxypropanoic acid; BDBM23233; L-lactic acid or dl-lactic acid; DL-Lactic acid, ~90% (T); INS-270; DL-Lactic acid, AR, >=88%; DL-Lactic acid, LR, >=88%; Propanoic acid, 2-hydroxy- (9CI); Tox21_111049; Tox21_202455; Tox21_303616; BBL027466; NSC367919; STL282744; AKOS000118855; AKOS017278364; Tox21_111049_1; AM87208; DB04398; MCULE-5387110670; SB44647; SB44652; DL-Lactic acid, 85 % (w/w), syrup; Propanoic acid,2-hydroxy-,(.+/-.)-; NCGC00090972-02; NCGC00090972-03; NCGC00257515-01; NCGC00260004-01; 26811-96-1; I487; Lactic acid, 1.0N Standardized Solution; DB-071134; E-270; FT-0624390; FT-0625477; FT-0627927; FT-0696525; FT-0774042; L0226; Lactic acid solution, ACS reagent, >=85%; Lactic acid solution, USP, 88.0-92.0%; Lactic acid solution, p.a., 84.5-85.5%; Lactic acid, meets USP testing specifications; D00111; PROPANOIC ACID, 2-HYDROXY-, (.+-.)-; A877374; DL-Lactic acid, SAJ first grade, 85.0-92.0%; Q161249; DL-Lactic acid, JIS special grade, 85.0-92.0%; Lactic acid solution, Vetec(TM) reagent grade, 85%; F2191-0200; BC10F553-5D5D-4388-BB74-378ED4E24908; Lactic acid, United States Pharmacopeia (USP) Reference Standard; Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material; DL-Lactic acid 90%, synthetic, meets the analytical specifications of Ph. Eur.",Topical Agents,Small molecule,"InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)",JVTAAEKCZFNVCJ-UHFFFAOYSA-N,CC(C(=O)O)O,.,C3H6O3,.,.
D0887,Lactitol,157355,Importal; Portolac; NS-4,Laxatives,Small molecule,"1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1",VQHSOMBJVWLPSR-JVCRWLNRSA-N,C(C1C(C(C(C(O1)OC(C(CO)O)C(C(CO)O)O)O)O)O)O,585-86-4,C12H24O11,75323,DB90-DB9Z: Liver disease
D0888,Lactulose,11333,Cephulac;Cholac;Heptalac;Enulose;Enulose,Laxatives,Small molecule,"1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1",JCQLYHFGKNRPGE-FCVZTGTOSA-N,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,4618-18-2,C12H22O11,6359,DD91: Irritable bowel syndrome
D0889,Lamivudine,60825,"lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X;  DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate",Anti-Hiv Agents,Small molecule,"1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1",JTEGQNOMFQHVDC-NKWVEPMBSA-N,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,134678-17-4,C8H11N3O3S,63577,1E50-1E51: Hepatitis virus infection; 1C60-1C62: Human immunodeficiency virus disease
D0890,Lamotrigine,3878,"Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine",Anticonvulsants,Small molecule,"1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)",PYZRQGJRPPTADH-UHFFFAOYSA-N,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,84057-84-1,C9H7Cl2N5,6367,6A60: Bipolar disorder; 8A61-8A6Z: Epilepsy/seizure
D0891,Lanreotide,71349,"Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;  Somatuline lp (TN); Lanreotide Autogel",Somatostatin/Somatostatin Analogs,Small molecule,"1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)",PUDHBTGHUJUUFI-UHFFFAOYSA-N,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,108736-35-2,C54H69N11O10S2,.,5A60-5A61: Pituitary gland disorder
D0892,Lansoprazole,3883,"lansoprazole; 103577-45-3; Prevacid; Bamalite; Limpidex; Monolitum; Agopton; Lanzor; Ogastro; Lansoprazol; Takepron; Opiren; Prevacid SoluTab; Lanzopral; Zoton; Lanproton; Lansopep; Lasoprol; Mesactol; Aprazol; Blason; Ketian; Lancid; Lanston; Lanz; AG-1749; Lansoprazolum; Ogast; Prevacid Iv; Lansox; AG 1749; Lanzo; PrevOnco; (S)-Lansoprazole; A-65006; Prevacid 24HR; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:6375; Prezal; Pro Ulco; Compraz; Ilsatec; Prosogan; Suprecid; Dakar; Promp; Zoprol; TAK-390MR; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; MLS000069705; Lanzol-30; MFCD00866873; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; NSC-758638; C16H14F3N3O2S; NCGC00015615-02; SMR000058469; Lansoprazol [INN-Spanish]; Lansoprazolum [INN-Latin]; CAS-103577-45-3; DSSTox_CID_3200; MLS-0003247.0001; Prevacid NapraPAC; 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; DSSTox_RID_76922; DSSTox_GSID_23200; 1261394-42-6; Prevacid I.V.; TAK 390MR; Lansophed; Lanzol; Lanzul; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; Prevacid (TN); 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole; HSDB 7204; SR-01000000169; A 65006; BRN 4333393; Lanfast; Ogastoro; Lapraz; NSC-758710; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole; ABT-006; Lansoprazole,(S); Lansoprazole [USAN:USP:INN:BAN]; CG-4801; Spectrum_001580; CPD000058469; Prevacid Delayed Release; Opera_ID_1676; Prestwick0_001072; Prestwick1_001072; Prestwick2_001072; Prestwick3_001072; Spectrum2_000444; Spectrum3_000295; Spectrum4_000856; Spectrum5_001521; Dexlansoprazole-[13C6]; Lopac-L-8533; CHEMBL480; L 8533; cid_3883; Lopac0_000709; SCHEMBL22365; BSPBio_001084; BSPBio_001830; KBioGR_001491; KBioSS_002060; MLS000759405; MLS001074170; MLS001424235; BIDD:GT0006; DivK1c_000920; SPECTRUM1503926; SPBio_000488; SPBio_002992; BPBio1_001194; GTPL7208; DTXSID4023200; BDBM47032; HMS502N22; KBio1_000920; KBio2_002060; KBio2_004628; KBio2_007196; KBio3_001330; Lansoprazole (JP17/USP/INN); 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[(S)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Levolansoprazole;(-)-Lansoprazole; NINDS_000920; HMS1571G06; HMS1922M04; HMS2052F05; HMS2093M07; HMS2098G06; HMS2234B10; HMS3262M19; HMS3264E12; HMS3269D15; HMS3371E21; HMS3394F05; HMS3413J05; HMS3654J17; HMS3677J05; HMS3715G06; Pharmakon1600-01503926; Pharmakon1600-01504282; ACT03358; BCP22331; BCP34129; Tox21_110184; Tox21_301023; Tox21_500709; BBL029072; BDBM50070208; CCG-39952; NSC758638; NSC758710; s1354; STK621169; AKOS005554811; Tox21_110184_1; AC-1233; CS-1847; DB00448; KS-1075; Lansoprazole, >=98% (TLC), powder; LP00709; MCULE-8446262134; NC00411; NSC 758638; SB19127; SDCCGSBI-0050687.P004; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; IDI1_000920; NCGC00015615-01; NCGC00015615-03; NCGC00015615-04; NCGC00015615-05; NCGC00015615-06; NCGC00015615-07; NCGC00015615-08; NCGC00015615-09; NCGC00015615-10; NCGC00015615-11; NCGC00015615-12; NCGC00015615-14; NCGC00015615-15; NCGC00023826-03; NCGC00023826-04; NCGC00023826-05; NCGC00023826-06; NCGC00023826-07; NCGC00254925-01; NCGC00261394-01; NCGC00381720-13; BL166173; HY-13662; SBI-0050687.P003; AB00052388; EU-0100709; FT-0610894; FT-0670721; FT-0670722; L0233; SW197226-4; D00355; F20528; AB00052388-17; AB00052388_18; AB00052388_19; 577L453; A800764; A921066; Q254296; J-007154; SR-01000000169-2; SR-01000000169-6; SR-01000000169-9; BRD-A49172652-001-05-7; BRD-A49172652-001-13-1; F2173-0222; Lansoprazole, British Pharmacopoeia (BP) Reference Standard; Lansoprazole, European Pharmacopoeia (EP) Reference Standard; Lansoprazole, United States Pharmacopeia (USP) Reference Standard; (+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole; 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; 1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-[[[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YL]METHYL]SULFINYL]-1H-BENZO[D]IMIDAZOLE",Proton Pump Inhibitors,Small molecule,"InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)",MJIHNNLFOKEZEW-UHFFFAOYSA-N,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,.,C16H14F3N3O2S,.,.
D0893,Lanthanum carbonate,168924,"Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey",Phosphate Binders,Small molecule,"1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6",NZPIUJUFIFZSPW-UHFFFAOYSA-H,C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3],587-26-8,C3La2O9,.,5C64: Mineral absorption/transport disorder
D0894,Lapatinib,208908,"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)",Antineoplastics,Small molecule,"1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,231277-92-2,C29H26ClFN4O4S,49603,2C60-2C6Y: Breast cancer
D0895,Laronidase,.,Aldurazyme (TN),Lysosomal Enzymes,Protein/peptide,.,.,.,.,.,.,5C56: Lysosomal disease
D0896,Larotrectinib,46188928,"UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470",Multikinase Inhibitors,Small molecule,"1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1",NYNZQNWKBKUAII-KBXCAEBGSA-N,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,1223403-58-4,C21H22F2N6O2,.,2A00-2F9Z: Solid tumour/cancer
D0897,Lasmiditan,11610526,"COL-144; LY-573144; Migraine therapy, CoLucid",Antimigraine Agents,Small molecule,"1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)",XEDHVZKDSYZQBF-UHFFFAOYSA-N,CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F,439239-90-4,C19H18F3N3O2,.,8A80: Migraine
D0898,Ledipasvir,67505836,"Ledipasvir; 1256388-51-8; GS-5885; UNII-013TE6E4WV; GS5885; GS 5885; WHO 9796; Ledipasvir (GS5885); 013TE6E4WV; CHEBI:85089; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; SCHEMBL15116943; CHEMBL2374220; EX-A411; DTXSID90154829; MolPort-039-138-665",Antiviral Agents,Small molecule,"1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1",VRTWBAAJJOHBQU-KMWAZVGDSA-N,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,1256388-51-8,C49H54F2N8O6,85089,1E50-1E51: Hepatitis virus infection
D0899,Lefamulin,25185057,"UNII-21904A5386; 1061337-51-6; CHEMBL3291398; 21904A5386; Lefamulin [INN]; Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester; Lefamulin(BC-3781); Lefamulin [USAN:INN]; Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten",Antibiotics,Small molecule,"1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1",KPVIXBKIJXZQJX-FCEONZPQSA-N,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C,1061337-51-6,C28H45NO5S,.,1A00-1C4Z: Bacterial infection; CA40: Pneumonia
D0900,Leflunomide,3899,"Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide",Antiinflammatory Agents,Small molecule,"1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,75706-12-6,C12H9F3N2O2,6402,FA20: Rheumatoid arthritis; 8A40: Multiple sclerosis
D0901,Lemborexant,56944144,E2006,Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1",MUGXRYIUWFITCP-PGRDOPGGSA-N,CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C,1369764-02-2,C22H20F2N4O2,.,8A20: Alzheimer disease; 7A00-7A0Z: Insomnia
D0902,Lenalidomide,216326,"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)",Antineoplastics,Small molecule,"1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,191732-72-6,C13H13N3O3,63791,2A83: Multiple myeloma
D0903,Lenvatinib,9823820,"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide",Vegf/Vegfr Inhibitors,Small molecule,"1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,417716-92-8,C21H19ClN4O4,85994,2C73: Ovarian cancer; 2C12: Liver cancer; 2C30: Melanoma; 2A00-2F9Z: Solid tumour/cancer; 2C25: Lung cancer; 2C90: Renal cell carcinoma; 2D10: Thyroid cancer
D0904,Lepirudin,118856773,Refludan; Refludin; Aventis Behring Brand of Lepirudin; Aventis Brand Lepirudin; Aventis Pharma Brand of Lepirudin; Berlex Brand of Lepirudin; Hoechst Brand of Lepirudin; Lepirudin recombinant; Pharmion Brand of Lepirudin; Schering Brand of Lepirudin; Hbw 023; Hbw-023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudomedicinalis isoform HV1); 1-Leu-2-thr-63-desulfohirudin,Antithrombotic Agents,Small molecule,"1S/C287H440N80O111S6/c1-24-132(17)225-280(470)345-162(87-126(5)6)236(426)306-111-209(396)320-181(116-370)267(457)344-176(101-220(416)417)238(428)307-105-203(390)316-152(61-74-213(402)403)243(433)321-146(40-29-32-80-288)241(431)339-171(96-198(298)385)259(449)326-153(56-69-194(294)381)250(440)351-186(121-482-479-118-183-240(430)310-107-202(389)313-148(54-67-192(292)379)233(423)303-108-206(393)317-170(95-197(297)384)258(448)322-147(41-30-33-81-289)242(432)350-187(272(462)359-225)122-483-480-119-184(269(459)323-150(60-73-212(400)401)235(425)304-110-208(395)319-180(115-369)266(456)342-174(99-201(301)388)265(455)357-223(130(13)14)278(468)355-183)352-254(444)165(90-129(11)12)335-270(460)185-120-481-484-123-188(354-263(453)178(103-222(420)421)347-283(473)230(137(22)375)362-264(454)168(93-141-48-52-144(378)53-49-141)346-282(472)228(135(20)373)361-232(422)145(291)86-125(3)4)273(463)363-229(136(21)374)281(471)330-158(65-78-217(410)411)249(439)348-179(114-368)239(429)309-106-204(391)315-151(55-68-193(293)380)244(434)340-172(97-199(299)386)260(450)334-164(89-128(9)10)253(443)353-185)271(461)358-224(131(15)16)279(469)364-227(134(19)372)277(467)311-112-205(392)314-149(59-72-211(398)399)234(424)305-113-210(397)356-231(138(23)376)286(476)367-85-37-45-191(367)276(466)331-160(42-31-34-82-290)284(474)365-83-35-43-189(365)274(464)328-154(57-70-195(295)382)248(438)349-182(117-371)268(458)338-169(94-142-104-302-124-312-142)257(447)341-173(98-200(300)387)261(451)343-175(100-219(414)415)237(427)308-109-207(394)318-177(102-221(418)419)262(452)337-166(91-139-38-27-26-28-39-139)255(445)327-155(62-75-214(404)405)245(435)325-159(66-79-218(412)413)251(441)360-226(133(18)25-2)285(475)366-84-36-44-190(366)275(465)329-157(64-77-216(408)409)246(436)324-156(63-76-215(406)407)247(437)336-167(92-140-46-50-143(377)51-47-140)256(446)333-163(88-127(7)8)252(442)332-161(287(477)478)58-71-196(296)383/h26-28,38-39,46-53,104,124-138,145-191,223-231,368-378H,24-25,29-37,40-45,54-103,105-123,288-291H2,1-23H3,(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H2,301,388)(H,302,312)(H,303,423)(H,304,425)(H,305,424)(H,306,426)(H,307,428)(H,308,427)(H,309,429)(H,310,430)(H,311,467)(H,313,389)(H,314,392)(H,315,391)(H,316,390)(H,317,393)(H,318,394)(H,319,395)(H,320,396)(H,321,433)(H,322,448)(H,323,459)(H,324,436)(H,325,435)(H,326,449)(H,327,445)(H,328,464)(H,329,465)(H,330,471)(H,331,466)(H,332,442)(H,333,446)(H,334,450)(H,335,460)(H,336,437)(H,337,452)(H,338,458)(H,339,431)(H,340,434)(H,341,447)(H,342,456)(H,343,451)(H,344,457)(H,345,470)(H,346,472)(H,347,473)(H,348,439)(H,349,438)(H,350,432)(H,351,440)(H,352,444)(H,353,443)(H,354,453)(H,355,468)(H,356,397)(H,357,455)(H,358,461)(H,359,462)(H,360,441)(H,361,422)(H,362,454)(H,363,463)(H,364,469)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,477,478)/t132-,133-,134+,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1",FIBJDTSHOUXTKV-BRHMIFOHSA-N,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CNC=N7)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C,138068-37-8,C287H440N80O111S6,142437,3B64: Thrombocytopenia
D0905,Lesinurad,53465279,"LESINURAD; 878672-00-5; RDEA594; Zurampic; RDEA 594; UNII-09ERP08I3W; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 09ERP08I3W; AK323774; C17H14BrN3O2S; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid",Antihyperuricemic Agents,Small molecule,"1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)",FGQFOYHRJSUHMR-UHFFFAOYSA-N,C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O,878672-00-5,C17H14BrN3O2S,90929,5C55: Inborn purine/pyrimidine/nucleotide metabolism error
D0906,Letermovir,45138674,Letermovir,Antiviral Agents,Small molecule,"1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1",FWYSMLBETOMXAG-QHCPKHFHSA-N,COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O,917389-32-3,C29H28F4N4O4,.,1D82: Cytomegaloviral disease
D0907,Letrozole,3902,"Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile",Antineoplastics,Small molecule,"1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H",HPJKCIUCZWXJDR-UHFFFAOYSA-N,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,112809-51-5,C17H11N5,6413,2C60-2C6Y: Breast cancer
D0908,Leuprolide,657181,Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide,Antineoplastics,Small molecule,"1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1",GFIJNRVAKGFPGQ-LIJARHBVSA-N,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,53714-56-0,C59H84N16O12,6427,2C82: Prostate cancer
D0909,Levacetylmethadol,15130,"LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)",Analgesics,Small molecule,"1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1",XBMIVRRWGCYBTQ-AVRDEDQJSA-N,CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,1477-40-3,C23H31NO2,6441,6C43: Opioid use disorder
D0910,Levamisole,26879,"Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole",Antineoplastics,Small molecule,"1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1",HLFSDGLLUJUHTE-SNVBAGLBSA-N,C1CSC2=NC(CN21)C3=CC=CC=C3,14769-73-4,C11H12N2S,6432,1D0Y-1G2Z: Parasitic infection; 2B90: Colon cancer
D0911,Levamlodipine,9822750,"Levamlodipine (hypertension); S-amlodipine gentisate; Levamlodipine (hypertension), SK Chemicals; S-amlodipine (hypertension), SK Chemicals",Antihypertensives Agent,Small molecule,"1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1",HTIQEAQVCYTUBX-KRWDZBQOSA-N,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,103129-82-4,C20H25ClN2O5,53796,BA00-BA04: Hypertension
D0912,Levetiracetam,5284583,"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,;  Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam",Anticonvulsants,Small molecule,"1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",HPHUVLMMVZITSG-LURJTMIESA-N,CCC(C(=O)N)N1CCCC1=O,102767-28-2,C8H14N2O2,6437,MG30: Chronic pain; 8A61-8A6Z: Epilepsy/seizure
D0913,Levmetamfetamine (nasal),36604,"Levmetamfetamine; L-Methamphetamine; 33817-09-3; l-Methylamphetamine; (-)-Methamphetamine; (-)-Deoxyephedrine; levomethamphetamine; R(-)-N-Methylamphetamine; l-1-Phenyl-2-methylaminopropane; NSC 6084; UNII-Y24T9BT2Q2; (R)-N-Methyl-1-phenylpropan-2-amine; (-)-Methyl(alpha-methylphenethyl)amine; l-1-Phenyl-2-methylamino-propan; Levmetamfetamine (in methanol); Y24T9BT2Q2; Benzeneethanamine, N,alpha-dimethyl-, (R)-; CHEMBL1927030; Vicks; (R)-Deoxyephedrine; (R)-Methylamphetamine; Benzeneethanamine, N,.alpha.-dimethyl-, (R)-; L-DESOXYEPHEDRINE; EINECS 251-687-0; l-1-Phenyl-2-methylamino-propan [German]; Vicks Inhaler; Benzeneethanamine, N,alpha-dimethyl-, (-)-; PHENETHYLAMINE, N,alpha-DIMETHYL-, (-)-; Levmetamfetamine [USAN:USP:INN]; Levmetamfetamine cii; r(-)-methamphetamine; Methyl-((R)-1-methyl-2-phenyl-ethyl; (2R)-N-methyl-1-phenylpropan-2-amine; (-)-(R)-N,alpha-Dimethylphenethylamine; l-(-)-Methamphetamine; 1-METHAMPHETAMINE; (R)-N-Methylamphetamine; (-)-N-Methylamphetamine; 2R-(-)-Methamphetamine; NCGC00247704-01; (R)-(-)-Deoxyephedrine; (R)-(-)-Methamphetamine; R-(-)-N-Methylamphetamine; Levmetamfetamine (USP/INN); SCHEMBL727412; DTXSID30187474; NSC6084; CHEBI:136013; NSC-6084; ZINC8466459; BDBM50359500; AKOS015962949; Phenethylamine,.alpha.-dimethyl-, D-; DB09571; (-)-Deoxyephedrine, analytical standard; (2R)-N-methyl-1-phenyl-2-propanamine; (-)-2--(Methyl-amino)-1-phenylpropane; AC-18760; N-Methyl-1-phenyl-2-propanamine, (-)-; Phenethylamine,.alpha.-dimethyl-, (-)-; (-)-(R)-N,.alpha.-Dimethylphenethylamine; Benzeneethanamine,.alpha.-dimethyl-, (-)-; Benzeneethanamine,.alpha.-dimethyl-, (R)-; Phenethylamine, N,.alpha.-dimethyl-, (-)-; Benzeneethanamine, N,.alpha.-dimethyl-, (-)-; D02291; benzeneethanamine, N,alpha-dimethyl-, (alphaR)-; Phenethylamine, N,alpha-dimethyl-, (-)- (8CI); Q402846; Benzeneethanamine, N,alpha-dimethyl-, (R)- (9CI); UNII-13ZT6YG5SD component MYWUZJCMWCOHBA-SECBINFHSA-N; Levmetamfetamine, United States Pharmacopeia (USP) Reference Standard; R(-)-Methamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material",Decongestants,Small molecule,"InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1",MYWUZJCMWCOHBA-SECBINFHSA-N,C[C@H](CC1=CC=CC=C1)NC,.,C10H15N,.,.
D0914,Levobetaxolol (ophthalmic),60657,Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol,Cardiotonic Agents,Small molecule,"1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1",NWIUTZDMDHAVTP-KRWDZBQOSA-N,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O,93221-48-8,C18H29NO3,59254,9C61: Glaucoma
D0915,Levobunolol (ophthalmic),39468,"Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one",Sympatholytics,Small molecule,"1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1",IXHBTMCLRNMKHZ-LBPRGKRZSA-N,CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O,47141-42-4,C17H25NO3,6438,9C61: Glaucoma
D0916,Levobupivacaine,92253,"Novabupi; Chirocaine (TN); Levobupivacaine (INN); Levobupivacaine [INN:BAN]; Novabupi (TN); L(-)-Bupivacaine; L-(-)-bupivacaine; L-(-)-1-Butyl-2',6'-pipecoloxylidide; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (S)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine",Anesthetics,Small molecule,"1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1",LEBVLXFERQHONN-INIZCTEOSA-N,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,27262-47-1,C18H28N2O,6149,9A76-9A78: Corneal disease
D0917,Levocetirizine,1549000,"Levocetirizine; 130018-77-8; (R)-cetirizine; (-)-Cetirizine; Xyzal; Levocetirizine HCl; UNII-6U5EA9RT2O; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Xarlin; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; 130018-87-0; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; SMR000466315; Vozet; Xazal; R-levocetirizine; Levocetirizine [USAN:INN:BAN]; 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; Cetirizine, (r)-; Cetirizine (r)-form; Xazal (TN); Cetirizine, (-)-; Cetirizine (-) isomer; SCHEMBL4914; Levocetirizine (USAN/INN); MLS000759420; MLS001401375; BIDD:GT0791; Singulair and xyzal combination; GTPL1214; CHEMBL1201191; BDBM85030; CHEBI:94559; DTXSID60156294; HCP1102; HMS2051N10; HMS2231M24; HCP 1102; HY-B0814; PDSP1_000117; PDSP1_000269; PDSP2_000117; PDSP2_000268; s5864; ZINC19364230; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; AKOS016844241; CCG-101021; DB06282; NCGC00263567-04; AC-15295; CS-0012812; 18L778; D07402; AB00639972-08; A806002; Q421091; H230000000; UNII-YO7261ME24 component ZKLPARSLTMPFCP-OAQYLSRUSA-N; 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid; 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid; Acetic acid, 2-[2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-",Antihistamines,Small molecule,"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1",ZKLPARSLTMPFCP-OAQYLSRUSA-N,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl,.,C21H25ClN2O3,.,.
D0918,Levodopa,6047,"Levodopa (optimized formulation, Parkinson's disease); More effective levodopa (Parkinson's disease), Orion; Levodopa (optimized formulation, Parkinson's disease), Orion",Dopaminergic Antiparkinsonism Agents,Small molecule,"1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1",WTDRDQBEARUVNC-LURJTMIESA-N,C1=CC(=C(C=C1CC(C(=O)O)N)O)O,59-92-7,C9H11NO4,15765,8A00: Parkinsonism
D0919,Levofloxacin,149096,"Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin",Antibiotics,Small molecule,"1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1",GSDSWSVVBLHKDQ-JTQLQIEISA-N,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,100986-85-4,C18H20FN3O4,63598,1A00-1C4Z: Bacterial infection
D0920,Levomilnacipran,6917779,"Fetzima; UNII-UGM0326TXX; Levomilnacipran HCl; 96847-54-0; UGM0326TXX; CHEMBL99946; F-2695; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran [USAN:INN]; Milnacipram; AC1OCEN8; F 2695; Levomilnacipran (USAN/INN); ZINC506; SCHEMBL1414867; GTPL7435; GJJFMKBJSRMPLA-DZGCQCFKSA-N; CHEBI:136040; BDBM50032379; SB17447; DB08918; f2-695; D10072",Snris/Antidepressants,Small molecule,"1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1",GJJFMKBJSRMPLA-DZGCQCFKSA-N,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,96847-54-0,C15H22N2O,136040,MG30: Chronic pain
D0921,Levonordefrin,164739,"levonordefrin; Corbadrine; Neo-Cobefrin; Nordefrin; 829-74-3; Corbadrinum; Corbadrina; alpha-Methylnoradrenaline; Corbadrinum [INN-Latin]; Corbadrina [INN-Spanish]; L-alpha-Methylnoradrenaline; Levonordefrin [USP]; Nordefrin, (-)-; UNII-V008L6478D; CHEBI:10304; 4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol; Corbadrine (INN); Corbadrine [INN]; Levonordefrin (USP); V008L6478D; CAS-829-74-3; DSSTox_RID_81553; DSSTox_CID_26349",Local Anesthetics,Small molecule,"1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1",GEFQWZLICWMTKF-CDUCUWFYSA-N,CC(C(C1=CC(=C(C=C1)O)O)O)N,829-74-3,C9H13NO3,10304,.
D0922,Levonorgestrel,13109,"norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme;  Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS",Contraceptive Agents,Small molecule,"1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1",WWYNJERNGUHSAO-XUDSTZEESA-N,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,797-63-7,C21H28O2,6443,QA21: Contraceptive management
D0923,Levorphanol,5359272,"levorphanol; Levorphan; Methorphinan; Aromarone; Racemethorphanum; Dromoran; Cetarin; Antalgin; Levo-Dromoran; Racemic dromoran; Methorfinan [Czech]; Levorfanolo [DCIT]; Levorphanolum; Levorfanol; Orphan; Levorfanol [INN-Spanish]; Levorphanolum [INN-Latin]; Racemorfano [INN-Spanish]; 17-Methylmorphinan-3-ol; N-Methyl-3-hydroxymorphinan; Racemorphan; Racemorphan [INN:BAN]; Racemorphane [INN-French]; Racemorphanum [INN-Latin]; (-)-N-Methylmorphinan-3-ol; Morphinan-3-ol, 17-methyl-; Levorphanal; dl-3-Hydroxy-N-methylmorphinan; DEA No;  Antalgin; DEXTRORPHAN; Levodroman; Levorfanolo; Methorfinan; Racemorfano; Racemorphane; Racemorphanum; NU 2206; L-Dromoran; Levorphanol (INN); Ro 1-5431; Levo-Dromoran (TN); Dl-3-Hydroxy-N-methylmorphinan; (+)-3-Hydroxy-17-methylmorphinan; (+-)-17-Methylmorphinan-3-ol; (+-)-3-Hydroxy-N-methylmorphinan; (-)-3-Hydroxy-N-methylmorphinan; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; 3-Hydroxy-N-methylmorphinan; Dextrorphan",Analgesics,Small molecule,"1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1",JAQUASYNZVUNQP-USXIJHARSA-N,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)O,297-90-5,C17H23NO,6444,MG30-MG3Z: Pain; 8B11: Cerebral ischaemic stroke
D0924,Levosalbutamol,123600,"Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol",Adrenergic Bronchodilators,Small molecule,"1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1",NDAUXUAQIAJITI-LBPRGKRZSA-N,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,34391-04-3,C13H21NO3,8746,CA23: Asthma
D0925,Levothyroxine,5819,"Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5""-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine",Antithyroid Agents,Small molecule,"1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1",XUIIKFGFIJCVMT-LBPRGKRZSA-N,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,51-48-9,C15H11I4NO4,18332,5A00: Hypo-thyroidism
D0926,Licorice,163463,"Licorice acid; 85441-51-6; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid;zinc; Licorice; Licorice acid zinc; (3ss)-30-hydroxy-30-oxooleana-11,13(18)-dien-3-yl 2-O-ss-D-glucopyranuronosyl-a-D-glucopyranosiduronic acid; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-, zinc salt",Herbal Products,Natural product,"InChI=1S/C42H62O16.Zn/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50;/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54);/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+;/m0./s1",ZZPQSQFQHIGCRC-OOFFSTKBSA-N,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O.[Zn],.,C42H62O16Zn,.,.
D0927,Lidocaine,3676,"Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide",Anesthetics,Small molecule,"1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",NNJVILVZKWQKPM-UHFFFAOYSA-N,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,137-58-6,C14H22N2O,6456,9A76-9A78: Corneal disease; GA34: Female pelvic pain
D0928,Lidocaine (topical),3676,"Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide",Anesthetics,Small molecule,"1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",NNJVILVZKWQKPM-UHFFFAOYSA-N,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,137-58-6,C14H22N2O,6456,9A76-9A78: Corneal disease; GA34: Female pelvic pain
D0929,Linaclotide,16158208,Linaclotide (USAN),Guanylate Cyclase-C Agonists,Small molecule,"1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1",KXGCNMMJRFDFNR-WDRJZQOASA-N,CC1C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)O)C(=O)NC(CSSCC(C(=O)N3)N)C(=O)NC(C(=O)N5CCCC5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O,851199-59-2,C59H79N15O21S6,68551,DD91: Irritable bowel syndrome
D0930,Linagliptin,10096344,"Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione",Dpp4 Inhibitors/Antidiabetic Agents,Small molecule,"1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1",LTXREWYXXSTFRX-QGZVFWFLSA-N,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,668270-12-0,C25H28N8O2,68610,5A11: Type 2 diabetes mellitus
D0931,Lincomycin,3000540,"Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside",Antibiotics,Small molecule,"1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1",OJMMVQQUTAEWLP-KIDUDLJLSA-N,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O,154-21-2,C18H34N2O6S,6472,1B74-1F40: Gram-positive bacterial infection
D0932,Lindane,727,"Aalindan; Aficide; Agrocide; Agronexit; Ameisenatod; Ameisentod; Aparasin; Aphtiria; Aphtitria; Aplidal; Arbitex; BBH; Benhexachlor; Benhexol; Benzanex; Benzex; Bexol; Celanex; Chloresene; Codechine; Devoran; Dolmix; Entomoxan; Esoderm; Exagama; Forlin; Gallogama; Gamacarbatox; Gamacid; Gamacide; Gamaphex; Gamene; Gamiso; Gammahexa; Gammahexane; Gammalin; Gammasan; Gammaterr; Gammex; Gammexane; Gammopaz; Gamtox; Geobilan; Gexane; Gyben; HCH; Hcch; Heclotox; Hecoltox; Hexa; Hexablanc; Hexachlor; Hexachloran; Hexachlorane; Hexamul; Hexapoudre; Hexatox; Hexaverm; Hexcidum; Hexicide; Hexit; Hexyclan; Hilbeech; Hortex; Inexit; Isatox; Isotox; Jacutin; Kokotine; Kwell; Lasochron; Lendine; Lentox; Lidenal; Lindafor; Lindagam; Lindagrain; Lindagranox; Lindalo; Lindamul; Lindan; Lindano; Lindanum; Lindapoudre; Lindaterra; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Mszycol; Nexit; Nicochloran; Novigam; Novigan; Omnitox; Ovadziak; Owadziak; PLK; Pedraczak; Pflanzol; Quellada; Scabene; Silvanol; Streunex; Submar; Viton; Agrocide III; Agrocide WP; Am eisenatod; Arcotal S; BHCor HCH; Borer Spray; DOL GRANULE; Eso derm; Gamma BHC; HCH [BSI]; HCH [ISO]; Hilbeec h; Isot ox; Lacco HI lin; Lindam ul; Mglawik L; New kotol; Nexen fb; PMS Lindane; Sang gamma; Agrocide 2; Agrocide6G; Agrocide 7; Bentox 10; Detox 25; Gamacide 20; Gammalin 20; Geolin G 3; Hungaria L7; Latka 666; Milbol 49; PS71_SUPELCO; TAP 85; Agrisol G-20; Alpha-BHC; Alpha-HCH; Ben-Hex; Beta-BHC; Beta-HCH; Beta-Lindane; Beta-isomer; D-BHC; Delta-BHC; Delta-HCH; ENT 7,796; ENT 8,601; ENT 9,232; ENT 9,233; ENT 9,234; Epsilon-HCH; Forst-nexen; Gamma-BHC; Gamma-HCH; Gamma-col; HCH (alpha); HCH (beta); KWELL (TN); Kwell-R; Nexen-fb; Nexi t-stark; Nexit-stark; Nexol-E; Sang-gamma; T-HCH; TRI-6; Trives-T",Antiscabies Agent,Small molecule,1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H,JLYXXMFPNIAWKQ-UHFFFAOYSA-N,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,.,C6H6Cl6,24536,1G00: Pediculosis
D0933,Linezolid,441401,"Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017",Antibiotics,Small molecule,"1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1",TYZROVQLWOKYKF-ZDUSSCGKSA-N,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,165800-03-3,C16H20FN3O4,63607,1A00-1C4Z: Bacterial infection
D0934,Liothyronine,5920,"liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine",Hormone Replacement Agents,Small molecule,"1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1",AUYYCJSJGJYCDS-LBPRGKRZSA-N,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,15785-49-6,C15H12I3NO4,18258,5A00: Hypo-thyroidism; BD10-BD1Z: Heart failure
D0935,Liotrix,71371,"Liotrix; 8065-29-0; Combithyrex; Novothyral; Thyrolar; Diotroxin; disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate; Liotrix (USP); Liotrix (T4;T3); Liotrix [USAN:USP]; Liothyronine Sodium and Levothyroxine Sodium; W 1782; Levothyroxine Sodium mixture with Liothyronine Sodium; CHEBI:6485; DB01583; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, hydrate, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; Monosodium L-thyroxine hydrate mixt. with monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; D00361; Levothyroxine sodium - liothyronine sodium mixt; Q6556102",Thyroid Drugs,Small molecule,"InChI=1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1",LKYWLLWWYBVUPP-XOCLESOZSA-L,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+].[Na+],.,C30H21I7N2Na2O8,.,.
D0936,Liraglutide,16134956,Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide,Antidiabetic Agents,Small molecule,"1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1",YSDQQAXHVYUZIW-QCIJIYAXSA-N,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,204656-20-2,C172H265N43O51,71193,5A11: Type 2 diabetes mellitus; 5B80-5B81: Obesity
D0937,Lisdexamfetamine,11597698,NRP104; Lisdexamfetamine (INN); Vyvanse (TN),Cns Stimulants,Small molecule,"1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1",VOBHXZCDAVEXEY-JSGCOSHPSA-N,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,608137-32-2,C15H25N3O,135925,6A05: Attention deficit hyperactivity disorder
D0938,Lisinopril,5362119,Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN),Antihypertensive Agents,Small molecule,"1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1",RLAWWYSOJDYHDC-BZSNNMDCSA-N,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,76547-98-3,C21H31N3O5,43755,BA00-BA04: Hypertension
D0939,Lisocabtagene maraleucel,.,JCAR017,Antineoplastics,Autologous cell transplant,.,.,.,.,.,.,2B33: Malignant haematopoietic neoplasm; 2A70: Precursor B-lymphoblastic neoplasm; 2A80: Follicular lymphoma; 2A81: Diffuse large B-cell lymphoma
D0940,Lithium carbonate,11125,Lithobid; Eskalith; Eskalith Cr; Lithane; Lithotabs,Antimanic Agents,Small molecule,"1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",XGZVUEUWXADBQD-UHFFFAOYSA-L,[Li+].[Li+].C(=O)([O-])[O-],554-13-2,CLi2O3,6504,6A70-6A7Z: Depression
D0941,Lixisenatide,90472060,Lyxumia (TN),Antidiabetic Agents,Small molecule,"1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1",XVVOERDUTLJJHN-IAEQDCLQSA-N,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,320367-13-3,C215H347N61O65S,85662,5A11: Type 2 diabetes mellitus
D0942,Lofexidine,30668,"Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole",Antihypertensive Agents,Small molecule,"1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)",KSMAGQUYOIHWFS-UHFFFAOYSA-N,CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl,31036-80-3,C11H12Cl2N2O,51368,6C43: Opioid use disorder
D0943,Lomefloxacin,3948,"LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride",Antibiotics,Small molecule,"1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)",ZEKZLJVOYLTDKK-UHFFFAOYSA-N,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,98079-51-7,C17H19F2N3O3,116278,1A00-1C4Z: Bacterial infection
D0944,Lomitapide,9853053,AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01,Antihyperammonia Agents,Small molecule,"1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)",MBBCVAKAJPKAKM-UHFFFAOYSA-N,C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F,182431-12-5,C39H37F6N3O2,72297,5C80: Hyper-lipoproteinaemia
D0945,Lomustine,3950,"Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea",Antineoplastics,Small molecule,"1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)",GQYIWUVLTXOXAJ-UHFFFAOYSA-N,C1CCC(CC1)NC(=O)N(CCCl)N=O,13010-47-4,C9H16ClN3O2,6520,2A00: Brain cancer
D0946,Lonafarnib,148195,"Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE",Antineoplastics,Small molecule,"1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1",DHMTURDWPRKSOA-RUZDIDTESA-N,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,193275-84-2,C27H31Br2ClN4O2,47097,2C25: Lung cancer; 1E50-1E51: Hepatitis virus infection; 2A37: Myelodysplastic syndrome; LD2B: Premature ageing appearance
D0947,Loperamide,3955,Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide,Antidiarrheals,Small molecule,"1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3",RDOIQAHITMMDAJ-UHFFFAOYSA-N,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,53179-11-6,C29H33ClN2O2,6532,ME05: Bowel habit change
D0948,Lopinavir,92727,AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378,Anti-Hiv Agents,Small molecule,"1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1",KJHKTHWMRKYKJE-SUGCFTRWSA-N,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,192725-17-0,C37H48N4O5,31781,1C60-1C62: Human immunodeficiency virus disease
D0949,Loracarbef,5284585,"Lorabid; Loracarbefum; Lorafem; Loracarbef hydrate; KT-3777; LY-163892; Lorabid (TN); (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate",Antibiotics,Small molecule,"1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1",JAPHQRWPEGVNBT-UTUOFQBUSA-N,C1CC(=C(N2C1C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl,76470-66-1,C16H16ClN3O4,47544,1A00-1C4Z: Bacterial infection
D0950,Loratadine,3957,"Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester",Antihistamines,Small molecule,"1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3",JCCNYMKQOSZNPW-UHFFFAOYSA-N,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,79794-75-5,C22H23ClN2O2,6538,4A80-4A8Z: Allergic/hypersensitivity disorder; CA08: Vasomotor/allergic rhinitis
D0951,Lorazepam,3958,"Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one",Antianxiety Agents,Small molecule,"1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)",DIWRORZWFLOCLC-UHFFFAOYSA-N,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,846-49-1,C15H10Cl2N2O2,6539,6B00-6B0Z: Anxiety disorder
D0952,Lorcaserin,11658860,"APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene",Anorexiants,Small molecule,"1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1",XTTZERNUQAFMOF-QMMMGPOBSA-N,CC1CNCCC2=C1C=C(C=C2)Cl,616202-92-7,C11H14ClN,65353,5B80-5B81: Obesity; 6C4G: Psychoactive substances use disorder
D0953,Lorlatinib,71731823,"Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39",Multikinase Inhibitors,Small molecule,"1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1",IIXWYSCJSQVBQM-LLVKDONJSA-N,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,1454846-35-5,C21H19FN6O2,143117,2C25: Lung cancer
D0954,Losartan,3961,Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan,Antihypertensive Agents,Small molecule,"1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)",PSIFNNKUMBGKDQ-UHFFFAOYSA-N,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,114798-26-4,C22H23ClN6O,6541,BA00-BA04: Hypertension
D0955,Loteprednol (ophthalmic),9865442,"loteprednol; 129260-79-3; UNII-Z8CBU6KR16; Z8CBU6KR16; Androsta-1,4-diene-17-carboxylic acid, 11,17-dihydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)-; chloromethyl (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylate; Loteprednol [INN:BAN]; Loteprednol (INN); SCHEMBL3826; CHEBI:50848; DTXSID10156128; AKOS015840095; DB00873; chloromethyl (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate; D08147; 260L793; chloromethyl 11beta,17alpha-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate",Ophthalmic Steroids,Small molecule,"InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1",YPZVAYHNBBHPTO-MXRBDKCISA-N,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)OCCl)O)CCC4=CC(=O)C=C[C@]34C)O,.,C21H27ClO5,.,.
D0956,Lovastatin,53232,"lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD;  Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1",PCZOHLXUXFIOCF-BXMDZJJMSA-N,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,75330-75-5,C24H36O5,40303,5C80: Hyper-lipoproteinaemia; BA00-BE2Z: Cardiovascular disease
D0957,Loxapine,3964,"Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine",Antipsychotic Agents,Small molecule,"1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",XJGVXQDUIWGIRW-UHFFFAOYSA-N,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,28400,C18H18ClN3O,50841,6A20: Schizophrenia
D0958,Lumacaftor,16678941,VRT-325; VRT-422; VRT-532; VX-809,Cftr Combinations,Small molecule,"1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)",UFSKUSARDNFIRC-UHFFFAOYSA-N,CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O,936727-05-8,C24H18F2N2O5,90951,CA25: Cystic fibrosis
D0959,Lumateperone,21302490,.,Atypical Antipsychotics,Small molecule,"1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1",HOIIHACBCFLJET-SFTDATJTSA-N,CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,313369-37-8,C24H28FN3O,.,7A00-7A0Z: Insomnia; 6A20: Schizophrenia; 6A70-6A7Z: Depression
D0960,Lumefantrine,6437380,"Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol",Antimalarial Agents,Small molecule,"1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-",DYLGFOYVTXJFJP-MYYYXRDXSA-N,CCCCN(CCCC)CC(C1=CC(=CC2=C1C3=C(C2=CC4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O,82186-77-4,C30H32Cl3NO,156095,1F40-1F45: Malaria
D0961,Lurasidone,213046,"Lurasidone; 367514-87-2; (3aR,4S,7R,7aS)-2-((1R,2R)-2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2H-isoindole-1,3-dione; UNII-22IC88528T; CHEBI:70735; 22IC88528T; SM13496; (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione; Lurasidone [INN]; lurasidona; lurasidonum; HSDB 8228; (3aR,4S,7R,7aS)-2-{(1R,2R)-2-(4-(1,2-Benzisothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; SM13,496; SM 13,496; SM-13,496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide; SCHEMBL677525; GTPL7461; CHEMBL1237021; Lurasidone hydrochloride solution; BDBM85222; EX-A504; HMS3886A20; AMY32530; ZINC3927822; PDSP2_001043; s5714; AKOS037643746; CCG-269635; DB08815; EX-3124; NCGC00386382-03; SM-13496SM13496; AS-35077; CAS_441351-20-8; AB01566875_01; Q416992; J-521660; (1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; (1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0?,?]decane-3,5-dione; (1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; (3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[4-(1,2-Benzoisothiazole-3-yl)piperazine-1-ylmethyl]cyclohexyl]methyl]-3a,4,5,6,7,7a-hexahydro-4,7-methano-2H-isoindole-1,3-dione",Atypical Antipsychotics,Small molecule,"InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1",PQXKDMSYBGKCJA-CVTJIBDQSA-N,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,.,C28H36N4O2S,.,.
D0962,Lurbinectedin,57327016,UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B,Alkylating Agents,Small molecule,"1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1",YDDMIZRDDREKEP-HWTBNCOESA-N,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O,497871-47-3,C41H44N4O10S,.,2A60-2B33: Leukaemia; 2A00-2F9Z: Solid tumour/cancer; 2C76: Endometrial cancer; 2C73: Ovarian cancer; 2C25: Lung cancer
D0963,Lusutrombopag,49843517,"LUSUTROMBOPAG; mulpleta; UNII-6LL5JFU42F; 6LL5JFU42F; 2-Propenoic acid, Lusutrombopag [USAN:INN]; SCHEMBL3062",Platelet-Stimulating Agents,Small molecule,"1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1",NOZIJMHMKORZBA-KJCUYJGMSA-N,CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl,1110766-97-6,C29H32Cl2N2O5S,136051,3B64: Thrombocytopenia; DB90-DB9Z: Liver disease
D0964,Lutetium Lu 177 dotatate,76966897,.,Therapeutic Radiopharmaceuticals,Small molecule,"1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2",MXDPZUIOZWKRAA-PRDSJKGBSA-K,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(C(C)O)C(=O)O)O.[Lu+3],437608-50-9,C65H87LuN14O19S2,.,1E50-1E51: Hepatitis virus infection
D0965,Macimorelin,9804938,Solorel; AEZS-130; ARD-07; ARD-0705; EP-01572; EP-1572; JMV-1843,Growth Hormones,Small molecule,"1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1",UJVDJAPJQWZRFR-DHIUTWEWSA-N,CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N,381231-18-1,C26H30N6O3,.,5A60-5A61: Pituitary gland disorder
D0966,Macitentan,16004692,Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; Z9K9Y9WMVL; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Actelion-1; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; SCHEMBL1445625; GTPL7352; CHEMBL2103873; ZLA0005; EX-A544; DTXSID50196063,Agents For Pulmonary Hypertension,Small molecule,"1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)",JGCMEBMXRHSZKX-UHFFFAOYSA-N,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,441798-33-0,C19H20Br2N6O4S,76607,BA00-BE2Z: Cardiovascular disease
D0967,Magaldrate,3086011,"aluminum;magnesium;hydroxide;sulfate; AY-5710; Magaldrato; Magaldratum; Agastrin; Bemolan; Malumix; Dynese; Riopan; Riopan Plus; Magaldratum [Latin]; Magaldrato [Spanish]; Magaldrate [USAN:USP:INN:BAN]; AY 5710; Aluminum magnesium hydroxide sulfate, hydrate; Q419991; Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2.xH2O); Pentaaluminium-decamagnesium-hentriacontahydroxid-bis(sufat)-n-wasser",Antacids,Small molecule,"InChI=1S/Al.Mg.H2O4S.H2O/c;;1-5(2,3)4;/h;;(H2,1,2,3,4);1H2/q+3;+2;;/p-3",JIFPTBLGXRKRAO-UHFFFAOYSA-K,[OH-].[O-]S(=O)(=O)[O-].[Mg+2].[Al+3],.,AlHMgO5S+2,.,.
D0968,Magnesium carbonate,11029,"MAGNESIUM CARBONATE; 546-93-0; Magnesite; Carbonic acid, magnesium salt (1:1); 13717-00-5; Carbonic acid, magnesium salt; magnesium;carbonate; Magnesite dust; Magnesium carbonate anhydrous; Magnesite (Mg(CO3)); Magnesium carbonate basic; Hydromagnesite; Magmaster; Magnesium carbonate (1:1); Carbonate magnesium; 7757-69-9; UNII-0IHC698356; C.I. 77713; Stan-mag magnesium carbonate; Magnesium carbonate,light; Magnesium carbonate (MgCO3); DCI light magnesium carbonate; Magnesium(II) carbonate (1:1); CHEBI:31793; MFCD00064632; 0IHC698356; Kimboshi; Apolda; Destab; Magfy; Magnesium Carbonate, Hydrated; Caswell No. 530; GP 20 (carbonate); MA 70 (carbonate); Giobertite; Gold Star (carbonate); Magnesium carbonate [USAN]; Australian magnesite; HSDB 211; NSC-83511; EINECS 208-915-9; NSC 83511; Carbonic acid, magnesium salt (1:?); EPA Pesticide Chemical Code 073503; CI 77713; AI3-00768; Magnesiumkarbonat; EINECS 231-817-2; CMgO3; MgCO3; Magnesium Carbonate USP; Light magnesium carbonate; Magnesium (as carbonate); Magnesium Carbonate Light; Ins no.504(i); EC 208-915-9; Anhydrous magnesium carbonate; Ins-504(i); Magnesium carbonate gold star; Magnesium carbonate, USP grade; CHEMBL1200736; DTXSID4049660; Magnesium Carbonate Microparticles; CS-B1764; E-504(i); AKOS015903527; DB09481; E504; FT-0774766; Q407931; Cyclopentanecarboxylic acid, 3-methyl-2-oxo-, methyl ester; 53678-75-4",Antacids,Small molecule,"InChI=1S/CH2O3.Mg/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",ZLNQQNXFFQJAID-UHFFFAOYSA-L,C(=O)([O-])[O-].[Mg+2],.,CMgO3,.,.
D0969,Magnesium chloride,643991,"MFCD00149781; Cl2Mg.6H2O; Magnesiumchloridehexahydrate; DSSTox_CID_789; Magnesium chloride hexahydrate (MgCl2.6H2O); dichloromagnesium hexahydrate; DSSTox_RID_75789; DSSTox_GSID_20789; Magnesium chloride (JAN/USP); Tox21_200246; 1843AH; 8316AF; AKOS015902790; Magnesium chloride (MgCl2), hexahydrate; NCGC00257800-01; CAS-7791-18-6; Magnesium chloride hexahydrate, AR, >=99%; Magnesium chloride hexahydrate, LR, >=98%; D04834; Magnesium chloride hexahydrate, BioXtra, >=99.0%; Magnesium chloride hexahydrate, BP, Ph. Eur. grade; Magnesium chloride hexahydrate, Cell Culture Reagent; Magnesium chloride hexahydrate, Molecular biology grade; Magnesium chloride hexahydrate, 99.999% (metals basis); Magnesium chloride hexahydrate, 99.995% trace metals basis; Magnesium chloride hexahydrate, ACS reagent, 99.0-102.0%; Magnesium chloride hexahydrate, BioUltra, >=99.0% (KT); Magnesium chloride hexahydrate, p.a. plus, 98.0-101.0%; Magnesium chloride hexahydrate, ReagentPlus(R), >=99.0%; Magnesium chloride hexahydrate, SAJ first grade, >=98.0%; Magnesium chloride hexahydrate, tested according to Ph.Eur.; Magnesium chloride hexahydrate, JIS special grade, >=98.0%; Magnesium chloride hexahydrate, meets USP testing specifications; Magnesium chloride hexahydrate, Vetec(TM) reagent grade, 98%; Magnesium chloride hexahydrate, Reag. Ph. Eur., USP, 99.0-101.0%, FCC; Magnesium chloride, United States Pharmacopeia (USP) Reference Standard; Magnesium chloride hexahydrate, BioUltra, for molecular biology, >=99.0% (KT); Magnesium chloride hexahydrate, BioReagent, suitable for cell culture, suitable for insect cell culture; Magnesium chloride hexahydrate, puriss., meets analytical specification of Ph. Eur., BP, FCC, E511, 99-101%, <=0.0001% Al",Minerals And Electrolytes,Small molecule,InChI=1S/2ClH.Mg.6H2O/h2*1H;;6*1H2/q;;+2;;;;;;/p-2,DHRRIBDTHFBPNG-UHFFFAOYSA-L,O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-],.,Cl2H12MgO6,.,.
D0970,Magnesium citrate,6099959,"Trimagnesium dicitrate; MAGNESIUM CITRATE; 3344-18-1; Trimagnesium citrate; UNII-RHO26O1T9V; magnesium dicitrate; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (2:3); 7779-25-1; RHO26O1T9V; Magnesium citrate, Mg3(C6H5O7)2; trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate; Trimagnesiumdicitrat; MAGNESIUMCITRATE; NSC-83517; Magnesium citrate (VAN); Magnesium citrate [USP]; Magnesium citrate (3:2); Trimagnesiumdicitrate; EINECS 222-093-9; Tectlol (TN); NSC 83517; Tri Magnesium Citrate; EC 222-093-9; Magnesium citrate (JAN/USP); C12H10Mg3O14; CHEMBL3989480; CHEBI:131391; DTXSID601015151; AKOS028109620; DB11110; H259; DB-048405; Citric acid, magnesium salt (2:3) (8CI); FT-0628080; FT-0628081; D03265; Q4177438; magnesium 2-hydroxypropane-1,2,3-tricarboxylate (3/2); 1,2,3-Propanetricarboxylic acid, hydroxy-, magnesium salt (2:3); 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (2:3) (9CI); Citric acid, magnesium salt (2:3),  Citric acid, magnesium salt (2:3) (8CI),  EINECS 222-093-9,  LS-121081,  MAGNESIUM CITRATE,  Magnesium citrate (3:2),  Magnesium citrate, Mg3(C6H5O7)2,  Magnesium; MAGNESIUM CITRATE,  Magnesium citrate (3:2),  Magnesium citrate, Mg3(C6H5O7)2,  Magnesium citrate [USAN],  Magnesium citrate (VAN),  NSC 83517,  Trimagnesiumdicitrat,  Trimagnesium dicitrate",Minerals And Electrolytes,Small molecule,"1S/2C6H8O7.3Mg/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6",PLSARIKBYIPYPF-UHFFFAOYSA-H,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Mg+2].[Mg+2].[Mg+2],3344-18-1,C12H10Mg3O14,131391,BA00: Essential hypertension
D0971,Magnesium gluconate,11418570,"Magnesium gluconate; 3632-91-5; D-Gluconic acid, magnesium salt (2:1); Magnesium gluconate anhydrous; Almora; UNII-TH52F4317B; 17140-79-3; TH52F4317B; magnesium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Magnesium gluconate hydrate; Glucomag; Glucosium; Menesia; GYN; Magnesium digluconate; Magnesium D-gluconate (1:2); EINECS 222-848-2; magnesium (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Magnesium(II) Gluconate; Gluconic acid, magnesium salt (2:1), D-; SCHEMBL24660; Bis(D-gluconic acid) magnesium; CHEMBL2107145; DTXSID50890579; Gluconic Acid Magnesium(II) Salt; AKOS025310186; AS-17666; G0276; H11318; Q6731392",Minerals And Electrolytes,Small molecule,"InChI=1S/2C6H12O7.Mg/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",CTUVIUYTHWPELF-IYEMJOQQSA-L,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Mg+2],.,C12H22MgO14,.,.
D0972,Magnesium glycinate,84645,"magnesium 2-aminoacetate; MAGNESIUM GLYCINATE; 14783-68-7; Bis(glycinato-N,O)magnesium; Magnesium diglycinate; magnesium;2-aminoacetate; UNII-IFN18A4Y6B; IFN18A4Y6B; C4H8MgN2O4; Magnesium glycinate [USAN]; EINECS 238-852-2; Glycine, magnesuim salt; SCHEMBL33936; DTXSID90163815; AMY37022; AKOS015915000; DB11189; AS-17715; Magnesium,bis(glycinato)- (6CI,7CI,8CI); FT-0656603; V1500; Q19597808",Minerals And Electrolytes,Small molecule,"InChI=1S/2C2H5NO2.Mg/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2",AACACXATQSKRQG-UHFFFAOYSA-L,C(C(=O)[O-])N.C(C(=O)[O-])N.[Mg+2],.,C4H8MgN2O4,.,.
D0973,Magnesium hydroxide,14791,"Magnesium dihydroxide; Nemalite; magnesium;dihydroxide; 1317-43-7; Milmag; Magnesiamaito; Reachim; Versamag; Duhor; Brucite (Mg(OH)2); Magmesia hydrate; Kyowamag F; Hydrofy N; Marinco H; Duhor N; Hydro-mag MA; Ebson RF; FloMag H; MagneClear 58; Di-Gel; FloMag HUS; Kisuma 5; Kisuma 5A; Kisuma 5B; Kisuma 5E; Combustrol 500; Haley's MO; Kisuma 4AF; Kisuma 5BG; Mint-O-Mag; Baschem 12; Magnifin H 10; Kisuma 5B-N; Kisuma 78; Kisuma S 4; Alcanex NHC 25; Hydrofy G 1.0; Hydrofy G 1.5; Hydrofy G 2.5; Magnesium Hydroxide Nanoparticles / Nanopowder; Lycal 96 HSE; Mag Chem MH 10; Magnesium hydroxide gel; Marinco H 1241; Martinal VPF 8812; H2MgO2; Phillips magnesia tablets; Star 200; Asahi Glass 200-06; Magnesium oxide (Mg(OH)2); CCRIS 3342; CCRIS 6159; HSDB 659; KX 8S(A); KX 8S(B); Ki 22-5B; Phillips milk of magnesia liquid; DSB 100; EINECS 215-170-3; EINECS 215-274-9; DP 393; Milmag (TN); S/G 84; Mint-o-mag (TN); Magnesium Hydroxide, powder; 200-06H; Magnesium Hydroxide Nanopowder; Magnesia, (Milk of) (USP); C16H17KN2O4S; Magnesium hydroxide (JAN/USP); Magnesium hydroxide [USP:JAN]; CS-B1709; Magnesium hydroxide, BioXtra, >=95%; Magnesium hydroxide, reagent grade, 95%; Magnesium hydroxide, 95.00-100.50%; Magnesium hydroxide, Vetec(TM) reagent grade; D00731; EC 215-170-3; Magnesium hydroxide, BioUltra, >=99.0% (KT); Magnesium hydroxide, SAJ first grade, >=95.0%; Magnesium hydroxide, United States Pharmacopeia (USP) Reference Standard; Magnesium hydroxide, nanopowder, <100 nm particle size (laser PSA), 99.8% trace metals basis",Antacids/Laxatives,Small molecule,InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2,VTHJTEIRLNZDEV-UHFFFAOYSA-L,[OH-].[OH-].[Mg+2],.,H2MgO2,.,.
D0974,Magnesium oxide,14792,"1309-48-4; Magnesia; oxomagnesium; Periclase; Magnesium oxide (MgO); Seawater magnesia; Magnesium oxide fume; Heavy magnesium oxide; Uro-Mag; 1317-74-4; Magnesium oxide, heavy; MFCD00011109; Magnesium oxide, -325 mesh; Magnesia grooves; Causmag; Granmag; Maglite; Seasorb; Animag; Magcal; Marmag; Oxymag; Heavy magnesia; Light magnesia; BayMag; Maglite de; Calcined brucite; Magnesa preprata; Akro-mag; Liquimag A; Liquimag B; Calcined magnesia; Caustic magnesite; Maglite D; Maglite K; Maglite S; Maglite Y; Magnesia monoxide; Anscor P; Hamag LP; Magox OP; FloMag HP; Fert-O-Mag; Kyowamag 20; Kyowamag 30; Kyowamag 40; Kyowamag 60; Elastomag 100; Elastomag 170; FloMag HP-ER; Kyowamag 100; Kyowamag 150; Kyowamag 150B; Kyowaway 150; Kyowaad 100; Luvatol MK 35; Magchem 100; Magox 85; Magox 90; Magox 95; Magox 98; Mag Chem 10; Mag Chem 35; Heavy calcined magnesia; Mag Chem 200AD; KM 3 (oxide); KMACH-F; Mag Chem 200D; FMR-PC; Magnesium oxide, p.a., 95.0%; HP 10 (oxide); Magmilax bolus; Magnezu tlenek; 100A (oxide); Magnezu tlenek [Polish]; Mag Chem 10-40; AM 2 (cement additive); Mag Chem 10-200; Mag Chem 10-325; Magnesium oxide substrate, 10x10x0.5mm, polished one side, 100 orientation; Magnesium oxide substrate, 10x10x0.5mm, polished one side, 110 orientation; Periclase (MgO); CCRIS 3659; Magnesium oxide, fume; HSDB 1652; SLO 369; SLO 469; KM 40; EINECS 215-171-9; KMB 100-200; Magnesium oxide [USP:JAN]; Magnesii oxidum; Maox; Magnesia oxydata; Calcined magnesite; MgO Nanoparticles; Mag-Ox; Magnesium oxide (fume), Inhalable; Magmitt (TN); Light magnesium oxide; Magnesium oxide heavy; Magnesium oxide, CP; Magnesium (as oxide); Magnesium oxide, light; Magnesium oxide (fume); Magnesium oxide, 97%; Magnesium Oxide nanowire; Magnesium Oxide DC USP; Magnesium Oxide Dispersion; Magnesium Oxide Nanopowder; Magnesium oxide ACS Reagent; Magnesium Oxide DC Granular; Nano Magnesium Oxide Powder; Magnesium Oxide Light, USP; Magnesium oxide, Respirable dust and fume, as Mg; Magnesium oxide (JP17/USP); Magnesium oxide, light, 95%; Active Magnesium Oxide RA 40; INS NO.530; CHEMBL1200572; DTXSID9049665; Active Magnesium Oxide RA 110; Active Magnesium Oxide RA 150; INS-530; Magnesium Oxide-Technical Grade KP; Light Active Magnesium Oxide RA 70; Magnesium Oxide Powder,  99% Nano; Magnesium oxide, ACS reagent, 97%; NSC761263; Magnesium Oxide Powder,>= 99% Nano; NSC-761263; Pharmaceutical Grade Magnesium Oxide HA4; E530; Magnesium Oxide (MgO) Sputtering Targets; Magnesium Oxide Single Crystal Substrates; Magnesium oxide, -10-+50 mesh, 98%; Magnesium oxide, Vetec(TM) reagent grade; Magnesium Oxide Nanoparticles / Nanopowder; Magnesium oxide, 99.995% (metals basis); E-530; FT-0628095; Magnesium Oxide Special Industrial Grade SIG; Magnesium oxide, 99.99% trace metals basis; Active Pharmaceutical Magnesium Oxide PHRA50; Magnesium Oxide Reactive Technical Grade KPLL; Magnesium oxide, SAJ first grade, >=96.0%; Magnesium oxide, SAJ first grade, >=98.0%; D01167; Magnesium oxide, >=99.99% trace metals basis; Magnesium oxide, 2 part ceramic adhesive paste; Magnesium oxide, SAJ special grade, >=99.0%; Pharmaceutical Magnesium Oxide Grade HA and HA5; Magnesium oxide, >26% in a non hazardous diluent; Magnesium oxide, fused, 150-325 mesh, >=95%; Q214769; Magnesium oxide, tested according to Ph.Eur., heavy; Magnesium oxide, >=99% trace metals basis, -325 mesh; Magnesium oxide, nanopowder, <50 nm particle size (BET); Magnesium oxide, BioUltra, >=97.0% (calcined substance, KT); Magnesia sticks, for pearl-tests, package of 100 magnesia sticks; Magnesia sticks, for pearl-tests, package of 25 magnesia sticks; Magnesium oxide, fused, chips, -4 mesh, 99.9% trace metals basis; Magnesium oxide substrate, 10x10x0.5mm, polished one side, 111 orientation; Magnesium oxide substrate, 10x10x1mm, polished one side, 100 orientation; Magnesium oxide substrate, 10x10x1mm, polished one side, 110 orientation; Magnesium oxide substrate, 10x10x1mm, polished two sides, 100 orientation; Magnesium oxide, puriss. p.a., >=98.0% (based on calcined substance, KT); Magnesium oxide, purum, >=97.0% (based on calcined substance, KT), light; Magnesia Rectangular Plate,Length (mm), 105,Width (mm), 50,Thickness (mm), 10; Magnesia Rectangular Plate,Length (mm), 145,Width (mm), 70,Thickness (mm), 15; Magnesium oxide Crucible, Cylindrical, Flat Base, HtxOD (mm), 37x20, Vol (ml), 5; Magnesium oxide Crucible, Cylindrical, Flat Base, HtxOD (mm), 43x24, Vol (ml), 10; Magnesium oxide Crucible, Cylindrical, Flat Base, HtxOD (mm), 90x45, Vol (ml), 100; Magnesium Oxide Crucible, Cylindrical, Flat Base,OD (mm), 25,Height (mm), 25; Magnesium Oxide Crucible, Cylindrical, Flat Base,OD (mm), 32,Height (mm), 32; Magnesium Oxide Crucible, Cylindrical, Flat Base,OD (mm), 44,Height (mm), 44; Magnesium Oxide Crucible, Cylindrical, Flat Base,OD (mm), 76,Height (mm), 76; Magnesium Oxide Rectangular Tray,Length (mm), 100,Width (mm), 100,Height (mm), 25.4; Magnesium Oxide Rectangular Tray,Length (mm), 100,Width (mm), 25,Height (mm), 12.7; Magnesium Oxide Rectangular Tray,Length (mm), 100,Width (mm), 50,Height (mm), 12.7; Magnesium Oxide Rectangular Tray,Length (mm), 150,Width (mm), 100,Height (mm), 25.4; Magnesium Oxide Rectangular Tray,Length (mm), 150,Width (mm), 75,Height (mm), 25.4; Magnesium Oxide Rectangular Tray,Length (mm), 50,Width (mm), 50,Height (mm), 12.7; Magnesium Oxide Rectangular Tray,Length (mm), 75,Width (mm), 75,Height (mm), 25.4; Magnesium oxide sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick; Magnesium oxide sputtering target, 50.8mm (2.0in) dia x 6.35mm (0.250in) thick; Magnesium oxide sputtering target, 76.2mm (3.0in) dia x 3.18mm (0.125in) thick; Magnesium oxide sputtering target, 76.2mm (3.0in) dia x 6.35mm (0.250in) thick; Magnesium oxide substrate, 10x10x0.5mm, polished two sides, 100 orientation; Magnesium oxide, puriss. p.a., ACS reagent, >=97% (calcined substance, KT); Magnesium oxide, (single crystal substrate), <111>, >=99.9% trace metals basis, L x W x thickness 10 mm x 10 mm x 0.5 mm; Magnesium oxide, (single crystal substrate), >=99.9% trace metals basis, <100>, L x W x thickness 10 mm x 10 mm x 0.5 mm; Magnesium oxide, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E 530, light, 98.0-100.5% (calc. for dried substance)",Minerals And Electrolytes,Small molecule,InChI=1S/Mg.O,CPLXHLVBOLITMK-UHFFFAOYSA-N,O=[Mg],.,MgO,.,.
D0975,Magnesium sulfate,24083,"Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt",Analgesics,Small molecule,"1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",CSNNHWWHGAXBCP-UHFFFAOYSA-L,[O-]S(=O)(=O)[O-].[Mg+2],7487-88-9,MgO4S,32599,MG31: Acute pain
D0976,Manganese (chloride),23930,"7439-96-5; Manganese; Mn; Colloidal manganese; Mangan; Manganese, elemental; Manganese metal alloy; Manganese fume; manganide; Manganese metal; UNII-42Z2K6ZL8P; manganese(4+); Manganese(1-); Manganese, ion (Mn1-); MANGANESE (II) ION; 42Z2K6ZL8P; Manganese powder; MFCD00011111; Cutaval; Magnacat; Tronamang; Mangan [Polish]; MANGANESE COMPOUNDS; Manganese powder, -325 mesh; manganeso; Teprosyn M; Manganese element; Mangan nitridovany; Mangan nitridovany [Czech]; Manganese-55; Manganese(4 ); Manganese(7+); CCRIS 1579; HSDB 550; Manganese ion(4 ); EINECS 231-105-1; Manganese, ion (Mn4 ); MNE 06PB; manganum; manganese atom; Manganese, ion (Mn(7+)); Manganese chips; manganese(0); manganese (IV); manganide(-I); manganese (0); manganide(1-); MN3; manganese(4+) ion; Manganese, 99%; manganese(IV) cation; Manganese fume, as Mn; Manganese fume (as Mn); Mn(IV); Manganese, -200 mesh; 25Mn; EC 231-105-1; Manganese pieces, irregular; Manganese compounds, n.o.s.; Mn(-); Mn(0); Manganese, metal, electrolytic; DTXSID2024169; CHEBI:18291; CHEBI:25158; CHEBI:33011; CHEBI:35154; HSDB 6945; Mn(4+); Manganese powder, APS <10 micron; Manganese nanopowder, APS 30-50nm; Manganese powder, -140+325 mesh; AKOS015833390; Manganese powder, 99.9% (metal basis); Mn4; S618; Manganese pieces, 10mm & down, ultrapure; FT-0689227; Manganese, chips, thickness <2.0 mm, 99%; C00034; Manganese granules, 0.8-3mm (0.03-0.12in); Manganese, powder, >=99.9% trace metals basis; Q27109868; Q27115185; M008000000; Manganese powder , -325 mesh, =99% trace metals basis; Manganese, rod, 10mm, diameter 4.0mm, cast, 99.5%; Manganese, rod, 35mm, diameter 2.0mm, cast, 99.5%; Manganese, rod, 47mm, diameter 2.0mm, cast, 99.5%; Manganese, rod, 50mm, diameter 4.0mm, cast, 99.5%; Manganese, rod, 50mm, diameter 6.35mm, cast, 99.5%; Manganese, flake, 25 mm, weight 100 g, purity 99.95%; Manganese, flake, 25 mm, weight 50 g, purity 99.95%; Manganese, flake, weight 200 g, 25 mm, purity 99.95%; Manganese, plasma standard solution, Specpure, Mn 10g/ml; Manganese, powder, -325 mesh, >=99% trace metals basis; Manganese, AAS standard solution, Specpure?, Mn 1000?g/ml; Manganese, Oil based standard solution, Specpure, Mn 5000g/g; Manganese, plasma standard solution, Specpure?, Mn 1000?g/ml; Manganese, foil, 25x25mm, thickness 2mm, hot-pressed, 99.95%; Manganese, foil, 50x50mm, thickness 2mm, hot-pressed, 99.95%; Manganese, Oil based standard solution, Specpure?, Mn 1000?g/g; Manganese, plasma standard solution, Specpure?, Mn 10,000?g/ml; Manganese, rod, 2.0 mm diameter, length 52 mm, purity 99.5%; Manganese, rod, length 25 mm, 2.0 mm diameter, purity 99.5%; Manganese standard for AAS, ready-to-use, traceable to BAM, in nitric acid; Manganese, foil, thickness 0.016 mm, size 25 x 25 mm, purity 98.7%; Manganese, foil, thickness 0.016 mm, size 50 x 50 mm, purity 98.7%; Manganese sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick; Manganese sputtering target, 50.8mm (2.0in) dia x 6.35mm (0.250in) thick; Manganese sputtering target, 76.2mm (3.0in) dia x 3.18mm (0.125in) thick; Manganese sputtering target, 76.2mm (3.0in) dia x 6.35mm (0.250in) thick; Manganese standard for IC, certified reference material, ready-to-use, traceable to BAM; Manganese standard for ICP, for ICP, ready-to-use, traceable to BAM, in nitric acid; Manganese, powder, 300 max. part. size (micron), weight 1000 g, purity 99.5%; Manganese, powder, 300 max. part. size (micron), weight 2000 g, purity 99.5%; Manganese, powder, 45 max. part. size (micron), weight 2000 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 100 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 200 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 500 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 100 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 1000 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 200 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 500 g, purity 99.5%; Manganese, foil, not light tested, 100x100mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.001mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.0025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.002mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.003mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.004mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.005mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.006mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.007mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.008mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.009mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.05mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.001mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.0025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.002mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.003mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.004mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.005mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.006mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.007mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.008mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.009mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.05mm, permanent polyester support, 98.7%",Minerals And Electrolytes,Small molecule,InChI=1S/Mn,PWHULOQIROXLJO-UHFFFAOYSA-N,[Mn],.,Mn,.,.
D0977,Manganese (sulfate),23930,"7439-96-5; Manganese; Mn; Colloidal manganese; Mangan; Manganese, elemental; Manganese metal alloy; Manganese fume; manganide; Manganese metal; UNII-42Z2K6ZL8P; manganese(4+); Manganese(1-); Manganese, ion (Mn1-); MANGANESE (II) ION; 42Z2K6ZL8P; Manganese powder; MFCD00011111; Cutaval; Magnacat; Tronamang; Mangan [Polish]; MANGANESE COMPOUNDS; Manganese powder, -325 mesh; manganeso; Teprosyn M; Manganese element; Mangan nitridovany; Mangan nitridovany [Czech]; Manganese-55; Manganese(4 ); Manganese(7+); CCRIS 1579; HSDB 550; Manganese ion(4 ); EINECS 231-105-1; Manganese, ion (Mn4 ); MNE 06PB; manganum; manganese atom; Manganese, ion (Mn(7+)); Manganese chips; manganese(0); manganese (IV); manganide(-I); manganese (0); manganide(1-); MN3; manganese(4+) ion; Manganese, 99%; manganese(IV) cation; Manganese fume, as Mn; Manganese fume (as Mn); Mn(IV); Manganese, -200 mesh; 25Mn; EC 231-105-1; Manganese pieces, irregular; Manganese compounds, n.o.s.; Mn(-); Mn(0); Manganese, metal, electrolytic; DTXSID2024169; CHEBI:18291; CHEBI:25158; CHEBI:33011; CHEBI:35154; HSDB 6945; Mn(4+); Manganese powder, APS <10 micron; Manganese nanopowder, APS 30-50nm; Manganese powder, -140+325 mesh; AKOS015833390; Manganese powder, 99.9% (metal basis); Mn4; S618; Manganese pieces, 10mm & down, ultrapure; FT-0689227; Manganese, chips, thickness <2.0 mm, 99%; C00034; Manganese granules, 0.8-3mm (0.03-0.12in); Manganese, powder, >=99.9% trace metals basis; Q27109868; Q27115185; M008000000; Manganese powder , -325 mesh, =99% trace metals basis; Manganese, rod, 10mm, diameter 4.0mm, cast, 99.5%; Manganese, rod, 35mm, diameter 2.0mm, cast, 99.5%; Manganese, rod, 47mm, diameter 2.0mm, cast, 99.5%; Manganese, rod, 50mm, diameter 4.0mm, cast, 99.5%; Manganese, rod, 50mm, diameter 6.35mm, cast, 99.5%; Manganese, flake, 25 mm, weight 100 g, purity 99.95%; Manganese, flake, 25 mm, weight 50 g, purity 99.95%; Manganese, flake, weight 200 g, 25 mm, purity 99.95%; Manganese, plasma standard solution, Specpure, Mn 10g/ml; Manganese, powder, -325 mesh, >=99% trace metals basis; Manganese, AAS standard solution, Specpure?, Mn 1000?g/ml; Manganese, Oil based standard solution, Specpure, Mn 5000g/g; Manganese, plasma standard solution, Specpure?, Mn 1000?g/ml; Manganese, foil, 25x25mm, thickness 2mm, hot-pressed, 99.95%; Manganese, foil, 50x50mm, thickness 2mm, hot-pressed, 99.95%; Manganese, Oil based standard solution, Specpure?, Mn 1000?g/g; Manganese, plasma standard solution, Specpure?, Mn 10,000?g/ml; Manganese, rod, 2.0 mm diameter, length 52 mm, purity 99.5%; Manganese, rod, length 25 mm, 2.0 mm diameter, purity 99.5%; Manganese standard for AAS, ready-to-use, traceable to BAM, in nitric acid; Manganese, foil, thickness 0.016 mm, size 25 x 25 mm, purity 98.7%; Manganese, foil, thickness 0.016 mm, size 50 x 50 mm, purity 98.7%; Manganese sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick; Manganese sputtering target, 50.8mm (2.0in) dia x 6.35mm (0.250in) thick; Manganese sputtering target, 76.2mm (3.0in) dia x 3.18mm (0.125in) thick; Manganese sputtering target, 76.2mm (3.0in) dia x 6.35mm (0.250in) thick; Manganese standard for IC, certified reference material, ready-to-use, traceable to BAM; Manganese standard for ICP, for ICP, ready-to-use, traceable to BAM, in nitric acid; Manganese, powder, 300 max. part. size (micron), weight 1000 g, purity 99.5%; Manganese, powder, 300 max. part. size (micron), weight 2000 g, purity 99.5%; Manganese, powder, 45 max. part. size (micron), weight 2000 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 100 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 200 g, purity 99.5%; Manganese, powder, max. particle size 300 micron, weight 500 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 100 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 1000 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 200 g, purity 99.5%; Manganese, powder, max. particle size 45 micron, weight 500 g, purity 99.5%; Manganese, foil, not light tested, 100x100mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 100x100mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.001mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.0025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.002mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.003mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.004mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.005mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.006mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.007mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.008mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.009mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 25x25mm, thickness 0.05mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.001mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.0025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.002mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.003mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.004mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.005mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.006mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.007mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.008mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.009mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.0125mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.015mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.01mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.025mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.02mm, permanent polyester support, 98.7%; Manganese, foil, not light tested, 50x50mm, thickness 0.05mm, permanent polyester support, 98.7%",Minerals And Electrolytes,Small molecule,InChI=1S/Mn,PWHULOQIROXLJO-UHFFFAOYSA-N,[Mn],.,Mn,.,.
D0978,Mannitol,6251,"Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol",Sweetening Agents,Small molecule,"1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1",FBPFZTCFMRRESA-KVTDHHQDSA-N,C(C(C(C(C(CO)O)O)O)O)O,69-65-8,C6H14O6,16899,CA24: Bronchiectasis; GB60-GB6Z: Kidney failure
D0979,Maprotiline,4011,"Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine",Antidepressants,Small molecule,"1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3",QSLMDECMDJKHMQ-UHFFFAOYSA-N,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,10262-69-8,C20H23N,6690,6A70-6A7Z: Depression
D0980,Maraviroc,3002977,"376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc",Anti-Hiv Agents,Small molecule,"1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1",GSNHKUDZZFZSJB-HLMSNRGBSA-N,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,376348-65-1,C29H41F2N5O,63608,1C60-1C62: Human immunodeficiency virus disease; CA22: Chronic obstructive pulmonary disease
D0981,Mazindol,4020,"mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547;  Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol",Cns Stimulants,Small molecule,"1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2",ZPXSCAKFGYXMGA-UHFFFAOYSA-N,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,22232-71-9,C16H13ClN2O,6702,5B80-5B81: Obesity
D0982,Mebendazole,4030,"Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester",Antinematodal Agents,Small molecule,"1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)",OPXLLQIJSORQAM-UHFFFAOYSA-N,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,31431-39-7,C16H13N3O3,6704,1F90: Parasitic worm infestation
D0983,Mecamylamine,4032,"Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane",Antihypertensive Agents,Small molecule,"1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3",IMYZQPCYWPFTAG-UHFFFAOYSA-N,CC1(C2CCC(C2)C1(C)NC)C,60-40-2,C11H21N,6706,BA00: Essential hypertension
D0984,Mecasermin,.,Increlex (TN),Insulin-Like Growth Factors,Hormones,.,.,.,.,.,.,LD2F: Multiple structural anomalies syndrome
D0985,Mecasermin rinfabate,.,DB14751; Mecasermin rinfabate; Mecasermin rinfabate recombinant; rhIGF-I/rhIGFBP-3,Insulin-Like Growth Factors,Hormones,.,.,.,.,.,.,.
D0986,Mechlorethamine,4033,"Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine",Antineoplastics,Small molecule,"1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3",HAWPXGHAZFHHAD-UHFFFAOYSA-N,CN(CCCl)CCCl,51-75-2,C5H11Cl2N,28925,2A90: Mature T-cell lymphoma; 2B30: Hodgkin lymphoma
D0987,Meclizine,4034,Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine,Antiallergic Agents,Small molecule,"1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3",OCJYIGYOJCODJL-UHFFFAOYSA-N,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,569-65-3,C25H27ClN2,6709,MB48: Dizziness and giddiness
D0988,Meclofenamic acid,4037,"Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid",Analgesics,Small molecule,"1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)",SBDNJUWAMKYJOX-UHFFFAOYSA-N,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,644-62-2,C14H11Cl2NO2,6710,FA92: Inflammatory spondyloarthritis; ME82: Joint pain
D0989,Mecobalamin,10898559,Methycobal; Methycobal S; E-0302,Vitamins,Small molecule,"1S/C62H90N13O14P.CH3.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);1H3;/q;-1;+3/p-2/t31?,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1",ZFLASALABLFSNM-WYVZQNDMSA-L,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3],13422-55-4,C63H91CoN13O14P,.,3A00-3A9Z: Anemia
D0990,Medroxyprogesterone acetate,6279,"Medroxyprogesterone acetate; Medroxyprogesterone 17-acetate; 71-58-9; Provera; Metigestrona; Farlutin; Gestapuran; Perlutex; Veramix; Methylacetoxyprogesterone; Medroxyacetate progesterone; Depo-Provera; Depcorlutin; Deporone; Lutopolar; Nadigest; Prodasone; Progestalfa; Progevera; Proverone; Repromix; Sirprogen; Supprestral; Lutoral; Nidaxin; Oragest; Depo-Promone; Promone-E; 6-alpha-Methyl-17-alpha-acetoxyprogesterone; Medroxyprogesteroneacetate; NSC-26386; 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate; 17alpha-Hydroxy-6alpha-methylprogesterone acetate; 6alpha-Methyl-17alpha-hydroxyprogesterone acetate; Amen; 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate; Depot medroxyprogesterone acetate; Depot-medroxyprogesterone acetate; UNII-C2QI4IOI2G; DP150; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-; 17-Acetoxy-6alpha-methylprogesterone; Aragest; Clinovir; Ralovera; 6alpha-Methyl-17-acetoxy progesterone; Hysron; Provera dosepak; Depo-clinovir; Depo-Ralovera; (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate; U 8839; C2QI4IOI2G; Medroxyprogesterone (acetate); Medroxyprogesterone-17-acetate; MLS000069442; (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; CHEBI:6716; ONCO-Provera; NSC-21171; Medrosterona; Clinofem; Cykrina; Depocon; Indivina; Mepastat; Meprate; Repromap; SMR000059125; Sumiferm; Suprestral; Veraplex; Dugen; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-; Depo-progestin; Depo-Prodasone; Depo-Progevera; Perlutex Leo; DSSTox_CID_5527; Depo-Map; Aragest 5; Med-Pro; MPA-beta; DSSTox_RID_77819; MPA Hexal; MPA-Noury; DSSTox_GSID_25527; [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; MAP (steroid); 17alpha-Acetoxy-6alpha-methylprogesterone; Depomedroxyprogesterone acetate; MPA GYM; Depo-Medroxyprogesterone acetate; Depo-subq provera; CAS-71-58-9; CCRIS 371; 17.alpha.-Acetoxy-6.alpha.-methylprogesterone; EINECS 200-757-9; 6alpha-Methyl-17-acetoxyprogesterone; NSC 21171; Depo-Provera Contraceptive; 17-Acetoxy-6-alpha-methylprogesterone; (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; 17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate; Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate; 6-alpha-Methyl-17-acetoxy progesterone; BRN 2066112; Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-; AI3-60127; 17-Acetoxy-6.alpha.-methylprogesterone; 6.alpha.-Methyl-17-acetoxyprogesterone; Farlutal inyectable; NCGC00094713-01; 17alpha-Hydroxy-6-alpha-methylprogesterone acetate; Progesterone, 17-hydroxy-6alpha-methyl-, acetate; 17-alpha-Hydroxy-6-alpha-methylprogesterone acetate; Provera (TN); Depo-provera (TN); 6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione; Medroxyprogesterone acetate [USP:JAN]; 17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione; 6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione; Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate; Medroxyprogesterone acetate [Progestins]; 6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate; 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone; (6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate; 6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; CPD000653524; 17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate; Medroxyprogesteroni acetas; Opera_ID_1110; medroxyprogesterone-acetate; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate; Medroxiprogesterone Acetate; CHEMBL717; SCHEMBL4276; 6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione; 17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione; 4-08-00-02212 (Beilstein Handbook Reference); 6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate; MLS001148217; MLS002207115; 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate; Depo-subq provera 104 (TN); DTXSID0025527; G03AC06; HMS2233O07; HMS2235E05; HMS3259O14; HMS3884B10; (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; (6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CBP-1011; HY-B0469; NSC21171; NSC26386; ZINC5029557; Tox21_111319; Tox21_200141; BDBM50067678; s2567; AKOS015894870; Tox21_111319_1; AC-2174; CCG-264965; DB00603; NC00574; Medroxyprogesterone acetate (JP17/USP); MRF-0000023; NCGC00022037-03; NCGC00022037-04; NCGC00022037-05; NCGC00022037-07; NCGC00257695-01; NCGC00263480-01; AS-13981; I028; SMR000653524; TV-46046; C08150; C76275; D00951; AB00384270-14; AB00384270_15; Medroxyprogesterone 17-acetate, >=97% (HPLC); 010M483; Q2823834; (6?)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate; 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; Medroxyprogesterone-17-acetate 100 microg/mL in Acetonitrile; Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard; Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard; Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate (8CI); Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard; Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard; Medroxyprogesterone acetate, for performance test, European Pharmacopoeia (EP) Reference Standard",Contraceptives/Hormones/Antineoplastics,Small molecule,"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1",PSGAAPLEWMOORI-PEINSRQWSA-N,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,.,C24H34O4,.,.
D0991,Mefenamic acid,4044,"ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid",Antiinflammatory Agents,Small molecule,"1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)",HYYBABOKPJLUIN-UHFFFAOYSA-N,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,61-68-7,C15H15NO2,6717,GA34: Female pelvic pain
D0992,Mefloquine,4046,"Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol",Antimalarial Agents,Small molecule,"1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2",XEEQGYMUWCZPDN-UHFFFAOYSA-N,C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,49752-90-1,C17H16F6N2O,63681,1F40-1F45: Malaria
D0993,Megestrol acetate,11683,"MEGESTROL ACETATE; 595-33-5; Megace; Megace ES; Niagestin; Megestryl acetate; Megeron; Megestat; Ovaban; Ovarid; Maygace; Pallace; Magestin; BDH 1298; SC 10363; NSC-71423; Volidan; SC10363; UNII-TJ2M0FR8ES; 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate; TJ2M0FR8ES; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; SC-10363; MLS000028633; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; BDH1298; BDH-1298; SMR000058691; DSSTox_CID_20683; DSSTox_RID_79539; DSSTox_GSID_40683; Megestil; 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione; Ovaban (Veterinary); 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone; MegestrolAcetate; 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate; (8xi,9xi,10xi,13xi,14xi)-6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; CCRIS 372; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; Megestrol-17-acetate; EINECS 209-864-5; Megestin; Megestrol acetole [Progestins]; Megestrol acetate [USAN:USP]; Megestrol acetole; Megestrol-Acetate; Megesterol acetate; 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone; NCGC00016516-01; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CAS-595-33-5; Megace (TN); 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone; 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone; 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate; 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone; 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone; Megestrol acetate (USP); Opera_ID_1511; Prestwick0_000956; Prestwick1_000956; Prestwick2_000956; Prestwick3_000956; 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate; SCHEMBL745; BSPBio_000952; Megestrol 17.alpha.-acetate; MLS000759501; MLS001074091; MLS001424055; par-100,2; SPBio_003101; BPBio1_001048; CHEBI:6723; CHEMBL1201139; DTXSID9040683; BCPP000168; HMS1570P14; HMS2051I20; HMS2090N04; HMS2097P14; HMS2235D16; HMS3714P14; Nia; NSC71423; ZINC4097467; Tox21_110469; Tox21_302360; LMST02030118; MFCD00056470; s1304; AKOS015894927; Tox21_110469_1; BCP9000904; CCG-100899; CS-2065; DB00351; NC00149; 17-Acetoxy-6-methylpregna-4,20-dione; NCGC00024196-03; NCGC00024196-05; NCGC00255456-01; AC-24570; AS-13384; HY-13676; I040; 17.alpha.-Acetoxy-6-methyl-4,20-dione; AB00490013; B1377; 17-Hydroxy-6-methylpregna-4,20-dione acetate; 17.alpha.-Acetoxy-6-methylpregna-4,20-dione; C08151; D00952; D91560; AB00383046-13; AB00383046-14; AB00383046-15; AB00383046_16; Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-; 595M335; A832354; SR-01000000258; Megestrol-17-acetate 100 microg/mL in Acetonitrile; Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate; Q-201346; Q6808975; SR-01000000258-4; BRD-K19507340-001-03-1; Megestrol acetate, VETRANAL(TM), analytical standard; 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione; Megestrol acetate, analytical standard, for drug analysis; WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1; 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; Megestrol acetate, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate, United States Pharmacopeia (USP) Reference Standard; Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard",Hormones/Antineoplastics,Small molecule,"InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1",RQZAXGRLVPAYTJ-GQFGMJRRSA-N,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,.,C24H32O4,.,.
D0994,Melatonin,896,"73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; 5-Methoxy-N-acetyltryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Melatonex; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; UNII-JL5DK93RCL; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-acetyl-5-methoxy-tryptamine; NSC 113928; CCRIS 3472; CHEMBL45; EINECS 200-797-7; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; BRN 0205542;  Circadin; Melapure; Melatonina; Posidorm; Vivitas; Night Rest; Pineal Hormone; Revital Melatonin; Rx Balance; Sleep Right; IN1244; M 5250; M1105; ML1; MT6; TNP00300; M-1200; M-1250; Mela-T; Melatonex, Melatonin; Melatonina (TN); NMR/14327425; Nature'S Harmony; PREVENTION 2 (MELATONIN); PREVENTION 3 (MELATONIN); PREVENTION 4 (MELATONIN); PREVENTION 5 (MELATONIN); PREVENTION 1 (MELATONIN) (PREVENTION 1); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-(6CI,8CI); N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-(9CI); Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI); 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; [3H]melatonin; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide",Cns Stimulants,Small molecule,"1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",DRLFMBDRBRZALE-UHFFFAOYSA-N,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,73-31-4,C13H16N2O2,16796,7A00-7A0Z: Insomnia
D0995,Meloxicam,54677470,"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica",Nsaids/Analgesics,Small molecule,"1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)",ZRVUJXDFFKFLMG-UHFFFAOYSA-N,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,71125-38-7,C14H13N3O4S2,6741,FA20: Rheumatoid arthritis
D0996,Melphalan,460612,"Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine",Antineoplastics,Small molecule,"1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1",SGDBTWWWUNNDEQ-LBPRGKRZSA-N,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,148-82-3,C13H18Cl2N2O2,28876,2A83: Multiple myeloma; 2C12: Liver cancer
D0997,Melphalan flufenamide,9935639,"J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides",Alkylating Agents,Small molecule,"1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1",YQZNKYXGZSVEHI-VXKWHMMOSA-N,CCOC(=O)C(CC1=CC=C(C=C1)F)NC(=O)C(CC2=CC=C(C=C2)N(CCCl)CCCl)N,380449-51-4,C24H30Cl2FN3O3,.,2C73: Ovarian cancer; 2A83: Multiple myeloma
D0998,Memantine,4054,"Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest",Cholinesterase Inhibitors,Small molecule,"1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3",BUGYDGFZZOZRHP-UHFFFAOYSA-N,CC12CC3CC(C1)(CC(C3)(C2)N)C,19982-08-2,C12H21N,64312,8A20: Alzheimer disease
D0999,Meningococcal polysaccharide vaccine group C,.,DB13890; Meningococcal group C polysaccharide; Meningococcal group CCRM197 conjugate vaccine; Meningococcal polysaccharide antigen group C; Meningococcal polysaccharide vaccine group C; Neisseria meningitidis group C (strain C11) oligosaccharide CRM-197 adipic acid conjugate; Neisseria meningitidis group C capsular polysaccharide antigen,Vaccines,Vaccine,.,.,.,.,.,.,.
D1000,Mepenzolate,4057,"Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide",Parasympatholytics,Small molecule,"1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1",GKNPSSNBBWDAGH-UHFFFAOYSA-N,C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,25990-43-6,C21H26NO3+,94411,DE2Z: Digestive system disease; DA61: Peptic ulcer
D1001,Meperidine,4058,"Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester",Anesthetics,Small molecule,"1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3",XADCESSVHJOZHK-UHFFFAOYSA-N,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,57-42-1,C15H21NO2,6754,MG30-MG3Z: Pain
D1002,Mephentermine,3677,"Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane",Vasoconstrictor Agents,Small molecule,"1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3",RXQCGGRTAILOIN-UHFFFAOYSA-N,CC(C)(CC1=CC=CC=C1)NC,100-92-5,C11H17N,6755,BA00: Essential hypertension
D1003,Mephenytoin,4060,"Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione",Anticonvulsants,Small molecule,"1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)",GMHKMTDVRCWUDX-UHFFFAOYSA-N,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,18601,C12H14N2O2,6757,8A61-8A6Z: Epilepsy/seizure
D1004,Mepivacaine,4062,"Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE",Anesthetics,Small molecule,"1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)",INWLQCZOYSRPNW-UHFFFAOYSA-N,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,96-88-8,C15H22N2O,6759,MB40: Sensation disturbance
D1005,Meprobamate,4064,"meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas;  Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455",Antianxiety Agents,Small molecule,"1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)",NPPQSCRMBWNHMW-UHFFFAOYSA-N,CCCC(C)(COC(=O)N)COC(=O)N,57-53-4,C9H18N2O4,6761,1F40-1F45: Malaria; 6B00-6B0Z: Anxiety disorder; DB98: Liver vascular disorder
D1006,Mepyramine,4992,"Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine",Antiasthmatic Agents,Small molecule,"1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3",YECBIJXISLIIDS-UHFFFAOYSA-N,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,91-84-9,C17H23N3O,6762,4A80-4A8Z: Allergic/hypersensitivity disorder
D1007,Mercaptopurine,667490,"6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)",Antineoplastics,Small molecule,"1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",GLVAUDGFNGKCSF-UHFFFAOYSA-N,C1=NC2=C(N1)C(=S)N=CN2,50-44-2,C5H4N4S,2208,2A85: Mature B-cell lymphoma; DD70: Crohn disease
D1008,Meropenem,441130,"MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid",Antibiotics,Small molecule,"1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1",DMJNNHOOLUXYBV-PQTSNVLCSA-N,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O,96036-03-2,C17H25N3O5S,43968,1A00-1C4Z: Bacterial infection
D1009,Mesalazine,4075,"Apriso; Asacol; Asacolitin; Asacolon; Asalit; Ascolitin; Canasa; Claversal; Fisalamine; Fivasa; Iialda; Ipocol; Lialda; Lixacol; Mesacol; Mesalamine; Mesalazina; Mesalazinum; Mesasal; Mesavance; Mesavancol; Mezavant; Pentacol; Pentasa; Rowasa; Salofalk; Salozinal; SfRowasa; Allphar Brand of Mesalamine; Antigen Brand of Mesalamine; Asacol HD; Axcan Brand of Mesalamine; Byk Brand of Mesalamine; Celltech Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Ferring Brand of Mesalamine; GlaxoSmithKline Brand of Mesalamine; Henning Berlin Brand of Mesalamine; M Aminosalicylic Acid; Merckle Brand of Mesalamine; Mesalamine Hydrochloride; Mesalamine Monosodium Salt; Mesalamine [USAN]; Mesalazina[Spanish]; Mesalazine MMX; Mesalazinum [Latin]; Meta Aminosalicylic Acid; Mezavant XL; Minosalicylic acid; Norgine Brand of Mesalamine; Novopharm Brand of Mesalamine; Provalis Brand of Mesalamine; Sanofi Synthelabo Brand of Mesalamine; Schering Plough Brand of Mesalamine; SmithKline Brand of Mesalamine; Solvay Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Novo 5 ASA; Novo5 ASA; AJG-501; Apriso (TN); Asacol (TN); Canasa (TN); Hydrochloride, Mesalamine; Iialda (TN); Ipocal (TN); Lialda (TN); M-A; M-Aminosalicylic acid; MAX-002; MD-0901; Masacol (TN); Mesalamine (USP); Meta-AminosalicylicAcid; Monosodium Salt, Mesalamine; Novo-5 ASA; P-Aminosalicylsaeure; P-Aminosalicylsaeure [German]; Pentasa (TN); Procter & Gamble Brand of Mesalamine; Rowasa (TN); SPD-476; SPD-480; Salofalk (TN); Salofalk Granu-Stix; Schering-Plough Brand of Mesalamine; Z-206; Mesalazine (JAN/INN); Salicylic acid, 5-amino-(8CI); 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; 5 Aminosalicylate; 5 Aminosalicylic Acid; 5-AS; 5-ASA; 5-Amino-2-hydroxybenzoic acid; 5-Aminosalicylate; 5-Aminosalicylic acid; 5-amino-2-hydroxy-benzoic acid; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine",Antiinflammatory Agents,Small molecule,"1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)",KBOPZPXVLCULAV-UHFFFAOYSA-N,C1=CC(=C(C=C1N)C(=O)O)O,89-57-6,C7H7NO3,6775,DD71: Ulcerative colitis
D1010,Mesoridazine,4078,Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine,Antipsychotic Agents,Small molecule,"1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",SLVMESMUVMCQIY-UHFFFAOYSA-N,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C,5588-33-0,C21H26N2OS2,6780,6A20: Schizophrenia
D1011,Mestranol,6291,"Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol",Estrogens,Small molecule,"1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1",IMSSROKUHAOUJS-MJCUULBUSA-N,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)OC,72-33-3,C21H26O2,6784,QA21: Contraceptive management
D1012,Metamfetamine,10836,"METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine;  Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine",Cns Stimulants,Small molecule,"1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1",MYWUZJCMWCOHBA-VIFPVBQESA-N,CC(CC1=CC=CC=C1)NC,537-46-2,C10H15N,6809,MG30-MG3Z: Pain; 6A05: Attention deficit hyperactivity disorder
D1013,Metaraminol,5906,"Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol",Antihypertensive Agents,Small molecule,"1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1",WXFIGDLSSYIKKV-RCOVLWMOSA-N,CC(C(C1=CC(=CC=C1)O)O)N,54-49-9,C9H13NO2,6794,BA20-BA21: Hypotension
D1014,Metaxalone,15459,Skelaxin,Muscle Relaxants,Small molecule,"1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)",IMWZZHHPURKASS-UHFFFAOYSA-N,CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C,1665-48-1,C12H15NO3,6797,MG30-MG3Z: Pain
D1015,Metformin,4091,"657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin",Antidiabetic Agents,Small molecule,"1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)N=C(N)N,657-24-9,C4H11N5,6801,5A11: Type 2 diabetes mellitus
D1016,Methacholine,1993,"methacholine; Acetylmethylcholine; beta-Methylacetylcholine; Provocholine; 55-92-5; Acetyl-beta-methylcholine; MCH; Mecholin; CHEBI:6804; Methacholin; Mecholin; Mecholine; Methacholinum; UNII-03V657ZD3V; Choline, acetyl-beta-methyl-; BRN 1769932; Methacholine ion; Methacholine cation; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; 03V657ZD3V; Prestwick0_000759; Prestwick1_000759; Prestwick2_000759; Prestwick3_000759; CHEMBL978; cid_6114; Lopac0_000025; SCHEMBL69103; BSPBio_000778; BSPBio_001985; SPBio_002717; BPBio1_000856; GTPL7438; DTXSID2046967; BDBM48918; 2-acetyloxypropyl-trimethylazanium; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); PDSP1_000136; PDSP2_000135; [2-(acetyloxy)propyl]trimethylazanium; CCG-204121; DB06709; MCULE-6246299571; NCGC00015045-03; NCGC00015045-04; NCGC00015045-06; NCGC00015045-13; NCGC00089798-02; 2-acetoxypropyl(trimethyl)ammonium;chloride; SBI-0050014.P003; 2-acetyloxy-N,N,N-trimethylpropan-1-aminium; 2-acetyloxypropyl(trimethyl)ammonium;chloride; C07471; Q413188",Bronchodilators,Small molecule,"InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1",NZWOPGCLSHLLPA-UHFFFAOYSA-N,CC(C[N+](C)(C)C)OC(=O)C,.,C8H18NO2+,.,.
D1017,Methadone,4095,"Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone",Analgesics,Small molecule,"1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3",USSIQXCVUWKGNF-UHFFFAOYSA-N,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,76-99-3,C21H27NO,6807,MD12: Cough
D1018,Methazolamide,4100,"Methazolamide (oral, sustained release)",Carbonic Anhydrase Inhibitors,Small molecule,"1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)",FLOSMHQXBMRNHR-UHFFFAOYSA-N,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,554-57-4,C5H8N4O3S2,6822,9C61: Glaucoma
D1019,Methdilazine,14677,Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine,Antihistamines,Small molecule,"1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3",HTMIBDQKFHUPSX-UHFFFAOYSA-N,CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,1982-37-2,C18H20N2S,6823,CA08: Vasomotor/allergic rhinitis
D1020,Methenamine,4101,Hiprex; Methenamine Hippurate,Urinary Antispasmodics,Small molecule,1S/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2,VKYKSIONXSXAKP-UHFFFAOYSA-N,C1N2CN3CN1CN(C2)C3,100-97-0,C6H12N4,6824,GC08: Urinary tract infection
D1021,Methimazole,1349907,"methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Mercazolyl; 1-Methylimidazole-2-thiol; Thymidazole; Mercazole; Methimazol; Thymidazol; Thiamazol; Metazolo; Thycapzol; Metothyrine; Metothyrin; Merkazolil; Mercaptazole; Strumazol; Favistan; Basolan; Thycapsol; Metotirin; Danantizol; Thacapzol; Merkastan; Frentirox; Metizol; Tiamazol; Mercasolyl; 1-Methyl-1H-imidazole-2-thiol; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; Usaf el-30; Methimazolum; Mercazolylum; Tapuzole; Metimazol; Thimazole;  Basolan; MMZ; Mercazol; Methamazole; Methizol; Methymazol; Metisol; Strumazole; Thiamazole; Thiamazolum; Thimazol; Thyrozol; Tiamazolo; Tirodril; EliLilly Brand of Methimazole; Estedi Brand of Methimazole; Henning Berlin Brand of Methimazole; Hexal Brand of Methimazole; Jones Brand of Methimazole; Merck Brand of Methimazole; Nourypharma Brand of Methimazole; Philopharm Brand of Methimazole; Sanofi Synthelabo Brand of Methimazole; Temmler Brand of Methimazole; Thiamazol Henning; Thiamazol Hexal; Tiamazolo [DCIT]; M0868; Henning, Thiamazol; Hexal, Thiamazol; Methimazole (USP); Methimazole [USAN:BAN]; Tapazole (TN); Thiamazol [INN-French]; Thiamazolum [INN-Latin]; Tiamazol [INN-Spanish]; Mestinon, Regonol, Pyridostigmine Bromide;Thiamazole (JP15/INN); N-Methyl-2-mercaptoimidazole; 1 Methyl 2 mercaptoimidazole; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-Imidazolethione; 1-Methyl-2-imidazolethiol; 1-Methyl-imidazole-2-thiol; 1-Methylimidazole-2(3H)-thione; 1-Metylo 2 merkaptoimidazolem; 1-Metylo 2 merkaptoimidazolem [Polish]; 2-Mercaptomethylimidazole; 3-methyl-1H-imidazole-2-thione",Antithyroid Agents,Small molecule,"1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)",PMRYVIKBURPHAH-UHFFFAOYSA-N,CN1C=CNC1=S,60-56-0,C4H6N2S,50673,5A02: Thyrotoxicosis
D1022,Methionine,6137,Acimethin; Cymethion,Nutritional Supplements,Small molecule,"1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1",FFEARJCKVFRZRR-BYPYZUCNSA-N,CSCCC(C(=O)O)N,63-68-3,C5H11NO2S,16643,.
D1023,Methocarbamol,4107,methocarbamol; 532-03-6; Robaxin; Metocarbamol; Metocarbamolo; Lumirelax; Parabaxin; Relestrid; Myolaxene; Miolaxene; Metofenia; Miorilas; Surquetil; Reflexyn; Neuraxin; Methocal; Tresortil; Romethocarb; Etroflex; Miowas; Perilax; Delaxin; Avetil; Robinax; Metofenina; Guaiacol glyceryl ether carbamate; Guaiphenesin carbamate; Guaiphenesine carbamate; Glycerylguaiacolate carbamate; Glycerylguajacol-carbamat; Methocarbamolum; Forbaxin; 2-Hydroxy-3-(2-methoxyphenoxy)propyl carbamate; AHR 85; Robaxine; Robamol; Traumacut; Robaxon; Robaxan,Muscle Relaxants,Small molecule,"1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)",GNXFOGHNGIVQEH-UHFFFAOYSA-N,COC1=CC=CC=C1OCC(COC(=O)N)O,532-03-6,C11H15NO5,77498,FA00-FC0Z: Musculoskeletal disorder
D1024,Methohexital,9034,"Brevital; Brietal; Enallynymall; Enallynymalum; Methodrexitone; Methohexitalum; Methohexitone; Metoesital; Metohexital; Metoesital [DCIT]; Brevital (TN); Methohexital, Monosodium Salt; Methohexitalum [INN-Latin]; Metohexital [INN-Spanish]; Methohexital (USP/INN); Alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituricacid; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",Anesthetics,Small molecule,"1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)",NZXKDOXHBHYTKP-UHFFFAOYSA-N,CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,151-83-7,C14H18N2O3,102216,9A76-9A78: Corneal disease
D1025,Methotrexate,126941,"methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate",Antimetabolites,Small molecule,"1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,21672,C20H22N8O5,44185,2A60-2B33: Leukaemia; 2A00-2F9Z: Solid tumour/cancer; 2C82: Prostate cancer; FA20: Rheumatoid arthritis; 9B78: Vitreoretinopathy
D1026,Methotrimeprazine,72287,METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine,Cns Agents,Small molecule,"1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1",VRQVVMDWGGWHTJ-CQSZACIVSA-N,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,60-99-1,C19H24N2OS,6838,6A20-6A25: Psychotic disorder; 6A60: Bipolar disorder
D1027,Methoxamine,6082,"Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol",Antihypertensive Agents,Small molecule,"1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3",WJAJPNHVVFWKKL-UHFFFAOYSA-N,CC(C(C1=C(C=CC(=C1)OC)OC)O)N,390-28-3,C11H17NO3,6839,BA00-BA04: Hypertension
D1028,Methoxsalen,4114,"Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one",Antineoplastics,Small molecule,"1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3",QXKHYNVANLEOEG-UHFFFAOYSA-N,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,298-81-7,C12H8O4,18358,2B01: Mycosis fungoides; EA90: Psoriasis
D1029,Methoxsalen (topical),4114,"Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one",Antineoplastics,Small molecule,"1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3",QXKHYNVANLEOEG-UHFFFAOYSA-N,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,298-81-7,C12H8O4,18358,2B01: Mycosis fungoides; EA90: Psoriasis
D1030,Methoxyflurane,4116,"Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether",Anesthetics,Small molecule,"1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3",RFKMCNOHBTXSMU-UHFFFAOYSA-N,COC(C(Cl)Cl)(F)F,76-38-0,C3H4Cl2F2O,6843,9A76-9A78: Corneal disease
D1031,Methscopolamine,71183,"Methscopolamine; methscopolamine; N-Methylscopolamine; N-methyl scopolamine; UNII-VDR09VTQ8U; VDR09VTQ8U; 13265-10-6; CHEMBL376897; (1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane; Metylskopolamin; 56552-70-6; 3-Oxa-9-azoniatricyclo[33102,4]nonane, 7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b); HSDB 5420; [3H]N-methylscopolamine; [3H]N-methyl scopolamine; [3H]NMS; Methyl scopolamine; 3C0",Anticholinergic Agents,Small molecule,"1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12?,13-,14-,15+,16-,17+/m1/s1",LZCOQTDXKCNBEE-XJMZPCNVSA-N,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C,13265-10-6,C18H24NO4+,135361,DA61: Peptic ulcer
D1032,Methsuximide,6476,"Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione",Anticonvulsants,Small molecule,"1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3",AJXPJJZHWIXJCJ-UHFFFAOYSA-N,CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2,77-41-8,C12H13NO2,6846,8A61-8A6Z: Epilepsy/seizure
D1033,Methyl aminolevulinate (topical),157922,"Metvix; Aminolevulinic acid methyl ester; Methyl 5-aminolevulinate; Methyl delta-aminolevulinate; Methyl5-amino-4-oxopentanoate; Levulinic acid, 5-amino-, methyl ester; Pentanoic acid, 5-amino-4-oxo-, methyl ester; 5-Aminolevulinic acid methyl ester",Antineoplastics,Small molecule,"1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3",YUUAYBAIHCDHHD-UHFFFAOYSA-N,COC(=O)CCC(=O)CN,33320-16-0,C6H11NO3,724125,ED80: Acne vulgaris
D1034,Methylcellulose,44263857,"E461; methylated cellulose; CHEBI:53448; 4-O-[4-O-(2-O,3-O,4-O,6-O-Tetramethyl-beta-D-glucopyranosyl)-2-O,3-O,6-O-trimethyl-beta-D-glucopyranosyl]-1-O,2-O,3-O,6-O-tetramethyl-beta-D-glucopyranose",Laxatives,Small molecule,"InChI=1S/C29H54O16/c1-30-12-15-18(33-4)21(34-5)25(38-9)28(42-15)45-20-17(14-32-3)43-29(26(39-10)23(20)36-7)44-19-16(13-31-2)41-27(40-11)24(37-8)22(19)35-6/h15-29H,12-14H2,1-11H3/t15-,16-,17-,18-,19-,20-,21+,22+,23+,24-,25-,26-,27-,28+,29+/m1/s1",LNAZSHAWQACDHT-XIYTZBAFSA-N,COC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2OC)OC)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3OC)OC)OC)COC)COC)OC)OC)OC,.,C29H54O16,.,.
D1035,Methyldopa,38853,"AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine",Antihypertensive Agents,Small molecule,"1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1",CJCSPKMFHVPWAR-JTQLQIEISA-N,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N,555-30-6,C10H13NO4,61058,BA00-BA04: Hypertension
D1036,Methylene blue,6099,"methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium",Antidotes/Mao Inhibitors,Small molecule,"1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1",CXKWCBBOMKCUKX-UHFFFAOYSA-M,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-],61-73-4,C16H18ClN3S,6872,3A93: Acquired methaemoglobinaemia
D1037,Methylergometrine,8226,"Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide",Oxytocics,Small molecule,"1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1",UNBRKDKAWYKMIV-QWQRMKEZSA-N,CCC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,113-42-8,C20H25N3O2,92607,JA00: Abortion
D1038,Methylnaltrexone,5361918,"Methylnaltrexone; Methylnaltrexonium; Relistor; Mrz-2663; 83387-25-1; MNTX; Naltrexone MB; Methylnaltrexone ion; CHEMBL470617; Methylnaltrexone cation; N-Methylnaltrexone; Quaternary ammonium naltrexone; Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-; MRZ 2663; 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one; SCHEMBL49356; GTPL7563; CHEMBL1186579; DTXSID20873339; CHEBI:136007; ZINC5764759; BDBM50278337; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium; NCGC00378877-01; Q411515; (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one",Peripheral Opioid Receptor Antagonists,Small molecule,"InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22?/m1/s1",JVLBPIPGETUEET-GAAHOAFPSA-O,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,.,C21H26NO4+,.,.
D1039,Methylphenidate,4158,"Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester",Cns Stimulants,Small molecule,"1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3",DUGOZIWVEXMGBE-UHFFFAOYSA-N,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,113-45-1,C14H19NO2,84276,6A05: Attention deficit hyperactivity disorder; NA07: Intracranial injury
D1040,Methylphenobarbital,8271,"Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)",ALARQZQTBTVLJV-UHFFFAOYSA-N,CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2,115-38-8,C13H14N2O3,6758,6B00-6B0Z: Anxiety disorder
D1041,Methylprednisolone,6741,Depo-medrol; M-predrol; Medrol; Medrol Acetate,Antineoplastics,Small molecule,"1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1",VHRSUDSXCMQTMA-PJHHCJLFSA-N,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,83-43-2,C22H30O5,6888,2A00-2F9Z: Solid tumour/cancer; ND51: Spine/trunk injury
D1042,Methyltestosterone,6010,Android (TN),Androgens/Anabolic Steroids,Small molecule,"1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1",GCKMFJBGXUYNAG-HLXURNFRSA-N,CC12CCC(=O)C=C1CCC3C2CCC4(C3CCC4(C)O)C,58-18-4,C20H30O2,27436,2A00-2F9Z: Solid tumour/cancer
D1043,Methysergide,9681,"Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide",Vasoconstrictor Agents,Small molecule,"1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1",KPJZHOPZRAFDTN-ZRGWGRIASA-N,CCC(CO)NC(=O)C1CN(C2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,361-37-5,C21H27N3O2,92629,8A80: Migraine
D1044,Meticillin,6087,"Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid",Antibiotics,Small molecule,"1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1",RJQXTJLFIWVMTO-TYNCELHUSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C,61-32-5,C17H20N2O6S,6827,1A00-1C4Z: Bacterial infection; 6B60: Dissociative neurological symptom disorder
D1045,Metipranolol (ophthalmic),31477,"Disorat; Methypranol; Metipranololum; Trimepranol; Turoptin; BM-01004; Betanol (TN); Disorat (TN); Metipranololum [INN-Latin]; OptiPranolol (TN); Trimepranol (TN); VUAB-6453; VUFB-6453; Metipranolol (USAN/INN); Metipranolol [USAN:BAN:INN]; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); Phenol,4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; 62164P",Antihypertensive Agents,Small molecule,"1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3",BQIPXWYNLPYNHW-UHFFFAOYSA-N,CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O,22664-55-7,C17H27NO4,6897,9C61: Glaucoma
D1046,Metoclopramide,4168,"Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide",Antiemetics,Small molecule,"1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",TTWJBBZEZQICBI-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,364-62-5,C14H22ClN3O2,107736,MD90: Nausea/vomiting
D1047,Metocurine,21233,"METOCURINE; 5152-30-7; UNII-V0M92G2U26; CHEBI:6900; O,O-Dimethylchondrocurarine; V0M92G2U26; O,O'-Dimethyltubocurarine; 6,6',7',12'-Tetramethoxy-2,2,2',2'-Tetramethyltubocuraran-2,2'-Diium; dimethylchondrocurarine; N,N',O,O-Tetramethyl-(+)-tubocurine; BRN 3583380; Metocurine ion; Metocurine cation; CU9; Dimethyl tubocurarine; Tubocurarine, O,O'-dimethyl-, (+)-; CHEMBL1259; SCHEMBL447436; DTXSID0048262; ZINC4097448; BDBM50237609; DB01336; Chondrocurarine, O,O'-dimethyl- (8CI); 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, (13aR,25aS)-; C07919; Q6824186; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl- (9CI); (1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2^{3,6}.1^{8,12}.1^{18,22}.0^{27,31}.0^{16,34}]hexatriaconta-3,5,8,10,12(34),18(33),19,21,24(32),25,27(31),35-dodecaene-15,30-diium",Neuromuscular Blocking Agents,Small molecule,"InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1",JFXBEKISTKFVAB-AJQTZOPKSA-N,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C,.,C40H48N2O6+2,.,.
D1048,Metolazone,4170,"Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide",Antihypertensive Agents,Small molecule,"1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)",AQCHWTWZEMGIFD-UHFFFAOYSA-N,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,17560-51-9,C16H16ClN3O3S,64354,MG29: Oedema; BA00-BA04: Hypertension
D1049,Metoprolol,4171,"Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol",Antihypertensive Agents,Small molecule,"1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3",IUBSYMUCCVWXPE-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,51384-51-1,C15H25NO3,6904,BA00-BA04: Hypertension
D1050,Metreleptin,.,.,Metabolic Agents,Hormones,.,.,.,.,.,.,5A2Y: Acute diabete complication
D1051,Metronidazole,4173,APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ,Antiinfective Agents,Small molecule,"1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3",VAOCPAMSLUNLGC-UHFFFAOYSA-N,CC1=NC=C(N1CCO)[N+](=O)[O-],443-48-1,C6H9N3O3,6909,1A36: Amoebiasis; DD70: Crohn disease
D1052,Metronidazole (topical),4173,APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ,Antiinfective Agents,Small molecule,"1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3",VAOCPAMSLUNLGC-UHFFFAOYSA-N,CC1=NC=C(N1CCO)[N+](=O)[O-],443-48-1,C6H9N3O3,6909,1A36: Amoebiasis; DD70: Crohn disease
D1053,Metyrosine,441350,"Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine",Antineoplastics,Small molecule,"1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1",NHTGHBARYWONDQ-JTQLQIEISA-N,CC(CC1=CC=C(C=C1)O)(C(=O)O)N,672-87-7,C10H13NO3,6912,5A75: Adrenomedullary hyperfunction
D1054,Mexiletine,4178,"Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene",Antiarrhythmic Agents,Small molecule,"1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3",VLPIATFUUWWMKC-UHFFFAOYSA-N,CC1=C(C(=CC=C1)C)OCC(C)N,31828-71-4,C11H17NO,6916,BC71: Ventricular tachyarrhythmia
D1055,Mezlocillin,656511,"Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid",Antibiotics,Small molecule,"1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1",YPBATNHYBCGSSN-VWPFQQQWSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C,51481-65-3,C21H25N5O8S2,6919,GC08: Urinary tract infection
D1056,Micafungin,477468,Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM),Antifungal Agents,Small molecule,"1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1",PIEUQSKUWLMALL-YABMTYFHSA-N,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O,235114-32-6,C56H71N9O23S,600520,1F23: Candidosis
D1057,Miconazole,4189,"Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole",Antifungal Agents,Small molecule,"1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2",BYBLEWFAAKGYCD-UHFFFAOYSA-N,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,22916-47-8,C18H14Cl4N2O,82892,1F29-1F2F: Fungal infection
D1058,Miconazole (topical),4189,"Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole",Antifungal Agents,Small molecule,"1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2",BYBLEWFAAKGYCD-UHFFFAOYSA-N,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,22916-47-8,C18H14Cl4N2O,82892,1F29-1F2F: Fungal infection
D1059,Microcrystalline cellulose,783,"1333-74-0; H; Hydrogen; Molecular hydrogen; Dihydrogen; Atomic hydrogen; H2; Microcrystalline cellulose; Polystyrene,mw 190000; Hydrogen gas; Hydrogen, atomic; hidrogeno; hydrogene; Wasserstoff; alpha-cellulose; Polystyrene,; Cellulose powder; o-Hydrogen; p-Hydrogen; hydrogen molecule; Elemental hydrogen; Powdered cellulose; monoatomic hydrogen; 3A molecular sieve; Polystyrene, HIPS; Polystyrene,1000; Cellulose Nanoparticles; Latex beads,polystyrene; Polystyrene,mw 1200; alpha-Cellulose, 90mum; Polystyrene,mw 45000; Polystyrene,atactic pellets; T101 Monoclonal Antibody; Polystyrene,mw 210000; Polystyrene,mw 260000; Polystyrene,mw 50,000; COware 20ml with H-Caps; Polystyrene, extrusion grade; Polystyrene latex microsphere; Hydrogen, >=99.99%; Hydrogen, >=99.999%; Poly[titanium(IV) n-butoxide]; Polystyrene,mw 800-5,000; DTXSID9029643; CHEBI:18276; CHEBI:33251; CHEBI:49637; Polystyrene,monohydroxy terminated; DTXSID501014229; Cellulose Nanopowder / Nanoparticles; BBL103822; NSC356464; Polystyrene syndiotactic,mw 300000; STL557632; alpha-Cellulose, 25mum particle size; alpha-Cellulose, 65mum particle size; Latex beads,amine-modified polystyrene; AKOS016038407; MCULE-3166658688; NSC-356464; Polystyrene, General-II, high strength; UN 1049; UN 1966; E949; Hydrogen, Messer(R) CANgas, 99.999%; Latex beads,carboxylate-modified polystyrene; E 949; E-949; Polystyrene,monohydroxy terminated,mw 10000; Polystyrene, General-I, for injection molding; C00282; Polystyrene,monomethacrylate terminated,mw 15000; alpha-Cellulose, Partical size: d50,180-280mum; alpha-Cellulose, Partical size: d50,90-150mum; Q3027893; Latex beads,polystyrene, diameter 9.0-9.9mum ,5% w/v; Latex beads,polystyrene, diameter 1.0 - 1.9mum ,5% w/v; Latex beads,polystyrene, diameter 2.0- 2.9 mum ,5% w/v; Latex beads,polystyrene, diameter 3.0 - 3 .9mum ,5% w/v; Latex beads,polystyrene, diameter 4.0 - 4.9mum ,5% w/v; Latex beads,polystyrene, diameter 6.0 - 6.9mum ,5% w/v; Latex beads,polystyrene, diameter 7.0 - 7.9mum ,5% w/v; Latex beads,polystyrene, diameter 8.0 - 8.9mum ,5% w/v; Latex beads,polystyrene, diameter 9.0-9.9mum ,2.5% w/v; Latex beads,polystyrene, diameter 0.05 - 0.1mum ,2.5% w/v; Latex beads,polystyrene, diameter 0.2 - 0.5mum ,2.5% w/v; Latex beads,polystyrene, diameter 0.6 - 1.0 mum ,2.5% w/v; Latex beads,amine-modified polystyrene, diameter >10mum ,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 0.05 - 0.1mum ,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 0.2 - 0.5mum ,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 0.6 - 1.0mum,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 1.0 - 1.9mum,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 2.0 - 2.9mum,2.5% w/v; Latex beads,amine-modified polystyrene, diameter 3.0 - 3.9mum,5% w/v; Latex beads,amine-modified polystyrene, diameter 4.0 - 4.9mum,5% w/v; Latex beads,amine-modified polystyrene, diameter 6.0 - 6.9mum,5% w/v; Latex beads,amine-modified polystyrene, diameter 7.0 - 7.9mum,5% w/v; Latex beads,amine-modified polystyrene, diameter 8.0 - 8.9mum,5% w/v; Latex beads,amine-modified polystyrene, diameter 9.0 - 9.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter >10mum ,2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 1.0 - 1.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 3.0 - 3.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 4.0 - 4.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 5.0 - 5.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 6.0 - 6.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 7.0 - 7.9mum,5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 8.0 - 8.9mum,5% w/v; Carboxylated polystyrene latex particles of blue, diameter 6.0 - 6.9mum, 2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 0.05 - 0.1mum ,2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 0.2 - 0.5mum ,2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 0.6 - 1.0mum,2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 2.0 - 2.9mum,2.5% w/v; Latex beads,carboxylate-modified polystyrene, diameter 9.0 - 9.9 mum,5% w/v; 1H; H-H",Excipients,Small molecule,InChI=1S/H2/h1H,UFHFLCQGNIYNRP-UHFFFAOYSA-N,[HH],.,H2,.,.
D1060,Midazolam,4192,"Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3",DDLIGBOFAVUZHB-UHFFFAOYSA-N,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,59467-70-8,C18H13ClFN3,6931,MB24: Mood/affect symptom; 8A61-8A6Z: Epilepsy/seizure
D1061,Midodrine,4195,"Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride",Vasoconstrictor Agents,Small molecule,"1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)",PTKSEFOSCHHMPD-UHFFFAOYSA-N,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,42794-76-3,C12H18N2O4,6933,BA21: Orthostatic hypotension
D1062,Midostaurin,9829523,"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN);  CPG 41251",Antineoplastics,Small molecule,"1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,120685-11-2,C35H30N4O4,63452,2A60: Acute myeloid leukaemia; 2A21: Mastocytosis; 2B91: Colorectal cancer; 2A40: Chronic myelomonocytic leukaemia
D1063,Mifepristone,55245,"Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma",Uterotonic Agents,Small molecule,"1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1",VKHAHZOOUSRJNA-GCNJZUOMSA-N,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,84371-65-3,C29H35NO2,50692,5A70: Cushing syndrome
D1064,Miglitol,441314,"Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",Antidiabetic Agents,Small molecule,"1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1",IBAQFPQHRJAVAV-ULAWRXDQSA-N,C1C(C(C(C(N1CCO)CO)O)O)O,72432-03-2,C8H17NO5,6935,5A2Y: Acute diabete complication
D1065,Milk thistle,1548994,"Silybin B; Milk thistle; 142797-34-0; UNII-853OHH1429; Flavobion; Legalon 70; 853OHH1429; CCRIS 7096; Wild Artichoke; Silybum marianum; Silybin A and B; Milk thistle [NF]; Silymarin + Melatonin; AC1LU7MH; UNII-U946SH95EE; Milk Thistle (Silybum marianum) Extract or Powder; SCHEMBL751461; Silybin B, analytical standard; U946SH95EE; CHEMBL592675; Milk Thistle (Silybum marianum) Extract or Powder [seed]; DTXSID30858697; SEBFKMXJBCUCAI-WAABAYLZSA-N; MolPort-039-139-345; ZINC1530850; BDBM50088491; 2717AH; AKOS015912848",Antineoplastics,Small molecule,"1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23-,24-,25+/m0/s1",SEBFKMXJBCUCAI-WAABAYLZSA-N,COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O,65666-07-1,C25H22O10,.,2A00-2F9Z: Solid tumour/cancer
D1066,Milnacipran,65833,"Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl",Antidepressants,Small molecule,"1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1",GJJFMKBJSRMPLA-HIFRSBDPSA-N,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,96847-55-1,C15H22N2O,94468,6A70-6A7Z: Depression
D1067,Milrinone,4197,"Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4&prime;-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile",Cardiotonic Agents,Small molecule,"1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)",PZRHRDRVRGEVNW-UHFFFAOYSA-N,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,78415-72-2,C12H9N3O,50693,BD10-BD1Z: Heart failure
D1068,Miltefosine,3599,"HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide",Antifungal Agents,Small molecule,"1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3",PQLXHQMOHUQAKB-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,58066-85-6,C21H46NO4P,75283,1F54: Leishmaniasis
D1069,Mineral oil,.,.,Laxatives,Small molecule,.,.,.,.,.,.,DD91: Irritable bowel syndrome
D1070,Minocycline,54675783,"Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline",Antibiotics,Small molecule,"1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1",FFTVPQUHLQBXQZ-KVUCHLLUSA-N,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,10118-90-8,C23H27N3O7,50694,1A00-1C4Z: Bacterial infection; ED90: Rosacea
D1071,Minocycline (topical),54675783,"Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline",Antibiotics,Small molecule,"1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1",FFTVPQUHLQBXQZ-KVUCHLLUSA-N,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,10118-90-8,C23H27N3O7,50694,1A00-1C4Z: Bacterial infection; ED90: Rosacea
D1072,Minoxidil,4201,"Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide",Antihypertensive Agents,Small molecule,"1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2",ZIMGGGWCDYVHOY-UHFFFAOYSA-N,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,38304-91-5,C9H15N5O,6942,BA00-BA04: Hypertension
D1073,Mipomersen,118984467,Mipomerson; Mipomersen [INN]; DB05528,Antihyperammonia Agents,Small interfering RNA,"InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m0/s1",XLTMQWVJFPYGMC-QVKFEXRMSA-N,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O)S,.,C230H324N67O122P19S19,.,.
D1074,Mirabegron,9865528,Myrbetriq (TN),Urinary Antispasmodics,Small molecule,"1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1",PBAPPPCECJKMCM-IBGZPJMESA-N,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,223673-61-8,C21H24N4O2S,65349,GC50: Functional bladder disorder
D1075,Mirtazapine,4205,"Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin",Antidepressants,Small molecule,"1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3",RONZAEMNMFQXRA-UHFFFAOYSA-N,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,85650-52-8,C17H19N3,6950,6A70-6A7Z: Depression
D1076,Misoprostol,5282381,"Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester",Abortifacient Agents,Small molecule,"1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1",OJLOPKGSLYJEMD-URPKTTJQSA-N,CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O,59122-46-2,C22H38O5,94387,JA00: Abortion
D1077,Mitomycin,5746,"Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,;  Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free",Antineoplastics,Small molecule,"1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1",NWIBSHFKIJFRCO-WUDYKRTCSA-N,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,18451,C15H18N4O5,27504,2C60-2C6Y: Breast cancer; 2C11: Malignant digestive organ neoplasm; 2A00-2F9Z: Solid tumour/cancer
D1078,Mitotane,4211,"Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane",Antineoplastics,Small molecule,"1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H",JWBOIMRXGHLCPP-UHFFFAOYSA-N,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,53-19-0,C14H10Cl4,6954,2D11: Adrenal cancer
D1079,Mitoxantrone,4212,"DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)",Analgesics,Small molecule,"1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2",KKZJGLLVHKMTCM-UHFFFAOYSA-N,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,65271-80-9,C22H28N4O6,50729,2A00-2F9Z: Solid tumour/cancer; 2B33: Malignant haematopoietic neoplasm
D1080,Mivacurium,5281042,"Mivacron; Chlorure de mivacurium; Chlorure de mivacurium [French]; Cloruro de mivacurio; Cloruro de mivacurio [Spanish]; MIVACURIUM CHLORIDE; Mivacurii chloridum; Mivacurii chloridum [Latin]; BW B109OU dichloride; BWB109OU; BW-B1090U; BW-B109OU; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; Mivacron (TN); Mivacurium chloride(USAN/INN); Mivacurium chloride [USAN:INN:BAN]; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)",Neuromuscular Blocking Agents,Small molecule,"1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1",ILVYCEVXHALBSC-OTBYEXOQSA-N,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C,133814-19-4,C58H80N2O14+2,6958,9A76-9A78: Corneal disease
D1081,Modafinil,4236,Provigil; Modiodal,Cns Stimulants,Small molecule,"1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)",YFGHCGITMMYXAQ-UHFFFAOYSA-N,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,68693-11-8,C15H15NO2S,77585,7A20: Narcolepsy; NA07: Intracranial injury; 6A60: Bipolar disorder
D1082,Moexipril,91270,"Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1",UWWDHYUMIORJTA-HSQYWUDLSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC,103775-10-6,C27H34N2O7,6960,BA00-BA04: Hypertension
D1083,Mogamulizumab,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B01: Mycosis fungoides; 2A00-2F9Z: Solid tumour/cancer; 2A90: Mature T-cell lymphoma; 2B02: Sezary syndrome
D1084,Molindone,23897,"Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one",Antipsychotic Agents,Small molecule,"1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3",KLPWJLBORRMFGK-UHFFFAOYSA-N,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,7416-34-4,C16H24N2O2,6965,6A20: Schizophrenia
D1085,Monomethyl fumarate,5369209,"Monomethyl fumarate; 2756-87-8; 4-methoxy-4-oxobut-2-enoic acid; Methyl hydrogen fumarate; mono-Methyl fumarate; Fumaric acid monomethyl ester; (E)-4-methoxy-4-oxobut-2-enoic acid; UNII-45IUB1PX8R; (2E)-4-Methoxy-4-oxobut-2-enoic acid; 45IUB1PX8R; CHEMBL589586; Monomethyl fumarate (USAN); Monomethyl fumarate [USAN]; 44836-34-2; Maleicacidmonomethylester; Bafiertam; MFCD00063174; NSC-523835; (Z)-4-methoxy-4-oxobut-2-enoic acid; monomethyl-fumarate; monomethylis fumaras; EINECS 220-412-6; methylhydrogenfumarate; fumarato de monometilo; fumarate de monomethyle; Fumaric acid 1-methyl; (2E)-3-(methoxycarbonyl)prop-2-enoic acid; mono-Methyl fumarate, 97%; SCHEMBL60132; SCHEMBL60133; MONO-METHYLFUMARATE97; Maleic acid mono(methyl ester); GTPL5786; FumarsA currencyuremonomethylester; CHEBI:167450; DTXSID801016498; 2-Butenedioic acid 1-methyl ester; BCP18454; ZINC4416885; BDBM50342426; s6889; WHO 11163; (E)-2-Butendioic acid, methyl ester; AKOS015892642; 2(E)-Butenedioic acid 1-methyl ester; DB14219; NSC 523835; MRF-0000756; AS-15353; O997; (E)-But-2-enedioic acid monomethyl ester; (2E)-4-Methoxy-4-oxo-2-butenoic acid #; HY-103252; 2-Butenedioic acid (2E)-, 1-methyl ester; B7674; CS-0026484; M2413; 56M878; D11492; A876896; J-017996; J-522708; Q27087639; mono-Methyl fumarate, certified reference material, TraceCERT(R)",Selective Immunosuppressants,Small molecule,"InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+",NKHAVTQWNUWKEO-NSCUHMNNSA-N,COC(=O)/C=C/C(=O)O,.,C5H6O4,.,.
D1086,Monopotassium phosphate,516951,"Potassium dihydrogen phosphate; 7778-77-0; Potassium phosphate monobasic; MONOPOTASSIUM PHOSPHATE; Monobasic potassium phosphate; Phosphoric acid, monopotassium salt; Potassium acid phosphate; Potassium phosphate, monobasic; Monopotassiumphosphate; Potassium dihydrogen orthophosphate; Monopotassium monophosphate; Monopotassium orthophosphate; Monopotassium dihydrogen phosphate; Potassium dihydrogenorthophosphate; potassium dihydrogenphosphate; potassium;dihydrogen phosphate; Sorensen's potassium phosphate; Potassium phosphate (K(H2PO4)); KH2PO4; UNII-4J9FJ0HL51; Orthophosphoric acid, monopotassium salt; CHEBI:63036; MFCD00011401; Phosphoric acid, potassium salt (1:1); 4J9FJ0HL51; MKP; Chlorine Titrimeter Reagent; Buffer Solution, pH 6.00; Buffer Solution, pH 7.00; Buffer Solution, pH 7.40; MFCD00147253; Potassium dihydrogen orthophosphate(V); potassium biphosphate; HSDB 5046; Buffer Solution, pH 7.00, Color-Coded Yellow; Potassium orthophosphate, dihydrogen; EINECS 231-913-4; EPA Pesticide Chemical Code 076413; Potassium hydrogen phosphate (KH2PO4); Potassium phosphate, monobasic [NF]; Phosphoric acid, potassium salt (1:?); mono potassium phosphate; mono-potassium phosphate; prim.-Potassium phosphate; H2KO4P; EC 231-913-4; Potassium phosphate,monobasic; potassium di-hydrogen phosphate; CHEMBL1200925; DTXSID0035667; Potassium Dihydrogen Phosphate,(S); EINECS 240-213-8; BDBM50004328; Monopotassium dihydrogen monophosphate; AKOS015902364; AKOS028109678; Monopotassium dihydrogen orthophosphate; DB09413; Potassium dihydrogen phosphate monobasic; Potassium phosphate monobasic (anhydrous); Potassium phosphate, monobasic (JAN/NF); Potassium dihydrogen phosphate, Puratronic?; B7291; FT-0645117; W8424; D02050; Potassium phosphate monobasic, Trace metals grade; Q415049; Potassium phosphate, 0.2M buffer solution, pH 7.0; Potassium phosphate, 0.2M buffer solution, pH 7.2; Potassium phosphate, 0.2M buffer solution, pH 7.4; Potassium phosphate, 0.2M buffer solution, pH 7.5; Potassium phosphate, 0.2M buffer solution, pH 7.6; Potassium phosphate, 0.5M buffer solution, pH 7.0; Potassium phosphate, 0.5M buffer solution, pH 7.4; Potassium phosphate, 0.5M buffer solution, pH 7.5; Potassium phosphate, 0.5M buffer solution, pH 7.6; UNII-B7862WZ632 component GNSKLFRGEWLPPA-UHFFFAOYSA-M; Potassium phosphate monobasic powder suitable for cell culture; Buffer solution, pH 1.68 (+/-0.01 at 25?C), No Color, Specpure, NIST Traceable",Minerals And Electrolytes,Small molecule,"InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1",GNSKLFRGEWLPPA-UHFFFAOYSA-M,OP(=O)(O)[O-].[K+],.,H2KO4P,.,.
D1087,Montelukast,5281040,Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid,Antiasthmatic Agents,Small molecule,"1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1",UCHDWCPVSPXUMX-TZIWLTJVSA-N,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,158966-92-8,C35H36ClNO3S,50730,CA23: Asthma
D1088,Moricizine,34633,"Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester",Antiarrhythmic Agents,Small molecule,"1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)",FUBVWMNBEHXPSU-UHFFFAOYSA-N,CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4,31883-05-3,C22H25N3O4S,6997,BC9Z: Cardiac arrhythmia; BC65: Genetic cardiac arrhythmia
D1089,Morphine,5288826,Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr,Analgesics,Small molecule,"1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",BQJCRHHNABKAKU-KBQPJGBKSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,57-27-2,C17H19NO3,17303,MG30: Chronic pain
D1090,Morphine (liposomal),5288826,Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr,Analgesics,Small molecule,"1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1",BQJCRHHNABKAKU-KBQPJGBKSA-N,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,57-27-2,C17H19NO3,17303,MG30: Chronic pain
D1091,Moxetumomab Pasudotox,.,DB12688; Moxetumomab Pasudotox; moxetumomab pasudotox-tdfk,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,.
D1092,Moxifloxacin,152946,"Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid",Antibiotics,Small molecule,"1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1",FABPRXSRWADJSP-MEDUHNTESA-N,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,151096-09-2,C21H24FN3O4,63611,1A00-1C4Z: Bacterial infection
D1093,Muromonab,.,.,Immunomodulatory Agents,Monoclonal antibody,.,.,.,.,.,.,NE84: Transplant rejection
D1094,Mycophenolate mofetil,5281078,"mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190;  CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)",Immunosuppressive Agents,Small molecule,"1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O,128794-94-5,C23H31NO7,8764,NE84: Transplant rejection; 4A01-4B41: Immune system disease; EB40: Pemphigus
D1095,Mycophenolic acid,446541,Acide mycophenolique; Acide mycophenolique [INN-French]; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycoph; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T,Antiviral Agents,Small molecule,"1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+",HPNSFSBZBAHARI-RUDMXATFSA-N,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,24280-93-1,C17H20O6,168396,1D64: Middle East Respiratory Syndrome
D1096,Nabilone,5284592,"Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-",Antiemetics,Small molecule,"1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1",GECBBEABIDMGGL-RTBURBONSA-N,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,51022-71-0,C24H36O3,.,7A00-7A0Z: Insomnia
D1097,Nabumetone,4409,"NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex",Nsaids/Analgesics,Small molecule,"1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3",BLXXJMDCKKHMKV-UHFFFAOYSA-N,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,42924-53-8,C15H16O2,7443,MG30-MG3Z: Pain
D1098,Nadolol,39147,"Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol",Antihypertensive Agents,Small molecule,"1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1",VWPOSFSPZNDTMJ-UCWKZMIHSA-N,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,220045-89-6,C17H27NO4,.,BA00: Essential hypertension
D1099,Nafcillin,8982,"Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1",GPXLMGHLHQJAGZ-JTDSTZFVSA-N,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,147-52-4,C21H22N2O5S,7447,FA20: Rheumatoid arthritis
D1100,Nalbuphine,5311304,"Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol",Analgesics,Small molecule,"1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1",NETZHAKZCGBWSS-CEDHKZHLSA-N,C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O,20594-83-6,C21H27NO4,7454,EC91: Prurigo; EC90: Pruritus; MG30-MG3Z: Pain
D1101,Naldemedine,54732242,"NALDEMEDINE; UNII-03KSI6WLXH; 03KSI6WLXH; S-297,995; 916072-89-4; Naldemedine [USAN:INN]; Naldemedine (USAN/INN); S 297995; SCHEMBL9880572; GTPL9150; CHEMBL2105755; AKOS032945757; DB11691; Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14- trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-; J3.573.009E; D10188",Peripheral Opioid Receptor Antagonists,Small molecule,"1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1",AXQACEQYCPKDMV-RZAWKFBISA-N,CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O,916072-89-4,C32H34N4O6,.,6C43: Opioid use disorder
D1102,Nalidixic acid,4421,"Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one",Antibiotics,Small molecule,"1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)",MHWLWQUZZRMNGJ-UHFFFAOYSA-N,CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O,389-08-2,C12H12N2O3,100147,GC08: Urinary tract infection
D1103,Nalmefene,5284594,"Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol",Antidotes,Small molecule,"1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1",WJBLNOPPDWQMCH-MBPVOVBZSA-N,C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O,55096-26-9,C21H25NO3,7457,6C43: Opioid use disorder
D1104,Naloxegol,56959087,NKTR-118,Peripheral Opioid Receptor Antagonists,Small molecule,"1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1",XNKCCCKFOQNXKV-ZRSCBOBOSA-N,COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O,854601-70-0,C34H53NO11,82975,DB32: Large intestine motility disorder
D1105,Naloxone,5284596,"Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one",Antinarcotic Agents,Small molecule,"1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1",UZHSEJADLWPNLE-GRGSLBFTSA-N,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,465-65-6,C19H21NO4,7459,6A70-6A7Z: Depression; 6C43: Opioid use disorder; MD11: Breathing abnormality; EC90: Pruritus
D1106,Naltrexone,5360515,"Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes",Antidotes,Small molecule,"1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1",DQCKKXVULJGBQN-XFWGSAIBSA-N,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,16590-41-3,C20H23NO4,7465,6C40: Substance abuse; 1C60-1C62: Human immunodeficiency virus disease
D1107,Naphazoline (nasal),4436,"Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole",Antineoplastics,Small molecule,"1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)",CNIIGCLFLJGOGP-UHFFFAOYSA-N,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32,835-31-4,C14H14N2,93363,1F28-1G07: Itching; 9A61-9B7Y: Hyperaemia
D1108,Naphazoline (ophthalmic),4436,"Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole",Antineoplastics,Small molecule,"1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)",CNIIGCLFLJGOGP-UHFFFAOYSA-N,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32,835-31-4,C14H14N2,93363,1F28-1G07: Itching; 9A61-9B7Y: Hyperaemia
D1109,Naproxen,156391,NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex,Nsaids/Analgesics,Small molecule,"1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1",CMWTZPSULFXXJA-VIFPVBQESA-N,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,22204-53-1,C14H14O3,7476,FA00-FA05: Osteoarthritis; GA10: Endometriosis; MG30-MG3Z: Pain
D1110,Naratriptan,4440,"Colatan; Naramig; Naratriptanum; Amerge (TN); Naramig (TN); Naratriptan (INN); Amerge, Naramig,Naratriptan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide",Vasoconstrictor Agents,Small molecule,"1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3",AMKVXSZCKVJAGH-UHFFFAOYSA-N,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C,121679-13-8,C17H25N3O2S,7478,8A80: Migraine
D1111,Natalizumab,.,Anti-alpha4 integrin; Anti-VLA4; DB00108; Natalizumab,Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,.
D1112,Nateglinide,5311309,"Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid",Antidiabetic Agents,Small molecule,"1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1",OELFLUMRDSZNSF-OFLPRAFFSA-N,CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O,105816-04-4,C19H27NO3,31897,5A2Y: Acute diabete complication
D1113,Naxitamab,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B51: Osteosarcoma; 2D11: Adrenal cancer
D1114,Nebivolol,71301,"Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]",Antihypertensive Agents,Small molecule,"1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2",KOHIRBRYDXPAMZ-UHFFFAOYSA-N,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O,99200-09-6,C22H25F2NO4,64019,BA00-BA04: Hypertension
D1115,Necitumumab,.,LY3012211,Egfr Inhibitors,Monoclonal antibody,.,.,.,.,.,.,2B91: Colorectal cancer
D1116,Nedocromil,50294,"NEDOCROMIL; 69049-73-6; 9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid; FPL 59002; Nedocromilo; Nedocromilum; FPL-59002; Rapitil; UNII-0B535E0BN0; C19H17NO7; 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid; CHEBI:7492; 0B535E0BN0; 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsaeure; NCGC00182073-02; Nedocromilum [Latin]; Nedocromilo [Spanish]; DSSTox_CID_3356; 9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid; DSSTox_RID_76990; DSSTox_GSID_23356; CAS-69049-73-6; Nedocromil [USAN:INN:BAN]; FPL59002; Nedocromil (USAN/INN); CHEMBL746; SCHEMBL4611; 4H-Pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-; BIDD:GT0716; GTPL7607; DTXSID7023356; Nedocromil, >=98% (HPLC); EX-A098; BCP22724; ZINC3782807; Tox21_113148; MFCD00864606; 9-ethyl-4,6-dioxo-10-propylpyrano[3,2-g]quinoline-2,8-dicarboxylic acid; AKOS016014051; Tox21_113148_1; DB00716; NCGC00182073-03; NCGC00182073-07; AC-30178; AS-56153; HY-13448; DB-055217; FT-0630782; X6180; C07255; D05129; 049N736; L001326; Q416706; SR-01000944506; SR-01000944506-1; 9-ethyl-4,6-dioxo-10-propylpyrano[5,6-g]quinoline-2,8-dicarboxylic acid; 9-ethyl-4,6-dioxo-10-propyl-4H,6H,9H-chromeno[7,6-b]pyridine-2,8-dicarboxylic acid",Mast Cell Stabilizers,Small molecule,"InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)",RQTOOFIXOKYGAN-UHFFFAOYSA-N,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O,.,C19H17NO7,.,.
D1117,Nefazodone,4449,"Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one",Antidepressants,Small molecule,"1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",VRBKIVRKKCLPHA-UHFFFAOYSA-N,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,83366-66-9,C25H32ClN5O2,7494,6A70-6A7Z: Depression
D1118,Nelarabine,3011155,"Arranon; ArranonG; Atriance; Nelzarabine; Nelarabine [USAN]; Nelzarabine [USAN]; GW 506U78; GW506U78; U78; Arranon (GlaxoSmithKline); Arranon (TN); Arranon, Nelarabine; Atriance (TN); GW-506U; GW-506U78; Nelarabine (INN); Nelzarabine (USAN); O-Methoxydeoxyguanosine; O-Methylguanosine; Nelarabine (JAN/USAN); (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Amino-6-methoxypurine arabinoside; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; 6'-O-Methylguanosine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine",Antineoplastics,Small molecule,"1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1",IXOXBSCIXZEQEQ-UHTZMRCNSA-N,COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N,121032-29-9,C11H15N5O5,63612,2A60-2B33: Leukaemia
D1119,Nelfinavir,64143,"nelfinavir; 159989-64-7; Viracept; AG-1343; UNII-HO3OGH5D7I; C32H45N3O4S; Viracept (TN); HO3OGH5D7I; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; CHEBI:7496; NSC-747167; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; NLF; Nelfinavir [INN:BAN]; NFV; CHEMBL1205; (3S,4aS,8aS)-N-(tert-Butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; Nelfinavir (INN); SMR000596515; NSC722664; NCGC00090782-03; NELFINAVIR MESYLATE AG1343; Met-SDF-1.beta. & Nelfinavir; 1ohr; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; CHEMBL584; BIDD:PXR0143; SCHEMBL38218; MLS001195634; MLS001304729; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; BIDD:GT0395; DTXSID5035080; GTPL11090; HMS2232I04; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; ZINC3833846; BDBM50061306; NSC747167; AKOS000280862; AM84529; CS-0677; DB00220; NSC 747167; MRF-0000208; NCGC00090782-04; NCGC00090782-05; NCGC00090782-17; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; AC-20032; AS-75258; HY-15287; 89N647; C07257; C73027; D08259; AB00698259-15; A810095; A810096; Q423366; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4abeta,8abeta)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-(2-methyl-3-hydroxybenzoylamino)-4-(phenylthio)butyl]decahydroisoquinoline-3alpha-carboxamide; (3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide; compound with methanesulfonic acid; (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-3-[(2-methyl-3-oxidanyl-phenyl)carbonylamino]-2-oxidanyl-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-; N-(tert-Butyl)-2-(2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide",Protease Inhibitors,Small molecule,"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1",QAGYKUNXZHXKMR-HKWSIXNMSA-N,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,.,C32H45N3O4S,.,.
D1120,Neomycin,8378,"Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy",Antibiotics,Small molecule,"1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",PGBHMTALBVVCIT-VCIWKGPPSA-N,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,119-04-0,C23H46N6O13,7508,DB94: Alcoholic liver disease; DB91: Acute/subacute hepatic failure; 1A00-1C4Z: Bacterial infection
D1121,Neomycin (topical),8378,"Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy",Antibiotics,Small molecule,"1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",PGBHMTALBVVCIT-VCIWKGPPSA-N,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,119-04-0,C23H46N6O13,7508,DB94: Alcoholic liver disease; DB91: Acute/subacute hepatic failure; 1A00-1C4Z: Bacterial infection
D1122,Neostigmine,4456,"Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium",Parasympathomimetics,Small molecule,"1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1",ALWKGYPQUAPLQC-UHFFFAOYSA-N,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,59-99-4,C12H19N2O2+,7514,8C6Y: Myasthenia gravis
D1123,Nepafenac (ophthalmic),151075,Nevanac; AHR-9434; AL-6515,Ophthalmic Anti-Inflammatory Agents,Small molecule,"1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)",QEFAQIPZVLVERP-UHFFFAOYSA-N,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,78281-72-8,C15H14N2O2,75922,FA00-FA05: Osteoarthritis
D1124,Neratinib,9915743,Neratinib (ERBB2 inhibitor),Antineoplastics,Small molecule,"1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,698387-09-6,C30H29ClN6O3,61397,2C60-2C6Y: Breast cancer
D1125,Nesiritide,53325981,"Natriuretic peptide, brain; Brain natriuretic peptide; Natriuretic factor, brain; Natriuretic peptide type-B; Brain natriuretic factor; Nesiritide [USAN:INN]; B-Tye natriuretic peptide; UNII-07Y2V56IUP; 07Y2V56IUP; Human brain natriuretic factor-32; Human brain natriuretic peptide-32; Natriuretic factor-32 (human brain clone lambda hBNP57); Natriuretic factor-32 (human brain clone lambdahBNP57); 1,2-Dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane, cyclic peptide deriv.; L-Histidine, L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L_arginyl-L-lysyl-L-methionyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-, cyclic (10-26)-disulfide; L-Seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-L-histidine cyclic (10-26)-disulfide",Recombinant Natriuretic Peptide,Hormones,"InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1",HPNRHPKXQZSDFX-OAQDCNSJSA-N,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO,.,C143H244N50O42S4,.,.
D1126,Netilmicin,441306,"NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside",Antibiotics,Small molecule,"1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1",CIDUJQMULVCIBT-MQDUPKMGSA-N,CCNC1CC(C(C(C1OC2C(C(C(CO2)(C)O)NC)O)O)OC3C(CC=C(O3)CN)N)N,56391-56-1,C21H41N5O7,.,1A00-1C4Z: Bacterial infection
D1127,Netupitant,6451149,"R-1124; NK1 antagonist (emesis), Roche; Ro-67-3189",Antiemetics,Small molecule,"1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3",WAXQNWCZJDTGBU-UHFFFAOYSA-N,CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C,290297-26-6,C30H32F6N4O,85155,MD90: Nausea/vomiting
D1128,Nevirapine,4463,"NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one",Anti-Hiv Agents,Small molecule,"1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,129618-40-2,C15H14N4O,63613,1C60-1C62: Human immunodeficiency virus disease
D1129,Niacin,938,Niacin (TN); Niacinamide (TN); Nicotinamide (TN),Vitamins/Antihyperlipidemic Agents,Small molecule,"1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",PVNIIMVLHYAWGP-UHFFFAOYSA-N,C1=CC(=CN=C1)C(=O)O,59-67-6,C6H5NO2,15940,5C52: Inborn lipid metabolism error
D1130,Nicardipine,4474,"Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate",Antihypertensive Agents,Small molecule,"1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3",ZBBHBTPTTSWHBA-UHFFFAOYSA-N,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,55985-32-5,C26H29N3O6,7550,BA00: Essential hypertension
D1131,Niclosamide,4477,"niclosamide; 50-65-7; Niclocide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Tredemine; Bayluscid; Phenasal; Yomesan; Fenasal; Dichlosale; Helmiantin; Sagimid; Iomezan; Devermine; Atenase; Vermitid; Radeverm; Mansonil; Iomesan; Devermin; Cestocid; Sulqui; Lintex; Nasemo; Mato; Fedal-Telmin; Bayer 73; Radewerm; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; Chemagro 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; Niclosamidum [I",Anthelmintics,Small molecule,"1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)",RJMUSRYZPJIFPJ-UHFFFAOYSA-N,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,50-65-7,C13H8Cl2N2O4,7553,1F70-1F76: Cestodes infection
D1132,Nicotinamide,936,"Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide",Antiinflammatory Agents,Small molecule,"1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)",DFPAKSUCGFBDDF-UHFFFAOYSA-N,C1=CC(=CN=C1)C(=O)N,98-92-0,C6H6N2O,17154,EF20: Acquired cutaneous blood vessel malformation
D1133,Nicotine,89594,"Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine",Smoking Cessation Agents,Small molecule,"1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1",SNICXCGAKADSCV-JTQLQIEISA-N,CN1CCCC1C2=CN=CC=C2,20033,C10H14N2,17688,6C4A: Nicotine use disorder
D1134,Nifedipine,4485,"Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]",Analgesics,Small molecule,"1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3",HYIMSNHJOBLJNT-UHFFFAOYSA-N,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,21829-25-4,C17H18N2O6,7565,BA40: Angina pectoris
D1135,Nifurtimox,6842999,"NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide",Antibiotics,Small molecule,"1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+",ARFHIAQFJWUCFH-IZZDOVSWSA-N,CC1CS(=O)(=O)CCN1N=CC2=CC=C(O2)[N+](=O)[O-],23256-30-6,C10H13N3O5S,7566,1D51-1F53: Trypanosomiasis; 1F53: Chagas disease
D1136,Nilotinib,644241,"NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)",Antineoplastics,Small molecule,"1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,641571-10-0,C28H22F3N7O,52172,2A20: Myeloproliferative neoplasm
D1137,Nilutamide,4493,"Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione",Antineoplastics,Small molecule,"1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)",XWXYUMMDTVBTOU-UHFFFAOYSA-N,CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C,63612-50-0,C12H10F3N3O4,7573,2C82: Prostate cancer
D1138,Nimodipine,4497,"Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3&prime;-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide",Vasodilator Agents,Small molecule,"1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3",UIAGMCDKSXEBJQ-UHFFFAOYSA-N,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,66085-59-4,C21H26N2O7,7575,BA85: Coronary vasospastic disease
D1139,Nintedanib,135423438,"Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate",Multikinase Inhibitors,Small molecule,"1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3",CPMDPSXJELVGJG-UHFFFAOYSA-N,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,656247-17-5,C31H33N5O4,85164,2B91: Colorectal cancer; CB03: Idiopathic interstitial pneumonitis; 2C73: Ovarian cancer; 2C25: Lung cancer; 2C51: Peritoneal cancer
D1140,Niraparib,24958200,1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226,Poly (Adp-Ribose) Polymerase Inhibitors,Small molecule,"1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,1038915-60-4,C19H20N4O,.,2B52: Ewing sarcoma; 2C73: Ovarian cancer; 2C60-2C6Y: Breast cancer
D1141,Nisoldipine,4499,"Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate",Antihypertensive Agents,Small molecule,"1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3",VKQFCGNPDRICFG-UHFFFAOYSA-N,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,63675-72-9,C20H24N2O6,76917,BA00-BA04: Hypertension
D1142,Nitazoxanide,41684,"Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide",Antiparasitic Agents,Small molecule,"1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)",YQNQNVDNTFHQSW-UHFFFAOYSA-N,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],55981-09-4,C12H9N3O5S,94807,ME05: Bowel habit change
D1143,Nitisinone,115355,"Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione",Antineoplastics,Small molecule,"1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",OUBCNLGXQFSTLU-UHFFFAOYSA-N,C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-],104206-65-7,C14H10F3NO5,50378,5C50: Metabolism inborn error
D1144,Nitric Oxide,145068,"Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO;  HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)",Bronchodilators,Small molecule,1S/NO/c1-2,MWUXSHHQAYIFBG-UHFFFAOYSA-N,[N]=O,10102-43-9,NO,16480,CB41: Respiratory failure; 2A00-2F9Z: Solid tumour/cancer; 1F28: Dermatophytosis
D1145,Nitrofurantoin,6604200,"Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin",Antiinfective Agents,Small molecule,"1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+",NXFQHRVNIOXGAQ-YCRREMRBSA-N,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-],67-20-9,C8H6N4O5,71415,GC08: Urinary tract infection
D1146,Nitroglycerin,4510,"nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong;  Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401",Vasodilator Agents,Small molecule,"1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2",SNIOPGDIGTZGOP-UHFFFAOYSA-N,C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],55-63-0,C3H5N3O9,28787,BD54: Diabetic foot ulcer; BA40: Angina pectoris
D1147,Nitroprusside,11953891,C07269; LS-187044,Antihypertensive Agents,Small molecule,1S/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+6;-1,CDLSWOALPINAJL-UHFFFAOYSA-N,[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+6],.,C5FeN6O,.,BA00-BA04: Hypertension
D1148,Nitrous acid,24529,"NITROUS ACID; Nitrosyl hydroxide; 7782-77-6; HNO2; Kyselina dusite; dioxonitric acid; UNII-T2I5UM75DN; hydroxidooxidonitrogen; HONO; Nitrite (NO2-); CHEBI:25567; T2I5UM75DN; Kyselina dusite [Czech]; EINECS 231-963-7; HSDB 7801; Nitrogen dioxide ion; Nitrous acid, trans; NITROUSACID; Nitrogen peroxide ion; hydrogen dioxonitrate(1-); [NO(OH)]; CHEMBL1161681; DTXSID7064813; BDBM50147619; DB09112; C00088; Q207895; Q211891",Antidotes,Small molecule,"InChI=1S/HNO2/c2-1-3/h(H,2,3)",IOVCWXUNBOPUCH-UHFFFAOYSA-N,N(=O)O,.,HNO2,.,.
D1149,Nitrous oxide,948,"Distickstoffmonoxid; Lachgas; Stickdioxyd; Dinitrogen monoxide; Dinitrogen oxide; Factitious air; Gaz hilarant; Hyponitrous acid anhydride; Laughing gas; Nitrogen hypoxide; Nitrogenium oxydulatum; Nitrous oxide [JAN]; Oxido nitroso; Oxido nitroso [Spanish]; Oxyde nitreux; Stickdioxyd [German]; N2O; Nitrous oxide [UN1070] [Nonflammable gas]; Diazyne 1-oxide; Gas, Laughing; NITROUS-OXIDE; Nitrogen oxide (N2O); Nitrous oxide (TN); Nitrous oxide [Anaesthetics, volatile]; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Oxide, Nitrous; Protoxyde d'azote; Protoxyde d'azote [French]; Nitrous oxide (JP15/USP); Oxidodinitrogen(N-N); Stickstoff(I)-oxid",Respiratory Agents,Small molecule,1S/N2O/c1-2-3,GQPLMRYTRLFLPF-UHFFFAOYSA-N,[N-]=[N+]=O,10024-97-2,N2O,17045,6B00-6B0Z: Anxiety disorder
D1150,Nivolumab,.,.,Antineoplastics/Anti-Pd-1 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2B33: Malignant haematopoietic neoplasm; 2A20: Myeloproliferative neoplasm; 2A81: Diffuse large B-cell lymphoma; 2A80: Follicular lymphoma; 2C26: Pleural mesothelioma; 2A83: Multiple myeloma; 2C73: Ovarian cancer; 2C10: Pancreatic cancer; 2C82: Prostate cancer; 2C25: Lung cancer; 2B70: Esophageal cancer; 2B72: Stomach cancer; 2A00: Brain cancer; 2C90: Renal cell carcinoma; 2C60-2C6Y: Breast cancer; 2C30: Melanoma
D1151,Nizatidine,3033637,"Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine",Antiulcer Agents,Small molecule,"1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+",SGXXNSQHWDMGGP-IZZDOVSWSA-N,CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C,76963-41-2,C12H21N5O2S2,7601,DA22: Gastro-oesophageal reflux disease
D1152,Norelgestromin,9568628,"Norelgestromin; 53016-31-2; UNII-UM2XKY25DH; UM2XKY25DH; Evra; Ortho Evra; RWJ-10553; Norgestimate metabolite Norelgestromin; 17-Desacetyl Norgestimate; DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE); C21H29NO2; Deacetylnorgestimate; anti-Norelgestromin; NCGC00168787-01; ((E)-Norelgestromin); Norelgestromin, (E)-; Norelgestromin (USP/INN); DSSTox_CID_26788; DSSTox_RID_81906; DSSTox_GSID_46788; (E)-17-Deacetylnorgestimate; Norgestimate impurity C [EP]; SCHEMBL3163347; 17-Deacetylnorgestimate, (E)-; CHEMBL1200807; DTXSID9046788; CHEBI:135398; HY-G0018; Tox21_112647; 3046AH; BDBM50103633; AKOS015917579; NCGC00485891-01; CAS-53016-31-2; D05205; UNII-R0TAY3X631 component ISHXLNHNDMZNMC-VTKCIJPMSA-N; (3E)-13beta-Ethyl-3-(hydroxyimino)-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, oxime, (3E,17alpha)-; (3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; (8R,9S,10R,13S,14S,17R,E)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one oxime; 74183-55-4",Hormones/Antineoplastics,Small molecule,"InChI=1S/C21H29NO2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23-24H,3,5-12H2,1H3/b22-15+/t16-,17+,18+,19-,20-,21-/m0/s1",ISHXLNHNDMZNMC-VTKCIJPMSA-N,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C/C(=N/O)/CC[C@H]34,.,C21H29NO2,.,.
D1153,Norepinephrine,439260,"norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins",Vasoconstrictor Agents,Small molecule,"1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1",SFLSHLFXELFNJZ-QMMMGPOBSA-N,C1=CC(=C(C=C1C(CN)O)O)O,51-41-2,C8H11NO3,18357,1G40-1G41: Sepsis
D1154,Norethisterone,6230,"Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one",Contraceptive Agents,Small molecule,"1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1",VIKNJXKGJWUCNN-XGXHKTLJSA-N,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,68-22-4,C20H26O2,7627,2A00-2F9Z: Solid tumour/cancer
D1155,Norfloxacin,4539,"Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid",Antibiotics,Small molecule,"1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)",OGJPXUAPXNRGGI-UHFFFAOYSA-N,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,70458-96-7,C16H18FN3O3,100246,1A00-1C4Z: Bacterial infection
D1156,Norgestimate,6540478,"Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate",Contraceptive Agents,Small molecule,"1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1",KIQQMECNKUGGKA-NMYWJIRASA-N,CCC12CCC3C(C1CCC2(C#C)OC(=O)C)CCC4=CC(=NO)CCC34,20799-27-3,C23H31NO3,50815,QA21: Contraceptive management
D1157,Norgestrel,13109,"norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme;  Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS",Contraceptive Agents,Small molecule,"1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1",WWYNJERNGUHSAO-XUDSTZEESA-N,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,797-63-7,C21H28O2,6443,QA21: Contraceptive management
D1158,Nortriptyline,4543,"Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene",Antidepressants,Small molecule,"1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3",PHVGLTMQBUFIQQ-UHFFFAOYSA-N,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,72-69-5,C19H21N,7640,6A70-6A7Z: Depression
D1159,Novobiocin,54675769,"Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one",Antibiotics,Small molecule,"1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1",YJQPYGGHQPGBLI-KGSXXDOSSA-N,CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O,303-81-1,C31H36N2O11,28368,1A00-1C4Z: Bacterial infection
D1160,Obeticholic acid,447715,INT747; INT-747; 6-ethylchenodeoxycholic acid; 6-ECDCA; OCA; 6-Et CDCA,Gi Agents,Small molecule,"1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1",ZXERDUOLZKYMJM-ZWECCWDJSA-N,CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O,459789-99-2,C26H44O4,43602,DB96: Autoimmune liver disease; 7A00-7A0Z: Insomnia
D1161,Obinutuzumab,.,GA101/RG7159,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A82: Mature B-cell leukaemia; 2B33: Malignant haematopoietic neoplasm
D1162,Ocrelizumab,.,Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,8A40: Multiple sclerosis; 2A81: Diffuse large B-cell lymphoma
D1163,Octreotide,448601,"Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide",Somatostatin/Somatostatin Analogs,Small molecule,"1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1",DEQANNDTNATYII-OULOTJBUSA-N,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,83150-76-9,C49H66N10O10S2,.,5A60-5A61: Pituitary gland disorder
D1164,Ofatumumab,.,Arzerra (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A82: Mature B-cell leukaemia; FA20: Rheumatoid arthritis; 2A81: Diffuse large B-cell lymphoma; 2B33: Malignant haematopoietic neoplasm
D1165,Ofloxacin,4583,"Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",Antibiotics,Small molecule,"1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)",GSDSWSVVBLHKDQ-UHFFFAOYSA-N,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,82419-36-1,C18H20FN3O4,7731,1A00-1C4Z: Bacterial infection
D1166,Olanzapine,135398745,"Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine",Antipsychotic Agents,Small molecule,"1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",KVWDHTXUZHCGIO-UHFFFAOYSA-N,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,132539-06-1,C17H20N4S,7735,6A20: Schizophrenia
D1167,Olaparib,23725625,"AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one",Poly (Adp-Ribose) Polymerase Inhibitors,Small molecule,"1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,763113-22-0,C24H23FN4O3,83766,2C73: Ovarian cancer; 2C10: Pancreatic cancer; 2C82: Prostate cancer
D1168,Olaratumab,.,LY3012207,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B57: Kaposi sarcoma; 2C25: Lung cancer
D1169,Oliceridine,66553195,TRV130A,Narcotic Analgesics,Small molecule,"1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1",DMNOVGJWPASQDL-OAQYLSRUSA-N,COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4,1401028-24-7,C22H30N2O2S,.,5A00-5A06: Thyroid disease; MG31: Acute pain
D1170,Olmesartan,158781,"Olmesartan; 144689-24-7; Olmesartan Acid; RNH 6270; RNH-6270; UNII-8W1IQP3U10; CS-088; 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; CHEMBL1516; 8W1IQP3U10; CHEBI:48416; MFCD00914967; NSC-759810; Votum; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; omesartan; Olme sartan; 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; SMR000466337; Olmesartan [USAN:INN:BAN]; Benicar;Olmetec; HSDB 8214; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; Olmesartan medoximil; CS 088; Diclofenacdiethylamine; Olmesartan (USAN/INN); EC 646-413-5; SCHEMBL94037; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; MLS000759446; MLS001424016; MLS006011945; DTXSID2040571; Olmesartan, >=98% (HPLC); HMS2051K12; HMS2235O24; HMS3369I09; HMS3393K12; HMS3604J06; Pharmakon1600-01505206; ZINC538621; BCP12007; 3949AH; BDBM50241364; DE-092; NSC759810; s5581; AKOS015900241; AKOS024458255; AC-9385; CCG-100868; CCG-269198; CS-0576; DB00275; MCULE-9101392328; NC00118; NSC 759810; NCGC00246968-01; NCGC00246968-02; NCGC00246968-04; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-; 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid; AS-10242; HY-17004; Olmesartan medoxomil impurity, olmesartan-; SMR004703526; DB-042742; FT-0631169; O-125; O0507; C21543; D05246; 689O247; A853148; L001097; Olmesartan 100 microg/mL in Acetonitrile:Methanol; Q421156; W-201270; Z1583819783; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate; 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid; 1H-IMidazole-5-carboxylicacid,4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (Olmesartan); 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid; 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid; 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.; OLM",Antihypertensive Agents,Small molecule,"InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)",VTRAEEWXHOVJFV-UHFFFAOYSA-N,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O,.,C24H26N6O3,.,.
D1171,Olodaterol,11504295,BI-1744,Adrenergic Bronchodilators,Small molecule,"1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1",COUYJEVMBVSIHV-SFHVURJKSA-N,CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O,868049-49-4,C21H26N2O5,82700,CA22: Chronic obstructive pulmonary disease
D1172,Olopatadine (nasal),5281071,"Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride",Antiallergic Agents,Small molecule,"1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-",JBIMVDZLSHOPLA-LSCVHKIXSA-N,CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,113806-05-6,C21H23NO3,94593,9A60: Conjunctiva disorder; 4A80-4A8Z: Allergic/hypersensitivity disorder
D1173,Olsalazine,22419,Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine,Immunosuppressive Agents,Small molecule,"1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)",QQBDLJCYGRGAKP-UHFFFAOYSA-N,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,15722-48-2,C14H10N2O6,7770,DD71: Ulcerative colitis
D1174,Omacetaxine mepesuccinate,285033,Synribo (TN),Antineoplastics,Small molecule,"1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1",HYFHYPWGAURHIV-JFIAXGOJSA-N,CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O,26833-87-4,C29H39NO9,71019,2A20: Myeloproliferative neoplasm
D1175,Omadacycline,54697325,UNII-090IP5RV8F; 090IP5RV8F; Omadacycline [USAN:INN]; Omadacycline (USAN); AC1NUY3H; Amadacycline methanesulfonate; SCHEMBL152,Tetracyclines,Small molecule,"1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1",VJYKVCURWJGLPG-IQZGDKDPSA-N,CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,389139-89-3,C29H40N4O7,.,1A00-1C4Z: Bacterial infection; CA40: Pneumonia
D1176,Omalizumab,.,Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN),Antiasthmatic Agents,Monoclonal antibody,.,.,.,.,.,.,CA23: Asthma; EB00: Spontaneous urticaria
D1177,Ombitasvir,54767916,"HCV therapeutic, Abbott",Antiviral Agents,Small molecule,"1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1",PIDFDZJZLOTZTM-KHVQSSSXSA-N,CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,1258226-87-7,C50H67N7O8,85183,1E50-1E51: Hepatitis virus infection
D1178,Omega-3 fatty acids,56842239,"Omefas; Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera",Nutritional Supplements,Small molecule,"1S/C22H32O2.C20H30O2.C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;4-3-,7-6-,10-9-,13-12-,16-15-;4-3-,7-6-,10-9-",QPEOIOLHJXXJFN-GNGJDXFDSA-N,CCC=CCC=CCC=CCCCCCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O.CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O,.,C60H92O6,.,5C80: Hyper-lipoproteinaemia
D1179,Omeprazole,4594,Losec (TN),Antiulcer Agents,Small molecule,"1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)",SUBDBMMJDZJVOS-UHFFFAOYSA-N,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,73590-58-6,C17H19N3O3S,77260,DA22: Gastro-oesophageal reflux disease
D1180,Onasemnogene abeparvovec,.,DB15528; Onasemnogene abeparvovec; onasemnogene abeparvovec-xioi,Gene Therapies,Small interfering RNA,.,.,.,.,.,.,.
D1181,Ondansetron,4595,"DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one",Antiemetics,Small molecule,"1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,99614-02-5,C18H19N3O,7773,MD90: Nausea/vomiting; 6C40: Substance abuse
D1182,Opicapone,135565903,BIA-9-1067,Dopaminergic Antiparkinsonism Agents,Small molecule,"1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3",ASOADIZOVZTJSR-UHFFFAOYSA-N,CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-],923287-50-7,C15H10Cl2N4O6,134699,8A00: Parkinsonism
D1183,Opium,.,"8002-76-4; A mixture of 253 parts of morphine hydrochloride, 23 parts of papaverine hydrochloride and 20 parts of codeine hydrochloride; Concentrated opium; DTXSID50230012; Omnopon; Omnopone; Pantopium; Pantopon; Papaveretum; Papaveretum [BAN]; Tetrapon",Narcotic Analgesics,Small molecule,.,.,.,.,.,.,.
D1184,Oprelvekin,.,Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN),Platelet-Stimulating Agents,Interferons,.,.,.,.,.,.,3B64: Thrombocytopenia
D1185,Orciprenaline,4086,"metaproterenol; ORCIPRENALINE; 586-06-1; Alupent; Orciprenalinum; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Prometa; Orciprenaline [INN]; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; Orciprenaline (INN); CHEMBL776; CHEBI:6792; 5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol; Orciprenalina; CCRIS 9017; TH-152; SR-01000075168; EINECS 209-569-1; Orciprenaline [INN:BAN]; BRN 2807247; Orciprenalin; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; Spectrum_000925; Prestwick0_000505; Prestwick1_000505; Prestwick2_000505; Prestwick3_000505; Spectrum2_000096; Spectrum3_000492; Spectrum4_000044; Spectrum5_000952; M-3070; SCHEMBL4270; Lopac0_000734; BSPBio_000429; BSPBio_001983; KBioGR_000507; KBioSS_001405; DivK1c_000645; SPECTRUM1500390; SPBio_000052; SPBio_002350; BPBio1_000473; GTPL7250; DTXSID8048529; CHEBI:83329; HMS502A07; HY-B1276A; KBio1_000645; KBio2_001405; KBio2_003973; KBio2_006541; KBio3_001483; NINDS_000645; HMS1920L09; HMS2091D04; HMS3259J13; Pharmakon1600-01500390; 1,3-Benzenediol, 5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-; Benzyl alcohol, 3,5-dihydroxy-alpha-((isopropylamino)methyl)-; BDBM50295572; CCG-38914; NSC757089; DB00816; MCULE-8722254342; NC00651; NSC 757089; NSC-757089; SDCCGSBI-0050712.P005; IDI1_000645; NCGC00015655-02; NCGC00015655-03; NCGC00015655-04; NCGC00015655-05; NCGC00015655-06; NCGC00015655-14; NCGC00094718-01; NCGC00094718-02; NCGC00094718-03; SBI-0050712.P004; AB00052037; CS-0013668; C07144; D08300; 1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; AB00052037_09; AB00052037_10; 586O061; L000678; Q416473; SR-01000075168-1; SR-01000075168-4; BRD-A07780951-001-06-3; 5-(1-Hydroxy-2-(isopropylamino)ethyl)benzene-1,3-diol; 5-(1-Hydroxy-2-isopropylamino-ethyl)-benzene-1,3-diol; 3,5-dihydroxy-alpha-[(isopropylamino)methyl]benzenemethanol; 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol; 5-[1-Hydroxy-2-(isopropylamino)ethyl]-1,3-benzenediol #; [2-(3,5-Dihydroxy-phenyl)-2-hydroxy-ethyl]-isopropyl-ammonium; 3,5-Dihydroxy-.alpha.-((isopropylamino)methyl)benzyl alcohol; 5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,3-diol, 6; Benzyl alcohol, 3,5-dihydroxy-.alpha.-((isopropylamino)methyl)-; 1,3-Benzenediol, 5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- (9CI); [2-(3,5-Dihydroxy-phenyl)-2-hydroxy-ethyl]-isopropyl-ammonium (orciprenaline)",Adrenergic Bronchodilators,Small molecule,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3",LMOINURANNBYCM-UHFFFAOYSA-N,CC(C)NCC(C1=CC(=CC(=C1)O)O)O,.,C11H17NO3,.,.
D1186,Oritavancin,16136912,"Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin",Glycopeptide Antibiotics,Small molecule,"1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1",VHFGEBVPHAGQPI-LXKZPTCJSA-N,CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O,171099-57-3,C86H97Cl3N10O26,82699,1A00-1C4Z: Bacterial infection; 1B74-1F40: Gram-positive bacterial infection
D1187,Orlistat,3034010,"orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247;  Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN",Antiobesity Agents,Small molecule,"1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1",AHLBNYSZXLDEJQ-FWEHEUNISA-N,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,96829-58-2,C29H53NO5,94686,5B80-5B81: Obesity
D1188,Orphenadrine,4601,"Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine",Antiparkinson Agents,Small molecule,"1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3",QVYRGXJJSLMXQH-UHFFFAOYSA-N,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,83-98-7,C18H23NO,7789,8A00: Parkinsonism
D1189,Osilodrostat,44139752,"LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile",Adrenal Corticosteroid Inhibitors,Small molecule,"1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1",USUZGMWDZDXMDG-CYBMUJFWSA-N,C1CC2=CN=CN2C1C3=C(C=C(C=C3)C#N)F,928134-65-0,C13H10FN3,.,5A70: Cushing syndrome
D1190,Osimertinib,71496458,Tagrisso,Egfr Inhibitors,Small molecule,"1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,1421373-65-0,C28H33N7O2,90943,2C25: Lung cancer; 2C30: Melanoma
D1191,Ospemifene,3036505,"Ospemifene; 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2",Selective Estrogen Receptor Modulators,Small molecule,"1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-",LUMKNAVTFCDUIE-VHXPQNKSSA-N,C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=C(C=C3)OCCO)CCCl,128607-22-7,C24H23ClO2,73275,GA12: Dyspareunia; GA30: Menopausal disorder
D1192,Oxacillin,6196,"Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid",Antibiotics,Small molecule,"1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1",UWYHMGVUTGAWSP-JKIFEVAISA-N,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,66-79-5,C19H19N3O5S,7809,1A00-1C4Z: Bacterial infection
D1193,Oxaliplatin,9887053,Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN),Antineoplastics,Small molecule,"1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1",DRMCATBEKSVAPL-BNTLRKBRSA-N,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],61825-94-3,C8H14N2O4Pt,.,2B91: Colorectal cancer
D1194,Oxamniquine,4612,"Mansil; Oxaminiquine; Oxamniquina; Oxamniquinum; Vansil; UK 4261; UK 4271; Mansil (TN); Oxamniquina [INN-Spanish]; Oxamniquinum [INN-Latin]; UK-4271; Vansil (TN); Oxamniquine (USAN/INN); Oxamniquine [USAN:BAN:INN]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline",Schistosomicides,Small molecule,"1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3",XCGYUJZMCCFSRP-UHFFFAOYSA-N,CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO,21738-42-1,C14H21N3O3,78416,1F86: Schistosomiasis
D1195,Oxandrolone,5878,"Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)",Androgens/Anabolic Steroids,Small molecule,"1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1",QSLJIVKCVHQPLV-PEMPUTJUSA-N,CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C,53-39-4,C19H30O3,7820,DB94: Alcoholic liver disease
D1196,Oxaprozin,4614,"Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid",Antiinflammatory Agents,Small molecule,"1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)",OFPXSFXSNFPTHF-UHFFFAOYSA-N,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,21256-18-8,C18H15NO3,7822,FA20: Rheumatoid arthritis
D1197,Oxazepam,4616,"Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)",ADIMAYPTOBDMTL-UHFFFAOYSA-N,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,604-75-1,C15H11ClN2O2,7823,6B00-6B0Z: Anxiety disorder
D1198,Oxcarbazepine,34312,"Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide",Anticonvulsants,Small molecule,"1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)",CTRLABGOLIVAIY-UHFFFAOYSA-N,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,28721-07-5,C15H12N2O2,7824,8A61-8A6Z: Epilepsy/seizure
D1199,Oxidronic acid,27304,"OXIDRONIC ACID; HMDP; 15468-10-7; Hydroxymethanediphosphonic acid; [hydroxy(phosphono)methyl]phosphonic acid; Oxidronate; UNII-71MR4V32TI; (Hydroxymethylene)diphosphonic acid; HMD-P; 71MR4V32TI; Phosphonic acid, (hydroxymethylene)bis-; Oxidronsaeure; Acido oxidronico; Acide oxidronique; Acidum oxidronicum; Acide oxidronique [INN-French]; Acido oxidronico [INN-Spanish]; Acidum oxidronicum [INN-Latin]; (Hydroxymethylen)diphosphonsaeure; Oxidronic acid [USAN:INN:BAN]; (Hydroxymethylene)disphosphonic acid; Oxidronic acid (USAN); hydroxymethane diphosphonate; SCHEMBL393281; CHEMBL1615775; DTXSID10165699; CHEBI:134844; ZINC24740492; DB14159; FT-0700046; D05296; Q27265970",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/CH6O7P2/c2-1(9(3,4)5)10(6,7)8/h1-2H,(H2,3,4,5)(H2,6,7,8)",HJZKOAYDRQLPME-UHFFFAOYSA-N,C(O)(P(=O)(O)O)P(=O)(O)O,.,CH6O7P2,.,.
D1200,Oxitriptan,439280,5-hydroxytryptophan,Antidepressants,Small molecule,"1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1",LDCYZAJDBXYCGN-VIFPVBQESA-N,C1=CC2=C(C=C1O)C(=CN2)CC(C(=O)O)N,895096,C11H12N2O3,17780,.
D1201,Oxtriphylline,656652,"Choledyl; Cholegyl; Cholinophyllin; Cholinophylline; Filoral; Oxtrimethylline; Sabidal; Soliphylline; Teofilcolina; Teokolin; Theoxylline; Choline theophylline salt; Cholini theophyllinas; Colina teofillinato; Colina teofillinato [DCIT]; Oxtriphylline [USAN]; Oxtriphylline pediatric; Teofilinato de colina; Theophyllinate de choline; Theophylline cholinate; Theophylline salt of choline; Choledyl SA 400; Zy 15061; Choledyl (TN); Cholini theophyllinas [INN-Latin]; Teofilinato de colina [INN-Spanish]; Theophyllinate de choline[INN-French]; Choline salt with theophylline (1:1); Theophylline, compd. with choline; Choline, compd. with theophylline (1:1); Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); (2-Hydroxyethyl)trimethylammonium compound with theophylline; 1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium",Bronchodilators,Small molecule,"1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1",SOELXOBIIIBLRJ-UHFFFAOYSA-M,CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO,4499-40-5,C12H21N5O3,.,MD12: Cough
D1202,Oxybutynin,4634,"5633-20-5; Ditropan; Oxytrol; Oxibutyninum; Oxybutyninum; Oxibutinina; Oxybutyninum [INN-Latin]; Oxybutynine [INN-French]; Oxybutinin; Cystrin; Oxibutinina [INN-Spanish]; Oxybutynin Base; transdermal patch; Lyrinel XL; Oxybutynin [USAN:INN:BAN]; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; CCRIS 1923; oxybutynin topical gel; Ditropan Xl; Oxybutynin (Ditropan); HSDB 3270; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; CHEMBL1231; Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-b",Urinary Antispasmodics,Small molecule,"1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3",XIQVNETUBQGFHX-UHFFFAOYSA-N,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,5633-20-5,C22H31NO3,7856,.
D1203,Oxycodone,5284603,.,Analgesics,Small molecule,"1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1",BRUQQQPBMZOVGD-XFKAJCMBSA-N,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,76-42-6,C18H21NO4,7852,MG30-MG3Z: Pain; ME84: Spinal pain
D1204,Oxymetazoline (nasal),4636,"Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol",Decongestants,Small molecule,"1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)",WYWIFABBXFUGLM-UHFFFAOYSA-N,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,1491-59-4,C16H24N2O,7862,9A02: Eyelid inflammatory disorder; MD11: Breathing abnormality
D1205,Oxymetazoline (ophthalmic),4636,"Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol",Decongestants,Small molecule,"1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)",WYWIFABBXFUGLM-UHFFFAOYSA-N,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,1491-59-4,C16H24N2O,7862,9A02: Eyelid inflammatory disorder; MD11: Breathing abnormality
D1206,Oxymetazoline (topical),4636,"Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol",Decongestants,Small molecule,"1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)",WYWIFABBXFUGLM-UHFFFAOYSA-N,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,1491-59-4,C16H24N2O,7862,9A02: Eyelid inflammatory disorder; MD11: Breathing abnormality
D1207,Oxymetholone,5281034,oxymetholone; Anasterone; 434-07-1; HMS3393H15,Androgens/Anabolic Steroids,Small molecule,"1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1",ICMWWNHDUZJFDW-DHODBPELSA-N,CC12CCC3C(C1CCC2(C)O)CCC4C3(CC(=CO)C(=O)C4)C,434-07-1,C21H32O3,7864,3A70: Aplastic anaemia
D1208,Oxymorphone,5284604,"Oxymorphone (abuse-resistant, pain); Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals; Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer",Narcotic Analgesics,Small molecule,"1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1",UQCNKQCJZOAFTQ-ISWURRPUSA-N,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,76-41-5,C17H19NO4,7865,MG30-MG3Z: Pain
D1209,Oxytetracycline,54675779,"Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline",Antibiotics,Small molecule,"1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1",OWFJMIVZYSDULZ-PXOLEDIWSA-N,CC1(C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,2058-46-0,C22H24N2O9,27701,1A00-1C4Z: Bacterial infection
D1210,Oxytocin,439302,"OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior;  Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat)",Uterotonic Agents,Small molecule,"1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1",XNOPRXBHLZRZKH-DSZYJQQASA-N,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,50-56-6,C43H66N12O12S2,7872,6A02: Autism spectrum disorder; JB46: Childbirth associated breast/lactation disorder
D1211,Ozanimod,52938427,"1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1",Selective Immunosuppressants,Small molecule,"1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1",XRVDGNKRPOAQTN-FQEVSTJZSA-N,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N,1306760-87-1,C23H24N4O3,.,DD70: Crohn disease; DD71: Ulcerative colitis; 2C25: Lung cancer; 8A40: Multiple sclerosis
D1212,Paclitaxel,36314,"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-",Antineoplastics/Mitotic Inhibitors,Small molecule,"1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",RCINICONZNJXQF-MZXODVADSA-N,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,33069-62-4,C47H51NO14,45863,2B72: Stomach cancer; 2C73: Ovarian cancer; 2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer; 2C10: Pancreatic cancer
D1213,Paclitaxel (protein-bound),36314,"C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-",Antineoplastics/Mitotic Inhibitors,Small molecule,"1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1",RCINICONZNJXQF-MZXODVADSA-N,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,33069-62-4,C47H51NO14,45863,2B72: Stomach cancer; 2C73: Ovarian cancer; 2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer; 2C10: Pancreatic cancer
D1214,Palbociclib,5330286,"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE;  LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934",Antineoplastics,Small molecule,"1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,571190-30-2,C24H29N7O2,85993,2A00-2F9Z: Solid tumour/cancer; 6A20: Schizophrenia; 2C60-2C6Y: Breast cancer
D1215,Paliperidone,115237,"Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson",Atypical Antipsychotics,Small molecule,"1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3",PMXMIIMHBWHSKN-UHFFFAOYSA-N,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,144598-75-4,C23H27FN4O3,83804,6A20: Schizophrenia
D1216,Palonosetron,6337614,"Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one",Antiemetics,Small molecule,"1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1",CPZBLNMUGSZIPR-NVXWUHKLSA-N,C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5,135729-61-2,C19H24N2O,85161,MD90: Nausea/vomiting
D1217,Pamidronic acid,4674,"AHPrBP; Amidronate; Aminomux; Aminopropanehydroxydiphosphonate; Aredia; Ribodroat; Acide pamidronique; Acido pamidronico; Acidum pamidronicum; Aminohydroxypropylidene diphosphonate; Novartis brand of pamidronate disodium salt; PAMIDRONATE DISODIUM; PAMIDRONIC ACID; Pamidronate calcium; Pamidronate monosodium; Bisphosphonate 6; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; Pamidronic acid (INN); Pamidronic acid [INN:BAN]; Ribodroat (TN); Amino-1-hydroxypropane-1,1-diphosphonate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; 1-hydroxy-3-aminopropane-1,1-diphosphonic acid; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate",Antiinflammatory Agents,Small molecule,"1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)",WRUUGTRCQOWXEG-UHFFFAOYSA-N,C(CN)C(O)(P(=O)(O)O)P(=O)(O)O,40391-99-9,C3H11NO7P2,7903,5B91: Mineral excesses
D1218,Pancrelipase,8519,"Endothal-disodium; 13114-29-9; Sodium Demethylcantharidate; 129-67-9; Aguathol; Disodium endothall; Sodium 7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylate; disodium;7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylate; Sodium 3-carboxy-7-oxabicyclo[2.2.1]heptane-2-carboxylate; Pancrelipase; Disodium endothal; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid, disodium salt; Sodium norcantharidin; ENDOTHALL-SODIUM; Sodium-Demethylcantharidate; 53608-75-6; SCHEMBL1006891; DTXSID1041899; CHEBI:81916; FT-0775390; C18724; Q27155657",Digestive Enzymes,Protein/peptide,"InChI=1S/C8H10O5.2Na/c9-7(10)5-3-1-2-4(13-3)6(5)8(11)12;;/h3-6H,1-2H2,(H,9,10)(H,11,12);;/q;2*+1/p-2",XRHVZWWRFMCBAZ-UHFFFAOYSA-L,C1CC2C(C(C1O2)C(=O)[O-])C(=O)[O-].[Na+].[Na+],.,C8H8Na2O5,.,.
D1219,Pancuronium,441289,"Mioblock; Pavulon; Bromure de pancuronium; Bromuro de pancuronio; PANCURONIUM BROMIDE; Pancuronii bromidum; Pancuronium dibromide; Poncuronium bromide; NA 97; ORG NA 97; P 1918; Bromure de pancuronium [INN-French]; Bromuro de pancuronio [INN-Spanish]; ORG-NA 97; Pancuronii bromidum [INN-Latin]; Pavulon (TN); Pancuronium bromide (JP15/USAN/INN); Pancuronium bromide [USAN:BAN:INN:JAN]; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate",Neuromuscular Blocking Agents,Small molecule,"1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",GVEAYVLWDAFXET-XGHATYIMSA-N,CC(=O)OC1CC2CCC3C(C2(CC1[N+]4(CCCCC4)C)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C,16974-53-1,C35H60N2O4+2,7907,9A76-9A78: Corneal disease
D1220,Panitumumab,.,Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B91: Colorectal cancer; 2D42: Head and neck cancer
D1221,Panobinostat,6918837,"Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide",Histone Deacetylase Inhibitors,Small molecule,"1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,404950-80-7,C21H23N3O2,85990,2A83: Multiple myeloma; 2A20: Myeloproliferative neoplasm; 5A11: Type 2 diabetes mellitus
D1222,Pantoprazole,4679,"Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole",Antiulcer Agents,Small molecule,"1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",IQPSEEYGBUAQFF-UHFFFAOYSA-N,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,102625-70-7,C16H15F2N3O4S,7915,DA22: Gastro-oesophageal reflux disease
D1223,Papaverine,4680,"papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE",Vasodilator Agents,Small molecule,"1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3",XQYZDYMELSJDRZ-UHFFFAOYSA-N,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,58-74-2,C20H21NO4,28241,MB47: Tonus and reflex abnormality
D1224,Paraldehyde,31264,UNII-S6M3YBG8QA; S6M3YBG8QA,Cns Depressants,Small molecule,"1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3",SQYNKIJPMDEDEG-UHFFFAOYSA-N,CC1OC(OC(O1)C)C,123-63-7,C6H12O3,27909,7A00-7A0Z: Insomnia
D1225,Paramethadione,8280,"Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione",Anticonvulsants,Small molecule,"1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3",VQASKUSHBVDKGU-UHFFFAOYSA-N,CCC1(C(=O)N(C(=O)O1)C)C,115-67-3,C7H11NO3,7921,8A61-8A6Z: Epilepsy/seizure; LD2F: Multiple structural anomalies syndrome
D1226,Paricalcitol,5281104,"Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)",Parasympathomimetics,Small molecule,"1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1",BPKAHTKRCLCHEA-UBFJEZKGSA-N,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,131918-61-1,C27H44O3,7931,5A51: Hyper-parathyroidism
D1227,Paritaprevir,45110509,.,Antiviral Agents,Small molecule,"1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1",UAUIUKWPKRJZJV-QPLHLKROSA-N,CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8,1216941-48-8,C40H43N7O7S,.,1E50-1E51: Hepatitis virus infection
D1228,Paromomycin,165580,"Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine",Antibiotics,Small molecule,"1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",UOZODPSAJZTQNH-LSWIJEOBSA-N,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,7542-37-2,C23H45N5O14,7934,1A36: Amoebiasis
D1229,Paroxetine,43815,Seroxat (TN),Antidepressants,Small molecule,"1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1",AHOUBRCZNHFOSL-YOEHRIQHSA-N,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,61869-08-7,C19H20FNO3,7936,6A70-6A7Z: Depression
D1230,Pasireotide,9941444,"Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate;  Signifor (TN); SOM 230; SOM-230",Somatostatin/Somatostatin Analogs,Small molecule,"1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1",VMZMNAABQBOLAK-DBILLSOUSA-N,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,396091-73-9,C58H66N10O9,72312,5A70: Cushing syndrome
D1231,Patiromer,.,DB09263; Patiromer; Patiromer FOS,Cation Exchange Resins,Small molecule,.,.,.,.,.,.,.
D1232,Pazopanib,10113978,"Pazopanib; 444731-52-6; GW786034; UNII-7RN5DR86CK; Pazopanib (GW-786034); GW 786034; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide; 7RN5DR86CK; GW 78603; CHEBI:71219; MFCD11616589; NSC-752782; NCGC00188865-01; 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; DSSTox_CID_28659; DSSTox_RID_82929; DSSTox_GSID_48733; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfonamide; GW-786034; C21H23N7O2S; 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide; CAS-444731-52-6; 790713-33-6; Pazopanib [INN:BAN]; pazopanibum; HSDB 8210; Pazopanib- Bio-X; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-; GW 786034B; indazolylpyrimidine 13; Pazopanib (free base); Kinome_3790; GW780604; GW-780604; Pazopanib-d6 (deuterated); 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; SCHEMBL588608; CHEMBL477772; GTPL5698; JMC514632 Compound 13; DTXSID8048733; BDBM26474; QCR-110; SYN1058; cid_10113978; BCPP000129; HMS3244C21; HMS3244C22; HMS3244D21; HMS3656L14; HMS3745G05; AOB87179; BCP01839; EX-A1241; Tox21_113174; NSC752782; NSC800839; s3012; ZINC11617039; AKOS005145819; Tox21_113174_1; AC-8522; BCP9001053; CCG-265010; CS-0269; DB06589; MCULE-2193898201; NSC 752782; NSC-800839; SB17290; NCGC00188865-02; NCGC00188865-03; NCGC00188865-10; AS-11066; BD164238; HY-10208; AM20090659; FT-0659928; FT-0684794; SW218082-3; A19406; P-6706; AB01273967-01; AB01273967-02; AB01273967_05; AB01273967_06; A839572; AR-270/43507999; Q-101400; Q7157043; BRD-K74514084-003-02-7; Z1541638525; 5-(3-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)phenylamino)-2-methylbenzenesulfonamide; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide; 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]-pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide",Vegf/Vegfr Inhibitors,Small molecule,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,.,C21H23N7O2S,.,.
D1233,Pectin,441476,"pectin; BETA-D-GALACTOPYRANURONIC ACID; 18968-14-4; beta-D-galacturonic acid; UNII-55NG3O9NDD; (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid; 55NG3O9NDD; oligogalacturonide; SCHEMBL3407163; CHEBI:47954; Galactopyranuronic acid, beta-D-; ZINC4097542; MFCD00006618; DB03652; C08348; WURCS=2.0/1,1,0/[a2112A-1b_1-5]/1/; (2S,3R,4S,5R,6R)-3,4,5,6-Tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid",Antidiarrheals,Natural product,"InChI=1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2+,3+,4-,6+/m0/s1",AEMOLEFTQBMNLQ-DTEWXJGMSA-N,[C@@H]1([C@H]([C@H](O[C@H]([C@@H]1O)O)C(=O)O)O)O,.,C6H10O7,.,.
D1234,Pegaspargase,436058,.,Antineoplastics,Small molecule,"1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3",QXLQZLBNPTZMRK-UHFFFAOYSA-N,CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C,116218-49-6,C14H19NO,.,.
D1235,Pegfilgrastim,70683024,Neulasta; Neulasta (TN); Pegfilgrastim (INN),Immunomodulatory Agents,Small molecule,"1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1",GAQMWPRWVIGRRV-IVDGIBIRSA-N,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,.,C27H46N4O19,.,2A00-2F9Z: Solid tumour/cancer
D1236,Peginesatide,.,DB08894; Hematide; Peginesatide,Recombinant Human Erythropoietins,Protein/peptide,.,.,.,.,.,.,.
D1237,Peginterferon alfa-2a,.,Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a (USAN/INN); Peginterferon alfa-2a (genetical recombination) (JAN),Antineoplastics,Interferons,.,.,.,.,.,.,2A82: Mature B-cell leukaemia
D1238,Peginterferon alfa-2b,.,PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN),Antiviral Agents,Interferons,.,.,.,.,.,.,1E50-1E51: Hepatitis virus infection
D1239,Peginterferon beta-1a,.,DB09122; Peginterferon beta-1a,Interferons,Interferons,.,.,.,.,.,.,.
D1240,Pembrolizumab,.,.,Antineoplastics/Anti-Pd-1 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2A00-2F9Z: Solid tumour/cancer; 2C12: Liver cancer; 2C73: Ovarian cancer; 2A81: Diffuse large B-cell lymphoma; 2C82: Prostate cancer; 2C90: Renal cell carcinoma; 2C25: Lung cancer; 2C60-2C6Y: Breast cancer; 2B91: Colorectal cancer; 2C30: Melanoma; 2B70: Esophageal cancer
D1241,Pemetrexed,135410875,"Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID",Antineoplastics,Small molecule,"1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1",WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,137281-23-3,C20H21N5O6,63616,2C26: Pleural mesothelioma
D1242,Pemigatinib,86705695,"Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828",Multikinase Inhibitors,Small molecule,"1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)",HCDMJFOHIXMBOV-UHFFFAOYSA-N,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,1513857-77-6,C24H27F2N5O4,.,2C94: Bladder cancer; 2A20: Myeloproliferative neoplasm; 2C12: Liver cancer
D1243,Pemoline,4723,.,Cns Stimulants,Small molecule,"1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)",NRNCYVBFPDDJNE-UHFFFAOYSA-N,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,2152-34-3,C9H8N2O2,7953,6A05: Attention deficit hyperactivity disorder
D1244,Penbutolol,37464,Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol,Antihypertensive Agents,Small molecule,"1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1",KQXKVJAGOJTNJS-HNNXBMFYSA-N,CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O,38363-40-5,C18H29NO2,7954,BA00-BA04: Hypertension
D1245,Penicillamine,5852,"D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Beta-Thiovaline; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; Beta,beta-Dimethylcysteine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine; D-penicillamine",Antidotes,Small molecule,"1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1",VVNCNSJFMMFHPL-VKHMYHEASA-N,CC(C)(C(C(=O)O)N)S,771431-20-0,C5H11NO2S,7959,FA20: Rheumatoid arthritis
D1246,Pentamidine,4735,"Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide",Antifungal Agents,Small molecule,"1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)",XDRYMKDFEDOLFX-UHFFFAOYSA-N,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,100-33-4,C19H24N4O2,45081,1F29-1F2F: Fungal infection; 1C60-1C62: Human immunodeficiency virus disease
D1247,Pentazocine,441278,"Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol",Anesthetics,Small molecule,"1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1",VOKSWYLNZZRQPF-GDIGMMSISA-N,CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O,359-83-1,C19H27NO,7982,MG30-MG3Z: Pain
D1248,Pentobarbital,4737,"Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",WEXRUCMBJFQVBZ-UHFFFAOYSA-N,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC,76-74-4,C11H18N2O3,7983,7A00-7A0Z: Insomnia
D1249,Pentosan polysulfate,37720,"Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate",Anticoagulants,Small molecule,"1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1",FCCNSUIJIOOXEZ-SJYYZXOBSA-N,C1C(C(C(C(O1)OC2COC(C(C2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O,37300-21-3,C10H18O21S4,.,MG30: Chronic pain; GC00: Cystitis
D1250,Pentostatin,439693,"Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin",Antineoplastics,Small molecule,"1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1",FPVKHBSQESCIEP-JQCXWYLXSA-N,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,53910-25-1,C11H16N4O4,.,2A82: Mature B-cell leukaemia
D1251,Pentoxifylline,4740,"Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione",Vasodilator Agents,Small molecule,"1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3",BYPFEZZEUUWMEJ-UHFFFAOYSA-N,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,1677687,C13H18N4O3,7986,BD40: Arterial occlusive disease
D1252,Pentoxyverine,2562,"Carbetapentane citrate; Pentoxyverine citrate; 23142-01-0; Loucarbate; Pentoxiverine citrate; Carbetapentane citrate salt; Toclase; Toclase citrate; Carbetapentone citrate; Carbetapentane (citrate); UNII-4SH0MFJ5HJ; Carbetapentane citrate [NF]; EINECS 245-449-5; 4SH0MFJ5HJ; 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentanecarboxylate citrate; 2-(2(Diethylamino)ethoxy)ethyl 1-phenyl-cyclopentanecarboxylate citrate (1:1); 2-(2-(Diethylamino)ethoxy)ethyl 1-phenylcyclopentyl-1-carboxylate dihydrogen citrate; Ethanol, 2-(2-(die",Antitussives,Small molecule,"1S/C20H31NO3/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3",CFJMRBQWBDQYMK-UHFFFAOYSA-N,CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2,77-23-6,C20H31NO3,94484,MD12: Cough
D1253,Perampanel,9924495,"Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one",Anticonvulsants,Small molecule,"1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H",PRMWGUBFXWROHD-UHFFFAOYSA-N,C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4,380917-97-5,C23H15N3O,71013,8C0Z: Neuropathy; 8A00: Parkinsonism
D1254,Perflutren,6432,"Perfluoropropane; Perflutren; OCTAFLUOROPROPANE; Definity; 76-19-7; Freon 218; 1,1,1,2,2,3,3,3-Octafluoropropane; Propane, octafluoro-; Oktafluorpropan; Genetron 218; Octafluorpropan; DMP 115; MRX-115; FC 218; FC 218 (refrigerant); 9048-46-8; Bovine serum albumin; HFC 218; PFC 218; UNII-CK0N3WH0SR; FS069; UN 2424; R 218; CK0N3WH0SR; Optison; CHEBI:31980; Propane, 1,1,1,2,2,3,3,3-octafluoro-; C3F8-gas; Perflutren Lipid Microsphere; EINECS 200-941-9; UN2424; Perflutren lipid microspheres; Bovine albumin; Perflutren [USAN:INN:BAN]; C3F8; HSDB 8074; DMP-115; Definity (TN); FS-069; MFCD00039239; Optison (Salt/Mix); EC 200-941-9; Perflutren-lipid microsphere; Perflutren Protein-Type A Microspheres injection; CHEMBL1663; Perflutren (JAN/USAN/INN); DTXSID9052503; AMY6865; MRX 115; octafluoropropane-lipid microsphere; YM454; ZINC8214651; AKOS006228213; DB00556; FS-6566; Octafluoropropaneor Refrigerant gas R 218; DB-056033; FT-0621948; FT-0631321; liposome-encapsulated perfluoropane microsphere; 1,1,1,2,2,3,3,3-octakis(fluoranyl)propane; D01738; A838638; Q412659; Octafluoropropaneor Refrigerant gas R 218  [UN2424]  [Nonflammable gas]",Ultrasound Contrast Media,Small molecule,"InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11",QYSGYZVSCZSLHT-UHFFFAOYSA-N,C(C(F)(F)F)(C(F)(F)F)(F)F,.,C3F8,.,.
D1255,Pergolide,47811,"Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline",Antiparkinson Agents,Small molecule,"1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1",YEHCICAEULNIGD-MZMPZRCHSA-N,CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC,66104-22-1,C19H26N2S,63617,8A00: Parkinsonism
D1256,Perindopril,107807,"ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1",IPVQLZZIHOAWMC-QXKUPLGCSA-N,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,82834-16-0,C19H32N2O5,8024,BA00-BA04: Hypertension
D1257,Perphenazine,4748,"Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin;PZC; Perfenazina; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; Perfenazina [Italian]; Perphenazine [Trilafon]; Perphenazine maleate; P 6402; Sch 3940; Apo-Perphenazine; F-mon; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; SCH-3940; Siquil (TN); Triavil (TN); Perphenazine [INN:BAN:JAN]; Perphenazine (JP15/USP/INN); Gamma-[4-(beta-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; Gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol",Antipsychotic Agents,Small molecule,"1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2",RGCVKNLCSQQDEP-UHFFFAOYSA-N,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,58-39-9,C21H26ClN3OS,8028,6A20: Schizophrenia
D1258,Pexidartinib,25151352,PLX-3397,Multikinase Inhibitors,Small molecule,"1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)",JGWRKYUXBBNENE-UHFFFAOYSA-N,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F,1029044-16-3,C20H15ClF3N5,145373,8A20: Alzheimer disease; FA2Z: Inflammatory arthropathy; LD2D: Phakomatoses/hamartoneoplastic syndrome; 2F7B: Bone/articular cartilage neoplasm
D1259,Pfizer-BioNTech Covid-19 Vaccine,.,2417899-74-0; BNT162 vaccine; BNT162-01; Bnt162a1; Bnt-162a1; N38TVC63NU; Pfizer-BioNTech COVID-19 vaccine; UNII-N38TVC63NU,Vaccines,Vaccine,.,.,.,.,.,.,.
D1260,Phenacemide,4753,Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea,Anticonvulsants,Small molecule,"1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)",XPFRXWCVYUEORT-UHFFFAOYSA-N,C1=CC=C(C=C1)CC(=O)NC(=O)N,63-98-9,C9H10N2O2,8049,8A61-8A6Z: Epilepsy/seizure
D1261,Phenazopyridine,4756,"phenazopyridine; Pyridiate; Gastracid; 94-78-0; Baridium; Pyrazofen; Urogesic; 3-(Phenylazo)-2,6-pyridinediamine; Geridium; Gastrotest; Viridium; 2,6-Pyridinediamine, 3-(phenylazo)-; Pyridacil; Fenazopiridina; Eridium; 2,6-Diamino-3-phenylazopyridine; Phenazopyridinum; 2,6-Diamino-3-(phenylazo)pyridine; Phenazopyridine [INN:BAN]; UNII-K2J09EMJ52; Phenazopyridinum [INN-Latin]; Fenazopiridina [INN-Spanish]; NSC 145895; HSDB 3153; EINECS 202-363-2; BRN 0184497; 3-(phenyldiazenyl)pyridine-2,6-diamine; Pyridine, 2,6-diamino-3-(phenylazo)-",Genitourinary Tract Agents,Small molecule,"1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)",QPFYXYFORQJZEC-UHFFFAOYSA-N,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N,94-78-0,C11H11N5,71416,MG30-MG3Z: Pain
D1262,Phendimetrazine,30487,"Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine",Anorexiants,Small molecule,"1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1",MFOCDFTXLCYLKU-CMPLNLGQSA-N,CC1C(OCCN1C)C2=CC=CC=C2,634-03-7,C12H17NO,8059,5B80-5B81: Obesity
D1263,Phenelzine,3675,Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine,Antidepressants,Small molecule,"1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2",RMUCZJUITONUFY-UHFFFAOYSA-N,C1=CC=C(C=C1)CCNN,51-71-8,C8H12N2,8060,EK71: Skin tag/polyp; 6A70-6A7Z: Depression
D1264,Phenindamine,11291,"Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine",Antihistamines,Small molecule,"1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3",ISFHAYSTHMVOJR-UHFFFAOYSA-N,CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4,82-88-2,C19H19N,8065,CA00: Nasopharyngitis
D1265,Phenobarbital,4763,"Adonal; Aephenal; Agrypnal; Amylofene; Antrocol; Aphenylbarbit; Aphenyletten; Austrominal; Barbapil; Barbellen; Barbellon; Barbenyl; Barbilehae; Barbinal; Barbipenyl; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Donphen; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Ezibarbitur; Fenbital; Fenemal; Fenobarbital; Fenobarbitale; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nunol; PHOB; Parkotal; Pharmetten; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarb; Phenobarbitalum; Phenobarbitol; Phenobarbitone; Phenobarbitonum; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylaethylbarbitursaeure; Phenylethylbarbiturate; Phenylethylbarbitursaeure; Phenylethylmalonylurea; Phenyletten; Phenylral; Phenyral; Polcominal; Promptonal; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sedophen; Sevenal; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Theominal; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal; Aephe nal; Component of Antrocol; Component of Bronkotabs; Component of Hecadrol; Component of Primatene P; Component of Slowten; Component of Tedral; Elixir of phenobarbital; Fen osed; Fenobarbitale [DCIT]; Le phebar; Levsin PB Drops and Tablets; PUBERTAL PHENOBARBITAL STUDY; Pamine PB; Phenobarbitalum [INN]; Phenobarbituric acid; Phenylethyl barbituric acid; Phenylethylbarbituric acid; Solfoton talpheno; Stental Extentabs; Stental exte ntabs; Arco-Lase Plus; Barbilehae (barbilettae); Blu-phen; Chardonna-2; Component of Valpin 50-PB; Fenobarbital [INN-Spanish]; Gustase-Plus; Hypno-Tablinetten; Luminal (TN); Nova-Pheno; Phazyme-PB; Phen-Bar; Phenobarbital (PB); Phenobarbital, Monosodium Salt; Phenobarbitalum [INN-Latin]; SK-Phenobarbital; Seda-Tablinen; Seda-tabl inen; Sedonal (sedative); Solu-Barb; Valprin 50-PB; Phenobarbital [USAN:INN:JAN]; Phenyl-ethyl-barbituric acid; Acido 5-fenil-5-etilbarbiturico; Acido 5-fenil-5-etilbarbiturico [Italian]; Phenobarbital (JP15/USP/INN); 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione",Anticonvulsants,Small molecule,"1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)",DDBREPKUVSBGFI-UHFFFAOYSA-N,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,18420,C12H12N2O3,8069,8A61-8A6Z: Epilepsy/seizure
D1266,Phenolphthalein,4764,"phenolphthalein; 77-09-8; Phthalimetten; Phthalin; Euchessina; Phenolax; Purgophen; Espotabs; Koprol; Trilax; Laxogen; Purga; Lilo; Spulmako-lax; Feen-A-Mint Gum; Chocolax; Purgen; 3,3-Bis(4-hydroxyphenyl)phthalide; Ex-Lax; Fenolftalein; Correctol; Alophen; Medilax; Doxidan; Colax; Laxin; FemiLax; Dihydroxyphthalophenone; Phillips Gelcaps; 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; Lax-Pills; Evac-Q-Tabs; Evac-Q-Kwik; Evac-U-Gen; Evac-Q-Kit; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-; Phenolphtaleine; Fenolftaleina; Phenophthalein",Laxatives,Small molecule,"1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H",KJFMBFZCATUALV-UHFFFAOYSA-N,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,28376,C20H14O4,34914,DD91: Irritable bowel syndrome
D1267,Phenoxybenzamine,4768,Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A,Antihypertensive Agents,Small molecule,"1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3",QZVCTJOXCFMACW-UHFFFAOYSA-N,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,59-96-1,C18H22ClNO,8077,BA00: Essential hypertension
D1268,Phenoxymethylpenicillin,6869,"Apocillin; Apopen; Beromycin; Calcipen; Fenacilin; Fenospen; Fenossimetilpenicillina; Fenoximetilpenicilina; Fenoxymethylpenicillin; Fenoxypen; Meropenin; Oracillin; Oratren; Ospen; PNV; PVA; Phenocillin; Phenomycilline; Phenopenicillin; Phenoximethylpenicillinum; Phenoxomethylpenicillanyl; Phenoxomethylpenicillin; Phenoxymethylpenicillanyl; Phenoxymethylpenicillin; Phenoxymethylpenicilline; Phenoxymethylpenicillinum; Robicillin; Rocilin; Stabicillin; Vebecillin; Vegacillin; Acipen V; Compocillin V; Crystapen V; Distaquaine V; Eskacillian V; Eskacillin V; Fenossimetilpenicillina [DCIT]; Penicillin V [USAN]; Penicillin phenoxymethyl; Phenoxymethyl penicillin; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillinic acid; Phenoxymethylpenicillinic acid potassium salt; Acipen-v; Beromycin, Penicillin; Berromycin, Penicillin; Fenoximetilpenicilina [INN-Spanish]; Pen-Oral; Pen-V; Pen-vee; Penicillin V (USP); Penicillin, Phenoxymethyl; Phenoxymethylpenicillin (INN); Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; V-Cil; V-Cillin; V-Cylina; V-Cyline; V-Tablopen; P-Mega-Tablinen; V-Cillin (TN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); 6-Phenoxyacetamidopenicillanic acid",Antibiotics,Small molecule,"1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1",BPLBGHOLXOTWMN-MBNYWOFBSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,31990,C16H18N2O5S,27446,1A00-1C4Z: Bacterial infection
D1269,Phensuximide,6839,"Phensuximide; Milontin; Succitimal; Lifene; Phenylsuximide; Epimid; Fensuccimide; Fenosuccimide; Phensuximidum; 86-34-0; phensuccimide; Fensuximida; Phensuximid; Methylphenylsuccinimide; Fensuccimide [DCIT]; Succinimide, N-methyl-2-phenyl-; Phensuximidum [INN-Latin]; Fensuximida [INN-Spanish]; 1-methyl-3-phenylpyrrolidine-2,5-dione; Mirontin; Milonton; N-Methyl-alpha-phenylsuccinimide; PM 334; N-Methyl-2-phenylsuccinimide; Milontin (TN); 1-Methyl-3-phenylpyrrolidin-2,5-dione; 1-Methyl-3-phenyl-2,5-pyrrolidinedione; EINECS 201-664-6",Anticonvulsants,Small molecule,"1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3",WLWFNJKHKGIJNW-UHFFFAOYSA-N,CN1C(=O)CC(C1=O)C2=CC=CC=C2,86-34-0,C11H11NO2,8079,8A61-8A6Z: Epilepsy/seizure
D1270,Phentermine,4771,"Duromine; Fastin; Fentermina; Inoamin; Ionamin; Ionamine; Linyl; Lipopill; Lonamin; Mirapront; Normephentermine; Obenix; Obermine; Omnibex; Ortetamin; Ortetamina; Ortetaminum; Phentercot; Phenterminum; Phentride; Phentrol; Wilpo; Zantryl; Ona Mast; Ortetamine [INN]; Phentermine HCl; Phentermine resin complex; AmbkkkkK744; Phentermine Resin 30; Phentrol 2; Phentrol 3; Phentrol 4; Adipex P (TN); Adipex-P; Alpha-Benzylisopropylamine; Duromine (TN); Fastin (TN); Fentermina [INN-Spanish]; Ionamin (TN); Mirapront (TN); Obenix (TN); Obephen (TN); Obermine (TN); Oby-Trim; Panbesy (TN); Phenterex (TN); Phentermine (TN); Phenterminum [INN-Latin]; Phentremene (TN); Phentrol (TN); Phentromin (TN); Pro-Fast; Redusa (TN); Sinpet (TN); Supremin (TN); Teramine (TN); Trenker (TN); Umine (TN); Weltmine (TN); Zantryl (TN); Alpha,alpha-Dimethylbenzeneethanamine; Alpha,alpha-Dimethylphenethylamine; Anoxine-AM (TN); Obestin-30 (TN); Oby-Trim (TN); Phentermine (USAN/INN); Phentermine [USAN:INN:BAN]; Phenyl-tert-butylamine; Phenyl-tertiary-butylamine; Pro-Fast SA (TN); Alpha,alpha-Dimethyl-beta-phenylethylamine; Alpha.,.alpha.-dimethyl-Benzeneethanamine; (alpha,alpha)-Dimethylphenethylamine; 1,1-Dimethyl-2-phenylethylamine; 1-(2-Methylphenyl)-2-propylamin; 1-(2-Tolyl)-2-propylamine; 2-Amino-2-methyl-1-phenylpropane; 2-Methyl-1-phenyl-2-propanamine; 2-Phenyl-tert-butylamine",Appetite Depressants,Small molecule,"1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3",DHHVAGZRUROJKS-UHFFFAOYSA-N,CC(C)(CC1=CC=CC=C1)N,122-09-8,C10H15N,8080,5B80-5B81: Obesity
D1271,Phentolamine,5775,"Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol",Antihypertensive Agents,Small molecule,"1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)",MRBDMNSDAVCSSF-UHFFFAOYSA-N,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,50-60-2,C17H19N3O,8081,MC85: Gangrene
D1272,Phenyl salicylate,8361,"Phenyl salicylate; 118-55-8; PHENYL 2-HYDROXYBENZOATE; Salol; Phenol salicylate; Salphenyl; Musol; Benzoic acid, 2-hydroxy-, phenyl ester; 2-Phenoxycarbonylphenol; Salicylic acid, phenyl ester; 2-Hydroxybenzoic acid phenyl ester; Phenyl-2-hydroxybenzoate; 2-Hydroxy-benzoic acid phenyl ester; Fenylester kyseliny salicylove; NSC 33406; Salicylic Acid Phenyl Ester; UNII-28A37T47QO; Seesorb 201; Seesorb K 201; 2-Hydroxybenzoic acid, phenyl ester; MFCD00002213; NSC-33406; CHEBI:34918; 28A37T47QO; NSC33406; NCGC00090887-02; DSSTox_CID_1957; DSSTox_RID_76426; DSSTox_GSID_21957; CAS-118-55-8; CCRIS 4859; Phenyl salicylate [NF]; EINECS 204-259-2; Fenylester kyseliny salicylove [Czech]; BRN 0393969; phenylsalicylate; AI3-00195; phenyl-salicylate; salicylic acid phenyl; salicylic phenyl ester; WLN: QR BVOR; Oprea1_020651; Oprea1_771794; SCHEMBL24326; BIDD:ER0018; CHEMBL1339216; DTXSID6021957; FEMA NO. 3960; ZINC38545; Phenyl salicylate, >=99%, FG; STR06361; Tox21_113459; Tox21_201811; Tox21_302949; Phenyl Salicylate, Crystal, Purified; STK052177; AKOS000121203; NSC33406NSC 33406; Tox21_113459_1; DB11071; MCULE-3642683340; PS-7960; Phenyl salicylate melting point standard; NCGC00090887-01; NCGC00090887-03; NCGC00090887-04; NCGC00090887-05; NCGC00091499-03; NCGC00256612-01; NCGC00259360-01; AC-11469; M822; Phenyl salicylate, ReagentPlus(R), 99%; DB-024372; FT-0689174; S0017; AB00443435-03; A804056; Phenyl salicylate, Vetec(TM) reagent grade, 98%; Q421259; SR-01000883691; J-200110; SR-01000883691-1; Z57206005; Mettler-Toledo Calibration substance ME 30034252, Phenyl salicylate; Mettler-Toledo Calibration substance ME 30034252, Phenyl salicylate, traceable to primary standards; Phenyl salicylate melting point standard, approximately 41 degrees, United States Pharmacopeia (USP) Reference Standard; Phenyl salicylate melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material",Salicylates,Small molecule,"InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H",ZQBAKBUEJOMQEX-UHFFFAOYSA-N,C1=CC=C(C=C1)OC(=O)C2=CC=CC=C2O,.,C13H10O3,.,.
D1273,Phenylacetic acid,999,"PHENYLACETIC ACID; 2-Phenylacetic acid; Benzeneacetic acid; 103-82-2; Phenylethanoic acid; alpha-Toluic acid; phenylacetate; Benzenacetic acid; Acetic acid, phenyl-; Benzylformic acid; Phenyllacetic acid; Benzylcarboxylic acid; PHENYL ACETIC ACID; Kyselina fenyloctova; Phenylacetic acid (natural); Kyselina fenyloctova [Czech]; omega-Phenylacetic acid; UNII-ER5I1W795A; NSC 125718; BRN 1099647; .alpha.-Toluic acid; CHEBI:30745; AI3-08920; PHENYL-ACETIC ACID; .omega.-Phenylacetic acid; CHEMBL1044; ER5I1W795A; Benzeneacetate; MFCD00004313; NSC125718; NCGC00159477-02; DSSTox_CID_1656; DSSTox_RID_76268; DSSTox_GSID_21656; 1173020-54-6; CAS-103-82-2; FEMA No. 2878; HSDB 5010; EINECS 203-148-6; Phenylacetic; Phenylethanoate; Phenylessigsaure; w-Phenylacetate; alpha-Toluate; phenylactic acid; a-Toluate; a-Toluic acid; Benzeneacetiic acid; omega-Phenylacetate; organic white solid; w-Phenylacetic acid; Phenylacetate, XIX; 2-phenyl-acetic acid; Phenylacetic acid, 99%; bmse000220; Epitope ID:116202; EC 203-148-6; SCHEMBL1459; 4-09-00-01614 (Beilstein Handbook Reference); Phenyl-[13C6]-acetic acid; DTXSID2021656; BDBM16419; ZINC388462; Phenylacetic acid_GurudeebanSatyavani; Tox21_113042; Tox21_200533; NSC139637; Phenylacetic acid, natural, >=99%; STK297835; Phenylacetic acid, analytical standard; AKOS000291351; Tox21_113042_1; DB09269; DL-0063; MCULE-6701370784; NSC-125718; NSC-139637; Phenylacetic acid, >=99%, FCC, FG; NCGC00159477-03; NCGC00159477-05; NCGC00258087-01; 51146-16-8; BP-11383; NCI60_000596; NCI60_002571; Phenylacetic acid, natural, >=99%, FG; DB-003759; DB-055176; FT-0641197; FT-0701063; Phenylacetic acid, plant cell culture tested; C07086; Q410842; 8727557E-AA75-49E9-8E5A-7A2412D71888; Tropicamide Related Compound D, United States Pharmacopeia (USP) Reference Standard; 17303-65-0; Tropicamide impurity D (Phenylacetic acid - Drug Precursor), European Pharmacopoeia (EP) Reference Standard",Antihyperammonia Agents,Small molecule,"InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)",WLJVXDMOQOGPHL-UHFFFAOYSA-N,C1=CC=C(C=C1)CC(=O)O,.,C8H8O2,.,.
D1274,Phenylbutazone,4781,"Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione",Analgesics,Small molecule,"1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3",VYMDGNCVAMGZFE-UHFFFAOYSA-N,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,50-33-9,C19H20N2O2,48574,MG30: Chronic pain
D1275,Phenylbutyric acid,4775,"Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate",Antihyperammonia Agents,Small molecule,"1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)",OBKXEAXTFZPCHS-UHFFFAOYSA-N,C1=CC=C(C=C1)CCCC(=O)O,1821-12-1,C10H12O2,41500,5C50: Metabolism inborn error
D1276,Phenylephrine,6041,"Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol",Mydriatics/Decongestants,Small molecule,"1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,CNCC(C1=CC(=CC=C1)O)O,61-76-7,C9H13NO2,8093,ME07: Faecal incontinence; 5A02: Thyrotoxicosis
D1277,Phenylephrine (nasal),6041,"Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol",Mydriatics/Decongestants,Small molecule,"1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,CNCC(C1=CC(=CC=C1)O)O,61-76-7,C9H13NO2,8093,ME07: Faecal incontinence; 5A02: Thyrotoxicosis
D1278,Phenylephrine (ophthalmic),6041,"Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol",Mydriatics/Decongestants,Small molecule,"1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,CNCC(C1=CC(=CC=C1)O)O,61-76-7,C9H13NO2,8093,ME07: Faecal incontinence; 5A02: Thyrotoxicosis
D1279,Phenylephrine (otic),6041,"Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol",Mydriatics/Decongestants,Small molecule,"1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,CNCC(C1=CC(=CC=C1)O)O,61-76-7,C9H13NO2,8093,ME07: Faecal incontinence; 5A02: Thyrotoxicosis
D1280,Phenylephrine (topical),6041,"Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol",Mydriatics/Decongestants,Small molecule,"1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",SONNWYBIRXJNDC-VIFPVBQESA-N,CNCC(C1=CC(=CC=C1)O)O,61-76-7,C9H13NO2,8093,ME07: Faecal incontinence; 5A02: Thyrotoxicosis
D1281,Phenylpropanolamine,26934,"Norephedrine; phenylpropanolamine; Rhindecon; dl-Norephedrine; (+)-Norephedrine; Propagest; Dexatrim; Mucron; d-Norephedrine; Propadrine; 1r,2s-phenylpropylamine; Super Odrinex; 14838-15-4; (1S,2R)-2-amino-1-phenylpropan-1-ol; Fenilpropanolamina; dl-1-Phenyl-2-aminopropanol-1; UNII-7875H6443P; Phenylpropanolaminum; (+-)-Norephedrin; dl-Phenylpropanolamine; dl-2-Amino-1-hydroxy-1-phenylpropane; CHEBI:36; Naldecon; Cathinum [INN-Latin]; (+-)-Phenylpropanolamine; NSC9920; DLNKOYKMWOXYQA-VXNVDRBHSA-N; 37577-28-9; Cathina [INN-Spanish];  Acutrim; Cathina; Cathine; Cathinum; Codimal; Conex; Contuss; Despec; Exponcit; Fansia; Fugoa; Gentab; Guaipax; Katine; Minusine; Mydriatin; Myminic; Nolex; Norpseudoephedrine; Partuss; Phenoxine; Phenyldrine; Phenylfenesin; Phenylpropanolamina; Pseudonorephedrine; Rhymed; Snaplets; ULR; Vanex; Cathine [INN]; Fugoa Depot; Ami-Tex; D-Norpseudoephedrine; Dl-Norephedrine; Dura-Vent; Fansia (TN); L-Norephedrine; Proin (TN); Propalin (TN); Psi-Norephedrine; TAVIST-D; USAF CS-6; D-Nor-psi-ephedrine; L-Nor-psi-ephedrin; L-Nor-psi-ephedrine; D-(+)-Norephedrine; L-(-)-Norephedrine; (+-)-Norephedrine; (+/-)-Norephedrin; (+/-)-Norephedrine; (-)-Norephedrin; (-)-Norephedrine; (1R,2S)-Norephedrine",Appetite Depressants,Small molecule,"1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1",DLNKOYKMWOXYQA-VXNVDRBHSA-N,CC(C(C1=CC=CC=C1)O)N,37577-28-9,C9H13NO,36,5B80-5B81: Obesity
D1282,Phenyltoloxamine,7077,"Bristamin hydrochloride; Phenyltoloxamine hydrochloride; HL 2153; (2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride; N,N-Dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride; ETHYLAMINE, 2-(o-BENZYLPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE; Ethylamine, N,N-dimethyl-2-((alpha-phenyl-o-tolyl)oxy)-, hydrochloride; N-(2'-Dimethylaminoaethyl)-(o-benzylphenol)-aether hydrochlorid [German]; AC1L2KJQ; 92-12-6 (Parent); LS-67923; 2-(2-benzylphenoxy)ethyl-dimethylazanium chloride",Antispasmodics,Small molecule,"1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3",IZRPKIZLIFYYKR-UHFFFAOYSA-N,CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2,33944,C17H21NO,135047,4A80-4A8Z: Allergic/hypersensitivity disorder
D1283,Phenytoin,1775,"Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione",Anticonvulsants,Small molecule,"1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)",CXOFVDLJLONNDW-UHFFFAOYSA-N,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,57-41-0,C15H12N2O2,8107,8A61-8A6Z: Epilepsy/seizure
D1284,Phylloquinone,5284607,"Phyllochinon; Phyllohydroquinone; Phytomenadione; Fitomenadione [DCIT]; Phyllochinon [German]; LT00452032; Fitomenadiona [INN-Spanish]; Mephyton (TN); Phylloquinone (8CI); Phytomenadione (INN); Phytomenadionum [INN-Latin]; Phytonadione [USAN:JAN]; Vitamin K1 (TN); Vitamin K1 (VAN); Vitamin K1 (generic); Phythyl-menadion (GERMAN); Phytonadione (JP15/USP); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened-ione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 3-Phytylmenadione",Vitamins,Small molecule,"1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1",MBWXNTAXLNYFJB-NKFFZRIASA-N,CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C,79083-00-4,C31H46O2,18067,GA20-GA21: Bleeding disorder; 5B55-5B5F: Vitamin deficiency
D1285,Physostigmine,5983,"Xalieve; Acetylcholinesterase inhibitor (dry mouth), Calabar; Physostigmine (local acting gel, xerostomia); Physostigmine (buccal, xerostomia), Calabar; Physostigmine (local acting gel, xerostomia), Calabar",Ophthalmic Glaucoma Agents/Antidotes,Small molecule,"1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1",PIJVFDBKTWXHHD-HIFRSBDPSA-N,CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,57-47-6,C15H21N3O2,27953,DA02: Lips/oral mucosa miscellaneous disorder
D1286,Physostigmine (ophthalmic),5983,"Xalieve; Acetylcholinesterase inhibitor (dry mouth), Calabar; Physostigmine (local acting gel, xerostomia); Physostigmine (buccal, xerostomia), Calabar; Physostigmine (local acting gel, xerostomia), Calabar",Ophthalmic Glaucoma Agents/Antidotes,Small molecule,"1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1",PIJVFDBKTWXHHD-HIFRSBDPSA-N,CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,57-47-6,C15H21N3O2,27953,DA02: Lips/oral mucosa miscellaneous disorder
D1287,Picosulfuric acid,5243,"Picosulfuric acid; Picosulfate; UNII-95D580798S; 10040-34-3; 95D580798S; Picosulphate; sodium-picosulfate; CHEMBL1741134; SCHEMBL18552552; DTXSID70143251; ZINC3873921; Phenol, 4,4'-(2-pyridinylmethylene)bis-, 1,1'-bis(hydrogen sulfate); DB09268; Bis(sulfuric acid)2-pyridinylmethylenebis(1,4-phenylene) ester",Vitamins,Small molecule,"InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)",UJIDKYTZIQTXPM-UHFFFAOYSA-N,C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)O)C3=CC=C(C=C3)OS(=O)(=O)O,.,C18H15NO8S2,.,.
D1288,Pilocarpine,5910,"Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one",Cholinergic Agents,Small molecule,"1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1",QCHFTSOMWOSFHM-WPRPVWTQSA-N,CCC1C(COC1=O)CC2=CN=CN2C,92-13-7,C11H16N2O2,8207,9C61: Glaucoma
D1289,Pilocarpine (ophthalmic),5910,"Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one",Cholinergic Agents,Small molecule,"1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1",QCHFTSOMWOSFHM-WPRPVWTQSA-N,CCC1C(COC1=O)CC2=CN=CN2C,92-13-7,C11H16N2O2,8207,9C61: Glaucoma
D1290,Pimavanserin,10071196,ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea,Atypical Antipsychotics,Small molecule,"1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)",RKEWSXXUOLRFBX-UHFFFAOYSA-N,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,706779-91-1,C25H34FN3O2,133017,8A00: Parkinsonism
D1291,Pimecrolimus (topical),6509979,Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin,Dermatologic Agents,Small molecule,"1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1",KASDHRXLYQOAKZ-XDSKOBMDSA-N,CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)Cl)C)O)C)OC)OC)C)C,137071-32-0,C43H68ClNO11,135888,EA80: Atopic eczema
D1292,Pimozide,16362,"Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one",Antipsychotic Agents,Small molecule,"1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)",YVUQSNJEYSNKRX-UHFFFAOYSA-N,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,2062-78-4,C28H29F2N3O,8212,6A20: Schizophrenia
D1293,Pindolol,4828,Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole,Antihypertensive Agents,Small molecule,"1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",JZQKKSLKJUAGIC-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,13523-86-9,C14H20N2O2,8214,BA00-BA04: Hypertension
D1294,Pioglitazone,4829,"111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A;  Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1",Antidiabetic Agents,Small molecule,"1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",HYAFETHFCAUJAY-UHFFFAOYSA-N,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,111025-46-8,C19H20N2O3S,8228,5A2Y: Acute diabete complication; 5B80-5B81: Obesity; 5A11: Type 2 diabetes mellitus
D1295,Pipecuronium,50192,"Arduan; Pipecurium; Arduan (TN); Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",Analgesics,Small molecule,"1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",OWWLUIWOFHMHOQ-XGHATYIMSA-N,CC(=O)OC1CC2CCC3C(C2(CC1N4CC[N+](CC4)(C)C)C)CCC5(C3CC(C5OC(=O)C)N6CC[N+](CC6)(C)C)C,68399-58-6,C35H62N4O4+2,8230,MB47: Tonus and reflex abnormality
D1296,Piperacillin,43672,"PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1",IVBHGBMCVLDMKU-GXNBUGAJSA-N,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,61477-96-1,C23H27N5O7S,8232,1A00-1C4Z: Bacterial infection
D1297,Piperazine,4837,"Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine",Antinematodal Agents,Small molecule,"1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2",GLUUGHFHXGJENI-UHFFFAOYSA-N,C1CNCCN1,110-85-0,C4H10N2,28568,1F65: Enterobiasis; 1F62: Ascariasis
D1298,Pirbuterol,4845,"Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol",Bronchodilators,Small molecule,"1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3",VQDBNKDJNJQRDG-UHFFFAOYSA-N,CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O,38677-81-5,C12H20N2O3,8245,CA23: Asthma
D1299,Pirfenidone,40632,Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one,Pulmonary Fibrosis Inhibitors,Small molecule,"1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",ISWRGOKTTBVCFA-UHFFFAOYSA-N,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,53179-13-8,C12H11NO,32016,CB03: Idiopathic interstitial pneumonitis
D1300,Piroxicam,54676228,"Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide",Analgesics,Small molecule,"1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)",QYSPLQLAKJAUJT-UHFFFAOYSA-N,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,36322-90-4,C15H13N3O4S,8249,MG30-MG3Z: Pain
D1301,Pitavastatin,5282452,"Pitavastatin; Itavastatin; 147511-69-1; Livalo; Pitavastatin calcium; NK 104; UNII-M5681Q5F9P; NK-104; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; C25H24FNO4; CHEBI:32020; M5681Q5F9P; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P-872441; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; Pitavastatin [INN]; Pitavastatin calcium (JAN); (3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (3R,5S,6E)-; 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)-; NSC-760423; pitavastatia; pitavastatine; pitavastatinum; Itavastin; (3r,5s,6e)-7-[2-cyclopropyl-4-(p-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid; 121659-03-8; P 872441; SCHEMBL3369; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; MLS006010096; SCHEMBL464781; GTPL3035; CHEMBL1201753; DTXSID1048384; BDBM86707; HSDB 8367; HY-B0144A; ZINC1534965; 3972AH; AKOS005145916; AM84440; DB08860; NSC 760423; 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (S-(R*,S*-(E)))-; SMR003965244; CAS_147511-69-1; Q412677; BRD-K75958547-001-01-2; (3R,5S)-3,5-Dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-6-heptenoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy hept-6-enoic acid; (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-(3R,5S)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid; (e)-(3r,5s)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6enoic acid; E-(3R,5S)-7-[2-Cyclopropyl-4-(4fluoro-phenyl)quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid; Itavastatin; ; ; Nisvastatin; ; ; NK-104; ; ; P-872441; ; ; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid",Statins/Antihyperlipidemic Agents,Small molecule,"InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1",VGYFMXBACGZSIL-MCBHFWOFSA-N,C1CC1C2=NC3=CC=CC=C3C(=C2/C=C/[C@H](C[C@H](CC(=O)O)O)O)C4=CC=C(C=C4)F,.,C25H24FNO4,.,.
D1302,Pitolisant,9948102,"Pitolisant; 362665-56-3; TIPROLISANT; BF2.649; UNII-4BC83L4PIY; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; Pitolisant (BF2.649); 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 4BC83L4PIY; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; CHEMBL462605; wakix; 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Tirolisant; Pitolisant (INN); tiprolisant [USAN]; Wakix (TN); Pitolisant [USAN:INN]; SCHEMBL117648; GTPL8924; CTK1B6404; HBS-101",Cns Stimulants,Small molecule,"1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2",NNACHAUCXXVJSP-UHFFFAOYSA-N,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl,362665-56-3,C17H26ClNO,134709,6A20: Schizophrenia; MG42: Somnolence
D1303,Plantago seed,.,DB11097; Plantago seed; Psyllium; Psyllium husk,Herbal Products,Natural product,.,.,.,.,.,.,.
D1304,Plazomicin,42613186,"ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN);  ZINC68150640; DB12615; D10151; D-Streptamine,",Aminoglycosides//Antibiotics,Small molecule,"1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1",IYDYFVUFSPQPPV-PEXOCOHZSA-N,CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CNCCO)N)N)NC(=O)C(CCN)O)O,1154757-24-0,C25H48N6O10,.,GC08: Urinary tract infection; GA91: Prostate disease; CA20: Bronchitis; 2C10: Pancreatic cancer
D1305,Plicamycin,163659,A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01,Antineoplastics,Small molecule,"1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1",CFCUWKMKBJTWLW-BKHRDMLASA-N,CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O,18378-89-7,C52H76O24,31856,2C25: Lung cancer; 2C73: Ovarian cancer; 2C80: Testicular cancer; 5B91: Mineral excesses; 2A00-2F9Z: Solid tumour/cancer
D1306,Polatuzumab vedotin,.,.,Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2A80: Follicular lymphoma; 2B33: Malignant haematopoietic neoplasm; 2A81: Diffuse large B-cell lymphoma
D1307,Poliovirus type 1 antigen (formaldehyde inactivated),.,"DB10795; Inactivated poliomyelitis vaccine (V.C.O.) type 1 Mahoney; Inactivated poliovirus type I; Poliovirus type 1 antigen (formaldehyde inactivated); poliovirus vaccine inactivated, type 1 (Mahoney)",Vaccines,Vaccine,.,.,.,.,.,.,.
D1308,Polyethylene glycol (3350 with electrolytes),174,"ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F",Laxatives,Small molecule,"1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2",LYCAIKOWRPUZTN-UHFFFAOYSA-N,C(CO)O,107-21-1,C2H6O2,30742,DD91: Irritable bowel syndrome
D1309,Polyethylene glycol (3350),174,"ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F",Laxatives,Small molecule,"1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2",LYCAIKOWRPUZTN-UHFFFAOYSA-N,C(CO)O,107-21-1,C2H6O2,30742,DD91: Irritable bowel syndrome
D1310,Polymyxin B,49800004,polymyxin b; 1404-26-8; POLUMYXIN B; BDBM50410807; DB00781,Antibiotics,Small molecule,"InChI=1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)/t32?,33-,34-,36+,37+,38-,39+,40+,41+,42+,43-,45+,46+/m1/s1",WQVJHHACXVLGBL-BPJDFBQWSA-N,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)[C@@H](C)O,.,C56H98N16O13,.,.
D1311,Polythiazide,4870,"Drenusil; Nephril; Politiazida; Polythiazidum; Renese; P 2525; P-2525; Politiazida [INN-Spanish]; Polythiazidum [INN-Latin]; Renese (TN); Polythiazide (JAN/USAN/INN); Polythiazide [USAN:INN:BAN:JAN]; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",Antihypertensive Agents,Small molecule,"1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)",CYLWJCABXYDINA-UHFFFAOYSA-N,CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,346-18-9,C11H13ClF3N3O4S3,8327,MG29: Oedema; BA00-BA04: Hypertension
D1312,Pomalidomide,134780,Actimid (TN); Pomalidomide (Immunomodulator),Antineoplastics/Immunosuppressants,Small molecule,"1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,19171-19-8,C13H11N3O4,72690,4A42: Systemic sclerosis
D1313,Ponatinib,24826799,Iclusig (TN),Multikinase Inhibitors,Small molecule,"1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",PHXJVRSECIGDHY-UHFFFAOYSA-N,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,943319-70-8,C29H27F3N6O,78543,2A85: Mature B-cell lymphoma
D1314,Porfimer sodium,135577896,Porfimer Sodium; SCHEMBL19272; HY-13729,Antineoplastics,Small molecule,"InChI=1S/C68H74N8O11/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50/h21-28,37-40,71,73-74,76-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86)",AMYWSBYLSVHSHG-UHFFFAOYSA-N,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4C)C(C)OC(C)C6=C(C7=CC8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C)C(=C3CCC(=O)O)C)CCC(=O)O,.,C68H74N8O11,.,.
D1315,Posaconazole,468595,"Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one",Antifungal Agents,Small molecule,"1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1",RAGOYPUPXAKGKH-XAKZXMRKSA-N,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,171228-49-2,C37H42F2N8O4,64355,1F20: Aspergillosis
D1316,Potassium acetate,517044,Potassium Acetate In Plastic Container,Minerals And Electrolytes,Small molecule,"1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",SCVFZCLFOSHCOH-UHFFFAOYSA-M,CC(=O)[O-].[K+],127-08-2,C2H3KO2,32029,GB70: Urinary tract disease
D1317,Potassium bicarbonate,516893,"Potassium bicarbonate; 298-14-6; Potassium hydrogen carbonate; Potassium hydrogencarbonate; Potassium acid carbonate; CARBONIC ACID, MONOPOTASSIUM SALT; Monopotassium carbonate; POTASSIUMBICARBONATE; potassium;hydrogen carbonate; KHCO3; UNII-HM5Z15LEBN; HM5Z15LEBN; Potassium bicarbonate [USP]; CHEBI:81862; MFCD00011402; Carbonic acid, potassium salt (1:1); Potassium bicarbonate (USP); CCRIS 3510; EINECS 206-059-0; EPA Pesticide Chemical Code 073508; Armicarb; Kafylox; Kaligreen; Milstop; Purple k; potasium bicarbonate; potassium bicabonate; potassium bicarbonat; PBC; EINECS 241-378-9; K-vescent (TN); potassiumhydrogencarbonate; potassium hydogencarbonate; potassium;hydron;carbonate; CHO3.K; EC 206-059-0; potassium carbonate solution; potassium hydrogen-carbonate; SCHEMBL2420; CHEMBL2106975; DTXSID0021177; INS-501(II); Potassium bicarbonate, ACS grade; 8301AF; E-501(II); AKOS009159056; DB11098; E501; FT-0645098; C18606; D02077; Potassium bicarbonate, Trace metals grade 99.98%; Q410529; J-017655",Minerals And Electrolytes,Small molecule,"InChI=1S/CH2O3.K/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1",TYJJADVDDVDEDZ-UHFFFAOYSA-M,C(=O)(O)[O-].[K+],.,CHKO3,.,.
D1318,Potassium chloride,4873,"Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA",Dietary Supplement,Small molecule,1S/ClH.K/h1H;/q;+1/p-1,WCUXLLCKKVVCTQ-UHFFFAOYSA-M,[Cl-].[K+],7447-40-7,ClK,32588,5C77: Hypo-kalaemia
D1319,Potassium citrate,13344,Urocit-k,Minerals And Electrolytes,Small molecule,"1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",QEEAPRPFLLJWCF-UHFFFAOYSA-K,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[K+].[K+].[K+],866-84-2,C6H5K3O7,64733,GB70: Urinary tract disease
D1320,Potassium gluconate,16760467,"potassium gluconate; 299-27-4; Potassium D-gluconate; Gluconic acid potassium salt; D-Gluconic acid, monopotassium salt; potassium (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; Monopotassium D-gluconate; D-Gluconic acid potassium salt; HSDB 3165; UNII-12H3K5QKN9; D-Gluconic acid, potassium salt; 12H3K5QKN9; Potassuril; Kaon elixir; PotassiumD-gluconate; MFCD00064211; Katorin; Potalium; Potasoral; Sirokal; Kalium-beta; Gluconsan K; Kalium Gluconate; Potassiumgluconate; K-Iao; 2,3,4,5,6-Pentahydroxycaproic acid potassium salt; D-Gluconic acid, potassium salt (1:?); Gluconic acid, monopotassium salt; EINECS 206-074-2; Kali gluconicum; Potassium gluconate [USP:JAN]; EINECS 252-355-8; Gluconsan-K (TN); Gluconic acid, monopotassium salt, D-; DSSTox_CID_9617; EC 206-074-2; DSSTox_RID_78789; Gluconic Acid (Food Grade); DSSTox_GSID_29617; SCHEMBL40567; C6H11KO7; INS NO.577; Potassium gluconate (JAN/USP); CHEMBL2106978; DTXSID7029617; Potassium D-gluconate, >=99%; CHEBI:32032; Gluconic Acid (Technical Grade); HY-Y0569C; INS-577; Tox21_202774; AKOS000277995; DB13620; NCGC00260321-01; AC-15968; AS-83530; CAS-299-27-4; M845; CS-0108842; E-577; G0040; D01298; A876352; Q1122870; W-202242; Potassium gluconate, meets USP testing specifications, anhydrous; potassium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; D-Gluconic acid monopotassium salt; Gluconic acid potassium salt;; Potassium gluconate, United States Pharmacopeia (USP) Reference Standard; Potassium gluconate, Pharmaceutical Secondary Standard; Certified Reference Material",Minerals And Electrolytes,Small molecule,"InChI=1S/C6H12O7.K/c7-1-2(8)3(9)4(10)5(11)6(12)13;/h2-5,7-11H,1H2,(H,12,13);/q;+1/p-1/t2-,3-,4+,5-;/m1./s1",HLCFGWHYROZGBI-JJKGCWMISA-M,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[K+],.,C6H11KO7,.,.
D1321,Potassium Iodide,4875,potassium iodide; 7681-11-0; Potassium iodide (KI); Pima; Kali iodide; Thyro-Block; Knollide; Kisol; Asmofug E; Potassium diiodide; Potassium monoiodide; Thyroshield; Joptone; Potide; Kalii iodidum; Iodure de potassium; Potassium iodide (K2I2); Potassium iodide (K(I2)); Tripotassium triiodide; Caswell No. 694; iodopotassium; K1-N; Potassium iodide (K3I3); UNII-1C4QK22F9J; HSDB 5040; EINECS 231-659-4; NSC 77362; MFCD00011405; EPA Pesticide Chemical Code 075701; AI3-52931; CHEBI:8346; 1C4QK22F9J; Potassium salt of hydriodic acid; Iosat,Minerals And Electrolytes,Small molecule,1S/HI.K/h1H;/q;+1/p-1,NLKNQRATVPKPDG-UHFFFAOYSA-M,[K+].[I-],7681-11-0,IK,8346,5A02: Thyrotoxicosis
D1322,Potassium perchlorate,516900,Perchloracap,Oxidizers,Small molecule,"1S/ClHO4.K/c2-1(3,4)5;/h(H,2,3,4,5);/q;+1/p-1",YLMGFJXSLBMXHK-UHFFFAOYSA-M,[O-]Cl(=O)(=O)=O.[K+],7778-74-7,ClKO4,.,5A02: Thyrotoxicosis
D1323,Pralatrexate,148121,Folotyn (TN),Antimetabolites,Small molecule,"1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1",OGSBUKJUDHAQEA-WMCAAGNKSA-N,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,146464-95-1,C23H23N7O5,71223,2C60-2C6Y: Breast cancer; 2A90: Mature T-cell lymphoma
D1324,Pralsetinib,129073603,GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide,Multikinase Inhibitors,Small molecule,"1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1",GBLBJPZSROAGMF-SIYOEGHHSA-N,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,2097132-94-8,C27H32FN9O2,.,2A00-2F9Z: Solid tumour/cancer; 2C25: Lung cancer
D1325,Pramipexole,119570,"Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole",Antiparkinson Agents,Small molecule,"1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1",FASDKYOPVNHBLU-ZETCQYMHSA-N,CCCNC1CCC2=C(C1)SC(=N2)N,104632-26-0,C10H17N3S,8356,8A00: Parkinsonism
D1326,Pramlintide,70691388,Symlin; Triproamylin; Pramlintide [USAN]; Pramlintide acetate; Pramlintide acetate [USAN]; Pramlintide acetate hydrate; AC 0137,Antidiabetic Agents,Small molecule,"1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1",TZIRZGBAFTZREM-MKAGXXMWSA-N,CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N,151126-32-8,C171H267N51O53S2,135922,5A10-5A11: Type-1/2 diabete
D1327,Prasterone enantate,163331,"23983-43-9; Dehydroepiandrosterone enanthate; Prasterone enanthate; UNII-2W8I1S6T5L; 2W8I1S6T5L; [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] heptanoate; Androst-5-en-17-one, 3-[(1-oxoheptyl)oxy]-, (3b)-; DHEA enanthate; DHEA oenanthate; Prasterone enantate; Dehydroepiandrosterone oenanthate; EINECS 245-970-8; 3beta-Heptanoyloxy-5-androsten-17-one; 3beta-Hydroxyandrost-5-en-17-one heptanoate; SCHEMBL2453080; (3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl heptanoate; BCP10784; ZINC5820240; AKOS025310707; 5-Androsten-3beta-ol-17-one enanthate; DS-13434; 3beta-(1-Oxoheptyloxy)androst-5-en-17-one; 983A439; Q27255695",Androgens,Small molecule,"InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1",HHENOUDBWKNPAB-BNCSLUSBSA-N,CCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=O)C)C,.,C26H40O3,.,.
D1328,Prasugrel,6918456,Effient (TN),Antiplatelet Agents,Small molecule,"1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3",DTGLZDAWLRGWQN-UHFFFAOYSA-N,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,150322-43-3,C20H20FNO3S,87723,BA41-BA43: Myocardial infarction
D1329,Pravastatin,54687,"Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1",TUZYXOIXSAXUGO-PZAWKZKUSA-N,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,81093-37-0,C23H36O7,63618,5C80: Hyper-lipoproteinaemia
D1330,Praziquantel,4891,"Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY",Anthelmintics,Small molecule,"1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2",FSVJFNAIGNNGKK-UHFFFAOYSA-N,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,55268-74-1,C19H24N2O2,91583,1F70-1F86: Flatworm infection
D1331,Prazosin,4893,"Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone",Antihypertensive Agents,Small molecule,"1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)",IENZQIKPVFGBNW-UHFFFAOYSA-N,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,19216-56-9,C19H21N5O4,8364,BD10-BD1Z: Heart failure; GA90: Prostate hyperplasia; BA00-BA04: Hypertension
D1332,Prednisolone,5755,"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos",Antineoplastics,Small molecule,"1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",OIGNJSKKLXVSLS-VWUMJDOOSA-N,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,50-24-8,C21H28O5,8378,2A00-2F9Z: Solid tumour/cancer; 8A40: Multiple sclerosis
D1333,Prednisolone (ophthalmic),5755,"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos",Antineoplastics,Small molecule,"1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",OIGNJSKKLXVSLS-VWUMJDOOSA-N,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,50-24-8,C21H28O5,8378,2A00-2F9Z: Solid tumour/cancer; 8A40: Multiple sclerosis
D1334,Prednisone,5865,"Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione",Antiinflammatory Agents,Small molecule,"1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1",XOFYZVNMUHMLCC-ZPOLXVRWSA-N,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,19420,C21H26O5,8382,EA80: Atopic eczema; EA80-EA89: Eczema; 1A00-CA43: Postoperative inflammation
D1335,Pregabalin,5486971,"Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer",Gaba Analogs,Small molecule,"1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1",AYXYPKUFHZROOJ-ZETCQYMHSA-N,CC(C)CC(CC(=O)O)CN,148553-50-8,C8H17NO2,64356,CA22: Chronic obstructive pulmonary disease
D1336,Pretomanid,456199,"PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011",Antituberculosis Agents,Small molecule,"1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1",ZLHZLMOSPGACSZ-NSHDSACASA-N,C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F,187235-37-6,C14H12F3N3O5,.,1B10-1B21: Mycobacterium infection; 1B10-1B14: HIV-infected patients with tuberculosis
D1337,Prilocaine,4906,"Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide",Anesthetics,Small molecule,"1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",MVFGUOIZUNYYSO-UHFFFAOYSA-N,CCCNC(C)C(=O)NC1=CC=CC=C1C,721-50-6,C13H20N2O,8404,MG30-MG3Z: Pain
D1338,Prilocaine (topical),4906,"Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide",Anesthetics,Small molecule,"1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",MVFGUOIZUNYYSO-UHFFFAOYSA-N,CCCNC(C)C(=O)NC1=CC=CC=C1C,721-50-6,C13H20N2O,8404,MG30-MG3Z: Pain
D1339,Primaquine,4908,"Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline",Antimalarial Agents,Small molecule,"1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3",INDBQLZJXZLFIT-UHFFFAOYSA-N,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,90-34-6,C15H21N3O,8405,1F40-1F45: Malaria
D1340,Primidone,4909,"Cyral; Desoxyphenobarbital; Desoxyphenobarbitone; Hexadiona; Lepimidin; Lepsiral; Liskantin; Majsolin; Midone; Milepsin; Misodine; Misolyne; Mizodin; Mizolin; Myidone; Mylepsin; Mylepsinum; Mysedon; Mysoline; Neurosyn; Prilepsin; Primacione; Primaclone; Primacone; Primakton; Primidon; Primidona; Primidonum; Primoline; Prysoline; Resimatil; Sertan; Apotex Brand of Primidone; Astra Brand of Primidone; AstraZeneca Brand of Primidone; Desitin Brand of Primidone; Draxis Brand of Primidone; Holsten Brand of Primidone; Pms Primidone; Primidon Holsten; Primidone Methanol Solution; Xcel Brand of Primidone; Zeneca Brand of Primidone; P 7295; Roe 101; Apo-Primidone; Hexamidine (the antispasmodic); Hexamidine(the antispasmodic); Liskantin (TN); Medi-Pets; Mylepsinum (TN); Mysoline (TN); Primidona [INN-Spanish]; Primidone (primaclone); Primidonum [INN-Latin]; Prysoline (TN); Pyrimidone Medi-pets; Resimatil (TN); Sanofi-Synthelabo Brand of Primidone; Sertan (TN); Apo-Primidone (TN); Pyrimidone (Medi-pets); Primidone (JP15/USP/INN); Primidone [USAN:INN:BAN:JAN]; 2-Deoxyphenobarbital; 2-Desoxyphenobarbital; 4,4'-(Hexamethylenedioxy)dibenzamidine; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine",Anticonvulsants,Small molecule,"1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)",DQMZLTXERSFNPB-UHFFFAOYSA-N,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,125-33-7,C12H14N2O2,8412,8A61-8A6Z: Epilepsy/seizure
D1341,Probenecid,4911,"Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid",Uricosuric Agents,Small molecule,"1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)",DBABZHXKTCFAPX-UHFFFAOYSA-N,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,57-66-9,C13H19NO4S,8426,5C55: Inborn purine/pyrimidine/nucleotide metabolism error; FA25: Gout
D1342,Probucol,4912,"Biphenabid; Bisbid; Bisphenabid; Lesterol; Lorelco; Lursell; Lurselle; Panavir; Probucolum; Sinlestal; Superlipid; Almirall Brand of Probucol; Aventis Brand of Probucol; Hoechst Brand of Probucol; DH 581; DH581; DE-3872; DH-581; LORELCO (TN); Probucolum [INN-Latin]; ZERO/001429; Probucol (JAN/USP/INN); Probucol [USAN:BAN:INN:JAN]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]",Antihyperammonia Agents,Small molecule,"1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3",FYPMFJGVHOHGLL-UHFFFAOYSA-N,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,23288-49-5,C31H48O2S2,8427,BA80: Coronary atherosclerosis
D1343,Procainamide,4913,"Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide",Antiarrhythmic Agents,Small molecule,"1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)",REQCZEXYDRLIBE-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,18788,C13H21N3O,8428,BC71: Ventricular tachyarrhythmia
D1344,Procaine,4914,"Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester",Anesthetics,Small molecule,"1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3",MFDFERRIHVXMIY-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,59-46-1,C13H20N2O2,8430,9A76-9A78: Corneal disease
D1345,Procarbazine,4915,"Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide",Antineoplastics,Small molecule,"1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)",CPTBDICYNRMXFX-UHFFFAOYSA-N,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,671-16-9,C12H19N3O,71417,2B30: Hodgkin lymphoma
D1346,Prochlorperazine,4917,CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP,Antipsychotic Agents,Small molecule,"1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3",WIKYUJGCLQQFNW-UHFFFAOYSA-N,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,58-38-8,C20H24ClN3S,8435,MD90: Nausea/vomiting
D1347,Procyclidine,4919,Arpicolin; Elorine; Kemadrin; Kemadrine; Lergine; Metanin; Osnervan; Prociclidina; Procidlidina; Procyclid; Procyclidinum; Procyklidin; Prosyklidin; Spamol; Triciclidina; Triciloid; Tricoloid; Tricyclamol; Vagosin; Prociclidina [INN-Spanish]; Procyclidine (INN); Procyclidine [INN:BAN]; Procyclidinum [INN-Latin]; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol,Antiparkinson Agents,Small molecule,"1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2",WYDUSKDSKCASEF-UHFFFAOYSA-N,C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O,77-37-2,C19H29NO,8448,8A00: Parkinsonism
D1348,Progesterone,5994,"progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite;  LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine",Progesterone Receptor Modulators,Small molecule,"1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1",RJKFOVLPORLFTN-LEKSSAKUSA-N,CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C,57-83-0,C21H30O2,17026,JB00: Preterm labour/delivery; QA21: Contraceptive management
D1349,Progesterone (topical),5994,"progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite;  LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine",Progesterone Receptor Modulators,Small molecule,"1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1",RJKFOVLPORLFTN-LEKSSAKUSA-N,CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C,57-83-0,C21H30O2,17026,JB00: Preterm labour/delivery; QA21: Contraceptive management
D1350,Proguanil,6178111,Bigumal; Chlorguanid; Chlorguanide; Chloriguane; Chloroguanide; Paludrin; Proguanile; Proguanilum; Proguanile [DCIT]; Diguanyl (hydrochloride); Drinupal (hydrochloride); Paludrine (TN); Paludrine (hydrochloride); Palusil (hydrochloride); Proguanil [INN:BAN]; Proguanilum [INN-Latin]; RP-3359; Tirian (hydrochloride); M-4888 (hydrochloride); SN-12837 (hydrochloride); N1-p-Chlorophenyl-N5-isopropylbiguanide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 1-(p-Chlorophenyl)-5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide,Antimalarial Agents,Small molecule,"1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)",SSOLNOMRVKKSON-UHFFFAOYSA-N,CC(C)N=C(N)N=C(N)NC1=CC=C(C=C1)Cl,500-92-5,C11H16ClN5,8455,1F40-1F45: Malaria
D1351,Promazine,4926,"Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride",Antipsychotic Agents,Small molecule,"1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3",ZGUGWUXLJSTTMA-UHFFFAOYSA-N,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,58-40-2,C17H20N2S,8459,MB23: Appearance/behaviour symptom
D1352,Promethazine,4927,Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN),Antiallergic Agents,Small molecule,"1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3",PWWVAXIEGOYWEE-UHFFFAOYSA-N,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,60-87-7,C17H20N2S,8461,MD90: Nausea/vomiting
D1353,Propafenone,4932,Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one,Antiarrhythmic Agents,Small molecule,"1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3",JWHAUXFOSRPERK-UHFFFAOYSA-N,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,54063-53-5,C21H27NO3,63619,BC71: Ventricular tachyarrhythmia
D1354,Propantheline,4934,"Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)",Antispasmodics,Small molecule,"1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1",VVWYOYDLCMFIEM-UHFFFAOYSA-N,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,298-50-0,C23H30NO3+,8481,DA60: Gastric ulcer; EE00: Hyperhidrosis
D1355,Propiomazine,4940,Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine,Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3",UVOIBTBFPOZKGP-UHFFFAOYSA-N,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C,362-29-8,C20H24N2OS,8491,7A00-7A0Z: Insomnia
D1356,Propofol,4943,"Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3",OLBCVFGFOZPWHH-UHFFFAOYSA-N,CC(C)C1=C(C(=CC=C1)C(C)C)O,2078-54-8,C12H18O,44915,9A76-9A78: Corneal disease
D1357,Propranolol,4946,"Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol",Antianxiety Agents,Small molecule,"1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,525-66-6,C16H21NO2,8499,8A80: Migraine
D1358,Propylhexedrine (nasal),7558,"Propylhexedrine hydrochloride; Eggobesin; Eventin hydrochloride; Benzedrex hydrochloride; Pernsator-wirkstoff; dl-Propylhexedrine Hydrochloride; 1007-33-6; Cyclohexylisopropylmethylamine hydrochloride; NSC 27110; NSC 170998; Cyclohexyl(isopropyl)methylammonium chloride; 1-Cyclohexyl-2-methylaminopropane hydrochloride; EINECS 213-753-7; (+-)-Propylhexedrine hydrochloride; N,alpha-Dimethylcyclohexaneethylamine hydrochloride; Propylhexedrine dl-form hydrochloride; Cyclohexaneethylamine, N,alpha-dimethyl-, hydrochloride",Decongestants,Small molecule,"1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3",JCRIVQIOJSSCQD-UHFFFAOYSA-N,CC(CC1CCCCC1)NC,101-40-6,C10H21N,134783,5B80-5B81: Obesity
D1359,Propylthiouracil,657298,"propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil;  Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile",Antithyroid Agents,Small molecule,"1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)",KNAHARQHSZJURB-UHFFFAOYSA-N,CCCC1=CC(=O)NC(=S)N1,51-52-5,C7H10N2OS,8502,5A02: Thyrotoxicosis
D1360,Protein C,.,"Activated Protein C (390-404), human",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D1361,Protriptyline,4976,"Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene",Antidepressants,Small molecule,"1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3",BWPIARFWQZKAIA-UHFFFAOYSA-N,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13,438-60-8,C19H21N,8597,6A70-6A7Z: Depression
D1362,Prucalopride,3052762,"Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]",Serotoninergic Neuroenteric Modulators,Small molecule,"1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)",ZPMNHBXQOOVQJL-UHFFFAOYSA-N,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,179474-81-8,C18H26ClN3O3,135552,DD91: Irritable bowel syndrome
D1363,Pseudoephedrine,7028,"Balminil Decongestant Syrup; Dimetapp Decongestant; Dimetapp Decongestant Pediatric Drops; Drixoral Nasal Decongestant; Pseudoephedrine Ephedrine; Sudafed Decongestant Extra Strength; Triaminic AM Decongestant Formula; Triaminic Infant Oral Decongestant Drops; Efidac 24 PseudoephedrineHcl; Sudafed Decongestant 12 Hour; Pseudoefedrina [INN-Spanish]; Pseudoephedrine (INN); Pseudoephedrine [INN:BAN]; Pseudoephedrine d-form; Pseudoephedrinum [INN-Latin]; Sudafed (TN); Alpha-(1-(Methylamino)ethyl)benzyl alcohol; D-psi-2-Methylamino-1-phenyl-1-propanol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI); (+)-(1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; (1S,2S)-Pseudoephedrine; (1S,2S)-Pseudoephedrine, polymer-bound",Decongestants,Small molecule,"1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1",KWGRBVOPPLSCSI-WCBMZHEXSA-N,CC(C(C1=CC=CC=C1)O)NC,90-82-4,C10H15NO,51209,MD11: Breathing abnormality
D1364,Pyrazinamide,1046,"Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine",Antitubercular Agents,Small molecule,"1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)",IPEHBUMCGVEMRF-UHFFFAOYSA-N,C1=CN=C(C=N1)C(=O)N,98-96-4,C5H5N3O,45285,1B10-1B21: Mycobacterium infection
D1365,Pyridostigmine,4991,"Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium",Parasympathomimetics,Small molecule,"1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1",RVOLLAQWKVFTGE-UHFFFAOYSA-N,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,155-97-5,C9H13N2O2+,8665,8C6Y: Myasthenia gravis
D1366,Pyrimethamine,4993,"Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine",Antimalarial Agents,Small molecule,"1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)",WKSAUQYGYAYLPV-UHFFFAOYSA-N,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,58-14-0,C12H13ClN4,8673,1F40-1F45: Malaria
D1367,Quazepam,4999,"Cetrane; Doral; Dormalin; Oniria; Prosedar; Quazapam; Quazepamum; Quazium; Selepam; Sch 16134; Doral (TN); Dormalin (TN); Quazepamum [INN-Latin]; Sch-161; Sch-16134; Quazepam (JAN/USP); Quazepam [USAN:BAN:INN]; Quazepam (JAN/USP/INN); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2",IKMPWMZBZSAONZ-UHFFFAOYSA-N,C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F,36735-22-5,C17H11ClF4N2S,8694,7A00-7A0Z: Insomnia
D1368,Quetiapine,5002,"quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760",Antipsychotic Agents,Small molecule,"1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2",URKOMYMAXPYINW-UHFFFAOYSA-N,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,111974-69-7,C21H25N3O2S,8707,6A20: Schizophrenia; 6C40: Substance abuse
D1369,Quinapril,54892,"Ectren; Koretic; Quinaprilum; QUINAPRIL HCL; Quinaprilum [Latin]; Accupril (TN); Quinapril [INN:BAN]; Quinapril (USP/INN); [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1",JSDRRTOADPPCHY-HSQYWUDLSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O,85441-61-8,C25H30N2O5,8713,BA00-BA04: Hypertension
D1370,Quinestrol,9046,"EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol",Antineoplastics,Small molecule,"1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1",PWZUUYSISTUNDW-VAFBSOEGSA-N,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5,152-43-2,C25H32O2,8716,2C60-2C6Y: Breast cancer
D1371,Quinidine,441074,"quinidine; 56-54-2; (+)-Quinidine; Conquinine; Pitayine; Conchinin; Chinidin; Quinidex; (8R,9S)-Quinidine; beta-Quinine; Cin-Quin; (9S)-6'-Methoxycinchonan-9-ol; Kinidin; Conchinine; chinidinum; quinidina; Quiniduran; Chinidine; Cinchonan-9-ol, 6'-methoxy-, (9S)-; UNII-ITX08688JL; Quinaglute; Auriquin; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; Quinidine sulfate; CHEBI:28593; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; Quinicardine; CHEMBL1294; Duraquin; Quinact; Quinalan; Quinatime; (1S)-(6-Methoxyquinolin-4-yl)((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; ITX08688JL; 6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; QUINIDINE HYDROCHLORIDE; MFCD00135581; beta-Quinidine; (3'.alpha., 9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; .beta.-Quinidine; TCMDC-131239; NCI-C56246; (R)-(6-methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-methoxy-4-quinolyl)-[(2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (S)-[(4S,5R,7R)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol; Chinidin [German]; SMR000857275; Quinidine [BAN:NF]; Quinindine; CCRIS 672; HSDB 225; (8R,9S)-6'-Methoxycinchonan-9-ol; (S)-(6-methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; QDN; EINECS 200-279-0; Quinidine, anhydrous; Prestwick3_000280; bmse000511; Epitope ID:141803; SCHEMBL15943; BSPBio_000160; MLS001335913; MLS001335914; MLS002548869; BPBio1_000176; GTPL2342; DTXSID4023549; SCHEMBL17537608; HMS2234L10; HMS3259O09; ACT09863; HY-B1751; ZINC3831405; (9S)-6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol (9S)-; BDBM50121975; AKOS015920101; CCG-256507; CS-7812; DB00908; MCULE-7178915526; NC00478; SDCCGMLS-0066600.P001; NCGC00091231-01; NCGC00091231-02; NCGC00091231-03; NCGC00091231-18; AS-30538; AB00514657; AB01562940_01; Q412496; W-109256; BRD-K59632282-052-01-5; BRD-K59632282-052-02-3; BRD-K70799801-311-02-7; Quinidine, crystallized, >=98.0% (dried material, NT); 101143-86-6",Group I Antiarrhythmics,Small molecule,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1",LOUPRKONTZGTKE-LHHVKLHASA-N,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O,.,C20H24N2O2,.,.
D1372,Quinine,3034034,"Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine",Antimalarial Agents,Small molecule,"1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1",LOUPRKONTZGTKE-WZBLMQSHSA-N,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,72402-53-0,C20H24N2O2,15854,1F40-1F45: Malaria
D1373,Rabeprazole,5029,Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole,Antiulcer Agents,Small molecule,"1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)",YREYEVIYCVEVJK-UHFFFAOYSA-N,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,117976-89-3,C18H21N3O3S,8768,1A00-1C4Z: Bacterial infection
D1374,Racepinephrine,838,"DL-Adrenaline; 329-65-7; dl-Epinephrine; Racepinefrine; Racepinephrine; Epinephrine racemic; (+-)-Adrenaline; Racepinefrina; Racepinefrinum; Epirenamine; (+-)-Epinephrine; DL-Adrenalin; 4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol; Vaponefrin; D-Epinephrine; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; 2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol; L-(-)-EPINEPHRINE; Alipogene tiparvovec; d-Adrenaline; (+/-)-adrenaline; 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-; 1-(3,4-Dihydroxy)phenyl-2-methylaminoethanol; CHEMBL1740; Micronefrin; Suprarenin; CHEBI:33568; (  )-Epinephrine; L-(+)-Adrenaline; 6912-68-1; (+/-)-Epinephrine;DL-Adrenaline;(+/-)-Adrenaline; Micronephrine; Epinephrine dl-; MLS001333244; (-)-Epinephrine (+)-bitartrate salt;L-Adrenaline (+)-bitartrate salt; D-(+)-Epinephrine; (+/-)-Epinephrine; BRN 2938799; Racepinefrine, (S)-; Racepinefrinum [INN-Latin]; Racemic Epinephrine; Racepinefrina [INN-Spanish]; 929881-05-0; Racepinephrine [USP]; SMR000058236; EINECS 206-347-6; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-; BRN 2212160; Epinepherine; rac Epinephrine; CCRIS 8140; Epinephrine-d3; Epinephrine-d6; DL-Adrenali; Racemic adrenaline; Adrenaline,(S); Epinephrine, dl-; Adrenaline, racemic; Epinephrine dl form; Epinephrine dl-form; (plusmn)-adrenaline; Epinephrine, Racemic; Racepinefrine [INN]; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (R,S)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzylalkohol; EPINEPHRINE,(+); (.+/-.)-Adrenaline; Racemic mixture adrenaline; (.+/-.)-Epinephrine; Oxidized-adrenal-ferredoxin; Racemic mixture epinephrine; 4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol #; Adrenaline, racemic mixture; Mixture adrenaline, racemic; Racepinephrine (USP/INN); AROCLOR1016; cid_5924; SCHEMBL3815; Epinephrine, racemic mixture; Mixture epinephrine, racemic; (r)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol; Hydrochloride, racepinephrine; NCIOpen2_000082; Lopac0_000522; GTPL509; 4-13-00-02927 (Beilstein Handbook Reference); SGCUT00008; BDBM84342; DTXSID80858965; (+/-)-Epinephrine, >=95%; HMS3259B19; HMS3656E12; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (+-)-; 104655-05-2; BCP17220; HY-B0447; to_000046; AC-395; BBL028091; Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (+-)-; PDSP1_000587; PDSP2_000584; s2523; STL146338; AKOS005721043; CCG-204612; MCULE-4868062157; NC00671; SDCCGSBI-0050505.P002; BRN-2938799; ( inverted exclamation markA)-Adrenaline; Adrenaline hydrochloride, racemic mixture; NCGC00015417-02; NCGC00015417-03; NCGC00015417-16; NCGC00162177-01; ( inverted exclamation markA)-Epinephrine; AS-12580; Epinephrine hydrochloride, racemic mixture; A0172; FT-0625455; FT-0695432; D05688; D88221; AB00514461_07; 329A657; A821533; L000877; 4-(1-hydroxy-2-methylaminoethyl)benzene-1,2-diol; J-018952; Q7279006; SR-01000075862-8; 4-(1-Hydroxy-2-methylamino-ethyl)-benzene-1,2-diol; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol, 1; 9561B8BB-366F-4A33-B295-1C6E682AC6BB; (.+/-.)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[1-hydroxy-2-(methylamino)ethyl]pyrocatechol;hydrochloride; (.+/-.)-3,4-Dihydroxy-.alpha.-[(methylamino)methyl]benzyl alcohol; 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (.+/-.)-; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;DL-Adrenaline; 4-[2-(methylamino)-1-oxidanyl-ethyl]benzene-1,2-diol;hydrochloride; Benzyl alcohol, 3,4-dihydroxy-.alpha.-((methylamino)methyl)-, (.+/-.)-; ( inverted exclamation markA)-Epinephrine;( inverted exclamation markA)-Adrenaline;DL-Adrenaline; (+/-)-Epinephrine-D6 solution, 100 mug/mL in methanol with 5% 1 M HCl, ampule of 1 mL, certified reference material",Adrenergic Bronchodilators,Small molecule,"InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3",UCTWMZQNUQWSLP-UHFFFAOYSA-N,CNCC(C1=CC(=C(C=C1)O)O)O,.,C9H13NO3,.,.
D1375,Radium Ra 223 dichloride,.,DB08913; Radium chloride Ra-223; Radium Ra 223 dichloride; Radium Ra-223 dichloride; Radium-223 chloride; Radium-223 dichloride,Diagnostic Radiopharmaceuticals,Small molecule,.,.,.,.,.,.,.
D1376,Raloxifene,5035,"Raloxifene (extended-release, CDT)",Hormones/Antineoplastics,Small molecule,"1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2",GZUITABIAKMVPG-UHFFFAOYSA-N,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,84449-90-1,C28H27NO4S,8772,FB83: Low bone mass disorder
D1377,Raltegravir,54671008,"RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL",Antiviral Agents,Small molecule,"1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)",CZFFBEXEKNGXKS-UHFFFAOYSA-N,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,518048-05-0,C20H21FN6O5,.,1C60-1C62: Human immunodeficiency virus disease
D1378,Ramelteon,208902,"Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1",YLXDSYKOBKBWJQ-LBPRGKRZSA-N,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,196597-26-9,C16H21NO2,109549,7A00-7A0Z: Insomnia; 7A60-7A65: Circadian rhythm sleep disorder
D1379,Ramipril,5362129,"Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]",Antihypertensive Agents,Small molecule,"1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1",HDACQVRGBOVJII-JBDAPHQKSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,87333-19-5,C23H32N2O5,8774,BD10-BD1Z: Heart failure
D1380,Ramucirumab,.,LY3009806,Vegf/Vegfr Inhibitors,Monoclonal antibody,.,.,.,.,.,.,2B72: Stomach cancer
D1381,Ranitidine,3001055,"Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine",Antiulcer Agents,Small molecule,"1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+",VMXUWOKSQNHOCA-UKTHLTGXSA-N,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,82530-72-1,C13H22N4O3S,8776,DA61: Peptic ulcer
D1382,Ranitidine (bismuth citrate),3001055,"Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine",Antiulcer Agents,Small molecule,"1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+",VMXUWOKSQNHOCA-UKTHLTGXSA-N,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,82530-72-1,C13H22N4O3S,8776,DA61: Peptic ulcer
D1383,Ranolazine,56959,"RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D;  Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination",Analgesics,Small molecule,"1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)",XKLMZUWKNUAPSZ-UHFFFAOYSA-N,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,95635-55-5,C24H33N3O4,87690,BA40: Angina pectoris; BC81: Supraventricular tachyarrhythmia
D1384,Rapacuronium,5311399,"Rapacuronium; UNII-GG1LBM463S; GG1LBM463S; 465499-11-0; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-acetyloxy-10,13-dimethyl-2-piperidin-1-yl-16-(1-prop-2-enylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate; NCGC00183839-01; Rapacuronium ion; Rapacuronium cation; CHEMBL1201352; SCHEMBL16977930; CHEBI:135845; ZINC3943562; DB04834",Neuromuscular Blocking Agents,Small molecule,"InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1",HTIKWNNIPGXLGM-YLINKJIISA-N,CCC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)OC(=O)C)N5CCCCC5)C)C)[N+]6(CCCCC6)CC=C,.,C37H61N2O4+,.,.
D1385,Rasagiline,3052776,"RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)",Antiparkinson Agents,Small molecule,"1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1",RUOKEQAAGRXIBM-GFCCVEGCSA-N,C#CCNC1CCC2=CC=CC=C12,136236-51-6,C12H13N,63620,2C30-2C37: Skin cancer; EK71: Skin tag/polyp; 8A00: Parkinsonism
D1386,Rasburicase,.,Fasturtec (TN),Antihyperuricemic Agents,Protein/peptide,.,.,.,.,.,.,5C55: Inborn purine/pyrimidine/nucleotide metabolism error
D1387,Regorafenib,11167602,Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN],Vegf/Vegfr Inhibitors,Small molecule,"1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,755037-03-7,C21H15ClF4N4O3,68647,2B91: Colorectal cancer
D1388,Relugolix,10348973,"737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917",Gonadotropin-Releasing Hormone Antagonists,Small molecule,"1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)",AOMXMOCNKJTRQP-UHFFFAOYSA-N,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,737789-87-6,C29H27F2N7O5S,.,GA10: Endometriosis; 2C82: Prostate cancer
D1389,Remdesivir,121304016,"L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE",Purine Nucleosides,Small molecule,"1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1",RWWYLEGWBNMMLJ-YSOARWBDSA-N,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,1809249-37-3,C27H35N6O8P,145994,1D60: Filovirus disease; 1D6YCoronavirus Disease 2019
D1390,Remifentanil,60815,"Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3",ZTVQQQVZCWLTDF-UHFFFAOYSA-N,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,132875-61-7,C20H28N2O5,8802,9A76-9A78: Corneal disease
D1391,Remimazolam,9867812,"CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK",Benzodiazepines,Small molecule,"1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1",CYHWMBVXXDIZNZ-KRWDZBQOSA-N,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4,308242-62-8,C21H19BrN4O2,.,9A76-9A78: Corneal disease; JB0C: Labour/delivery anaesthesia complication
D1392,Repaglinide,65981,"Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid",Antidiabetic Agents,Small molecule,"1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1",FAEKWTJYAYMJKF-QHCPKHFHSA-N,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,135062-02-1,C27H36N2O4,8805,5A2Y: Acute diabete complication
D1393,Reserpine,5770,"Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L""-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp",Antihypertensive Agents,Small molecule,"1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1",QEVHRUUCFGRFIF-MDEJGZGSSA-N,COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,50-55-5,C33H40N2O9,28487,BA00-BA04: Hypertension
D1394,Retapamulin (topical),6918462,Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN),Antibiotics,Small molecule,"1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1",STZYTFJPGGDRJD-FJJJPKKESA-N,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CC5CCC(C4)N5C)C,224452-66-8,C30H47NO4S,166679,1B72: Impetigo
D1395,Reteplase,.,Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN),Thrombolytics,Protein/peptide,.,.,.,.,.,.,BA41-BA43: Myocardial infarction
D1396,Revefenacin,11753673,UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7,Anticholinergic Agents/Bronchodilators,Small molecule,"1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)",FYDWDCIFZSGNBU-UHFFFAOYSA-N,CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N,864750-70-9,C35H43N5O4,.,CA22: Chronic obstructive pulmonary disease
D1397,Ribavirin,37542,"ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus);  Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin",Antiviral Agents,Small molecule,"1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1",IWUCXVSUMQZMFG-AFCXAGJDSA-N,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,36791-04-5,C8H12N4O5,63580,1E50-1E51: Hepatitis virus infection
D1398,Ribociclib,44631912,"Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013",Antineoplastics/Cdk 4/6 Inhibitors,Small molecule,"1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,1211441-98-3,C23H30N8O,.,2A00-2F9Z: Solid tumour/cancer; 2C60-2C6Y: Breast cancer
D1399,Rifabutin,135398743,"Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S",Antibiotics,Small molecule,"1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1",ZWBTYMGEBZUQTK-PVLSIAFMSA-N,CC1C=CC=C(C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)OC(C6=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C,72559-06-9,C46H62N4O11,.,1B10-1B21: Mycobacterium infection; 1B10-1B14: HIV-infected patients with tuberculosis
D1400,Rifampicin,135398735,"Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)",Antituberculosis Agents,Small molecule,"1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1",JQXXHWHPUNPDRT-WLSIYKJHSA-N,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,13292-46-1,C43H58N4O12,28077,1B10-1B14: HIV-infected patients with tuberculosis
D1401,Rifapentine,135403821,"RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE",Antituberculosis Agents,Small molecule,"1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1",WDZCUPBHRAEYDL-GZAUEHORSA-N,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C,61379-65-5,C47H64N4O12,45304,1B10-1B14: HIV-infected patients with tuberculosis; 9B71: Retinopathy
D1402,Rifaximin,6436173,"RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals",Antibiotics,Small molecule,"1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1",NZCRJKRKKOLAOJ-XRCRFVBUSA-N,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,80621-81-4,C43H51N3O11,75246,1A00-1C4Z: Bacterial infection
D1403,Rilonacept,.,Rilonacept (USAN/INN),Interleukin Inhibitors,Protein/peptide,.,.,.,.,.,.,FA20: Rheumatoid arthritis; FA25: Gout
D1404,Rilpivirine,6451164,"500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888;  RPV; Mu O-conotoxin",Antiviral Agents,Small molecule,"1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+",YIBOMRUWOWDFLG-ONEGZZNKSA-N,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,500287-72-9,C22H18N6,68606,1C60-1C62: Human immunodeficiency virus disease; MG30-MG3Z: Pain
D1405,Riluzole,5070,"Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine",Anticonvulsants,Small molecule,"1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)",FTALBRSUTCGOEG-UHFFFAOYSA-N,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,1744-22-5,C8H5F3N2OS,8863,8B60: Motor neuron disease
D1406,Rimantadine,5071,"Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine",Antiviral Agents,Small molecule,"1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3",UBCHPRBFMUDMNC-UHFFFAOYSA-N,CC(C12CC3CC(C1)CC(C3)C2)N,13392-28-4,C12H21N,94440,1E30-1E32: Influenza
D1407,Rimegepant,51049968,"BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991",Cgrp Inhibitors,Small molecule,"1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1",KRNAOFGYEFKHPB-ANJVHQHFSA-N,C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,1289023-67-1,C28H28F2N6O3,.,8A80: Migraine
D1408,Riociguat,11304743,"Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester",Vasodilator Agents,Small molecule,"1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)",WXXSNCNJFUAIDG-UHFFFAOYSA-N,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,625115-55-1,C20H19FN8O2,76018,BB01: Pulmonary hypertension
D1409,Ripretinib,71584930,"1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-",Multikinase Inhibitors,Small molecule,"1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)",CEFJVGZHQAGLHS-UHFFFAOYSA-N,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,1442472-39-0,C24H21BrFN5O2,.,2A00: Brain cancer; 2A00-2F9Z: Solid tumour/cancer; 2A21: Mastocytosis; 2B5B: Gastrointestinal stromal tumour
D1410,Risankizumab,.,.,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FA21: Psoriatic arthritis; EA90: Psoriasis
D1411,Risdiplam,118513932,"UNII-76RS4S2ET1; 76RS4S2ET1; 1825352-65-5; Risdiplam [INN]; SCHEMBL17260852; EX-A2074; RG-7916; HY-109101; RO7034067; CS-0039501; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one",Mrna Splicing Modifier,Small molecule,"1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3",ASKZRYGFUPSJPN-UHFFFAOYSA-N,CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6,1825352-65-5,C22H23N7O,.,8B61: Muscular atrophy
D1412,Risedronic acid,5245,"Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,;  Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID",Bone Density Conservation Agents,Small molecule,"1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)",IIDJRNMFWXDHID-UHFFFAOYSA-N,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,105462-24-6,C7H11NO7P2,8869,FB85: Bone paget disease
D1413,Risperidone,5073,"Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one",Antipsychotic Agents,Small molecule,"1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3",RAPZEAPATHNIPO-UHFFFAOYSA-N,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,.,C23H27FN4O2,8871,6A20: Schizophrenia
D1414,Ritodrine,33572,"Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol",Sympathomimetics,Small molecule,"1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1",IOVGROKTTNBUGK-SJCJKPOMSA-N,CC(C(C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O,26652-09-5,C17H21NO3,8872,JB00: Preterm labour/delivery
D1415,Ritonavir,392622,"Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT",Anti-Hiv Agents,Small molecule,"1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1",NCDNCNXCDXHOMX-XGKFQTDJSA-N,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,155213-67-5,C37H48N6O5S2,45409,1C60-1C62: Human immunodeficiency virus disease
D1416,Rituximab,.,MAbThera (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B33: Malignant haematopoietic neoplasm
D1417,Rivaroxaban,9875401,XARELTO (TN),Anticoagulants/Factor Xa Inhibitors,Small molecule,"1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",KGFYHTZWPPHNLQ-AWEZNQCLSA-N,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,366789-02-8,C19H18ClN3O5S,68579,BD71: Deep vein thrombosis
D1418,Rivastigmine,77991,Rivastigmine (transdermal patch),Cholinesterase Inhibitors,Small molecule,"1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1",XSVMFMHYUFZWBK-NSHDSACASA-N,CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C,123441-03-2,C14H22N2O2,8874,8A20: Alzheimer disease
D1419,Rizatriptan,5078,"Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine",Antiinflammatory Agents,Small molecule,"1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3",ULFRLSNUDGIQQP-UHFFFAOYSA-N,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3,144034-80-0,C15H19N5,48273,8A80: Migraine
D1420,Rocuronium,441290,"Esmeron (TN); Zemuron (TN); (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate",Neuromuscular Blocking Agents,Small molecule,"1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1",YXRDKMPIGHSVRX-OOJCLDBCSA-N,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,143558-00-3,C32H53N2O4+,8884,MB47: Tonus and reflex abnormality
D1421,Rofecoxib,5090,Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one,Antiinflammatory Agents,Small molecule,"1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3",RZJQGNCSTQAWON-UHFFFAOYSA-N,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,162011-90-7,C17H14O4S,8887,FA00-FA05: Osteoarthritis
D1422,Roflumilast,449193,"162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;  DAXAS; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast",Selective Phosphodiesterase-4 Inhibitors,Small molecule,"1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",MNDBXUUTURYVHR-UHFFFAOYSA-N,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,162401-32-3,C17H14Cl2F2N2O3,47657,CA23: Asthma; EA80: Atopic eczema; 5A11: Type 2 diabetes mellitus; CA22: Chronic obstructive pulmonary disease
D1423,Rolapitant,10311306,"Rolapitant; 552292-08-7; Sch 619734; Varubi; UNII-NLE429IZUC; SCH-619734; NLE429IZUC; 914462-92-3; (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one; Rolapitant [USAN:INN]; Varuby; Varubi (TN); Rolapitant (USAN/INN); Rolapitant(sch619734); SCHEMBL354305; GTPL5749; CHEMBL3707331; CHEBI:90908; DTXSID90203740; MolPort-035-942-975; EX-A1288; BCP09609; ZINC3816514",Nk1 Receptor Antagonists,Small molecule,"1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1",FIVSJYGQAIEMOC-ZGNKEGEESA-N,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4,552292-08-7,C25H26F6N2O2,90908,MD90: Nausea/vomiting
D1424,Romidepsin,5352062,"Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",Histone Deacetylase Inhibitors,Small molecule,"1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1",OHRURASPPZQGQM-GCCNXGTGSA-N,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,128517-07-7,C24H36N4O6S2,61080,2B01: Mycosis fungoides; 2A90: Mature T-cell lymphoma; 2C90: Renal cell carcinoma
D1425,Romiplostim,5329098,.,Platelet-Stimulating Agents,Small molecule,"1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-",WUWDLXZGHZSWQZ-WQLSENKSSA-N,CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C,194413-58-6,C15H14N2O,91083,3B64: Thrombocytopenia; 2A83: Multiple myeloma; 2A37: Myelodysplastic syndrome
D1426,Romosozumab,.,AMG 785,Bone Resorption Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FB83: Low bone mass disorder
D1427,Ropinirole,5095,"Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one",Antiparkinson Agents,Small molecule,"1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)",UHSKFQJFRQCDBE-UHFFFAOYSA-N,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,91374-21-9,C16H24N2O,8888,8A00: Parkinsonism
D1428,Ropivacaine,175805,"Naropin; ROPIVACAINE HCl; Ropivacaine hydrochloride; Ropivacaine monohydrochloride; Naropin (TN); Ropivacaine monohydrochloride, (S)-isomer; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride",Anesthetics,Small molecule,"1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1",ZKMNUMMKYBVTFN-HNNXBMFYSA-N,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,84057-95-4,C17H26N2O,8890,9A76-9A78: Corneal disease
D1429,Rosiglitazone,77999,"rosiglitazone; 122320-73-4; Avandia; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Rosiglizole; Brl-49653; Brl 49653; BRL49653; rosiglitazone (Avandia); Avandaryl; TDZ 01; Rezult; Avandamet; C18H19N3O3S; CHEBI:50122; MFCD00871760; Rosigilitazone; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; NSC-758698; NCGC00095124-01; BRL 49653C; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; DSSTox_CID_17131; DSSTox_RID_79303; DSSTox_GSID_37131; 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; Rosiglitazone [INN:BAN]; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; CAS-122320-73-4; SR-01000763023; rosiglitazona; rosiglitazonum; Gaudil; Rosvel; Rosi; DTXSID7037131; HSDB 7555; Rosiglitazone base; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; RGZ; Gaudil (TN); Rosiglitazone (INN); Rosiglitazone- Bio-X; Spectrum_001703; 1217260-35-9; Spectrum2_001241; Spectrum3_000997; Spectrum4_001125; Spectrum5_001464; SCHEMBL5169; Dioxopromethazinehydrochloride; BSPBio_002693; KBioGR_001609; KBioSS_002183; SPECTRUM1504263; SPBio_001142; GTPL1056; TDZ-01; SCHEMBL14383595; KBio2_002183; KBio2_004751; KBio2_007319; KBio3_001913; Rosiglitazone, >=98% (HPLC); HMS1922J11; HMS2094O13; HMS3649G08; HMS3656K16; HMS3744M11; HMS3871L03; HMS3884N08; Pharmakon1600-01504263; ACT04332; BCP03047; Tox21_111434; BDBM50030474; CCG-39102; NSC758698; STL350047; AKOS015894872; Tox21_111434_1; AC-3459; BCP9000017; CS-1088; DB00412; MCULE-8293284864; NSC 758698; SB17326; NCGC00095124-02; NCGC00095124-03; NCGC00095124-04; NCGC00095124-05; NCGC00095124-06; NCGC00095124-08; BR164372; HY-17386; SY031184; BCP0726000232; FT-0602578; R0106; S2556; SW197573-6; 20R734; 6P-065; D08491; J10213; S00306; AB00698473-15; AB00698473-17; AB00698473-18; AB00698473-19; AB00698473_20; AB00698473_21; AB00698473_22; AB00698473_23; Q424771; Q-201681; SR-01000763023-5; SR-01000763023-6; BRD-A97437073-001-02-3; BRD-A97437073-001-03-1; BRD-A97437073-001-04-9; SR-01000763023-12; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione; IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin); (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione",Thiazolidinediones,Small molecule,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",YASAKCUCGLMORW-UHFFFAOYSA-N,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,.,C18H19N3O3S,.,.
D1430,Rosuvastatin,446157,"Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1",BPRHUIZQVSMCRT-VEUZHWNKSA-N,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,287714-41-4,C22H28FN3O6S,38545,5C80: Hyper-lipoproteinaemia; MA14: Blood/blood-forming organ sympton
D1431,Rotigotine,59227,"Rotigotine; 99755-59-6; Leganto; SPM 962; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-rotigotine; UNII-87T4T8BO2E; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-962; N 0923; CHEMBL1303; 87T4T8BO2E; 99755-59-6 (free base); (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; NCGC00168748-01; Rotigotine CDS Patch; (6s)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol; DSSTox_CID_26772; DSSTox_RID_81893; DSSTox_GSID_46772; C19H25NOS; Rotigotine CDS; (S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol; CAS-99755-59-6; Neupro (TN); N-0923; Rotigotine [USAN:INN:BAN]; (S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol; (S)-6-[Propyl[2-(thiophen-2-yl)ethyl]amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-936; SPM-937; PubChem16423; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; GTPL941; cc-129; Rotigotine (JAN/USAN/INN); (-)-N-0437; SCHEMBL1088585; ZINC4028; DTXSID5046772; HSDB 8254; (2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol; CHEBI:135351; HMS3885D17; EX-A1164; Tox21_112627; 2696AH; BDBM50123626; MFCD00870193; s4274; AKOS016340728; Tox21_112627_1; AC-3547; CCG-267650; CS-0376; DB05271; SB19528; SS-4572; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; NCGC00168748-02; HY-75502; AB0088886; SW220014-1; D05768; W-5179; 572R932; A846076; Q411985; J-502471; UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N; (6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (6S)-",Dopaminergic Antiparkinsonism Agents,Small molecule,"1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1",KFQYTPMOWPVWEJ-INIZCTEOSA-N,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,99755-59-6,C19H25NOS,135351,8A00: Parkinsonism; 7A80: Restless legs syndrome
D1432,Rucaparib,9931954,"RUCAPARIB; 283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one",Poly (Adp-Ribose) Polymerase Inhibitors,Small molecule,"1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,283173-50-2,C19H18FN3O,94311,2C73: Ovarian cancer
D1433,Rufinamide,129228,"106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506;  Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel",Anticonvulsants,Small molecule,"1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)",POGQSBRIGCQNEG-UHFFFAOYSA-N,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,106308-44-5,C10H8F2N4O,134966,8A61-8A6Z: Epilepsy/seizure; 8A62: Epileptic encephalopathy
D1434,Ruxolitinib,25126798,Ruxolitinib (JAK inhibitor),Multikinase Inhibitors,Small molecule,"1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,941678-49-5,C17H18N6,66919,2A20: Myeloproliferative neoplasm; 2C10: Pancreatic cancer; 3B63: Thrombocytosis; EA80: Atopic eczema; ED63: Acquired hypomelanotic disorder
D1435,Sacituzumab govitecan,91668186,Sacituzumab govitecan; 1491917-83-9; UNII-M9BYU8XDQ6; hRS 7SN38; hRS7-SN38; Sacituzumab govitecan [USAN]; IMMU 132; IMMU-132; Satralizumab linker; sacituzumab-govitecan; M9BYU8XDQ6; EX-A4354; UNII-DA64T2C2IO component ULRUOUDIQPERIJ-PQURJYPBSA-N; UNII-SZB83O1W42 component ULRUOUDIQPERIJ-PQURJYPBSA-N,Antineoplastics,Monoclonal antibody,"InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1",ULRUOUDIQPERIJ-PQURJYPBSA-N,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)[C@H](CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SC[C@@H](C(=O)O)N)C2=NC9=C1C=C(C=C9)O,.,C76H104N12O24S,.,.
D1436,Sacubitril,9811834,"Sacubitril; 149709-62-6; AHU-377; AHU377; AHU 377; 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid; UNII-17ERJ0MKGI; 17ERJ0MKGI; 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid; MFCD00920862; AHU-377(Sacubitril); 3-{[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]carbamoyl}propanoic acid; alpha-ethyl (alphaR,gammaS)-gamma-<(3-carboxy-1-oxopropyl)amino>-alpha-methyl<1,1'-biphenyl>-4-pentanoate; Sacubitril [USAN:INN]; Neparvis; Sacubitril (JAN/USAN/INN); AMBZ0404; GTPL7857; SCHEMBL2707112; CHEMBL3137301; AOB2046; DTXSID20164370; CHEBI:134714; 4-(((2S,4R)-1-([1,1-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid; ZINC3792417; AKOS027321509; AM85599; CM14438; DB09292; NCGC00387800-02; AC-28899; AS-16703; HY-15407; D10225; J-008612; Q17811448; (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester; (2R,4S)-5-Biphenyl-4-yl-4-(3-carboxypropionylamino)-2-methylpentanoic acid ethyl ester; (2R,4S)-5-(biphenyl-4-yl)-4-((3-carboxypropionyl) amino)-2-methylpentanoic acid ethyl ester; (alphaR,gammaS)-gamma-[(3-Carboxy-1-oxopropyl)amino]-alpha-methyl-4-biphenylpentanoic acid alpha-ethyl ester; [1,1'-Biphenyl]-4-pentanoic acid, -[(3-carboxy-1-oxopropyl)amino]-alpha-methyl-, alpha-ethyl ester, (alphaR,S)-; [1,1'-Biphenyl]-4-pentanoic acid, gamma-[(3-carboxy-1-oxopropyl)amino]-alpha-methyl-, alpha-ethyl ester, (alphaR,gammaS)-; AHU-377, (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester",Neprilysin Inhibitors,Small molecule,"InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1",PYNXFZCZUAOOQC-UTKZUKDTSA-N,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,.,C24H29NO5,.,.
D1437,Safinamide,131682,133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na,Dopaminergic Antiparkinsonism Agents,Small molecule,"1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1",NEMGRZFTLSKBAP-LBPRGKRZSA-N,CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F,133865-89-1,C17H19FN2O2,134718,8A00: Parkinsonism
D1438,Salbutamol,2083,"Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol",Bronchodilators,Small molecule,"1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3",NDAUXUAQIAJITI-UHFFFAOYSA-N,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,18559-94-9,C13H21NO3,2549,CA23: Asthma
D1439,Salicylic acid (sodium),338,"Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart;  Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE",Antiinflammatory Agents,Small molecule,"1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",YGSDEFSMJLZEOE-UHFFFAOYSA-N,C1=CC=C(C(=C1)C(=O)O)O,69-72-7,C7H6O3,16914,EA81: Seborrhoeic dermatitis
D1440,Salmeterol,5152,"Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol",Bronchodilators,Small molecule,"1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2",GIIZNNXWQWCKIB-UHFFFAOYSA-N,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O,89365-50-4,C25H37NO4,64064,CA22: Chronic obstructive pulmonary disease
D1441,Salmon calcitonin,16129616,"Astronin; Biocalcin; Bionocalcin; Cadens; Calciben; Calcihexal; Calcimar; Calcimonta; Calcinil; Calcioton; Calcitonina; Calcitoran; Calco; Calogen; Calsynar; Caltine; Casalm; Catonin; Cibacalcine; Citonina; Eptacalcin; Forcaltonin; Fortical; Ipocalcin; Kalsimin; Karil; Miacalcic; Miacalcin; Miracalcic; Oseototal; Osseocalcina; Osteobion; Osteovis; Ostosalm; Ostostabil; Porostenina; Prontocalcin; Quosten; Riostin; Rulicalcin; Salcat; Salcatonin; Salcatyn; Salmocalcin; Salmofar; Sical; Stalcin; Staporos; Steocin; Tonocalcin; Ucecal; Calcitonin salmon; Calcitonin vom lachs; Calcitonine de saumon; Calsynar Lyo L; Recombinant salmon calcitonin; Salmon calcitonin I; Synthetic salmon calcitonin; CALCITONIN, SALMON; Calcimar (TN); Calcitonin (salmon); Calcitonin salmon (synthesis); Calcitonin, salmar; Calcitonin,salmon; Calcitonin-salmon; Fortical (TN); Isi-calcin; Miacalcin (TN); TZ-CT; Thyrocalcitonin (salmon); Calcitonin salmon (USAN/INN); Calcitonin salmon (synthesis) (JAN); Calcitonin, salmon, for bioassay; Salmon calcitonin (1-32); Calcitonin [USAN:INN:BAN:JAN]; Salmon calcitonin-(I-32)",Antiosteporotic Agents,Small molecule,"1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)",BBBFJLBPOGFECG-UHFFFAOYSA-N,CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO,2596122,C145H240N44O48S2,.,FB83: Low bone mass disorder
D1442,Salsalate,5161,"Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid",Antiinflammatory Agents,Small molecule,"1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)",WVYADZUPLLSGPU-UHFFFAOYSA-N,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,552-94-3,C14H10O5,9014,FA20: Rheumatoid arthritis
D1443,Samarium (153Sm) lexidronam,23951,"7440-19-9; Samarium; Sm; samario; samarium atom; UNII-42OD65L39F; 62Sm; 42OD65L39F; MFCD00011233; MFCD00151299; Samarium, elemental; Samariumpowder; Samarium powder; Samarium ingot; HSDB 7863; Samarium Nanofoil; EINECS 231-128-7; Samarium foil, 3N; Samarium ingot, 3N; Samarium Nanoparticles; Samarium pieces, 3N; Samarium chunks,99.9%; Samarium powder,99.9%; Samarium powder, -40 mesh; Ultra Thin Samarium Nanofoil; Samarium Nanoparticle Dispersion; DTXSID4064688; Samarium Metal Organic Framework; Samarium Metal-Organic Framework; 1,2-Diacylglycerol-LD-SM-pool; CHEBI:33374; Samarium pieces, sublimed dendritic; AMY22263; 8996AF; AKOS024438061; DB12403; Samarium rod, 12.7mm (0.5in) dia; Samarium foil, 1.0mm (0.04in) thick; Samarium rod, 6.35mm (0.25in) dia; BP-21451; Samarium foil, 0.1mm (0.004in) thick; Samarium foil, 0.25mm (0.01in) thick; Samarium foil, 0.75mm (0.03in) thick; Samarium pieces, 12mm (0.47in) & down; Samarium foil, 0.62mm (0.024in) thick; Samarium powder (99.9% REO) 325 mesh; Q1819; Samarium foil, 0.025mm (0.001in) thick; Samarium foil, 0.127mm (0.005in) thick; D78246; Lanthanum Vanadium (LaVO3) Sputtering Targets; Samarium ingot/button, ca. 50.8mm (2.0in) dia; Samarium, chips, 99.9% trace rare earth metals basis; Samarium, ingot, 99.9% trace rare earth metals basis; Samarium, rod, 100mm, diameter 6.35mm, cast, 99%; Samarium, rod, 50mm, diameter 6.35mm, cast, 99%; Samarium, -40 mesh, 99% trace rare earth metals basis; Samarium, AAS standard solution, Specpure?, Sm 1000?g/ml; Samarium, foil, 25x25mm, thickness 0.1mm, as rolled, 99%; Samarium, foil, 25x25mm, thickness 0.25mm, as rolled, 99%; Samarium, foil, 50x50mm, thickness 0.1mm, as rolled, 99%; Samarium, foil, 50x50mm, thickness 0.25mm, as rolled, 99%; Samarium, plasma standard solution, Specpure?, Sm 1000?g/ml; Samarium, foil, thickness 0.5 mm, 15 mm diameter, purity 99%; Samarium, foil, thickness 0.7 mm, 15 mm diameter, purity 99%; Samarium, lump, 25 mm max. lump size, weight 10 g, purity 99.9%; Samarium, lump, 25 mm max. lump size, weight 20 g, purity 99.9%; Samarium, lump, 25 mm max. lump size, weight 50 g, purity 99.9%; Samarium, plasma standard solution, Specpure?, Sm 10,000?g/ml; Samarium hydride, 99.9%, - 325 mesh SmH2 -3, Hydrogen level may vary; Samarium, foil, thickness 1 mm, 99.9% trace rare earth metals basis; AA Grade Samarium 1,000 mg/L  inverted exclamation markA 2% in 2% HNO3, 100 ml; Samarium, foil, not light tested, 25x25mm, thickness 0.005mm, as rolled, 99%; Samarium, foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%; Samarium, foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%; Samarium, powder, 500 max. part. size (micron), weight 10 g, purity 99.9%; Samarium, powder, 500 max. part. size (micron), weight 20 g, purity 99.9%; Samarium, powder, max. particle size 500 micron, weight 50 g, purity 99.9%",Therapeutic Radiopharmaceuticals,Small molecule,InChI=1S/Sm,KZUNJOHGWZRPMI-UHFFFAOYSA-N,[Sm],.,Sm,.,.
D1444,Saquinavir,441243,"Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide",Anti-Hiv Agents,Small molecule,"1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1",QWAXKHKRTORLEM-UGJKXSETSA-N,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,127779-20-8,C38H50N6O5,63621,1C60-1C62: Human immunodeficiency virus disease
D1445,Sarecycline,54681908,Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666,Tetracyclines,Small molecule,"1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1",AYUMVPHUMFKFPJ-SBAJWEJLSA-N,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC,1035654-66-0,C24H29N3O8,.,ED80: Acne vulgaris
D1446,Sargramostim,.,Leukine; Leukine (TN); Sargramostim (genetical recombination); Sargramostim (USAN/INN); Sargramostim (genetical recombination) (JAN),Colony Stimulating Factors,Protein/peptide,.,.,.,.,.,.,QB63: Transplanted organ/tissue
D1447,Sarilumab,.,Kevzara,Antirheumatics/Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FA20: Rheumatoid arthritis
D1448,Satralizumab,.,.,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,8E4A: Nervous system paraneoplastic/autoimmune disorder
D1449,Saxagliptin,11243969,"Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3",Dpp4 Inhibitors/Antidiabetic Agents,Small molecule,"1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1",QGJUIPDUBHWZPV-SGTAVMJGSA-N,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,361442-04-8,C18H25N3O2,71272,5A11: Type 2 diabetes mellitus
D1450,Scopolamine,3000322,"Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate",Antispasmodics,Small molecule,"1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1",STECJAGHUSJQJN-USLFZFAMSA-N,CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4,114-49-8,C17H21NO4,16794,6C50-6C5Z: Addictive disorder; MD90: Nausea/vomiting
D1451,Scopolamine (ophthalmic),3000322,"Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate",Antispasmodics,Small molecule,"1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1",STECJAGHUSJQJN-USLFZFAMSA-N,CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4,114-49-8,C17H21NO4,16794,6C50-6C5Z: Addictive disorder; MD90: Nausea/vomiting
D1452,Secnidazole,71815,3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539,Amebicides/Antibiotics,Small molecule,"1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3",KPQZUUQMTUIKBP-UHFFFAOYSA-N,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],3366-95-8,C7H11N3O3,94433,MF3A: Vaginal discharge; 1A36: Amoebiasis
D1453,Secobarbital,5193,"Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)",KQPKPCNLIDLUMF-UHFFFAOYSA-N,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,76-73-3,C12H18N2O3,9073,7A00: Chronic insomnia
D1454,Secukinumab,.,.,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA80: Atopic eczema; ED70: Alopecia; 5A10: Diabetes mellitus; FA21: Psoriatic arthritis; 8A40: Multiple sclerosis; 9E1Z: Visual system disease; FA20: Rheumatoid arthritis; EA90: Psoriasis
D1455,Selegiline,26757,"selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic",Dopaminergic Antiparkinsonism Agents/Mao Inhibitors,Small molecule,"1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1",MEZLKOACVSPNER-GFCCVEGCSA-N,CC(CC1=CC=CC=C1)N(C)CC#C,14611-51-9,C13H17N,9086,EK71: Skin tag/polyp; 6A70-6A7Z: Depression; MD90: Nausea/vomiting
D1456,Selenium,6326970,"7782-49-2; Se; Selenium; SELENIUM ATOM; Selenium, elemental; Selenium and compounds; Elemental selenium; Selenium elemental; Selen; SELENIUM COMPOUNDS; Selenium dihydride; SELENIUM POWDER; Hydrogen selenide (H2Se); UNII-H6241UJ22B; MFCD00134090; UNII-V91P54KPAM; H6241UJ22B; Vandex; Gray selenium; Selenium alloy; Selenium base; Selenium dust; Colloidal selenium; Selen [Polish]; Selenium, metallic; Selenium homopolymer; Selenium, colloidal; Caswell No. 732; selenio; Selenium anhydride; Electronic E-2; Selenium metallicum; CCRIS 4250; HSDB 4493; EINECS 231-957-4; UN2658; EPA Pesticide Chemical Code 072001; Selenium compounds, n.o.s.; CI 77805; Selenium metal; Selenium and selenium compounds; HSDB 548; C.I. 77805; Selenium, powder; EINECS 231-978-9; Selenium shot, 4N; UN2202; UN3283; Dihydrogen monoselenide; selenium (iv) hydride; Selenium hydride (SeH2); 34Se; EC 231-957-4; Selenium, powder, 99+%; Selenium compound, n.o.s.; Hydrogen selenide, anhydrous; Selenium powder, -200 mesh; Selenium powder, -325 mesh; Selenium, p.a., 99.5%; CHEMBL1235891; DTXSID9021261; CHEBI:27568; HSDB 6909; DTXSID20872822; Selenium Nanopowder in aq. media; 8988AF; MFCD00011224; DB11135; Selenium, pellets, < 5mm, >=99.999%; FT-0701285; Selenium ingot/button, ~38mm (1.5in) dia; C01529; Selenium, 1 - 2% in a non hazardous diluent; Selenium powder [UN2658]  [Keep away from food]; Selenium shot, amorphous, 1-5mm (0.04-0.20in); Selenium, foil, 25x25mm, thickness 3mm, 99.95%; Hydrogen selenide, anhydrous [UN2202]  [Poison gas]; S008000000; Selenium, plasma standard solution, Specpure, Se 10g/ml; Selenium, shots, 99.99999% (7N), diameter 2-4 mm; Selenium, AAS standard solution, Specpure?, Se 1000?g/ml; Selenium, pellets, <5 mm, >=99.99% trace metals basis; Selenium, powder, -100 mesh, >=99.5% trace metals basis; Selenium, powder, -100 mesh, 99.99% trace metals basis; Selenium, plasma standard solution, Specpure?, Se 1000?g/ml; Selenium, Oil based standard solution, Specpure?, Se 1000?g/g; Selenium, plasma standard solution, Specpure?, Se 10,000?g/ml; Selenium compound, n.o.s. [UN3283]  [Poison, Keep away from food]; Selenium, lump, 3 mm max. lump size, weight 100 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 20 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 50 g, high purity 99.999%; Selenium, pellets, <5 mm particle size, >=99.999% trace metals basis; Selenium shot, amorphous, 2-6mm (0.08-0.2in), Puratronic(R), 99.999% (metals basis); Selenium, powder, 250 max. part. size (micron), purity 99.95%, weight 100 g; Selenium, powder, 250 max. part. size (micron), weight 50 g, purity 99.95%; Selenium, powder, max. particle size 250 micron, weight 200 g, purity 99.95%; Selenium, rod, 99.9999% (6N), diameter 20 mm, length 55 mm, approx. 74g; Selenium, rod, 99.99999% (7N), diameter 20 mm, length 55 mm, approx. 74 g; Se0; Selenium atomic spectroscopy standard concentrate 1.00 g Se, 1.00 g/L, for 1L standard solution, analytical standard",Minerals And Electrolytes,Small molecule,InChI=1S/Se,BUGBHKTXTAQXES-UHFFFAOYSA-N,[Se],.,Se,.,.
D1457,Selexipag,9913767,"Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)",Agents For Pulmonary Hypertension,Small molecule,"1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)",QXWZQTURMXZVHJ-UHFFFAOYSA-N,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,475086-01-2,C26H32N4O4S,90844,BB01: Pulmonary hypertension
D1458,Selinexor,71481097,Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F,Antineoplastics,Small molecule,"1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-",DEVSOMFAQLZNKR-RJRFIUFISA-N,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,1393477-72-9,C17H11F6N7O,.,2A00-2F9Z: Solid tumour/cancer; 2A81: Diffuse large B-cell lymphoma; 2A60: Acute myeloid leukaemia; 2A83: Multiple myeloma; 2B59: Liposarcoma; 2B72: Stomach cancer; 2A00: Brain cancer
D1459,Selpercatinib,134436906,"Selpercatinib; 2152628-33-4; LOXO-292; CEGM9YBNGD; UNII-CEGM9YBNGD; LOXO292; 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile; 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile; LY3527723; 6-(2-Hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile; Serpercatinib; Retevmo; 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile; Retevmo (TN); Selpercatinib [INN]; Selpercatinib [USAN]; Ret inhibitor loxo-292; LOXO-292; Selpercatinib; Selpercatinib(LOXO-292); CHEMBL4559134; SCHEMBL20071478; Selpercatinib (JAN/USAN/INN); GTPL10318; BDBM296429; BCP29047; CLD62833; EX-A2859; NSC818434; s8781; WHO 10967; ZB1574; US10112942, Example 163; US10112942, Example 166; US10112942, Example 183; AKOS037649115; NSC-818434; AC-31588; BS-16622; LOXO-292;LOXO 292;LOXO292; Selpercatinib (LOXO-292, ARRY-192); example 163 [WO2018071447A1]; HY-114370; CS-0084279; LY-3527723; D11713; D77980; A929273; Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-",Antineoplastics,Small molecule,"InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3",XIIOFHFUYBLOLW-UHFFFAOYSA-N,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,.,C29H31N7O3,.,.
D1460,Selumetinib,10127622,Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U,Multikinase Inhibitors,Small molecule,"1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,606143-52-6,C17H15BrClFN4O3,90227,2C25: Lung cancer; 2C30: Melanoma; 2D10: Thyroid cancer; 2A00-2F9Z: Solid tumour/cancer
D1461,Sertraline,68617,"Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine",Antidepressants,Small molecule,"1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1",VGKDLMBJGBXTGI-SJCJKPOMSA-N,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,79617-96-2,C17H17Cl2N,9123,6A70-6A7Z: Depression
D1462,Sevelamer,3085017,Sevelamer; 52757-95-6; 2-(chloromethyl)oxirane;prop-2-en-1-amine; Sevelamer anhydrous; Sevelamer (INN); SCHEMBL726092; 3-(Trifluoromethoxy)cinnamicacid; CHEMBL1201798; DB00658; NCGC00522026-01; D08512; 2-Propen-1-amine - 2-(chloromethyl)oxirane (1:1); 2-Propen-1-amine Hydrochloride polymer with 2-(Chloromethyl)oxirane,Phosphate Binders,Small molecule,"InChI=1S/C3H5ClO.C3H7N/c4-1-3-2-5-3;1-2-3-4/h3H,1-2H2;2H,1,3-4H2",ZNSIZMQNQCNRBW-UHFFFAOYSA-N,C=CCN.C1C(O1)CCl,.,C6H12ClNO,.,.
D1463,Sevoflurane,5206,"Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane",Anesthetics,Small molecule,"1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2",DFEYYRMXOJXZRJ-UHFFFAOYSA-N,C(OC(C(F)(F)F)C(F)(F)F)F,28523-86-6,C4H3F7O,9130,9A76-9A78: Corneal disease
D1464,Sibutramine,5210,"Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine",Appetite Depressants,Small molecule,"1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3",UNAANXDKBXWMLN-UHFFFAOYSA-N,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,106650-56-0,C17H26ClN,9137,5B80-5B81: Obesity
D1465,Sildenafil,135398744,"sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil",Impotence Agents/Agents For Pulmonary Hypertension,Small molecule,"1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",BNRNXUUZRGQAQC-UHFFFAOYSA-N,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,139755-83-2,C22H30N6O4S,9139,4A00: Innate/adaptive immunodeficiency; HA00-HA01: Sexual dysfunction
D1466,Silodosin,5312125,"Silodosin; 160970-54-7; Rapaflo; Urief; Silodyx; Urorec; KMD-3213; Silodosin-d6; UNII-CUZ39LUY82; KMD 3213; KAD 3213; CUZ39LUY82; CHEMBL24778; KAD-3213; (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; Q-102517; Rapflo",Alpha-Adrenergic Antagonists,Small molecule,"1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1",PNCPYILNMDWPEY-QGZVFWFLSA-N,CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F,160970-54-7,C25H32F3N3O4,135929,GA90: Prostate hyperplasia
D1467,Siltuximab,.,.,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,3A00-3A9Z: Anemia; 2A83: Multiple myeloma
D1468,Silver nitrate (ophthalmic),24470,"SILVER NITRATE; 7761-88-8; Silvernitrate; Lunar caustic; Nitric acid silver(I) salt; silver(I) nitrate; Silbernitrat; Argenti nitras; Nitrate d'argent; Silver mononitrate; Argerol; Silver(1+) nitrate; AgNO3; Nitric acid silver(1+) salt; Silver nitrate(DOT); Caswell No. 737; UNII-95IT3W8JZE; Nitrate d'argent [French]; Nitrato de plata [Spanish]; Silver(I) nitrate (1:1); HSDB 685; Nitric acid, silver(1+) salt; UTS Silverator Water Treatment Unit; EINECS 231-853-9; UN1493; NSC 135800; EPA Pesticide Chemical Code 072503; 95IT3W8JZE",Antiseptic/Germicides,Small molecule,1S/Ag.NO3/c;2-1(3)4/q+1;-1,SQGYOTSLMSWVJD-UHFFFAOYSA-N,[N+](=O)([O-])[O-].[Ag+],7761-88-8,AgNO3,32130,1A81: Sexually transmitted chlamydial infection
D1469,Silver nitrate (topical),24470,"SILVER NITRATE; 7761-88-8; Silvernitrate; Lunar caustic; Nitric acid silver(I) salt; silver(I) nitrate; Silbernitrat; Argenti nitras; Nitrate d'argent; Silver mononitrate; Argerol; Silver(1+) nitrate; AgNO3; Nitric acid silver(1+) salt; Silver nitrate(DOT); Caswell No. 737; UNII-95IT3W8JZE; Nitrate d'argent [French]; Nitrato de plata [Spanish]; Silver(I) nitrate (1:1); HSDB 685; Nitric acid, silver(1+) salt; UTS Silverator Water Treatment Unit; EINECS 231-853-9; UN1493; NSC 135800; EPA Pesticide Chemical Code 072503; 95IT3W8JZE",Antiseptic/Germicides,Small molecule,1S/Ag.NO3/c;2-1(3)4/q+1;-1,SQGYOTSLMSWVJD-UHFFFAOYSA-N,[N+](=O)([O-])[O-].[Ag+],7761-88-8,AgNO3,32130,1A81: Sexually transmitted chlamydial infection
D1470,Silver sulfadiazine (topical),441244,"Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt",Antiinfective Agents,Small molecule,"1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1",UEJSSZHHYBHCEL-UHFFFAOYSA-N,C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+],22199-08-2,C10H9AgN4O2S,9142,1A00-1C4Z: Bacterial infection
D1471,Simeprevir,24873435,TMC436,Antiinfective Agents,Small molecule,"1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1",JTZZSQYMACOLNN-VDWJNHBNSA-N,CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,923604-59-5,C38H47N5O7S2,134743,1E50-1E51: Hepatitis virus infection
D1472,Simethicone,6433516,"Phazyme; Antifoam A; DC antifoam A; Sentry Simethicone; Mylanta Gas Relief; Gas-X; Rioplus; Mylicon Infant's Drops; Simeco; Asidopan Plus; Wydrate Plus; Riopan Plus; Sentry Simethicone Emulsion; 8050-81-5; HSDB 3906; Silicone antifoam agent S 184; Silicone antifoam emulsions SE 6 and SE 9; alpha-(Trimethylsilyl)-omega-methylpoly(oxy(dimethylsilylene)), mixture with silicon dioxide; Disflatyl; Sab Simplex; Simethicone [USAN]; Simethicone [USAN:USP]; SIMETICONE; AC1O5GCS; SCHEMBL339371; LS-145411; FT-0674588; 24135-EP2305254A1",Gi Agents,Small molecule,"1S/C6H18O2Si2.O2Si/c1-7-10(5,6)8-9(2,3)4;1-3-2/h1-6H3;",AMTWCFIAVKBGOD-UHFFFAOYSA-N,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,8050-81-5,C6H18O4Si3,.,MD92: Dyspepsia
D1473,Simvastatin,54454,"Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one",Statins/Antihyperlipidemic Agents,Small molecule,"1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",RYMZZMVNJRMUDD-HGQWONQESA-N,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,79902-63-9,C25H38O5,9150,5C80: Hyper-lipoproteinaemia
D1474,Siponimod,44599207,BAF312,Selective Immunosuppressants,Small molecule,"1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+",KIHYPELVXPAIDH-HNSNBQBZSA-N,CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O,1230487-00-9,C29H35F3N2O3,.,2C12: Liver cancer; FA20: Rheumatoid arthritis; 8A40: Multiple sclerosis
D1475,Sipuleucel-T,.,APC8015,Antineoplastics,Autologous cell transplant,.,.,.,.,.,.,1C60-1C62: Human immunodeficiency virus disease; 2C82: Prostate cancer
D1476,Sirolimus,5284616,"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)",Immunosuppressive Agents,Small molecule,"1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,53123-88-9,C51H79NO13,9168,NE84: Transplant rejection; 8D64: Hydrocephalus; 2A83: Multiple myeloma
D1477,Sitagliptin,4369359,"486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE;  Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin",Antidiabetic Agents,Small molecule,"1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1",MFFMDFFZMYYVKS-SECBINFHSA-N,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,486460-32-6,C16H15F6N5O,40237,5A11: Type 2 diabetes mellitus; BD4Z: Chronic arterial occlusive disease
D1478,Sodium acetate,517045,Sodium Acetate In Plastic Container,Minerals And Electrolytes,Small molecule,"1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",VMHLLURERBWHNL-UHFFFAOYSA-M,CC(=O)[O-].[Na+],127-09-3,C2H3NaO2,32954,5C72: Hypo-osmolality/hyponatraemia
D1479,Sodium aurothiomalate,22318,Sodium aurothiomalate,Antirheumatics,Small molecule,"1S/C4H6O4S.Au.2Na/c5-3(6)1-2(9)4(7)8;;;/h2,9H,1H2,(H,5,6)(H,7,8);;;/q;3*+1/p-3",VXIHRIQNJCRFQX-UHFFFAOYSA-K,C(C(C(=O)[O-])[S-])C(=O)[O-].[Na+].[Na+].[Au+],12244-57-4,C4H3AuNa2O4S,35864,FA20: Rheumatoid arthritis
D1480,Sodium bicarbonate,516892,"Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder",Antidiarrheals,Small molecule,"1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1",UIIMBOGNXHQVGW-UHFFFAOYSA-M,C(=O)(O)[O-].[Na+],144-55-8,CHNaO3,32139,5C73: Acidosis
D1481,Sodium cellulose phosphate,.,"Cellulose dihydrogen phosphate, disodium salt; Cellulose disodium phosphate; Cellulose sodium phosphate; DB06776; Sodium cellulose phosphate",Minerals And Electrolytes,Small molecule,.,.,.,.,.,.,.
D1482,Sodium chloride,5234,"sodium chloride; 7647-14-5; Halite; Salt; Table salt; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Top flake; Sodium chloride (NaCl); Hyposaline; Flexivial; Gingivyl; Iodized salt; Slow Sodium; Sea salt; SS salt; Sodium monochloride; Natriumchlorid; Hypersal; Adsorbanac; Trisodium trichloride; White crystal; NaCl; HG blending; Salt (ingredient); sodiumchloride; Colyte; Sodium chloride (Na4Cl4); Caswell No 754; Extra Fine 325 Salt; Extra Fine 200 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; sterling",Minerals And Electrolytes,Small molecule,1S/ClH.Na/h1H;/q;+1/p-1,FAPWRFPIFSIZLT-UHFFFAOYSA-M,[Na+].[Cl-],7647-14-5,ClNa,26710,ME65: Skin sensation disturbance
D1483,Sodium citrate,6224,"Sodium citrate; 68-04-2; TRISODIUM CITRATE; Citrosodine; Sodium citrate anhydrous; Citrosodina; Natrocitral; Citrosodna; Citreme; Citnatin; sodium citrate, anhydrous; Sodium 2-hydroxypropane-1,2,3-tricarboxylate; Trisodium citrate anhydrous; Citric acid, trisodium salt; Trisodium citrate, anhydrous; Citric acid trisodium salt; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt; UNII-RS7A450LGA; FEMA No. 3026; CCRIS 3293; Sodium citrate (Na3C6H5O7); HSDB 5201; EINECS 200-675-3; RS7A450LGA; CHEBI:53258; Trisodium 2-hydroxy-1",Minerals And Electrolytes,Small molecule,"1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",HRXKRNGNAMMEHJ-UHFFFAOYSA-K,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+],24930,C6H5Na3O7,53258,.
D1484,Sodium ferric gluconate complex,23693558,Ferrlecit,Iron Supplement,Small molecule,"1S/C6H12O7.Fe.Na/c7-1-2(8)3(9)4(10)5(11)6(12)13;;/h2-5,7-11H,1H2,(H,12,13);;/q;+3;+1/p-1/t2-,3-,4+,5-;;/m1../s1",PKNUOQOQWGOWBO-ZBHRUSISSA-M,C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Na+].[Fe+3],34089-81-1,C6H11FeNaO7+3,.,3A00: Iron deficiency anaemia
D1485,Sodium oxybate,23663870,"Sodium oxybate; 502-85-2; Sodium 4-hydroxybutyrate; sodium 4-hydroxybutanoate; Anetamin; Somsanit; Oxybate sodium; 4-Hydroxybutyric acid sodium salt; Gamma OH; Sodium Oxybate [USAN]; Oxybate (sodium); 4-Hydroxybutyrate sodium; Butanoic acid, 4-hydroxy-, monosodium salt; gamma-Hydroxybutyrate sodium; Sodium gamma-hydroxybutyrate; sodium;4-hydroxybutanoate; gamma-Hydroxy sodium butyrate; UNII-7G33012534; WY-3478; EB 27; Hydroxybutyric acid monosodium salt; 4-Hydroxybutyric acid monosodium salt; WY 3478; Sodium oxybate (USAN); Butanoic acid, 4-hydroxy-, sodium salt (1:1); Butanoic acid, 4-hydroxy-, sodium salt; 7G33012534; BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT; Natrium 4-hydroxybutyrat; Sodium-4-hydroxybutyrate; Sodium Oxybutyrate; Sodium Oxybate (Sodium 4-Hydroxybutanoate); NSC-84223; GHB Sodium Salt (Sodium Gammahydroxybutyrate); 4-Hydroxybuttersaeure natriumsalz; gamma-Hydroxybutyrate sodium salt; NCGC00247714-01; EINECS 207-953-3; NSC 84223; gamma-Hydroxybutyric acid, sodium salt; JZP-6; Catabate; Sodium oxybat; SODIUM4-HYDROXYBUTYRATE; Xyrem (TN); GHB; ; ; Sodium oxybate; Sodium gammahydroxybutyrate; DSSTox_CID_28866; DSSTox_RID_83135; DSSTox_GSID_48940; SCHEMBL61823; DEA No. 2012; CHEMBL1200682; DTXSID3048940; HMS2091E15; .gamma.-hydroxybutyrate sodium salt; HY-B1187; Tox21_112871; Gamma Hydroxybutyric Acid preparations; AKOS006221428; CCG-212465; CS-4796; DB09072; CAS-502-85-2; DB-071156; FT-0626615; D05866; H-4040; Butyric acid, 4-hydroxy-, monosodium salt (8CI); Q7553347; Acetamide,2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-,rel-",Anxiolytics/Sedatives/Hypnotics,Small molecule,"InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1",XYGBKMMCQDZQOZ-UHFFFAOYSA-M,C(CC(=O)[O-])CO.[Na+],.,C4H7NaO3,.,.
D1486,"Sodium phosphate, monobasic",.,"2-Methyl-3-(pyridin-4-ylmethyl)quinazolin-4(3H)-one; 7558-80-7; 8871AF; 89140-32-9; Acid sodium phosphate; AKOS024433265; Anhydrous monobasic sodium phosphate; Armite; AT32901; B7779; Buromin; CHEBI:37585; Clicolon; D04400; DB09449; disodium hydrogen phosphate anhydrous; DTXSID7035222; E339; E-339(I); EC 231-449-2; EINECS 231-449-2; EINECS 231-558-5; FT-0698935; Hemisodium phosphate; HSDB 738; HY-Phos; INKP 100; INKP-100; INS NO.339(I); INS-339(I); Instant calgon; KH7I04HPUU; MFCD00003527; MFCD00146206; Monobasic sodium phosphate; Monosodium dihydrogen monophosphate; Monosodium dihydrogen orthophosphate; Monosodium dihydrogen phosphate; Monosodium hydrogen phosphate; Monosodium monophosphate; Monosodium orthophosphate; Monosodium phosphate; Monosodium phosphate anhydrous; Monosodium phosphate, anhydrous; Monosorb XP-4; Na.H2PO4; NaH2PO4; natriumdihydrogen-phosphate; Phosphate, 0.2M buffer solution, pH 4.4; Phosphate, 0.2M buffer solution, pH 6.8; Phosphate, 0.2M buffer solution, pH 7.0; Phosphate, 0.2M buffer solution, pH 7.2; Phosphate, 0.2M buffer solution, pH 7.4; Phosphate, 0.2M buffer solution, pH 7.5; Phosphate, 0.2M buffer solution, pH 7.6; Phosphate, 0.5M buffer solution, pH 6.5; Phosphate, 0.5M buffer solution, pH 7.0; Phosphate, 0.5M buffer solution, pH 7.2; Phosphate, 0.5M buffer solution, pH 7.4; Phosphate, 0.5M buffer solution, pH 8.0; Phosphate, 0.5M buffer solution, pH 8.5; Phosphate, 0.5M buffer solution, pH 9.0; Phosphoric acid, monosodium salt; phosphoric acid, monosodium salt, anhydrous; Phosphoric acid, sodium salt; Phosphoric acid, sodium salt (1:?); Phosphoric acid, sodium salt (1:1); Phosphosoda; Primary sodium phosphate; Q415877; Sodium acid phosphate; Sodium biphosphate anhydrous; Sodium biphosphate, anhydrous; Sodium dihydrogen monophosphate; Sodium dihydrogen orthophosphate; SODIUM DIHYDROGEN PHOSPHATE; Sodium dihydrogen phosphate (1:2:1); Sodium dihydrogen phosphate (NaH2PO4); Sodium dihydrogen phosphate, anhydrous; Sodium dihydrogenorthophosphate; sodium dihydrogenphoshate; sodium dihydrogenphospate; sodium dihydrogenphosphat; sodium dihydrogenphosphate; sodium dihydrogen-phosphate; Sodium dihydrogenphosphate (granular); Sodium monobasic phosphate (NaH2PO4); Sodium orthophosphate monobasic; Sodium orthophosphate, primary; Sodium phosphate (Na(H2PO4)); Sodium phosphate (NaH2PO4); Sodium phosphate glass; Sodium phosphate monobasic; sodium phosphate mono-basic; Sodium phosphate monobasic (anhydrate); Sodium phosphate monobasic (anhydrous); Sodium phosphate monobasic anhydrous; Sodium phosphate monobasic Molecular Biology Grade, suitable for cell culture, insect cell culture, and plant cell culture; Sodium phosphate monobasic solution; Sodium phosphate monobasic solution, BioUltra, 5 M in H2O; Sodium phosphate monobasic, 99.999% trace metals basis; Sodium phosphate monobasic, anhydrous; Sodium phosphate monobasic, anhydrous, free-flowing, Redi-Dri(TM), >=99.0%; Sodium phosphate monobasic, AR, >=98%; Sodium phosphate monobasic, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99.0% (titration); Sodium phosphate monobasic, BioReagent, for molecular biology, anhydrous, >=98%; Sodium phosphate monobasic, Biotechnology Performance Certified, Cell Culture Tested; Sodium phosphate monobasic, BioXtra, >=99.0%; Sodium phosphate monobasic, for HPLC, 99%; Sodium phosphate monobasic, LR, >=97%; Sodium phosphate monobasic, meets USP testing specifications, anhydrous; Sodium phosphate monobasic, purum p.a., anhydrous, >=99.0% (T); Sodium phosphate monobasic, ReagentPlus(R), >=99.0%; Sodium phosphate monobasic, SAJ first grade, 98.0-101.0%; Sodium phosphate monobasic, SAJ special grade, 99.0-101.0%; Sodium phosphate monobasic, USP, 98.0-103.0%; Sodium phosphate monobasic, Vetec(TM) reagent grade, 99%; Sodium phosphate, 0.2M buffer solution, pH 7.0; Sodium phosphate, 0.2M buffer solution, pH 7.2; Sodium phosphate, 0.2M buffer solution, pH 7.4; Sodium phosphate, 0.2M buffer solution, pH 7.5; Sodium phosphate, 0.2M buffer solution, pH 7.6; Sodium phosphate, 0.2M buffer solution, pH 8.0; Sodium phosphate, 0.2M buffer solution, pH 8.5; Sodium phosphate, 0.2M buffer solution, pH 9.0; Sodium phosphate, 0.2M buffer solution, pH 9.5; Sodium phosphate, 0.5M buffer solution, pH 7.0; Sodium phosphate, 0.5M buffer solution, pH 7.5; Sodium phosphate, 0.5M buffer solution, pH 7.6; Sodium phosphate, 0.5M buffer solution, pH 8.0; Sodium phosphate, 0.5M buffer solution, pH 8.5; Sodium phosphate, 0.5M buffer solution, pH 9.0; Sodium phosphate, 0.5M buffer solution, pH 9.5; Sodium phosphate, monobasic (USP); SODIUM PHOSPHATE, MONOBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; Sodium phosphate,monobasic; Sodium primary phosphate; Sodium salt of phosphoric acid; sodium;dihydrogen phosphate; sodiumdihydrogen phosphate; Sodiumdihydrogenphosphate-16O4; Turrixin ST; UNII-3980JIH2SW component AJPJDKMHJJGVTQ-UHFFFAOYSA-M; UNII-KH7I04HPUU; UNII-SE337SVY37 component AJPJDKMHJJGVTQ-UHFFFAOYSA-M",Laxatives/Minerals And Electrolytes,Small molecule,.,.,.,.,.,.,.
D1487,"Sodium phosphate, monobasic (p32)",.,"54227-48-4; 8027-28-9; DTXSID00969204; FEB963GEFV; Fosfato sodico (32 P); Fosfato sodico (32 P) [INN-Spanish]; Monosodium phosphate (P32); Natrii phosphas (32 P); Natrii phosphas (32 P) [INN-Latin]; Natrii radiophosphas; Natrium radio-phosphoricum (32 P); NSC 78064; Phosphate (32 P) de sodium; Phosphate (32 P) de sodium [INN-French]; Phosphoric acid, sodium salt, radioactive; Phosphoric-32P acid, sodium salt; Q27277948; Radioactive sodium phosphate; Sodium (32P)phosphate; Sodium acid 32P-phosphate; Sodium dihydrogen (~32~P)phosphate; Sodium dihydrogen phosphate (32P); sodium phosphate p-32 (indefinite stoichiometry); Sodium phosphate, laveled with phosphorus-32; Sodium phosphate, radioactive; Sodium radiophosphate (32P); Sodium radiophosphate (P32); UNII-FEB963GEFV",Laxatives/Minerals And Electrolytes,Small molecule,.,.,.,.,.,.,.
D1488,Sodium sulfate,24436,"SODIUM SULFATE; 7757-82-6; Disodium sulfate; Sodium sulfate, anhydrous; Sodium sulphate; Salt cake; Sodium sulfate anhydrous; Sulfuric acid disodium salt; sodiumsulfate; disodium;sulfate; Disodium sulphate; Sulfuric acid, sodium salt; Sulfate, sodium; 15124-09-1; Sodium sulfate anyhdrous; Sodium sulphate anhydrous; Sulfuric acid sodium salt (1:2); UNII-36KCS0R750; Na2SO4; MFCD00003504; Sodium sulfate, dried [JAN]; CHEBI:32149; 36KCS0R750; Sodium sulfate, dried (JAN); Dibasic sodium sulfate; Natriumsulfat (German); Na sulphate; Caswell No. 793; HSDB 5042; Sodium sulfate (solution); Thenardite (Na2(SO4)); Mirabilite; Natriumsulfat; Sodium tallow alcohol sulfate; Glaubers salt; EINECS 231-820-9; EINECS 268-366-6; EINECS 268-773-9; EINECS 270-211-2; EPA Pesticide Chemical Code 005604; NSC 403914; Sulfuric acid, mono-C14-18-alkyl esters, sodium salts; Sodium Sulfate ACS HE; AI3-02398; Na2O4S; SDA 17-062-04; Sulfuric acid sodium salt; DSSTox_CID_1291; Sodium sulphate, anhydrous; EC 231-820-9; DSSTox_RID_76063; DSSTox_GSID_21291; Sodium sulfate, ACS reagent; Sodium sulfate, dried (TN); CHEMBL233406; INS NO.514(II); DTXSID1021291; INS NO.514(I); Anhydous sodium sulfate (JP17); INS-514(II); Sodium Sulfate - Drilling Grade; INS-514(I); 7757-82-6 (anhyd.); BCP13313; Sodium sulfate, for residue analysis; Tox21_201045; E-514(II); AKOS015833463; Sodium Sulfate Anhydrous Granular ACS; Sodium sulfate, BioXtra, >=99.0%; Sulfuric acid disodium salt, anhydrous; DB09472; NCGC00258598-01; Sodium sulfate, LR, anhydrous, >=99%; 13759-07-4; E-514(I); E514; K354; Sodium Sulfate Anhydrous; Sodium sulphate; CAS-7757-82-6; Sodium sulfate, AR, anhydrous, >=99.5%; FT-0645112; S0566; Sodium sulfate, 99.9955% (metals basis); Sodium sulfate, ReagentPlus(R), >=99.0%; Sodium sulfate, for pesticide residue analysis; Sodium sulfate, Trace metals grade, 99.99%; D01732; Sodium sulfate, >=99.99% trace metals basis; Sodium sulfate, JIS special grade, >=99.0%; Sodium sulfate, Vetec(TM) reagent grade, 99%; Sodium sulfate, meets USP testing specifications; Q211737; Sodium sulfate, for HPLC, 99.0-101.0% (T); Sodium sulfate, purum, anhydrous, >=99.0% (T); Sodium sulfate, SAJ first grade, >=99.0%, beads; Sodium sulfate, SAJ first grade, >=99.0%, powder; Sodium sulfate, >=99.0%, plant cell culture tested; Sodium sulfate, BioUltra, anhydrous, >=99.0% (T); Sodium sulfate, p.a., 99.0-101.0%, reag. ISO; Sodium sulfate, for pesticide residue analysis, 99.0%; Sodium sulfate, tested according to Ph.Eur., anhydrous; Sodium sulfate, ACS reagent, >=99.0%, anhydrous, powder; Sodium sulfate, ACS reagent, >=99.0%, anhydrous, granular; Sodium sulfate, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Sodium sulfate anhydrous, United States Pharmacopeia (USP) Reference Standard; Sodium sulfate, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), >=99%; Sodium sulfate, anhydrous, granular, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Sodium sulfate, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., anhydrous, >=99.0%; Sodium sulfate, puriss., meets analytical specification of Ph. Eur., BP, USP, anhydrous, 99.0-100.5% (calc. to the dried substance)",Laxatives,Small molecule,"InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",PMZURENOXWZQFD-UHFFFAOYSA-L,[O-]S(=O)(=O)[O-].[Na+].[Na+],.,Na2O4S,.,.
D1489,Sodium zirconium cyclosilicate,91799284,UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7,Cation Exchange Resins,Small molecule,"1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;",CBTCHTJSGLCFMY-UHFFFAOYSA-N,O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr],17141-74-1,H6Na2O9Si3Zr+2,.,5C76: Hyperkalaemia
D1490,Sofosbuvir,45375808,"1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,",Antiviral Agents,Small molecule,"1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1",TTZHDVOVKQGIBA-IQWMDFIBSA-N,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,1190307-88-0,C22H29FN3O9P,85083,1E50-1E51: Hepatitis virus infection
D1491,Solifenacin,154059,"Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)",Antispasmodics,Small molecule,"1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1",FBOUYBDGKBSUES-VXKWHMMOSA-N,C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5,242478-37-1,C23H26N2O2,135530,GC50: Functional bladder disorder
D1492,Solriamfetol,10130337,"JZP-110; (R)-2-Amino-3-phenylpropyl carbamate; UNII-939U7C91AI; 939U7C91AI; (2R)-2-amino-3-phenylpropyl carbamate; Solriamfetol [USAN]; Adx-N05 free base; SCHEMBL2739637; O-Carbamoyl-(D)-phenylalaninol; UCTRAOBQFUDCSR-SECBINFHSA-N; ZINC34278783; (R)-2-amino-3-phenylpropyl carbamate; Benzenepropanol, beta-amino-, 1-carbamate, (betaR)-; Benzenepropanol, beta-amino-, carbamate (ester), (R)-; 178429-62-4",Cns Agents,Small molecule,"1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1",UCTRAOBQFUDCSR-SECBINFHSA-N,C1=CC=C(C=C1)CC(COC(=O)N)N,178429-62-4,C10H14N2O2,.,7A20: Narcolepsy; MG42: Somnolence
D1493,Somapacitan,129894493,1338578-34-9; Somapacitan [INN]; Somapacitan [WHO-DD]; Somapacitan [USAN:INN]; UNII-8FOJ430U94; 8FOJ430U94; EX-A4353; UNII-F1 component VTUYEWRWJTWXPQ-IWWWZYECSA-N; Q27270325,Growth Hormones,Protein/peptide,"1S/C54H95N13O20S2/c55-39(52(76)77)37-88-38-50(74)57-25-15-14-17-40(51(56)75)60-48(72)35-86-32-30-85-29-27-59-45(69)23-21-41(53(78)79)61-46(70)24-22-42(54(80)81)62-49(73)36-87-33-31-84-28-26-58-44(68)20-16-34-89(82,83)65-47(71)19-13-11-9-7-5-3-1-2-4-6-8-10-12-18-43-63-66-67-64-43/h39-42H,1-38,55H2,(H2,56,75)(H,57,74)(H,58,68)(H,59,69)(H,60,72)(H,61,70)(H,62,73)(H,65,71)(H,76,77)(H,78,79)(H,80,81)(H,63,64,66,67)/t39-,40-,41-,42-/m0/s1",VTUYEWRWJTWXPQ-IWWWZYECSA-N,C(CCCCCCCC1=NNN=N1)CCCCCCCC(=O)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NC(CCCCNC(=O)CSCC(C(=O)O)N)C(=O)N)C(=O)O)C(=O)O,1338578-34-9,C54H95N13O20S2,.,5A60-5A61: Pituitary gland disorder
D1494,Somatotropin,.,Somatotropin (1-43),Growth Hormones,Hormones,.,.,.,.,.,.,.
D1495,Somatrem,5487805,Protropin (TN),Growth Hormones,Protein/peptide,"1S/C43H72N14O14/c1-21(2)33(44)40(69)51-23(5)36(65)55-34(22(3)4)41(70)49-19-29(58)52-25(12-14-31(60)61)37(66)54-26(13-15-32(62)63)42(71)57-18-8-10-27(57)38(67)50-20-30(59)56-17-7-11-28(56)39(68)53-24(35(45)64)9-6-16-48-43(46)47/h21-28,33-34H,6-20,44H2,1-5H3,(H2,45,64)(H,49,70)(H,50,67)(H,51,69)(H,52,58)(H,53,68)(H,54,66)(H,55,65)(H,60,61)(H,62,63)(H4,46,47,48)/t23-,24-,25-,26-,27-,28-,33-,34-/m0/s1",BDIVMSNLPYLUFI-FYNIJPSQSA-N,CC(C)C(C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)N1CCCC1C(=O)NCC(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)N)N,88389-69-9,C43H72N14O14,.,5A60-5A61: Pituitary gland disorder
D1496,Sonidegib,24775005,Erismodegib,Antineoplastics/Hedgehog Pathway Inhibitors,Small molecule,"1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+",VZZJRYRQSPEMTK-CALCHBBNSA-N,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,956697-53-3,C26H26F3N3O3,90863,2C30-2C37: Skin cancer; 2A00: Brain cancer
D1497,Sorafenib,216239,Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor),Antineoplastics,Small molecule,"1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,284461-73-0,C21H16ClF3N4O3,50924,2C90: Renal cell carcinoma; 2A37: Myelodysplastic syndrome; 2C12: Liver cancer
D1498,Sotalol,5253,"Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid",Antiarrhythmic Agents,Small molecule,"1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3",ZBMZVLHSJCTVON-UHFFFAOYSA-N,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,3930-20-9,C12H20N2O3S,63622,BC9Z: Cardiac arrhythmia
D1499,Sparfloxacin,60464,"Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid",Antibiotics,Small molecule,"1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+",DZZWHBIBMUVIIW-DTORHVGOSA-N,CC1CN(CC(N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,110871-86-8,C19H22F2N4O3,9212,1A00-1C4Z: Bacterial infection
D1500,Spectinomycin,15541,"Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt)",Antibiotics,Small molecule,"1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1",UNFWWIHTNXNPBV-WXKVUWSESA-N,CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O,1695-77-8,C14H24N2O7,9215,1A00-1C4Z: Bacterial infection
D1501,Spironolactone,5833,"Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone",Diuretics,Small molecule,"1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1",LXMSZDCAJNLERA-ZHYRCANASA-N,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,19000,C24H32O4S,9241,BD10-BD1Z: Heart failure
D1502,St. John's Wort,.,Common st johnswort flowering top; Common st. john's wort flowering top; Common st. john's wort herb; Common st. johnswort flowering top; DB01323; Guanyejinsitao; Hyperici herba; Hypericum nachitschevanicum flowering top; Hypericum perforatum flowering top; Hypoxis hemerocallidea root extract; Klamath weed flowering top; Klamathweed flowering top; Saint johns wort; St Johns Wort; St john's wort; St. johns wort; St. John's Wort; St. johnswort flowering top,Herbal Products/Antidepressants,Natural product,.,.,.,.,.,.,.
D1503,Stanozolol,25249,"stanozolol; Androstanazole; Winstrol; Androstanazol; 10418-03-8; Stromba; Stanazolol; Winstrol Depot; Strombaject; Tevabolin; Estazol; Winstroid; Anabol; Winstrol V; Estanozolol; Stanozololum; Stanozolo [DCIT]; Androstanazole (VAN); WIN 14833; Stanozolol (1'H form); Winstrol-V; Stanozololum [INN-Latin]; Estanozolol [INN-Spanish]; UNII-4R1VB9P8V3; Androstanazolestanazol; HSDB 3185; Stanozolol (2'H form); EINECS 233-894-8; NSC 43193; NSC 233046; 4R1VB9P8V3; CHEBI:9249; 2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-",Androgens/Anabolic Steroids,Small molecule,"1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1",LKAJKIOFIWVMDJ-IYRCEVNGSA-N,CC12CCC3C(C1CCC2(C)O)CCC4C3(CC5=C(C4)NN=C5)C,302-96-5,C21H32N2O,9249,4A00: Innate/adaptive immunodeficiency
D1504,Stavudine,18283,"DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T",Anti-Hiv Agents,Small molecule,"1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1",XNKLLVCARDGLGL-JGVFFNPUSA-N,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,3056-17-5,C10H12N2O4,63581,1C60-1C62: Human immunodeficiency virus disease
D1505,Stiripentol,5311454,"Diacomit; ME-2080; Stiripentol (oral); Stiripentol (oral), Laboratoires Biocodex",Gamma-Aminobutyric Acid Reuptake Inhibitors,Small molecule,"1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+",IBLNKMRFIPWSOY-FNORWQNLSA-N,CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,49763-96-4,C14H18O3,94435,8A61-8A6Z: Epilepsy/seizure
D1506,Streptokinase,9815560,Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid,Thrombolytics,Protein/peptide,"1S/C11H19NO2/c13-11(14)10-6-9(7-12-10)8-4-2-1-3-5-8/h8-10,12H,1-7H2,(H,13,14)",XRZWVSXEDRYQGC-UHFFFAOYSA-N,C1CCC(CC1)C2CC(NC2)C(=O)O,2593954,C11H19NO2,.,BB00: Pulmonary thromboembolism
D1507,Streptomycin,19649,"Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}",Antibiotics,Small molecule,"1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1",UCSJYZPVAKXKNQ-HZYVHMACSA-N,CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O,57-92-1,C21H39N7O12,17076,1A00-1C4Z: Bacterial infection
D1508,Streptozocin,29327,"Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose",Antineoplastics,Small molecule,"1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1",ZSJLQEPLLKMAKR-GKHCUFPYSA-N,CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O,18883-66-4,C8H15N3O7,9288,2C10: Pancreatic cancer
D1509,Strontium chloride Sr-89,5388879,Metastron,Therapeutic Radiopharmaceuticals,Small molecule,1S/2ClH.Sr/h2*1H;/q;;+2/p-2/i;;1+1,AHBGXTDRMVNFER-FCHARDOESA-L,[Cl-].[Cl-].[Sr+2],38270-90-5,Cl2Sr,.,MG30: Chronic pain
D1510,Succinylcholine,5314,"Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)",Analgesics,Small molecule,"1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2",AXOIZCJOOAYSMI-UHFFFAOYSA-N,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,306-40-1,C14H30N2O4+2,45652,MB47: Tonus and reflex abnormality
D1511,Sucralfate,121494085,"SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova",Gi Agents,Small molecule,"1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1",YZPQNHUVIVIUCT-JTJNLBSYSA-F,C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],54182-58-0,C12H54Al9O55S8,.,ED80: Acne vulgaris
D1512,Sufentanil,41693,Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide,Anesthetics,Small molecule,"1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3",GGCSSNBKKAUURC-UHFFFAOYSA-N,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,56030-54-7,C22H30N2O2S,9316,MB40: Sensation disturbance
D1513,Sulfadiazine,5215,"Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ",Antiinfective Agents,Small molecule,"1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)",SEEPANYCNGTZFQ-UHFFFAOYSA-N,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,68-35-9,C10H10N4O2S,9328,1B40: Rheumatic fever
D1514,Sulfadoxine,17134,"2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653",Antimalarial Agents,Small molecule,"1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",PJSFRIWCGOHTNF-UHFFFAOYSA-N,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,2447-57-6,C12H14N4O4S,9329,1F40-1F45: Malaria
D1515,Sulfamethizole,5328,"Ayerlucil; Famet; Lucosil; Methazol; Microsul; Proklar; Renasul; Rufol; SULFAMETHIAZOLE; Salimol; Solfametizolo; Sulamethizole; Sulfamethazole; Sulfamethizol; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur;Thiosulfil; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; Solfametizolo [DCIT]; Sulfa gram; Thiosulfil Forte; RP 2145; VK 53; Sulfamethizolum [INN-Latin]; Sulfametizol [INN-Spanish]; Thiosulfil (TN); Sulfamethizole [USAN:INN:JAN]; Thiosulfil-A-Forte; Sulfamethizole (JP15/USP/INN); N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole",Antiinfective Agents,Small molecule,"1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)",VACCAVUAMIDAGB-UHFFFAOYSA-N,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,144-82-1,C9H10N4O2S2,9331,GC08: Urinary tract infection
D1516,Sulfamethoxazole,5329,"sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole",Antiinfective Agents,Small molecule,"1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)",JLKIGFTWXXRPMT-UHFFFAOYSA-N,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,723-46-6,C10H11N3O3S,9332,1A00-1C4Z: Bacterial infection; 1F40-1F45: Malaria
D1517,Sulfasalazine,5339,sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine,Antiinflammatory Agents,Small molecule,"1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)",NCEXYHBECQHGNR-UHFFFAOYSA-N,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,599-79-1,C18H14N4O5S,9334,FA20: Rheumatoid arthritis; DD91: Irritable bowel syndrome
D1518,Sulfinpyrazone,5342,"Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione",Uricosuric Agents,Small molecule,"1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2",MBGGBVCUIVRRBF-UHFFFAOYSA-N,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,57-96-5,C23H20N2O3S,9342,FA25: Gout
D1519,Sulfisoxazole,5344,"Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole",Antiinfective Agents,Small molecule,"1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3",NHUHCSRWZMLRLA-UHFFFAOYSA-N,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,127-69-5,C11H13N3O3S,102484,GC08: Urinary tract infection
D1520,Sulindac,1548887,Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid,Antiinflammatory Agents,Small molecule,"1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-",MLKXDPUZXIRXEP-MFOYZWKCSA-N,CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,38194-50-2,C20H17FO3S,9352,FA20: Rheumatoid arthritis
D1521,Sumatriptan,5358,Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide,Vasoconstrictor Agents,Small molecule,"1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3",KQKPFRSPSRPDEB-UHFFFAOYSA-N,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,103628-46-2,C14H21N3O2S,10650,8A80: Migraine
D1522,Sunitinib,5329102,"Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)",Antineoplastics,Small molecule,"1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,557795-19-4,C22H27FN4O2,38940,2B5B: Gastrointestinal stromal tumour; 2C11: Malignant digestive organ neoplasm
D1523,Suprofen (ophthalmic),5359,"Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure",Antiinflammatory Agents,Small molecule,"1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)",MDKGKXOCJGEUJW-UHFFFAOYSA-N,CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,40828-46-4,C14H12O3S,9362,LA11: Eye anterior segment structural developmental anomaly
D1524,Suvorexant,24965990,"Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1",JYTNQNCOQXFQPK-MRXNPFEDSA-N,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,1030377-33-3,C23H23ClN6O2,82698,7A00-7A0Z: Insomnia
D1525,Tacrine,1935,"Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine",Parasympathomimetics,Small molecule,"1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,321-64-2,C13H14N2,45980,8A20: Alzheimer disease
D1526,Tacrolimus,445643,"Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN",Immunosuppressive Agents,Small molecule,"1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1",QJJXYPPXXYFBGM-LFZNUXCKSA-N,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,104987-11-3,C44H69NO12,61049,NE84: Transplant rejection; 4A80-4A8Z: Allergic/hypersensitivity disorder
D1527,Tadalafil,110635,"ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione",Impotence Agents,Small molecule,"1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1",WOXKDUGGOYFFRN-IIBYNOLFSA-N,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,171596-29-5,C22H19N3O4,71940,HA00-HA01: Sexual dysfunction
D1528,Tafamidis,11001318,"TAFAMIDIS; 594839-88-0; FX-1006; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; UNII-8FG9H9D31J; CHEBI:78538; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 8FG9H9D31J; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; C14H7Cl2NO3; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; Tafamidis [USAN:INN]; tafamidisum; 4his; Fx 1006; 3MI; Tafamidis (USAN/INN); SCHEMBL442508; GTPL8378; CHEMBL2103837; KS-00000TIG; DTXSID00208185; MolPort-027-352-897; BCP29089; 3096AH; ZINC43206271; BDBM50197883; AKOS017550076",Transthyretin Stabilizers,Small molecule,"1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)",TXEIIPDJKFWEEC-UHFFFAOYSA-N,C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl,594839-88-0,C14H7Cl2NO3,78538,2C30: Melanoma
D1529,Tafasitamab,.,Xmab 5574/MOR208,Antineoplastics/Cd19 Monoclonal Antibodies,Monoclonal antibody,.,.,.,.,.,.,2A82: Mature B-cell leukaemia; 2A81: Diffuse large B-cell lymphoma
D1530,Tafenoquine,115358,106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN,Antimalarial Agents,Small molecule,"1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3",LBHLFPGPEGDCJG-UHFFFAOYSA-N,CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC,106635-80-7,C24H28F3N3O3,141487,1F40-1F45: Malaria
D1531,Tagraxofusp,.,Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor,Antineoplastics,Protein/peptide,.,.,.,.,.,.,2A60: Acute myeloid leukaemia
D1532,Talazoparib,135565082,Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ,Poly (Adp-Ribose) Polymerase Inhibitors,Small molecule,"1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1",HWGQMRYQVZSGDQ-HZPDHXFCSA-N,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,1207456-01-6,C19H14F2N6O,.,2C60-2C6Y: Breast cancer; FA21: Psoriatic arthritis
D1533,Tamoxifen,2733526,"tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen",Antineoplastics,Small molecule,"1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,10540-29-1,C26H29NO,41774,2C60-2C6Y: Breast cancer
D1534,Tamsulosin,129211,Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide,Antineoplastics,Small molecule,"1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1",DRHKJLXJIQTDTD-OAHLLOKOSA-N,CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,106133-20-4,C20H28N2O5S,9398,GA90: Prostate hyperplasia
D1535,Tapentadol,9838022,"Tapentadol; 175591-23-8; Nucynta; Palexia; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; UNII-H8A007M585; CG5503; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; BN 200 (BASE); CG5503 (BASE); BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; BN 200; CG 5503; NSC-759619; 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol; Tapentadol (USAN/INN); SCHEMBL116924; GTPL7477; DEA No. 9780; CHEMBL1201776; CG5503 IR; HSDB 8309; ZINC20783; DTXSID30170003; CHEBI:135935; CS-M0020; 4084AH; BDBM50386381; AKOS015951190; BCP9000118; DB06204; NSC 759619; QC-1146; FT-0699883; A26964; D06007; AR-270/43507984; Q414463; 3-[(2R,3R)-1-dimethylamino-2-methylpentan-3-yl]phenol; (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol; Phenol,3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-",Narcotic Analgesics,Small molecule,"InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1",KWTWDQCKEHXFFR-SMDDNHRTSA-N,CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C,.,C14H23NO,.,.
D1536,Tasimelteon,10220503,"Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1",PTOIAAWZLUQTIO-GXFFZTMASA-N,CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2,609799-22-6,C15H19NO2,79042,7A00-7A0Z: Insomnia
D1537,Tazarotene (topical),5381,"Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester",Dermatologic Agents,Small molecule,"1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",OGQICQVSFDPSEI-UHFFFAOYSA-N,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,118292-40-3,C21H21NO2S,32184,EA90: Psoriasis
D1538,Tazemetostat,66558664,"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-",Antineoplastics,Small molecule,"1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,1403254-99-8,C34H44N4O4,.,2A00: Brain cancer; 2A81: Diffuse large B-cell lymphoma; 2C51: Peritoneal cancer; 2A00-2F9Z: Solid tumour/cancer; 2B5A: Synovial sarcoma; 2A80: Follicular lymphoma
D1539,Tedizolid,11234049,Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855,Oxazolidinone Antibiotics,Small molecule,"1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1",XFALPSLJIHVRKE-GFCCVEGCSA-N,CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F,856866-72-3,C17H15FN6O3,82717,1F28-1G0Z: Skin and skin-structure infection
D1540,Teduglutide,16139605,Gattex (TN),Gi Agents,Small molecule,"1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1",CILIXQOJUNDIDU-ASQIGDHWSA-N,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N,197922-42-2,C164H252N44O55S,.,KB89: Neonatal malabsorption syndrome
D1541,Telaprevir,3010818,"402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; Telavic; VX-950(Telaprevir); LY-570310; UNII-655M5O3W0U; VRT-111950; CHEMBL231813; CHEBI:68595; 655M5O3W0U; S-Telaprevir; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide",Protease Inhibitors,Small molecule,"1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1",BBAWEDCPNXPBQM-GDEBMMAJSA-N,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5,402957-28-2,C36H53N7O6,68595,1E50-1E51: Hepatitis virus infection
D1542,Telavancin,3081362,"telavancinum; telavancina; telavancine; 372151-71-8; UNII-XK134822Z0; CHEBI:71229; XK134822Z0; Telavancin [INN]; HSDB 8194; AC1MIWRX; SCHEMBL8287015; CHEMBL507870; DB06402; LS-192933; T-1455; Telavancin, Antibiotic for Culture Media Use Only; Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-",Glycopeptide Antibiotics,Small molecule,"1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1",ONUMZHGUFYIKPM-MXNFEBESSA-N,CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C,372151-71-8,C80H106Cl2N11O27P,71229,1B5Y: Staphylococcal/streptococcal disease
D1543,Telbivudine,159269,"Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine",Antiviral Agents,Small molecule,"1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1",IQFYYKKMVGJFEH-CSMHCCOUSA-N,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,3424-98-4,C10H14N2O5,63624,1E50-1E51: Hepatitis virus infection
D1544,Telithromycin,3002190,"Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A",Antibiotics,Small molecule,"1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1",LJVAJPDWBABPEJ-PNUFFHFMSA-N,CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,191114-48-4,C43H65N5O10,29688,1A00-1C4Z: Bacterial infection
D1545,Telmisartan,65999,"Kinzal; Kinzalmono; Micardis; Pritor; Abbott brand of telmisartan; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; BIBR 277; BIBR 277SE; BIBR-277; BIBR-277SE; Bay 68-9291; Micardis (TN); Telmisartan [USAN:INN]; YM-086; BIBR-277-SE; Telmisartan (JAN/USAN/INN); Micardis, Targit, Temax, BIBR277, Telmisartan; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",RMMXLENWKUUMAY-UHFFFAOYSA-N,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,144701-48-4,C33H30N4O2,9434,BA00-BA04: Hypertension
D1546,Telotristat ethyl,25181577,"Telotristat; Telotristat etiprate; LP-778902; LX-1032; LX-1606; Serotonin modulator (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon; Tryptophan hydroxylase inhibitor (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon",Serotonin Synthesis Inhibitors,Small molecule,"1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1",MDSQOJYHHZBZKA-GBXCKJPGSA-N,CCOC(=O)C(CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)OC(C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N,1033805-22-9,C27H26ClF3N6O3,.,DA90: Small intestine developmental anomaly; 5B10: Carcinoid syndrome
D1547,Temazepam,5391,"Cerepax; Crisonar; Dasuen; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; Lenal; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; Nocturne; Nomapam; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temador; Temaz; Temaze; Temazepamum; Temtabs; Tenox; AHP Brand of Temazepam; Alphapharm Brand of Temazepam; Apo Temazepam; Apotex Brand of Temazepam; Ct Arzneimittel Brand of Temazepam; Desitin Brand of Temazepam; Gen Temazepam; Genopharm Brand of Temazepam; Genpharm Brand of Temazepam; ICN Brand of Temazepam; Katwijk Brand of Temazepam; Knoll Brand of Temazepam; Mallinckrodt Brand of Temazepam; Neodorm SP; Norkotral Tema; Norton Brand of Temazepam; Novartis Brand of Temazepam; Novo Temazepam; Novopharm Brand of Temazepam; Nu Pharm Brand of Temazepam; Nu Temazepam; Orion Brand of Temazepam; PMS Temazepam; Pharmascience Brand of Temazepam; Pronervon T; Scheffler Brand of Temazepam; Sigma Brand of Temazepam; Temazep von ct; Uvamin Retard; Wyeth Brand of Temazepam; ER 115; K3917; Pfizer Brand 1 of Temazepam; Pfizer Brand 2 of Temazepam; Ro 5 5345; Ro55345; SaH 47 603; SaH 47603; WY 2917; WY 3917; WY3917; Apo-Temazepam; Ct-Arzneimittel Brand of Temazepam; Euhypnos (TN); Gen-Temazepam; K-3917; N-Methyloxazepam; Norkotral (TN); Normison (TN); Novo-Temazepam; Nu-Pharm Brand of Temazepam; Nu-Temazepam; PMS-Temazepam; Remestan (TN); Restoril (TN); Ro 5-5345; SaH 47-603; Tema, Norkotral; Temazepam, pharmaceutical grade; Temazepamum [INN-Latin]; Temtabs (TN); Tenox (TN); Wy-3917; Ro-5-5345; Temazepam (USP/INN); Temazepam [USAN:INN:BAN]; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3 Hydroxydiazepam; 3-Hydroxydiazepam; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3",SEQDDYPDSLOBDC-UHFFFAOYSA-N,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,846-50-4,C16H13ClN2O2,9435,7A00-7A0Z: Insomnia
D1548,Temozolomide,5394,"Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ",Antineoplastics,Small molecule,"1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,85622-93-1,C6H6N6O2,72564,2A00: Brain cancer
D1549,Temsirolimus,6918289,Torisel,Antineoplastics/Mtor Inhibitors,Small molecule,"1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,162635-04-3,C56H87NO16,79699,2C90: Renal cell carcinoma
D1550,Tenecteplase,.,Tnkase; Tnkase (TN); Tenecteplase (USAN/INN),Thrombolytics,Protein/peptide,.,.,.,.,.,.,BA41-BA43: Myocardial infarction
D1551,Teniposide,452548,"PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside",Antineoplastics,Small molecule,"1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1",NRUKOCRGYNPUPR-QBPJDGROSA-N,COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O,29767-20-2,C32H32O13S,.,2A85: Mature B-cell lymphoma
D1552,Terazosin,5401,"Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine",Antineoplastics,Small molecule,"1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)",VCKUSRYTPJJLNI-UHFFFAOYSA-N,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,63590-64-7,C19H25N5O4,9445,GA90: Prostate hyperplasia
D1553,Terbinafine,1549008,"Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride",Antifungal Agents,Small molecule,"1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+",DOMXUEMWDBAQBQ-WEVVVXLNSA-N,CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21,91161-71-6,C21H25N,9448,1F29-1F2F: Fungal infection; EE12: Nail/perionychium infection
D1554,Terbutaline,5403,"Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol",Bronchodilators,Small molecule,"1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3",XWTYSIMOBUGWOL-UHFFFAOYSA-N,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,23031-25-6,C12H19NO3,9449,CA23: Asthma
D1555,Terfenadine,5405,"Aldaban; Allerplus; Cyater; Hisfedin; Rapidal; Seldane; Teldane; Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadina; Terfenadinum; Terfenidine; Terfex; Ternadin; Triludan; Aliud Brand of Terfenadine; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hoechst Brand of Terfenadine; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; Ratiopharm Brand of Terfenadine; Sigma Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Wolff Brand of Terfenadine; MDL 9918; RMI 9918; RMI9918; T 9652; Ct-Arzneimittel Brand of Terfenadine; MDL-9918; RMI-9918; Seldane (TN); Sigma-Tau Brand of Terfenadine; Teldane (TN); Terfenadin-ratiopharm; Terfenadina [INN-Spanish]; Terfenadinum [INN-Latin]; Triludan (TN); Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol",Antihistamines,Small molecule,"1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3",GUGOEEXESWIERI-UHFFFAOYSA-N,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,50679-08-8,C32H41NO2,9453,4A80-4A8Z: Allergic/hypersensitivity disorder
D1556,Teriflunomide,54684141,.,Selective Immunosuppressants,Small molecule,"1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-",UTNUDOFZCWSZMS-YFHOEESVSA-N,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,163451-81-8,C12H9F3N2O2,68540,5C80: Hyper-lipoproteinaemia; 8A40: Multiple sclerosis; 1E50-1E51: Hepatitis virus infection; FA20: Rheumatoid arthritis
D1557,Testolactone,13769,"Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone",Antineoplastics,Small molecule,"1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1",BPEWUONYVDABNZ-DZBHQSCQSA-N,CC12CCC3C(C1CCC(=O)O2)CCC4=CC(=O)C=CC34C,968-93-4,C19H24O3,9460,2C60-2C6Y: Breast cancer
D1558,Testosterone,6013,"AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one",Antiandrogens,Small molecule,"1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",MUMGGOZAMZWBJJ-DYKIIFRCSA-N,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C,58-22-0,C19H28O2,17347,FB83: Low bone mass disorder; 5A81: Testicular dysfunction; 5A60-5A61: Pituitary gland disorder
D1559,Testosterone (topical),6013,"AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one",Antiandrogens,Small molecule,"1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",MUMGGOZAMZWBJJ-DYKIIFRCSA-N,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C,58-22-0,C19H28O2,17347,FB83: Low bone mass disorder; 5A81: Testicular dysfunction; 5A60-5A61: Pituitary gland disorder
D1560,Tetrabenazine,6018,"Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one",Nephropathic Cystinosis Therapy,Small molecule,"1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3",MKJIEFSOBYUXJB-UHFFFAOYSA-N,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC,718635-93-9,C19H27NO3,64028,6B60: Dissociative neurological symptom disorder; 8A01: Choreiform disorder
D1561,Tetracaine,5411,"Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester",Anesthetics,Small molecule,"1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3",GKCBAIGFKIBETG-UHFFFAOYSA-N,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,94-24-6,C15H24N2O2,9468,MB40: Sensation disturbance; MG30-MG3Z: Pain
D1562,Tetracaine (topical),5411,"Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester",Anesthetics,Small molecule,"1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3",GKCBAIGFKIBETG-UHFFFAOYSA-N,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,94-24-6,C15H24N2O2,9468,MB40: Sensation disturbance; MG30-MG3Z: Pain
D1563,Tetracosactide,16133802,"Tetracosactide; COSYNTROPIN; 16960-16-0; Tetracosactrin; Tetracosactide acetate; VICOTROPE; Cortrosyn; CHEBI:3901; Cosyntropin acetate; CORTICOTROPIN TETRACOSAPEPTIDE; Cosyntropin hexaacetate; Tetracosactide hexaacetate; C136H210N40O31S; Tetracosactide hexacetate; TetracosactrinTetracosactrin; SCHEMBL33366; ACTH (1-24), Human; CHEMBL2103784; AMY25377; BDBM50017180; AKOS015994630; HS-2001; U943; 960S160; W-107889; Adrenocorticotropic Hormone Fragment 1-24 human, rat, >=97% (HPLC); H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH; L-Seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-alpha-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valylglycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline",Diagnostic Agents,Small molecule,"InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,109-,110-,111-/m0/s1",ZOEFCCMDUURGSE-SQKVDDBVSA-N,CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)N,.,C136H210N40O31S,.,.
D1564,Tetracycline,54675776,"Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide",Antibiotics,Small molecule,"1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1",NWXMGUDVXFXRIG-WESIUVDSSA-N,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,60-54-8,C22H24N2O8,27902,1A00-1C4Z: Bacterial infection
D1565,Tetracycline (topical),54675776,"Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide",Antibiotics,Small molecule,"1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1",NWXMGUDVXFXRIG-WESIUVDSSA-N,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,60-54-8,C22H24N2O8,27902,1A00-1C4Z: Bacterial infection
D1566,Tetraferric tricitrate decahydrate,90478690,tetraferric tricitrate decahydrate; ferric citrate hydrate; UNII-Q91187K011; DB14520; Q91187K011; Q22075864,Phosphate Binders,Small molecule,"InChI=1S/3C6H7O7.4Fe.10H2O/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;;;;;;;;/h3*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;10*1H2/q3*-1;4*+3;;;;;;;;;;/p-9",UISKQNNAQKPSDO-UHFFFAOYSA-E,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])[O-].O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3],.,C18H32Fe4O31,.,.
D1567,Tetryzoline (nasal),5419,Tyzine,Alpha-Adrenergic Agonists,Small molecule,"1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)",BYJAVTDNIXVSPW-UHFFFAOYSA-N,C1CC(C2=CC=CC=C2C1)C3=NCCN3,84-22-0,C13H16N2,28674,1F00: Herpes simplex infection
D1568,Tetryzoline (ophthalmic),5419,Tyzine,Alpha-Adrenergic Agonists,Small molecule,"1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)",BYJAVTDNIXVSPW-UHFFFAOYSA-N,C1CC(C2=CC=CC=C2C1)C3=NCCN3,84-22-0,C13H16N2,28674,1F00: Herpes simplex infection
D1569,Thalidomide,5426,"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide",Immunosuppressive Agents,Small molecule,"1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,50-35-1,C13H10N2O4,74947,2A83: Multiple myeloma
D1570,Theophylline,2153,"Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione",Bronchodilators,Small molecule,"1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)",ZFXYFBGIUFBOJW-UHFFFAOYSA-N,CN1C2=C(C(=O)N(C1=O)C)NC=N2,58-55-9,C7H8N4O2,28177,CA22: Chronic obstructive pulmonary disease
D1571,Thiabendazole,5430,"Biogard; Bioguard; Bovizole; Cropasal; Drawipas; Eprofil; Equizole; Hymush; Lombristop; Mertec; Mertect; Mintesol; Mintezol; Mintezole; Minzolum; Mycozol; Nemacin; Nemapan; Omnizole; Ormogal; Pitrizet; Polival; RPH; Sistesan; Storite; Tbdz; Tebuzate; Tecto; Testo; Thiaben; Thiabendazol; Thiabendazolum; Thiabendole; Thiabenzazole; Thiabenzole; Thibendole; Thibenzol; Thibenzole; Thiprazole; Tiabenda; Tiabendazol; Tiabendazole; Tiabendazolum; Tobaz; Tresaderm; Triasox; Tubazole; Captan T; Equivet TZ; Equizole A; Helmindrax octelmin; Hokustar HP; Mertect lsp; RTU Flowable Fungicide; Tecto B; Tecto rph; Thibenzole att; Top Form Wormer; Chemviron TK 100; G 491; MK 360; Mertect 160; Mertect 340f; Metasol TK 100; Metasol tk 10; PS1057_SUPELCO; Sanaizol 100; Syntol M100; TBZ 6; TBZ 60W; Tecto 10P; Tecto 40F; Tecto 60; Thibenzole 200; Tibimix 20; APL-luster; Arbotect (TN); MK-360; Metasol TK-100; Mintezol (TN); TBZ-6; Thiabendazole (USP); Thiabendazole [BSI:ISO]; Thiabendazole [USAN:BAN]; Tiabendazolum [INN-Latin]; Tresaderm (TN); E-Z-Ex; Mintezol, Equizole, Thiabendazole; Tiabendazol [INN-Spanish, French]; Tiabendazole (JAN/INN); 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; 2-(1,3-Thiazol-4-yl)benzimidazole; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; 2-(4'-Thiazolyl)benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazole; 2-(4-Thiazolyl)benzimidazole; 2-(Thiazol-4-yl)benzimidazole; 2-Thiazol-4-yl-1H-benzoimidazole; 2-Thiazole-4-ylbenzimidazole; 2-[4-Thiazoly]benzimidazole; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; 4-(2-Benzimidazolyl)thiazole",Antinematodal Agents,Small molecule,"1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)",WJCNZQLZVWNLKY-UHFFFAOYSA-N,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,148-79-8,C10H7N3S,45979,1F90: Parasitic worm infestation; 8D64: Hydrocephalus
D1572,Thiethylperazine,5440,ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*),Antiemetics,Small molecule,"1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3",XCTYLCDETUVOIP-UHFFFAOYSA-N,CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C,1420-55-9,C22H29N3S2,9544,MD90: Nausea/vomiting
D1573,Thiopental,3000715,"Intraval; Penthiobarbital; Pentothiobarbital; Thiomebumal; Thionembutal; Thiopentobarbital; Thiopentobarbitone; Thiopentone; Thiothal; Tiopentale; Trapanal; Thiopental [BAN]; Thiopental solution; Thiopentobarbituric acid; Tiopentale [Italian]; Sodium Pentothal (TN); Thiopental (TN); Thiopentone sodium (TN); Trapanal (TN); (+-)-Thiopental; (+/-)-THIOPENTAL; (+/-)-Thiopental solution; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-(9CI); 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",IUJDSEJGGMCXSG-UHFFFAOYSA-N,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,76-75-5,C11H18N2O2S,102166,9A76-9A78: Corneal disease
D1574,Thioridazine,5452,"Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine",Antipsychotic Agents,Small molecule,"1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",KLBQZWRITKRQQV-UHFFFAOYSA-N,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,50-52-2,C21H26N2S2,9566,6A20: Schizophrenia
D1575,Thiotepa,5453,"thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosyl; Tiofosfamid; Thiofozil; Tiofozil; Thioplex; Tespamin; Oncotepa; Tespamine; Girostan; Thiotef; Stepa; Tio-tef; Thio-Tep; Oncotiotepa; Tifosyl; Oncothio-tepa; TESPA; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; N,N',N''-Triethylenethiophosphoramide; Tris(1-aziridinyl)phosphine sulfide; Thiophosphamidum; 1,1',1''-phosphorothioyltriaziridine; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide",Alkylating Agents,Small molecule,"1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2",FOCVUCIESVLUNU-UHFFFAOYSA-N,C1CN1P(=S)(N2CC2)N3CC3,52-24-4,C6H12N3PS,9570,2C60-2C6Y: Breast cancer
D1576,Thiothixene,941651,"Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene",Antipsychotic Agents,Small molecule,"1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-",GFBKORZTTCHDGY-UWVJOHFNSA-N,CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,3313-26-6,C23H29N3O2S2,9571,6A20: Schizophrenia
D1577,"Thyroid, porcine",.,"DB09100; Pig thyroid; Porcine thyroid; Sus scrofa thyroid; Thyroid (pork); Thyroid extract, porcine; Thyroid, porcine",Thyroid Drugs,Hormones,.,.,.,.,.,.,.
D1578,Tiagabine,60648,"tiagabine; 115103-54-3; Gabitril; Tiagabinum; Tiagabina; (R)-Tiagabine; Tiagabinum [INN-Latin]; Tiagabina [INN-Spanish]; Tiagabine [INN:BAN]; Tiagabine [INN]; Abbott-70569; UNII-Z80I64HMNP; Tiagabine (INN); ABBOTT-70569-1; Gabitril (TN); CHEMBL1027; Z80I64HMNP; ABT-569; CHEBI:9586; NO-328; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; A-70569-1; (R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid; Gabatril; NO 329;  Gabitril; NO-329; Tiagabina [INN-Spanish];Tiagabine (INN); N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; [3H]tiagabine",Anticonvulsants,Small molecule,"1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1",PBJUNZJWGZTSKL-MRXNPFEDSA-N,CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C,115103-54-3,C20H25NO2S2,9586,8A61-8A6Z: Epilepsy/seizure; 6B00-6B0Z: Anxiety disorder
D1579,Ticagrelor,9871419,"Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;  Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique",Antiplatelet Agents,Small molecule,"1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1",OEKWJQXRCDYSHL-FNOIDJSQSA-N,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,274693-27-5,C23H28F2N6O4S,68558,BA41-BA43: Myocardial infarction; DB61-DD30: Arterial thrombosis; DB61-GB90: Thrombosis
D1580,Ticarcillin,36921,"TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid",Antibiotics,Small molecule,"1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1",OHKOGUYZJXTSFX-KZFFXBSXSA-N,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CSC=C3)C(=O)O)C(=O)O)C,34787-01-4,C15H16N2O6S2,9587,1A00-1C4Z: Bacterial infection
D1581,Ticlopidine,5472,"Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine",Fibrinolytic Agents,Small molecule,"1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2",PHWBOXQYWZNQIN-UHFFFAOYSA-N,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,55142-85-3,C14H14ClNS,9588,8B20: Ischaemic/haemorrhagic stroke
D1582,Tigecycline,54686904,"Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline",Antibiotics,Small molecule,"1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1",SOVUOXKZCCAWOJ-HJYUBDRYSA-N,CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,220620-09-7,C29H39N5O8,149836,1F28-1G0Z: Skin and skin-structure infection
D1583,Tildrakizumab,.,UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis
D1584,Tiludronic acid,60937,Skelid; Tiludronate disodium; ME-3737; SR-41319,Bisphosphonates,Small molecule,"1S/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)",DKJJVAGXPKPDRL-UHFFFAOYSA-N,C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl,89987-06-4,C7H9ClO6P2S,9598,FB83: Low bone mass disorder
D1585,Timolol,33624,"Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol",Antiarrhythmic Agents,Small molecule,"1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",BLJRIMJGRPQVNF-JTQLQIEISA-N,CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O,26839-75-8,C13H24N4O3S,9599,BA00: Essential hypertension
D1586,Timolol (ophthalmic),33624,"Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol",Antiarrhythmic Agents,Small molecule,"1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",BLJRIMJGRPQVNF-JTQLQIEISA-N,CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O,26839-75-8,C13H24N4O3S,9599,BA00: Essential hypertension
D1587,Tinidazole,5479,"Tinidazole (oral), Mission Pharmacal",Amebicides/Antibiotics,Small molecule,"1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3",HJLSLZFTEKNLFI-UHFFFAOYSA-N,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,148159-84-6,C8H13N3O4S,63627,1A00-1C4Z: Bacterial infection
D1588,Tinzaparin,772,"Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene",Anticoagulants,Small molecule,"1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",HTTJABKRGRZYRN-UHFFFAOYSA-N,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,9005-49-6,C26H42N2O37S5,.,BA43: Coronary thrombosis; DB61-GB90: Thrombosis; BD71: Deep vein thrombosis; BD72: Venous thromboembolism
D1589,Tioguanine,2723601,"6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)",Antineoplastics,Small molecule,"1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)",WYWHKKSPHMUBEB-UHFFFAOYSA-N,C1=NC2=C(N1)C(=S)N=C(N2)N,154-42-7,C5H5N5S,9555,2A60: Acute myeloid leukaemia
D1590,Tiotropium,5487427,"186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide",Bronchodilators,Small molecule,"1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+",LERNTVKEWCAPOY-FPISHFTHSA-N,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,186691-13-4,C19H22NO4S2+,90960,CA22: Chronic obstructive pulmonary disease
D1591,Tipiracil,6323266,"Tipiracil; 183204-74-2; TPI (freebase); UNII-NGO10K751P; MA-1; 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dione; NGO10K751P; 5-CHLORO-6-(1-(2-IMINOPYRROLIDINYL) METHYL) URACIL; 5-CHLORO-6-[(2-IMINOPYRROLIDIN-1-YL)METHYL]PYRIMIDINE-2,4(1H,3H)-DIONE; TAS-1-462; TPI; 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidinedione; Tipiracil [USAN:INN]; 5-CIMU; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione; CHEMBL235668; GTPL8696; SCHEMBL1682960; BDBM20079; CHEBI:90879; HY-A0063A; HMS3745A05; BCP24231; BDBM50531739; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4-(1H,3H)-dione; ZINC100032379; CS-5895; DB02631; DB09343; NCGC00389632-02; NCGC00389632-07; DB-065427; FT-0758894; A927069; Q21098889; Q27458871; 2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-; 5-Chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione,; 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-Chloro-6-{[(2E)-2-imino-1-pyrrolidinyl]methyl}-2,4(1H,3H)-pyrimidinedione; 5-chloro-6-{[(2Z)-2-iminopyrrolidin-1-yl]methyl}pyrimidine-2,4(1H,3H)-dione",Antineoplastics,Small molecule,"InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)",QQHMKNYGKVVGCZ-UHFFFAOYSA-N,C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl,.,C9H11ClN4O2,.,.
D1592,Tipranavir,54682461,"Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE",Anti-Hiv Agents,Small molecule,"1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1",SUJUHGSWHZTSEU-FYBSXPHGSA-N,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,174484-41-4,C31H33F3N2O5S,63628,1C60-1C62: Human immunodeficiency virus disease
D1593,Tirofiban,60947,"AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid",Fibrinolytic Agents,Small molecule,"1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1",COKMIXFXJJXBQG-NRFANRHFSA-N,CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,144494-65-5,C22H36N2O5S,9605,BA41-BA43: Myocardial infarction
D1594,Tisagenlecleucel,.,Tisagenlecleucel-T,Antineoplastics,Autologous cell transplant,.,.,.,.,.,.,2A81: Diffuse large B-cell lymphoma; 2A82: Mature B-cell leukaemia; 2A80: Follicular lymphoma; 2A85: Mature B-cell lymphoma; 2A60: Acute myeloid leukaemia
D1595,Tivozanib,9911830,ASP4130/AV-951,Antineoplastics,Small molecule,"1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",SPMVMDHWKHCIDT-UHFFFAOYSA-N,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,475108-18-0,C22H19ClN4O5,91327,2C90: Renal cell carcinoma
D1596,Tizanidine,5487,"Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine",Analgesics,Small molecule,"1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)",XFYDIVBRZNQMJC-UHFFFAOYSA-N,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl,51322-75-9,C9H8ClN5S,63629,MB47: Tonus and reflex abnormality
D1597,Tobramycin,36294,"Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B",Antibiotics,Small molecule,"1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1",NLVFBUXFDBBNBW-PBSUHMDJSA-N,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N,32986-56-4,C18H37N5O9,28864,1A00-1C4Z: Bacterial infection
D1598,Tocainide,38945,"Taquidil; Tocainida; Tocainidum; Tonocard; Astra W 36095; Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; W-36095; Tocainide (USAN/INN); Tocainide [USAN:BAN:INN]; Alanyl-2,6-xylidide; N-(2,6-dimethylphenyl)alaninamide; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; 2-Amino-2',6'-propionoxylidide; 2-Amino-N-(2,6-dimethylphenyl)propionamid",Antiarrhythmic Agents,Small molecule,"1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)",BUJAGSGYPOAWEI-UHFFFAOYSA-N,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,41708-72-9,C11H16N2O,9611,BC71: Ventricular tachyarrhythmia
D1599,Tocilizumab,.,Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody,Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,FA20: Rheumatoid arthritis; FA24: Juvenile idiopathic arthritis
D1600,Tofacitinib,9926791,"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200;  Xeljanz (TN)",Antirheumatics,Small molecule,"1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",UJLAWZDWDVHWOW-YPMHNXCESA-N,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,477600-75-2,C16H20N6O,71200,FA20: Rheumatoid arthritis
D1601,Tolazamide,5503,"Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P",Antidiabetic Agents,Small molecule,"1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)",OUDSBRTVNLOZBN-UHFFFAOYSA-N,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,1156-19-0,C14H21N3O3S,9613,5A2Y: Acute diabete complication
D1602,Tolazoline,5504,"Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole",Vasodilator Agents,Small molecule,"1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)",JIVZKJJQOZQXQB-UHFFFAOYSA-N,C1CN=C(N1)CC2=CC=CC=C2,59-98-3,C10H12N2,28502,BB01: Pulmonary hypertension
D1603,Tolbutamide,5505,Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea,Antidiabetic Agents,Small molecule,"1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)",JLRGJRBPOGGCBT-UHFFFAOYSA-N,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,64-77-7,C12H18N2O3S,27999,5A11: Type 2 diabetes mellitus
D1604,Tolcapone,4659569,"Tasmar; Roche brand of tolcapone; Ro 40-7592; Tasmar (TN); Tolcapone [USAN:INN]; Ro-40-7592; Tolcapone (JAN/USAN/INN); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone",Antiparkinson Agents,Small molecule,"1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3",MIQPIUSUKVNLNT-UHFFFAOYSA-N,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],134308-13-7,C14H11NO5,63630,8A00: Parkinsonism
D1605,Tolevamer,58817179,Tolevamer; SCHEMBL13423754,Potassium-Binding Resin,Small molecule,"InChI=1S/C11H16O3S/c1-3-9(4-2)10-5-7-11(8-6-10)15(12,13)14/h5-9H,3-4H2,1-2H3,(H,12,13,14)",LZNNAMNPSXBDOT-UHFFFAOYSA-N,CCC(CC)C1=CC=C(C=C1)S(=O)(=O)O,.,C11H16O3S,.,.
D1606,Tolmetin,5509,"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid",Antiinflammatory Agents,Small molecule,"1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)",UPSPUYADGBWSHF-UHFFFAOYSA-N,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,26171-23-3,C15H15NO3,71941,FA20: Rheumatoid arthritis
D1607,Tolterodine,443879,Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol,Antispasmodics,Small molecule,"1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1",OOGJQPCLVADCPB-HXUWFJFHSA-N,CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,124937-51-5,C22H31NO,9622,GC50: Functional bladder disorder
D1608,Tolvaptan,216237,"Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine",Vasopressin Antagonists,Small molecule,"1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",GYHCTFXIZSNGJT-UHFFFAOYSA-N,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,150683-30-0,C26H25ClN2O3,32246,5C72: Hypo-osmolality/hyponatraemia; BD10-BD1Z: Heart failure
D1609,Topiramate,5284627,"Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta",Anticonvulsants,Small molecule,"1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1",KJADKKWYZYXHBB-XBWDGYHZSA-N,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,97240-79-4,C12H21NO8S,63631,6C40: Substance abuse; 8A61-8A6Z: Epilepsy/seizure
D1610,Topotecan,60700,"Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin",Antineoplastics,Small molecule,"1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1",UCFGDBYHRUNTLO-QHCPKHFHSA-N,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,123948-87-8,C23H23N3O5,63632,2C25: Lung cancer; 2C73: Ovarian cancer; 2A00-2F9Z: Solid tumour/cancer
D1611,Torasemide,41781,"Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea",Diuretics,Small molecule,"1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)",NGBFQHCMQULJNZ-UHFFFAOYSA-N,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,56211-40-6,C16H20N4O3S,9637,BD10-BD1Z: Heart failure
D1612,Toremifene,3005573,"Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine",Antineoplastics,Small molecule,"1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-",XFCLJVABOIYOMF-QPLCGJKRSA-N,CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3,89778-26-7,C26H28ClNO,9635,2C60-2C6Y: Breast cancer
D1613,Tositumomab,.,Bexxar (TN),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2B33: Malignant haematopoietic neoplasm
D1614,Tositumomab (I-131),.,"131Iodine-Anti-B1; 192391-48-3; Bexxar; Bexxar therapeutic regimen; I-131 Tositumomab therapeutic regimen; Immunoglobulin G2a anti-(human antigen CD 20) (mouse monoclonal clone B1R1 gamma2a-chain), disulfide with mouse monoclonal clone B1R1 lambdax-chain, dimer, Iodine-131I-labeled; Immunoglobulin G2a, anti-(human CD20 (antigen)) (mouse monoclonal clone B1R1 gamma2a-chain), disulfide with mouse monoclonal clone B1R1 lambdax-chain, dimer, iodine-131I salt; Iodine-131 Anti-B1 Antibody; Iodine-131 Tositumomab; K1KT5M40JC; Tositumomab / iodine I 131; Tositumomab and iodine I 131 tositumomab; Tositumomab I 131; Tositumomab I-131; UNII-K1KT5M40JC",Therapeutic Radiopharmaceuticals,Small molecule,.,.,.,.,.,.,.
D1615,Trabectedin,108150,Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN),Alkylating Agents,Small molecule,"1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1",PKVRCIRHQMSYJX-AIFWHQITSA-N,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,114899-77-3,C39H43N3O11S,84050,2A00-2F9Z: Solid tumour/cancer; 2C73: Ovarian cancer
D1616,Tramadol,33741,Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram,Analgesics,Small molecule,"1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1",TVYLLZQTGLZFBW-ZBFHGGJFSA-N,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,123154-38-1,C16H25NO2,75725,MG30-MG3Z: Pain
D1617,Trametinib,11707110,GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN,Multikinase Inhibitors,Small molecule,"1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,871700-17-3,C26H23FIN5O4,75998,2C30: Melanoma
D1618,Trandolapril,5484727,"Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid",Antihypertensive Agents,Small molecule,"1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1",VXFJYXUZANRPDJ-WTNASJBWSA-N,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O,87679-37-6,C24H34N2O5,9649,BA00-BA04: Hypertension
D1619,Tranexamic acid,5526,"AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid",Antifibrinolytic Agents,Small molecule,"1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)",GYDJEQRTZSCIOI-UHFFFAOYSA-N,C1CC(CCC1CN)C(=O)O,701-54-2,C8H15NO2,48669,GA30: Menopausal disorder
D1620,Tranylcypromine,19493,"GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine",Antidepressants,Small molecule,"1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1",AELCINSCMGFISI-DTWKUNHWSA-N,C1C(C1N)C2=CC=CC=C2,3721-26-4,C9H11N,94631,2C82: Prostate cancer; 6A70-6A7Z: Depression
D1621,Trastuzumab,.,Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C60-2C6Y: Breast cancer; 2B72: Stomach cancer
D1622,Trastuzumab deruxtecan,.,.,Antineoplastics/Her2 Inhibitors,Monoclonal antibody,.,.,.,.,.,.,2B91: Colorectal cancer; 2C60-2C6Y: Breast cancer
D1623,Trastuzumab emtansine,.,.,Antineoplastics/Her2 Inhibitors,Monoclonal antibody,.,.,.,.,.,.,2C60-2C6Y: Breast cancer
D1624,Trazodone,5533,"Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride",Antidepressants,Small molecule,"1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",PHLBKPHSAVXXEF-UHFFFAOYSA-N,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,19794-93-5,C19H22ClN5O,9654,6A70-6A7Z: Depression
D1625,Treprostinil,6918140,"Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid",Antihypertensive Agents,Small molecule,"1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1",PAJMKGZZBBTTOY-ZFORQUDYSA-N,CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,81846-19-7,C23H34O5,50861,BB01: Pulmonary hypertension
D1626,Tretinoin,444795,"Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid",Keratolytic Agents,Small molecule,"1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+",SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,302-79-4,C20H28O2,15367,ED80: Acne vulgaris; 2A60: Acute myeloid leukaemia
D1627,Tretinoin (topical),444795,"Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid",Keratolytic Agents,Small molecule,"1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+",SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,302-79-4,C20H28O2,15367,ED80: Acne vulgaris; 2A60: Acute myeloid leukaemia
D1628,Triamcinolone,31307,"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone",Antiinflammatory Agents,Small molecule,"1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1",GFNANZIMVAIWHM-OBYCQNJPSA-N,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,124-94-7,C21H27FO6,9667,CA08: Vasomotor/allergic rhinitis
D1629,Triamcinolone (nasal),31307,"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone",Antiinflammatory Agents,Small molecule,"1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1",GFNANZIMVAIWHM-OBYCQNJPSA-N,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,124-94-7,C21H27FO6,9667,CA08: Vasomotor/allergic rhinitis
D1630,Triamcinolone (ophthalmic),31307,"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone",Antiinflammatory Agents,Small molecule,"1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1",GFNANZIMVAIWHM-OBYCQNJPSA-N,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,124-94-7,C21H27FO6,9667,CA08: Vasomotor/allergic rhinitis
D1631,Triamterene,5546,"Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine",Diuretics,Small molecule,"1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)",FNYLWPVRPXGIIP-UHFFFAOYSA-N,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,396-01-0,C12H11N7,9671,BD10-BD1Z: Heart failure; MG29: Oedema; BA00-BA04: Hypertension
D1632,Triazolam,5556,"Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3",JOFWLTCLBGQGBO-UHFFFAOYSA-N,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl,28911-01-5,C17H12Cl2N4,9674,7A00-7A0Z: Insomnia
D1633,Trichlormethiazide,5560,"Achletin; Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Cretonin; Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naquasone; Schebitran; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazidum; Trichloromethiadiazide; Trichloromethiazide; Triclordiuride; Triclormetiazida; Triclormetiazide; Triflumen;American Urologicals Brand of Trichloromethiazide; Jones Brand of Trichloromethiazide; Schering Brand of Trichlormethiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Achletin (TN); Ciba 7057-Su; Diu-Hydrin; Flurese (VAN); Naqua (TN); Salurin (wadel); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum [INN-Latin]; Trichloromethiazide, 6; Triclormetiazida[INN-Spanish]; Triflumen (TN); Diu-Hydrin (TN); Trichlormethiazide (JP15/USP/INN); (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide",Antihypertensive Agents,Small molecule,"1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)",LMJSLTNSBFUCMU-UHFFFAOYSA-N,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,133-67-5,C8H8Cl3N3O4S2,9683,BA00-BA04: Hypertension
D1634,Triclabendazole,50248,"Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole",Anthelmintics,Small molecule,"1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)",NQPDXQQQCQDHHW-UHFFFAOYSA-N,CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl,68786-66-3,C14H9Cl3N2OS,94759,1F90: Parasitic worm infestation
D1635,Triethylenetetramine,5565,"Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride",Chelating Agents,Small molecule,"1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2",VILCJCGEZXAXTO-UHFFFAOYSA-N,C(CNCCNCCN)N,112-24-3,C6H18N4,39501,5C50-5C59: Inborn metabolism deficiency
D1636,Trifarotene (topical),11518241,"Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-",Topical Acne Agents,Small molecule,"1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)",MFBCDACCJCDGBA-UHFFFAOYSA-N,CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4,895542-09-3,C29H33NO4,.,ED80: Acne vulgaris
D1637,Trifluoperazine,5566,Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine,Antipsychotic Agents,Small molecule,"1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3",ZEWQUBUPAILYHI-UHFFFAOYSA-N,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,117-89-5,C21H24F3N3S,45951,6A20: Schizophrenia
D1638,Triflupromazine,5568,Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN),Antipsychotic Agents,Small molecule,"1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3",XSCGXQMFQXDFCW-UHFFFAOYSA-N,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F,146-54-3,C18H19F3N2S,9711,6A20-6A25: Psychotic disorder
D1639,Trifluridine,6256,"Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine",Antiviral Agents,Small molecule,"1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1",VSQQQLOSPVPRAZ-RRKCRQDMSA-N,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,70-00-8,C10H11F3N2O5,75179,1A24-1D9Z: Virus infection
D1640,Triheptanoin,69286,"Triheptanoin; 620-67-7; GLYCERYL TRIHEPTANOATE; Propane-1,2,3-triyl triheptanoate; Triheptylin; Trienanthoin; Trioenanthoin; Triheptanoic glyceride; Glycerol triheptanoate; UNII-2P6O7CFW5K; Propane-1,2,3-triyl trisheptanoate; BRN 1807724; EINECS 210-647-2; 2P6O7CFW5K; 3-02-00-00769 (Beilstein Handbook Reference); Heptanoin, tri- (6CI,7CI,8CI); 2,3-di(heptanoyloxy)propyl heptanoate; W-109093; Dermofeel TC 7; Lanol 37T; 1,2,3-propanetriyl triheptanoate; Trienantin; UX007; Glyceryl trienanthate; Triheptanoin [USAN]; Heptanoic acid, 1,",Nutritional Supplements,Small molecule,"1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3",PJHKBYALYHRYSK-UHFFFAOYSA-N,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,620-67-7,C24H44O6,.,8A61-8A6Z: Epilepsy/seizure; BC43: Cardiomyopathy
D1641,Trihexyphenidyl,5572,"trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959;  Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA",Antiparkinson Agents,Small molecule,"1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2",HWHLPVGTWGOCJO-UHFFFAOYSA-N,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,144-11-6,C20H31NO,9720,8A02: Dystonic disorder; 8A00: Parkinsonism; 5B80-5B81: Obesity
D1642,Trimethadione,5576,"Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]",Anticonvulsants,Small molecule,1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3,IRYJRGCIQBGHIV-UHFFFAOYSA-N,CC1(C(=O)N(C(=O)O1)C)C,127-48-0,C6H9NO3,9727,2C10: Pancreatic cancer; 8A61-8A6Z: Epilepsy/seizure
D1643,Trimethaphan,23576,"Thimethaphan; Trimetaphan; Trimetaphanum; Arfonad (TN); Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-(VAN); 1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium",Antihypertensive Agents,Small molecule,"1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1",CHQOEHPMXSHGCL-UHFFFAOYSA-N,C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,7187-66-8,C22H25N2OS+,9728,BD50: Aneurysm/dissection; BA03: Hypertensive crisis
D1644,Trimethobenzamide,5577,Tigan; Trimethobenzamide Hydrochloride; Trimethobenzamide Hydrochloride Preservative Free,Anticholinergic Agents/Antiemetics,Small molecule,"1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)",FEZBIKUBAYAZIU-UHFFFAOYSA-N,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC,138-56-7,C21H28N2O5,27796,MD90: Nausea/vomiting
D1645,Trimethoprim,5578,Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN],Antiinfective Agents,Small molecule,"1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)",IEDVJHCEMCRBQM-UHFFFAOYSA-N,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,738-70-5,C14H18N4O3,45924,GC08: Urinary tract infection
D1646,Trimetrexate,5583,"TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine",Antifungal Agents,Small molecule,"1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC,52128-35-5,C19H23N5O3,9737,1F57: Toxoplasmosis
D1647,Trimipramine,5584,"Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP",Antidepressants,Small molecule,"1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3",ZSCDBOWYZJWBIY-UHFFFAOYSA-N,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,3564-75-8,C20H26N2,9738,6A70-6A7Z: Depression
D1648,Trioxsalen,5585,"trioxsalen; 3902-71-4; Trioxysalen; Trisoralen; Trimethylpsoralen; 4,5',8-Trimethylpsoralen; Elder 8011; Trioxysalenum; Trioxisaleno; Trioxysalene; 2',4,8-Trimethylpsoralen; 4,5',8-Trimethylpsoralene; NSC-71047; 2,5,9-Trimethyl-7H-furo[3,2-g]chromen-7-one; UNII-Y6UY8OV51T; Trioxysalene [INN-French]; Trioxysalenum [INN-Latin]; NSC71047; Trioxisaleno [INN-Spanish]; NSC 71047; TRIOXSALIN; 7H-Furo[3,2-g][1]benzopyran-7-one, 2,5,9-trimethyl-; EINECS 223-459-0; 4,8,5'-Trimethylpsoralen; BRN 0221723; Y6UY8OV51T",Pigmenting Photosensitizing Agents,Small molecule,"1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3",FMHHVULEAZTJMA-UHFFFAOYSA-N,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,3902-71-4,C14H12O3,28329,ED63: Acquired hypomelanotic disorder
D1649,Tripelennamine,5587,"Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine",Antiallergic Agents,Small molecule,"1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3",UFLGIAIHIAPJJC-UHFFFAOYSA-N,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2,91-81-6,C16H21N3,9741,4A80-4A8Z: Allergic/hypersensitivity disorder
D1650,Triprolidine,5282443,"Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride",Antiallergic Agents,Small molecule,"1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+",CBEQULMOCCWAQT-WOJGMQOQSA-N,CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC=N3,486-12-4,C19H22N2,84116,CA08: Vasomotor/allergic rhinitis
D1651,Triptorelin,25074470,Gonapeptyl depot (TN),Hormones/Antineoplastics,Small molecule,"1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1",VXKHXGOKWPXYNA-PGBVPBMZSA-N,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,57773-63-4,C64H82N18O13,63633,2A00-2F9Z: Solid tumour/cancer; 2C82: Prostate cancer
D1652,Troglitazone,5591,"Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione",Antiinflammatory Agents,Small molecule,"1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)",GXPHKUHSUJUWKP-UHFFFAOYSA-N,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,97322-87-7,C24H27NO5S,9753,5A2Y: Acute diabete complication
D1653,Troleandomycin,202225,"Aovine; Cyclamycin; Evramicina; Matromicina; Oleandocetin; Oleandocetine; TAO; Treolmicina; Triacetyloleandomycin; Triacetyloleandomycinum; Tribiocillina; Triocetin; Triolan; Troleandomicina; Troleandomycine; Troleandomycinum; Viamicina; Wytrion; Matromycin T; Oleandomycin triacetate; Oleandomycin triacetyl ester; Triacetyl ester of oleandomycin; WY 651; Tao (TN); Tao (VAN); Tekmisin (TN); Treis-Micina; Triacetyloleandomycin (JAN); Triocetin (TN); Troleandomicina [INN-Spanish]; Troleandomycin (TAO); Troleandomycin [USAN:INN]; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; Oleandomycin, triacetate (ester); T.A.O; Troleandomycin (USP/INN); T.A.O.",Antibiotics,Small molecule,"1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1",LQCLVBQBTUVCEQ-QTFUVMRISA-N,CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,311074,C41H67NO15,45735,1A00-1C4Z: Bacterial infection
D1654,Tromethamine,6503,"Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane",Genitourinary Tract Agents,Small molecule,"1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2",LENZDBCJOHFCAS-UHFFFAOYSA-N,C(C(CO)(CO)N)O,77-86-1,C4H11NO3,9754,5C73: Acidosis
D1655,Tropicamide (ophthalmic),5593,"Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide",Diagnostic Agents,Small molecule,"1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3",BGDKAVGWHJFAGW-UHFFFAOYSA-N,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,1508-75-4,C17H20N2O2,9757,LA11: Eye anterior segment structural developmental anomaly
D1656,Trospium,5284632,"Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride",Parasympatholytics,Small molecule,"1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23?",OYYDSUSKLWTMMQ-AIZNXBIQSA-N,C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,47608-32-2,C25H30NO3+,145791,MB47: Tonus and reflex abnormality; GC50: Functional bladder disorder
D1657,Trovafloxacin,62959,"TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid",Antiinfective Agents,Small molecule,"1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?",WVPSKSLAZQPAKQ-SOSAQKQKSA-N,C1C2C(C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,147059-72-1,C20H15F3N4O3,9763,1A00-1C4Z: Bacterial infection
D1658,Tryptophan,6305,"Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine",Antidepressants,Small molecule,"1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1",QIVBCDIJIAJPQS-VIFPVBQESA-N,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,73-22-3,C11H12N2O2,16828,6A70-6A7Z: Depression
D1659,Tubocurarine,6000,"Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium",Neuromuscular Blocking Agents,Small molecule,"1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1",JFJZZMVDLULRGK-URLMMPGGSA-O,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,57-95-4,C37H41N2O6+,9774,9A76-9A78: Corneal disease; 6C4A: Nicotine use disorder
D1660,Tucatinib,51039094,"Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE",Antineoplastics/Her2 Inhibitors,Small molecule,"1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)",SDEAXTCZPQIFQM-UHFFFAOYSA-N,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,937263-43-9,C26H24N8O2,.,2B72: Stomach cancer; 2C60-2C6Y: Breast cancer
D1661,Turmeric,969516,"curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil",Herbal Products,Small molecule,"1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+",VFLDPWHFBUODDF-FCXRPNKRSA-N,COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O,458-37-7,C21H20O6,3962,2A00-2F9Z: Solid tumour/cancer
D1662,Typhoid vaccine (inactivated),.,DB14022; Typhoid vaccine,Vaccines,Vaccine,.,.,.,.,.,.,.
D1663,Ubrogepant,68748835,"1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide",Cgrp Inhibitors,Small molecule,"1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1",DDOOFTLHJSMHLN-ZQHRPCGSSA-N,CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6,1374248-77-7,C29H26F3N5O3,.,8A80: Migraine
D1664,Ulipristal,13559281,Ella (TN),Progesterone Receptor Modulators,Small molecule,"1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1",HKDLNTKNLJPAIY-WKWWZUSTSA-N,CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,159811-51-5,C28H35NO3,.,QA21: Contraceptive management
D1665,Umeclidinium,11519070,573719,Bronchodilators,Small molecule,"1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1",FVTWTVQXNAJTQP-UHFFFAOYSA-N,C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5,869185-19-3,C29H34NO2+,79041,CA22: Chronic obstructive pulmonary disease
D1666,Upadacitinib,58557659,ABT-494,Antirheumatics,Small molecule,"1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1",WYQFJHHDOKWSHR-MNOVXSKESA-N,CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F,1310726-60-3,C17H19F3N6O,.,EA80: Atopic eczema; FA21: Psoriatic arthritis; DD70: Crohn disease; DD71: Ulcerative colitis; FA20: Rheumatoid arthritis
D1667,Uracil mustard,6194,"Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol",Antineoplastics,Small molecule,"1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)",IDPUKCWIGUEADI-UHFFFAOYSA-N,C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl,66-75-1,C8H11Cl2N3O2,9884,2A60: Acute myeloid leukaemia
D1668,Urea,1176,"carbamide; 57-13-6; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Carbamimidic acid; Pseudourea; Ureaphil; Urevert; Carbaderm; Alphadrate; Keratinamin; Calmurid; Aquadrate; Carbonyl diamide; Pastaron; Urepearl; Carbamide resin; Ultra Mide; Varioform ii; Aqua Care; Prespersion, 75 urea; carmol; basodexan; Harnstoff; Nutraplus; Mocovina; Urea solution; Supercel 3000; Aqua Care HP; Ureacin-20; Ureacin-40 Creme; Ureacin-10 lotion; Polyurea; Panafil; Onychomal; Hyanit; Caswell No. 902; Carbonyl Diamine; Mocovina [Czech]; Harnstoff [Ge",Topical Emollients,Small molecule,"1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)",XSQUKJJJFZCRTK-UHFFFAOYSA-N,C(=O)(N)N,57-13-6,CH4N2O,16199,DA24: Oesophagitis
D1669,Urokinase,.,.,Thrombolytics,Protein/peptide,.,.,.,.,.,.,BA41-BA43: Myocardial infarction
D1670,Ursodeoxycholic acid,31401,"Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid",Choleretic Agents,Small molecule,"1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1",RUDATBOHQWOJDD-UZVSRGJWSA-N,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,128-13-2,C24H40O4,9907,DB96: Autoimmune liver disease
D1671,Ustekinumab,.,"6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine;  Stelara (TN)",Interleukin Inhibitors,Monoclonal antibody,.,.,.,.,.,.,EA90: Psoriasis; 1F40-1F45: Malaria; DD72: Indeterminate colitis
D1672,Valaciclovir,135398742,"Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate",Antiviral Agents,Small molecule,"1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1",HDOVUKNUBWVHOX-QMMMGPOBSA-N,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,124832-26-4,C13H20N6O4,35854,1A24-1D9Z: Virus infection
D1673,Valbenazine,24795069,"Valbenazine; 1025504-45-3; UNII-54K37P50KH; Valbenazine free base; NBI 98854; 54K37P50KH; 1025504-45-3 (free base); (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; SB17456; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester",Vmat2 Inhibitors,Small molecule,"1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1",GEJDGVNQKABXKG-CFKGEZKQSA-N,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C(C(C)C)N)OC)OC,1025504-45-3,C24H38N2O4,.,8A05: Tic disorder; 8A02: Dystonic disorder
D1674,Valdecoxib,119607,"Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide",Antiinflammatory Agents,Small molecule,"1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",LNPDTQAFDNKSHK-UHFFFAOYSA-N,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,181695-72-7,C16H14N2O3S,63634,FA00-FA05: Osteoarthritis
D1675,Valerian,.,"UNII-8A47JLA8P4; 2-Propenoic acid, 3-(1-(acetyloxy)-2,4,5,6,7,7a-hexahydro-3,7-dimethyl-1H-inden-4-yl)-2-methyl-, (1R-(1alpha,4alpha(E),7alpha,7aalpha))-; 8A47JLA8P4; Acetoxyvalerenic Acid; Acetoxyvalerenic acid (constituent of valerian) [DSC]; Acetoxyvalerenic acid (stn); Valerenolic acid, acetyl-",Herbal Products,Natural product,.,.,.,.,.,.,.
D1676,Valganciclovir,135413535,"Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one",Antiviral Agents,Small molecule,"1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1",WPVFJKSGQUFQAP-GKAPJAKFSA-N,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,175865-60-8,C14H22N6O5,63635,1A24-1D9Z: Virus infection
D1677,Valproic acid,3121,"99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)",Anticonvulsants,Small molecule,"1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,99-66-1,C8H16O2,39867,8A61-8A6Z: Epilepsy/seizure; 6C40: Substance abuse
D1678,Valrubicin,454216,"Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester",Antineoplastics,Small molecule,"1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1",ZOCKGBMQLCSHFP-KQRAQHLDSA-N,CCCCC(=O)OCC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)OC5CC(C(C(O5)C)O)NC(=O)C(F)(F)F)O,56124-62-0,C34H36F3NO13,135876,2C94: Bladder cancer; EA90: Psoriasis
D1679,Valsartan,60846,"valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis;  Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan",Antihypertensive Agents,Small molecule,"1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1",ACWBQPMHZXGDFX-QFIPXVFZSA-N,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,137862-53-4,C24H29N5O3,9927,BA00-BA04: Hypertension
D1680,Vancomycin,14969,"Vancomycin (oral, MRSA), AuricX; Vancomycin (oral/pill, MSRA); Vancomycin (oral/pill, MSRA), AuricX/SRI International",Antiinfective Agents,Small molecule,"1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1",MYPYJXKWCTUITO-LYRMYLQWSA-N,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,1404-90-6,C66H75Cl2N9O24,28001,1A00-1A09: Anaerobic bacterial infection; 1D01: Infectious meningitis
D1681,Vandetanib,3081361,"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)",Antineoplastics,Small molecule,"1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,443913-73-3,C22H24BrFN4O2,49960,2A00-2F9Z: Solid tumour/cancer
D1682,Vardenafil,135400189,"VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol",Impotence Agents,Small molecule,"1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)",SECKRCOLJRRGGV-UHFFFAOYSA-N,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,224785-90-4,C23H32N6O4S,46295,HA00-HA01: Sexual dysfunction
D1683,Vasopressin,644077,Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP),Vasoconstrictor Agents,Small molecule,"1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1",KBZOIRJILGZLEJ-LGYYRGKSSA-N,C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,113-79-1,C46H65N15O12S2,34543,5A60-5A61: Pituitary gland disorder; MF55: Polyuria; 6C00: Enuresis
D1684,Vecuronium,39765,"Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",Analgesics,Small molecule,"1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1",BGSZAXLLHYERSY-XQIGCQGXSA-N,CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C,86029-43-8,C34H57N2O4+,9939,MB47: Tonus and reflex abnormality
D1685,Vedolizumab,.,DB09033; Vedolizumab,Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,.
D1686,Velpatasvir,67683363,.,Antiviral Agents,Small molecule,"1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1",FHCUMDQMBHQXKK-CDIODLITSA-N,CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC,1377049-84-7,C49H54N8O8,133009,1E50-1E51: Hepatitis virus infection
D1687,Vemurafenib,42611257,PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor),Multikinase Inhibitors,Small molecule,"1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,918504-65-1,C23H18ClF2N3O3S,63637,2C30: Melanoma
D1688,Venetoclax,49846579,.,Antineoplastics,Small molecule,"1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,1257044-40-8,C45H50ClN7O7S,133021,2A82: Mature B-cell leukaemia; 2A00-2F9Z: Solid tumour/cancer
D1689,Venlafaxine,5656,"Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol",Antidepressants,Small molecule,"1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",PNVNVHUZROJLTJ-UHFFFAOYSA-N,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,93413-69-5,C17H27NO2,9943,6A70-6A7Z: Depression
D1690,Verapamil,2520,"Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)",Analgesics,Small molecule,"1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3",SGTNSNPWRIOYBX-UHFFFAOYSA-N,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,52-53-9,C27H38N2O4,77733,BA00-BA04: Hypertension
D1691,Verteporfin,11980904,Visudyne (TN),Antineoplastics,Small molecule,"1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1",NJLRKAMQPVVOIU-IDLGWYNRSA-N,CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C,.,C82H84N8O16,.,EA90: Psoriasis
D1692,Vibrio cholerae CVD 103-HgR strain live antigen,.,"Cholera Vaccine; Cholera Vaccine Live Oral; Cholera vaccine, live, oral; DB14443; Vibrio cholerae CVD 103-HgR strain live antigen",Vaccines,Vaccine,.,.,.,.,.,.,.
D1693,Vibrio cholerae CVD 103-HgR strain live antigen (live),.,"Cholera Vaccine; Cholera Vaccine Live Oral; Cholera vaccine, live, oral; DB14443; Vibrio cholerae CVD 103-HgR strain live antigen",Vaccines,Vaccine,.,.,.,.,.,.,.
D1694,Vigabatrin,5665,"GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid",Anticonvulsants,Small molecule,"1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)",PJDFLNIOAUIZSL-UHFFFAOYSA-N,C=CC(CCC(=O)O)N,68506-86-5,C6H11NO2,63638,8A61-8A6Z: Epilepsy/seizure; 8A62: Epileptic encephalopathy
D1695,Vilanterol,10184665,"503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair",Bronchodilators,Small molecule,"1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1",DAFYYTQWSAWIGS-DEOSSOPVSA-N,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,503068-34-6,C24H33Cl2NO5,75037,CA22: Chronic obstructive pulmonary disease
D1696,Vilazodone,6918314,Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide,Antidepressants,Small molecule,"1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)",SGEGOXDYSFKCPT-UHFFFAOYSA-N,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N,163521-12-8,C26H27N5O2,70707,6A70-6A7Z: Depression
D1697,Vinblastine,13342,"Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid",Antineoplastics,Small molecule,"1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1",JXLYSJRDGCGARV-CFWMRBGOSA-N,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,865-21-4,C46H58N4O9,.,2A00-2F9Z: Solid tumour/cancer
D1698,Vincristine,5978,"LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine",Antineoplastics,Small molecule,"1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1",OGWKCGZFUXNPDA-XQKSVPLYSA-N,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,57-22-7,C46H56N4O10,28445,2A85: Mature B-cell lymphoma
D1699,Vincristine (liposome),5978,"LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine",Antineoplastics,Small molecule,"1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1",OGWKCGZFUXNPDA-XQKSVPLYSA-N,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,57-22-7,C46H56N4O10,28445,2A85: Mature B-cell lymphoma
D1700,Vinorelbine,5311497,"Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate",Antineoplastics,Small molecule,"1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1",GBABOYUKABKIAF-IELIFDKJSA-N,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,71486-22-1,C45H54N4O8,480999,2A00-2F9Z: Solid tumour/cancer
D1701,Vismodegib,24776445,879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide;  Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449,Antineoplastics/Hedgehog Pathway Inhibitors,Small molecule,"1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",BPQMGSKTAYIVFO-UHFFFAOYSA-N,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,879085-55-9,C19H14Cl2N2O3S,66903,2C32: Basal cell carcinoma; 2A00: Brain cancer
D1702,Vitamin A,445354,"Retinol; retinol; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Oleovitamin A; Chocola A; Ophthalamin; Epiteliol; Biosterol; Aquasynth; Apostavit; Alphasterol; Veroftal; Testavol; Anatola; Prepalin; Myvpack; Agoncal; Agiolan; Vogan; Axerol; Vitpex; Avibon; Apexol; Aoral; Vaflol; Dofsol; Avitol; Vitamin A alcohol; Disatabs Tabs; Lard Factor; Bentavit A; Dohyfral A; all-trans-Retinyl alcohol; Alcovit A; Vogan-Neu; Anatola A; Plivit A; A-Mulsal; Vi-Alpha; A-Vitan; All-trans retinol; Atars; Vafol; trans-retinol; all-trans-Vitamin A;  ACON; ATAV; Alin; Avita; Axerophtholum; Cylasphere; LPK; Retinolo; Retinolum; TROL; Thalasphere; Wachstumsvitamin; All Trans Retinol; Antixerophthalmic vitamin; Antixerophthalmisches Vitamin; Aquasol A Parenteral; Homagenets Aoral; Homagenets aorl; Hydrovit A; Mvc Plus; Retinol solution; Retinolo [DCIT]; Retrovitamin A; Sehkraft A; Super A; Testavol S; Vitamin A cryst; Vitamine A; Vitaminum A; Vitavel A; Zinosan N; Rovimix A 500; Vitamin A1 alcohol; A-Sol; Anti-infective vitamin; Beta-Retinol; Retinol [INN:BAN]; Retinolum [INN-Latin]; Solu-A; Trans-Vitamin A alcohol; Trans-retinol; Vi-a; Vi-alpha; Vio-A; Vitamin A (Feed); Vitamin A (USP); Vitamin A alcohol (VAN); Vitamin A1 alcohol, all trans; Vitamin-A; Vitamin-A alcohol; Vitamin-A alcohol solution; Vitamin-A1; Vitavel-A; Vogan-nu; A-Vi-Pel; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); All-trans-Retinol; All-trans-Retinyl alcohol; All-trans-Vitamin A; All-trans-Vitamin A alcohol; All-trans-Vitamin A1; Del-VI-A; Hi-A-Vita; Nio-A-Let; Ro-a-vit; Trans-Retinol acid (Vitamin A); Vi-Dom-A; [11,12-3H]-Retinol; MVC 9+3; MVI-12; Retinol, all-trans-(8CI); Retin-11,12-t2-ol (9CI); Retinol-(cellular-retinol-binding-protein); Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; All-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; Tricyclics",Vitamins,Small molecule,"1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+",FPIPGXGPPPQFEQ-OVSJKPMPSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C,11103-57-4,C20H30O,17336,9D45: Light sensitivity impairment; 1F61-1G2Z: Kinetoplastids
D1703,Vitamin E,14985,"Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol)",Vitamins,Small molecule,"1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1",GVJHHUAWPYXKBD-IEOSBIPESA-N,CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C,21590,C29H50O2,18145,BA00-BE2Z: Cardiovascular disease
D1704,Von Willebrand Factor Human,.,"DB13133; Human von willebrand factor; Von willebrand factor; Von willebrand factor (human); Von willebrand factor complex (human); Von Willebrand Factor Human; von Willebrand factor, human; Von willebrand's factor",Coagulation Modifiers,Protein/peptide,.,.,.,.,.,.,.
D1705,Vorapaxar,10077130,"Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny",Antiplatelet Agents/Protease-Activated Receptor-1 Antagonists,Small molecule,"1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1",ZBGXUVOIWDMMJE-QHNZEKIYSA-N,CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C,618385-01-6,C29H33FN2O4,82702,BA41-BA43: Myocardial infarction
D1706,Voriconazole,71616,"VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC",Antifungal Agents,Small molecule,"1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1",BCEHBSKCWLPMDN-MGPLVRAMSA-N,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,188416-29-7,C16H14F3N5O,10023,1F20: Aspergillosis
D1707,Vorinostat,5311,"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)",Antineoplastics,Small molecule,"1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,149647-78-9,C14H20N2O3,45716,2B01: Mycosis fungoides
D1708,Vortioxetine,9966051,"VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004",Antidepressants,Small molecule,"1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3",YQNWZWMKLDQSAC-UHFFFAOYSA-N,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,508233-74-7,C18H22N2S,76016,6A70-6A7Z: Depression; 6A60-6E23: Mood disorder
D1709,Voxelotor,71602803,"Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S",Hemoglobin S Polymerization Inhibitor,Small molecule,"1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3",FWCVZAQENIZVMY-UHFFFAOYSA-N,CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O,1446321-46-5,C19H19N3O3,.,3A51: Sickle-cell disorder
D1710,Voxilaprevir,89921642,.,Antiviral Agents,Small molecule,"1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1",MZBLZLWXUBZHSL-FZNJKFJKSA-N,CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C,1535212-07-7,C40H52F4N6O9S,.,1E50-1E51: Hepatitis virus infection
D1711,Warfarin,54678486,Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin,Anticoagulants,Small molecule,"1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3",PJVWKTKQMONHTI-UHFFFAOYSA-N,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,81-81-2,C19H16O4,87732,BC81: Supraventricular tachyarrhythmia; DB61-GB90: Thrombosis
D1712,Xylometazoline (nasal),5709,"Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences",Decongestants,Small molecule,"1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)",HUCJFAOMUPXHDK-UHFFFAOYSA-N,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C,526-36-3,C16H24N2,10082,CA08: Vasomotor/allergic rhinitis
D1713,Yohimbine,8969,"APHRODINE; Actibine; Aphrodyne; Aphrosol; Corynine; Johimbin; Quebrachin; Quebrachine; Thybine; Yocon; Yohimar; Yohimbin; Yohimex; Yoman; Yovital; Dayto himbin; Yohimbic acid methyl ester; Baron-X; Trans-Quinolizidine yohimbine; Yohimbine (DCF); Methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-(9CI); Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; (+)-Yohimbin; (+)-Yohimbine; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester",Mydriatics,Small molecule,"1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1",BLGXFZZNTVWLAY-SCYLSFHTSA-N,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,146-48-5,C21H26N2O3,10093,HA00-HA01: Sexual dysfunction
D1714,Zafirlukast,5717,"Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide",Antiasthmatic Agents,Small molecule,"1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)",YEEZWCHGZNKEEK-UHFFFAOYSA-N,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,107753-78-6,C31H33N3O6S,10100,CA23: Asthma
D1715,Zalcitabine,24066,"zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188;  DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC",Anti-Hiv Agents,Small molecule,"1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1",WREGKURFCTUGRC-POYBYMJQSA-N,C1CC(OC1CO)N2C=CC(=NC2=O)N,7481-89-2,C9H13N3O3,10101,1C60-1C62: Human immunodeficiency virus disease
D1716,Zaleplon,5719,"Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3",HUNXMJYCHXQEGX-UHFFFAOYSA-N,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,151319-34-5,C17H15N5O,10102,7A00-7A0Z: Insomnia
D1717,Zanamivir,60855,"zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7;  GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir",Antiviral Agents,Small molecule,"1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1",ARAIBEBZBOPLMB-UFGQHTETSA-N,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,139110-80-8,C12H20N4O7,50663,1E30-1E32: Influenza
D1718,Zanubrutinib,135565884,UNII-AG9MHG098Z; AG9MHG098Z; BGB3111; Brukinsa; Brukinsa (TN); Zanubrutinib [INN]; Zanubrutinib [USAN]; Zanubrutinib [USAN:INN]; Zanubrutinib (USAN/INN); D11422; BGB-3111; BGB 311,Antiviral Agents,Small molecule,"1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1",RNOAOAWBMHREKO-QFIPXVFZSA-N,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,1691249-45-2,C27H29N5O3,.,1D64-1D65: COVID-19
D1719,Ziconotide,16135415,"Prialt; Ziconotide [USAN]; SNX 111; DRG-0250; Omega-Conotoxin M VIIA; Omega-conotoxin MVIIA; Prialt (TN); SNX-111; Omega-ConopeptideMVIIA (Conus); Omega-Conotoxin mviia, conus magus; Omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide)",Analgesics,Small molecule,"1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1",BPKIMPVREBSLAJ-QTBYCLKRSA-N,CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN,107452-89-1,C102H172N36O32S7,135912,MG30-MG3Z: Pain; NA07: Intracranial injury
D1720,Zidovudine,35370,"zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S;  AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3&prime;-Azido-3&prime;-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422",Anti-Hiv Agents,Small molecule,"1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1",HBOMLICNUCNMMY-XLPZGREQSA-N,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],30516-87-1,C10H13N5O4,10110,1C60-1C62: Human immunodeficiency virus disease; 1A24-1D9Z: Virus infection
D1721,Zileuton,60490,"Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea",Antiinflammatory Agents,Small molecule,"1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)",MWLSOWXNZPKENC-UHFFFAOYSA-N,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,111406-87-2,C11H12N2O2S,10112,CA23: Asthma
D1722,Zinc acetate,11192,.,Minerals And Electrolytes,Small molecule,"1S/2C2H4O2.Zn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",DJWUNCQRNNEAKC-UHFFFAOYSA-L,CC(=O)[O-].CC(=O)[O-].[Zn+2],557-34-6,C4H6O4Zn,62984,5C64: Mineral absorption/transport disorder; 1C60-1C62: Human immunodeficiency virus disease
D1723,Zinc chloride,5727,Zinc Chloride In Plastic Container,Minerals And Electrolytes,Small molecule,1S/2ClH.Zn/h2*1H;/q;;+2/p-2,JIAARYAFYJHUJI-UHFFFAOYSA-L,Cl[Zn]Cl,7646-85-7,Cl2Zn,.,CA00: Nasopharyngitis
D1724,Zinc gluconate,443445,"ZINC GLUCONATE; 4468-02-4; Gluconic Acid Zinc(II) Salt; Zinc gluconate hydrate; Zinc gluconate (USP); UNII-U6WSN5SQ1Z; U6WSN5SQ1Z; Zinc D-gluconate (1:2); Bis(D-gluconato-O1,O2) zinc; Zincgluconate; Zincum gluconicum; Gluconic acid zinc; Zinc(II) Gluconate; Gluconic acid zinc complex; 455.67 (anhydrous); SCHEMBL21280; 12H22O14Zn??xH2O; CHEMBL3833377; CHEBI:29708; DTXSID20894125; AKOS015951235; DB11248; N027; G0277; D02390; A826659; Q-201160; Q3822815; Zinc(II) (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate; zinc (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;Zinc gluconate hydrate",Minerals And Electrolytes,Small molecule,"InChI=1S/2C6H12O7.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1",WHMDKBIGKVEYHS-IYEMJOQQSA-L,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Zn+2],.,C12H22O14Zn,.,.
D1725,Zinc sulfate,24424,"Zinc sulfate; Zinc sulphate; 7733-02-0; Zincate; White vitriol; Zinc sulfate (1:1); Complexonat; Zinklet; Orazinc; Bonazen; Zinkosite; Zincomed; Solvezinc; Solvezink; Optraex; Optised; Medizinc; Neozin; ZnSO4; Zinc sulfate anhydrous; White copperas; Zinc vitriol; Zinci Sulfas; Visine-ac; Prefrin-Z; Zincum Sulfuricum; Zink-Gro; OP-Thal-zin; Bufopto zinc sulfate; Sulfuric acid, zinc salt (1:1); Zinc vitriol (VAN); component of Phenylzin; Caswell No. 927; Zinc Sulfate [USP]; White vitriol (VAN); Zinc sulfate (ZnSO4); Zinc-200; NU-Z",Minerals And Electrolytes,Small molecule,"1S/H2O4S.Zn/c1-5(2,3)4;/h(H2,1,2,3,4);/q;+2/p-2",NWONKYPBYAMBJT-UHFFFAOYSA-L,[O-]S(=O)(=O)[O-].[Zn+2],7733-02-0,O4SZn,35176,5B5K: Mineral deficiency
D1726,Ziprasidone,60854,"146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one;  Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280",Antipsychotic Agents,Small molecule,"1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)",MVWVFYHBGMAFLY-UHFFFAOYSA-N,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,146939-27-7,C21H21ClN4OS,10119,6A20: Schizophrenia
D1727,Zoledronic acid,68740,"Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid",Bone Density Conservation Agents,Small molecule,"1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",XRASPMIURGNCCH-UHFFFAOYSA-N,C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O,118072-93-8,C5H10N2O7P2,46557,5B91: Mineral excesses
D1728,Zolmitriptan,60857,"AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one",Antimigraine Agents,Small molecule,"1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1",ULSDMUVEXKOYBU-ZDUSSCGKSA-N,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,139264-17-8,C16H21N3O2,10124,8A80: Migraine
D1729,Zolpidem,5732,"zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide;  ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem",Anxiolytics/Sedatives/Hypnotics,Small molecule,"1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3",ZAFYATHCZYHLPB-UHFFFAOYSA-N,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,82626-48-0,C19H21N3O,10125,7A00-7A0Z: Insomnia
D1730,Zonisamide,5734,"Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole",Analgesics,Small molecule,"1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",UBQNRHZMVUUOMG-UHFFFAOYSA-N,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,68291-97-4,C8H8N2O3S,.,8A61-8A6Z: Epilepsy/seizure
D1731,Ethionamide,2761171,"Aethionamidum; Aetina; Aetiva; Amidazin; Amidazine; Atina; Ethatyl; Ethimide; Ethina; Ethinamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etimid; Etiocidan; Etionamid; Etionamida; Etionamide; Etioniamid; Etionid; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isothin; Isotiamida; Itiocide; Nicotion; Nisotin; Nizotin; Rigenicid; Sertinon; Teberus; Thianid; Thianide; Thioamide; Thiomid; Thioniden; Tianid; Tiomid; Trecator; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Ethionamid prothionamid; Etionamide [DCIT]; Iridocin Bayer; Trecator SC; Wyeth Brand of Ethionamide; Bayer 5312; Bayer5312; E0695; TH 1314; Alpha-Ethylisonicotinic acid thioamide; Alpha-Ethylisonicotinoylthioamide; Alpha-Ethylisothionicotinamide; Alpha-Ethylthioisonicotinamide; Alpha-ethylt hioisonicotinamide; Ethina (VAN); Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Tio-Mid; Trecator-SC; Alpha-Ethyl-thioisonicotinamide; Trecator-SC (TN); Ethionamide (JP15/USP/INN); Ethionamide [USAN:INN:BAN:JAN]; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; 2-Ethyl-4-thioamidylpyridine; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 2-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethylisonicotinothioamide; 2-Ethylisonicotinoylthioamide; 2-Ethylisothionicotinamide; 2-Ethylthioisonicotinamide; 2-e thylisothionicotinamide; 2-ethyl-4-aminothiocarbonylpyridine; 2-ethylisonicotinic acid thiomide; 2-ethylpyridine-4-carbothioamide; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; 3-Ethylisothionicotinamide",Antituberculosis Agents,Small molecule,"1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)",AEOCXXJPGCBFJA-UHFFFAOYSA-N,CCC1=NC=CC(=C1)C(=S)N,536-33-4,C8H10N2S,4885,1B10-1B14: HIV-infected patients with tuberculosis
D1732,Abaloparatide,145705876,Abaloparatide|Abaloparatide acetate|247062-33-5,Hormone Modulators,Hormones,"InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)",BVISQZFBLRSESR-UHFFFAOYSA-N,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N,CAS 247062-33-5,C174H300N56O49,.,FB83: Low bone mass disorder
D1733,Acyclovir (topical),135398513,acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir,Antiviral Agents,Small molecule,"1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)",MKUXAQIIEYXACX-UHFFFAOYSA-N,C1=NC2=C(N1COCCO)N=C(NC2=O)N,CAS 59277-89-3,C8H11N5O3,CHEBI:2453,1A24-1D9Z: Virus infection; 1F00: Herpes simplex infection
D1734,Agalsidase beta,52918379,Fabrazyme (TN),Metabolic Agents,Protein/peptide,"1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1",KUBARPMUNHKBIQ-VTHUDJRQSA-N,CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O,CAS 928659-70-5,C50H78N4O14,CHEBI:83353,5C50-5D2Z: Metabolic disorder
D1735,Alclometasone (topical),5311000,"Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone",Antiinflammatory Agents,Small molecule,"1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1",FJXOGVLKCZQRDN-PHCHRAKRSA-N,CC1CC2C3C(CC4=CC(=O)C=CC4(C3C(CC2(C1(C(=O)CO)O)C)O)C)Cl,CAS 67452-97-5,C22H29ClO5,CHEBI:53776,1A00-CA43: Postoperative inflammation
D1736,Aloe Vera Leaf,10207,"Aloe-emodin; Aloe emodin; 481-72-1; Aloeemodin; Aloe-emodine; Rhabarberone; EMODINE; 3-Hydroxymethylchrysazin; 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione; 3-Hydroxymethylchrysazine; 1,8-Dihydroxy-3-hydroxymethylanthraquinone; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; NSC 38628; 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione; UNII-C8IYT9CR7C; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)-; CCRIS 3526; EINECS 207-571-7; C8IYT9CR7C; 3-(Hydroxymethyl)chrysazin; BRN 2059062; CHEMBL40275; CHEBI:2607",Herbal Products,Natural product,"1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H2",YDQWDHRMZQUTBA-UHFFFAOYSA-N,C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CO,CAS 481-72-1,C15H10O5,CHEBI:2607,.
D1737,Amcinonide,443958,"Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate",Antiinflammatory Agents,Small molecule,"1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1",ILKJAFIWWBXGDU-MOGDOJJUSA-N,CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CCC5=CC(=O)C=CC54C)F)O)C)OC6(O2)CCCC6,CAS 51022-69-6,C28H35FO7,CHEBI:31199,1A00-CA43: Postoperative inflammation
D1738,Angiotensin II,172198,"Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]",Hormone Modulators,Hormones,"1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1",CZGUSIXMZVURDU-JZXHSEFVSA-N,CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N,CAS 4474-91-3,C50H71N13O12,CHEBI:2719,BA04: Secondary hypertension
D1739,Anidulafungin,166548,Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002,Antiviral Agents,Small molecule,"1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1",JHVAMHSQVVQIOT-MFAJLEFUSA-N,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,CAS 166663-25-8,C58H73N7O17,CHEBI:55346,8A60: Epilepsy; 1D64-1D65COVID-19
D1740,Anti-inhibitor coagulant complex,.,Anti inhibitor coagulant complex; Anti-inhibitor coagulant complex; Antiinhibitor coagulant complex; Factor viii bypassing fraction; Factor viii inhibitor bypassing fraction; Feiba,Coagulation Modifiers,Protein/peptide,.,.,.,.,.,CHEMBL:4297953,.
D1741,Aprotinin,16130295,"Trasylol|Iniprol|Trazinin|Zymofren|APROTININ|BPTI|Riker 52G|Bayer A 128|Pancreatic trypsin inhibitor|RP-9921|UNII-04XPW8C0FL|04XPW8C0FL|9087-70-1|Antilysine|Aprotinina|Aprotinine|Aprotininum|Antagosan|Antikrein|Contrykal|Inhibin|Onquinin|Pantinol|Protimbin|Repulson|Trascolan|Fosten|Gordox|Tzalol|Kir richter|Trypsin inhibitor|Aprotinin solution|APROTININ BOVINE|Basic protease inhibitor|Aprotinine [INN-French]|Aprotininum [INN-Latin]|Aprotinina [INN-Spanish]|Kallikrein-trypsin inactivator|Kunitz and Northrop inhibitor|basic protease inhibitor (BPI)|BAYA0128|GTPL6570|HSDB 7502|Aprotinin [USAN:USP:INN:BAN]|Basic pancreatic trypsin inhibitor|Pancreatic basic trypsin inhibitor|Trypsin inhibitor, pancreatic basic|EINECS 232-994-9|Pancreatic trypsin inhibitor (kunitz)|Trypsin-kallikrein inhibitor (kunitz)|RP 9921|RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA",Serine Protease Inhibitor,Small molecule,"InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147-,148-,149-,150-,151-,152+,153+,154+,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,221-,222-,223-,224-,225-,226-/m0/s1",ZPNFWUPYTFPOJU-LPYSRVMUSA-N,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N6CCC[C@H]6C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CCC(=O)N)[C@@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)[C@@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@@H](C)CC,CAS 9087-70-1,C284H432N84O79S7,.,GA20-GA21: Bleeding disorder
D1742,Avelumab,.,"KXG2PJ551I; 1537032-82-8; Immunoglobulin G1-lambda1, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), homo sapiens monoclonal antibody; MSB-0010718C; UNII-KXG2PJ551I; Avelumab; Avelumab [USAN:INN]; MSB0010718C",Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C30: Melanoma; 2C73: Ovarian cancer; 2A00-2F9Z: Solid tumour/cancer; 2C90: Renal cell carcinoma; 2C34: Neuroendocrine carcinoma
D1743,Azelaic acid (topical),2266,"AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid",Dermatologic Agents,Small molecule,"1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)",BDJRBEYXGGNYIS-UHFFFAOYSA-N,C(CCCC(=O)O)CCCC(=O)O,CAS 123-99-9,C9H16O4,CHEBI:48131,ED80: Acne vulgaris
D1744,Bacillus calmette-guerin substrain tice live antigen,.,"Bacillus calmette-guerin substrain tice live antigen; BCG, Live, Tice Strain; DB10343",Vaccine,Vaccine,.,.,.,.,.,.,.
D1745,Bazedoxifene,154257,Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424,Hormone Modulators,Small molecule,"1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3",UCJGJABZCDBEDK-UHFFFAOYSA-N,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,CAS 198481-32-2,C30H34N2O3,CHEBI:135947,LD24: Skeletal anomaly
D1746,Benzoyl peroxide (topical),7187,"BENZOYL PEROXIDE; 94-36-0; Dibenzoyl peroxide; Peroxide, dibenzoyl; Benzoperoxide; Benzoyl superoxide; Acetoxyl; Lucidol; Panoxyl; Benoxyl; Benzol peroxide; Benzoylperoxid; Asidopan; Persadox; Eloxyl; Mytolac; Oxylite; Benzac; Dibenzoylperoxid; Resdan Akne; Diphenylglyoxal peroxide; Epi-Clear; Persa-Gel; Dry and Clear; Akneroxid 5; Duresthin 5; Nayper BO; Luperco AST; Benzoylperoxyde; Theraderm; Dibenzoylperoxyde; Peroxyde de benzoyle; benzoyl benzenecarboperoxoate; Perossido di benzoile; Lucidol G 20; Lucidol B 50; Benzoic acid, peroxide",Topical Anti-Infectives/Acne Agents,Small molecule,1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H,OMPJBNCRMGITSC-UHFFFAOYSA-N,C1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=CC=C2,CAS 94-36-0,C14H10O4,CHEBI:82405,ED80: Acne vulgaris
D1747,Beta carotene,5280489,"beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]",Vitamins,Small molecule,"1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+",OENHQHLEOONYIE-JLTXGRSLSA-N,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C)C)C,CAS 7235-40-7,C40H56,CHEBI:17579,5B50-5B71: Nutritional deficiency
D1748,Betamethasone (topical),9782,"betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",UREBDLICKHMUKA-DVTGEIKXSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,CAS 378-44-9,C22H29FO5,CHEBI:3077,1A00-CA43: Postoperative inflammation
D1749,Bifidobacterium longum infantis,.,Bifidobacterium longum infantis; Bifidobacterium infantis; Bifidobacterium infantis whole; Bifidobacterium lactentis whole; Bifidobacterium liberorum whole; Bifidobacterium longum bv. infantis whole; Bifidobacterium longum infantis whole; Bifidobacterium longum subsp. infantis; Bifidobacterium longum subsp. infantis whole;DB14222,Flora Modifiers,Probiotic,.,.,.,.,.,.,.
D1750,Bimatoprost (ophthalmic),5311027,"Bimatoprost (topical, alopecia)",Ophthalmic Glaucoma Agents,Small molecule,"1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1",AQOKCDNYWBIDND-FTOWTWDKSA-N,CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O,CAS 155206-00-1,C25H37NO4,CHEBI:51230,ED70: Alopecia; 9C61: Glaucoma
D1751,Bimatoprost (topical ophthalmic),5311027,"Bimatoprost (topical, alopecia)",Ophthalmic Glaucoma Agents,Small molecule,"1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1",AQOKCDNYWBIDND-FTOWTWDKSA-N,CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O,CAS 155206-00-1,C25H37NO4,CHEBI:51230,ED70: Alopecia; 9C61: Glaucoma
D1752,Bupivacaine (liposome),2474,"Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide",Anesthetics,Small molecule,"1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",LEBVLXFERQHONN-UHFFFAOYSA-N,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,CAS 38396-39-3,C18H28N2O,CHEBI:77431,9A76-9A78: Corneal disease; MG30-MG3Z: Pain
D1753,Calcipotriol (topical),5288783,"Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3",Antipsoriatic Agents,Small molecule,"1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1",LWQQLNNNIPYSNX-UROSTWAQSA-N,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,CAS 112965-21-6,C27H40O3,CHEBI:50749,EA90: Psoriasis
D1754,Calcitriol (topical),5280453,"calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101;  Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)",Vitamins/Topical Antipsoriatics,Small molecule,"1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1",GMRQFYUYWCNGIN-NKMMMXOESA-N,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,CAS 32222-06-3,C27H44O3,CHEBI:17823,LC30: Hair/hair growth developmental defect
D1755,Candida albicans,118855431,"Alkaline Proteinase, Tritirachium; Endopeptidase K; Protease K; Proteinase K; Proteinase, Tritirachium Alkaline; Tritirachium Alkaline Proteinase;39450-01-6; (4-nitrophenyl)methyl (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3,4-diphenoxy-5-phosphonooxy-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; Endopeptidase K; EINECS 254-457-8",Allergy Test,Allergenics,"1S/C29H27N2O12P/c1-18(32)23-26(33)30-24(27(34)40-17-19-13-15-20(16-14-19)31(35)36)25(41-21-9-5-3-6-10-21)28(2,29(23,30)43-44(37,38)39)42-22-11-7-4-8-12-22/h3-16,18,23,32H,17H2,1-2H3,(H2,37,38,39)/t18-,23-,28-,29+/m1/s1",OUPAKHMWUJJXOM-ANOMEZDXSA-N?,C[C@H]([C@@H]1C(=O)N2[C@]1([C@](C(=C2C(=O)OCC3=CC=C(C=C3)[N+](=O)[O-])OC4=CC=CC=C4)(C)OC5=CC=CC=C5)OP(=O)(O)O)O  ,39450-01-6,C29H27N2O12P,.,.
D1756,Capromab pendetide,135509147,"Capromab pendetide|guanosine 3',5'-diphosphate|Guanosine-3',5'-Diphosphate|145464-28-4|[(2R,3S,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate|guanosine 3',5'-bis(dihydrogen phosphate)|SCHEMBL2315499|ZINC13507796|Q27464412|[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate",Diagnostic Agents,Monoclonal antibody,"InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6(26-28(21,22)23)3(25-9)1-24-27(18,19)20/h2-3,5-6,9,16H,1H2,(H2,18,19,20)(H2,21,22,23)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1",XYVNHPYNSPGYLI-UUOKFMHZSA-N,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)OP(=O)(O)O)O)N=C(NC2=O)N,.,C10H15N5O11P2,.,.
D1757,Capsaicin (topical),1548943,"Capsaicin (transdermal patch formulation, neuropathic pain)",Topical Analgesic Agent,Small molecule,"1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+",YKPUWZUDDOIDPM-SOFGYWHQSA-N,CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC,CAS 404-86-4,C18H27NO3,CHEBI:3374,8E43: General pain disorder
D1758,Chorionic Gonadotropin (Human),16132030,"beta subunit HCG (123-145); HCG-beta (123-145); human chorionic gonadotropin, beta-subunit (123-145)",Hormone Modulators,Hormones,"1S/C105H169N27O32/c1-11-56(8)81(95(154)117-64(46-55(6)7)99(158)126-37-15-25-71(126)90(149)113-60(104(163)164)32-33-78(107)138)122-94(153)75-29-19-41-130(75)103(162)82(58(10)137)123-84(143)61(47-80(140)141)114-86(145)66(50-134)118-89(148)70-24-13-35-124(70)79(139)48-111-88(147)69-23-14-36-125(69)97(156)62(44-53(2)3)115-83(142)59(22-12-34-110-105(108)109)112-85(144)65(49-133)119-91(150)72-26-17-39-128(72)100(159)68(52-136)121-93(152)73-27-16-38-127(73)98(157)63(45-54(4)5)116-87(146)67(51-135)120-92(151)74-28-18-40-129(74)101(160)77-31-21-43-132(77)102(161)76-30-20-42-131(76)96(155)57(9)106/h53-77,81-82,133-137H,11-52,106H2,1-10H3,(H2,107,138)(H,111,147)(H,112,144)(H,113,149)(H,114,145)(H,115,142)(H,116,146)(H,117,154)(H,118,148)(H,119,150)(H,120,151)(H,121,152)(H,122,153)(H,123,143)(H,140,141)(H,163,164)(H4,108,109,110)/t56-,57-,58+,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,81-,82-/m0/s1",UQHLFCUMFKQWEV-QBBOMDFKSA-N,CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C2CCCN2C(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C3CCCN3C(=O)CNC(=O)C4CCCN4C(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C5CCCN5C(=O)C(CO)NC(=O)C6CCCN6C(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C7CCCN7C(=O)C8CCCN8C(=O)C9CCCN9C(=O)C(C)N,66053-67-6,C105H169N27O32,.,.
D1759,Chromic chloride,.,Chromic Chloride In Plastic Container,Intravenous Nutritional Products,Small molecule,1S/3ClH.Cr/h3*1H;/q;;;+3/p-3,QSWDMMVNRMROPK-UHFFFAOYSA-K,Cl[Cr](Cl)Cl,CAS 10025-73-7,NA,.,1A24-1D9Z: Virus infection
D1760,Citric acid,311,"Citric acid; 77-92-9; Citric acid, anhydrous; citrate; Citro; Anhydrous citric acid; Aciletten; Citretten; Chemfill; Hydrocerol A; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Kyselina citronova; 2-hydroxy-1,2,3-propanetricarboxylic acid; 2-Hydroxytricarballylic acid; Citric acid anhydrous; Caswell No 221C; F 0001 (polycarboxylic acid); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; 2-Hydroxypropanetricarboxylic acid; beta-Hydroxytricarballylic acid; FEMA Number 2306; K-Lyte",Anticoagulants,Small molecule,"1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",KRKNYBCHXYNGOX-UHFFFAOYSA-N,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,CAS 77-92-9,C6H8O7,CHEBI:30769,.
D1761,Clioquinol (topical),2788,clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Iodochloroxyquinoline; Cliquinol; Vioform; Iodochlorohydroxyquinoline; Chlorojodochin; Iodochloroxine; Iodochloroquine; Enteroquinol; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; 5-Chloro-7-iodo-8-quinolinol; Iodochlorhydroxyquinoline; Iodoxyquinoline; Rheaform; Quinoform; Quinambicide; Lekosept; Dioquinol; Dermaform; Iodenterol; Entrokin; Enteroseptol; Domeform; Barquinol,Topical Antifungal Agents,Small molecule,"1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",QCDFBFJGMNKBDO-UHFFFAOYSA-N,C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1,CAS 130-26-7,C9H5ClINO,CHEBI:74460,.
D1762,Clobetasol (topical),5311051,"Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione",Antiinflammatory Agents,Small molecule,"1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",FCSHDIVRCWTZOX-DVTGEIKXSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,CAS 25122-41-2,C22H28ClFO4,CHEBI:205919,ED90: Rosacea; EA91: Lichen planus
D1763,Clocortolone (topical),5311052,"Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione",Topical Glucocorticoids,Small molecule,"1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1",YMTMADLUXIRMGX-RFPWEZLHSA-N,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)Cl)C)F,CAS 4828-27-7,C22H28ClFO4,CHEBI:59582,ED90: Rosacea
D1764,Clomifene,1548953,"Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine",Fertility Agents,Small molecule,"1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+",GKIRPKYJQBWNGO-OCEACIFDSA-N,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,CAS 15690-57-0,C26H28ClNO,CHEBI:3752,GA31: Female infertility
D1765,Coccidioides immitis spherule,.,Coccidioides immitis spherule; DB11294,Allergy Test,Allergenics,.,.,.,.,.,.,.
D1766,Coenzyme M,598,"2-Mercaptoethanesulfonic acid|3375-50-6|2-sulfanylethanesulfonic acid|coenzyme M|2-Mercaptoethanesulphonic acid|HS-CoM|reduced coenzyme M|beta-Mercaptoethanesulfonic acid|UNII-VHD28S0H7F|2-mercaptoethanesulfonate|Ethanesulfonic acid, 2-mercapto-|2-sulfanylethylsulfonate|2-Mercaptoethanesulfonic acid solution|1-THIOETHANESULFONIC ACID|VHD28S0H7F|2-mercaptoethylsulfonate|CoM|CHEBI:17905|Mistabronco|NSC113891|coenzima M|reduced CoM|2-sulfanylethane-1-sulfonic acid|EINECS 222-167-0|Spectrum_000153|2-MERCAPTOETHANE|2-mercaptoethylsulfonic acid|SCHEMBL80705|KBioSS_000633|BIDD:GT0428|DivK1c_000755|2-mercapto-ethanesulfonic acid|CHEMBL1098319|DTXSID8023264|KBio1_000755|KBio2_000633|KBio2_003201|KBio2_005769|2-mercapto-1-ethanesulfonic acid|NINDS_000755|ZINC3831040|AKOS006227755|DB09110|IDI1_000755|NCI60_000306|DB-048487|FT-0603636|C03576|375M506|Q27102715|3190F3F8-4A38-4A3A-85D6-6442B8D6C991|2-Mercaptoethanesulfonic acid solution, for protein sequence analysis, ampule, 3.0 M+/-0.1 M in H2O (T)",Antidotes,Small molecule,"InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)",ZNEWHQLOPFWXOF-UHFFFAOYSA-N,C(CS(=O)(=O)O)S,.,C2H6O3S2,.,.
D1767,Collagenase clostridium histolyticum (topical),18680304,UNII-15Z7208B52; UNII-231982L46K; Collagenase (Clostridium histolyticum gene colG isoenzyme AUX-I); Collagenase (clostridium histolyticum gene colh isoenzyme aux-ii),Collagenase,Protein/peptide,1S/2Ca/q2*+2,XRZGBICBMVJLMH-UHFFFAOYSA-N,[Ca+2].[Ca+2],955089-04-0,Ca2+4,.,FB51?Fibroblastic disorders
D1768,Creatine,586,"Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena",.,Small molecule,"1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)",CVSVTCORWBXHQV-UHFFFAOYSA-N,CN(CC(=O)O)C(=N)N,CAS 57-00-1,C4H9N3O2,CHEBI:16919,8B60: Motor neuron disease
D1769,Deoxycholic acid,222528,"ATX-101, APIM Therapeutics; Proliferating cell nuclear antigen (peptide, cancer), APIM",Cytolytic Agents,Small molecule,"1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1",KXGVEGMKQFWNSR-LLQZFEROSA-N,CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C,CAS 83-44-3,C24H40O4,CHEBI:28834,5B80-5B81: Obesity
D1770,Desonide (topical),5311066,"Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide",Antiinflammatory Agents,Small molecule,"1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1",WBGKWQHBNHJJPZ-LECWWXJVSA-N,CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)C,CAS 638-94-8,C24H32O6,CHEBI:204734,EA80: Atopic eczema
D1771,Desoximetasone (topical),5311067,"Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone",Antiinflammatory Agents,Small molecule,"1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1",VWVSBHGCDBMOOT-IIEHVVJPSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C,CAS 140218-14-0,C22H29FO4,CHEBI:691037,1A00-CA43: Postoperative inflammation
D1772,Dexamethasone (topical),5743,"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone",Antiinflammatory Agents,Small molecule,"1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",UREBDLICKHMUKA-CXSFZGCWSA-N,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,CAS 50-02-2,C22H29FO5,CHEBI:41879,FA20: Rheumatoid arthritis
D1773,Diflorasone (topical),71415,"Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione",Antiinflammatory Agents,Small molecule,"1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1",WXURHACBFYSXBI-XHIJKXOTSA-N,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F,CAS 2557-49-5,C22H28F2O5,CHEBI:59750,ED90: Rosacea
D1774,Difluprednate (ophthalmic),443936,Durezol (TN),Topical Glucocorticoids,Small molecule,"1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1",WYQPLTPSGFELIB-JTQPXKBDSA-N,CCCC(=O)OC1(CCC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C(=O)COC(=O)C,CAS 23674-86-4,C27H34F2O7,CHEBI:31485,MC18: Ocular pain
D1775,Diiodohydroxyquinoline (topical),3728,"iodoquinol; Diiodohydroxyquinoline; 83-73-8; 5,7-diiodoquinolin-8-ol; 5,7-Diiodo-8-hydroxyquinoline; 5,7-Diiodo-8-quinolinol; Diiodoquin; DIIODOHYDROXYQUIN; Yodoxin; Diodoquin; Sebaquin; Diodohydroxyquin; Dijodoxichinoline; 8-Quinolinol, 5,7-diiodo-; Enterodiamoebin; Moebiquin; Floraquin; Enterosept; Dinoleine; Lanodoxin; Embequin; Diodoxylin; Searlequin; Disoquin; Direxiode; Diodoquine; Diamoebin; Quinadome; Fluoraquin; Zoaquin; Ioquin; Dyodin; Di-quinol; Stanquinate; Rafamebin; 5,7-Diiodo-oxine; Ioquin suspension; Dijodoxichinolinum",Antiamoebic Agents,Small molecule,"1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",UXZFQZANDVDGMM-UHFFFAOYSA-N,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,CAS 83-73-8,C9H5I2NO,CHEBI:5950,1A36: Amoebiasis
D1776,Dimercaprol,3080,"DIMERCAPROL|2,3-Dimercapto-1-propanol|59-52-9|2,3-Dimercaptopropanol|Dithioglycerine|Dicaptol|Sulfactin|2,3-Dithiopropanol|dimercaptopropanol|British Anti-Lewisite|1,2-Dithioglycerol|Dimersol|Antoxol|Panobal|British antilewisite|Dimercaprolum|1-Propanol, 2,3-dimercapto-|BAL in Oil|2,3-bis(sulfanyl)propan-1-ol|1,2-Dimercapto-3-propanol|Dimercaprol propanol|Dithioglycerol|2,3-Dimercaptol-1-propanol|Usaf me-1|3-Hydroxy-1,2-propanedithiol|BAL|2,3-Dimercaptopropan-1-ol|alpha,beta-Dithioglycerol|Dimerkaprol|2,3-Mercaptopropanol|Glycerol, 1,2-dithio-|2,3-Mercaptopropan-1-ol|NSC 4646|2,3-disulfanylpropan-1-ol|NSC 39515|1-Propanol, 2,3-dimercapto|CHEBI:64198|Dimercaptol|2,3-dimercapto-propan-1-ol|.alpha.,.beta.-Dithioglycerol|NSC4646|NSC-4646|Glycerol,2-dithio-|MFCD00004864|NSC-39515|2,3-Dimercapto-1-propanol; Dithioglycerol|WLN: SH1YSH1Q|1-Propanol,3-dimercapto-|Sulfactin (VAN)|Dimerkaprol [Czech]|Dimercaprolo [DCIT]|Dithioglycerol (VAN)|Dimercaprolo|Dimercaptopropanol (VAN)|DMP (VAN)|Dimercaprolum [INN-Latin]|2,3-Dimercapro|NSC16865|CCRIS 3616|HSDB 4004|EINECS 200-433-7|BRN 1732058|dithiopropanol|AI3-61820|Anti-Lewisite|Dimercaprol [USP:INN:BAN:JAN]|Spectrum_001965|2, 3-dimercaptopropanol|2,3-dithiopropan-1-ol|Spectrum2_001218|Spectrum4_001275|Spectrum5_001622|BAL (TN)|CHEMBL1597|DSSTox_CID_20461|DSSTox_RID_79496|DSSTox_GSID_40461|SCHEMBL15969|KBioGR_001890|KBioSS_002524|2,3 -dimercapto-1-propanol|2,3,-dimercapto-1-propanol|4-01-00-02770 (Beilstein Handbook Reference)|DivK1c_000997|SPBio_001036|2,3-Disulfanyl-1-propanol #|Dimercaprol (JP17/USP/INN)|DTXSID5040461|HMS503G15|KBio1_000997|KBio2_002516|KBio2_005084|KBio2_007652|NINDS_000997|Pharmakon1600-01500252|BCP18145|HY-B1285|NSC39515|Tox21_110014|BDBM50103608|CCG-39156|NSC760094|s4446|AKOS015895110|DB06782|NSC-760094|CAS-59-52-9|IDI1_000997|NCGC00013216-01|NCGC00344527-01|LS-12962|NCI60_001345|SBI-0051351.P002|DB-053404|CS-0013059|D0621|FT-0625021|C02924|D00167|D89691|AB00051971_02|004D864|2,3-Dimercapto-1-propanol, >=98% (iodometric)|Q413968|SR-05000001839|SR-05000001839-1|W-105317",Antidotes,Small molecule,"1S/C3H8OS2/c4-1-3(6)2-5/h3-6H,1-2H2",WQABCVAJNWAXTE-UHFFFAOYSA-N,C(C(CS)S)O,CAS 59-52-9,C3H8OS2,CHEBI:64198,NE6Z: Unspecific substance harmful effect
D1777,Dinoprostone (topical),5280360,"Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid",Prostaglandins,Small molecule,"1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1",XEYBRNLFEZDVAW-ARSRFYASSA-N,CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O,CAS 363-24-6,C20H32O5,CHEBI:15551,JA00: Abortion
D1778,Dotatate,11170867,Dotatate|DOTA-octreotate|DOTA-TATE|UNII-MRL3739G66|CHEMBL441920|MRL3739G66|177943-88-3|Oxodotreotide|DITA-TATE|DTXSID60170399|BDBM50165166|DB14554|Q5205896,Diagnostic Agents,Small molecule,"InChI=1S/C65H90N14O19S2/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98)/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+/m1/s1",QVFLVLMYXXNJDT-CSBVGUNJSA-N,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O,.,C65H90N14O19S2,.,.
D1779,Dulaglutide,.,GLP-1 analog,Antidiabetic Agents,Protein/peptide,.,.,.,.,.,.,5A11: Type 2 diabetes mellitus
D1780,Emicizumab,.,"7NL2E3F6K3; 1610943-06-0; UNII-7NL2E3F6K3; Emicizumab; Emicizumab [INN]; Immunoglobulin G4-kappa, bispecific, anti-(homo sapiens F9a (activated coagulation factor F9, activated coagulation factor IX) and anti-(homo sapiens F10 (coagulation factor 10, coagulation factor X)), humanized monoclonal antibody; Hemlibra; Emicizumab-kxwh",Coagulation Modifiers,Monoclonal antibody,.,.,.,.,.,.,3B10: Coagulation defect
D1781,Ergoloid mesylate,592735,Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN),Vasodilator Agents,Small molecule,"1S/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39)",YLXBZBPHTNJZQE-UHFFFAOYSA-N,CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O,.,C33H45N5O5,.,8A20: Alzheimer disease
D1782,Ertugliflozin,44814423,"Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7;  PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729",Antidiabetic Agents,Small molecule,"1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1",MCIACXAZCBVDEE-CUUWFGFTSA-N,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,CAS 1210344-57-2,C22H25ClO7,.,5A11: Type 2 diabetes mellitus
D1783,Ethiodized oil,.,"Ethiodized Oil; 8008-53-5; Ethiodized Oil (Injection); Oils, Ethiodized; Ethiodized Oils; Ethiodol; Oil, Ethiodized; Ethiodized Poppy Seed Oil; Lipiodol",Diagnostic Agents,Small molecule,.,.,.,.,.,.,BD9Z: Lymphatic vessel/lymph nodes disorder
D1784,Exenatide,45588096,Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide,Hypoglycemic Agents,Small molecule,"1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1",HTQBXNHDCUEHJF-XWLPCZSASA-N,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,CAS 141758-74-9,C184H282N50O60S,.,BA00-BE2Z: Cardiovascular disease; 5A11: Type 2 diabetes mellitus
D1785,Flumazenil,3373,"flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N;  FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus",Antidotes,Small molecule,"1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3",OFBIFZUFASYYRE-UHFFFAOYSA-N,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CAS 78755-81-4,C15H14FN3O3,CHEBI:5103,PC91: Intentional self-harm
D1786,Fluocinonide (topical),9642,"Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate",Antiinflammatory Agents,Small molecule,"1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1",WJOHZNCJWYWUJD-IUGZLZTKSA-N,CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CC(C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C,CAS 356-12-7,C26H32F2O7,CHEBI:5109,1A00-CA43: Postoperative inflammation
D1787,Fluorescein,16850,Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070,Diagnostic Agents,Small molecule,"1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H",GNBHRKFJIUUOQI-UHFFFAOYSA-N,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,CAS 2321-07-5,C20H12O5,CHEBI:31624,1F00: Herpes simplex infection
D1788,Flurandrenolide (topical),15209,"Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide",Antiinflammatory Agents,Small molecule,"1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",POPFMWWJOGLOIF-XWCQMRHXSA-N,CC1(OC2CC3C4CC(C5=CC(=O)CCC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C,CAS 1524-88-5,C24H33FO6,CHEBI:5127,1A00-CA43: Postoperative inflammation
D1789,Follitropin,.,Follitropin; Follicle stimulating hormone; Follitrophin alfa; Follitrophin alpha; Follitrophin beta; Follitropin alfa; Follitropin alfa/beta; Follitropin alpha; Follitropin beta; Follitropin delta; Follitropin gamma; Follotropin recombinant; FSH; FSH alpha; FSH-a; FSH-b; FSH-beta; Recombinant human follicle stimulating hormone beta,Hormone Modulators,Hormones,.,.,.,.,.,.,.
D1790,Fosfomycin,446987,"FCM; Phosphomycin; Phosphonemycin; Phosphonomycin; Priomicina; Veramina; Disodium fosfomycin; Disodium phosphonomycin; Fosfocina disodium salt; Fosfomycin disodium; Fosfomycin disodium salt; Fosfomycin sodium; Fosfomycin sodium salt; Fosmicin S; Phosphomycin disodium salt; Phosphonomycin disodium salt; Phosphonomycin sodium; Sodium fosfomycin; MK 955; FOM-Na; Fosfomycin sodium (JP15); Fosmicin S (TN); Fosfomycin (USAN/INN); L-cis-1,2-epoxypropylphosphonic acid; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-(9CI); (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonicacid; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; (1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonate; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt",Antibiotics,Small molecule,"1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1",YMDXZJFXQJVXBF-STHAYSLISA-N,CC1C(O1)P(=O)(O)O,CAS 23155-02-4,C3H7O4P,CHEBI:28915,1A00-1C4Z: Bacterial infection
D1791,Gadobenic acid,9852779,Gadobenic acid|Q5516409,Diagnostic Agents,Small molecule,"InChI=1S/C22H31N3O11.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);/q;+3/p-3",MXZROTBGJUUXID-UHFFFAOYSA-K,C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)O)CC(=O)O.[Gd+3],.,C22H28GdN3O11,.,.
D1792,Gadobutrol,6102852,Gadavist (TN),Diagnostic Agents,Small molecule,"1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1",ZPDFIIGFYAHNSK-CTHHTMFSSA-K,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3],CAS 770691-21-9,C18H31GdN4O9,.,5C61: Carbohydrate absorption/transport disorder
D1793,Gadodiamide,153921,Omniscan; Gadodiamide hydrate; DV-7572; GdDTPA-BMA; S-041,Diagnostic Agents,Small molecule,"1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3",HZHFFEYYPYZMNU-UHFFFAOYSA-K,CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],CAS 131410-48-5,C16H26GdN5O8,.,8A04-8D87: Central nervous system disease
D1794,Gadofosveset trisodium,73049652,Gadofosveset trisodium|MS 325; Vasovist|193901-90-5|DB06705,Diagnostic Agents,Small molecule,"InChI=1S/C33H44N3O14P.Gd.3Na/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;/q;+3;3*+1/p-6",XGOSYNSWSRUASG-UHFFFAOYSA-H,C1CC(CCC1OP(=O)([O-])OCC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Na+].[Na+].[Na+].[Gd+3],.,C33H38GdN3Na3O14P,.,.
D1795,Gadopentetic acid,6857474,"Gadopentetic acid|gadopentetate|Gadolinium dtpa|80529-93-7|2-[bis[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]acetate;gadolinium(3+)|Gadolinium diethylenetriamine pentaacetic acid|Gd(H2dtpa)|SCHEMBL180468|CHEBI:35778|DB00789|Q-201143|Q27116583|gadolinium (bis{2-[(carboxylatomethyl)(carboxymethyl)amino]ethyl}amino)acetate|gadolinium(III) 2,2'-(2,2'-(carboxylatomethylazanediyl)bis(ethane-2,1-diyl)bis((carboxymethyl)azanediyl))diacetate",Diagnostic Agents,Small molecule,"InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3",IZOOGPBRAOKZFK-UHFFFAOYSA-K,C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-].[Gd+3],.,C14H20GdN3O10,.,.
D1796,Gadoteric acid,158536,"Gadoteric acid|72573-82-1|Gadoterate|DOTA-Gd|Gd-Dota|UNII-QVF9Y6955W|2-[4,7-bis(carboxylatomethyl)-10-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)|QVF9Y6955W|83678-67-5|Artirem (TN)|Gadoteric acid (INN)|AMY5807|DTXSID001003675|DB09132|D08007|Q1490905|[2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-kappa4N1,N4,N7,N10)tetraacetato(3-)]gadolinium|gadolinium 2,2',2''-[10-(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate",Diagnostic Agents,Small molecule,"InChI=1S/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3",GFSTXYOTEVLASN-UHFFFAOYSA-K,C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],.,C16H25GdN4O8,.,.
D1797,Gadoteridol,60714,ProHance; SQ-32692; GD-HP-DO 3A; Gadolinium-HP-D03A,Diagnostic Agents,Small molecule,"1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3",DPNNNPAKRZOSMO-UHFFFAOYSA-K,CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3],CAS 120066-54-8,C17H29GdN4O7,.,8C70-8E61: Brain disease
D1798,Gadoversetamide,444013,"Optimark; MRI contrast agent, Mallinckrodt",Diagnostic Agents,Small molecule,"1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3",HBEAOBRDTOXWRZ-UHFFFAOYSA-K,COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],CAS 131069-91-5,C20H34GdN5O10,CHEBI:31644,BA41-BA43: Myocardial infarction
D1799,Ganirelix,16130957,Ganirelixum; Orgalutran; Ganirelix acetate; Antagon (TN); Ganirelix (INN); Ganirelix [INN:BAN]; Ganirelixum [INN-Latin]; Orgalutran (TN); RS-26306,Abortifacient Agents,Small molecule,"1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1",GJNXBNATEDXMAK-PFLSVRRQSA-N,CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC,CAS 124904-93-4,C80H113ClN18O13,CHEBI:135910,5A80: Ovarian dysfunction
D1800,Glatiramer,65370,"Glatiramer|28704-27-0|COP-1|(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid|DTXSID50182865",Immunomodulatory Agents,Protein/peptide,"InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6)/t8-;5-;3-;2-/m0000/s1",YLOCGHYTXIINAI-XKUOMLDTSA-N,C[C@@H](C(=O)O)N.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N,.,C23H41N5O11,.,.
D1801,Glucagon,16132283,"glucagon|Glucagonum|Glucagone|His-ser-glu(nh2)-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-glu(NH2)-asp-phe-val-glu(NH2)-trp-leu-met-asp(NH2)-thr|Glucagon-like-immunoreactivity|Glucaton|Bovine glucagon|Human glucagon|Glukagon Novo|Glucagon, pig|Glucagon (dog)|Glucagon (pig)|Glucagon (ox)|Big plasma glucagon|Glucagone [DCIT]|Glucagonum [INN-Latin]|L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-arginyl-L-arginyl-L-alanyl-L-glutaminyl-L-alpha-aspartyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-tryptophyl-L-leucyl-L-methionyl-L-asparaginyl-L-threonine|Glucagon (Xenopus laevis)|Glucagon (Saimiri sciureus)|Glucagon (Mesocricetus auratus)|Glucagon, porcine, for bioassay|Glucagon [USP:INN:BAN:JAN]|SCHEMBL15268863|Gut glucagon-like immunoreactants|HSDB 3337|DTXSID101016809|Glucagon, porcine, for immunoassay|HSQGTFTSDYSKYLDSRRAQDFVQWLMNT|EINECS 232-708-2|NCGC00167140-01|Glucagon, acetate salt, >=97.0% (HPLC)|Human glucagon, European Pharmacopoeia (EP) Reference Standard|His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr|L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-.alpha.-aspartyl-L-seryl-L-arginyl-L-argin yl-L-alanyl-L-glutaminyl-L-.alpha.-aspartyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-tryptophyl-L-leucyl-L-methionyl-L-asparaginyl-|L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-arginyl-L-arginyl-L-alanyl-L-glytaminyl-L-alpha-aspartyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-tryptophyl-L-leucyl-L-methionyl-L-asparaginyl-",Hormone Modulators/Antidiabetic Agents,Hormones,"InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1",MASNOZXLGMXCHN-ZLPAWPGGSA-N,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CN=CN7)N)O,.,C153H225N43O49S,.,5A41: Hypo-glycaemia
D1802,Glucarpidase,21195079,Voraxaze (TN),Antidotes,Small molecule,1S/4Zn/q4*+2,LZQXMCNBQHANEY-UHFFFAOYSA-N,[Zn+2].[Zn+2].[Zn+2].[Zn+2],.,Zn4+8,.,.
D1803,Gonadorelin,638793,"Dirigestran; Factrel; Fertagyl; Gonadorelina; Gonadorelinum; Hypocrine; Kryptocur; LFRH; LHFSHRH; Luforan; Luliberin; Lutal; Lutamin; Lutrefact; Relefact; Relisorm; Dirigestran Spofa; Gonadoliberin I; Gonadotropin releasing hormone; LHFSH Releasing Hormone; LUTEINIZING HORMONE; Lutrepulse KIT; MammalianGnRH; Relisorm l; Synthetic LRF; Synthetic gonadoliberin; HOE 471; AY-24031; FSH-Releasing Hormone; Fertagyl (TN); GnRH-I; Gonadorelin (INN); Gonadorelin [INN:BAN]; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone I; Human LH-RH; LH-FSH Releasing Hormone; LH-Releasing hormone; Luteinizing hormone-releasing hormone; Mammalian LH-RH; Mammalian gonadotropin-releasing hormone; Ovine LH-RH; Ovine gonadotropin-releasing hormone; Porchine LH-RH; Porcine LH-releasing factor; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; Synthetic gonadotropin-releasing hormone; LH-RH (swine); LH-Releasing factor (pig); LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing factor (swine); Luteinizing hormone-releasing hormone (swin); Synthetic LH-FSH-RH; Synthetic decapeptide FSH/LH-RH; Follicle-stimulating hormone-releasing factor (pig); Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Synthetic LH-RH/FSH-RH; Synthetic LH-releasing hormone/FSH-releasing hormone; PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2",Fertility Agents,Small molecule,"1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1",XLXSAKCOAKORKW-AQJXLSMYSA-N,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,CAS 9034-40-6,C55H75N17O13,CHEBI:5520,5A60-5A61: Pituitary gland disorder
D1804,Halcinonide (topical),443943,Halog; Halog-e,Topical Glucocorticoids,Small molecule,"1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1",MUQNGPZZQDCDFT-JNQJZLCISA-N,CC1(OC2CC3C4CCC5=CC(=O)CCC5(C4(C(CC3(C2(O1)C(=O)CCl)C)O)F)C)C,CAS 3093-35-4,C24H32ClFO5,CHEBI:31663,EA00-EM0Z: Skin disease
D1805,Hepatitis B Immune Globulin,.,Anti-HBV polyclonal antibodies,Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,1E50-1E51: Hepatitis virus infection
D1806,Hexaminolevulinate,6433083,"Hexaminolevulinate|Hexyl 5-amino-4-oxopentanoate|5-Aminolevulinic acid hexyl ester|140898-97-1|UNII-G7H20TKI67|G7H20TKI67|Hexyl 5-aminolevulinate|Aminolevulinic acid hexyl ester|Pentanoic acid, 5-amino-4-oxo-, hexyl ester|starbld0000848|SCHEMBL1070663|CHEMBL1201784|5-aminolevulinic acid hexyl-ester|DTXSID40161487|CHEBI:134892|ZINC1554392|DB06261|4-Hexyloxycarbonyl-2-oxobutylammoniumchloride|Q27095709",Malignancy Photosensitizers,Small molecule,"InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3",RYQOILLJDKPETL-UHFFFAOYSA-N,CCCCCCOC(=O)CCC(=O)CN,.,C11H21NO3,.,.
D1807,Histamine,774,"Eramin; Ergamine; Histamine; Histaminum; Istamina; Theramine; Free histamine; Histamine Base; Histamine [USAN]; Istamina [Italian]; H7125_SIGMA; [3H]histamine; ALBB-005968; Beta-Aminoethylglyoxaline; Beta-Aminoethylimidazole; Beta-aminothethylglyoxaline; Histamine (DCF); Histamine, Free Base; Histaminum (TN); L-histamine; ZERO/004089; Imidazole-4-ethylamine; Beta-Imidazolyl-4-ethylamine; F411C768-A159-4FC0-A195-291A08BB03AA; 1H-Imidazole-4-ethanamine; 1H-Imidazole-5-ethanamine; 2-(1H-Imidazol-4-yl)ethanamine; 2-(1H-imidazol-4-yl)ethan-1-amine; 2-(1H-imidazol-5-yl)ethanamine; 2-(3H-Imidazol-4-yl)-ethylamine; 2-(4-Imidazolyl)ethylamine; 2-Imidazol-4-ylethylamine; 2-[4-Imidazolyl]ethylamine; 4-(2-Aminoethyl)-1H-imidazole; 4-Imidazoleethylamine; 5-Imidazoleethylamine",Antiallergic Agents,Small molecule,"1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)",NTYJJOPFIAHURM-UHFFFAOYSA-N,C1=C(NC=N1)CCN,CAS 51-45-6,C5H9N3,CHEBI:18295,4A80-4A8Z: Allergic/hypersensitivity disorder
D1808,Human adenovirus e serotype 4 strain cl-68578 antigen,.,"Human adenovirus e serotype 4 strain cl-68578 antigen; Adenovirus Type 4 Strain Cl-68578; Adenovirus Type 4 Vaccine Live; Adenovirus Vaccine, Live, Oral, Type 4; Human Adenovirus E Serotype 4 Strain Cl-68578; Human Adenovirus Serotype 4 Strain Cl-68578; Human Adenovirus Serotype 4 Vaccine Strain Cl-68578; Mastadenovirus Human Adenovirus B Type 4 Strain Cl-68578; DB14409",Vaccine,Vaccine,.,.,.,.,.,.,.
D1809,Human rabies virus immune globulin,.,"Human rabies virus immune globulin; Rabies immune globulin; Rabies immune globulin (human); Rabies immune globulin human; Rabies immune globulin, human; Rabies immune globulin,human; Rabies immunoglobulin (human); Rabies immunoglobulins; DB11603",Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D1810,Human vaccinia virus immune globulin,.,Human vaccinia virus immune globulin; Human vaccinia immune globulin; Vaccinia immune globulin; Vaccinia immune globulin intravenous (human); Vaccinia immunoglobulins; VIG; DB14112,Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D1811,Human Varicella-Zoster Immune Globulin,.,Human Varicella-Zoster Immune Globulin; Human herpesvirus 3 immune globulin; Varicella zoster immune globulin; Varicella zoster immune globulin (human); Varicella zoster immune globulin human; Varicella zoster immunoglobulin (human); Varicella-zoster immune globulin; Varicella-zoster immune globulin human; VZV immune globulin; DB11621,Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,.
D1812,Hyaluronidase,91820602,"Hyaluronidase|37326-33-3|9001-54-1|6-(3,3-dimethyl-2-methylideneindol-1-yl)hexanoic acid;hydrobromide|1-Bromo-2,6-difluoro-3,5-dimethoxybenzene[2,6-difluoro-3,5-dimethoxybromobenzene|4-Amine-3-fluoropyridine|Pyridine 2-fluoro-3-methanol|4-Chloro-2-fluoro acetophenone|Pyridine2-chloro-3-boronic acid|Methyl 3-amino-5-fluoro benzoate|Methyl 2-Fluoro-3-nitro benzoate|Methyl 3-Fluoro-5-nitro benzoate|Pridine-4-methoxy-3-carboxaldehyde|Pyridine 4-methoxy-3-carboxaldehyde|Pyridine 3-methyl-5-carboxylic acid|s4424|AKOS025293742|AS03872|AS04570|AS04571|AS04678|AS04679|AS04680|AS04681|AS04689|AS04690|AS04692|AS04693|AS04734|AS04739|AS04772|AS04776|AS04777|AS04808|AS04814|AS04815|AS04830|AS04831|AS04832|AS04839|AS04842|AS04852|AS04853|AS04856|AS04859|AS04860|AS04861|AS04874|AS04880|AS04882|AS04929|AS04930|AS04935|AS04940|AS04942|AS04951|AS04955|AS04956|AS04957|AS04976|AS04979|AS05266|AS05636|AS05678|AS05679|AS05764|AS05765|AS05766|AS05914|AS05925|AS05926|AS06193|AS06617|AS06673|AS06716|AS06745|AS06771|Pyridine2-fluoro-6-methyl- 5-methanol|2-Fluoro-4-(trifluoromethylbenzaldehyde|3'-5'-Dimethoxy-4'-methylacetophenone|Pyridine2-Chloro-3-fluoro-5-boronicacid|5-Chloro-2-Isopropylamine-4-iodopyridine|PYRIDINE 2-FLUORO-3-BORONIC ACID|PYRIDINE 2-FLUORO-4-BORONIC ACID|PYRIDINE 2-FLUORO-5-BORONIC ACID|Pyridine2-fluoro-3-methyl-5-boronic acid|3-AMINE-4-FLUOROPHENYLBORONIC ACID|Pridine-2-chloro-6-methyl-3-boronic acid|PYRIDINE 2-CHLORO-3-CARBOXALDEHYDE|PYRIDINE 2-FLUORO-3-CARBOXALDEHYDE|Pyridine 2-fluoro-4-iodo-3-carboxaldehyde|PYRIDINE 2-FLUORO-6-CARBOXALDEHYDE|Pyridine2-Chloro-5-fluoro-4-carboxaldehyde|Pyridine 6-Fluoro-2-methyl-3-carboxaldehyde|Pyridine 5-fluoro-2-methoxy-4-carboxaldehyde|PYRIDINE 2-FLUORO-6-METHYL-3-BORONIC ACID|3-Methyl-5-[3,5-bis(trifluoromethyl)phenylpyridine|PYRIDINE 2-CHLORO-5-FLUORO-6-CARBOXALDEHYDE|PYRIDINE 5-FLUORO-2-METHOXY-3-CARBOXALDEHYDE|Methyl6-Chloro-2-[2,4-bis(chlorophenyl)pyridinebenzoate|(R)-ethyl 2-(4-fluorophenyl)-2-(4-oxopiperidin-1-yl)acetate HCl",Absorption Enhancers,Protein/peptide,"InChI=1S/C17H23NO2.BrH/c1-13-17(2,3)14-9-6-7-10-15(14)18(13)12-8-4-5-11-16(19)20;/h6-7,9-10H,1,4-5,8,11-12H2,2-3H3,(H,19,20);1H",SVMKEDBUSSWSFY-UHFFFAOYSA-N,CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br,.,C17H24BrNO2,.,.
D1813,Hydrocortisone (topical),5754,Cortisol; Acticort; Cetacort; Hydrasson; Hydrocortisyl; Cobadex; Hycort; Signef; Hytone; Cortef; 17-Hydroxycorticosterone; Optef,Antiviral Agents,Small molecule,"1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1",JYGXADMDTFJGBT-VWUMJDOOSA-N,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,CAS 50-23-7,C21H30O5,CHEBI:17650,1D64-1D65: COVID-19
D1814,Icatibant,6918173,Firazyr; Icatibant [INN]; HOE 140; HOE140; JE049; WIN 65365; Hoe-140; WIN-65365; D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK,Antiinflammatory Agents,Small molecule,"1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1",QURWXBZNHXJZBE-SKXRKSCCSA-N,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,CAS 130308-48-4,C59H89N19O13S,.,4A00: Innate/adaptive immunodeficiency
D1815,Icosapent,446284,"Eicosapentaenoic acid|Timnodonic acid|Icosapent|10417-94-4|Icosapentaenoic acid|EPA|cis-5,8,11,14,17-Eicosapentaenoic acid|5,8,11,14,17-EICOSAPENTAENOIC ACID|(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid|Icosapento|Icosapentum|5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid|(all-Z)-5,8,11,14,17-Eicosapentaenoic acid|UNII-AAN7QOV9EA|eicosapentaenoate|(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid|Icosapent [INN]|(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid|5,8,11,14,17-Icosapentaenoic acid|CCRIS 3279|AAN7QOV9EA|(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid|Omega-3-Carboxylic Acids|CHEMBL460026|(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate|all-cis-5,8,11,14,17-icosapentaenoic acid|CHEBI:28364|all-cis-icosa-5,8,11,14,17-pentaenoic acid|Icosapent (INN)|cis-Delta(5,8,11,14,17)-eicosapentaenoic acid|5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-|Icosapentaenoate|(all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid|C20:5n-3,6,9,12,15|MFCD00065716|cis-5,8,11,14,17-EPA|NCGC00161344-03|EICOSAPENTAENOIC ACID (20:5 n-3)|all-cis-5,8,11,14,17-eicosapentaenoic acid|Miraxion|Eicosapentanoic acid|Eye Q|Eye-Q|5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-|EPA [drug]|Icosapentum [INN-Latin]|Icosapento [INN-Spanish]|(5Z,8Z,11Z,14Z,17Z)-icosapentaenoate|Timnodonate|3gwx|FA 20:5|all cis-5,8,11,14,17-Eicosapentaenoic Acid|Ropufa 70|Incromega e 7010sr|all-cis-icosapentaenoate|all-cis-icosapentaenoic acid|DSSTox_CID_21023|DSSTox_RID_79612|DSSTox_GSID_41023|SCHEMBL20469|BSPBio_001328|EPA 45G|BML3-B01|GTPL3362|DTXSID9041023|HMS1361C10|HMS1791C10|HMS1989C10|HMS3402C10|HMS3649D19|All-cis-fatty acid 20:5 omega-3|HY-B0660|ZINC4474603|5,8,11,14,17-Icosapentaenoate|Eicosapentaenoic acid (c20:5 n3)|Tox21_111991|1755AH|5,8,11,14,17-Eicosapentaenoate|BDBM50242349|LMFA01030759|s6476|AKOS027470327|CCG-207957|CCG-208136|DB00159|cis-5,8,11,14,17-eicosapentaenoate|IDI1_033798|NCGC00161344-01|NCGC00161344-02|NCGC00161344-04|NCGC00161344-07|5Z,8Z,11Z,14Z,17Z-Eicosapentaenoate|AC-31072|AS-53730|C20:5 (n-3)|CAS-10417-94-4|E0441|5,8,11,14,17-Eicosapentaenoic acid (6CI)|all cis-5,8,11,14,17-Icosapentaenoic Acid|C06428|D08061|P16966|(all-cis)-5,8,11,14,17-Eicosapentaenoic acid|L001256|Q409990|SR-01000946647|J-001125|SR-01000946647-1|z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid|(Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid|BRD-K47192521-001-02-1|cis-5,8,11,14,17-Eicosapentaenoic acid, >=99%|7F8BF016-B146-4F72-A52E-B9298BA3A9AB|C20H30O2 (cis-5,8,11,14,17-eicosapentaenoic acid)|Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-|5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI)|cis-5,8,11,14,17-Eicosapentaenoic acid, >=85%, liquid|UNII-317SQ4W8IJ component JAZBEHYOTPTENJ-JLNKQSITSA-N|UNII-71M78END5S component JAZBEHYOTPTENJ-JLNKQSITSA-N|UNII-9B22238JYI component JAZBEHYOTPTENJ-JLNKQSITSA-N|UNII-F85N2YHE4E component JAZBEHYOTPTENJ-JLNKQSITSA-N|cis-5,8,11,14,17-Eicosapentaenoic acid, analytical standard|Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3)|(5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid|(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid|cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid|5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI)|cis-5,8,11,14,17-Eicosapentaenoic acid, 500 mug/mL in ethanol, certified reference material",Dietary Supplement,Small molecule,"1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-",JAZBEHYOTPTENJ-JLNKQSITSA-N,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,CAS 10417-94-4,C20H30O2,CHEBI:28364,3B14: Inherited coagulation factor deficiency; 5C80: Hyper-lipoproteinaemia
D1816,Imiglucerase,.,Cerezyme (TN),Metabolic Agents,Protein/peptide,.,.,.,.,.,.,5C56: Lysosomal disease
D1817,Indium In-111 oxyquinoline,16685037,indium 8-quinolinolate|AKOS002375061|Q27282981,Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/3C9H7NO.In/c3*11-8-5-1-3-7-4-2-6-10-9(7)8;/h3*1-6,11H;/q;;;+3/p-3",AEGSYIKLTCZUEZ-UHFFFAOYSA-K,C1=CC2=C(C(=C1)O[In](OC3=CC=CC4=C3N=CC=C4)OC5=CC=CC6=C5N=CC=C6)N=CC=C2,CAS 65389-08-4,C27H18InN3O3,.,.
D1818,Indium In-111 pentetate,76967078,"UNII-5K3UP561AX|5K3UP561AX|Indium In 111 pentetate|Indium (111In) pentetic acid|INDIUM IN-111 PENTETATE|Indate(2-)-111In, (N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinato(5-))-, dihydrogen|135998-32-2",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C14H23N3O10.In/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3/i;1-4",BLALCKLYSDDAOC-JWFOFJTQSA-K,[H+].[H+].C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[111In+3],.,C14H20InN3O10,.,.
D1819,Indium In-111 pentetreotide,131704321,Indium In-111 pentetreotide|Indium In 111 Pentreotide|Indium (111in) pentetreotide|DB11835,Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C62H84N12O19S2.In/c1-35(76)47(32-75)69-59(88)49-34-95-94-33-48(70-55(84)44(25-37-13-5-3-6-14-37)65-50(78)29-74(31-52(81)82)24-23-73(30-51(79)80)22-20-41(61(90)91)62(92)93)58(87)67-45(26-38-15-7-4-8-16-38)56(85)68-46(27-39-28-64-42-18-10-9-17-40(39)42)57(86)66-43(19-11-12-21-63)54(83)72-53(36(2)77)60(89)71-49;/h3-10,13-18,28,35-36,41,43-49,53,64,75-77H,11-12,19-27,29-34,63H2,1-2H3,(H,65,78)(H,66,86)(H,67,87)(H,68,85)(H,69,88)(H,70,84)(H,71,89)(H,72,83)(H,79,80)(H,81,82)(H,90,91)(H,92,93);/q;+3/p-4/i;1-4",ZKZPXKKVDJOAIS-JWFOFJTQSA-J,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=N1)[O-])CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N=C(CN(CCN(CCC(C(=O)O)C(=O)O)CC(=O)[O-])CC(=O)[O-])[O-])C(=O)NC(CO)C(C)O)O.[111In+3],.,C62H80InN12O19S2-,.,.
D1820,Inulin,24763,Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27,Hypoglycemic Agents,Small molecule,"1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1",JYJIGFIDKWBXDU-MNNPPOADSA-N,C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O,CAS 9005-80-5,C228H382O191,.,MG02: Kidney malfunction
D1821,Iobenguane (I-123),60860,"Iobenguane|m-Iodobenzylguanidine|80663-95-2|Metaiodobenzylguanidine|meta-Iodobenzylguanidine|3-Iodobenzylguanidine|2-[(3-iodophenyl)methyl]guanidine|UNII-35MRW7B4AD|MIBG|Guanidine, ((3-iodophenyl)methyl)-|139755-80-9|Guanidine,N-[(3-iodophenyl)methyl]-|1-(3-Iodobenzyl)guanidine|2-(3-Iodobenzyl)guanidine|35MRW7B4AD|(3-Iodobenzyl)guanidine|NCGC00015572-04|SR-01000075167|Prestwick-07A11|starbld0001019|Iobenguane (127-i)|meta-iodobenzyl guanidine|Prestwick0_000490|Prestwick1_000490|Prestwick2_000490|Prestwick3_000490|Lopac-I-9890|2-m-iodo-benzyl guanidine|CHEMBL818|Lopac0_000644|BSPBio_000359|SCHEMBL140591|SPBio_002280|BPBio1_000395|((3-iodophenyl)methyl)guanidine|DTXSID4048438|CHEBI:92769|1-[(3-iodophenyl)methyl]guanidine|ZINC1538318|CCG-204731|DB06704|SDCCGSBI-0050624.P002|NCGC00015572-01|NCGC00015572-02|NCGC00015572-03|NCGC00015572-06|NCGC00015572-09|NCGC00162211-01|DA-02654|Q3154058|SR-01000075167-1|BRD-K43860855-065-03-6",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)",PDWUPXJEEYOOTR-UHFFFAOYSA-N,C1=CC(=CC(=C1)I)CN=C(N)N,.,C8H10IN3,.,.
D1822,Iodide I-123,135300,Iodide ion I-123|iodine-123(1-)|UNII-98QPV8670C|69239-56-1|98QPV8670C|I-123|Iodide-123|Iodide (123I(1-))|Iodine 123|Iodide I-123|(~123~I)Iodide|DTXSID40988959|DB09420|123I-|Q3801335,Diagnostic Radiopharmaceuticals,Small molecule,InChI=1S/HI/h1H/p-1/i1-4,XMBWDFGMSWQBCA-AHCXROLUSA-M,[123I-],.,I-,.,.
D1823,Iodine,807,"7553-56-2|I|Iodine|Molecular iodine|Diiodine|Iodine crystals|Iodine solution|Iodine sublimed|Tincture iodine|Vistarin|Eranol|Iodio|Iode|Iosan superdip|Jood|Iodine-127|Iodine tincture|Iodine colloidal|Iodine Tincture USP|Ethanolic solution of iodine|Iodine ((127)I2)|Jod [German, Polish]|Iodum|I2|12190-71-5|UNII-9679TC07X4|MFCD00011355|Jod|CHEBI:17606|Iodine, crystalline|NSC-42355|9679TC07X4|Iodine Solution, Wijs|Actomar|Iodio [Italian]|Jod (GERMAN, POLISH)|Jood [Dutch]|IODE [French]|Caswell No. 501|diiodane|HSDB 34|Iodine (resublimed)|CCRIS 9223|Iodine [USP:JAN]|EINECS 231-442-4|NSC 42355|EPA Pesticide Chemical Code 046905|Jodosan|Tegodyne|iodine-iodide|iodonium iodide|Diatomic iodine|Iodine strong|Iodine mild|AI3-08544|Iodine,|Iodine, elemental|Iodine, resublimed|I2I|Cadex (TN)|Iodine, ACS reagent|Iodine Solution, 1N|IODINE-MOLECULE|Iodine lump, ultra dry|Iodine solution, 5 mM|Iodine (JP17/USP)|Iodine solution, 0.5 M|EC 231-442-4|Iodine, resublimed crystals|DSSTox_CID_14672|DSSTox_RID_79188|Iodine solution, 0.05 M|DSSTox_GSID_34672|Iodine Solution, 5%, Lugol|Iodine 0.1N Standard Solution|CHEMBL1201225|DTXSID7034672|Iodine, 99.99% metals basis|Iodine, AR, >=99.8%|Iodine, LR, >=99.5%|Iodine , LUGOL's Solution 5%|AMY39508|BCP31677|NSC42355|Iodine, 1.0N Standardized Solution|Tox21_301294|MFCD00164163|Iodine Solution, 0.02N (N/50)|Iodine, 0.01N Standardized Solution|AKOS015902439|Iodine spheres, ultra dry, -10 mesh|DB05382|Iodine, 99.999% trace metals basis|Iodine, SAJ first grade, >=99.0%|MCULE-3297948557|Iodine, >=99.99% trace metals basis|Iodine, USP, 99.8-100.5%|Iodine, JIS special grade, >=99.8%|Iodine, Vetec(TM) reagent grade, 99%|NCGC00257544-01|BP-21210|Iodine, ACS reagent, >=99.8%, solid|Iodine, ReagentPlus(R), >=99%, chips|CAS-7553-56-2|Iodine, purum p.a., >=99.5% (RT)|Diiodine;IODUM; Jood; Iode; Jod; LUGOL|Iodine, resublimed crystals, Puratronic(R)|FT-0627248|FT-0696506|I0604|C01382|D00108|Iodine, 1.0N Standardized Solution in Ethanol|Iodine, ReagentPlus(R), >=99.8% (titration)|Q2064483|Iodine, puriss., >=99.5% (RT), particles (round)|Iodine spheres, ultra dry, -10 mesh, 99.998% metals basis|Iodine, anhydrous, beads, -10 mesh, 99.999% trace metals basis|Iodine, ReagentPlus(R), 99.7% trace metals basis, beads, 1-3 mm|Iodide, Ion chromatography standard solution, Specpure, I- 1000g/ml|Iodine, 0.1N Standardized Solution in water, contain 1-2% Potassium iodide|Iodine Solution (0.02M in THF/pyridine/H2O 70:20:10), for DNA synthesis|Iodine Solution (0.05M in THF/H2O/pyridine 70:20:10), for DNA synthesis|Iodine, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%",Nutritional Supplements,Small molecule,InChI=1S/I2/c1-2,PNDPGZBMCMUPRI-UHFFFAOYSA-N,II,.,I2,.,.
D1824,Iodine (topical),807,"7553-56-2|I|Iodine|Molecular iodine|Diiodine|Iodine crystals|Iodine solution|Iodine sublimed|Tincture iodine|Vistarin|Eranol|Iodio|Iode|Iosan superdip|Jood|Iodine-127|Iodine tincture|Iodine colloidal|Iodine Tincture USP|Ethanolic solution of iodine|Iodine ((127)I2)|Jod [German, Polish]|Iodum|I2|12190-71-5|UNII-9679TC07X4|MFCD00011355|Jod|CHEBI:17606|Iodine, crystalline|NSC-42355|9679TC07X4|Iodine Solution, Wijs|Actomar|Iodio [Italian]|Jod (GERMAN, POLISH)|Jood [Dutch]|IODE [French]|Caswell No. 501|diiodane|HSDB 34|Iodine (resublimed)|CCRIS 9223|Iodine [USP:JAN]|EINECS 231-442-4|NSC 42355|EPA Pesticide Chemical Code 046905|Jodosan|Tegodyne|iodine-iodide|iodonium iodide|Diatomic iodine|Iodine strong|Iodine mild|AI3-08544|Iodine,|Iodine, elemental|Iodine, resublimed|I2I|Cadex (TN)|Iodine, ACS reagent|Iodine Solution, 1N|IODINE-MOLECULE|Iodine lump, ultra dry|Iodine solution, 5 mM|Iodine (JP17/USP)|Iodine solution, 0.5 M|EC 231-442-4|Iodine, resublimed crystals|DSSTox_CID_14672|DSSTox_RID_79188|Iodine solution, 0.05 M|DSSTox_GSID_34672|Iodine Solution, 5%, Lugol|Iodine 0.1N Standard Solution|CHEMBL1201225|DTXSID7034672|Iodine, 99.99% metals basis|Iodine, AR, >=99.8%|Iodine, LR, >=99.5%|Iodine , LUGOL's Solution 5%|AMY39508|BCP31677|NSC42355|Iodine, 1.0N Standardized Solution|Tox21_301294|MFCD00164163|Iodine Solution, 0.02N (N/50)|Iodine, 0.01N Standardized Solution|AKOS015902439|Iodine spheres, ultra dry, -10 mesh|DB05382|Iodine, 99.999% trace metals basis|Iodine, SAJ first grade, >=99.0%|MCULE-3297948557|Iodine, >=99.99% trace metals basis|Iodine, USP, 99.8-100.5%|Iodine, JIS special grade, >=99.8%|Iodine, Vetec(TM) reagent grade, 99%|NCGC00257544-01|BP-21210|Iodine, ACS reagent, >=99.8%, solid|Iodine, ReagentPlus(R), >=99%, chips|CAS-7553-56-2|Iodine, purum p.a., >=99.5% (RT)|Diiodine;IODUM; Jood; Iode; Jod; LUGOL|Iodine, resublimed crystals, Puratronic(R)|FT-0627248|FT-0696506|I0604|C01382|D00108|Iodine, 1.0N Standardized Solution in Ethanol|Iodine, ReagentPlus(R), >=99.8% (titration)|Q2064483|Iodine, puriss., >=99.5% (RT), particles (round)|Iodine spheres, ultra dry, -10 mesh, 99.998% metals basis|Iodine, anhydrous, beads, -10 mesh, 99.999% trace metals basis|Iodine, ReagentPlus(R), 99.7% trace metals basis, beads, 1-3 mm|Iodide, Ion chromatography standard solution, Specpure, I- 1000g/ml|Iodine, 0.1N Standardized Solution in water, contain 1-2% Potassium iodide|Iodine Solution (0.02M in THF/pyridine/H2O 70:20:10), for DNA synthesis|Iodine Solution (0.05M in THF/H2O/pyridine 70:20:10), for DNA synthesis|Iodine, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%",Nutritional Supplements,Small molecule,InChI=1S/I2/c1-2,PNDPGZBMCMUPRI-UHFFFAOYSA-N,II,.,I2,.,.
D1825,Ioflupane I-123,3086674,Datscan (TN),Diagnostic Radiopharmaceuticals,Small molecule,"1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4",HXWLAJVUJSVENX-HFIFKADTSA-N,COC(=O)C1C2CCC(N2CCCF)CC1C3=CC=C(C=C3)I,CAS 155798-07-5,C18H23FINO2,CHEBI:68855,8A00: Parkinsonism
D1826,Iopanoic acid,3735,NSC 41706,Diagnostic Agents,Small molecule,"1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)",OIRFJRBSRORBCM-UHFFFAOYSA-N,CCC(CC1=C(C(=C(C=C1I)I)N)I)C(=O)O,CAS 96-83-3,C11H12I3NO2,CHEBI:5951,BE2Z: Circulatory system disease
D1827,Lactobacillus acidophilus,.,Lactobacillus Acidophilus Freeze-Drying Powder; Lactobacillus Acidophilus Freeze-Drying Powder; Lactobacillus Acidophilus,Flora Modifiers,Probiotic,.,.,.,.,.,.,.
D1828,Latanoprost (ophthalmic),5311221,"Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate",Antihypertensive Agents,Small molecule,"1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1",GGXICVAJURFBLW-CEYXHVGTSA-N,CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O,CAS 130209-82-4,C26H40O5,CHEBI:6384,9C61: Glaucoma; 1F00: Herpes simplex infection
D1829,Latanoprostene bunod (ophthalmic),11156438,"Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb",Ophthalmic Glaucoma Agents,Small molecule,"1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1",LOVMMUBRQUFEAH-UIEAZXIASA-N,C1C(C(C(C1O)CC=CCCCC(=O)OCCCCO[N+](=O)[O-])CCC(CCC2=CC=CC=C2)O)O,CAS 860005-21-6,C27H41NO8,.,9C61: Glaucoma; 2C90: Renal cell carcinoma
D1830,Leucovorin,135403648,"folinic acid|leucovorin|5-Formyltetrahydrofolic acid|58-05-9|Folinic acid-SF|Welcovorin|Acide folinique|5-Formyl-5,6,7,8-tetrahydrofolic acid|folinate|N5-Formyltetrahydrofolic acid|10-Formyl-7,8-dihydrofolic acid|Leucal|N5-Formyl-5,6,7,8-tetrahydrofolic acid|5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid|CHEBI:15640|(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid|(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate|HSDB 6544|N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid|Leucoverin|1492-18-8|[3H]folinic acid|NSC3590|Leucovorinum (acid)|Leucovorin [USAN]|CHEMBL69905|5-Formyl-tetrahydrofolate|Leucovorinum|Levocovorin|5-Formyltetrahydropteroylglutamic acid|Citrovoeum factor|EINECS 200-361-6|L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid|L-(+)-Folinic acid|Spectrum_000859|Prestwick0_000738|Prestwick1_000738|Prestwick2_000738|Prestwick3_000738|Spectrum2_000116|Spectrum3_000479|Spectrum4_000031|Spectrum5_000910|SCHEMBL8349|CHEMBL1679|5-formyltetrahydro-folic acid|BSPBio_000696|BSPBio_002218|KBioGR_000461|KBioSS_001339|DivK1c_000222|SPBio_000132|SPBio_002635|BPBio1_000766|GTPL4816|GTPL6690|DTXSID0048216|SCHEMBL10068238|KBio1_000222|KBio2_001339|KBio2_003907|KBio2_006475|KBio3_001438|NINDS_000222|DW385|BDBM50039121|MFCD00867488|s5790|AKOS015961207|DB00650|IDI1_000222|AC-13429|HY-17556|L-Glutamic acid, N-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-|SBI-0051427.P003|SD-204098|D93089|BRD-A75919782-238-01-8|Q45435667|(2S)-2-(4-((2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methylamino)benzamido)pentanedioic acid|(2S)-2-[(4-{[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid|(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid|(S)-2-{4-[(2-Amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid|2-{4-[(2-Amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid|Glutamic acid, N-(p-(((2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-, L-|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-|N-[4-({[2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid|N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6(RS)-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid",Folate Supplements,Small molecule,"1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1",VVIAGPKUTFNRDU-ABLWVSNPSA-N,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,CAS 58-05-9,C20H23N7O7,CHEBI:15640,.
D1831,Levocarnitine,10917,"Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine;  Nicetile (TN); L-Carnitine",Nutritional Supplements,Small molecule,"1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1",PHIQHXFUZVPYII-ZCFIWIBFSA-N,C[N+](C)(C)CC(CC(=O)[O-])O,CAS 541-15-1,C7H15NO3,CHEBI:16347,5B50-5B71: Nutritional deficiency; 6D71: Mild neurocognitive disorder
D1832,Levoleucovorin,135398559,FUSILEV (TN),Folate Supplements,Small molecule,"1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1",VVIAGPKUTFNRDU-STQMWFEESA-N,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,CAS 68538-85-2,C20H23N7O7,CHEBI:63606,3A00-3A9Z: Anemia
D1833,Levomefolic acid,135398561,"Levomefolic acid|Levomefolinic acid|31690-09-2|LMSR|LEVOMEFOLATE|Metafolin|L-methylfolate|5-Methyltetrahydrofolate|L-5-Methyltetrahydrofolate|UNII-8S95DH25XC|(S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid|L-5-MTHF|(6S)-5-methyltetrahydrofolate|8S95DH25XC|(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid|CHEBI:15641|(6s)-5-methyltetrahydrofolic acid|C20H25N7O6|[(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate|N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid|Metafolin (TN)|N-[4-({[(6S)-2-AMINO-4-HYDROXY-5-METHYL-5,6,7,8-TETRAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID|5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID|134-35-0|N-[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid|Levomefolinic acid [USAN]|Levomefolicacid|L-5-Methyltetrahydrofolic acid|5-Methyltetrahydropteroyl monoglutamate|THH|5- methyltetrahydrofolate|SCHEMBL79586|Levomefolic acid (USAN/INN)|Levomefolic acid [USAN:INN]|CHEMBL1231574|SCHEMBL12704423|(6S)-5-MTHF|(See also L375720)''|DTXSID00185583|CHEBI:136009|AMY39069|N-[4-[[[(6S)-2-Amino-5-methyl-1,4,5,6,7,8-hexahydro-4-oxopteridine-6-yl]methyl]amino]benzoyl]-L-glutamic acid|ZINC2005305|5-methyl-(6s)-tetrahydrofolic acid|3779AH|BDBM50391007|MFCD00870135|s6909|AKOS025402272|AC-7460|CS-1067|DB11256|NCGC00378841-01|NCGC00485934-01|HY-14781|L-Glutamic acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, (S)-|L0335|(6s)-5-methyl-5,6,7,8-tetrahydrofolic acid|C00440|D09353|690L092|Q192553|J-018513|Levomefolic acid 100 microg/mL in Acetonitrile:Water|UNII-TYK22LML8F component ZNOVTXRBGFNYRX-STQMWFEESA-N|(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid|(2S)-2-{[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid|L-Glutamic acid, N-[4-[[(2-amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-|N-(4-((((6S)-2-Amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamic acid|N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acid|N-{[4-({[(6S)-2-amino-4-hydroxy-5-methyl-5,6,7,8-tetrahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid|N-{[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid",Folate Supplements,Small molecule,"InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1",ZNOVTXRBGFNYRX-STQMWFEESA-N,CN1[C@H](CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,.,C20H25N7O6,.,.
D1834,Levomefolic acid (calcium),135398561,"Levomefolic acid|Levomefolinic acid|31690-09-2|LMSR|LEVOMEFOLATE|Metafolin|L-methylfolate|5-Methyltetrahydrofolate|L-5-Methyltetrahydrofolate|UNII-8S95DH25XC|(S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid|L-5-MTHF|(6S)-5-methyltetrahydrofolate|8S95DH25XC|(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid|CHEBI:15641|(6s)-5-methyltetrahydrofolic acid|C20H25N7O6|[(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate|N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid|Metafolin (TN)|N-[4-({[(6S)-2-AMINO-4-HYDROXY-5-METHYL-5,6,7,8-TETRAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID|5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID|134-35-0|N-[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid|Levomefolinic acid [USAN]|Levomefolicacid|L-5-Methyltetrahydrofolic acid|5-Methyltetrahydropteroyl monoglutamate|THH|5- methyltetrahydrofolate|SCHEMBL79586|Levomefolic acid (USAN/INN)|Levomefolic acid [USAN:INN]|CHEMBL1231574|SCHEMBL12704423|(6S)-5-MTHF|(See also L375720)''|DTXSID00185583|CHEBI:136009|AMY39069|N-[4-[[[(6S)-2-Amino-5-methyl-1,4,5,6,7,8-hexahydro-4-oxopteridine-6-yl]methyl]amino]benzoyl]-L-glutamic acid|ZINC2005305|5-methyl-(6s)-tetrahydrofolic acid|3779AH|BDBM50391007|MFCD00870135|s6909|AKOS025402272|AC-7460|CS-1067|DB11256|NCGC00378841-01|NCGC00485934-01|HY-14781|L-Glutamic acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, (S)-|L0335|(6s)-5-methyl-5,6,7,8-tetrahydrofolic acid|C00440|D09353|690L092|Q192553|J-018513|Levomefolic acid 100 microg/mL in Acetonitrile:Water|UNII-TYK22LML8F component ZNOVTXRBGFNYRX-STQMWFEESA-N|(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid|(2S)-2-{[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid|L-Glutamic acid, N-[4-[[(2-amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-|N-(4-((((6S)-2-Amino-5-methyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamic acid|N-[4-[[[(6S)-2-Amino-3,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-L-glutamic acid|N-{[4-({[(6S)-2-amino-4-hydroxy-5-methyl-5,6,7,8-tetrahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid|N-{[4-({[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid",Folate Supplements,Small molecule,"InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1",ZNOVTXRBGFNYRX-STQMWFEESA-N,CN1[C@H](CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,.,C20H25N7O6,.,.
D1835,Lidocaine (ophthalmic),3676,"Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide",Anesthetics,Small molecule,"1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",NNJVILVZKWQKPM-UHFFFAOYSA-N,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CAS 137-58-6,C14H22N2O,CHEBI:6456,9A76-9A78: Corneal disease; GA34: Female pelvic pain
D1836,Lipoic acid,6112,"Lipoic acid; lipoic acid; 1200-22-2; (R)-lipoic acid; R-(+)-alpha-Lipoic acid; (R)-5-(1,2-Dithiolan-3-yl)pentanoic acid; Heparlipon; Thioctic acid d-form; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-alpha-Lipoic acid; (R)-1,2-Dithiolane-3-pentanoic acid; Tioctic Acid; D-Thioctic acid; R-(+)-Thioctic acid; (R)-alpha-Lipoic acid; (R)-(+)-lipoic acid; (R)-6,8-thioctic acid; lipoate; (R)-1,2-Dithiolane-3-valeric Acid; 5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid; (R)-(+)-Lipoate; UNII-VLL71EBS9Z; R-Lipoic acid; INV-144",Antioxidants,Small molecule,"1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)/t7-/m1/s1",AGBQKNBQESQNJD-SSDOTTSWSA-N,C1CSSC1CCCCC(=O)O,CAS 1200-22-2,C8H14O2S2,CHEBI:30314,GB61: Chronic kidney disease
D1837,Lubiprostone,157920,"Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid",Anticonstipation Agents,Small molecule,"1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1",WGFOBBZOWHGYQH-MXHNKVEKSA-N,CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,CAS 333963-40-9,C20H32F2O5,.,DC32: Chronic pancreatitis
D1838,Lyme disease vaccine (recombinant OspA),.,Lyme disease vaccine (recombinant OspA); Lipoprotein OspA antigen recombinant; Lipoprotein outer surface a borrelia burgdorferi antigen; OspA lipoprotein; DB00045,Vaccine,Vaccine,.,.,.,.,.,.,.
D1839,Measles virus vaccine live attenuated,.,"Measles vaccine (live); Measles virus live antigen; Measles virus live antigen, a; Measles virus vaccine live; Measles virus vaccine, live; Measles, live attenuated; Measles-k; CHEMBL2109211",Vaccine,Vaccine,.,.,.,.,.,.,.
D1840,Mebrofenin,54158,"MEBROFENIN|78266-06-5|Choletec|SQ 26962|UNII-7PV0B6ED98|(3-BROMO-2,4,6-TRIMETHYLPHENYLCARBAMOYL)METHYLIMINODIACETIC ACID|2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid|SQ-26962|7PV0B6ED98|NCGC00181297-01|Mebrofenine|Mebrofenino|Mebrofeninum|Mebrofenine [INN-French]|Mebrofeninum [INN-Latin]|Mebrofenino [INN-Spanish]|EINECS 278-877-6|Mebrofenin [USAN:USP:INN:BAN]|MFCD00216974|((((3-Bromomesityl)carbamoyl)methyl)imino)diacetic acid|Mebrofenin (USP/INN)|DSSTox_CID_26891|DSSTox_RID_81994|N-(2-((3-Bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)glycine|DSSTox_GSID_46891|SCHEMBL135229|CHEMBL1605443|DTXSID1046891|CHEBI:135608|ZINC537957|HY-B1684|Tox21_112775|s3587|FC-3501|2,2'-((2-((3-Bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)azanediyl)diacetic acid|Glycine, N-(2-((3-bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)-|CAS-78266-06-5|DB-056297|CS-0013655|FT-0628182|D04869|SR-01000944486|SR-01000944486-1|Q27268694|(3-Bromo-2,4,6-trimethylphenylcarbamoyl)methyliminodiacetic acid, AldrichCPR|2,2'-((2-((3-Bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)azanediyl)diaceticacid|2,2'-(2-(3-bromo-2,4,6-trimethylphenylamino)-2-oxoethylazanediyl)diacetic acid|2,2'-[[2-[(3-bromo-2,4,6-trimethylphenyl)amino]-2-oxoethyl]imino]bisacetic acid",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C15H19BrN2O5/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23)",MHPZZZZLAQGTHT-UHFFFAOYSA-N,CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C,.,C15H19BrN2O5,.,.
D1841,Medrysone (ophthalmic),247839,"Hydroxymesterone; Medrifar; Medritonic; Medrocort; Visudrisone; Medrysone (USAN); U-8471; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone",Topical Glucocorticoids,Small molecule,"1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1",GZENKSODFLBBHQ-ILSZZQPISA-N,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)CC4)C)O)C)C(=O)C,CAS 2668-66-8,C22H32O3,CHEBI:34829,9A02: Eyelid inflammatory disorder
D1842,Menotropins,.,Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP),Hormone Modulators,Hormones,.,.,.,.,.,.,GA31: Female infertility
D1843,Methyl salicylate (topical),4133,"methyl salicylate; Methyl 2-hydroxybenzoate; 119-36-8; Wintergreen oil; Gaultheria oil; Betula oil; Teaberry oil; Sweet birch oil; OIL OF WINTERGREEN; Analgit; Spicewood Oil; Wintergruenoel; 2-Hydroxybenzoic acid methyl ester; Gaultheriaoel; Flucarmit; Exagien; Betula; Methyl o-hydroxybenzoate; 2-Carbomethoxyphenol; 2-(Methoxycarbonyl)phenol; Natural Wintergreen Oil; Betula Lenta; BIRCH-ME; Salicylic acid, methyl ester; Synthetic Wintergreen Oil; Benzoic acid, 2-hydroxy-, methyl ester; Gaultheria oil, artificial; Wintergreen Oil, syn",Topical Anti-Irritants,Small molecule,"1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3",OSWPMRLSEDHDFF-UHFFFAOYSA-N,COC(=O)C1=CC=CC=C1O,CAS 119-36-8,C8H8O3,CHEBI:31832,.
D1844,Methylprednisolone (topical),6741,Depo-medrol; M-predrol; Medrol; Medrol Acetate,Antiviral Agents,Small molecule,"1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1",VHRSUDSXCMQTMA-PJHHCJLFSA-N,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,CAS 83-43-2,C22H30O5,CHEBI:6888,NB31: Injury; 1D64-1D65COVID-19
D1845,Metyrapone,4174,"MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one",Antimetabolites,Small molecule,"1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3",FJLBFSROUSIWMA-UHFFFAOYSA-N,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CAS 54-36-4,C14H14N2O,CHEBI:44241,5A70: Cushing syndrome
D1846,Migalastat,176077,"DDIG; D-Galactitol, 1,5-dideoxy-1,5-imino; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-iminogalactitol; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride",Metabolic Agents,Small molecule,"1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1",LXBIFEVIBLOUGU-DPYQTVNSSA-N,C1C(C(C(C(N1)CO)O)O)O,CAS 108147-54-2,C6H13NO4,CHEBI:135923,5C56: Lysosomal disease
D1847,Miglustat,51634,"BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol",Anti-Hiv Agents,Small molecule,"1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1",UQRORFVVSGFNRO-UTINFBMNSA-N,CCCCN1CC(C(C(C1CO)O)O)O,CAS 72599-27-0,C10H21NO4,CHEBI:50381,5C56: Lysosomal disease
D1848,Minoxidil (topical),4201,"Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide",Antihypertensive Agents,Small molecule,"1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2",ZIMGGGWCDYVHOY-UHFFFAOYSA-N,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,CAS 38304-91-5,C9H15N5O,CHEBI:6942,BA00-BA04: Hypertension
D1849,Mumps virus strain B level jeryl lynn live antigen,.,"Mumps virus strain B level jeryl lynn live antigen; Mumps Virus Vaccine Live, Jeryl Lynn Strain; DB10316",Vaccine,Vaccine,.,.,.,.,.,.,.
D1850,Octasulfur (topical),66348,"Octathiocane|Octasulfur|Cyclooctasulfur|Sulphur yellow 2|10544-50-0|Cyclic octaatomic sulfur|Sulfur, mol. (S8)|1326-66-5|UNII-70FD1KFU70|70FD1KFU70|Cyclooctasulfane|Schwefelblum|Cyclooctasulphur|Sulfur octamer|alpha-Sulfur|Cyclic sulfur S8|Sulfur molecule (S8)|CHEBI:29385|DTXSID80872924|NSC603623|AKOS015903681|DB09353|FT-0689075|FT-0700849|Q7076759|From culture broth of actinomycete, strain TO 447(Streptomyces albulus)",Minerals And Electrolytes,Small molecule,InChI=1S/S8/c1-2-4-6-8-7-5-3-1,JLQNHALFVCURHW-UHFFFAOYSA-N,S1SSSSSSS1,.,S8,.,.
D1851,Oseltamivir,65028,Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV,Antiviral Agents,Small molecule,"1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1",VSZGPKBBMSAYNT-RRFJBIMHSA-N,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,CAS 196618-13-0,C16H28N2O4,CHEBI:7798,1E30: Influenza; 1D64-1D65COVID-19
D1852,Oxybuprocaine (ophthalmic),4633,"Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]",Anesthetics,Small molecule,"1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3",CMHHMUWAYWTMGS-UHFFFAOYSA-N,CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N,CAS 99-43-4,C17H28N2O3,CHEBI:309594,9A76-9A78: Corneal disease
D1853,Oxygen,977,"7782-44-7|O|Oxygen|Molecular oxygen|oxygen molecule|Dioxygen|Pure oxygen|Oxygenium|Liquid oxygen|Hyperoxia|Sauerstoff|Oxygen-16|Oxygen (liquid)|Oxygen, liquified|Oxygenium medicinale|oxygene|CCRIS 1228|HSDB 5054|O2|UN1072|UN1073|UNII-S88TT14065|Peroxide Ion|CHEBI:15379|S88TT14065|LOX|E948|E-948|Oxygene [French]|Oxigeno [Spanish]|OXY|Compressed oxygen|Oxygen [USP]|EINECS 231-956-9|dioxidanediyl|dioxygene|Disauerstoff|oxygen monoxide|Peroxy radical|singlet dioxygen|triplet dioxygen|Oxygen USP|Oxygen, compressed|Oxygen 93 percent|singlet molecular oxygen|triplet molecular oxygen|Oxygen (8CI,9CI)|Oxygen (JP17/USP)|dioxygen(2.) (triplet)|Oxygen, >=99.6%|Oxygen, compressed [UN1072] [Nonflammable gas]|RNS60 COMPONENT OXYGEN|[OO]|INS NO.948|Oxygen, >=99.998%|CHEMBL1234886|DTXSID2037681|RNS-60 COMPONENT OXYGEN|CHEBI:26689|CHEBI:27140|INS-948|Oxygen, refrigerated liquid (cryogenic liquid) [UN1073] [Nonflammable gas]|DB09140|UN 1072|UN 1073|Oxygen, Messer(R) CANGas, 99.999%|DS-014940|(1)O2|E 948|C00007|D00003|O2(2.)|Oxygen, refrigerated liquid (cryogenic liquid)|Oxygen, compressed [UN1072]  [Nonflammable gas]|(O2)(..)|(O2)(2.)|Q5203615|UNII-K21NZZ5Y0B component MYMOFIZGZYHOMD-UHFFFAOYSA-N|AQUANAL(TM)-plus oxygen (O2) 1-12 mg/L, refill pack for 37428|AQUANAL(TM)-plus oxygen (O2) 1-12 mg/L, test set with color comparator|4-Chloro-3-(chloro-difluoro-methyl)-4,4-difluoro-1-thiophen-2-yl-but-2-en-2-one|Oxygen, refrigerated liquid (cryogenic liquid) [UN1073]  [Nonflammable gas]",Nutritional Supplements,Small molecule,InChI=1S/O2/c1-2,MYMOFIZGZYHOMD-UHFFFAOYSA-N,O=O,.,O2,.,.
D1854,Oxyquinoline (topical),1923,"8-HYDROXYQUINOLINE; quinolin-8-ol; 8-quinolinol; 148-24-3; Oxyquinoline; Oxine; Quinophenol; 8-Quinol; 8-Oxyquinoline; Phenopyridine; Oxychinolin; Bioquin; Oxybenzopyridine; Oxin; Hydroxybenzopyridine; 1-Azanaphthalene-8-ol; Tumex; 8-Chinolinol; 8-Hydroxychinolin; 8-OQ; 8-Hydroxy-chinolin; Fennosan H 30; Fennosan; o-Oxychinolin; 8-Oxychinolin; Usaf ek-794; Fennosan HF-15; NCI-C55298; NSC 2039; Oxyquinoline [USAN]; Caswell No. 719; Oxoquinoline; 8-Chinolinol [Czech]; o-Oxychinolin [German]; Quinoline, 8-hydroxy-; NSC 615011; UNII-5UTX5635HP",Topical Agents,Small molecule,"1S/C9H7NO/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11H",MCJGNVYPOGVAJF-UHFFFAOYSA-N,C1=CC2=C(C(=C1)O)N=CC=C2,CAS 148-24-3,C9H7NO,CHEBI:48981,.
D1855,Palifermin,.,Kepivance; Kepivance (TN); Palifermin (USAN/INN),Antimucositis Agents,Protein/peptide,.,.,.,.,.,.,DA01: Oral mucositis
D1856,Papaya,61446,"1,1-Dimethyl-3-phenylpropyl isobutyrate; Dmpec isobutyrate; UNII-G0GW9X884I; Propanoic acid, 2-methyl-, 1,1-dimethyl-3-phenylpropyl ester; BETA PHENYL ETHYL DIMETHYL CARBINYL ISOBUTYRATE; Dmpec 2-methylpropanoate; Dimethyl phenethyl carbinyl isobutyrate; papaya isobutyrate",Allergy Test,Allergenics,"1S/C15H22O2/c1-12(2)14(16)17-15(3,4)11-10-13-8-6-5-7-9-13/h5-9,12H,10-11H2,1-4H3",WCEXWNUHYPYHDN-UHFFFAOYSA-N,CC(C)C(=O)OC(C)(C)CCC1=CC=CC=C1,10031-71-7,C15H22O2,.,.
D1857,Parathyroid hormone,.,"NPH-002; NPH-004; oral parathyroid hormone (osteoporosis), Nobex",Hormone Modulators,Hormones,.,.,.,.,.,.,.
D1858,Pegademase,.,130167-68-9; Pegademase Bovine; Pegademase [INN]; Adagen; Pegademase; Polyethylene glycol-modified adenosine deaminase; pegADA; PEG-ADA,Immunostimulants,Protein/peptide,.,.,.,.,.,.,.
D1859,Pegaptanib (ophthalmic),56603655,Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838,Antiangiogenic Agents,Aptamer,"InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)/t19-/m0/s1",WLCZTRVUXYALDD-IBGZPJMESA-N,COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC,.,C22H44N3O10P,.,9B71: Retinopathy
D1860,Pegloticase,.,Krystexxa (TN),Antihyperuricemic Agents,Protein/peptide,.,.,.,.,.,.,FA25: Gout
D1861,Pegvaliase,86278362,BMN 165; Pegvaliase [INN]; UNII-N6UAH27EUV; N6UAH27EUV,Metabolic Agents,Protein/peptide,"1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1",NPOCDVAOUKODSQ-ZDUSSCGKSA-N,COCCOCCCCCC(=O)NCCCCC(C(=O)O)N,CAS 1585984-95-7,C15H30N2O5,.,5C50: Metabolism inborn error
D1862,Pegvisomant,.,Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN),Anabolic Agents,Hormones,.,.,.,.,.,.,5A60-5A61: Pituitary gland disorder
D1863,Penciclovir (topical),135398748,penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2,Antiviral Agents,Small molecule,"1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)",JNTOCHDNEULJHD-UHFFFAOYSA-N,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,CAS 39809-25-1,C10H15N5O3,CHEBI:7956,1C62: Human immunodeficiency virus disease; 1D64-1D65COVID-19
D1864,Pentetic acid,3053,An-dtpa; Dtpa; Mpi Dtpa Kit - Chelate,Antidotes,Small molecule,"1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)",QPCDCPDFJACHGM-UHFFFAOYSA-N,C(CN(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O,CAS 67-43-6,C14H23N3O10,CHEBI:35739,.
D1865,Pertussis vaccine,.,"Adsorbed purified pertussis vaccine; Bordetella pertussis; Haemophilus pertussis whole; Hemophilus pertussis whole; Microbe de la coqueluche whole; Pertussis vaccine; Pertussis, purified antigen; CHEMBL2109219",Vaccine,Vaccine,.,.,.,.,.,.,.
D1866,Pertuzumab,.,Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor),Antineoplastics,Monoclonal antibody,.,.,.,.,.,.,2C60-2C6Y: Breast cancer
D1867,Plecanatide,70693500,Trulance,Laxatives,Small molecule,"1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1",NSPHQWLKCGGCQR-DLJDZFDSSA-N,CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC(C)C)C(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)N)N,CAS 467426-54-6,C65H104N18O26S4,.,DD91: Irritable bowel syndrome; DC32: Chronic pancreatitis; DD70: Crohn disease
D1868,Pralidoxime,135398747,"pralidoxime|Pralidoximum|2-PAM|UNII-P7MU9UTP52|PRALIDOXIME CHLORIDE|P7MU9UTP52|6735-59-7|2-[(E)-(hydroxyimino)methyl]-1-methylpyridinium|Pralidoxime ion|1-Methyl-2-pyridinium aldoxime|Pralidoxime cation|Pyridinium, 2-((hydroxyimino)methyl)-1-methyl-, iodide|NSC7760|NSC164614|Pralidoxime [INN:BAN]|94-63-3|CHEBI:8354|Pralidoxime (3)|Pyridinium, 2-((hydroxyimino)methyl)-1-methyl-, chloride|FP1|EINECS 229-787-0|Pralidoxime [VANDF]|Pralidoxime [MART.]|Pralidoxime [WHO-DD]|Prestwick2_000943|Prestwick3_000943|Spectrum5_001138|C07400|BSPBio_000906|BSPBio_003115|SCHEMBL439968|BPBio1_000998|DTXSID1044144|HSDB 8490|BDBM234367|STL371214|AKOS005207264|DB00733|MCULE-9475708961|IDI1_000770|25615-00-3|2-((Hydroxyimino)methyl)-1-methylpyridinium|AB00513971|AB00572627_09|(2E)-1-methylpyridin-1-ium-2-carbaldehyde oxime|(NE)-N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine",Antidotes,Small molecule,"InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1",JBKPUQTUERUYQE-UHFFFAOYSA-O,C[N+]1=CC=CC=C1/C=N/O,.,C7H9N2O+,.,.
D1869,Prednicarbate (topical),6714002,"Dermatop; Peitel; Dermatop (TN); Hoe-777; S-77 0777; S-770777; Prednicarbate (USP/INN); [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate",Antiinflammatory Agents,Small molecule,"1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1",FNPXMHRZILFCKX-KAJVQRHHSA-N,CCC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)OC(=O)OCC,CAS 73771-04-7,C27H36O8,CHEBI:135791,1A00-CA43: Postoperative inflammation
D1870,Proparacaine (ophthalmic),4935,"Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester",Anesthetics,Small molecule,"1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3",KCLANYCVBBTKTO-UHFFFAOYSA-N,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CAS 499-67-2,C16H26N2O3,CHEBI:8485,9A76-9A78: Corneal disease
D1871,Pyrantel,708857,"PYRANTEL; Pyrequan; 15686-83-6; Strongid; Pirantele [DCIT]; Pyrantelum; Pirantel; Pyrantel [INN:BAN]; Pyrantelum [INN-Latin]; Pirantel [INN-Spanish]; UNII-4QIH0N49E7; HSDB 3252; EINECS 239-774-1; CHEBI:8654; 4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; Pirantele; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; Pin-X",Anthelmintics,Small molecule,"1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+",YSAUAVHXTIETRK-AATRIKPKSA-N,CN1CCCN=C1C=CC2=CC=CS2,CAS 15686-83-6,C11H14N2S,CHEBI:8654,1F90: Parasitic worm infestation
D1872,Pyridoxine,1054,"Aderoxin; Alestrol; Becilan; Beesix; Benadon; Bonasanit; Godabion; Hexavibex; Hexermin; Hexermine; Hexobion; Nestrex; Paxadon; Pydox; Pyridipca; Pyridox; Spondylonal; Vitaped; Adermin hydrochloride; Adermine hydrochloride; Aderomine hydrochloride; Component of Alestrol; Hexabione hydrochloride; PN HCl; PYRIDOXINE HYDROCHLORIDE; Pyridoxin hydrochloride; Pyridoxine HCl; Pyridoxine chloride; Pyridoxine hydrogen chloride; Pyridoxine monohydrochloride; Pyridoxinium chloride; Pyridoxinum hydrochloricum; Pyridoxol hydrochloride; Rodex TD; AIDS006784; Campoviton 6; Vitamin V6; AIDS-006784; Cernevit-12; Pyridoxine (INN); Pyridoxine Hydrochloride (B6); Pyridoxine hydrochloride[USAN:JAN]; Pyridoxine, hydrochloride; Pyridoxine-HCl Microencapsulated; Pyridoxinum hydrochloricum (Hungarian); Pyridoxol, hydrochloride; Rodex (R); Vitamin B6-hydrochloride; Vitamin V6 (TN); Vitamin-B6 hydrochloride; Hexa-Betalin (R); Hexa-betalin (TN); Pyridoxine hydrochloride (JP15/USP); Tex Six T.R.; PYRIDOXINE HYDROCHLORIDE, U.S.P.; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 2-methyl-4,5-dimethylol-pyridin-3-ol; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; 4-Deoxypyridoxine 5'-phosphate; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride",Vitamins,Small molecule,"1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3",LXNHXLLTXMVWPM-UHFFFAOYSA-N,CC1=NC=C(C(=C1O)CO)CO,CAS 65-23-6,C8H11NO3,CHEBI:16709,5B55-5B5F: Vitamin deficiency
D1873,Pyrophosphoric acid,1023,pyrophosphoric acid; phosphonooxyphosphonic acid,Diagnostic Radiopharmaceuticals,Small molecule,"1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)",XPPKVPWEQAFLFU-UHFFFAOYSA-N,OP(=O)(O)OP(=O)(O)O,CAS 2466-09-3,H4O7P2,CHEBI:29888,.
D1874,Quinupristin,5388937,"Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA",Antibiotics,Small molecule,"1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1",WTHRRGMBUAHGNI-LCYNINFDSA-N,CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CC(C(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CSC6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C,CAS 120138-50-3,C53H67N9O10S,.,1A00-1C4Z: Bacterial infection
D1875,Ranibizumab (ophthalmic),.,Ranibizumab; Ranibizumab biosimilar pf582; SB-11; SB11 (RANIBIZUMAB BIOSIMILAR); CHEMBL1201825,Anti-Angiogenic Ophthalmic Agents,Monoclonal antibody,.,.,.,.,.,CHEMBL:1201825,.
D1876,Ravulizumab,.,Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210,Selective Immunosuppressants,Monoclonal antibody,.,.,.,.,.,.,3A20-3A2Z: Haemolytic anemia
D1877,Regadenoson,219024,Lexiscan (TN),Diagnostic Agents,Small molecule,"1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1",LZPZPHGJDAGEJZ-AKAIJSEGSA-N,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,CAS 313348-27-5,C15H18N8O5,CHEBI:135613,.
D1878,Resorcinol (topical),5054,"resorcinol; 108-46-3; 1,3-Benzenediol; Resorcin; 1,3-Dihydroxybenzene; benzene-1,3-diol; m-Hydroquinone; 3-Hydroxyphenol; m-Hydroxyphenol; m-Dihydroxybenzene; Resorcine; m-Dioxybenzene; m-Benzenediol; Dihydroxybenzol; Resorzin; Developer O; Developer R; Developer RS; Fouramine RS; Fourrine EW; Pelagol RS; Pelagol Grey RS; Resorcinolum; Fourrine 79; Nako TGG; Durafur developer G; Phenol, m-hydroxy-; C.I. Developer 4; Benzene, m-dihydroxy-; C.I. Oxidation Base 31; Rcra waste number U201; Sulforcin; Rezamid; Resorcino; Benzene, 1,3-dihydroxy-",Topical Antipsoriatics/Acne Agents,Small molecule,"1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H",GHMLBKRAJCXXBS-UHFFFAOYSA-N,C1=CC(=CC(=C1)O)O,CAS 108-46-3,C6H6O2,CHEBI:27810,.
D1879,Rifamycin,6324616,"Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus",Antituberculosis Agents,Small molecule,"1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1",HJYYPODYNSCCOU-ODRIEIDWSA-N,CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,CAS 6998-60-3,C37H47NO12,CHEBI:29673,ME05: Bowel habit change; 1A00-CA43: Postoperative inflammation
D1880,Rimexolone (ophthalmic),5311412,"Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)",Ophthalmic Steroids,Small molecule,"1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1",QTTRZHGPGKRAFB-OOKHYKNYSA-N,CCC(=O)C1(C(CC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)C)C,CAS 49697-38-3,C24H34O3,CHEBI:135566,FA20: Rheumatoid arthritis
D1881,Rotavirus vaccine,.,"Rotavirus vaccine; Rota virus, live attenuated; Rotavirus vaccine, live, oral; DB10276",Vaccine,Vaccine,.,.,.,.,.,.,5A11: Type 2 diabetes mellitus; 2A00-2F9Z: Solid tumour/cancer
D1882,Rubella virus vaccine,.,"Rubella virus vaccine; Rubella virus (vaccine strain ra27/3) live antigen; Rubella virus live antigen, A; Rubella virus strain wistar ra 27/3 live (attenuated) antigen; Rubella virus strain wistar ra 27/3 live antigen; Rubella virus vaccine live (wistar ra 27-3 strain); Rubella virus vaccine,live; Rubella, live attenuated; Rubivirus rubella virus wistar ra 27/3 whole; DB10317",Vaccine,Vaccine,.,.,.,.,.,.,.
D1883,Salicylic acid (topical),338,"Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart;  Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE",Antiinflammatory Agents,Small molecule,"1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",YGSDEFSMJLZEOE-UHFFFAOYSA-N,C1=CC=C(C(=C1)C(=O)O)O,CAS 69-72-7,C7H6O3,CHEBI:16914,EA81: Seborrhoeic dermatitis
D1884,Sapropterin,135398654,"Sapropterin|tetrahydrobiopterin|62989-33-7|R-THBP|6R-BH4|Sapropterina|Sapropterinum|Dapropterin|(6R)-L-erythro-tetrahydrobiopterin|5,6,7,8-tetrahydrobiopterin|Kuvan|Sapropterin [INN]|6R-5,6,7,8-Tetrahydrobiopterin|6R-L-5,6,7,8-Tetrahydrobiopterin|L-erythro-tetrahydrobiopterin|Sapropterin (INN)|UNII-EGX657432I|tetrahydro-l-biopterin|(6R)-5,6,7,8-Tetrahydrobiopterin|2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone|(-)-(6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone|(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one|CHEBI:59560|(6R)-L-erythro-5,6,7,8-Tetrahydrobiopterin|tetra-H-biopterin|(6R)-5,6,7,8-TETRAHYDRO-L-BIOPTERIN|EGX657432I|tetra-hydro-biopterin|(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-1H-pteridin-4-one|17528-72-2|(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(1H)-one|(R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(1H)-one|5,6,7,8-tetra-H-biopterin|BH4|(6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(1H)-one|4(1H)-Pteridinone, 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-, (6r)-|Sapropterin [MI]|Sapropterin [VANDF]|(6R)-Tetrahydrobiopterin|Sapropterin [EMA EPAR]|Sapropterinum [INN-Latin]|Sapropterina [INN-Spanish]|Tetrahydrobiopterin [WHO-DD]|5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone|(1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol|L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon|5,6,7,8-erythro-tetrahydrobiopterin|DAPROTERIN|6R-Tetrahydrobiopterin|tetrahydrobiopterin (THB)|bmse000911|THB|SCHEMBL258544|GTPL5276|CHEMBL1201774|DTXSID1041138|BCBcMAP01_000204|2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one|Biopterin, 5,6,7,8-tetrahydro-|BCP03735|EX-A2877|BDBM50373697|ZINC13585233|DB00360|(6R)-2-Amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone|4(1H)-Pteridinone, (6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-|SMP1_000285|NCGC00485328-01|(6r)-erythro-5,6,7,8-tet-rahydrobiopterin|(6R)-5,6,7,8-Tetrahydro-L-biopterin 2HCl|C00272|C16118|D08505|W-203341|W-203533|69081654-1FB6-4B89-B9B9-823C9887EE36|2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone|2-Amino-6R-(1R,2S-dihydroxypropyl)-5,6,7,8-tetrahydro-4(1H)-pteridinone|(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-3,4,5,6,7,8-hexahydropteridin-4-one|(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one|(R)-2-Amino-6-((1R,2S)-1,2-dihydroxy-propyl)-5,6,7,8-tetrahydro-1H-pteridin-4-one|4(1H)-Pteridinone,2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro|2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone|27070-47-9",Metabolic Agents,Small molecule,"1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1",FNKQXYHWGSIFBK-RPDRRWSUSA-N,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,CAS 62989-33-7,C9H15N5O3,CHEBI:59560,.
D1885,Saw palmetto,.,"84604-15-9; Sabal serulata; Saw Palmetto (Serenoa repens) Extract; Saw Palmetto (Serenoa repens) Extract; Prosta Urgenin; Sabal serulata (Michx.) Benth. et Hook. (Aracaceae); Extract of saw palmetto; Sabal serulata extract; Saw palmetto extract; Sabal serrulatum, ext.; EINECS 283-292-4; Saw Palmetto (Serenoa repens) Extract [berry]; Saw Palmetto [berry]; Saw Palmetto",Herbal Products,Natural product,.,.,.,.,.,.,.
D1886,Secretin human,16158474,"Secretin human|Secretin, unspecified|Secretin human [INN]|CHEMBL3039582|Secretin (human, porcine, etc.)|NCGC00167148-01|Secretin (pig), 15-L-glutamic acid-16-glycine-|L-Histidyl-L-seryl-L-a-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-a-glutamylglycyl -L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide|L-Valinamide, L-histidyl-L-seryl-L-.alpha.-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-.alpha.-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-",Hormone Modulators,Hormones,"InChI=1S/C130H220N44O40/c1-60(2)43-81(120(208)173-100(66(13)14)103(134)191)153-95(183)54-149-106(194)77(31-35-92(132)180)159-116(204)84(46-63(7)8)166-118(206)85(47-64(9)10)164-111(199)75(29-23-41-146-129(139)140)155-113(201)79(32-36-93(133)181)160-117(205)83(45-62(5)6)162-110(198)73(27-21-39-144-127(135)136)154-104(192)67(15)152-94(182)53-148-107(195)78(33-37-97(185)186)158-109(197)74(28-22-40-145-128(137)138)156-115(203)82(44-61(3)4)163-112(200)76(30-24-42-147-130(141)142)157-122(210)90(57-176)170-119(207)86(48-65(11)12)165-114(202)80(34-38-98(187)188)161-123(211)91(58-177)171-126(214)102(69(17)179)174-121(209)87(49-70-25-19-18-20-26-70)168-125(213)101(68(16)178)172-96(184)55-150-108(196)88(51-99(189)190)167-124(212)89(56-175)169-105(193)72(131)50-71-52-143-59-151-71/h18-20,25-26,52,59-69,72-91,100-102,175-179H,21-24,27-51,53-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H2,134,191)(H,143,151)(H,148,195)(H,149,194)(H,150,196)(H,152,182)(H,153,183)(H,154,192)(H,155,201)(H,156,203)(H,157,210)(H,158,197)(H,159,204)(H,160,205)(H,161,211)(H,162,198)(H,163,200)(H,164,199)(H,165,202)(H,166,206)(H,167,212)(H,168,213)(H,169,193)(H,170,207)(H,171,214)(H,172,184)(H,173,208)(H,174,209)(H,185,186)(H,187,188)(H,189,190)(H4,135,136,144)(H4,137,138,145)(H4,139,140,146)(H4,141,142,147)/t67-,68+,69+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,100-,101-,102-/m0/s1",OWMZNFCDEHGFEP-NFBCVYDUSA-N,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)O,.,C130H220N44O40,.,.
D1887,Semaglutide,56843331,NN9535,Antidiabetic Agents,Small molecule,"1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1",DLSWIYLPEUIQAV-CCUURXOWSA-N,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,CAS 910463-68-2,C187H291N45O59,.,5A11: Type 2 diabetes mellitus
D1888,Sermorelin,16132413,"Sermorelina; Sermoreline; Sermorelinum; Sermorelina [Spanish]; Sermoreline [French]; Sermorelinum [Latin]; Geref (TN); Sermorelin (INN); Sermorelin [INN:BAN]; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2",Hormone Replacement Agents,Small molecule,"1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1",WGWPRVFKDLAUQJ-MITYVQBRSA-N,CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N,CAS 86168-78-7,C149H246N44O42S,.,FB86: Bone growth disorder
D1889,Silver (topical),23954,"7440-22-4|Ag|Silver|Argentum|Colloidal silver|Silver metal|Silver, colloidal|Silber|Silver, bullion|Silver nanoparticles|Silver wire|Silver nanowires|Silver, flakes|UNII-3M4G523W1G|Silver needles|Silver powder|Silver flake|Silver foil|Silver shot|Silver on alumina|3M4G523W1G|Silver, elemental|69011-54-7|Caswell No. 735|argent|plata|Silver Nanowire|Silver Granufoam|Silver nanowires (stored in ethanol)|Metz 3000-1|Silver Powder, 99.95% (metal basis) Nano|HSDB 5034|SILVER COMPOUNDS|Silver nanoparticle ink|EINECS 231-131-3|FA 312|LA 113|LS 500|SR 999|EPA Pesticide Chemical Code 072501|Theraworx|Silver Nanofoil|Silver Nanorods|Silver plate|Silver wool|Ag Nanowires|CCRIS 9464|Silver rod|Silver, foil, 0.5m coil, thickness 0.025mm, annealed, 99.95+%|Silver, foil, 0.5m coil, thickness 0.035mm, as rolled, 99.95+%|Silver, foil, 1m coil, thickness 0.025mm, annealed, 99.95+%|Silver, foil, 1m coil, thickness 0.035mm, as rolled, 99.95+%|Silver Nanocubes|Silver Nanoflake|Silver Nanostars|Silver Nanotubes|C.I. 77820|Silver, foil, thickness 0.015 mm, size 25 x 25 mm, purity 99.95+%|Silver, foil, thickness 0.015 mm, size 50 x 50 mm, purity 99.95+%|Silver, foil, thickness 0.030 mm, size 260 x 300 mm, purity 99.95+%|Copper Dispersion|Silver Nanoplates|Silver Nanopowder|Silver Nanoprisms|Nanosilver colloid|silber(II)hydride|Silver nanoparticles (100nm, 0.02mg/ml in 2mM sodium citrate, abs. max. 490)|AgII|Ag nanowire-50|Ag nanowire-60|Silver, metal and soluble compounds|silver (II)|Ag nanowire -90|Conductive Film Ink|Silver and compounds|Silver Nanoflake Ink|Conductive Silver Paste|Conductive Silver Slurry|Silver, conductive paste|Conductive nanosilver ink|Ag nanowires - 40 nm|Silver Nanowire Biosensor|SILVER PROTEIN DAC|Silver, 99.9%|Ag nanowire - 120 nm|Silver Nanowire Dispersion|47Ag|Ag nanowires - 200 nm|Ag++|Ag2+|Silver Colloidal Dispersion|Silver Nanowires Properties|Ultra Thin Silver Nanofoil|EC 231-131-3|Silver powder, -100 mesh|Silver Nano Water Dispersion|Ag(0)|Silver Nanoparticle Dispersion|Silver Nanowires Antibacterial|Silver Dispersion Nanoparticles|Silver Nanoparticles Dispersion|CHEBI:9141|Silver Nanowire Pressure Sensor|DTXSID4024305|Nano Silver Colloidal Dispersion|Silver flake, APS 4-8 micron|CHEBI:30512|HSDB 7056|DTXSID80161148|Silver powder, APS 1-3 micron|Silver powder, APS 4-7 micron|Silver rod, 5mm (0.2in) dia|Silver flake, 80% <20 micron|Silver flake, 90% <20 micron|Silver nanopowder, APS 20-40nm|Silver, brazing flux, white paste|Silver Nanoparticles Conductive Ink|Silver on alumina, 2-4 mm spheres|Silver Nanowire Transparent Conductor|Silver powder, -120 mesh, Premion|AKOS005259067|Silver powder, spherical, -325 mesh|Silver powder, spherical, -500 mesh|Silver powder, spherical, -635 mesh|Silver Silica Core Shell Nanoparticles|DB12965|Silver powder, -22 mesh, Premion(R)|Silver powder, APS 0.7-1.3 micron|Silver rod, 6.35mm (0.25in) dia|Silver wool, 99.9+% (metal basis)|Silver, colloidal, 65-75% Ag basis|Ag-Doped Antibacterial Agent Nanopowder|Silver Powder, 99% (metal basis) Nano|Silver shot, 1-5mm (0.04-0.2in)|Silver X9 Silver Nanoparticles Dispersion|Silver powder, -120+325 mesh, atomized|Silver rod, 12.7mm (0.5in) dia, hard|Silver wire, 1.0mm (0.04in) dia, hard|Silver wire, 2.0mm (0.08in) dia, hard|CS-0158655|FT-0695892|Q1090|Silver foil, 1.0mm (0.04in) thick, hard|Silver foil, 2.0mm (0.08in) thick, hard|Silver plate, 3.175mm (0.125in) thick|Silver wire, 0.25mm (0.01in) dia, hard|Silver powder, spherical, APS 0.5-1 micron|Silver powder, spherical, APS 0.6-2 micron|Silver rod, 7mm (0.275in) dia, Premion?|Silver, solder alloy, 1.6mm (0.06in) dia|Silver, solder alloy, 3.0mm (0.13in) dia|C06710|Palladium Silver foil, 0.5mm (0.02in) thick|Silver (20nm,10 wt%) nanopowder, 99.99%|Silver foil, 0.28mm (0.011in) thick, hard|Silver foil, 0.38mm (0.015in) thick, hard|Silver rod, 3.175mm (0.125in) dia, hard|Silver wire, 0.025mm (0.001in) dia, hard|Silver wire, 0.127mm (0.005in) dia, hard|Silver wire, 0.203mm (0.008in) dia, hard|Silver wire, 0.5mm (0.02in) dia, annealed|Silver wire, 1.0mm (0.04in) dia, annealed|Silver wire, 1.0mm (0.04in) dia, Premion?|Silver wire, 1.5mm (0.06in) dia, Premion?|Silver wire, 2.0mm (0.08in) dia, annealed|Silver wire, 2.0mm (0.08in) dia, Premion?|Silver, brazing alloy, 1.6mm (0.06in) dia|Silver, rod, diam. 6.35 mm, >=99.95%|Iron Manganese (Fe-Mn) Alloy Sputtering Targets|Palladium Silver foil, 0.25mm (0.01in) thick|Silver (20nm, 25 wt%) nanopowder, 99.99%|Silver foil, 0.075mm (0.003in) thick, hard|Silver foil, 0.5mm (0.02in) thick, annealed|Silver foil, 1.0mm (0.04in) thick, annealed|Silver foil, 1.0mm (0.04in) thick, Premion?|Silver foil, 2.0mm (0.08in) thick, annealed|Silver foil, 2.0mm (0.08in) thick, Premion?|Silver freezing-point standard, NIST SRM 1746|Silver powder, spherical, APS 1.3-3.2 micron|Silver shot, 1-3mm (0.04-0.1in), Premion|Silver Thinfoil, 0.005mm (0.0002in) thick|Silver wire, 0.05mm (0.002in) dia, annealed|Silver wire, 0.1mm (0.004in) dia, Premion?|Silver wire, 0.25mm (0.01in) dia, annealed|Silver wire, 0.25mm (0.01in) dia, Premion?|Silver wire, 0.5mm (0.02in) dia, 1/2 hard|Silver wire, 0.64mm (0.025in) dia, annealed|Sodium Ammonium Trimolybdate Nanowires Properties|Silver foil, 0.05mm (0.002in) thick, annealed|Silver foil, 0.28mm (0.011in) thick, annealed|Silver plating solution, metal content ~28.7g/l|Silver rod, 12.5mm (0.492in) dia, Premion?|Silver shot, 1-5mm (0.04-0.2in), Premion?|Silver shot, 2-3mm (0.08-0.12in), Premion?|Silver Thinfoil, 0.0125mm (0.0005in) thick|Silver wire, 0.05mm (0.002in) dia, Premion?|Silver wire, 0.127mm (0.005in) dia, annealed|Silver wire, 0.5mm (0.02in) dia, Premion(R)|Silver foil, 0.025mm (0.001in) thick, annealed|Silver foil, 0.127mm (0.005in) thick, annealed|Silver foil, 0.5mm (0.02in) thick, Premion(R)|Silver powder, crystalline, -10+20 mesh, Premion?|Silver powder, crystalline, -60+80 mesh, Premion?|Silver wire, 0.404mm (0.0159in) dia, annealed|Silver wire, gold plated, 0.025mm (0.001in) dia|Silver, shot, 1-3 mm, 99.999% trace metals basis|S018000000|Silver casting grain, 1.6-6.35mm (0.063-0.25in)|Silver foil, 0.25mm (0.01in) thick, hard, Premion?|Silver nanopowder (80 nm), 99.9% (metals basis) Nano|Silver, flakes, 10 mum, >=99.9% trace metals basis|Silver, foil, 0.2m coil, thickness 0.003mm, 99.9%|Silver, foil, 0.5m coil, thickness 0.003mm, 99.9%|Silver, foil, 10mm disks, thickness 0.003mm, 99.9%|Silver, foil, 10mm disks, thickness 0.02mm, 99.97%|Silver, foil, 15mm disks, thickness 0.003mm, 99.9%|Silver, foil, 15mm disks, thickness 0.02mm, 99.97%|Silver, foil, 1m coil, thickness 0.008mm, 99.95+%|Silver, foil, 1m coil, thickness 0.01mm, 99.95+%|Silver, foil, 25mm disks, thickness 0.003mm, 99.9%|Silver, foil, 25mm disks, thickness 0.02mm, 99.97%|Silver, foil, 4mm disks, thickness 0.003mm, 99.9%|Silver, foil, 4mm disks, thickness 0.004mm, 99.97%|Silver, foil, 4mm disks, thickness 0.005mm, 99.97%|Silver, foil, 4mm disks, thickness 0.006mm, 99.97%|Silver, foil, 4mm disks, thickness 0.007mm, 99.97%|Silver, foil, 4mm disks, thickness 0.008mm, 99.97%|Silver, foil, 4mm disks, thickness 0.009mm, 99.97%|Silver, foil, 4mm disks, thickness 0.015mm, 99.97%|Silver, foil, 4mm disks, thickness 0.01mm, 99.95+%|Silver, foil, 4mm disks, thickness 0.02mm, 99.97%|Silver, foil, 50mm disks, thickness 0.003mm, 99.9%|Silver, foil, 6mm disks, thickness 0.003mm, 99.9%|Silver, foil, 6mm disks, thickness 0.004mm, 99.97%|Silver, foil, 6mm disks, thickness 0.005mm, 99.97%|Silver, foil, 6mm disks, thickness 0.006mm, 99.97%|Silver, foil, 6mm disks, thickness 0.007mm, 99.97%|Silver, foil, 6mm disks, thickness 0.008mm, 99.97%|Silver, foil, 6mm disks, thickness 0.009mm, 99.97%|Silver, foil, 6mm disks, thickness 0.015mm, 99.97%|Silver, foil, 6mm disks, thickness 0.01mm, 99.95+%|Silver, foil, 6mm disks, thickness 0.02mm, 99.97%|Silver, foil, 8mm disks, thickness 0.003mm, 99.9%|Silver, foil, 8mm disks, thickness 0.004mm, 99.97%|Silver, foil, 8mm disks, thickness 0.005mm, 99.97%|Silver, foil, 8mm disks, thickness 0.006mm, 99.97%|Silver, foil, 8mm disks, thickness 0.007mm, 99.97%|Silver, foil, 8mm disks, thickness 0.008mm, 99.97%|Silver, foil, 8mm disks, thickness 0.009mm, 99.97%|Silver, foil, 8mm disks, thickness 0.015mm, 99.97%|Silver, foil, 8mm disks, thickness 0.01mm, 99.95+%|Silver, foil, 8mm disks, thickness 0.02mm, 99.97%|Silver, plasma standard solution, Specpure, Ag 10g/ml|Silver, powder, <250 mum, 99.99% trace metals basis|Silver, powder, 5-8 mum, >=99.9% trace metals basis|Silver, shot, 1-3 mm, >=99.99% trace metals basis|Silver, wire, diam. 0.1 mm, 99.9% trace metals basis|Silver, wire, diam. 0.5 mm, 99.9% trace metals basis|Silver, wire, diam. 1.0 mm, 99.9% trace metals basis|Silver, wire, diam. 1.5 mm, 99.9% trace metals basis|Silver, wire, diam. 2.0 mm, 99.9% trace metals basis|Silver foil, 0.025mm (0.001in) thick, hard, Premion?|Silver foil, 0.1mm (0.004in) thick, annealed, Premion?|Silver foil, 0.1mm (0.004in) thick, hard, Premion(R)|Silver foil, 0.25mm (0.01in) thick, annealed, Premion?|Silver, AAS standard solution, Specpure?, Ag 1000?g/ml|Silver, foil, 0.2m coil, thickness 0.008mm, 99.95+%|Silver, foil, 0.2m coil, thickness 0.01mm, 99.95+%|Silver, foil, 0.5m coil, thickness 0.008mm, 99.95+%|Silver, foil, 0.5m coil, thickness 0.0125mm, 99.95+%|Silver, foil, 0.5m coil, thickness 0.01mm, 99.95+%|Silver, foil, 10mm disks, thickness 0.0025mm, 99.97%|Silver, foil, 10mm disks, thickness 0.004mm, 99.97%|Silver, foil, 10mm disks, thickness 0.005mm, 99.97%|Silver, foil, 10mm disks, thickness 0.006mm, 99.97%|Silver, foil, 10mm disks, thickness 0.007mm, 99.97%|Silver, foil, 10mm disks, thickness 0.008mm, 99.95+%|Silver, foil, 10mm disks, thickness 0.008mm, 99.97%|Silver, foil, 10mm disks, thickness 0.009mm, 99.97%|Silver, foil, 10mm disks, thickness 0.015mm, 99.97%|Silver, foil, 10mm disks, thickness 0.01mm, 99.95+%|Silver, foil, 15mm disks, thickness 0.0025mm, 99.97%|Silver, foil, 15mm disks, thickness 0.004mm, 99.97%|Silver, foil, 15mm disks, thickness 0.005mm, ",Topical Antibiotics,Small molecule,InChI=1S/Ag,BQCADISMDOOEFD-UHFFFAOYSA-N,[Ag],.,Ag,.,.
D1890,"Smallpox (Vaccinia) Vaccine, Live",.,"685563-13-7; Vaccinia; Inalimarev (cea, muc-1, vaccinia virus) [USAN]; Inalimarev (CEA, MUC-1, vaccinia virus); Panvac-V; Smallpox (Vaccinia) Vaccine, Live; Panvac",Vaccine,Vaccine,.,.,.,.,.,.,.
D1891,Sodium glycerophosphate,14754,"SODIUM GLYCEROPHOSPHATE|1555-56-2|Disodium alpha-glycerophosphate|alpha-Glycerophosphoric Acid Disodium Salt|Sodium 1-glycerophosphate|Disodium glycerol phosphate|disodium;2,3-dihydroxypropyl phosphate|1334-74-3|1300-25-0|Sodium glycerophosphate anhydrous|1,2,3-Propanetriol, mono(dihydrogen phosphate), disodium salt|alpha-glycerophosphate disodium salt|Sodium 2,3-dihydroxypropyl phosphate|Sodium glycerophosphate hydrate|1,2,3-Propanetriol, 1-(dihydrogen phosphate), disodium salt|1,2,3-Propanetriol, 1-(dihydrogen phosphate), sodium salt (1:2)|MFCD00150339|Sodium-|A-glycerophosphate|Disodium 1-glycerophosphate|Disodium DL-alpha-glycerophosphate|EINECS 215-613-0|EINECS 216-304-3|Sodium glycerophospate|AI3-52663|SCHEMBL124155|17603-42-8(anhydrou)|DTXSID4061678|DTXSID801014666|Glycerol, mono(dihydrogen phosphate), disodium salt. hydrate|7070AF|MFCD00150341|AKOS015914412|AKOS024319279|DB09561|G0096|D90711|Q27278714|ALPHA-GLYCEROPHOSPHORIC ACID DISODIUM SALT HYDRATE|1,2,3-Propanetriol, mono(dihydrogen phosphate), sodium salt (1:2)",Phosphorus Supplements,Small molecule,"InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2",GEKBIENFFVFKRG-UHFFFAOYSA-L,C(C(COP(=O)([O-])[O-])O)O.[Na+].[Na+],.,C3H7Na2O6P,.,.
D1892,Sodium iodide,5238,"sodium iodide|7681-82-5|Ioduril|Sodium monoiodide|Soiodin|Iodure de sodium|Sodium iodide (NaI)|sodiumiodide|Jodid sodny|sodium;iodide|UNII-F5WR8N145C|MFCD00003532|F5WR8N145C|CHEMBL1644695|CHEBI:33167|NSC-77388|Natriumjodid|Natrii iodidum|Sodium iodide, ultra dry|Jodid sodny [Czech]|Caswell No. 777|Natriumjodid [German]|HSDB 750|EINECS 231-679-3|NSC 77388|EPA Pesticide Chemical Code 075702|Sodium iodide [USP:JAN]|sodium-iodide|iodeto de sodio|ioduro di sodio|yoduro de sodio|sodium iodide-|Sodium Iodide,99%|Sodium iodide solution|Sodium iodide, anhydrous|Sodium iodide, ACS grade|Iodide (as sodium iodide)|WLN: NA I|EC 231-679-3|sodium iodine-131(1-)|DSSTox_CID_21125|DSSTox_RID_79629|DSSTox_GSID_41125|Sodium iodide (JP17/USP)|Fdy-5301|DTXSID2041125|Sodium iodide, Trace metals grade|BCP22179|NSC77388|Tox21_301379|AKOS015950612|AKOS016015354|DB11119|LS41973|NCGC00255631-01|K326|CAS-7681-82-5|CS-0013799|FT-0645131|S0564|D04874|Q390305",Antithyroid Agents,Small molecule,InChI=1S/HI.Na/h1H;/q;+1/p-1,FVAUCKIRQBBSSJ-UHFFFAOYSA-M,[Na+].[I-],.,INa,.,.
D1893,Sorbitol,5780,D-Sorbitol; sorbitol; D-Glucitol; 50-70-4; glucitol; L-Gulitol; (-)-Sorbitol; Glucarine; Sorbilande; Diakarmon; Sorbostyl; Multitol; Nivitin; Karion; Esasorb; Neosorb; D-(-)-Sorbitol; Sorbol; Cholaxine; Sorbite; Sionit; Sionite; Siosan; Sionon; Karion instant; Sorbitol F; Sorbitol FP; Sorbex Rp; Sorbitol syrup C; Sorbex X; Sorbex R; Sorbex M; Sorbex S; Sionit K; D-Sorbol; Hexahydric alcohol; Sorbicolan; Sorvilande; Neosorb P 60; D-Sorbite; Foodol D 70; Neosorb 20/60DC; Neosorb 70/70; Neosorb 70/02; Neosorb P 20/60; d-Sorbit; Karion (carbohydrate),Laxatives,Small molecule,"1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1",FBPFZTCFMRRESA-JGWLITMVSA-N,C(C(C(C(C(CO)O)O)O)O)O,CAS 50-70-4,C6H14O6,CHEBI:17924,DD91: Irritable bowel syndrome
D1894,Sugammadex,6918585,"Sugammadex|343306-71-8|Bridion|UNII-361LPM2T56|361LPM2T56|ORG-25969|Sugammadex [USAN:INN:BAN]|SCHEMBL13917069|CHEBI:90953|DTXSID90895043|DB06206|C74763|6A,6B,6C,6D,6E,6F,6G,6H-Octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-|A-cyclodextrin|WURCS=2.0/1,8,8/[a2122h-1a_1-5_6*SCCCO/5=O]/1-1-1-1-1-1-1-1/a1-h4_a4-b1_b4-c1_c4-d1_d4-e1_e4-f1_f4-g1_g4-h1",Anesthetics,Small molecule,"InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1",WHRODDIHRRDWEW-VTHZAVIASA-N,C(CSC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,.,C72H112O48S8,.,.
D1895,Sulfacetamide (ophthalmic),5320,Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide,Antibiotics,Small molecule,"1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)",SKIVFJLNDNKQPD-UHFFFAOYSA-N,CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N,CAS 144-80-9,C8H10N2O3S,CHEBI:63845,ED80: Acne vulgaris
D1896,Tafluprost (ophthalmic),9868491,Zioptan (TN),Ophthalmic Glaucoma Agents,Small molecule,"1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1",WSNODXPBBALQOF-VEJSHDCNSA-N,CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O,CAS 209860-87-7,C25H34F2O5,CHEBI:66899,9C61: Glaucoma
D1897,Talimogene laherparepvec,.,IMLYGIC,Anticancer Agents,Vaccine,.,.,.,.,.,.,2C30: Melanoma
D1898,Tazobactam,123630,"TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide",Antiinfective Agents,Small molecule,"1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1",LPQZKKCYTLCDGQ-WEDXCCLWSA-N,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,CAS 89786-04-9,C10H12N4O5S,CHEBI:9421,1A00-1C4Z: Bacterial infection
D1899,Tegaserod,135409453,Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine,Serotoninergic Neuroenteric Modulators,Small molecule,"1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+",IKBKZGMPCYNSLU-RGVLZGJSSA-N,CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC,CAS 145158-71-0,C16H23N5O,CHEBI:51043,DD91: Irritable bowel syndrome; DA22: Gastro-oesophageal reflux disease; MD92: Dyspepsia
D1900,Teprotumumab,.,RV001,Growth Hormone Receptor Blockers,Monoclonal antibody,.,.,.,.,.,.,9B71: Retinopathy; 5A02: Thyrotoxicosis
D1901,Teriparatide,16133850,Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN),Bone Density Conservation Agents,Protein/peptide,"1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1",OGBMKVWORPGQRR-UMXFMPSGSA-N,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,CAS 52232-67-4,C181H291N55O51S2,CHEBI:135983,LD24: Skeletal anomaly; EA90: Psoriasis
D1902,Tesamorelin,16137828,Egrifta (TN),Growth Hormones,Hormones,"1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1",QBEPNUQJQWDYKU-BMGKTWPMSA-N,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,CAS 804475-66-9,C221H366N72O67S,.,1C60-1C62: Human immunodeficiency virus disease
D1903,Tetanus Immune Globulin,.,"Tetanus immune globulin; Tetanus immune globulin (human ); Tetanus immune globulin (human); Tetanus immune globulin human; Tetanus immune globulin, human; Tetanus immune globulin,human; Tetanus immune human globulin; Tetanus immunoglobulin; CHEMBL1201582",Immune Globulins,Polyclonal antibody,.,.,.,.,.,.,1A04: Clostridium difficile enterocolitis
D1904,Tetracaine (ophthalmic),5411,"Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester",Anesthetics,Small molecule,"1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3",GKCBAIGFKIBETG-UHFFFAOYSA-N,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CAS 94-24-6,C15H24N2O2,CHEBI:9468,MB40: Sensation disturbance; MG30-MG3Z: Pain
D1905,Tetrofosmin,4274,"P53 (transmembrane carrier system); Gene plasmid drugs (TCS), Inex; P53 (transmembrane carrier system), Inex; TCS gene therapy (p53), Inex",Diagnostic Agents,Small molecule,"1S/C18H40O4P2/c1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4/h5-18H2,1-4H3",QCWJONLQSHEGEJ-UHFFFAOYSA-N,CCOCCP(CCOCC)CCP(CCOCC)CCOCC,CAS 127502-06-1,C18H40O4P2,CHEBI:135598,2A00-2F9Z: Solid tumour/cancer
D1906,Thallous Chloride,24642,"Thallium chloride|Thallium(I) chloride|THALLOUS CHLORIDE|Thallium monochloride|Thallium(1+) chloride|chlorothallium|7791-12-0|TlCl|Thallium chloride (TlCl)|Thallous chloride tl 201|Thallium chloride (VAN)|MFCD00011274|THALLOUS CHLORIDE TL-201|RCRA waste number U216|HSDB 6066|EINECS 232-241-4|NSC 15197|RCRA waste no. U216|chloridothallium|[TlCl]|WLN: TL G|Thallium chloride, (TlCl)|Thallium(I) chloride, 99%|CHEBI:37117|Thallium(I) chloride, ultra dry|NSC15197|8431AF|NSC-15197|AKOS015916191|DB09316|Q425234|Thallium(I) chloride, 99.999% trace metals basis",Diagnostic Radiopharmaceuticals,Small molecule,InChI=1S/ClH.Tl/h1H;/q;+1/p-1,GBECUEIQVRDUKB-UHFFFAOYSA-M,Cl[Tl],.,ClTl,.,.
D1907,Thimerosal (topical),16684434,"thimerosal|Thiomersal|54-64-8|Thiomersalate|Mercurothiolate|Sodium merthiolate|MERTHIOLATE|Sodium ethylmercurithiosalicylate|Ethylmercurithiosalicylate sodium|Ethylmercurithiosalicylic acid sodium salt|Thiomersalum|Tiomersal|Ethyl(2-mercaptobenzoato-S)mercury sodium salt|o-(Ethylmercurithio)benzoic acid sodium salt|UNII-2225PI3MOV|((o-Carboxyphenyl)thio)ethylmercury sodium salt|sodium;(2-carboxylatophenyl)sulfanyl-ethylmercury|[(o-Carboxyphenyl)thio]ethylmercury sodium salt|MFCD00013062|2225PI3MOV|CHEBI:9546|Thimerosalate|Thimerosalum|Thimerosol|Thimersalate|Thiomersalat|Thiomersal (INN)|Thiomersal [INN]|NCGC00094791-01|Elicide|Estivin|Merfamin|Merphol|Mertorgan|Merzonin|Nosemack|Tiomersale|Vitaseptol|Mercurothiolatum|Merzonin sodium|Aeroaid spray|Merthiolate salt|DSSTox_CID_5540|Merthiolate sodium|Vitaseptol Loesung|Mercury-([o-carboxyphenyl]thio)ethyl sodium salt|DSSTox_RID_77823|DSSTox_GSID_25540|Merseptyl (VAN)|Elcide 73|Elcide 75|Tiomersale [DCIT]|Caswell No. 766|C9H9HgO2S.Na|MLS001336050|Sodium ethylmercuric thiosalicylate|Tiomersal [INN-Spanish]|Thiomersalum [INN-Latin]|Sodium o-(ethylmercurithio)benzoate|Sodium 2-(ethylmercurithio)benzoate|CAS-54-64-8|Ethylmercurithiosalicylate sodium salt|Ethylmerkurithiosalicilan sodny|CCRIS 4839|HSDB 7151|(2-(Ethylmercuriomercapto)benzoic acid sodium salt|Thimerosal [USP:JAN]|NSC 4794|SMR000875330|EINECS 200-210-4|EPA Pesticide Chemical Code 078901|Ethylmerkurithiosalicilan sodny [Czech]|Ethyl (sodium o-mercaptobenzoato)mercury|Thime-rosal|Ethylmercurithiosalicyclic acid, sodium salt|Mercurate(1-), ethyl(2-mercaptobenzoato(2-)-O,S)-, sodium|Merthiolate (TN)|Mercury, ethyl(2-mercaptobenzoate-S)-, sodium salt|Mercury, ethyl(2-mercaptobenzoato-S)-, sodium salt|Mercury, ((o-carboxyphenyl)thio)ethyl-, sodium salt|Prestwick_1021|Mercurate(1-), ethyl(o-mercaptobenzoato(2-))-, sodium|Thimerosal (JAN/USP)|Mercurate(1-), ethyl(2-mercaptobenzoate(2-)-O,S)-, sodium salt|Epitope ID:119682|SCHEMBL3525|Ethyl(2-mercaptobenzoato-S)mercury, sodium salt|sodium (2-carboxylatophenyl)sulfanyl-ethyl-mercury|ethylmercury(1+) sodium 2-sulfidobenzoate(1:1:1)|MLS001336049|SET|SPECTRUM1500572|Mercury, ethyl (2-mercaptobenzoato-S)-, sodium salt|Thimerosal, EP/BP/USP grade|Thimerosal, analytical standard|DTXSID3025540|Thimerosal, >=97% (HPLC)|HMS501O19|Mercury, ethyl(hydrogen o-mercaptobenzoato)-, sodium salt|Thimerosal, >=95.0% (Hg)|BDBM512713|HMS1921E07|HMS2092M09|HMS2230I04|HMS3371N19|sodium ethyl[2-(sulfanyl-kappaS)benzoato(2-)]mercurate(1-)|SRCT-03744|Thimerosal, BioXtra, 97-101%|Tox21_111331|Tox21_302176|8171AF|CCG-39725|AKOS004910446|AKOS037503710|Mercurate(1-), ethyl(2-(mercapto-kappaS)benzoato(2-)-kappaO)-, sodium|Tox21_111331_1|DB11590|NCGC00094791-02|NCGC00164425-01|NCGC00178879-04|NCGC00255169-01|BP-30041|DB-052622|FT-0603231|Thimerosal, meets USP testing specifications|sodium (2-carboxylatophenylthio)(ethyl)mercury|D00864|H10793|sodium [(2-carboxylatophenyl)thio]-ethylmercury|T-3600|ETHYLMERCURITHIOSALICYLIC ACID NA Thimerosal|A830286|Q411046|sodium ethyl[2-(mercapto-kS)benzoato(2-)]mercurate(1-)|sodium [(2-carboxylatophenyl)sulfanyl](ethyl)mercurate(1-)|Thimerosal, European Pharmacopoeia (EP) Reference Standard|Thimerosal, United States Pharmacopeia (USP) Reference Standard|Thimerosal Ready Made Solution, 100 mg/mL in water, 0.2 mum filtered|Thimerosal, Pharmaceutical Secondary Standard; Certified Reference Material|Mercurate(1-), ethyl(2-(mercapto-kappaS)benzoato(2-)-kappaO)-, sodium (1:1)",Antifungal Agent,Small molecule,"InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2",RTKIYNMVFMVABJ-UHFFFAOYSA-L,CC[Hg]SC1=CC=CC=C1C(=O)[O-].[Na+],.,C9H9HgNaO2S,.,.
D1908,Thyrotropin alfa,32281,Protirelina|TRH|Protirelin;Thyrotropin Releasing Hormone|Thyrotropin alfa|NSC-760113|L-Pyroglutamyl-L-histidyl-L-prolinamide|Phe2TRH|pyro-Glu-His-Pro-NH2|SCHEMBL8364920|BDBM86214|HMS3264O18|Pharmakon1600-01506101|CAS_32281|NSC_32281|NSC760113|AKOS024284364|CCG-213612|MCULE-5812782214|SMP2_000152|NCGC00166322-01|NCGC00166322-02|1-{3-imidazol-5-yl-2-[(5-oxopyrrolidin-2-yl)carbonylamino]propanoyl}pyrrolidin e-2-carboxamide|DB-046389|FT-0638410|FT-0639185|Thyroid-stimulating hormone-releasing hormone|AB01563143_01|L001154|W-107333|1-[2-[(5-Oxo-2-pyrrolidinyl)carbonylamino]-3-(1H-imidazol-4-yl)propionyl]pyrrolidine-2-carboxamide,Diagnostic Agents,Hormones,"InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)",XNSAINXGIQZQOO-UHFFFAOYSA-N,C1CC(N(C1)C(=O)C(CC2=CN=CN2)NC(=O)C3CCC(=O)N3)C(=O)N,.,C16H22N6O4,.,2D10: Thyroid cancer
D1909,Tilmanocept,.,"Technetium Tc 99m Tilmanocept [USAN]; Technetium Tc 99m tilmanocept; Tilmanocept; Technetium-99Tc, dextran 3-((2-aminoethyl)thio)propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-((2-((1-imino-2-(D-mannopyranosylthio)ethyl)amino)ethyl)thio)propyl ether complexes; (1->6)-alpha-D-pyranoglucan partially etherified by 3-((2-aminoethyl)sulfanyl)propyl, 17- carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadecyl and 3-((2-{(2-(L-mannopyranosylsulfanyl)acetimidoyl)amino}ethyl)sulfanyl)propyl, (99mTc)Technetium coordination compound",Diagnostic Radiopharmaceuticals,Small molecule,.,.,.,.,.,.,.
D1910,Travoprost (ophthalmic),5282226,"Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)",Ophthalmologicals,Small molecule,"1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",MKPLKVHSHYCHOC-AHTXBMBWSA-N,CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O,CAS 157283-68-6,C26H35F3O6,CHEBI:746859,9C61: Glaucoma
D1911,Triamcinolone (topical),31307,"Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone",Antiinflammatory Agents,Small molecule,"1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1",GFNANZIMVAIWHM-OBYCQNJPSA-N,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,CAS 124-94-7,C21H27FO6,CHEBI:9667,CA08: Vasomotor/allergic rhinitis
D1912,Trichophyton mentagrophytes,.,Trichophyton mentagrophytes; DB10446,Allergy Test,Allergenics,.,.,.,.,.,.,.
D1913,Tuberculin purified protein derivative,.,"Tuberculin purified protein derivative; Mycobacterium tuberculosis purified protein derivative; Purified protein derivative of tuberculin; Tuberculin PPD; Tuberculin, purified protein derivative; Tuberculin,purified protein derivative; Tuberculinum; DB11601",Allergy Test,Allergenics,.,.,.,.,.,.,.
D1914,Typhoid vaccine (live),.,Typhoid Vaccine Live; Salmonella enterica subsp. enterica serovar typhi; Salmonella typhi Ty21a live antigen; Typhoid vaccine (salmonella typhi Ty21a); Typhoid Vaccine Live Ty21a; DB11050,Vaccine,Vaccine,.,.,.,.,.,.,.
D1915,Tyropanoic acid,5611,"Tyropanoic acid|TYROPANIC ACID|tyropanoate|27293-82-9|2-[3-(BUTYRYLAMINO)-2,4,6-TRIIODOBENZYL]BUTYRIC ACID|2-[[3-(butanoylamino)-2,4,6-triiodophenyl]methyl]butanoic acid|Bilopac|Bilopaque|Lumopaque|Tyropaque|2-(3-Butyramido-2,4,6-triiodobenzyl)butanoic acid|Tyropanoic acid sodium salt|Acidum tyropanoicum|NSC107434|WIN 8851-2|7246-21-1|2-(3-(Butyrylamino)-2,4,6-triiodobenzyl)butyric acid|EINECS 248-389-8|starbld0000838|Tyropanoate sodium(USAN|Sodium Tyropanoate (USAN)|SCHEMBL2788021|CHEMBL1201261|DTXSID5048269|CHEBI:135862|DB09340|Q6587055|2-(3-(Butyrylamino)-2,4,6-triiodobenzyl)butanoic acid|Hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4,6-triiodo-|Sodium 3-butyramido-.alpha.-ethyl-2,4,6-triiodohydrocinnamate|2-[[3-(butanoylamino)-2,4,6-triiodo-phenyl]methyl]butanoic acid|Benzenepropanoic acid, alpha-ethyl-2,4,6-triiodo-3-((1-oxobutyl)amino)-|Hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4,6-triiodo-, sodium salt|Hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4, 6-triiodo-, monosodium salt|Benzenepropanoic acid, .alpha.-ethyl-2,4, {6-triiodo-3-[(1-oxobutyl)amino]-,} monosodium salt",Diagnostic Radiopharmaceuticals,Small molecule,"InChI=1S/C15H18I3NO3/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22)",YMOXVLQZFAUUKI-UHFFFAOYSA-N,CCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)O)I)I,.,C15H18I3NO3,.,.
D1916,Ulobetasol (topical),5311167,"Halobetasol|98651-66-2|Ulobetasol|Ulobetasol [INN]|UNII-9P6159HM7T|9P6159HM7T|Ulobetasol (INN)|(6alpha,11beta,16beta)-21-chloro-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione|Pregna-1,4-diene-3,20-dione,21-chloro-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6a,11b,16b)-|Halobetasol [USAN]|SCHEMBL4679|(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one|CHEMBL1201360|DTXSID60243759|ZINC4214603|DB00596|D08660|Q7879715",Corticosteroids,Small molecule,"InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1",LEHFPXVYPMWYQD-XHIJKXOTSA-N,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C)F,.,C22H27ClF2O4,.,.
D1917,Unoprostone (ophthalmic),5311236,"Unoprostone|120373-36-6|UNII-6X4F561V3W|Unoprostone [INN]|13,14-dihydro-15-keto-20-ethyl PGF2alpha|CHEBI:39455|6X4F561V3W|Unoprostone (INN)|(+)-(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-5-heptenoic acid|(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid|(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid|9,11-dihydroxy-15-oxo-20a,20b-dihomoprost-5Z-en-1-oic acid|5-Heptenoic acid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-|Unoprostone [MI]|13,14-Dihydro-15-keto-20-ethyl prostaglandin f2alpha|(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)hept-5-enoic acid|SCHEMBL194651|CHEMBL1201407|DTXSID80905120|HMS3648D22|ZINC8214703|LMFA03010204|AKOS015950955|DB06826|HY-106916|CS-0026907|V1818|D08661|SR-01000946492|J-004324|J-525150|Q4859684|SR-01000946492-1|(5Z,9alpha,11alpha)-9,11-dihydroxy-15-oxo-20a,20b-dihomoprost-5-en-1-oic acid|9.alpha.,11.alpha.-Dihydroxy-13,14-dihydro-15-oxo-20a,20b-dihomoprost-5-en-1-oic acid",Ophthalmic Glaucoma Agents,Small molecule,"1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1",TVHAZVBUYQMHBC-SNHXEXRGSA-N,CCCCCCCC(=O)CCC1C(CC(C1CC=CCCCC(=O)O)O)O,CAS 120373-36-6,C22H38O5,CHEBI:39455,9C61: Glaucoma
D1918,Urofollitropin,62819,"Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin",Fertility Agents,Small molecule,"1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)",ZDRRIRUAESZNIH-UHFFFAOYSA-N,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O,.,C42H65N11O12S2,.,GA31: Female infertility
D1919,Varenicline,170361,"CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline",Smoking Cessation Agents,Small molecule,"1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2",JQSHBVHOMNKWFT-UHFFFAOYSA-N,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,CAS 249296-44-4,C13H13N3,.,6C4A: Nicotine use disorder
D1920,Varicella Zoster Vaccine (Recombinant),.,Varicella Zoster Vaccine (Recombinant); gE recombinant Varicella zoster virus (VZV) glycoprotein E; gE: Recombinant Varicella Zoster Virus (VZV) glycoprotein E; Recombinant Varicella zoster virus (VZV) glycoprotein E; DB13924,Vaccine,Vaccine,.,.,.,.,.,.,.
D1921,Vibegron,44472635,MK-4618,Urinary Antispasmodics,Small molecule,"1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1",DJXRIQMCROIRCZ-XOEOCAAJSA-N,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O,CAS 1190389-15-1,C26H28N4O3,CHEBI:142418,GC50: Functional bladder disorder
D1922,Yellow Fever Vaccine,.,"Yellow Fever Vaccine; Flavivirus yellow fever virus 17D-204 whole; Yellow fever virus 17D/tiantan live antigen; Yellow fever virus live antigen, A; Yellow fever virus strain 17D (live, attenuated); Yellow fever virus strain 17D-204 live (attenuated) antigen; Yellow fever virus strain 17D-204 live antigen; Yellow fever, live attenuated; DB10805",Vaccine,Vaccine,.,.,.,.,.,.,1D47: Yellow fever
